

DEX-0241

AG

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
15 August 2002 (15.08.2002)

PCT

(10) International Publication Number  
WO 02/062945 A2

- (51) International Patent Classification<sup>7</sup>: C12N (74) Agents: LICATA, Jane, Massey et al.; 66 E. Main Street, Marlton, NJ 08053 (US).
- (21) International Application Number: PCT/US01/45541
- (22) International Filing Date: 25 October 2001 (25.10.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/242,998 25 October 2000 (25.10.2000) US
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:  
US 60/242,998 (CIP)  
Filed on 25 October 2000 (25.10.2000)
- (71) Applicant (for all designated States except US): DI-ADEXUS, INC. [US/US]; 343 Oyster Point Boulevard, South San Francisco, CA 94080 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): RECIPON, Herve [FR/US]; 85 Fortuna Avenue, San Francisco, CA 94115 (US). SUN, Yongming [US/US]; 869 S. Winchester Boulevard, Apartment 260, San Jose, CA 95128 (US). CHEN, Sei-Yu [CN/US]; 160 Mira Street, Foster City, CA 94404 (US). LIU, Chenghua [CN/US]; 1125 Ranchero Way #14, San Jose, CA 95117 (US). TURNER, Leah, R. [US/US]; 939 Rosette Court, Sunnyvale, CA 94086 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— without international search report and to be republished upon receipt of that report  
— with sequence listing part of description published separately in electronic form and available upon request from the International Bureau
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/062945 A2

(54) Title: COMPOSITIONS AND METHODS RELATING TO LUNG SPECIFIC GENES AND PROTEINS

(57) Abstract: The present invention relates to newly identified nucleic acids and polypeptides present in normal and neoplastic lung cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions comprising the nucleic acids, polypeptides, antibodies, variants, derivatives, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating lung cancer and non-cancerous disease states in lung, identifying lung tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered lung tissue for treatment and research.

213  
213

426

2A

1450-180

DEX-0242

This page is not part of  
the pamphlet!

**WO 02-062945**

**1/4**

Date: 15 aug 2002

Destination: Agent

Address:

## COMPOSITIONS AND METHODS RELATING TO LUNG SPECIFIC GENES AND PROTEINS

This application claims the benefit of priority from U.S. Provisional Application  
5 Serial No. 60/242,998 filed October 25, 2000, which is herein incorporated by reference  
in its entirety.

### FIELD OF THE INVENTION

The present invention relates to newly identified nucleic acid molecules and  
10 polypeptides present in normal and neoplastic lung cells, including fragments, variants  
and derivatives of the nucleic acids and polypeptides. The present invention also relates  
to antibodies to the polypeptides of the invention, as well as agonists and antagonists of  
the polypeptides of the invention. The invention also relates to compositions comprising  
the nucleic acids, polypeptides, antibodies, variants, derivatives, agonists and antagonists  
15 of the invention and methods for the use of these compositions. These uses include  
identifying, diagnosing, monitoring, staging, imaging and treating lung cancer and non-  
cancerous disease states in lung, identifying lung tissue and monitoring and identifying  
and/or designing agonists and antagonists of polypeptides of the invention. The uses also  
include gene therapy, production of transgenic animals and cells, and production of  
20 engineered lung tissue for treatment and research.

### BACKGROUND OF THE INVENTION

Throughout the last hundred years, the incidence of lung cancer has steadily  
increased, so much so that now in many countries, it is the most common cancer. In fact,  
lung cancer is the second most prevalent type of cancer for both men and women in the  
25 United States and is the most common cause of cancer death in both sexes. Lung cancer  
deaths have increased ten-fold in both men and women since 1930, primarily due to an  
increase in cigarette smoking, but also due to an increased exposure to arsenic, asbestos,  
chromates, chloromethyl ethers, nickel, polycyclic aromatic hydrocarbons and other  
agents. See Scott, Lung Cancer: A Guide to Diagnosis and Treatment, Addicus Books  
30 (2000) and Alberg *et al.*, in Kane *et al.* (eds.) Biology of Lung Cancer, pp. 11-52, Marcel  
Dekker, Inc. (1998). Lung cancer may result from a primary tumor originating in the

lung or a secondary tumor which has spread from another organ such as the bowel or breast. Although there are over a dozen types of lung cancer, over 90% fall into two categories: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). See Scott, *supra*. About 20-25% of all lung cancers are characterized as SCLC, while 70-  
5 80% are diagnosed as NSCLC. *Id.* A rare type of lung cancer is mesothelioma, which is generally caused by exposure to asbestos, and which affects the pleura of the lung. Lung cancer is usually diagnosed or screened for by chest x-ray, CAT scans, PET scans, or by sputum cytology. A diagnosis of lung cancer is usually confirmed by biopsy of the tissue. *Id.*

10 SCLC tumors are highly metastatic and grow quickly. By the time a patient has been diagnosed with SCLC, the cancer has usually already spread to other parts of the body, including lymph nodes, adrenals, liver, bone, brain and bone marrow. See Scott, *supra*; Van Houtte *et al.* (eds.), Progress and Perspective in the Treatment of Lung Cancer, Springer-Verlag (1999). Because the disease has usually spread to such an  
15 extent that surgery is not an option, the current treatment of choice is chemotherapy plus chest irradiation. See Van Houtte, *supra*. The stage of disease is a principal predictor of long-term survival. Less than 5% of patients with extensive disease that has spread beyond one lung and surrounding lymph nodes, live longer than two years. *Id.* However, the probability of five-year survival is three to four times higher if the disease  
20 is diagnosed and treated when it is still in a limited stage, i.e., not having spread beyond one lung. *Id.*

NSCLC is generally divided into three types: squamous cell carcinoma, adenocarcinoma and large cell carcinoma. Both squamous cell cancer and adenocarcinoma develop from the cells that line the airways; however, adenocarcinoma  
25 develops from the goblet cells that produce mucus. Large cell lung cancer has been thus named because the cells look large and rounded when viewed microscopically, and generally are considered relatively undifferentiated. See Yesner, Atlas of Lung Cancer, Lippincott-Raven (1998).

Secondary lung cancer is a cancer initiated elsewhere in the body that has spread  
30 to the lungs. Cancers that metastasize to the lung include, but are not limited to, breast cancer, melanoma, colon cancer and Hodgkin's lymphoma. Treatment for secondary lung cancer may depend upon the source of the original cancer. In other words, a lung



cancer that originated from breast cancer may be more responsive to breast cancer treatments and a lung cancer that originated from the colon cancer may be more responsive to colon cancer treatments.

The stage of a cancer indicates how far it has spread and is an important indicator of the prognosis. In addition, staging is important because treatment is often decided according to the stage of a cancer. SCLC is divided into two stages: limited disease, *i.e.*, cancer that can only be seen in one lung and in nearby lymph nodes; and extensive disease, *i.e.*, cancer that has spread outside the lung to the chest or to other parts of the body. For most patients with SCLC, the disease has already progressed to lymph nodes or elsewhere in the body at the time of diagnosis. *See Scott, supra.* Even if spreading is not apparent on the scans, it is likely that some cancer cells may have spread away and traveled through the bloodstream or lymph system. In general, chemotherapy with or without radiotherapy is often the preferred treatment. The initial scans and tests done at first will be used later to see how well a patient is responding to treatment.

In contrast, non-small cell cancer may be divided into four stages. Stage I is highly localized cancer with no cancer in the lymph nodes. Stage II cancer has spread to the lymph nodes at the top of the affected lung. Stage III cancer has spread near to where the cancer started. This can be to the chest wall, the covering of the lung (pleura), the middle of the chest (mediastinum) or other lymph nodes. Stage IV cancer has spread to another part of the body. Stage I-III cancer is usually treated with surgery, with or without chemotherapy. Stage IV cancer is usually treated with chemotherapy and/or palliative care.

A number of chromosomal and genetic abnormalities have been observed in lung cancer. In NSCLC, chromosomal aberrations have been described on 3p, 9p, 11p, 15p and 17p, and chromosomal deletions have been seen on chromosomes 7, 11, 13 and 19. *See Skarin (ed.), Multimodality Treatment of Lung Cancer*, Marcel Dekker, Inc. (2000); Gemmill *et al.*, pp. 465-502, in Kane, *supra*; Bailey-Wilson *et al.*, pp. 53-98, in Kane, *supra*. Chromosomal abnormalities have been described on 1p, 3p, 5q, 6q, 8q, 13q and 17p in SCLC. *Id.* The loss of the short arm of chromosome 3p has also been seen in greater than 90% of SCLC tumors and approximately 50% of NSCLC tumors. *Id.*

A number of oncogenes and tumor suppressor genes have been implicated in lung cancer. *See Mabry*, pp. 391-412, in Kane, *supra* and Sclafani *et al.*, pp. 295-316, in

Kane, *supra*. In both SCLC and NSCLC, the p53 tumor suppressor gene is mutated in over 50% of lung cancers. See Yesner, *supra*. Another tumor suppressor gene, FHIT, which is found on chromosome 3p, is mutated by tobacco smoke. *Id.*; Skarin, *supra*. In addition, more than 95% of SCLCs and approximately 20-60% of NSCLCs have an  
5 absent or abnormal retinoblastoma (Rb) protein, another tumor suppressor gene. The *ras* oncogene (particularly K-*ras*) is mutated in 20-30% of NSCLC specimens and the *c-erbB2* oncogene is expressed in 18% of stage 2 NSCLC and 60% of stage 4 NSCLC specimens. See Van Houtte, *supra*. Other tumor suppressor genes that are found in a region of chromosome 9, specifically in the region of 9p21, are deleted in many cancer  
10 cells, including p16<sup>INK4A</sup> and p15<sup>INK4B</sup>. See Bailey-Wilson, *supra*; Sclafani *et al.*, *supra*. These tumor suppressor genes may also be implicated in lung cancer pathogenesis.

In addition, many lung cancer cells produce growth factors that may act in an autocrine fashion on lung cancer cells. See Siegfried *et al.*, pp. 317-336, in Kane, *supra*; Moody, pp. 337-370, in Kane, *supra* and Heasley *et al.*, 371-390, in Kane, *supra*. In  
15 SCLC, many tumor cells produce gastrin-releasing peptide (GRP), which is a proliferative growth factor for these cells. See Skarin, *supra*. Many NSCLC tumors express epidermal growth factor (EGF) receptors, allowing NSCLC cells to proliferate in response to EGF. Insulin-like growth factor (IGF-I) is elevated in greater than 95% of SCLC and greater than 80% of NSCLC tumors; it is thought to function as an autocrine  
20 growth factor. *Id.* Finally, stem cell factor (SCF, also known as steel factor or kit ligand) and c-Kit (a proto-oncoprotein tyrosine kinase receptor for SCF) are both expressed at high levels in SCLC, and thus may form an autocrine loop that increases proliferation.  
*Id.*

Although the majority of lung cancer cases are attributable to cigarette smoking,  
25 most smokers do not develop lung cancer. Epidemiological evidence has suggested that susceptibility to lung cancer may be inherited in a Mendelian fashion, and thus have an inherited genetic component. Bailey-Wilson, *supra*. Thus, it is thought that certain allelic variants at some genetic loci may affect susceptibility to lung cancer. *Id.* One way to identify which allelic variants are likely to be involved in lung cancer susceptibility, as  
30 well as susceptibility to other diseases, is to look at allelic variants of genes that are highly expressed in lung.

The lung is susceptible to a number of other debilitating diseases as well, including, without limitation, emphysema, pneumonia, cystic fibrosis and asthma. See Stockley (ed.), Molecular Biology of the Lung, Volume I: Emphysema and Infection, Birkhauser Verlag (1999), hereafter Stockley I, and Stockley (ed.), Molecular Biology of the Lung, Volume II: Asthma and Cancer, Birkhauser Verlag (1999), hereafter Stockley II. The cause of many these disorders is still not well understood and there are few, if any, good treatment options for many of these noncancerous lung disorders. Thus, there also remains a need for understanding of various noncancerous lung disorders and for identify treatments for these diseases.

10       The development and differentiation of the lung tissue during embryonic development is also very important. All of the epithelial cells of the respiratory tract, including those of the lung and bronchi, are derived from the primitive endodermal cells that line the embryonic outpouching. See Yesner, *supra*. During embryonic development, multipotent endodermal stem cells differentiate into many different types  
15 of specialized cells, which include ciliated cells for moving inhaled particles, goblet cells for producing mucus, Kulchitsky's cells for endocrine function, and Clara cells and type II pneumocytes for secreting surfactant protein. *Id.* Improper development and differentiation may cause respiratory disorders and distress in infants, particularly in premature infants, whose lungs cannot produce sufficient surfactant when they are born.  
20 Further, some lung cancer cells, particularly small cell carcinomas, appear multipotent, and can spontaneously differentiate into a number of cell types, including small cell carcinoma, adenocarcinoma and squamous cell carcinoma. *Id.* Thus, a better understanding of lung development and differentiation may help facilitate understanding of lung cancer initiation and progression.

25       Accordingly, there is a great need for more sensitive and accurate methods for predicting whether a person is likely to develop lung cancer, for diagnosing lung cancer, for monitoring the progression of the disease, for staging the lung cancer, for determining whether the lung cancer has metastasized and for imaging the lung cancer. There is also a need for better treatment of lung cancer. There is also a great need for diagnosing and  
30 treating noncancerous lung disorders such as emphysema, pneumonia, lung infection, pulmonary fibrosis, cystic fibrosis and asthma. There is also a need for compositions and methods of using compositions that are capable of identifying lung tissue for forensic

purposes and for determining whether a particular cell or tissue exhibits lung-specific characteristics.

#### SUMMARY OF THE INVENTION

5           The present invention solves these and other needs in the art by providing nucleic acid molecules and polypeptides as well as antibodies, agonists and antagonists, thereto that may be used to identify, diagnose, monitor, stage, image and treat lung cancer and non-cancerous disease states in lung; identify and monitor lung tissue; and identify and design agonists and antagonists of polypeptides of the invention. The invention also  
10   provides gene therapy, methods for producing transgenic animals and cells, and methods for producing engineered lung tissue for treatment and research.

          Accordingly, one object of the invention is to provide nucleic acid molecules that are specific to lung cells, lung tissue and/or the lung organ. These lung specific nucleic acids (LSNAs) may be a naturally-occurring cDNA, genomic DNA, RNA, or a fragment  
15   of one of these nucleic acids, or may be a non-naturally-occurring nucleic acid molecule. If the LSNA is genomic DNA, then the LSNA is a lung specific gene (LSG). In a preferred embodiment, the nucleic acid molecule encodes a polypeptide that is specific to lung. In a more preferred embodiment, the nucleic acid molecule encodes a polypeptide that comprises an amino acid sequence of SEQ ID NO: 143 through 277. In another  
20   highly preferred embodiment, the nucleic acid molecule comprises a nucleic acid sequence of SEQ ID NO: 1 through 142. By nucleic acid molecule, it is also meant to be inclusive of sequences that selectively hybridize or exhibit substantial sequence similarity to a nucleic acid molecule encoding an LSP, or that selectively hybridize or exhibit substantial sequence similarity to an LSNA, as well as allelic variants of a nucleic  
25   acid molecule encoding an LSP, and allelic variants of an LSNA. Nucleic acid molecules comprising a part of a nucleic acid sequence that encodes an LSP or that comprises a part of a nucleic acid sequence of an LSNA are also provided.

          A related object of the present invention is to provide a nucleic acid molecule comprising one or more expression control sequences controlling the transcription and/or  
30   translation of all or a part of an LSNA. In a preferred embodiment, the nucleic acid molecule comprises one or more expression control sequences controlling the

transcription and/or translation of a nucleic acid molecule that encodes all or a fragment of an LSP.

Another object of the invention is to provide vectors and/or host cells comprising a nucleic acid molecule of the instant invention. In a preferred embodiment, the nucleic acid molecule encodes all or a fragment of an LSP. In another preferred embodiment, the nucleic acid molecule comprises all or a part of an LSNA.

Another object of the invention is to provide methods for using the vectors and host cells comprising a nucleic acid molecule of the instant invention to recombinantly produce polypeptides of the invention.

Another object of the invention is to provide a polypeptide encoded by a nucleic acid molecule of the invention. In a preferred embodiment, the polypeptide is an LSP. The polypeptide may comprise either a fragment or a full-length protein as well as a mutant protein (mutin), fusion protein, homologous protein or a polypeptide encoded by an allelic variant of an LSP.

Another object of the invention is to provide an antibody that specifically binds to a polypeptide of the instant invention..

Another object of the invention is to provide agonists and antagonists of the nucleic acid molecules and polypeptides of the instant invention.

Another object of the invention is to provide methods for using the nucleic acid molecules to detect or amplify nucleic acid molecules that have similar or identical nucleic acid sequences compared to the nucleic acid molecules described herein. In a preferred embodiment, the invention provides methods of using the nucleic acid molecules of the invention for identifying, diagnosing, monitoring, staging, imaging and treating lung cancer and non-cancerous disease states in lung. In another preferred embodiment, the invention provides methods of using the nucleic acid molecules of the invention for identifying and/or monitoring lung tissue. The nucleic acid molecules of the instant invention may also be used in gene therapy, for producing transgenic animals and cells, and for producing engineered lung tissue for treatment and research.

The polypeptides and/or antibodies of the instant invention may also be used to identify, diagnose, monitor, stage, image and treat lung cancer and non-cancerous disease states in lung. The invention provides methods of using the polypeptides of the invention to identify and/or monitor lung tissue, and to produce engineered lung tissue.

The agonists and antagonists of the instant invention may be used to treat lung cancer and non-cancerous disease states in lung and to produce engineered lung tissue.

Yet another object of the invention is to provide a computer readable means of storing the nucleic acid and amino acid sequences of the invention. The records of the computer readable means can be accessed for reading and displaying of sequences for  
5 comparison, alignment and ordering of the sequences of the invention to other sequences.

## DETAILED DESCRIPTION OF THE INVENTION

### Definitions and General Techniques

Unless otherwise defined herein, scientific and technical terms used in connection  
10 with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Generally, nomenclatures used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, genetics and protein and nucleic acid  
15 chemistry and hybridization described herein are those well-known and commonly used in the art. The methods and techniques of the present invention are generally performed according to conventional methods well-known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. *See, e.g.,* Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press (1989) and  
20 Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 3d ed., Cold Spring Harbor Press (2001); Ausubel *et al.*, Current Protocols in Molecular Biology, Greene Publishing Associates (1992, and Supplements to 2000); Ausubel *et al.*, Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular  
25 Biology – 4<sup>th</sup> Ed., Wiley & Sons (1999); Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1990); and Harlow and Lane, Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1999); each of which is incorporated herein by reference in its entirety.

Enzymatic reactions and purification techniques are performed according to  
30 manufacturer's specifications, as commonly accomplished in the art or as described herein. The nomenclatures used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and

pharmaceutical chemistry described herein are those well-known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.

The following terms, unless otherwise indicated, shall be understood to have the following meanings:

A "nucleic acid molecule" of this invention refers to a polymeric form of nucleotides and includes both sense and antisense strands of RNA, cDNA, genomic DNA, and synthetic forms and mixed polymers of the above. A nucleotide refers to a ribonucleotide, deoxynucleotide or a modified form of either type of nucleotide. A "nucleic acid molecule" as used herein is synonymous with "nucleic acid" and "polynucleotide." The term "nucleic acid molecule" usually refers to a molecule of at least 10 bases in length, unless otherwise specified. The term includes single- and double-stranded forms of DNA. In addition, a polynucleotide may include either or both naturally-occurring and modified nucleotides linked together by naturally-occurring and/or non-naturally occurring nucleotide linkages.

The nucleic acid molecules may be modified chemically or biochemically or may contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those of skill in the art. Such modifications include, for example, labels, methylation, substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as uncharged linkages (*e.g.*, methyl phosphonates, phosphotriesters, phosphoramidates, carbamates, etc.), charged linkages (*e.g.*, phosphorothioates, phosphorodithioates, etc.), pendent moieties (*e.g.*, polypeptides), intercalators (*e.g.*, acridine, psoralen, etc.), chelators, alkylators, and modified linkages (*e.g.*, alpha anomeric nucleic acids, etc.) The term "nucleic acid molecule" also includes any topological conformation, including single-stranded, double-stranded, partially duplexed, triplexed, hairpinned, circular and padlocked conformations. Also included are synthetic molecules that mimic polynucleotides in their ability to bind to a designated sequence via hydrogen bonding and other chemical interactions. Such molecules are known in the art and include, for example, those in which peptide linkages substitute for phosphate linkages in the backbone of the molecule.

A "gene" is defined as a nucleic acid molecule that comprises a nucleic acid sequence that encodes a polypeptide and the expression control sequences that surround

the nucleic acid sequence that encodes the polypeptide. For instance, a gene may comprise a promoter, one or more enhancers, a nucleic acid sequence that encodes a polypeptide, downstream regulatory sequences and, possibly, other nucleic acid sequences involved in regulation of the expression of an RNA. As is well-known in the art, eukaryotic genes usually contain both exons and introns. The term "exon" refers to a nucleic acid sequence found in genomic DNA that is bioinformatically predicted and/or experimentally confirmed to contribute a contiguous sequence to a mature mRNA transcript. The term "intron" refers to a nucleic acid sequence found in genomic DNA that is predicted and/or confirmed to not contribute to a mature mRNA transcript, but rather to be "spliced out" during processing of the transcript.

A nucleic acid molecule or polypeptide is "derived" from a particular species if the nucleic acid molecule or polypeptide has been isolated from the particular species, or if the nucleic acid molecule or polypeptide is homologous to a nucleic acid molecule or polypeptide isolated from a particular species.

An "isolated" or "substantially pure" nucleic acid or polynucleotide (e.g., an RNA, DNA or a mixed polymer) is one which is substantially separated from other cellular components that naturally accompany the native polynucleotide in its natural host cell, e.g., ribosomes, polymerases, or genomic sequences with which it is naturally associated. The term embraces a nucleic acid or polynucleotide that (1) has been removed from its naturally occurring environment, (2) is not associated with all or a portion of a polynucleotide in which the "isolated polynucleotide" is found in nature, (3) is operatively linked to a polynucleotide which it is not linked to in nature, (4) does not occur in nature as part of a larger sequence or (5) includes nucleotides or internucleoside bonds that are not found in nature. The term "isolated" or "substantially pure" also can be used in reference to recombinant or cloned DNA isolates, chemically synthesized polynucleotide analogs, or polynucleotide analogs that are biologically synthesized by heterologous systems. The term "isolated nucleic acid molecule" includes nucleic acid molecules that are integrated into a host cell chromosome at a heterologous site, recombinant fusions of a native fragment to a heterologous sequence, recombinant vectors present as episomes or as integrated into a host cell chromosome.

A "part" of a nucleic acid molecule refers to a nucleic acid molecule that comprises a partial contiguous sequence of at least 10 bases of the reference nucleic acid



molecule. Preferably, a part comprises at least 15 to 20 bases of a reference nucleic acid molecule. In theory, a nucleic acid sequence of 17 nucleotides is of sufficient length to occur at random less frequently than once in the three gigabase human genome, and thus to provide a nucleic acid probe that can uniquely identify the reference sequence in a nucleic acid mixture of genomic complexity. A preferred part is one that comprises a nucleic acid sequence that can encode at least 6 contiguous amino acid sequences (fragments of at least 18 nucleotides) because they are useful in directing the expression or synthesis of peptides that are useful in mapping the epitopes of the polypeptide encoded by the reference nucleic acid. See, e.g., Geysen *et al.*, *Proc. Natl. Acad. Sci. USA* 81:3998-4002 (1984); and United States Patent Nos. 4,708,871 and 5,595,915, the disclosures of which are incorporated herein by reference in their entireties. A part may also comprise at least 25, 30, 35 or 40 nucleotides of a reference nucleic acid molecule, or at least 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400 or 500 nucleotides of a reference nucleic acid molecule. A part of a nucleic acid molecule may comprise no other nucleic acid sequences. Alternatively, a part of a nucleic acid may comprise other nucleic acid sequences from other nucleic acid molecules.

The term "oligonucleotide" refers to a nucleic acid molecule generally comprising a length of 200 bases or fewer. The term often refers to single-stranded deoxyribonucleotides, but it can refer as well to single- or double-stranded ribonucleotides, RNA:DNA hybrids and double-stranded DNAs, among others. Preferably, oligonucleotides are 10 to 60 bases in length and most preferably 12, 13, 14, 15, 16, 17, 18, 19 or 20 bases in length. Other preferred oligonucleotides are 25, 30, 35, 40, 45, 50, 55 or 60 bases in length. Oligonucleotides may be single-stranded, e.g. for use as probes or primers, or may be double-stranded, e.g. for use in the construction of a mutant gene. Oligonucleotides of the invention can be either sense or antisense oligonucleotides. An oligonucleotide can be derivatized or modified as discussed above for nucleic acid molecules.

Oligonucleotides, such as single-stranded DNA probe oligonucleotides, often are synthesized by chemical methods, such as those implemented on automated oligonucleotide synthesizers. However, oligonucleotides can be made by a variety of other methods, including *in vitro* recombinant DNA-mediated techniques and by expression of DNAs in cells and organisms. Initially, chemically synthesized DNAs

typically are obtained without a 5' phosphate. The 5' ends of such oligonucleotides are not substrates for phosphodiester bond formation by ligation reactions that employ DNA ligases typically used to form recombinant DNA molecules. Where ligation of such oligonucleotides is desired, a phosphate can be added by standard techniques, such as those that employ a kinase and ATP. The 3' end of a chemically synthesized oligonucleotide generally has a free hydroxyl group and, in the presence of a ligase, such as T4 DNA ligase, readily will form a phosphodiester bond with a 5' phosphate of another polynucleotide, such as another oligonucleotide. As is well-known, this reaction can be prevented selectively, where desired, by removing the 5' phosphates of the other polynucleotide(s) prior to ligation.

The term "naturally-occurring nucleotide" referred to herein includes naturally-occurring deoxyribonucleotides and ribonucleotides. The term "modified nucleotides" referred to herein includes nucleotides with modified or substituted sugar groups and the like. The term "nucleotide linkages" referred to herein includes nucleotides linkages such as phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoraniladate, phosphoroamidate, and the like. See e.g., LaPlanche *et al. Nucl. Acids Res.* 14:9081-9093 (1986); Stein *et al. Nucl. Acids Res.* 16:3209-3221 (1988); Zon *et al. Anti-Cancer Drug Design* 6:539-568 (1991); Zon *et al.*, in Eckstein (ed.) Oligonucleotides and Analogues: A Practical Approach, pp. 87-108, Oxford University Press (1991); United States Patent No. 5,151,510; Uhlmann and Peyman *Chemical Reviews* 90:543 (1990), the disclosures of which are hereby incorporated by reference.

Unless specified otherwise, the left hand end of a polynucleotide sequence in sense orientation is the 5' end and the right hand end of the sequence is the 3' end. In addition, the left hand direction of a polynucleotide sequence in sense orientation is referred to as the 5' direction, while the right hand direction of the polynucleotide sequence is referred to as the 3' direction. Further, unless otherwise indicated, each nucleotide sequence is set forth herein as a sequence of deoxyribonucleotides. It is intended, however, that the given sequence be interpreted as would be appropriate to the polynucleotide composition: for example, if the isolated nucleic acid is composed of RNA, the given sequence intends ribonucleotides, with uridine substituted for thymidine.

The term "allelic variant" refers to one of two or more alternative naturally-occurring forms of a gene, wherein each gene possesses a unique nucleotide sequence. In a preferred embodiment, different alleles of a given gene have similar or identical biological properties.

5       • The term "percent sequence identity" in the context of nucleic acid sequences refers to the residues in two sequences which are the same when aligned for maximum correspondence. The length of sequence identity comparison may be over a stretch of at least about nine nucleotides, usually at least about 20 nucleotides, more usually at least about 24 nucleotides, typically at least about 28 nucleotides, more typically at least about  
10 32 nucleotides, and preferably at least about 36 or more nucleotides. There are a number of different algorithms known in the art which can be used to measure nucleotide sequence identity. For instance, polynucleotide sequences can be compared using FASTA, Gap or Bestfit, which are programs in Wisconsin Package Version 10.0, Genetics Computer Group (GCG), Madison, Wisconsin. FASTA, which includes, *e.g.*,  
15 the programs FASTA2 and FASTA3, provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences (Pearson, *Methods Enzymol.* 183: 63-98 (1990); Pearson, *Methods Mol. Biol.* 132: 185-219 (2000); Pearson, *Methods Enzymol.* 266: 227-258 (1996); Pearson, *J. Mol. Biol.* 276: 71-84 (1998); herein incorporated by reference). Unless otherwise specified, default  
20 parameters for a particular program or algorithm are used. For instance, percent sequence identity between nucleic acid sequences can be determined using FASTA with its default parameters (a word size of 6 and the NOPAM factor for the scoring matrix) or using Gap with its default parameters as provided in GCG Version 6.1, herein incorporated by reference.

25       A reference to a nucleic acid sequence encompasses its complement unless otherwise specified. Thus, a reference to a nucleic acid molecule having a particular sequence should be understood to encompass its complementary strand, with its complementary sequence. The complementary strand is also useful, *e.g.*, for antisense therapy, hybridization probes and PCR primers.

30       In the molecular biology art, researchers use the terms "percent sequence identity", "percent sequence similarity" and "percent sequence homology"

interchangeably. In this application, these terms shall have the same meaning with respect to nucleic acid sequences only.

The term "substantial similarity" or "substantial sequence similarity," when referring to a nucleic acid or fragment thereof, indicates that, when optimally aligned with appropriate nucleotide insertions or deletions with another nucleic acid (or its complementary strand), there is nucleotide sequence identity in at least about 50%, more preferably 60% of the nucleotide bases, usually at least about 70%, more usually at least about 80%, preferably at least about 90%, and more preferably at least about 95-98% of the nucleotide bases, as measured by any well-known algorithm of sequence identity, such as FASTA, BLAST or Gap, as discussed above.

Alternatively, substantial similarity exists when a nucleic acid or fragment thereof hybridizes to another nucleic acid, to a strand of another nucleic acid, or to the complementary strand thereof, under selective hybridization conditions. Typically, selective hybridization will occur when there is at least about 55% sequence identity, preferably at least about 65%, more preferably at least about 75%, and most preferably at least about 90% sequence identity, over a stretch of at least about 14 nucleotides, more preferably at least 17 nucleotides, even more preferably at least 20, 25, 30, 35, 40, 50, 60, 70, 80, 90 or 100 nucleotides.

Nucleic acid hybridization will be affected by such conditions as salt concentration, temperature, solvents, the base composition of the hybridizing species, length of the complementary regions, and the number of nucleotide base mismatches between the hybridizing nucleic acids, as will be readily appreciated by those skilled in the art. "Stringent hybridization conditions" and "stringent wash conditions" in the context of nucleic acid hybridization experiments depend upon a number of different physical parameters. The most important parameters include temperature of hybridization, base composition of the nucleic acids, salt concentration and length of the nucleic acid. One having ordinary skill in the art knows how to vary these parameters to achieve a particular stringency of hybridization. In general, "stringent hybridization" is performed at about 25°C below the thermal melting point ( $T_m$ ) for the specific DNA hybrid under a particular set of conditions. "Stringent washing" is performed at temperatures about 5°C lower than the  $T_m$  for the specific DNA hybrid under a particular set of conditions. The  $T_m$  is the temperature at which 50% of the target sequence

hybridizes to a perfectly matched probe. See Sambrook (1989), *supra*, p. 9.51, hereby incorporated by reference.

The  $T_m$  for a particular DNA-DNA hybrid can be estimated by the formula:

$$T_m = 81.5^\circ\text{C} + 16.6 (\log_{10}[\text{Na}^+]) + 0.41 (\text{fraction G} + \text{C}) - 0.63 (\% \text{ formamide}) - (600/l)$$

5 where  $l$  is the length of the hybrid in base pairs.

The  $T_m$  for a particular RNA-RNA hybrid can be estimated by the formula:

$$T_m = 79.8^\circ\text{C} + 18.5 (\log_{10}[\text{Na}^+]) + 0.58 (\text{fraction G} + \text{C}) + 11.8 (\text{fraction G} + \text{C})^2 - 0.35 (\% \text{ formamide}) - (820/l).$$

The  $T_m$  for a particular RNA-DNA hybrid can be estimated by the formula:

$$10 \quad T_m = 79.8^\circ\text{C} + 18.5 (\log_{10}[\text{Na}^+]) + 0.58 (\text{fraction G} + \text{C}) + 11.8 (\text{fraction G} + \text{C})^2 - 0.50 (\% \text{ formamide}) - (820/l).$$

In general, the  $T_m$  decreases by 1-1.5°C for each 1% of mismatch between two nucleic acid sequences. Thus, one having ordinary skill in the art can alter hybridization and/or washing conditions to obtain sequences that have higher or lower degrees of  
15 sequence identity to the target nucleic acid. For instance, to obtain hybridizing nucleic acids that contain up to 10% mismatch from the target nucleic acid sequence, 10-15°C would be subtracted from the calculated  $T_m$  of a perfectly matched hybrid, and then the hybridization and washing temperatures adjusted accordingly. Probe sequences may also hybridize specifically to duplex DNA under certain conditions to form triplex or other  
20 higher order DNA complexes. The preparation of such probes and suitable hybridization conditions are well-known in the art.

An example of stringent hybridization conditions for hybridization of complementary nucleic acid sequences having more than 100 complementary residues on a filter in a Southern or Northern blot or for screening a library is 50% formamide/6X  
25 SSC at 42°C for at least ten hours and preferably overnight (approximately 16 hours). Another example of stringent hybridization conditions is 6X SSC at 68°C without formamide for at least ten hours and preferably overnight. An example of moderate stringency hybridization conditions is 6X SSC at 55°C without formamide for at least ten hours and preferably overnight. An example of low stringency hybridization conditions  
30 for hybridization of complementary nucleic acid sequences having more than 100 complementary residues on a filter in a Southern or Northern blot or for screening a library is 6X SSC at 42°C for at least ten hours. Hybridization conditions to identify

nucleic acid sequences that are similar but not identical can be identified by experimentally changing the hybridization temperature from 68°C to 42°C while keeping the salt concentration constant (6X SSC), or keeping the hybridization temperature and salt concentration constant (e.g. 42°C and 6X SSC) and varying the formamide concentration from 50% to 0%. Hybridization buffers may also include blocking agents to lower background. These agents are well-known in the art. *See* Sambrook *et al.* (1989), *supra*, pages 8.46 and 9.46-9.58, herein incorporated by reference. *See also* Ausubel (1992), *supra*, Ausubel (1999), *supra*, and Sambrook (2001), *supra*.

Wash conditions also can be altered to change stringency conditions. An example of stringent wash conditions is a 0.2x SSC wash at 65°C for 15 minutes (*see* Sambrook (1989), *supra*, for SSC buffer). Often the high stringency wash is preceded by a low stringency wash to remove excess probe. An exemplary medium stringency wash for duplex DNA of more than 100 base pairs is 1x SSC at 45°C for 15 minutes. An exemplary low stringency wash for such a duplex is 4x SSC at 40°C for 15 minutes. In general, signal-to-noise ratio of 2x or higher than that observed for an unrelated probe in the particular hybridization assay indicates detection of a specific hybridization.

As defined herein, nucleic acid molecules that do not hybridize to each other under stringent conditions are still substantially similar to one another if they encode polypeptides that are substantially identical to each other. This occurs, for example, when a nucleic acid molecule is created synthetically or recombinantly using high codon degeneracy as permitted by the redundancy of the genetic code.

Hybridization conditions for nucleic acid molecules that are shorter than 100 nucleotides in length (e.g., for oligonucleotide probes) may be calculated by the formula:  $T_m = 81.5^{\circ}\text{C} + 16.6(\log_{10}[\text{Na}^+]) + 0.41(\text{fraction G+C}) - (600/\text{N})$ , wherein N is change length and the  $[\text{Na}^+]$  is 1 M or less. *See* Sambrook (1989), *supra*, p. 11.46. For hybridization of probes shorter than 100 nucleotides, hybridization is usually performed under stringent conditions (5-10°C below the  $T_m$ ) using high concentrations (0.1-1.0 pmol/ml) of probe. *Id.* at p. 11.45. Determination of hybridization using mismatched probes, pools of degenerate probes or "guessmers," as well as hybridization solutions and methods for empirically determining hybridization conditions are well-known in the art. *See, e.g.*, Ausubel (1999), *supra*; Sambrook (1989), *supra*, pp. 11.45-11.57.

The term "digestion" or "digestion of DNA" refers to catalytic cleavage of the DNA with a restriction enzyme that acts only at certain sequences in the DNA. The various restriction enzymes referred to herein are commercially available and their reaction conditions, cofactors and other requirements for use are known and routine to the skilled artisan. For analytical purposes, typically, 1 µg of plasmid or DNA fragment is digested with about 2 units of enzyme in about 20 µl of reaction buffer. For the purpose of isolating DNA fragments for plasmid construction, typically 5 to 50 µg of DNA are digested with 20 to 250 units of enzyme in proportionately larger volumes. Appropriate buffers and substrate amounts for particular restriction enzymes are described in standard laboratory manuals, such as those referenced below, and they are specified by commercial suppliers. Incubation times of about 1 hour at 37°C are ordinarily used, but conditions may vary in accordance with standard procedures, the supplier's instructions and the particulars of the reaction. After digestion, reactions may be analyzed, and fragments may be purified by electrophoresis through an agarose or polyacrylamide gel, using well-known methods that are routine for those skilled in the art.

The term "ligation" refers to the process of forming phosphodiester bonds between two or more polynucleotides, which most often are double-stranded DNAs. Techniques for ligation are well-known to the art and protocols for ligation are described in standard laboratory manuals and references, such as, *e.g.*, Sambrook (1989), *supra*.

Genome-derived "single exon probes," are probes that comprise at least part of an exon ("reference exon") and can hybridize detectably under high stringency conditions to transcript-derived nucleic acids that include the reference exon but do not hybridize detectably under high stringency conditions to nucleic acids that lack the reference exon. Single exon probes typically further comprise, contiguous to a first end of the exon portion, a first intronic and/or intergenic sequence that is identically contiguous to the exon in the genome, and may contain a second intronic and/or intergenic sequence that is identically contiguous to the exon in the genome. The minimum length of genome-derived single exon probes is defined by the requirement that the exonic portion be of sufficient length to hybridize under high stringency conditions to transcript-derived nucleic acids, as discussed above. The maximum length of genome-derived single exon probes is defined by the requirement that the probes contain portions of no more than one

exon. The single exon probes may contain priming sequences not found in contiguity with the rest of the probe sequence in the genome, which priming sequences are useful for PCR and other amplification-based technologies.

The term "microarray" or "nucleic acid microarray" refers to a substrate-bound collection of plural nucleic acids, hybridization to each of the plurality of bound nucleic acids being separately detectable. The substrate can be solid or porous, planar or non-planar, unitary or distributed. Microarrays or nucleic acid microarrays include all the devices so called in Schena (ed.), DNA Microarrays: A Practical Approach (Practical Approach Series), Oxford University Press (1999); *Nature Genet.* 21(1)(suppl.):1 - 60 (1999); Schena (ed.), Microarray Biochip: Tools and Technology, Eaton Publishing Company/BioTechniques Books Division (2000). These microarrays include substrate-bound collections of plural nucleic acids in which the plurality of nucleic acids are disposed on a plurality of beads, rather than on a unitary planar substrate, as is described, *inter alia*, in Brenner *et al.*, *Proc. Natl. Acad. Sci. USA* 97(4):1665-1670 (2000).

The term "mutated" when applied to nucleic acid molecules means that nucleotides in the nucleic acid sequence of the nucleic acid molecule may be inserted, deleted or changed compared to a reference nucleic acid sequence. A single alteration may be made at a locus (a point mutation) or multiple nucleotides may be inserted, deleted or changed at a single locus. In addition, one or more alterations may be made at any number of loci within a nucleic acid sequence. In a preferred embodiment, the nucleic acid molecule comprises the wild type nucleic acid sequence encoding an LSP or is an LSNA. The nucleic acid molecule may be mutated by any method known in the art including those mutagenesis techniques described *infra*.

The term "error-prone PCR" refers to a process for performing PCR under conditions where the copying fidelity of the DNA polymerase is low, such that a high rate of point mutations is obtained along the entire length of the PCR product. *See, e.g.*, Leung *et al.*, *Technique* 1: 11-15 (1989) and Caldwell *et al.*, *PCR Methods Applic.* 2: 28-33 (1992).

The term "oligonucleotide-directed mutagenesis" refers to a process which enables the generation of site-specific mutations in any cloned DNA segment of interest. *See, e.g.*, Reidhaar-Olson *et al.*, *Science* 241: 53-57 (1988).



The term "assembly PCR" refers to a process which involves the assembly of a PCR product from a mixture of small DNA fragments. A large number of different PCR reactions occur in parallel in the same vial, with the products of one reaction priming the products of another reaction.

- 5       The term "sexual PCR mutagenesis" or "DNA shuffling" refers to a method of error-prone PCR coupled with forced homologous recombination between DNA molecules of different but highly related DNA sequence *in vitro*, caused by random fragmentation of the DNA molecule based on sequence similarity, followed by fixation of the crossover by primer extension in an error-prone PCR reaction. *See, e.g., Stemmer,*
- 10 *Proc. Natl. Acad. Sci. U.S.A.* 91: 10747-10751 (1994). DNA shuffling can be carried out between several related genes ("Family shuffling").

- The term "*in vivo* mutagenesis" refers to a process of generating random mutations in any cloned DNA of interest which involves the propagation of the DNA in a strain of bacteria such as *E. coli* that carries mutations in one or more of the DNA repair
- 15 pathways. These "mutator" strains have a higher random mutation rate than that of a wild-type parent. Propagating the DNA in a mutator strain will eventually generate random mutations within the DNA.

- The term "cassette mutagenesis" refers to any process for replacing a small region of a double-stranded DNA molecule with a synthetic oligonucleotide "cassette" that
- 20 differs from the native sequence. The oligonucleotide often contains completely and/or partially randomized native sequence.

- The term "recursive ensemble mutagenesis" refers to an algorithm for protein engineering (protein mutagenesis) developed to produce diverse populations of phenotypically related mutants whose members differ in amino acid sequence. This
- 25 method uses a feedback mechanism to control successive rounds of combinatorial cassette mutagenesis. *See, e.g., Arkin et al., Proc. Natl. Acad. Sci. U.S.A.* 89: 7811-7815 (1992).

- The term "exponential ensemble mutagenesis" refers to a process for generating combinatorial libraries with a high percentage of unique and functional mutants, wherein
- 30 small groups of residues are randomized in parallel to identify, at each altered position, amino acids which lead to functional proteins. *See, e.g., Delegrave et al., Biotechnology Research* 11: 1548-1552 (1993); Arnold, *Current Opinion in Biotechnology* 4: 450-455

(1993). Each of the references mentioned above are hereby incorporated by reference in its entirety.

“Operatively linked” expression control sequences refers to a linkage in which the expression control sequence is contiguous with the gene of interest to control the gene of interest, as well as expression control sequences that act in *trans* or at a distance to control the gene of interest.

The term “expression control sequence” as used herein refers to polynucleotide sequences which are necessary to affect the expression of coding sequences to which they are operatively linked. Expression control sequences are sequences which control the transcription, post-transcriptional events and translation of nucleic acid sequences. Expression control sequences include appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (*e.g.*, ribosome binding sites); sequences that enhance protein stability; and when desired, sequences that enhance protein secretion. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include the promoter, ribosomal binding site, and transcription termination sequence. The term “control sequences” is intended to include, at a minimum, all components whose presence is essential for expression, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences.

The term “vector,” as used herein, is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a “plasmid”, which refers to a circular double-stranded DNA loop into which additional DNA segments may be ligated. Other vectors include cosmids, bacterial artificial chromosomes (BAC) and yeast artificial chromosomes (YAC). Another type of vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome. Viral vectors that infect bacterial cells are referred to as bacteriophages. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication). Other vectors can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable

of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "recombinant expression vectors" (or simply, "expression vectors"). In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" may  
5 be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include other forms of expression vectors that serve equivalent functions.

The term "recombinant host cell" (or simply "host cell"), as used herein, is intended to refer to a cell into which an expression vector has been introduced. It should  
10 be understood that such terms are intended to refer not only to the particular subject cell but to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term "host cell" as used herein.

15 As used herein, the phrase "open reading frame" and the equivalent acronym "ORF" refer to that portion of a transcript-derived nucleic acid that can be translated in its entirety into a sequence of contiguous amino acids. As so defined, an ORF has length, measured in nucleotides, exactly divisible by 3. As so defined, an ORF need not encode the entirety of a natural protein.

20 As used herein, the phrase "ORF-encoded peptide" refers to the predicted or actual translation of an ORF.

As used herein, the phrase "degenerate variant" of a reference nucleic acid sequence intends all nucleic acid sequences that can be directly translated, using the standard genetic code, to provide an amino acid sequence identical to that translated from  
25 the reference nucleic acid sequence.

The term "polypeptide" encompasses both naturally-occurring and non-naturally-occurring proteins and polypeptides, polypeptide fragments and polypeptide mutants, derivatives and analogs. A polypeptide may be monomeric or polymeric. Further, a polypeptide may comprise a number of different modules within a single polypeptide  
30 each of which has one or more distinct activities. A preferred polypeptide in accordance with the invention comprises an LSP encoded by a nucleic acid molecule of the instant invention, as well as a fragment, mutant, analog and derivative thereof.

The term "isolated protein" or "isolated polypeptide" is a protein or polypeptide that by virtue of its origin or source of derivation (1) is not associated with naturally associated components that accompany it in its native state, (2) is free of other proteins from the same species (3) is expressed by a cell from a different species, or (4) does not occur in nature. Thus, a polypeptide that is chemically synthesized or synthesized in a cellular system different from the cell from which it naturally originates will be "isolated" from its naturally associated components. A polypeptide or protein may also be rendered substantially free of naturally associated components by isolation, using protein purification techniques well-known in the art.

10 A protein or polypeptide is "substantially pure," "substantially homogeneous" or "substantially purified" when at least about 60% to 75% of a sample exhibits a single species of polypeptide. The polypeptide or protein may be monomeric or multimeric. A substantially pure polypeptide or protein will typically comprise about 50%, 60%, 70%, 80% or 90% W/W of a protein sample, more usually about 95%, and preferably will be over 99% pure. Protein purity or homogeneity may be indicated by a number of means well-known in the art, such as polyacrylamide gel electrophoresis of a protein sample, followed by visualizing a single polypeptide band upon staining the gel with a stain well-known in the art. For certain purposes, higher resolution may be provided by using HPLC or other means well-known in the art for purification.

20 The term "polypeptide fragment" as used herein refers to a polypeptide of the instant invention that has an amino-terminal and/or carboxy-terminal deletion compared to a full-length polypeptide. In a preferred embodiment, the polypeptide fragment is a contiguous sequence in which the amino acid sequence of the fragment is identical to the corresponding positions in the naturally-occurring sequence. Fragments typically are at least 5, 6, 7, 8, 9 or 10 amino acids long, preferably at least 12, 14, 16 or 18 amino acids long, more preferably at least 20 amino acids long, more preferably at least 25, 30, 35, 40 or 45, amino acids, even more preferably at least 50 or 60 amino acids long, and even more preferably at least 70 amino acids long.

A "derivative" refers to polypeptides or fragments thereof that are substantially similar in primary structural sequence but which include, *e.g.*, *in vivo* or *in vitro* chemical and biochemical modifications that are not found in the native polypeptide. Such modifications include, for example, acetylation, acylation, ADP-ribosylation, amidation,

30

covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. Other modification include, *e.g.*, labeling with radionuclides, and various enzymatic modifications, as will be readily appreciated by those skilled in the art. A variety of methods for labeling polypeptides and of substituents or labels useful for such purposes are well-known in the art, and include radioactive isotopes such as  $^{125}\text{I}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ , and  $^3\text{H}$ , ligands which bind to labeled antiligands (*e.g.*, antibodies), fluorophores, chemiluminescent agents, enzymes, and antiligands which can serve as specific binding pair members for a labeled ligand. The choice of label depends on the sensitivity required, ease of conjugation with the primer, stability requirements, and available instrumentation. Methods for labeling polypeptides are well-known in the art. See Ausubel (1992), *supra*; Ausubel (1999), *supra*, herein incorporated by reference.

The term "fusion protein" refers to polypeptides of the instant invention comprising polypeptides or fragments coupled to heterologous amino acid sequences. Fusion proteins are useful because they can be constructed to contain two or more desired functional elements from two or more different proteins. A fusion protein comprises at least 10 contiguous amino acids from a polypeptide of interest, more preferably at least 20 or 30 amino acids, even more preferably at least 40, 50 or 60 amino acids, yet more preferably at least 75, 100 or 125 amino acids. Fusion proteins can be produced recombinantly by constructing a nucleic acid sequence which encodes the polypeptide or a fragment thereof in frame with a nucleic acid sequence encoding a different protein or peptide and then expressing the fusion protein. Alternatively, a fusion protein can be produced chemically by crosslinking the polypeptide or a fragment thereof to another protein.

The term "analog" refers to both polypeptide analogs and non-peptide analogs. The term "polypeptide analog" as used herein refers to a polypeptide of the instant invention that is comprised of a segment of at least 25 amino acids that has substantial identity to a portion of an amino acid sequence but which contains non-natural amino acids or non-natural inter-residue bonds. In a preferred embodiment, the analog has the same or similar biological activity as the native polypeptide. Typically, polypeptide analogs comprise a conservative amino acid substitution (or insertion or deletion) with respect to the naturally-occurring sequence. Analogs typically are at least 20 amino acids long, preferably at least 50 amino acids long or longer, and can often be as long as a full-length naturally-occurring polypeptide.

The term "non-peptide analog" refers to a compound with properties that are analogous to those of a reference polypeptide of the instant invention. A non-peptide compound may also be termed a "peptide mimetic" or a "peptidomimetic." Such compounds are often developed with the aid of computerized molecular modeling. Peptide mimetics that are structurally similar to useful peptides may be used to produce an equivalent effect. Generally, peptidomimetics are structurally similar to a paradigm polypeptide (*i.e.*, a polypeptide that has a desired biochemical property or pharmacological activity), but have one or more peptide linkages optionally replaced by a linkage selected from the group consisting of:  $-\text{CH}_2\text{NH}-$ ,  $-\text{CH}_2\text{S}-$ ,  $-\text{CH}_2-\text{CH}_2-$ ,  $-\text{CH}=\text{CH}-$  (cis and trans),  $-\text{COCH}_2-$ ,  $-\text{CH}(\text{OH})\text{CH}_2-$ , and  $-\text{CH}_2\text{SO}-$ , by methods well-known in the art. Systematic substitution of one or more amino acids of a consensus sequence with a D-amino acid of the same type (*e.g.*, D-lysine in place of L-lysine) may also be used to generate more stable peptides. In addition, constrained peptides comprising a consensus sequence or a substantially identical consensus sequence variation may be generated by methods known in the art (Rizo *et al.*, *Ann. Rev. Biochem.* 61:387-418 (1992), incorporated herein by reference). For example, one may add internal cysteine residues capable of forming intramolecular disulfide bridges which cyclize the peptide.

A "polypeptide mutant" or "mutein" refers to a polypeptide of the instant invention whose sequence contains substitutions, insertions or deletions of one or more amino acids compared to the amino acid sequence of a native or wild-type protein. A mutein may have one or more amino acid point substitutions, in which a single amino

acid at a position has been changed to another amino acid, one or more insertions and/or deletions, in which one or more amino acids are inserted or deleted, respectively, in the sequence of the naturally-occurring protein, and/or truncations of the amino acid sequence at either or both the amino or carboxy termini. Further, a mutein may have the same or different biological activity as the naturally-occurring protein. For instance, a mutein may have an increased or decreased biological activity. A mutein has at least 50% sequence similarity to the wild type protein, preferred is 60% sequence similarity, more preferred is 70% sequence similarity. Even more preferred are muteins having 80%, 85% or 90% sequence similarity to the wild type protein. In an even more preferred embodiment, a mutein exhibits 95% sequence identity, even more preferably 97%, even more preferably 98% and even more preferably 99%. Sequence similarity may be measured by any common sequence analysis algorithm, such as Gap or Bestfit.

Preferred amino acid substitutions are those which: (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for forming protein complexes, (4) alter binding affinity or enzymatic activity, and (5) confer or modify other physicochemical or functional properties of such analogs. For example, single or multiple amino acid substitutions (preferably conservative amino acid substitutions) may be made in the naturally-occurring sequence (preferably in the portion of the polypeptide outside the domain(s) forming intermolecular contacts. In a preferred embodiment, the amino acid substitutions are moderately conservative substitutions or conservative substitutions. In a more preferred embodiment, the amino acid substitutions are conservative substitutions. A conservative amino acid substitution should not substantially change the structural characteristics of the parent sequence (e.g., a replacement amino acid should not tend to disrupt a helix that occurs in the parent sequence, or disrupt other types of secondary structure that characterizes the parent sequence). Examples of art-recognized polypeptide secondary and tertiary structures are described in Creighton (ed.), Proteins, Structures and Molecular Principles, W. H. Freeman and Company (1984); Branden *et al.* (ed.), Introduction to Protein Structure, Garland Publishing (1991); Thornton *et al.*, *Nature* 354:105-106 (1991), each of which are incorporated herein by reference.

As used herein, the twenty conventional amino acids and their abbreviations follow conventional usage. See Golub *et al.* (eds.), Immunology - A Synthesis 2<sup>nd</sup> Ed.,

Sinauer Associates (1991), which is incorporated herein by reference. Stereoisomers (e.g., D-amino acids) of the twenty conventional amino acids, unnatural amino acids such as -, -disubstituted amino acids, N-alkyl amino acids, and other unconventional amino acids may also be suitable components for polypeptides of the present invention.

- 5 Examples of unconventional amino acids include: 4-hydroxyproline,  $\gamma$ -carboxyglutamate, -N,N,N-trimethyllysine, -N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, s-N-methylarginine, and other similar amino acids and imino acids (e.g., 4-hydroxyproline). In the polypeptide notation used herein, the lefthand direction is the amino terminal direction and the right hand
- 10 direction is the carboxy-terminal direction, in accordance with standard usage and convention.

- A protein has "homology" or is "homologous" to a protein from another organism if the encoded amino acid sequence of the protein has a similar sequence to the encoded amino acid sequence of a protein of a different organism and has a similar biological
- 15 activity or function. Alternatively, a protein may have homology or be homologous to another protein if the two proteins have similar amino acid sequences and have similar biological activities or functions. Although two proteins are said to be "homologous," this does not imply that there is necessarily an evolutionary relationship between the proteins. Instead, the term "homologous" is defined to mean that the two proteins have
- 20 similar amino acid sequences and similar biological activities or functions. In a preferred embodiment, a homologous protein is one that exhibits 50% sequence similarity to the wild type protein, preferred is 60% sequence similarity, more preferred is 70% sequence similarity. Even more preferred are homologous proteins that exhibit 80%, 85% or 90% sequence similarity to the wild type protein. In a yet more preferred embodiment, a
- 25 homologous protein exhibits 95%, 97%, 98% or 99% sequence similarity.

When "sequence similarity" is used in reference to proteins or peptides, it is recognized that residue positions that are not identical often differ by conservative amino acid substitutions. In a preferred embodiment, a polypeptide that has "sequence similarity" comprises conservative or moderately conservative amino acid substitutions.

- 30 A "conservative amino acid substitution" is one in which an amino acid residue is substituted by another amino acid residue having a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). In general, a conservative amino



acid substitution will not substantially change the functional properties of a protein. In cases where two or more amino acid sequences differ from each other by conservative substitutions, the percent sequence identity or degree of similarity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this  
5 adjustment are well-known to those of skill in the art. See, e.g., Pearson, *Methods Mol. Biol.* 24: 307-31 (1994), herein incorporated by reference.

For instance, the following six groups each contain amino acids that are conservative substitutions for one another:

- 1) Serine (S), Threonine (T);
- 10 2) Aspartic Acid (D), Glutamic Acid (E);
- 3) Asparagine (N), Glutamine (Q);
- 4) Arginine (R), Lysine (K);
- 5) Isoleucine (I), Leucine (L), Methionine (M), Alanine (A), Valine (V), and
- 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

15 Alternatively, a conservative replacement is any change having a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet *et al.*, *Science* 256: 1443-45 (1992), herein incorporated by reference. A "moderately conservative" replacement is any change having a nonnegative value in the PAM250 log-likelihood matrix.

Sequence similarity for polypeptides, which is also referred to as sequence  
20 identity, is typically measured using sequence analysis software. Protein analysis software matches similar sequences using measures of similarity assigned to various substitutions, deletions and other modifications, including conservative amino acid substitutions. For instance, GCG contains programs such as "Gap" and "Bestfit" which can be used with default parameters to determine sequence homology or sequence  
25 identity between closely related polypeptides, such as homologous polypeptides from different species of organisms or between a wild type protein and a mutin thereof. See, e.g., GCG Version 6.1. Other programs include FASTA, discussed *supra*.

A preferred algorithm when comparing a sequence of the invention to a database containing a large number of sequences from different organisms is the computer  
30 program BLAST, especially blastp or tblastn. See, e.g., Altschul *et al.*, *J. Mol. Biol.* 215: 403-410 (1990); Altschul *et al.*, *Nucleic Acids Res.* 25:3389-402 (1997); herein incorporated by reference. Preferred parameters for blastp are:

-28-

Expectation value: 10 (default)  
Filter: seg (default)  
Cost to open a gap: 11 (default)  
Cost to extend a gap: 1 (default)  
5 Max. alignments: 100 (default)  
Word size: 11 (default)  
No. of descriptions: 100 (default)  
Penalty Matrix: BLOSUM62

The length of polypeptide sequences compared for homology will generally be at  
10 least about 16 amino acid residues, usually at least about 20 residues, more usually at  
least about 24 residues, typically at least about 28 residues, and preferably more than  
about 35 residues. When searching a database containing sequences from a large number  
of different organisms, it is preferable to compare amino acid sequences.

Database searching using amino acid sequences can be measured by algorithms  
15 other than blastp are known in the art. For instance, polypeptide sequences can be  
compared using FASTA, a program in GCG Version 6.1. FASTA (*e.g.*, FASTA2 and  
FASTA3) provides alignments and percent sequence identity of the regions of the best  
overlap between the query and search sequences (Pearson (1990), *supra*; Pearson (2000),  
*supra*. For example, percent sequence identity between amino acid sequences can be  
20 determined using FASTA with its default or recommended parameters (a word size of 2  
and the PAM250 scoring matrix), as provided in GCG Version 6.1, herein incorporated  
by reference.

An "antibody" refers to an intact immunoglobulin, or to an antigen-binding  
portion thereof that competes with the intact antibody for specific binding to a molecular  
25 species, *e.g.*, a polypeptide of the instant invention. Antigen-binding portions may be  
produced by recombinant DNA techniques or by enzymatic or chemical cleavage of  
intact antibodies. Antigen-binding portions include, *inter alia*, Fab, Fab', F(ab')<sub>2</sub>, Fv,  
dAb, and complementarity determining region (CDR) fragments, single-chain antibodies  
(scFv), chimeric antibodies, diabodies and polypeptides that contain at least a portion of  
30 an immunoglobulin that is sufficient to confer specific antigen binding to the  
polypeptide. An Fab fragment is a monovalent fragment consisting of the VL, VH, CL  
and CH1 domains; an F(ab')<sub>2</sub> fragment is a bivalent fragment comprising two Fab

fragments linked by a disulfide bridge at the hinge region; an Fd fragment consists of the VH and CH1 domains; an Fv fragment consists of the VL and VH domains of a single arm of an antibody; and a dAb fragment consists of a VH domain. *See, e.g., Ward et al., Nature* 341: 544-546 (1989).

5 By "bind specifically" and "specific binding" is here intended the ability of the antibody to bind to a first molecular species in preference to binding to other molecular species with which the antibody and first molecular species are admixed. An antibody is said specifically to "recognize" a first molecular species when it can bind specifically to that first molecular species.

10 A single-chain antibody (scFv) is an antibody in which a VL and VH region are paired to form a monovalent molecule via a synthetic linker that enables them to be made as a single protein chain. *See, e.g., Bird et al., Science* 242: 423-426 (1988); Huston *et al., Proc. Natl. Acad. Sci. USA* 85: 5879-5883 (1988). Diabodies are bivalent, bispecific antibodies in which VH and VL domains are expressed on a single polypeptide chain, but  
15 using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen binding sites. *See e.g., Holliger et al., Proc. Natl. Acad. Sci. USA* 90: 6444-6448 (1993); Poljak *et al., Structure* 2: 1121-1123 (1994). One or more CDRs may be incorporated into a molecule either covalently or noncovalently to make it  
20 an immunoadhesin. An immunoadhesin may incorporate the CDR(s) as part of a larger polypeptide chain, may covalently link the CDR(s) to another polypeptide chain, or may incorporate the CDR(s) noncovalently. The CDRs permit the immunoadhesin to specifically bind to a particular antigen of interest. A chimeric antibody is an antibody that contains one or more regions from one antibody and one or more regions from one  
25 or more other antibodies.

An antibody may have one or more binding sites. If there is more than one binding site, the binding sites may be identical to one another or may be different. For instance, a naturally-occurring immunoglobulin has two identical binding sites, a single-chain antibody or Fab fragment has one binding site, while a "bispecific" or  
30 "bifunctional" antibody has two different binding sites.

An "isolated antibody" is an antibody that (1) is not associated with naturally-associated components, including other naturally-associated antibodies, that accompany

it in its native state, (2) is free of other proteins from the same species, (3) is expressed by a cell from a different species, or (4) does not occur in nature. It is known that purified proteins, including purified antibodies, may be stabilized with non-naturally-associated components. The non-naturally-associated component may be a protein, such as albumin (*e.g.*, BSA) or a chemical such as polyethylene glycol (PEG).

A "neutralizing antibody" or "an inhibitory antibody" is an antibody that inhibits the activity of a polypeptide or blocks the binding of a polypeptide to a ligand that normally binds to it. An "activating antibody" is an antibody that increases the activity of a polypeptide.

10 The term "epitope" includes any protein determinant capable of specifically binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three-dimensional structural characteristics, as well as specific charge characteristics. An antibody is said to specifically bind an antigen when  
15 the dissociation constant is less than  $1\ \mu\text{M}$ , preferably less than  $100\ \text{nM}$  and most preferably less than  $10\ \text{nM}$ .

The term "patient" as used herein includes human and veterinary subjects.

Throughout this specification and claims, the word "comprise," or variations such as "comprises" or "comprising," will be understood to imply the inclusion of a stated  
20 integer or group of integers but not the exclusion of any other integer or group of integers.

The term "lung specific" refers to a nucleic acid molecule or polypeptide that is expressed predominantly in the lung as compared to other tissues in the body. In a preferred embodiment, a "lung specific" nucleic acid molecule or polypeptide is  
25 expressed at a level that is 5-fold higher than any other tissue in the body. In a more preferred embodiment, the "lung specific" nucleic acid molecule or polypeptide is expressed at a level that is 10-fold higher than any other tissue in the body, more preferably at least 15-fold, 20-fold, 25-fold, 50-fold or 100-fold higher than any other tissue in the body. Nucleic acid molecule levels may be measured by nucleic acid  
30 hybridization, such as Northern blot hybridization, or quantitative PCR. Polypeptide levels may be measured by any method known to accurately quantitate protein levels, such as Western blot analysis.

Nucleic Acid Molecules, Regulatory Sequences, Vectors, Host Cells and Recombinant Methods of Making Polypeptides

*Nucleic Acid Molecules*

5           One aspect of the invention provides isolated nucleic acid molecules that are specific to the lung or to lung cells or tissue or that are derived from such nucleic acid molecules. These isolated lung specific nucleic acids (LSNAs) may comprise a cDNA, a genomic DNA, RNA, or a fragment of one of these nucleic acids, or may be a non-naturally-occurring nucleic acid molecule. In a preferred embodiment, the nucleic acid  
10 molecule encodes a polypeptide that is specific to lung, a lung-specific polypeptide (LSP). In a more preferred embodiment, the nucleic acid molecule encodes a polypeptide that comprises an amino acid sequence of SEQ ID NO: 143 through 277. In another highly preferred embodiment, the nucleic acid molecule comprises a nucleic acid sequence of SEQ ID NO: 1 through 142.

15           An LSNA may be derived from a human or from another animal. In a preferred embodiment, the LSNA is derived from a human or other mammal. In a more preferred embodiment, the LSNA is derived from a human or other primate. In an even more preferred embodiment, the LSNA is derived from a human.

          By "nucleic acid molecule" for purposes of the present invention, it is also meant  
20 to be inclusive of nucleic acid sequences that selectively hybridize to a nucleic acid molecule encoding an LSNA or a complement thereof. The hybridizing nucleic acid molecule may or may not encode a polypeptide or may not encode an LSP. However, in a preferred embodiment, the hybridizing nucleic acid molecule encodes an LSP. In a more preferred embodiment, the invention provides a nucleic acid molecule that  
25 selectively hybridizes to a nucleic acid molecule that encodes a polypeptide comprising an amino acid sequence of SEQ ID NO: 143 through 277. In an even more preferred embodiment, the invention provides a nucleic acid molecule that selectively hybridizes to a nucleic acid molecule comprising the nucleic acid sequence of SEQ ID NO: 1 through 142.

30           In a preferred embodiment, the nucleic acid molecule selectively hybridizes to a nucleic acid molecule encoding an LSP under low stringency conditions. In a more preferred embodiment, the nucleic acid molecule selectively hybridizes to a nucleic acid molecule encoding an LSP under moderate stringency conditions. In a more preferred

embodiment, the nucleic acid molecule selectively hybridizes to a nucleic acid molecule encoding an LSP under high stringency conditions. In an even more preferred embodiment, the nucleic acid molecule hybridizes under low, moderate or high stringency conditions to a nucleic acid molecule encoding a polypeptide comprising an amino acid sequence of SEQ ID NO: 143 through 277. In a yet more preferred embodiment, the nucleic acid molecule hybridizes under low, moderate or high stringency conditions to a nucleic acid molecule comprising a nucleic acid sequence selected from SEQ ID NO: 1 through 142. In a preferred embodiment of the invention, the hybridizing nucleic acid molecule may be used to express recombinantly a polypeptide of the invention.

By "nucleic acid molecule" as used herein it is also meant to be inclusive of sequences that exhibits substantial sequence similarity to a nucleic acid encoding an LSP or a complement of the encoding nucleic acid molecule. In a preferred embodiment, the nucleic acid molecule exhibits substantial sequence similarity to a nucleic acid molecule encoding human LSP. In a more preferred embodiment, the nucleic acid molecule exhibits substantial sequence similarity to a nucleic acid molecule encoding a polypeptide having an amino acid sequence of SEQ ID NO: 143 through 277. In a preferred embodiment, the similar nucleic acid molecule is one that has at least 60% sequence identity with a nucleic acid molecule encoding an LSP, such as a polypeptide having an amino acid sequence of SEQ ID NO: 143 through 277, more preferably at least 70%, even more preferably at least 80% and even more preferably at least 85%. In a more preferred embodiment, the similar nucleic acid molecule is one that has at least 90% sequence identity with a nucleic acid molecule encoding an LSP, more preferably at least 95%, more preferably at least 97%, even more preferably at least 98%, and still more preferably at least 99%. In another highly preferred embodiment, the nucleic acid molecule is one that has at least 99.5%, 99.6%, 99.7%, 99.8% or 99.9% sequence identity with a nucleic acid molecule encoding an LSP.

In another preferred embodiment, the nucleic acid molecule exhibits substantial sequence similarity to an LSNA or its complement. In a more preferred embodiment, the nucleic acid molecule exhibits substantial sequence similarity to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1 through 142. In a preferred embodiment, the nucleic acid molecule is one that has at least 60% sequence identity

with an LSNA, such as one having a nucleic acid sequence of SEQ ID NO: 1 through 142, more preferably at least 70%, even more preferably at least 80% and even more preferably at least 85%. In a more preferred embodiment, the nucleic acid molecule is one that has at least 90% sequence identity with an LSNA, more preferably at least 95%,  
5 more preferably at least 97%, even more preferably at least 98%, and still more preferably at least 99%. In another highly preferred embodiment, the nucleic acid molecule is one that has at least 99.5%, 99.6%, 99.7%, 99.8% or 99.9% sequence identity with an LSNA.

A nucleic acid molecule that exhibits substantial sequence similarity may be one  
10 that exhibits sequence identity over its entire length to an LSNA or to a nucleic acid molecule encoding an LSP, or may be one that is similar over only a part of its length. In this case, the part is at least 50 nucleotides of the LSNA or the nucleic acid molecule encoding an LSP, preferably at least 100 nucleotides, more preferably at least 150 or 200 nucleotides, even more preferably at least 250 or 300 nucleotides, still more preferably at  
15 least 400 or 500 nucleotides.

The substantially similar nucleic acid molecule may be a naturally-occurring one that is derived from another species, especially one derived from another primate, wherein the similar nucleic acid molecule encodes an amino acid sequence that exhibits significant sequence identity to that of SEQ ID NO: 143 through 277 or demonstrates  
20 significant sequence identity to the nucleotide sequence of SEQ ID NO: 1 through 142. The similar nucleic acid molecule may also be a naturally-occurring nucleic acid molecule from a human, when the LSNA is a member of a gene family. The similar nucleic acid molecule may also be a naturally-occurring nucleic acid molecule derived from a non-primate, mammalian species, including without limitation, domesticated  
25 species, *e.g.*, dog, cat, mouse, rat, rabbit, hamster, cow, horse and pig; and wild animals, *e.g.*, monkey, fox, lions, tigers, bears, giraffes, zebras, etc. The substantially similar nucleic acid molecule may also be a naturally-occurring nucleic acid molecule derived from a non-mammalian species, such as birds or reptiles. The naturally-occurring substantially similar nucleic acid molecule may be isolated directly from humans or other  
30 species. In another embodiment, the substantially similar nucleic acid molecule may be one that is experimentally produced by random mutation of a nucleic acid molecule. In another embodiment, the substantially similar nucleic acid molecule may be one that is

experimentally produced by directed mutation of an LSNA. Further, the substantially similar nucleic acid molecule may or may not be an LSNA. However, in a preferred embodiment, the substantially similar nucleic acid molecule is an LSNA.

By "nucleic acid molecule" it is also meant to be inclusive of allelic variants of an LSNA or a nucleic acid encoding an LSP. For instance, single nucleotide polymorphisms (SNPs) occur frequently in eukaryotic genomes. In fact, more than 1.4 million SNPs have already identified in the human genome, International Human Genome Sequencing Consortium, *Nature* 409: 860-921 (2001). Thus, the sequence determined from one individual of a species may differ from other allelic forms present within the population. Additionally, small deletions and insertions, rather than single nucleotide polymorphisms, are not uncommon in the general population, and often do not alter the function of the protein. Further, amino acid substitutions occur frequently among natural allelic variants, and often do not substantially change protein function.

In a preferred embodiment, the nucleic acid molecule comprising an allelic variant is a variant of a gene, wherein the gene is transcribed into an mRNA that encodes an LSP. In a more preferred embodiment, the gene is transcribed into an mRNA that encodes an LSP comprising an amino acid sequence of SEQ ID NO: 143 through 277. In another preferred embodiment, the allelic variant is a variant of a gene, wherein the gene is transcribed into an mRNA that is an LSNA. In a more preferred embodiment, the gene is transcribed into an mRNA that comprises the nucleic acid sequence of SEQ ID NO: 1 through 142. In a preferred embodiment, the allelic variant is a naturally-occurring allelic variant in the species of interest. In a more preferred embodiment, the species of interest is human.

By "nucleic acid molecule" it is also meant to be inclusive of a part of a nucleic acid sequence of the instant invention. The part may or may not encode a polypeptide, and may or may not encode a polypeptide that is an LSP. However, in a preferred embodiment, the part encodes an LSP. In one aspect, the invention comprises a part of an LSNA. In a second aspect, the invention comprises a part of a nucleic acid molecule that hybridizes or exhibits substantial sequence similarity to an LSNA. In a third aspect, the invention comprises a part of a nucleic acid molecule that is an allelic variant of an LSNA. In a fourth aspect, the invention comprises a part of a nucleic acid molecule that encodes an LSP. A part comprises at least 10 nucleotides, more preferably at least 15,



17, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400 or 500 nucleotides. The maximum size of a nucleic acid part is one nucleotide shorter than the sequence of the nucleic acid molecule encoding the full-length protein.

By "nucleic acid molecule" it is also meant to be inclusive of sequence that encoding a fusion protein, a homologous protein, a polypeptide fragment, a mutein or a polypeptide analog, as described below.

Nucleotide sequences of the instantly-described nucleic acids were determined by sequencing a DNA molecule that had resulted, directly or indirectly, from at least one enzymatic polymerization reaction (e.g., reverse transcription and/or polymerase chain reaction) using an automated sequencer (such as the MegaBACE™ 1000, Molecular Dynamics, Sunnyvale, CA, USA). Further, all amino acid sequences of the polypeptides of the present invention were predicted by translation from the nucleic acid sequences so determined, unless otherwise specified.

In a preferred embodiment of the invention, the nucleic acid molecule contains modifications of the native nucleic acid molecule. These modifications include nonnative internucleoside bonds, post-synthetic modifications or altered nucleotide analogues. One having ordinary skill in the art would recognize that the type of modification that can be made will depend upon the intended use of the nucleic acid molecule. For instance, when the nucleic acid molecule is used as a hybridization probe, the range of such modifications will be limited to those that permit sequence-discriminating base pairing of the resulting nucleic acid. When used to direct expression of RNA or protein *in vitro* or *in vivo*, the range of such modifications will be limited to those that permit the nucleic acid to function properly as a polymerization substrate. When the isolated nucleic acid is used as a therapeutic agent, the modifications will be limited to those that do not confer toxicity upon the isolated nucleic acid.

In a preferred embodiment, isolated nucleic acid molecules can include nucleotide analogues that incorporate labels that are directly detectable, such as radiolabels or fluorophores, or nucleotide analogues that incorporate labels that can be visualized in a subsequent reaction, such as biotin or various haptens. In a more preferred embodiment, the labeled nucleic acid molecule may be used as a hybridization probe.

Common radiolabeled analogues include those labeled with  $^{33}\text{P}$ ,  $^{32}\text{P}$ , and  $^{35}\text{S}$ , such as  $^{-32}\text{P}$ -dATP,  $^{-32}\text{P}$ -dCTP,  $^{-32}\text{P}$ -dGTP,  $^{-32}\text{P}$ -dTTP,  $^{-32}\text{P}$ -3'dATP,  $^{-32}\text{P}$ -ATP,  $^{-32}\text{P}$ -CTP,  $^{-32}\text{P}$ -GTP,  $^{-32}\text{P}$ -UTP,  $^{-35}\text{S}$ -dATP,  $\alpha$ - $^{35}\text{S}$ -GTP,  $\alpha$ - $^{33}\text{P}$ -dATP, and the like.

Commercially available fluorescent nucleotide analogues readily incorporated into the nucleic acids of the present invention include Cy3-dCTP, Cy3-dUTP, Cy5-dCTP, Cy3-dUTP (Amersham Pharmacia Biotech, Piscataway, New Jersey, USA), fluorescein-12-dUTP, tetramethylrhodamine-6-dUTP, Texas Red®-5-dUTP, Cascade Blue®-7-dUTP, BODIPY® FL-14-dUTP, BODIPY® TMR-14-dUTP, BODIPY® TR-14-dUTP, Rhodamine Green™-5-dUTP, Oregon Green® 488-5-dUTP, Texas Red®-12-dUTP, BODIPY® 630/650-14-dUTP, BODIPY® 650/665-14-dUTP, Alexa Fluor® 488-5-dUTP, Alexa Fluor® 532-5-dUTP, Alexa Fluor® 568-5-dUTP, Alexa Fluor® 594-5-dUTP, Alexa Fluor® 546-14-dUTP, fluorescein-12-UTP, tetramethylrhodamine-6-UTP, Texas Red®-5-UTP, Cascade Blue®-7-UTP, BODIPY® FL-14-UTP, BODIPY® TMR-14-UTP, BODIPY® TR-14-UTP, Rhodamine Green™-5-UTP, Alexa Fluor® 488-5-UTP, Alexa Fluor® 546-14-UTP (Molecular Probes, Inc. Eugene, OR, USA). One may also custom synthesize nucleotides having other fluorophores. See Henegariu *et al.*, *Nature Biotechnol.* 18: 345-348 (2000), the disclosure of which is incorporated herein by reference in its entirety.

Haptens that are commonly conjugated to nucleotides for subsequent labeling include biotin (biotin-11-dUTP, Molecular Probes, Inc., Eugene, OR, USA; biotin-21-UTP, biotin-21-dUTP, Clontech Laboratories, Inc., Palo Alto, CA, USA), digoxigenin (DIG-11-dUTP, alkali labile, DIG-11-UTP, Roche Diagnostics Corp., Indianapolis, IN, USA), and dinitrophenyl (dinitrophenyl-11-dUTP, Molecular Probes, Inc., Eugene, OR, USA).

Nucleic acid molecules can be labeled by incorporation of labeled nucleotide analogues into the nucleic acid. Such analogues can be incorporated by enzymatic polymerization, such as by nick translation, random priming, polymerase chain reaction (PCR), terminal transferase tailing, and end-filling of overhangs, for DNA molecules, and *in vitro* transcription driven, *e.g.*, from phage promoters, such as T7, T3, and SP6, for RNA molecules. Commercial kits are readily available for each such labeling approach. Analogues can also be incorporated during automated solid phase chemical synthesis. Labels can also be incorporated after nucleic acid synthesis, with the 5' phosphate and 3'

hydroxyl providing convenient sites for post-synthetic covalent attachment of detectable labels.

Other post-synthetic approaches also permit internal labeling of nucleic acids. For example, fluorophores can be attached using a cisplatin reagent that reacts with the N7 of guanine residues (and, to a lesser extent, adenine bases) in DNA, RNA, and PNA to provide a stable coordination complex between the nucleic acid and fluorophore label (Universal Linkage System) (available from Molecular Probes, Inc., Eugene, OR, USA and Amersham Pharmacia Biotech, Piscataway, NJ, USA); *see Alers et al., Genes, Chromosomes & Cancer* 25: 301- 305 (1999); Jelsma *et al., J. NIH Res.* 5: 82 (1994); Van Belkum *et al., BioTechniques* 16: 148-153 (1994), incorporated herein by reference. As another example, nucleic acids can be labeled using a disulfide-containing linker (FastTag™ Reagent, Vector Laboratories, Inc., Burlingame, CA, USA) that is photo- or thermally-coupled to the target nucleic acid using aryl azide chemistry; after reduction, a free thiol is available for coupling to a hapten, fluorophore, sugar, affinity ligand, or other marker.

One or more independent or interacting labels can be incorporated into the nucleic acid molecules of the present invention. For example, both a fluorophore and a moiety that in proximity thereto acts to quench fluorescence can be included to report specific hybridization through release of fluorescence quenching or to report exonucleotidic excision. *See, e.g., Tyagi et al., Nature Biotechnol.* 14: 303-308 (1996); Tyagi *et al., Nature Biotechnol.* 16: 49-53 (1998); Sokol *et al., Proc. Natl. Acad. Sci. USA* 95: 11538-11543 (1998); Kostrikis *et al., Science* 279: 1228-1229 (1998); Marras *et al., Genet. Anal.* 14: 151-156 (1999); U. S. Patent 5,846,726; 5,925,517; 5,925,517; 5,723,591 and 5,538,848; Holland *et al., Proc. Natl. Acad. Sci. USA* 88: 7276-7280 (1991); Heid *et al., Genome Res.* 6(10): 986-94 (1996); Kuimelis *et al., Nucleic Acids Symp. Ser.* (37): 255-6 (1997); the disclosures of which are incorporated herein by reference in their entireties.

Nucleic acid molecules of the invention may be modified by altering one or more native phosphodiester internucleoside bonds to more nuclease-resistant, internucleoside bonds. *See Hartmann et al. (eds.), Manual of Antisense Methodology: Perspectives in Antisense Science*, Kluwer Law International (1999); Stein *et al. (eds.), Applied Antisense Oligonucleotide Technology*, Wiley-Liss (1998); Chadwick *et al. (eds.),*

Oligonucleotides as Therapeutic Agents - Symposium No. 209, John Wiley & Son Ltd (1997); the disclosures of which are incorporated herein by reference in their entireties. Such altered internucleoside bonds are often desired for antisense techniques or for targeted gene correction. See Gamper *et al.*, *Nucl. Acids Res.* 28(21): 4332-4339 (2000),  
5 the disclosure of which is incorporated herein by reference in its entirety.

Modified oligonucleotide backbones include, without limitation, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including  
10 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Representative United States patents that teach the preparation of the above  
15 phosphorus-containing linkages include, but are not limited to, U. S. Patents 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050, the disclosures of which are incorporated herein by  
20 reference in their entireties. In a preferred embodiment, the modified internucleoside linkages may be used for antisense techniques.

Other modified oligonucleotide backbones do not include a phosphorus atom, but have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or  
25 more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and  
30 methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH<sub>2</sub> component parts. Representative U.S. patents that teach the preparation of the above backbones include, but are not limited to, U.S.

Patent 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437 and 5,677,439; the disclosures of which are incorporated herein by reference in their entireties.

In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage are replaced with novel groups, such as peptide nucleic acids (PNA). In PNA compounds, the phosphodiester backbone of the nucleic acid is replaced with an amide-containing backbone, in particular by repeating N-(2-aminoethyl) glycine units linked by amide bonds. Nucleobases are bound directly or indirectly to azanitrogen atoms of the amide portion of the backbone, typically by methylene carbonyl linkages. PNA can be synthesized using a modified peptide synthesis protocol. PNA oligomers can be synthesized by both Fmoc and tBoc methods. Representative U.S. patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Patent 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Automated PNA synthesis is readily achievable on commercial synthesizers (*see, e.g.*, "PNA User's Guide," Rev. 2, February 1998, Perseptive Biosystems Part No. 60138, Applied Biosystems, Inc., Foster City, CA).

PNA molecules are advantageous for a number of reasons. First, because the PNA backbone is uncharged, PNA/DNA and PNA/RNA duplexes have a higher thermal stability than is found in DNA/DNA and DNA/RNA duplexes. The  $T_m$  of a PNA/DNA or PNA/RNA duplex is generally 1°C higher per base pair than the  $T_m$  of the corresponding DNA/DNA or DNA/RNA duplex (in 100 mM NaCl). Second, PNA molecules can also form stable PNA/DNA complexes at low ionic strength, under conditions in which DNA/DNA duplex formation does not occur. Third, PNA also demonstrates greater specificity in binding to complementary DNA because a PNA/DNA mismatch is more destabilizing than DNA/DNA mismatch. A single mismatch in mixed a PNA/DNA 15-mer lowers the  $T_m$  by 8–20°C (15°C on average). In the corresponding DNA/DNA duplexes, a single mismatch lowers the  $T_m$  by 4–16°C (11°C on average). Because PNA probes can be significantly shorter than DNA probes, their specificity is greater. Fourth, PNA oligomers are resistant to degradation by enzymes, and the lifetime of these compounds is extended both *in vivo* and *in vitro* because nucleases and proteases

do not recognize the PNA polyamide backbone with nucleobase sidechains. *See, e.g.,* Ray *et al.*, *FASEB J.* 14(9): 1041-60 (2000); Nielsen *et al.*, *Pharmacol Toxicol.* 86(1): 3-7 (2000); Larsen *et al.*, *Biochim Biophys Acta.* 1489(1): 159-66 (1999); Nielsen, *Curr. Opin. Struct. Biol.* 9(3): 353-7 (1999), and Nielsen, *Curr. Opin. Biotechnol.* 10(1): 71-5  
5 (1999), the disclosures of which are incorporated herein by reference in their entireties.

Nucleic acid molecules may be modified compared to their native structure throughout the length of the nucleic acid molecule or can be localized to discrete portions thereof. As an example of the latter, chimeric nucleic acids can be synthesized that have discrete DNA and RNA domains and that can be used for targeted gene repair and  
10 modified PCR reactions, as further described in U.S. Patents 5,760,012 and 5,731,181, Misra *et al.*, *Biochem.* 37: 1917-1925 (1998); and Finn *et al.*, *Nucl. Acids Res.* 24: 3357-3363 (1996), the disclosures of which are incorporated herein by reference in their entireties.

Unless otherwise specified, nucleic acids of the present invention can include any  
15 topological conformation appropriate to the desired use; the term thus explicitly comprehends, among others, single-stranded, double-stranded, triplexed, quadruplexed, partially double-stranded, partially-triplexed, partially-quadruplexed, branched, hairpinned, circular, and padlocked conformations. Padlock conformations and their utilities are further described in Banér *et al.*, *Curr. Opin. Biotechnol.* 12: 11-15 (2001);  
20 Escude *et al.*, *Proc. Natl. Acad. Sci. USA* 14: 96(19):10603-7 (1999); Nilsson *et al.*, *Science* 265(5181): 2085-8 (1994), the disclosures of which are incorporated herein by reference in their entireties. Triplex and quadruplex conformations, and their utilities, are reviewed in Praseuth *et al.*, *Biochim. Biophys. Acta.* 1489(1): 181-206 (1999); Fox, *Curr. Med. Chem.* 7(1): 17-37 (2000); Kochetkova *et al.*, *Methods Mol. Biol.* 130: 189-201  
25 (2000); Chan *et al.*, *J. Mol. Med.* 75(4): 267-82 (1997), the disclosures of which are incorporated herein by reference in their entireties.

#### *Methods for Using Nucleic Acid Molecules as Probes and Primers*

The isolated nucleic acid molecules of the present invention can be used as  
30 hybridization probes to detect, characterize, and quantify hybridizing nucleic acids in, and isolate hybridizing nucleic acids from, both genomic and transcript-derived nucleic acid samples. When free in solution, such probes are typically, but not invariably,

detectably labeled; bound to a substrate, as in a microarray, such probes are typically, but not invariably unlabeled.

In one embodiment, the isolated nucleic acids of the present invention can be used as probes to detect and characterize gross alterations in the gene of an LSNA, such as deletions, insertions, translocations, and duplications of the LSNA genomic locus through fluorescence *in situ* hybridization (FISH) to chromosome spreads. *See, e.g.,* Andreeff *et al.* (eds.), Introduction to Fluorescence In Situ Hybridization: Principles and Clinical Applications, John Wiley & Sons (1999), the disclosure of which is incorporated herein by reference in its entirety. The isolated nucleic acids of the present invention can be used as probes to assess smaller genomic alterations using, *e.g.,* Southern blot detection of restriction fragment length polymorphisms. The isolated nucleic acid molecules of the present invention can be used as probes to isolate genomic clones that include the nucleic acid molecules of the present invention, which thereafter can be restriction mapped and sequenced to identify deletions, insertions, translocations, and substitutions (single nucleotide polymorphisms, SNPs) at the sequence level.

In another embodiment, the isolated nucleic acid molecules of the present invention can be used as probes to detect, characterize, and quantify LSNA in, and isolate LSNA from, transcript-derived nucleic acid samples. In one aspect, the isolated nucleic acid molecules of the present invention can be used as hybridization probes to detect, characterize by length, and quantify mRNA by Northern blot of total or poly-A<sup>+</sup>- selected RNA samples. In another aspect, the isolated nucleic acid molecules of the present invention can be used as hybridization probes to detect, characterize by location, and quantify mRNA by *in situ* hybridization to tissue sections. *See, e.g.,* Schwarczacher *et al.*, In Situ Hybridization, Springer-Verlag New York (2000), the disclosure of which is incorporated herein by reference in its entirety. In another preferred embodiment, the isolated nucleic acid molecules of the present invention can be used as hybridization probes to measure the representation of clones in a cDNA library or to isolate hybridizing nucleic acid molecules acids from cDNA libraries, permitting sequence level characterization of mRNAs that hybridize to LSNAs, including, without limitations, identification of deletions, insertions, substitutions, truncations, alternatively spliced forms and single nucleotide polymorphisms. In yet another preferred embodiment, the nucleic acid molecules of the instant invention may be used in microarrays.

All of the aforementioned probe techniques are well within the skill in the art, and are described at greater length in standard texts such as Sambrook (2001), *supra*; Ausubel (1999), *supra*; and Walker *et al.* (eds.), The Nucleic Acids Protocols Handbook, Humana Press (2000), the disclosures of which are incorporated herein by reference in  
5 their entirety.

Thus, in one embodiment, a nucleic acid molecule of the invention may be used as a probe or primer to identify or amplify a second nucleic acid molecule that selectively hybridizes to the nucleic acid molecule of the invention. In a preferred embodiment, the probe or primer is derived from a nucleic acid molecule encoding an LSP. In a more  
10 preferred embodiment, the probe or primer is derived from a nucleic acid molecule encoding a polypeptide having an amino acid sequence of SEQ ID NO: 143 through 277. In another preferred embodiment, the probe or primer is derived from an LSNA. In a more preferred embodiment, the probe or primer is derived from a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1 through 142.

15 In general, a probe or primer is at least 10 nucleotides in length, more preferably at least 12, more preferably at least 14 and even more preferably at least 16 or 17 nucleotides in length. In an even more preferred embodiment, the probe or primer is at least 18 nucleotides in length, even more preferably at least 20 nucleotides and even more preferably at least 22 nucleotides in length. Primers and probes may also be longer  
20 in length. For instance, a probe or primer may be 25 nucleotides in length, or may be 30, 40 or 50 nucleotides in length. Methods of performing nucleic acid hybridization using oligonucleotide probes are well-known in the art. *See, e.g.*, Sambrook *et al.*, 1989, *supra*, Chapter 11 and pp. 11.31-11.32 and 11.40-11.44, which describes radiolabeling of short probes, and pp. 11.45-11.53, which describe hybridization conditions for oligonucleotide  
25 probes, including specific conditions for probe hybridization (pp. 11.50-11.51).

Methods of performing primer-directed amplification are also well-known in the art. Methods for performing the polymerase chain reaction (PCR) are compiled, *inter alia*, in McPherson, PCR Basics: From Background to Bench, Springer Verlag (2000); Innis *et al.* (eds.), PCR Applications: Protocols for Functional Genomics, Academic  
30 Press (1999); Gelfand *et al.* (eds.), PCR Strategies, Academic Press (1998); Newton *et al.*, PCR, Springer-Verlag New York (1997); Burke (ed.), PCR: Essential Techniques, John Wiley & Son Ltd (1996); White (ed.), PCR Cloning Protocols: From Molecular



Cloning to Genetic Engineering, Vol. 67, Humana Press (1996); McPherson *et al.* (eds.), PCR 2: A Practical Approach, Oxford University Press, Inc. (1995); the disclosures of which are incorporated herein by reference in their entireties. Methods for performing RT-PCR are collected, *e.g.*, in Siebert *et al.* (eds.), Gene Cloning and Analysis by  
5 RT-PCR, Eaton Publishing Company/Bio Techniques Books Division, 1998; Siebert (ed.), PCR Technique: RT-PCR, Eaton Publishing Company/ BioTechniques Books (1995); the disclosure of which is incorporated herein by reference in its entirety.

PCR and hybridization methods may be used to identify and/or isolate allelic variants, homologous nucleic acid molecules and fragments of the nucleic acid molecules  
10 of the invention. PCR and hybridization methods may also be used to identify, amplify and/or isolate nucleic acid molecules that encode homologous proteins, analogs, fusion protein or muteins of the invention. The nucleic acid primers of the present invention can be used to prime amplification of nucleic acid molecules of the invention, using transcript-derived or genomic DNA as template.

15 The nucleic acid primers of the present invention can also be used, for example, to prime single base extension (SBE) for SNP detection (*See, e.g.*, U.S. Patent 6,004,744, the disclosure of which is incorporated herein by reference in its entirety).

Isothermal amplification approaches, such as rolling circle amplification, are also now well-described. *See, e.g.*, Schweitzer *et al.*, *Curr. Opin. Biotechnol.* 12(1): 21-7  
20 (2001); U.S. Patents 5,854,033 and 5,714,320; and international patent publications WO 97/19193 and WO 00/15779, the disclosures of which are incorporated herein by reference in their entireties. Rolling circle amplification can be combined with other techniques to facilitate SNP detection. *See, e.g.*, Lizardi *et al.*, *Nature Genet.* 19(3): 225-32 (1998).

25 Nucleic acid molecules of the present invention may be bound to a substrate either covalently or noncovalently. The substrate can be porous or solid, planar or non-planar, unitary or distributed. The bound nucleic acid molecules may be used as hybridization probes, and may be labeled or unlabeled. In a preferred embodiment, the bound nucleic acid molecules are unlabeled.

30 In one embodiment, the nucleic acid molecule of the present invention is bound to a porous substrate, *e.g.*, a membrane, typically comprising nitrocellulose, nylon, or positively-charged derivatized nylon. The nucleic acid molecule of the present invention

can be used to detect a hybridizing nucleic acid molecule that is present within a labeled nucleic acid sample, *e.g.*, a sample of transcript-derived nucleic acids. In another embodiment, the nucleic acid molecule is bound to a solid substrate, including, without limitation, glass, amorphous silicon, crystalline silicon or plastics. Examples of plastics include, without limitation, polymethylacrylic, polyethylene, polypropylene, polyacrylate, polymethylmethacrylate, polyvinylchloride, polytetrafluoroethylene, polystyrene, polycarbonate, polyacetal, polysulfone, celluloseacetate, cellulosenitrate, nitrocellulose, or mixtures thereof. The solid substrate may be any shape, including rectangular, disk-like and spherical. In a preferred embodiment, the solid substrate is a microscope slide or slide-shaped substrate.

The nucleic acid molecule of the present invention can be attached covalently to a surface of the support substrate or applied to a derivatized surface in a chaotropic agent that facilitates denaturation and adherence by presumed noncovalent interactions, or some combination thereof. The nucleic acid molecule of the present invention can be bound to a substrate to which a plurality of other nucleic acids are concurrently bound, hybridization to each of the plurality of bound nucleic acids being separately detectable. At low density, *e.g.* on a porous membrane, these substrate-bound collections are typically denominated macroarrays; at higher density, typically on a solid support, such as glass, these substrate bound collections of plural nucleic acids are colloquially termed microarrays. As used herein, the term microarray includes arrays of all densities. It is, therefore, another aspect of the invention to provide microarrays that include the nucleic acids of the present invention.

#### *Expression Vectors, Host Cells and Recombinant Methods of Producing Polypeptides*

Another aspect of the present invention relates to vectors that comprise one or more of the isolated nucleic acid molecules of the present invention, and host cells in which such vectors have been introduced.

The vectors can be used, *inter alia*, for propagating the nucleic acids of the present invention in host cells (cloning vectors), for shuttling the nucleic acids of the present invention between host cells derived from disparate organisms (shuttle vectors), for inserting the nucleic acids of the present invention into host cell chromosomes (insertion vectors), for expressing sense or antisense RNA transcripts of the nucleic acids of the present invention *in vitro* or within a host cell, and for expressing polypeptides

encoded by the nucleic acids of the present invention, alone or as fusions to heterologous polypeptides (expression vectors). Vectors of the present invention will often be suitable for several such uses.

Vectors are by now well-known in the art, and are described, *inter alia*, in Jones  
5 *et al.* (eds.), Vectors: Cloning Applications: Essential Techniques (Essential Techniques Series), John Wiley & Son Ltd. (1998); Jones *et al.* (eds.), Vectors: Expression Systems: Essential Techniques (Essential Techniques Series), John Wiley & Son Ltd. (1998); Gacesa *et al.*, Vectors: Essential Data, John Wiley & Sons Ltd. (1995); Cid-Arregui (eds.), Viral Vectors: Basic Science and Gene Therapy, Eaton Publishing Co. (2000);  
10 Sambrook (2001), *supra*; Ausubel (1999), *supra*; the disclosures of which are incorporated herein by reference in their entireties. Furthermore, an enormous variety of vectors are available commercially. Use of existing vectors and modifications thereof being well within the skill in the art, only basic features need be described here.

Nucleic acid sequences may be expressed by operatively linking them to an  
15 expression control sequence in an appropriate expression vector and employing that expression vector to transform an appropriate unicellular host. Expression control sequences are sequences which control the transcription, post-transcriptional events and translation of nucleic acid sequences. Such operative linking of a nucleic sequence of this invention to an expression control sequence, of course, includes, if not already part  
20 of the nucleic acid sequence, the provision of a translation initiation codon, ATG or GTG, in the correct reading frame upstream of the nucleic acid sequence.

A wide variety of host/expression vector combinations may be employed in expressing the nucleic acid sequences of this invention. Useful expression vectors, for example, may consist of segments of chromosomal, non-chromosomal and synthetic  
25 nucleic acid sequences.

In one embodiment, prokaryotic cells may be used with an appropriate vector. Prokaryotic host cells are often used for cloning and expression. In a preferred embodiment, prokaryotic host cells include *E. coli*, *Pseudomonas*, *Bacillus* and *Streptomyces*. In a preferred embodiment, bacterial host cells are used to express the  
30 nucleic acid molecules of the instant invention. Useful expression vectors for bacterial hosts include bacterial plasmids, such as those from *E. coli*, *Bacillus* or *Streptomyces*, including pBluescript, pGEX-2T, pUC vectors, col E1, pCR1, pBR322, pMB9 and their

derivatives, wider host range plasmids, such as RP4, phage DNAs, *e.g.*, the numerous derivatives of phage lambda, *e.g.*, NM989,  $\lambda$ GT10 and  $\lambda$ GT11, and other phages, *e.g.*, M13 and filamentous single-stranded phage DNA. Where *E. coli* is used as host, selectable markers are, analogously, chosen for selectivity in gram negative bacteria: *e.g.*,  
5 typical markers confer resistance to antibiotics, such as ampicillin, tetracycline, chloramphenicol, kanamycin, streptomycin and zeocin; auxotrophic markers can also be used.

In other embodiments, eukaryotic host cells, such as yeast, insect, mammalian or plant cells, may be used. Yeast cells, typically *S. cerevisiae*, are useful for eukaryotic  
10 genetic studies, due to the ease of targeting genetic changes by homologous recombination and the ability to easily complement genetic defects using recombinantly expressed proteins. Yeast cells are useful for identifying interacting protein components, *e.g.* through use of a two-hybrid system. In a preferred embodiment, yeast cells are useful for protein expression. Vectors of the present invention for use in yeast will  
15 typically, but not invariably, contain an origin of replication suitable for use in yeast and a selectable marker that is functional in yeast. Yeast vectors include Yeast Integrating plasmids (*e.g.*, YIp5) and Yeast Replicating plasmids (the YRp and YEp series plasmids), Yeast Centromere plasmids (the YCp series plasmids), Yeast Artificial Chromosomes (YACs) which are based on yeast linear plasmids, denoted YLp, pGPD-2,  
20 2 $\mu$  plasmids and derivatives thereof, and improved shuttle vectors such as those described in Gietz *et al.*, *Gene*, 74: 527-34 (1988) (YIplac, YEplac and YCplac). Selectable markers in yeast vectors include a variety of auxotrophic markers, the most common of which are (in *Saccharomyces cerevisiae*) URA3, HIS3, LEU2, TRP1 and LYS2, which complement specific auxotrophic mutations, such as *ura3-52*, *his3-D1*,  
25 *leu2-D1*, *trp1-D1* and *lys2-201*.

Insect cells are often chosen for high efficiency protein expression. Where the host cells are from *Spodoptera frugiperda*, *e.g.*, Sf9 and Sf21 cell lines, and expresSF<sup>TM</sup> cells (Protein Sciences Corp., Meriden, CT, USA)), the vector replicative strategy is typically based upon the baculovirus life cycle. Typically, baculovirus transfer vectors  
30 are used to replace the wild-type AcMNPV polyhedrin gene with a heterologous gene of interest. Sequences that flank the polyhedrin gene in the wild-type genome are positioned 5' and 3' of the expression cassette on the transfer vectors. Following co-

transfection with AcMNPV DNA, a homologous recombination event occurs between these sequences resulting in a recombinant virus carrying the gene of interest and the polyhedrin or p10 promoter. Selection can be based upon visual screening for lacZ fusion activity.

5 In another embodiment, the host cells may be mammalian cells, which are particularly useful for expression of proteins intended as pharmaceutical agents, and for screening of potential agonists and antagonists of a protein or a physiological pathway. Mammalian vectors intended for autonomous extrachromosomal replication will typically include a viral origin, such as the SV40 origin (for replication in cell lines  
10 expressing the large T-antigen, such as COS1 and COS7 cells), the papillomavirus origin, or the EBV origin for long term episomal replication (for use, *e.g.*, in 293-EBNA cells, which constitutively express the EBV EBNA-1 gene product and adenovirus E1A). Vectors intended for integration, and thus replication as part of the mammalian chromosome, can, but need not, include an origin of replication functional in mammalian  
15 cells, such as the SV40 origin. Vectors based upon viruses, such as adenovirus, adeno-associated virus, vaccinia virus, and various mammalian retroviruses, will typically replicate according to the viral replicative strategy. Selectable markers for use in mammalian cells include resistance to neomycin (G418), blasticidin, hygromycin and to zeocin, and selection based upon the purine salvage pathway using HAT medium.

20 Expression in mammalian cells can be achieved using a variety of plasmids, including pSV2, pBC12BI, and p91023, as well as lytic virus vectors (*e.g.*, vaccinia virus, adeno virus, and baculovirus), episomal virus vectors (*e.g.*, bovine papillomavirus), and retroviral vectors (*e.g.*, murine retroviruses). Useful vectors for insect cells include baculoviral vectors and pVL 941.

25 Plant cells can also be used for expression, with the vector replicon typically derived from a plant virus (*e.g.*, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) and selectable markers chosen for suitability in plants.

It is known that codon usage of different host cells may be different. For example, a plant cell and a human cell may exhibit a difference in codon preference for  
30 encoding a particular amino acid. As a result, human mRNA may not be efficiently translated in a plant, bacteria or insect host cell. Therefore, another embodiment of this invention is directed to codon optimization. The codons of the nucleic acid molecules of

the invention may be modified to resemble, as much as possible, genes naturally contained within the host cell without altering the amino acid sequence encoded by the nucleic acid molecule.

Any of a wide variety of expression control sequences may be used in these  
5 vectors to express the DNA sequences of this invention. Such useful expression control sequences include the expression control sequences associated with structural genes of the foregoing expression vectors. Expression control sequences that control transcription include, *e.g.*, promoters, enhancers and transcription termination sites. Expression control sequences in eukaryotic cells that control post-transcriptional events include  
10 splice donor and acceptor sites and sequences that modify the half-life of the transcribed RNA, *e.g.*, sequences that direct poly(A) addition or binding sites for RNA-binding proteins. Expression control sequences that control translation include ribosome binding sites, sequences which direct targeted expression of the polypeptide to or within particular cellular compartments, and sequences in the 5' and 3' untranslated regions that  
15 modify the rate or efficiency of translation.

Examples of useful expression control sequences for a prokaryote, *e.g.*, *E. coli*, will include a promoter, often a phage promoter, such as phage lambda pL promoter, the *trc* promoter, a hybrid derived from the *trp* and *lac* promoters, the bacteriophage T7 promoter (in *E. coli* cells engineered to express the T7 polymerase), the TAC or TRC  
20 system, the major operator and promoter regions of phage lambda, the control regions of fd coat protein, or the *araBAD* operon. Prokaryotic expression vectors may further include transcription terminators, such as the *aspA* terminator, and elements that facilitate translation, such as a consensus ribosome binding site and translation termination codon, Schomer *et al.*, *Proc. Natl. Acad. Sci. USA* 83: 8506-8510 (1986).

25 Expression control sequences for yeast cells, typically *S. cerevisiae*, will include a yeast promoter, such as the *CYC1* promoter, the *GAL1* promoter, the *GAL10* promoter, *ADH1* promoter, the promoters of the yeast  $\alpha$ -mating system, or the *GPD* promoter, and will typically have elements that facilitate transcription termination, such as the transcription termination signals from the *CYC1* or *ADH1* gene.

30 Expression vectors useful for expressing proteins in mammalian cells will include a promoter active in mammalian cells. These promoters include those derived from mammalian viruses, such as the enhancer-promoter sequences from the immediate early

gene of the human cytomegalovirus (CMV), the enhancer-promoter sequences from the Rous sarcoma virus long terminal repeat (RSV LTR), the enhancer-promoter from SV40 or the early and late promoters of adenovirus. Other expression control sequences include the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the  
5 promoters of acid phosphatase. Other expression control sequences include those from the gene comprising the LSNA of interest. Often, expression is enhanced by incorporation of polyadenylation sites, such as the late SV40 polyadenylation site and the polyadenylation signal and transcription termination sequences from the bovine growth hormone (BGH) gene, and ribosome binding sites. Furthermore, vectors can include  
10 introns, such as intron II of rabbit  $\beta$ -globin gene and the SV40 splice elements.

Preferred nucleic acid vectors also include a selectable or amplifiable marker gene and means for amplifying the copy number of the gene of interest. Such marker genes are well-known in the art. Nucleic acid vectors may also comprise stabilizing sequences (*e.g.*, *ori*- or *ARS*-like sequences and telomere-like sequences), or may  
15 alternatively be designed to favor directed or non-directed integration into the host cell genome. In a preferred embodiment, nucleic acid sequences of this invention are inserted in frame into an expression vector that allows high level expression of an RNA which encodes a protein comprising the encoded nucleic acid sequence of interest. Nucleic acid cloning and sequencing methods are well-known to those of skill in the art and are  
20 described in an assortment of laboratory manuals, including Sambrook (1989), *supra*, Sambrook (2000), *supra*; and Ausubel (1992), *supra*, Ausubel (1999), *supra*. Product information from manufacturers of biological, chemical and immunological reagents also provide useful information.

Expression vectors may be either constitutive or inducible. Inducible vectors  
25 include either naturally inducible promoters, such as the *trc* promoter, which is regulated by the *lac* operon, and the *pL* promoter, which is regulated by tryptophan, the MMTV-LTR promoter, which is inducible by dexamethasone, or can contain synthetic promoters and/or additional elements that confer inducible control on adjacent promoters. Examples of inducible synthetic promoters are the hybrid *Plac/ara-1* promoter and the  
30 *PLtetO-1* promoter. The *PLtetO-1* promoter takes advantage of the high expression levels from the *PL* promoter of phage lambda, but replaces the lambda repressor sites with two copies of operator 2 of the *Tn10* tetracycline resistance operon, causing this promoter to

be tightly repressed by the Tet repressor protein and induced in response to tetracycline (Tc) and Tc derivatives such as anhydrotetracycline. Vectors may also be inducible because they contain hormone response elements, such as the glucocorticoid response element (GRE) and the estrogen response element (ERE), which can confer hormone inducibility where vectors are used for expression in cells having the respective hormone receptors. To reduce background levels of expression, elements responsive to ecdysone, an insect hormone, can be used instead, with coexpression of the ecdysone receptor.

In one aspect of the invention, expression vectors can be designed to fuse the expressed polypeptide to small protein tags that facilitate purification and/or visualization. Tags that facilitate purification include a polyhistidine tag that facilitates purification of the fusion protein by immobilized metal affinity chromatography, for example using NiNTA resin (Qiagen Inc., Valencia, CA, USA) or TALON™ resin (cobalt immobilized affinity chromatography medium, Clontech Labs, Palo Alto, CA, USA). The fusion protein can include a chitin-binding tag and self-excising intein, permitting chitin-based purification with self-removal of the fused tag (IMPACT™ system, New England Biolabs, Inc., Beverly, MA, USA). Alternatively, the fusion protein can include a calmodulin-binding peptide tag, permitting purification by calmodulin affinity resin (Stratagene, La Jolla, CA, USA), or a specifically excisable fragment of the biotin carboxylase carrier protein, permitting purification of *in vivo* biotinylated protein using an avidin resin and subsequent tag removal (Promega, Madison, WI, USA). As another useful alternative, the proteins of the present invention can be expressed as a fusion protein with glutathione-S-transferase, the affinity and specificity of binding to glutathione permitting purification using glutathione affinity resins, such as Glutathione-Superflow Resin (Clontech Laboratories, Palo Alto, CA, USA), with subsequent elution with free glutathione. Other tags include, for example, the Xpress epitope, detectable by anti-Xpress antibody (Invitrogen, Carlsbad, CA, USA), a myc tag, detectable by anti-myc tag antibody, the V5 epitope, detectable by anti-V5 antibody (Invitrogen, Carlsbad, CA, USA), FLAG® epitope, detectable by anti-FLAG® antibody (Stratagene, La Jolla, CA, USA), and the HA epitope.

For secretion of expressed proteins, vectors can include appropriate sequences that encode secretion signals, such as leader peptides. For example, the pSecTag2 vectors (Invitrogen, Carlsbad, CA, USA) are 5.2 kb mammalian expression vectors that



carry the secretion signal from the V-J2-C region of the mouse Ig kappa-chain for efficient secretion of recombinant proteins from a variety of mammalian cell lines.

Expression vectors can also be designed to fuse proteins encoded by the heterologous nucleic acid insert to polypeptides that are larger than purification and/or  
5 identification tags. Useful fusion proteins include those that permit display of the encoded protein on the surface of a phage or cell, fusion to intrinsically fluorescent proteins, such as those that have a green fluorescent protein (GFP)-like chromophore, fusions to the IgG Fc region, and fusion proteins for use in two hybrid systems.

Vectors for phage display fuse the encoded polypeptide to, *e.g.*, the gene III  
10 protein (pIII) or gene VIII protein (pVIII) for display on the surface of filamentous phage, such as M13. *See* Barbas *et al.*, Phage Display: A Laboratory Manual, Cold Spring Harbor Laboratory Press (2001); Kay *et al.* (eds.), Phage Display of Peptides and Proteins: A Laboratory Manual, Academic Press, Inc., (1996); Abelson *et al.* (eds.), Combinatorial Chemistry (Methods in Enzymology, Vol. 267) Academic Press (1996).  
15 Vectors for yeast display, *e.g.* the pYD1 yeast display vector (Invitrogen, Carlsbad, CA, USA), use the  $\alpha$ -agglutinin yeast adhesion receptor to display recombinant protein on the surface of *S. cerevisiae*. Vectors for mammalian display, *e.g.*, the pDisplay™ vector (Invitrogen, Carlsbad, CA, USA), target recombinant proteins using an N-terminal cell surface targeting signal and a C-terminal transmembrane anchoring domain of platelet  
20 derived growth factor receptor.

A wide variety of vectors now exist that fuse proteins encoded by heterologous nucleic acids to the chromophore of the substrate-independent, intrinsically fluorescent green fluorescent protein from *Aequorea victoria* ("GFP") and its variants. The GFP-like chromophore can be selected from GFP-like chromophores found in naturally occurring  
25 proteins, such as *A. victoria* GFP (GenBank accession number AAA27721), *Renilla reniformis* GFP, FP583 (GenBank accession no. AF168419) (DsRed), FP593 (AF272711), FP483 (AF168420), FP484 (AF168424), FP595 (AF246709), FP486 (AF168421), FP538 (AF168423), and FP506 (AF168422), and need include only so much of the native protein as is needed to retain the chromophore's intrinsic  
30 fluorescence. Methods for determining the minimal domain required for fluorescence are known in the art. *See* Li *et al.*, *J. Biol. Chem.* 272: 28545-28549 (1997). Alternatively, the GFP-like chromophore can be selected from GFP-like chromophores modified from

those found in nature. The methods for engineering such modified GFP-like chromophores and testing them for fluorescence activity, both alone and as part of protein fusions, are well-known in the art. See Heim *et al.*, *Curr. Biol.* 6: 178-182 (1996) and Palm *et al.*, *Methods Enzymol.* 302: 378-394 (1999), incorporated herein by

5 reference in its entirety. A variety of such modified chromophores are now commercially available and can readily be used in the fusion proteins of the present invention. These include EGFP ("enhanced GFP"), EBFP ("enhanced blue fluorescent protein"), BFP2, EYFP ("enhanced yellow fluorescent protein"), ECFP ("enhanced cyan fluorescent protein") or Citrine. EGFP (*see, e.g.* Cormack *et al.*, *Gene* 173: 33-38

10 (1996); United States Patent Nos. 6,090,919 and 5,804,387) is found on a variety of vectors, both plasmid and viral, which are available commercially (Clontech Labs, Palo Alto, CA, USA); EBFP is optimized for expression in mammalian cells whereas BFP2, which retains the original jellyfish codons, can be expressed in bacteria (*see, e.g.* Heim *et al.*, *Curr. Biol.* 6: 178-182 (1996) and Cormack *et al.*, *Gene* 173: 33-38 (1996)).

15 Vectors containing these blue-shifted variants are available from Clontech Labs (Palo Alto, CA, USA). Vectors containing EYFP, ECFP (*see, e.g.*, Heim *et al.*, *Curr. Biol.* 6: 178-182 (1996); Miyawaki *et al.*, *Nature* 388: 882-887 (1997)) and Citrine (*see, e.g.*, Heikal *et al.*, *Proc. Natl. Acad. Sci. USA* 97: 11996-12001 (2000)) are also available from Clontech Labs. The GFP-like chromophore can also be drawn from other modified

20 GFPs, including those described in U.S. Patents 6,124,128; 6,096,865; 6,090,919; 6,066,476; 6,054,321; 6,027,881; 5,968,750; 5,874,304; 5,804,387; 5,777,079; 5,741,668; and 5,625,048, the disclosures of which are incorporated herein by reference in their entireties. See also Conn (ed.), Green Fluorescent Protein (Methods in Enzymology, Vol. 302), Academic Press, Inc. (1999). The GFP-like chromophore of

25 each of these GFP variants can usefully be included in the fusion proteins of the present invention.

Fusions to the IgG Fc region increase serum half life of protein pharmaceutical products through interaction with the FcRn receptor (also denominated the FcRp receptor and the Brambell receptor, FcRb), further described in International Patent Application

30 Nos. WO 97/43316, WO 97/34631, WO 96/32478, WO 96/18412.

For long-term, high-yield recombinant production of the proteins, protein fusions, and protein fragments of the present invention, stable expression is preferred. Stable

expression is readily achieved by integration into the host cell genome of vectors having selectable markers, followed by selection of these integrants. Vectors such as pUB6/V5-His A, B, and C (Invitrogen, Carlsbad, CA, USA) are designed for high-level stable expression of heterologous proteins in a wide range of mammalian tissue types and cell lines. pUB6/V5-His uses the promoter/enhancer sequence from the human ubiquitin C gene to drive expression of recombinant proteins: expression levels in 293, CHO, and NIH3T3 cells are comparable to levels from the CMV and human EF-1a promoters. The *bsd* gene permits rapid selection of stably transfected mammalian cells with the potent antibiotic blasticidin.

10 Replication incompetent retroviral vectors, typically derived from Moloney murine leukemia virus, also are useful for creating stable transfectants having integrated provirus. The highly efficient transduction machinery of retroviruses, coupled with the availability of a variety of packaging cell lines such as RetroPack™ PT 67, EcoPack2™-293, AmphiPack-293, and GP2-293 cell lines (all available from Clontech Laboratories, Palo Alto, CA, USA), allow a wide host range to be infected with high efficiency; varying the multiplicity of infection readily adjusts the copy number of the integrated provirus.

Of course, not all vectors and expression control sequences will function equally well to express the nucleic acid sequences of this invention. Neither will all hosts function equally well with the same expression system. However, one of skill in the art may make a selection among these vectors, expression control sequences and hosts without undue experimentation and without departing from the scope of this invention. For example, in selecting a vector, the host must be considered because the vector must be replicated in it. The vector's copy number, the ability to control that copy number, the ability to control integration, if any, and the expression of any other proteins encoded by the vector, such as antibiotic or other selection markers, should also be considered. The present invention further includes host cells comprising the vectors of the present invention, either present episomally within the cell or integrated, in whole or in part, into the host cell chromosome. Among other considerations, some of which are described above, a host cell strain may be chosen for its ability to process the expressed protein in the desired fashion. Such post-translational modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation,

and acylation, and it is an aspect of the present invention to provide LSPs with such post-translational modifications.

Polypeptides of the invention may be post-translationally modified. Post-translational modifications include phosphorylation of amino acid residues serine, threonine and/or tyrosine, N-linked and/or O-linked glycosylation, methylation, acetylation, prenylation, methylation, acetylation, arginylation, ubiquitination and racemization. One may determine whether a polypeptide of the invention is likely to be post-translationally modified by analyzing the sequence of the polypeptide to determine if there are peptide motifs indicative of sites for post-translational modification. There are a number of computer programs that permit prediction of post-translational modifications. See, e.g., [www.expasy.org](http://www.expasy.org) (accessed August 31, 2001), which includes PSORT, for prediction of protein sorting signals and localization sites, SignalP, for prediction of signal peptide cleavage sites, MITOPROT and Predotar, for prediction of mitochondrial targeting sequences, NetOGlyc, for prediction of type O-glycosylation sites in mammalian proteins, big-PI Predictor and DGPI, for prediction of prenylation-anchor and cleavage sites, and NetPhos, for prediction of Ser, Thr and Tyr phosphorylation sites in eukaryotic proteins. Other computer programs, such as those included in GCG, also may be used to determine post-translational modification peptide motifs.

General examples of types of post-translational modifications may be found in web sites such as the Delta Mass database <http://www.abrf.org/ABRF/Research/Committees/deltamass/deltamass.html> (accessed October 19, 2001); "GlycoSuiteDB: a new curated relational database of glycoprotein glycan structures and their biological sources" Cooper et al. *Nucleic Acids Res.* 29; 332-335 (2001) and <http://www.glycosuite.com/> (accessed October 19, 2001); "O-GLYCBASE version 4.0: a revised database of O-glycosylated proteins" Gupta et al. *Nucleic Acids Research*, 27: 370-372 (1999) and <http://www.cbs.dtu.dk/databases/OGLYCBASE/> (accessed October 19, 2001); "PhosphoBase, a database of phosphorylation sites: release 2.0.", Kreegipuu et al. *Nucleic Acids Res* 27(1):237-239 (1999) and <http://www.cbs.dtu.dk/databases/PhosphoBase/> (accessed October 19, 2001); or <http://pir.georgetown.edu/pirwww/search/textresid.html> (accessed October 19, 2001).

Tumorigenesis is often accompanied by alterations in the post-translational modifications of proteins. Thus, in another embodiment, the invention provides polypeptides from cancerous cells or tissues that have altered post-translational modifications compared to the post-translational modifications of polypeptides from normal cells or tissues. A number of altered post-translational modifications are known. One common alteration is a change in phosphorylation state, wherein the polypeptide from the cancerous cell or tissue is hyperphosphorylated or hypophosphorylated compared to the polypeptide from a normal tissue, or wherein the polypeptide is phosphorylated on different residues than the polypeptide from a normal cell. Another common alteration is a change in glycosylation state, wherein the polypeptide from the cancerous cell or tissue has more or less glycosylation than the polypeptide from a normal tissue, and/or wherein the polypeptide from the cancerous cell or tissue has a different type of glycosylation than the polypeptide from a noncancerous cell or tissue. Changes in glycosylation may be critical because carbohydrate-protein and carbohydrate-carbohydrate interactions are important in cancer cell progression, dissemination and invasion. See, e.g., Barchi, *Curr. Pharm. Des.* 6: 485-501 (2000), Verma, *Cancer Biochem. Biophys.* 14: 151-162 (1994) and Dennis et al., *Bioessays* 5: 412-421 (1999).

Another post-translational modification that may be altered in cancer cells is prenylation. Prenylation is the covalent attachment of a hydrophobic prenyl group (either farnesyl or geranylgeranyl) to a polypeptide. Prenylation is required for localizing a protein to a cell membrane and is often required for polypeptide function. For instance, the Ras superfamily of GTPase signaling proteins must be prenylated for function in a cell. See, e.g., Prendergast et al., *Semin. Cancer Biol.* 10: 443-452 (2000) and Khwaja et al., *Lancet* 355: 741-744 (2000).

Other post-translation modifications that may be altered in cancer cells include, without limitation, polypeptide methylation, acetylation, arginylation or racemization of amino acid residues. In these cases, the polypeptide from the cancerous cell may exhibit either increased or decreased amounts of the post-translational modification compared to the corresponding polypeptides from noncancerous cells.

Other polypeptide alterations in cancer cells include abnormal polypeptide cleavage of proteins and aberrant protein-protein interactions. Abnormal polypeptide cleavage may be cleavage of a polypeptide in a cancerous cell that does not usually occur

in a normal cell, or a lack of cleavage in a cancerous cell, wherein the polypeptide is cleaved in a normal cell. Aberrant protein-protein interactions may be either covalent cross-linking or non-covalent binding between proteins that do not normally bind to each other. Alternatively, in a cancerous cell, a protein may fail to bind to another protein to which it is bound in a noncancerous cell. Alterations in cleavage or in protein-protein interactions may be due to over- or underproduction of a polypeptide in a cancerous cell compared to that in a normal cell, or may be due to alterations in post-translational modifications (see above) of one or more proteins in the cancerous cell. See, e.g., Henschen-Edman, *Ann. N.Y. Acad. Sci.* 936: 580-593 (2001).

Alterations in polypeptide post-translational modifications, as well as changes in polypeptide cleavage and protein-protein interactions, may be determined by any method known in the art. For instance, alterations in phosphorylation may be determined by using anti-phosphoserine, anti-phosphothreonine or anti-phosphotyrosine antibodies or by amino acid analysis. Glycosylation alterations may be determined using antibodies specific for different sugar residues, by carbohydrate sequencing, or by alterations in the size of the glycoprotein, which can be determined by, e.g., SDS polyacrylamide gel electrophoresis (PAGE). Other alterations of post-translational modifications, such as prenylation, racemization, methylation, acetylation and arginylation, may be determined by chemical analysis, protein sequencing, amino acid analysis, or by using antibodies specific for the particular post-translational modifications. Changes in protein-protein interactions and in polypeptide cleavage may be analyzed by any method known in the art including, without limitation, non-denaturing PAGE (for non-covalent protein-protein interactions), SDS PAGE (for covalent protein-protein interactions and protein cleavage), chemical cleavage, protein sequencing or immunoassays.

In another embodiment, the invention provides polypeptides that have been post-translationally modified. In one embodiment, polypeptides may be modified enzymatically or chemically, by addition or removal of a post-translational modification. For example, a polypeptide may be glycosylated or deglycosylated enzymatically. Similarly, polypeptides may be phosphorylated using a purified kinase, such as a MAP kinase (e.g., p38, ERK, or JNK) or a tyrosine kinase (e.g., Src or erbB2). A polypeptide may also be modified through synthetic chemistry. Alternatively, one may isolate the polypeptide of interest from a cell or tissue that expresses the polypeptide with the

desired post-translational modification. In another embodiment, a nucleic acid molecule encoding the polypeptide of interest is introduced into a host cell that is capable of post-translationally modifying the encoded polypeptide in the desired fashion. If the polypeptide does not contain a motif for a desired post-translational modification, one  
5 may alter the post-translational modification by mutating the nucleic acid sequence of a nucleic acid molecule encoding the polypeptide so that it contains a site for the desired post-translational modification. Amino acid sequences that may be post-translationally modified are known in the art. See, e.g., the programs described above on the website [www.expasy.org](http://www.expasy.org). The nucleic acid molecule is then be introduced into a host cell that is  
10 capable of post-translationally modifying the encoded polypeptide. Similarly, one may delete sites that are post-translationally modified by either mutating the nucleic acid sequence so that the encoded polypeptide does not contain the post-translational modification motif, or by introducing the native nucleic acid molecule into a host cell that is not capable of post-translationally modifying the encoded polypeptide.

15 In selecting an expression control sequence, a variety of factors should also be considered. These include, for example, the relative strength of the sequence, its controllability, and its compatibility with the nucleic acid sequence of this invention, particularly with regard to potential secondary structures. Unicellular hosts should be selected by consideration of their compatibility with the chosen vector, the toxicity of the  
20 product coded for by the nucleic acid sequences of this invention, their secretion characteristics, their ability to fold the polypeptide correctly, their fermentation or culture requirements, and the ease of purification from them of the products coded for by the nucleic acid sequences of this invention.

The recombinant nucleic acid molecules and more particularly, the expression  
25 vectors of this invention may be used to express the polypeptides of this invention as recombinant polypeptides in a heterologous host cell. The polypeptides of this invention may be full-length or less than full-length polypeptide fragments recombinantly expressed from the nucleic acid sequences according to this invention. Such polypeptides include analogs, derivatives and muteins that may or may not have  
30 biological activity.

Vectors of the present invention will also often include elements that permit *in vitro* transcription of RNA from the inserted heterologous nucleic acid. Such vectors

typically include a phage promoter, such as that from T7, T3, or SP6, flanking the nucleic acid insert. Often two different such promoters flank the inserted nucleic acid, permitting separate *in vitro* production of both sense and antisense strands.

Transformation and other methods of introducing nucleic acids into a host cell  
5 (e.g., conjugation, protoplast transformation or fusion, transfection, electroporation, liposome delivery, membrane fusion techniques, high velocity DNA-coated pellets, viral infection and protoplast fusion) can be accomplished by a variety of methods which are well-known in the art (*See, for instance, Ausubel, supra, and Sambrook et al., supra*). Bacterial, yeast, plant or mammalian cells are transformed or transfected with an  
10 expression vector, such as a plasmid, a cosmid, or the like, wherein the expression vector comprises the nucleic acid of interest. Alternatively, the cells may be infected by a viral expression vector comprising the nucleic acid of interest. Depending upon the host cell, vector, and method of transformation used, transient or stable expression of the polypeptide will be constitutive or inducible. One having ordinary skill in the art will be  
15 able to decide whether to express a polypeptide transiently or stably, and whether to express the protein constitutively or inducibly.

A wide variety of unicellular host cells are useful in expressing the DNA sequences of this invention. These hosts may include well-known eukaryotic and prokaryotic hosts, such as strains of, fungi, yeast, insect cells such as *Spodoptera*  
20 *frugiperda* (SF9), animal cells such as CHO, as well as plant cells in tissue culture. Representative examples of appropriate host cells include, but are not limited to, bacterial cells, such as *E. coli*, *Caulobacter crescentus*, *Streptomyces* species, and *Salmonella typhimurium*; yeast cells, such as *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Pichia pastoris*, *Pichia methanolica*; insect cell lines, such as those from  
25 *Spodoptera frugiperda*, e.g., Sf9 and Sf21 cell lines, and expresSF™ cells (Protein Sciences Corp., Meriden, CT, USA), *Drosophila* S2 cells, and *Trichoplusia ni* High Five® Cells (Invitrogen, Carlsbad, CA, USA); and mammalian cells. Typical mammalian cells include BHK cells, BSC 1 cells, BSC 40 cells, BMT 10 cells, VERO cells, COS1 cells, COS7 cells, Chinese hamster ovary (CHO) cells, 3T3 cells, NIH 3T3  
30 cells, 293 cells, HEPG2 cells, HeLa cells, L cells, MDCK cells, HEK293 cells, WI38 cells, murine ES cell lines (e.g., from strains 129/SV, C57/BL6, DBA-1, 129/SVJ), K562 cells, Jurkat cells, and BW5147 cells. Other mammalian cell lines are well-known and



readily available from the American Type Culture Collection (ATCC) (Manassas, VA, USA) and the National Institute of General Medical Sciences (NIGMS) Human Genetic Cell Repository at the Coriell Cell Repositories (Camden, NJ, USA). Cells or cell lines derived from lung are particularly preferred because they may provide a more native post-translational processing. Particularly preferred are human lung cells.

Particular details of the transfection, expression and purification of recombinant proteins are well documented and are understood by those of skill in the art. Further details on the various technical aspects of each of the steps used in recombinant production of foreign genes in bacterial cell expression systems can be found in a number of texts and laboratory manuals in the art. *See, e.g.,* Ausubel (1992), *supra*, Ausubel (1999), *supra*, Sambrook (1989), *supra*, and Sambrook (2001), *supra*, herein incorporated by reference.

Methods for introducing the vectors and nucleic acids of the present invention into the host cells are well-known in the art; the choice of technique will depend primarily upon the specific vector to be introduced and the host cell chosen.

Nucleic acid molecules and vectors may be introduced into prokaryotes, such as *E. coli*, in a number of ways. For instance, phage lambda vectors will typically be packaged using a packaging extract (*e.g.,* Gigapack® packaging extract, Stratagene, La Jolla, CA, USA), and the packaged virus used to infect *E. coli*.

Plasmid vectors will typically be introduced into chemically competent or electrocompetent bacterial cells. *E. coli* cells can be rendered chemically competent by treatment, *e.g.,* with  $\text{CaCl}_2$ , or a solution of  $\text{Mg}^{2+}$ ,  $\text{Mn}^{2+}$ ,  $\text{Ca}^{2+}$ ,  $\text{Rb}^+$  or  $\text{K}^+$ , dimethyl sulfoxide, dithiothreitol, and hexamine cobalt (III), Hanahan, *J. Mol. Biol.* 166(4):557-80 (1983), and vectors introduced by heat shock. A wide variety of chemically competent strains are also available commercially (*e.g.,* Epicurian Coli® XL10-Gold® Ultracompetent Cells (Stratagene, La Jolla, CA, USA); DH5 competent cells (Clontech Laboratories, Palo Alto, CA, USA); and TOP10 Chemically Competent *E. coli* Kit (Invitrogen, Carlsbad, CA, USA)). Bacterial cells can be rendered electrocompetent, that is, competent to take up exogenous DNA by electroporation, by various pre-pulse treatments; vectors are introduced by electroporation followed by subsequent outgrowth in selected media. An extensive series of protocols is provided online in Electroprotocols

(BioRad, Richmond, CA, USA) ([http://www.biorad.com/LifeScience/pdf/New\\_Gene\\_Pulser.pdf](http://www.biorad.com/LifeScience/pdf/New_Gene_Pulser.pdf)).

Vectors can be introduced into yeast cells by spheroplasting, treatment with lithium salts, electroporation, or protoplast fusion. Spheroplasts are prepared by the  
5 action of hydrolytic enzymes such as snail-gut extract, usually denoted Glusulase, or Zymolyase, an enzyme from *Arthrobacter luteus*, to remove portions of the cell wall in the presence of osmotic stabilizers, typically 1 M sorbitol. DNA is added to the spheroplasts, and the mixture is co-precipitated with a solution of polyethylene glycol (PEG) and  $\text{Ca}^{2+}$ . Subsequently, the cells are resuspended in a solution of sorbitol, mixed  
10 with molten agar and then layered on the surface of a selective plate containing sorbitol.

For lithium-mediated transformation, yeast cells are treated with lithium acetate, which apparently permeabilizes the cell wall, DNA is added and the cells are co-precipitated with PEG. The cells are exposed to a brief heat shock, washed free of PEG and lithium acetate, and subsequently spread on plates containing ordinary selective  
15 medium. Increased frequencies of transformation are obtained by using specially-prepared single-stranded carrier DNA and certain organic solvents. Schiestl *et al.*, *Curr. Genet.* 16(5-6): 339-46 (1989).

For electroporation, freshly-grown yeast cultures are typically washed, suspended in an osmotic protectant, such as sorbitol, mixed with DNA, and the cell suspension  
20 pulsed in an electroporation device. Subsequently, the cells are spread on the surface of plates containing selective media. Becker *et al.*, *Methods Enzymol.* 194: 182-187 (1991). The efficiency of transformation by electroporation can be increased over 100-fold by using PEG, single-stranded carrier DNA and cells that are in late log-phase of growth. Larger constructs, such as YACs, can be introduced by protoplast fusion.

25 Mammalian and insect cells can be directly infected by packaged viral vectors, or transfected by chemical or electrical means. For chemical transfection, DNA can be coprecipitated with  $\text{CaPO}_4$  or introduced using liposomal and nonliposomal lipid-based agents. Commercial kits are available for  $\text{CaPO}_4$  transfection (CalPhos™ Mammalian Transfection Kit, Clontech Laboratories, Palo Alto, CA, USA), and lipid-mediated  
30 transfection can be practiced using commercial reagents, such as LIPOFECTAMINE™ 2000, LIPOFECTAMINE™ Reagent, CELLFECTIN® Reagent, and LIPOFECTIN® Reagent (Invitrogen, Carlsbad, CA, USA), DOTAP Liposomal Transfection Reagent,

FuGENE 6, X-tremeGENE Q2, DOSPER, (Roche Molecular Biochemicals, Indianapolis, IN USA), Effectene™, PolyFect®, Superfect® (Qiagen, Inc., Valencia, CA, USA).

Protocols for electroporating mammalian cells can be found online in Electroprotocols (Bio-Rad, Richmond, CA, USA) (<http://www.bio-rad.com/LifeScience/pdf/>

- 5 New\_Gene\_Pulser.pdf); Norton *et al.* (eds.), Gene Transfer Methods: Introducing DNA into Living Cells and Organisms, BioTechniques Books, Eaton Publishing Co. (2000); incorporated herein by reference in its entirety. Other transfection techniques include transfection by particle bombardment and microinjection. *See, e.g.,* Cheng *et al.*, *Proc. Natl. Acad. Sci. USA* 90(10): 4455-9 (1993); Yang *et al.*, *Proc. Natl. Acad. Sci. USA*  
10 87(24): 9568-72 (1990).

Production of the recombinantly produced proteins of the present invention can optionally be followed by purification.

- Purification of recombinantly expressed proteins is now well by those skilled in the art. *See, e.g.,* Thorner *et al.* (eds.), Applications of Chimeric Genes and Hybrid  
15 Proteins, Part A: Gene Expression and Protein Purification (Methods in Enzymology, Vol. 326), Academic Press (2000); Harbin (ed.), Cloning, Gene Expression and Protein Purification : Experimental Procedures and Process Rationale, Oxford Univ. Press (2001); Marshak *et al.*, Strategies for Protein Purification and Characterization: A Laboratory Course Manual, Cold Spring Harbor Laboratory Press (1996); and Roe (ed.),  
20 Protein Purification Applications, Oxford University Press (2001); the disclosures of which are incorporated herein by reference in their entireties, and thus need not be detailed here.

- Briefly, however, if purification tags have been fused through use of an expression vector that appends such tags, purification can be effected, at least in part, by  
25 means appropriate to the tag, such as use of immobilized metal affinity chromatography for polyhistidine tags. Other techniques common in the art include ammonium sulfate fractionation, immunoprecipitation, fast protein liquid chromatography (FPLC), high performance liquid chromatography (HPLC), and preparative gel electrophoresis.

#### Polypeptides

- 30 Another object of the invention is to provide polypeptides encoded by the nucleic acid molecules of the instant invention. In a preferred embodiment, the polypeptide is a lung specific polypeptide (LSP). In an even more preferred embodiment, the polypeptide

is derived from a polypeptide comprising the amino acid sequence of SEQ ID NO: 143 through 277. A polypeptide as defined herein may be produced recombinantly, as discussed *supra*, may be isolated from a cell that naturally expresses the protein, or may be chemically synthesized following the teachings of the specification and using methods well-known to those having ordinary skill in the art.

In another aspect, the polypeptide may comprise a fragment of a polypeptide, wherein the fragment is as defined herein. In a preferred embodiment, the polypeptide fragment is a fragment of an LSP. In a more preferred embodiment, the fragment is derived from a polypeptide comprising the amino acid sequence of SEQ ID NO: 143 through 277. A polypeptide that comprises only a fragment of an entire LSP may or may not be a polypeptide that is also an LSP. For instance, a full-length polypeptide may be lung-specific, while a fragment thereof may be found in other tissues as well as in lung. A polypeptide that is not an LSP, whether it is a fragment, analog, mutein, homologous protein or derivative, is nevertheless useful, especially for immunizing animals to prepare anti-LSP antibodies. However, in a preferred embodiment, the part or fragment is an LSP. Methods of determining whether a polypeptide is an LSP are described *infra*.

Fragments of at least 6 contiguous amino acids are useful in mapping B cell and T cell epitopes of the reference protein. See, e.g., Geysen *et al.*, *Proc. Natl. Acad. Sci. USA* 81: 3998-4002 (1984) and U.S. Patents 4,708,871 and 5,595,915, the disclosures of which are incorporated herein by reference in their entireties. Because the fragment need not itself be immunogenic, part of an immunodominant epitope, nor even recognized by native antibody, to be useful in such epitope mapping, all fragments of at least 6 amino acids of the proteins of the present invention have utility in such a study.

Fragments of at least 8 contiguous amino acids, often at least 15 contiguous amino acids, are useful as immunogens for raising antibodies that recognize the proteins of the present invention. See, e.g., Lerner, *Nature* 299: 592-596 (1982); Shinnick *et al.*, *Annu. Rev. Microbiol.* 37: 425-46 (1983); Sutcliffe *et al.*, *Science* 219: 660-6 (1983), the disclosures of which are incorporated herein by reference in their entireties. As further described in the above-cited references, virtually all 8-mers, conjugated to a carrier, such as a protein, prove immunogenic, meaning that they are capable of eliciting antibody for the conjugated peptide; accordingly, all fragments of at least 8 amino acids of the proteins of the present invention have utility as immunogens.

Fragments of at least 8, 9, 10 or 12 contiguous amino acids are also useful as competitive inhibitors of binding of the entire protein, or a portion thereof, to antibodies (as in epitope mapping), and to natural binding partners, such as subunits in a multimeric complex or to receptors or ligands of the subject protein; this competitive inhibition  
5 permits identification and separation of molecules that bind specifically to the protein of interest, U.S. Patents 5,539,084 and 5,783,674, incorporated herein by reference in their entireties.

The protein, or protein fragment, of the present invention is thus at least 6 amino acids in length, typically at least 8, 9, 10 or 12 amino acids in length, and often at least 15  
10 amino acids in length. Often, the protein of the present invention, or fragment thereof, is at least 20 amino acids in length, even 25 amino acids, 30 amino acids, 35 amino acids, or 50 amino acids or more in length. Of course, larger fragments having at least 75 amino acids, 100 amino acids, or even 150 amino acids are also useful, and at times preferred.

15 One having ordinary skill in the art can produce fragments of a polypeptide by truncating the nucleic acid molecule, *e.g.*, an LSNA, encoding the polypeptide and then expressing it recombinantly. Alternatively, one can produce a fragment by chemically synthesizing a portion of the full-length polypeptide. One may also produce a fragment by enzymatically cleaving either a recombinant polypeptide or an isolated naturally-  
20 occurring polypeptide. Methods of producing polypeptide fragments are well-known in the art. *See, e.g.*, Sambrook (1989), *supra*; Sambrook (2001), *supra*; Ausubel (1992), *supra*; and Ausubel (1999), *supra*. In one embodiment, a polypeptide comprising only a fragment of polypeptide of the invention, preferably an LSP, may be produced by chemical or enzymatic cleavage of a polypeptide. In a preferred embodiment, a  
25 polypeptide fragment is produced by expressing a nucleic acid molecule encoding a fragment of the polypeptide, preferably an LSP, in a host cell.

By "polypeptides" as used herein it is also meant to be inclusive of mutants, fusion proteins, homologous proteins and allelic variants of the polypeptides specifically exemplified.

30 A mutant protein, or mutein, may have the same or different properties compared to a naturally-occurring polypeptide and comprises at least one amino acid insertion, duplication, deletion, rearrangement or substitution compared to the amino acid sequence

of a native protein. Small deletions and insertions can often be found that do not alter the function of the protein. In one embodiment, the mutein may or may not be lung-specific. In a preferred embodiment, the mutein is lung-specific. In a preferred embodiment, the mutein is a polypeptide that comprises at least one amino acid insertion, duplication, deletion, rearrangement or substitution compared to the amino acid sequence of SEQ ID NO: 143 through 277. In a more preferred embodiment, the mutein is one that exhibits at least 50% sequence identity, more preferably at least 60% sequence identity, even more preferably at least 70%, yet more preferably at least 80% sequence identity to an LSP comprising an amino acid sequence of SEQ ID NO: 143 through 277. In yet a more preferred embodiment, the mutein exhibits at least 85%, more preferably 90%, even more preferably 95% or 96%, and yet more preferably at least 97%, 98%, 99% or 99.5% sequence identity to an LSP comprising an amino acid sequence of SEQ ID NO: 143 through 277.

A mutein may be produced by isolation from a naturally-occurring mutant cell, tissue or organism. A mutein may be produced by isolation from a cell, tissue or organism that has been experimentally mutagenized. Alternatively, a mutein may be produced by chemical manipulation of a polypeptide, such as by altering the amino acid residue to another amino acid residue using synthetic or semi-synthetic chemical techniques. In a preferred embodiment, a mutein may be produced from a host cell comprising an altered nucleic acid molecule compared to the naturally-occurring nucleic acid molecule. For instance, one may produce a mutein of a polypeptide by introducing one or more mutations into a nucleic acid sequence of the invention and then expressing it recombinantly. These mutations may be targeted, in which particular encoded amino acids are altered, or may be untargeted, in which random encoded amino acids within the polypeptide are altered. Muteins with random amino acid alterations can be screened for a particular biological activity or property, particularly whether the polypeptide is lung-specific, as described below. Multiple random mutations can be introduced into the gene by methods well-known to the art, *e.g.*, by error-prone PCR, shuffling, oligonucleotide-directed mutagenesis, assembly PCR, sexual PCR mutagenesis, *in vivo* mutagenesis, cassette mutagenesis, recursive ensemble mutagenesis, exponential ensemble mutagenesis and site-specific mutagenesis. Methods of producing muteins with targeted or random amino acid alterations are well-known in the art. *See, e.g.*,

Sambrook (1989), *supra*; Sambrook (2001), *supra*; Ausubel (1992), *supra*; and Ausubel (1999), U.S. Patent 5,223,408, and the references discussed *supra*, each herein incorporated by reference.

By "polypeptide" as used herein it is also meant to be inclusive of polypeptides  
5 homologous to those polypeptides exemplified herein. In a preferred embodiment, the polypeptide is homologous to an LSP. In an even more preferred embodiment, the polypeptide is homologous to an LSP selected from the group having an amino acid sequence of SEQ ID NO: 143 through 277. In a preferred embodiment, the homologous polypeptide is one that exhibits significant sequence identity to an LSP. In a more  
10 preferred embodiment, the polypeptide is one that exhibits significant sequence identity to an comprising an amino acid sequence of SEQ ID NO: 143 through 277. In an even more preferred embodiment, the homologous polypeptide is one that exhibits at least 50% sequence identity, more preferably at least 60% sequence identity, even more preferably at least 70%, yet more preferably at least 80% sequence identity to an LSP  
15 comprising an amino acid sequence of SEQ ID NO: 143 through 277. In a yet more preferred embodiment, the homologous polypeptide is one that exhibits at least 85%, more preferably 90%, even more preferably 95% or 96%, and yet more preferably at least 97% or 98% sequence identity to an LSP comprising an amino acid sequence of SEQ ID NO: 143 through 277. In another preferred embodiment, the homologous  
20 polypeptide is one that exhibits at least 99%, more preferably 99.5%, even more preferably 99.6%, 99.7%, 99.8% or 99.9% sequence identity to an LSP comprising an amino acid sequence of SEQ ID NO: 143 through 277. In a preferred embodiment, the amino acid substitutions are conservative amino acid substitutions as discussed above.

In another embodiment, the homologous polypeptide is one that is encoded by a  
25 nucleic acid molecule that selectively hybridizes to an LSNA. In a preferred embodiment, the homologous polypeptide is encoded by a nucleic acid molecule that hybridizes to an LSNA under low stringency, moderate stringency or high stringency conditions, as defined herein. In a more preferred embodiment, the LSNA is selected from the group consisting of SEQ ID NO: 1 through 142. In another preferred  
30 embodiment, the homologous polypeptide is encoded by a nucleic acid molecule that hybridizes to a nucleic acid molecule that encodes an LSP under low stringency, moderate stringency or high stringency conditions, as defined herein. In a more preferred

embodiment, the LSP is selected from the group consisting of SEQ ID NO: 143 through 277.

The homologous polypeptide may be a naturally-occurring one that is derived from another species, especially one derived from another primate, such as chimpanzee, gorilla, rhesus macaque, baboon or gorilla, wherein the homologous polypeptide comprises an amino acid sequence that exhibits significant sequence identity to that of SEQ ID NO: 143 through 277. The homologous polypeptide may also be a naturally-occurring polypeptide from a human, when the LSP is a member of a family of polypeptides. The homologous polypeptide may also be a naturally-occurring polypeptide derived from a non-primate, mammalian species, including without limitation, domesticated species, *e.g.*, dog, cat, mouse, rat, rabbit, guinea pig, hamster, cow, horse, goat or pig. The homologous polypeptide may also be a naturally-occurring polypeptide derived from a non-mammalian species, such as birds or reptiles. The naturally-occurring homologous protein may be isolated directly from humans or other species. Alternatively, the nucleic acid molecule encoding the naturally-occurring homologous polypeptide may be isolated and used to express the homologous polypeptide recombinantly. In another embodiment, the homologous polypeptide may be one that is experimentally produced by random mutation of a nucleic acid molecule and subsequent expression of the nucleic acid molecule. In another embodiment, the homologous polypeptide may be one that is experimentally produced by directed mutation of one or more codons to alter the encoded amino acid of an LSP. Further, the homologous protein may or may not encode polypeptide that is an LSP. However, in a preferred embodiment, the homologous polypeptide encodes a polypeptide that is an LSP.

Relatedness of proteins can also be characterized using a second functional test, the ability of a first protein competitively to inhibit the binding of a second protein to an antibody. It is, therefore, another aspect of the present invention to provide isolated proteins not only identical in sequence to those described with particularity herein, but also to provide isolated proteins ("cross-reactive proteins") that competitively inhibit the binding of antibodies to all or to a portion of various of the isolated polypeptides of the present invention. Such competitive inhibition can readily be determined using immunoassays well-known in the art.



As discussed above, single nucleotide polymorphisms (SNPs) occur frequently in eukaryotic genomes, and the sequence determined from one individual of a species may differ from other allelic forms present within the population. Thus, by "polypeptide" as used herein it is also meant to be inclusive of polypeptides encoded by an allelic variant of a nucleic acid molecule encoding an LSP. In a preferred embodiment, the polypeptide is encoded by an allelic variant of a gene that encodes a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO: 143 through 277. In a yet more preferred embodiment, the polypeptide is encoded by an allelic variant of a gene that has the nucleic acid sequence selected from the group consisting of SEQ ID NO: 1 through 142.

In another embodiment, the invention provides polypeptides which comprise derivatives of a polypeptide encoded by a nucleic acid molecule according to the instant invention. In a preferred embodiment, the polypeptide is an LSP. In a preferred embodiment, the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO: 143 through 277, or is a mutein, allelic variant, homologous protein or fragment thereof. In a preferred embodiment, the derivative has been acetylated, carboxylated, phosphorylated, glycosylated or ubiquitinated. In another preferred embodiment, the derivative has been labeled with, e.g., radioactive isotopes such as  $^{125}\text{I}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ , and  $^3\text{H}$ . In another preferred embodiment, the derivative has been labeled with fluorophores, chemiluminescent agents, enzymes, and antiligands that can serve as specific binding pair members for a labeled ligand.

Polypeptide modifications are well-known to those of skill and have been described in great detail in the scientific literature. Several particularly common modifications, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, for instance, are described in most basic texts, such as, for instance Creighton, Protein Structure and Molecular Properties, 2nd ed., W. H. Freeman and Company (1993). Many detailed reviews are available on this subject, such as, for example, those provided by Wold, in Johnson (ed.), Posttranslational Covalent Modification of Proteins, pgs. 1-12, Academic Press (1983); Seifter *et al.*, *Meth. Enzymol.* 182: 626-646 (1990) and Rattan *et al.*, *Ann. N.Y. Acad. Sci.* 663: 48-62 (1992).

It will be appreciated, as is well-known and as noted above, that polypeptides are not always entirely linear. For instance, polypeptides may be branched as a result of ubiquitination, and they may be circular, with or without branching, generally as a result of posttranslation events, including natural processing event and events brought about by human manipulation which do not occur naturally. Circular, branched and branched circular polypeptides may be synthesized by non-translation natural process and by entirely synthetic methods, as well. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. In fact, blockage of the amino or carboxyl group in a polypeptide, or both, by a covalent modification, is common in naturally occurring and synthetic polypeptides and such modifications may be present in polypeptides of the present invention, as well. For instance, the amino terminal residue of polypeptides made in *E. coli*, prior to proteolytic processing, almost invariably will be N-formylmethionine.

Useful post-synthetic (and post-translational) modifications include conjugation to detectable labels, such as fluorophores. A wide variety of amine-reactive and thiol-reactive fluorophore derivatives have been synthesized that react under nondenaturing conditions with N-terminal amino groups and epsilon amino groups of lysine residues, on the one hand, and with free thiol groups of cysteine residues, on the other.

Kits are available commercially that permit conjugation of proteins to a variety of amine-reactive or thiol-reactive fluorophores: Molecular Probes, Inc. (Eugene, OR, USA), *e.g.*, offers kits for conjugating proteins to Alexa Fluor 350, Alexa Fluor 430, Fluorescein-EX, Alexa Fluor 488, Oregon Green 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, and Texas Red-X.

A wide variety of other amine-reactive and thiol-reactive fluorophores are available commercially (Molecular Probes, Inc., Eugene, OR, USA), including Alexa Fluor® 350, Alexa Fluor® 488, Alexa Fluor® 532, Alexa Fluor® 546, Alexa Fluor® 568, Alexa Fluor® 594, Alexa Fluor® 647 (monoclonal antibody labeling kits available from Molecular Probes, Inc., Eugene, OR, USA), BODIPY dyes, such as BODIPY 493/503, BODIPY FL, BODIPY R6G, BODIPY 530/550, BODIPY TMR, BODIPY 558/568, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY TR, BODIPY 630/650, BODIPY 650/665, Cascade Blue, Cascade Yellow, Dansyl, lissamine rhodamine B, Marina Blue, Oregon Green 488, Oregon Green 514,

Pacific Blue, rhodamine 6G, rhodamine green, rhodamine red, tetramethylrhodamine, Texas Red (available from Molecular Probes, Inc., Eugene, OR, USA).

The polypeptides of the present invention can also be conjugated to fluorophores, other proteins, and other macromolecules, using bifunctional linking reagents. Common homobifunctional reagents include, *e.g.*, APG, AEDP, B'ASED, BMB, BMDB, BMH, BMOE, BM[PEO]3, BM[PEO]4, BS3, BSOCOES, DFDNB, DMA, DMP, DMS, DPDPB, DSG, DSP (Lomant's Reagent), DSS, DST, DTBP, DTME, DTSSP, EGS, HBVS, Sulfo-BSOCOES, Sulfo-DST, Sulfo-EGS (all available from Pierce, Rockford, IL, USA); common heterobifunctional cross-linkers include ABH, AMAS, ANB-NOS, APDP, ASBA, BMFA, BMPH, BMPS, EDC, EMCA, EMCH, EMCS, KMUA, KMH, GMBS, LC-SMCC, LC-SPDP, MBS, M2C2H, MPBH, MSA, NHS-ASA, PDPH, PMPI, SADP, SAED, SAND, SANPAH, SASD, SATP, SBAP, SFAD, SIA, SIAB, SMCC, SMPB, SMPH, SMPT, SPDP, Sulfo-EMCS, Sulfo-GMBS, Sulfo-HSAB, Sulfo-KMUS, Sulfo-LC-SPDP, Sulfo-MBS, Sulfo-NHS-LC-ASA, Sulfo-SADP, Sulfo-SANPAH, Sulfo-SIAB, Sulfo-SMCC, Sulfo-SMPB, Sulfo-LC-SMPT, SVSB, TFCS (all available from Pierce, Rockford, IL, USA).

The polypeptides, fragments, and fusion proteins of the present invention can be conjugated, using such cross-linking reagents, to fluorophores that are not amine- or thiol-reactive. Other labels that usefully can be conjugated to the polypeptides, fragments, and fusion proteins of the present invention include radioactive labels, echosonographic contrast reagents, and MRI contrast agents.

The polypeptides, fragments, and fusion proteins of the present invention can also usefully be conjugated using cross-linking agents to carrier proteins, such as KLH, bovine thyroglobulin, and even bovine serum albumin (BSA), to increase immunogenicity for raising anti-LSP antibodies.

The polypeptides, fragments, and fusion proteins of the present invention can also usefully be conjugated to polyethylene glycol (PEG); PEGylation increases the serum half-life of proteins administered intravenously for replacement therapy. Delgado *et al.*, *Crit. Rev. Ther. Drug Carrier Syst.* 9(3-4): 249-304 (1992); Scott *et al.*, *Curr. Pharm. Des.* 4(6): 423-38 (1998); DeSantis *et al.*, *Curr. Opin. Biotechnol.* 10(4): 324-30 (1999), incorporated herein by reference in their entireties. PEG monomers can be attached to the protein directly or through a linker, with PEGylation using PEG monomers activated

with tresyl chloride (2,2,2-trifluoroethanesulphonyl chloride) permitting direct attachment under mild conditions.

In yet another embodiment, the invention provides analogs of a polypeptide encoded by a nucleic acid molecule according to the instant invention. In a preferred embodiment, the polypeptide is an LSP. In a more preferred embodiment, the analog is derived from a polypeptide having part or all of the amino acid sequence of SEQ ID NO: 143 through 277. In a preferred embodiment, the analog is one that comprises one or more substitutions of non-natural amino acids or non-native inter-residue bonds compared to the naturally-occurring polypeptide. In general, the non-peptide analog is structurally similar to an LSP, but one or more peptide linkages is replaced by a linkage selected from the group consisting of --CH<sub>2</sub>NH--, --CH<sub>2</sub>S--, --CH<sub>2</sub>-CH<sub>2</sub>--,  
--CH=CH--(cis and trans), --COCH<sub>2</sub>--, --CH(OH)CH<sub>2</sub>-- and --CH<sub>2</sub>SO--. In another embodiment, the non-peptide analog comprises substitution of one or more amino acids of an LSP with a D-amino acid of the same type or other non-natural amino acid in order to generate more stable peptides. D-amino acids can readily be incorporated during chemical peptide synthesis: peptides assembled from D-amino acids are more resistant to proteolytic attack; incorporation of D-amino acids can also be used to confer specific three-dimensional conformations on the peptide. Other amino acid analogues commonly added during chemical synthesis include ornithine, norleucine, phosphorylated amino acids (typically phosphoserine, phosphothreonine, phosphotyrosine), L-malonyltyrosine, a non-hydrolyzable analog of phosphotyrosine (*see, e.g., Kole et al., Biochem. Biophys. Res. Com.* 209: 817-821 (1995)), and various halogenated phenylalanine derivatives.

Non-natural amino acids can be incorporated during solid phase chemical synthesis or by recombinant techniques, although the former is typically more common. Solid phase chemical synthesis of peptides is well established in the art. Procedures are described, inter alia, in Chan *et al.* (eds.), Fmoc Solid Phase Peptide Synthesis: A Practical Approach (Practical Approach Series), Oxford Univ. Press (March 2000); Jones, Amino Acid and Peptide Synthesis (Oxford Chemistry Primers, No 7), Oxford Univ. Press (1992); and Bodanszky, Principles of Peptide Synthesis (Springer Laboratory), Springer Verlag (1993); the disclosures of which are incorporated herein by reference in their entireties.

Amino acid analogues having detectable labels are also usefully incorporated during synthesis to provide derivatives and analogs. Biotin, for example can be added using biotinoyl-(9-fluorenylmethoxycarbonyl)-L-lysine (Fmoc biocytin) (Molecular Probes, Eugene, OR, USA). Biotin can also be added enzymatically by incorporation  
5 into a fusion protein of a *E. coli* BirA substrate peptide. The Fmoc and *t*BOC derivatives of dabcyL-L-lysine (Molecular Probes, Inc., Eugene, OR, USA) can be used to incorporate the dabcyL chromophore at selected sites in the peptide sequence during synthesis. The aminonaphthalene derivative EDANS, the most common fluorophore for pairing with the dabcyL quencher in fluorescence resonance energy transfer (FRET)  
10 systems, can be introduced during automated synthesis of peptides by using EDANS-Fmoc-L-glutamic acid or the corresponding *t*BOC derivative (both from Molecular Probes, Inc., Eugene, OR, USA). Tetramethylrhodamine fluorophores can be incorporated during automated Fmoc synthesis of peptides using (Fmoc)-TMR-L-lysine (Molecular Probes, Inc. Eugene, OR, USA).

15 Other useful amino acid analogues that can be incorporated during chemical synthesis include aspartic acid, glutamic acid, lysine, and tyrosine analogues having allyl side-chain protection (Applied Biosystems, Inc., Foster City, CA, USA); the allyl side chain permits synthesis of cyclic, branched-chain, sulfonated, glycosylated, and phosphorylated peptides.

20 A large number of other Fmoc-protected non-natural amino acid analogues capable of incorporation during chemical synthesis are available commercially, including, *e.g.*, Fmoc-2-aminobicyclo[2.2.1]heptane-2-carboxylic acid, Fmoc-3-endo-aminobicyclo[2.2.1]heptane-2-endo-carboxylic acid, Fmoc-3-exo-aminobicyclo[2.2.1]heptane-2-exo-carboxylic acid, Fmoc-3-endo-amino-  
25 bicyclo[2.2.1]hept-5-ene-2-endo-carboxylic acid, Fmoc-3-exo-amino-bicyclo[2.2.1]hept-5-ene-2-exo-carboxylic acid, Fmoc-cis-2-amino-1-cyclohexanecarboxylic acid, Fmoc-trans-2-amino-1-cyclohexanecarboxylic acid, Fmoc-1-amino-1-cyclopentanecarboxylic acid, Fmoc-cis-2-amino-1-cyclopentanecarboxylic acid, Fmoc-1-amino-1-cyclopropanecarboxylic acid, Fmoc-D-2-amino-4-(ethylthio)butyric acid, Fmoc-L-2-amino-4-(ethylthio)butyric acid, Fmoc-L-buthionine, Fmoc-S-methyl-L-Cysteine, Fmoc-  
30 2-aminobenzoic acid (anthranillic acid), Fmoc-3-aminobenzoic acid, Fmoc-4-aminobenzoic acid, Fmoc-2-aminobenzophenone-2'-carboxylic acid, Fmoc-N-(4-

aminobenzoyl)- $\beta$ -alanine, Fmoc-2-amino-4,5-dimethoxybenzoic acid, Fmoc-4-aminohippuric acid, Fmoc-2-amino-3-hydroxybenzoic acid, Fmoc-2-amino-5-hydroxybenzoic acid, Fmoc-3-amino-4-hydroxybenzoic acid, Fmoc-4-amino-3-hydroxybenzoic acid, Fmoc-4-amino-2-hydroxybenzoic acid, Fmoc-5-amino-2-hydroxybenzoic acid, Fmoc-2-amino-3-methoxybenzoic acid, Fmoc-4-amino-3-methoxybenzoic acid, Fmoc-2-amino-3-methylbenzoic acid, Fmoc-2-amino-5-methylbenzoic acid, Fmoc-2-amino-6-methylbenzoic acid, Fmoc-3-amino-2-methylbenzoic acid, Fmoc-3-amino-4-methylbenzoic acid, Fmoc-4-amino-3-methylbenzoic acid, Fmoc-3-amino-2-naphtoic acid, Fmoc-D,L-3-amino-3-phenylpropionic acid, Fmoc-L-Methyldopa, Fmoc-2-amino-4,6-dimethyl-3-pyridinecarboxylic acid, Fmoc-D,L-amino-2-thiophenacetic acid, Fmoc-4-(carboxymethyl)piperazine, Fmoc-4-carboxypiperazine, Fmoc-4-(carboxymethyl)homopiperazine, Fmoc-4-phenyl-4-piperidinecarboxylic acid, Fmoc-L-1,2,3,4-tetrahydronorharman-3-carboxylic acid, Fmoc-L-thiazolidine-4-carboxylic acid,

all available from The Peptide Laboratory (Richmond, CA, USA).

Non-natural residues can also be added biosynthetically by engineering a suppressor tRNA, typically one that recognizes the UAG stop codon, by chemical aminoacylation with the desired unnatural amino acid. Conventional site-directed mutagenesis is used to introduce the chosen stop codon UAG at the site of interest in the protein gene. When the acylated suppressor tRNA and the mutant gene are combined in an *in vitro* transcription/translation system, the unnatural amino acid is incorporated in response to the UAG codon to give a protein containing that amino acid at the specified position. Liu *et al.*, *Proc. Natl Acad. Sci. USA* 96(9): 4780-5 (1999); Wang *et al.*, *Science* 292(5516): 498-500 (2001).

## 25 *Fusion Proteins*

The present invention further provides fusions of each of the polypeptides and fragments of the present invention to heterologous polypeptides. In a preferred embodiment, the polypeptide is an LSP. In a more preferred embodiment, the polypeptide that is fused to the heterologous polypeptide comprises part or all of the amino acid sequence of SEQ ID NO: 143 through 277, or is a mutein, homologous polypeptide, analog or derivative thereof. In an even more preferred embodiment, the nucleic acid molecule encoding the fusion protein comprises all or part of the nucleic

acid sequence of SEQ ID NO: 1 through 142, or comprises all or part of a nucleic acid sequence that selectively hybridizes or is homologous to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1 through 142.

The fusion proteins of the present invention will include at least one fragment of the protein of the present invention, which fragment is at least 6, typically at least 8, often at least 15, and usefully at least 16, 17, 18, 19, or 20 amino acids long. The fragment of the protein of the present to be included in the fusion can usefully be at least 25 amino acids long, at least 50 amino acids long, and can be at least 75, 100, or even 150 amino acids long. Fusions that include the entirety of the proteins of the present invention have particular utility.

The heterologous polypeptide included within the fusion protein of the present invention is at least 6 amino acids in length, often at least 8 amino acids in length, and usefully at least 15, 20, and 25 amino acids in length. Fusions that include larger polypeptides, such as the IgG Fc region, and even entire proteins (such as GFP chromophore-containing proteins) are particular useful.

As described above in the description of vectors and expression vectors of the present invention, which discussion is incorporated here by reference in its entirety, heterologous polypeptides to be included in the fusion proteins of the present invention can usefully include those designed to facilitate purification and/or visualization of recombinantly-expressed proteins. *See, e.g., Ausubel, Chapter 16, (1992), supra.* Although purification tags can also be incorporated into fusions that are chemically synthesized, chemical synthesis typically provides sufficient purity that further purification by HPLC suffices; however, visualization tags as above described retain their utility even when the protein is produced by chemical synthesis, and when so included render the fusion proteins of the present invention useful as directly detectable markers of the presence of a polypeptide of the invention.

As also discussed above, heterologous polypeptides to be included in the fusion proteins of the present invention can usefully include those that facilitate secretion of recombinantly expressed proteins — into the periplasmic space or extracellular milieu for prokaryotic hosts, into the culture medium for eukaryotic cells — through incorporation of secretion signals and/or leader sequences. For example, a His<sup>6</sup> tagged protein can be purified on a Ni affinity column and a GST fusion protein can be purified on a

glutathione affinity column. Similarly, a fusion protein comprising the Fc domain of IgG can be purified on a Protein A or Protein G column and a fusion protein comprising an epitope tag such as myc can be purified using an immunoaffinity column containing an anti-c-myc antibody. It is preferable that the epitope tag be separated from the protein encoded by the essential gene by an enzymatic cleavage site that can be cleaved after  
5 purification. See also the discussion of nucleic acid molecules encoding fusion proteins that may be expressed on the surface of a cell.

Other useful protein fusions of the present invention include those that permit use of the protein of the present invention as bait in a yeast two-hybrid system. *See Bartel et al.* (eds.), The Yeast Two-Hybrid System, Oxford University Press (1997); *Zhu et al.*, Yeast Hybrid Technologies, Eaton Publishing (2000); *Fields et al.*, *Trends Genet.* 10(8): 286-92 (1994); *Mendelsohn et al.*, *Curr. Opin. Biotechnol.* 5(5): 482-6 (1994); *Luban et al.*, *Curr. Opin. Biotechnol.* 6(1): 59-64 (1995); *Allen et al.*, *Trends Biochem. Sci.* 20(12): 511-6 (1995); *Drees*, *Curr. Opin. Chem. Biol.* 3(1): 64-70 (1999); *Topcu et al.*,  
15 *Pharm. Res.* 17(9): 1049-55 (2000); *Fashena et al.*, *Gene* 250(1-2): 1-14 (2000); ; *Colas et al.*, (1996) Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. *Nature* 380, 548-550; *Norman, T. et al.*, (1999) Genetic selection of peptide inhibitors of biological pathways. *Science* 285, 591-595, *Fabrizio et al.*, (1999) Inhibition of mammalian cell proliferation by genetically selected peptide aptamers that  
20 functionally antagonize E2F activity. *Oncogene* 18, 4357-4363; *Xu et al.*, (1997) Cells that register logical relationships among proteins. *Proc Natl Acad Sci U S A.* 94, 12473-12478; *Yang, et al.*, (1995) Protein-peptide interactions analyzed with the yeast two-hybrid system. *Nuc. Acids Res.* 23, 1152-1156; *Kolonin et al.*, (1998) Targeting cyclin-dependent kinases in *Drosophila* with peptide aptamers. *Proc Natl Acad Sci U S A* 95,  
25 14266-14271; *Cohen et al.*, (1998) An artificial cell-cycle inhibitor isolated from a combinatorial library. *Proc Natl Acad Sci U S A* 95, 14272-14277; *Uetz, P.*; *Giot, L.*; *al. e.*; *Fields, S.*; *Rothberg, J. M.* (2000) A comprehensive analysis of protein-protein interactions in *Saccharomyces cerevisiae*. *Nature* 403, 623-627; *Ito, et al.*, (2001) A comprehensive two-hybrid analysis to explore the yeast protein interactome. *Proc Natl*  
30 *Acad Sci U S A* 98, 4569-4574, the disclosures of which are incorporated herein by reference in their entireties. Typically, such fusion is to either *E. coli* LexA or yeast



GAL4 DNA binding domains. Related bait plasmids are available that express the bait fused to a nuclear localization signal.

Other useful fusion proteins include those that permit display of the encoded protein on the surface of a phage or cell, fusions to intrinsically fluorescent proteins, such as green fluorescent protein (GFP), and fusions to the IgG Fc region, as described above, which discussion is incorporated here by reference in its entirety.

The polypeptides and fragments of the present invention can also usefully be fused to protein toxins, such as *Pseudomonas* exotoxin A, diphtheria toxin, shiga toxin A, anthrax toxin lethal factor, ricin, in order to effect ablation of cells that bind or take up the proteins of the present invention.

Fusion partners include, *inter alia*, myc, hemagglutinin (HA), GST, immunoglobulins,  $\beta$ -galactosidase, biotin trpE, protein A,  $\beta$ -lactamase,  $\alpha$ -amylase, maltose binding protein, alcohol dehydrogenase, polyhistidine (for example, six histidine at the amino and/or carboxyl terminus of the polypeptide), lacZ, green fluorescent protein (GFP), yeast  $\alpha$ -mating factor, GAL4 transcription activation or DNA binding domain, luciferase, and serum proteins such as ovalbumin, albumin and the constant domain of IgG. See, e.g., Ausubel (1992), *supra* and Ausubel (1999), *supra*. Fusion proteins may also contain sites for specific enzymatic cleavage, such as a site that is recognized by enzymes such as Factor XIII, trypsin, pepsin, or any other enzyme known in the art. Fusion proteins will typically be made by either recombinant nucleic acid methods, as described above, chemically synthesized using techniques well-known in the art (e.g., a Merrifield synthesis), or produced by chemical cross-linking.

Another advantage of fusion proteins is that the epitope tag can be used to bind the fusion protein to a plate or column through an affinity linkage for screening binding proteins or other molecules that bind to the LSP.

As further described below, the isolated polypeptides, muteins, fusion proteins, homologous proteins or allelic variants of the present invention can readily be used as specific immunogens to raise antibodies that specifically recognize LSPs, their allelic variants and homologues. The antibodies, in turn, can be used, *inter alia*, specifically to assay for the polypeptides of the present invention, particularly LSPs, e.g. by ELISA for detection of protein fluid samples, such as serum, by immunohistochemistry or laser scanning cytometry, for detection of protein in tissue samples, or by flow cytometry, for

detection of intracellular protein in cell suspensions, for specific antibody-mediated isolation and/or purification of LSPs, as for example by immunoprecipitation, and for use as specific agonists or antagonists of LSPs.

One may determine whether polypeptides including muteins, fusion proteins,  
5 homologous proteins or allelic variants are functional by methods known in the art. For instance, residues that are tolerant of change while retaining function can be identified by altering the protein at known residues using methods known in the art, such as alanine scanning mutagenesis, Cunningham *et al.*, *Science* 244(4908): 1081-5 (1989); transposon linker scanning mutagenesis, Chen *et al.*, *Gene* 263(1-2): 39-48 (2001); combinations of  
10 homolog- and alanine-scanning mutagenesis, Jin *et al.*, *J. Mol. Biol.* 226(3): 851-65 (1992); combinatorial alanine scanning, Weiss *et al.*, *Proc. Natl. Acad. Sci USA* 97(16): 8950-4 (2000), followed by functional assay. Transposon linker scanning kits are available commercially (New England Biolabs, Beverly, MA, USA, catalog. no. E7-102S; EZ::TN™ In-Frame Linker Insertion Kit, catalogue no. EZI04KN, Epicentre  
15 Technologies Corporation, Madison, WI, USA).

Purification of the polypeptides including fragments, homologous polypeptides, muteins, analogs, derivatives and fusion proteins is well-known and within the skill of one having ordinary skill in the art. See, e.g., Scopes, Protein Purification, 2d ed. (1987). Purification of recombinantly expressed polypeptides is described above. Purification of  
20 chemically-synthesized peptides can readily be effected, e.g., by HPLC.

Accordingly, it is an aspect of the present invention to provide the isolated proteins of the present invention in pure or substantially pure form in the presence of absence of a stabilizing agent. Stabilizing agents include both proteinaceous or non-proteinaceous material and are well-known in the art. Stabilizing agents, such as albumin  
25 and polyethylene glycol (PEG) are known and are commercially available.

Although high levels of purity are preferred when the isolated proteins of the present invention are used as therapeutic agents, such as in vaccines and as replacement therapy, the isolated proteins of the present invention are also useful at lower purity. For example, partially purified proteins of the present invention can be used as immunogens  
30 to raise antibodies in laboratory animals.

In preferred embodiments, the purified and substantially purified proteins of the present invention are in compositions that lack detectable ampholytes, acrylamide monomers, bis-acrylamide monomers, and polyacrylamide.

The polypeptides, fragments, analogs, derivatives and fusions of the present  
5 invention can usefully be attached to a substrate. The substrate can be porous or solid, planar or non-planar; the bond can be covalent or noncovalent.

For example, the polypeptides, fragments, analogs, derivatives and fusions of the present invention can usefully be bound to a porous substrate, commonly a membrane, typically comprising nitrocellulose, polyvinylidene fluoride (PVDF), or cationically  
10 derivatized, hydrophilic PVDF; so bound, the proteins, fragments, and fusions of the present invention can be used to detect and quantify antibodies, *e.g.* in serum, that bind specifically to the immobilized protein of the present invention.

As another example, the polypeptides, fragments, analogs, derivatives and fusions of the present invention can usefully be bound to a substantially nonporous substrate,  
15 such as plastic, to detect and quantify antibodies, *e.g.* in serum, that bind specifically to the immobilized protein of the present invention. Such plastics include polymethylacrylic, polyethylene, polypropylene, polyacrylate, polymethylmethacrylate, polyvinylchloride, polytetrafluoroethylene, polystyrene, polycarbonate, polyacetal, polysulfone, celluloseacetate, cellulosenitrate, nitrocellulose, or mixtures thereof; when  
20 the assay is performed in a standard microtiter dish, the plastic is typically polystyrene.

The polypeptides, fragments, analogs, derivatives and fusions of the present invention can also be attached to a substrate suitable for use as a surface enhanced laser desorption ionization source; so attached, the protein, fragment, or fusion of the present invention is useful for binding and then detecting secondary proteins that bind with  
25 sufficient affinity or avidity to the surface-bound protein to indicate biologic interaction there between. The proteins, fragments, and fusions of the present invention can also be attached to a substrate suitable for use in surface plasmon resonance detection; so attached, the protein, fragment, or fusion of the present invention is useful for binding and then detecting secondary proteins that bind with sufficient affinity or avidity to the  
30 surface-bound protein to indicate biological interaction there between.

### Antibodies

In another aspect, the invention provides antibodies, including fragments and derivatives thereof, that bind specifically to polypeptides encoded by the nucleic acid molecules of the invention, as well as antibodies that bind to fragments, muteins, derivatives and analogs of the polypeptides. In a preferred embodiment, the antibodies are specific for a polypeptide that is an LSP, or a fragment, mutein, derivative, analog or fusion protein thereof. In a more preferred embodiment, the antibodies are specific for a polypeptide that comprises SEQ ID NO: 143 through 277, or a fragment, mutein, derivative, analog or fusion protein thereof.

The antibodies of the present invention can be specific for linear epitopes, discontinuous epitopes, or conformational epitopes of such proteins or protein fragments, either as present on the protein in its native conformation or, in some cases, as present on the proteins as denatured, as, *e.g.*, by solubilization in SDS. New epitopes may be also due to a difference in post translational modifications (PTMs) in disease versus normal tissue. For example, a particular site on a LSP may be glycosylated in cancerous cells, but not glycosylated in normal cells or visa versa. In addition, alternative splice forms of a LSP may be indicative of cancer. Differential degradation of the C or N-terminus of a LSP may also be a marker or target for anticancer therapy. For example, a LSP may be N-terminal degraded in cancer cells exposing new epitopes to which antibodies may selectively bind for diagnostic or therapeutic uses.

As is well-known in the art, the degree to which an antibody can discriminate as among molecular species in a mixture will depend, in part, upon the conformational relatedness of the species in the mixture; typically, the antibodies of the present invention will discriminate over adventitious binding to non-LSP polypeptides by at least 2-fold, more typically by at least 5-fold, typically by more than 10-fold, 25-fold, 50-fold, 75-fold, and often by more than 100-fold, and on occasion by more than 500-fold or 1000-fold. When used to detect the proteins or protein fragments of the present invention, the antibody of the present invention is sufficiently specific when it can be used to determine the presence of the protein of the present invention in samples derived from human lung.

Typically, the affinity or avidity of an antibody (or antibody multimer, as in the case of an IgM pentamer) of the present invention for a protein or protein fragment of the present invention will be at least about  $1 \times 10^{-6}$  molar (M), typically at least about  $5 \times 10^{-7}$

-79-

<sup>7</sup> M,  $1 \times 10^{-7}$  M, with affinities and avidities of at least  $1 \times 10^{-8}$  M,  $5 \times 10^{-9}$  M,  $1 \times 10^{-10}$  M and up to  $1 \times 10^{-13}$  M proving especially useful.

The antibodies of the present invention can be naturally-occurring forms, such as IgG, IgM, IgD, IgE, IgY, and IgA, from any avian, reptilian, or mammalian species.

5 Human antibodies can, but will infrequently, be drawn directly from human donors or human cells. In this case, antibodies to the proteins of the present invention will typically have resulted from fortuitous immunization, such as autoimmune immunization, with the protein or protein fragments of the present invention. Such antibodies will typically, but will not invariably, be polyclonal. In addition, individual  
10 polyclonal antibodies may be isolated and cloned to generate monoclonals.

Human antibodies are more frequently obtained using transgenic animals that express human immunoglobulin genes, which transgenic animals can be affirmatively immunized with the protein immunogen of the present invention. Human Ig-transgenic mice capable of producing human antibodies and methods of producing human  
15 antibodies therefrom upon specific immunization are described, *inter alia*, in U.S. Patents 6,162,963; 6,150,584; 6,114,598; 6,075,181; 5,939,598; 5,877,397; 5,874,299; 5,814,318; 5,789,650; 5,770,429; 5,661,016; 5,633,425; 5,625,126; 5,569,825; 5,545,807; 5,545,806, and 5,591,669, the disclosures of which are incorporated herein by reference in their entireties. Such antibodies are typically monoclonal, and are typically  
20 produced using techniques developed for production of murine antibodies.

Human antibodies are particularly useful, and often preferred, when the antibodies of the present invention are to be administered to human beings as *in vivo* diagnostic or therapeutic agents, since recipient immune response to the administered antibody will often be substantially less than that occasioned by administration of an  
25 antibody derived from another species, such as mouse.

IgG, IgM, IgD, IgE, IgY, and IgA antibodies of the present invention can also be obtained from other species, including mammals such as rodents (typically mouse, but also rat, guinea pig, and hamster) lagomorphs, typically rabbits, and also larger mammals, such as sheep, goats, cows, and horses, and other egg laying birds or reptiles  
30 such as chickens or alligators. For example, avian antibodies may be generated using techniques described in WO 00/29444, published 25 May 2000, the contents of which are hereby incorporated in their entirety. In such cases, as with the transgenic human-

antibody-producing non-human mammals, fortuitous immunization is not required, and the non-human mammal is typically affirmatively immunized, according to standard immunization protocols, with the protein or protein fragment of the present invention.

As discussed above, virtually all fragments of 8 or more contiguous amino acids  
5 of the proteins of the present invention can be used effectively as immunogens when conjugated to a carrier, typically a protein such as bovine thyroglobulin, keyhole limpet hemocyanin, or bovine serum albumin, conveniently using a bifunctional linker such as those described elsewhere above, which discussion is incorporated by reference here.

Immunogenicity can also be conferred by fusion of the polypeptide and fragments  
10 of the present invention to other moieties. For example, peptides of the present invention can be produced by solid phase synthesis on a branched polylysine core matrix; these multiple antigenic peptides (MAPs) provide high purity, increased avidity, accurate chemical definition and improved safety in vaccine development. Tam *et al.*, *Proc. Natl. Acad. Sci. USA* 85: 5409-5413 (1988); Posnett *et al.*, *J. Biol. Chem.* 263: 1719-1725  
15 (1988).

Protocols for immunizing non-human mammals or avian species are well-established in the art. See Harlow *et al.* (eds.), Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory (1998); Coligan *et al.* (eds.), Current Protocols in Immunology, John Wiley & Sons, Inc. (2001); Zola, Monoclonal Antibodies: Preparation  
20 and Use of Monoclonal Antibodies and Engineered Antibody Derivatives (Basics: From Background to Bench), Springer Verlag (2000); Gross M, Speck *J.Dtsch. Tierarztl. Wochenschr.* 103: 417-422 (1996), the disclosures of which are incorporated herein by reference. Immunization protocols often include multiple immunizations, either with or without adjuvants such as Freund's complete adjuvant and Freund's incomplete adjuvant,  
25 and may include naked DNA immunization (Moss, *Semin. Immunol.* 2: 317-327 (1990)).

Antibodies from non-human mammals and avian species can be polyclonal or monoclonal, with polyclonal antibodies having certain advantages in immunohistochemical detection of the proteins of the present invention and monoclonal antibodies having advantages in identifying and distinguishing particular epitopes of the  
30 proteins of the present invention. Antibodies from avian species may have particular advantage in detection of the proteins of the present invention, in human serum or tissues (Viking *et al.*, *Biosens. Bioelectron.* 13: 1257-1262 (1998)).

Following immunization, the antibodies of the present invention can be produced using any art-accepted technique. Such techniques are well-known in the art, Coligan, *supra*; Zola, *supra*; Howard *et al.* (eds.), Basic Methods in Antibody Production and Characterization, CRC Press (2000); Harlow, *supra*; Davis (ed.), Monoclonal Antibody  
5 Protocols, Vol. 45, Humana Press (1995); Delves (ed.), Antibody Production: Essential Techniques, John Wiley & Son Ltd (1997); Kenney, Antibody Solution: An Antibody Methods Manual, Chapman & Hall (1997), incorporated herein by reference in their entireties, and thus need not be detailed here.

Briefly, however, such techniques include, *inter alia*, production of monoclonal  
10 antibodies by hybridomas and expression of antibodies or fragments or derivatives thereof from host cells engineered to express immunoglobulin genes or fragments thereof. These two methods of production are not mutually exclusive: genes encoding antibodies specific for the proteins or protein fragments of the present invention can be cloned from hybridomas and thereafter expressed in other host cells. Nor need the two  
15 necessarily be performed together: *e.g.*, genes encoding antibodies specific for the proteins and protein fragments of the present invention can be cloned directly from B cells known to be specific for the desired protein, as further described in U.S. Patent 5,627,052, the disclosure of which is incorporated herein by reference in its entirety, or from antibody-displaying phage.

20 Recombinant expression in host cells is particularly useful when fragments or derivatives of the antibodies of the present invention are desired.

Host cells for recombinant production of either whole antibodies, antibody fragments, or antibody derivatives can be prokaryotic or eukaryotic.

Prokaryotic hosts are particularly useful for producing phage displayed antibodies  
25 of the present invention.

The technology of phage-displayed antibodies, in which antibody variable region fragments are fused, for example, to the gene III protein (pIII) or gene VIII protein (pVIII) for display on the surface of filamentous phage, such as M13, is by now well-established. *See, e.g.*, Sidhu, *Curr. Opin. Biotechnol.* 11(6): 610-6 (2000); Griffiths *et al.*, *Curr. Opin. Biotechnol.* 9(1): 102-8 (1998); Hoogenboom *et al.*, *Immunotechnology*,  
30 4(1): 1-20 (1998); Rader *et al.*, *Current Opinion in Biotechnology* 8: 503-508 (1997); Aujame *et al.*, *Human Antibodies* 8: 155-168 (1997); Hoogenboom, *Trends in*

*Biotechnol.* 15: 62-70 (1997); de Kruif *et al.*, 17: 453-455 (1996); Barbas *et al.*, *Trends in Biotechnol.* 14: 230-234 (1996); Winter *et al.*, *Ann. Rev. Immunol.* 433-455 (1994).

Techniques and protocols required to generate, propagate, screen (pan), and use the antibody fragments from such libraries have recently been compiled. See, e.g., Barbas  
5 (2001), *supra*; Kay, *supra*; Abelson, *supra*, the disclosures of which are incorporated herein by reference in their entireties.

Typically, phage-displayed antibody fragments are scFv fragments or Fab fragments; when desired, full length antibodies can be produced by cloning the variable regions from the displaying phage into a complete antibody and expressing the full length  
10 antibody in a further prokaryotic or a eukaryotic host cell.

Eukaryotic cells are also useful for expression of the antibodies, antibody fragments, and antibody derivatives of the present invention.

For example, antibody fragments of the present invention can be produced in *Pichia pastoris* and in *Saccharomyces cerevisiae*. See, e.g., Takahashi *et al.*, *Biosci.*  
15 *Biotechnol. Biochem.* 64(10): 2138-44 (2000); Freyre *et al.*, *J. Biotechnol.* 76(2-3): 157-63 (2000); Fischer *et al.*, *Biotechnol. Appl. Biochem.* 30 (Pt 2): 117-20 (1999); Pennell *et al.*, *Res. Immunol.* 149(6): 599-603 (1998); Eldin *et al.*, *J. Immunol. Methods.* 201(1): 67-75 (1997);, Frenken *et al.*, *Res. Immunol.* 149(6): 589-99 (1998); Shusta *et al.*, *Nature Biotechnol.* 16(8): 773-7 (1998), the disclosures of which are incorporated herein  
20 by reference in their entireties.

Antibodies, including antibody fragments and derivatives, of the present invention can also be produced in insect cells. See, e.g., Li *et al.*, *Protein Expr. Purif.* 21(1): 121-8 (2001); Ailor *et al.*, *Biotechnol. Bioeng.* 58(2-3): 196-203 (1998); Hsu *et al.*, *Biotechnol. Prog.* 13(1): 96-104 (1997); Edelman *et al.*, *Immunology* 91(1): 13-9 (1997);  
25 and Nesbit *et al.*, *J. Immunol. Methods* 151(1-2): 201-8 (1992), the disclosures of which are incorporated herein by reference in their entireties.

Antibodies and fragments and derivatives thereof of the present invention can also be produced in plant cells, particularly maize or tobacco, Giddings *et al.*, *Nature Biotechnol.* 18(11): 1151-5 (2000); Gavilondo *et al.*, *Biotechniques* 29(1): 128-38 (2000);  
30 Fischer *et al.*, *J. Biol. Regul. Homeost. Agents* 14(2): 83-92 (2000); Fischer *et al.*, *Biotechnol. Appl. Biochem.* 30 (Pt 2): 113-6 (1999); Fischer *et al.*, *Biol. Chem.* 380(7-8): 825-39 (1999); Russell, *Curr. Top. Microbiol. Immunol.* 240: 119-38 (1999); and Ma *et*



*al.*, *Plant Physiol.* 109(2): 341-6 (1995), the disclosures of which are incorporated herein by reference in their entirety.

Antibodies, including antibody fragments and derivatives, of the present invention can also be produced in transgenic, non-human, mammalian milk. *See, e.g.*

- 5 Pollock et al., *J. Immunol. Methods.* 231: 147-57 (1999); Young et al., *Res. Immunol.* 149: 609-10 (1998); Limonta et al., *Immunotechnology* 1: 107-13 (1995), the disclosures of which are incorporated herein by reference in their entirety.

Mammalian cells useful for recombinant expression of antibodies, antibody fragments, and antibody derivatives of the present invention include CHO cells, COS

- 10 cells, 293 cells, and myeloma cells.

Verma et al., *J. Immunol. Methods* 216(1-2):165-81 (1998), herein incorporated by reference, review and compare bacterial, yeast, insect and mammalian expression systems for expression of antibodies.

- Antibodies of the present invention can also be prepared by cell free translation,  
15 as further described in Merk et al., *J. Biochem. (Tokyo)* 125(2): 328-33 (1999) and Ryabova et al., *Nature Biotechnol.* 15(1): 79-84 (1997), and in the milk of transgenic animals, as further described in Pollock et al., *J. Immunol. Methods* 231(1-2): 147-57 (1999), the disclosures of which are incorporated herein by reference in their entirety.

- The invention further provides antibody fragments that bind specifically to one or  
20 more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, or the binding of which can be competitively inhibited by one or more of the proteins and protein fragments of the present invention or one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention.

- 25 Among such useful fragments are Fab, Fab', Fv, F(ab)'<sub>2</sub>, and single chain Fv (scFv) fragments. Other useful fragments are described in Hudson, *Curr. Opin. Biotechnol.* 9(4): 395-402 (1998).

- It is also an aspect of the present invention to provide antibody derivatives that bind specifically to one or more of the proteins and protein fragments of the present  
30 invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, or the binding of which can be competitively inhibited by one or more of the proteins and protein fragments of the present invention or

one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention.

Among such useful derivatives are chimeric, primatized, and humanized antibodies; such derivatives are less immunogenic in human beings, and thus more  
5 suitable for *in vivo* administration, than are unmodified antibodies from non-human mammalian species. Another useful derivative is PEGylation to increase the serum half life of the antibodies.

Chimeric antibodies typically include heavy and/or light chain variable regions (including both CDR and framework residues) of immunoglobulins of one species,  
10 typically mouse, fused to constant regions of another species, typically human. *See, e.g.*, United States Patent No. 5,807,715; Morrison *et al.*, *Proc. Natl. Acad. Sci USA* 81(21): 6851-5 (1984); Sharon *et al.*, *Nature* 309(5966): 364-7 (1984); Takeda *et al.*, *Nature* 314(6010): 452-4 (1985), the disclosures of which are incorporated herein by reference in their entireties. Primatized and humanized antibodies typically include heavy and/or  
15 light chain CDRs from a murine antibody grafted into a non-human primate or human antibody V region framework, usually further comprising a human constant region, Riechmann *et al.*, *Nature* 332(6162): 323-7 (1988); Co *et al.*, *Nature* 351(6326): 501-2 (1991); United States Patent Nos. 6,054,297; 5,821,337; 5,770,196; 5,766,886; 5,821,123; 5,869,619; 6,180,377; 6,013,256; 5,693,761; and 6,180,370, the disclosures of  
20 which are incorporated herein by reference in their entireties.

Other useful antibody derivatives of the invention include heteromeric antibody complexes and antibody fusions, such as diabodies (bispecific antibodies), single-chain diabodies, and intrabodies.

It is contemplated that the nucleic acids encoding the antibodies of the present  
25 invention can be operably joined to other nucleic acids forming a recombinant vector for cloning or for expression of the antibodies of the invention. The present invention includes any recombinant vector containing the coding sequences, or part thereof, whether for eukaryotic transduction, transfection or gene therapy. Such vectors may be prepared using conventional molecular biology techniques, known to those with skill in  
30 the art, and would comprise DNA encoding sequences for the immunoglobulin V-regions including framework and CDRs or parts thereof, and a suitable promoter either with or without a signal sequence for intracellular transport. Such vectors may be transduced or

transfected into eukaryotic cells or used for gene therapy (Marasco et al., *Proc. Natl. Acad. Sci. (USA)* 90: 7889-7893 (1993); Duan et al., *Proc. Natl. Acad. Sci. (USA)* 91: 5075-5079 (1994), by conventional techniques, known to those with skill in the art.

The antibodies of the present invention, including fragments and derivatives thereof, can usefully be labeled. It is, therefore, another aspect of the present invention to provide labeled antibodies that bind specifically to one or more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, or the binding of which can be competitively inhibited by one or more of the proteins and protein fragments of the present invention or one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention.

The choice of label depends, in part, upon the desired use.

For example, when the antibodies of the present invention are used for immunohistochemical staining of tissue samples, the label is preferably an enzyme that catalyzes production and local deposition of a detectable product.

Enzymes typically conjugated to antibodies to permit their immunohistochemical visualization are well-known, and include alkaline phosphatase,  $\beta$ -galactosidase, glucose oxidase, horseradish peroxidase (HRP), and urease. Typical substrates for production and deposition of visually detectable products include o-nitrophenyl-beta-D-galactopyranoside (ONPG); o-phenylenediamine dihydrochloride (OPD); p-nitrophenyl phosphate (PNPP); p-nitrophenyl-beta-D-galactopyranoside (PNPG); 3',3'-diaminobenzidine (DAB); 3-amino-9-ethylcarbazole (AEC); 4-chloro-1-naphthol (CN); 5-bromo-4-chloro-3-indolyl-phosphate (BCIP); ABTS®; BlueGal; iodonitrotetrazolium (INT); nitroblue tetrazolium chloride (NBT); phenazine methosulfate (PMS); phenolphthalein monophosphate (PMP); tetramethyl benzidine (TMB); tetranitroblue tetrazolium (TNBT); X-Gal; X-Gluc; and X-Glucoside.

Other substrates can be used to produce products for local deposition that are luminescent. For example, in the presence of hydrogen peroxide ( $H_2O_2$ ), horseradish peroxidase (HRP) can catalyze the oxidation of cyclic diacylhydrazides, such as luminol. Immediately following the oxidation, the luminol is in an excited state (intermediate reaction product), which decays to the ground state by emitting light. Strong enhancement of the light emission is produced by enhancers, such as phenolic

compounds. Advantages include high sensitivity, high resolution, and rapid detection without radioactivity and requiring only small amounts of antibody. *See, e.g., Thorpe et al., Methods Enzymol.* 133: 331-53 (1986); Kricka *et al., J. Immunoassay* 17(1): 67-83 (1996); and Lundqvist *et al., J. Biolumin. Chemilumin.* 10(6): 353-9 (1995), the  
5 disclosures of which are incorporated herein by reference in their entireties. Kits for such enhanced chemiluminescent detection (ECL) are available commercially.

The antibodies can also be labeled using colloidal gold.

As another example, when the antibodies of the present invention are used, *e.g.,* for flow cytometric detection, for scanning laser cytometric detection, or for fluorescent  
10 immunoassay, they can usefully be labeled with fluorophores.

There are a wide variety of fluorophore labels that can usefully be attached to the antibodies of the present invention.

For flow cytometric applications, both for extracellular detection and for intracellular detection, common useful fluorophores can be fluorescein isothiocyanate  
15 (FITC), allophycocyanin (APC), R-phycoerythrin (PE), peridinin chlorophyll protein (PerCP), Texas Red, Cy3, Cy5, fluorescence resonance energy tandem fluorophores such as PerCP-Cy5.5, PE-Cy5, PE-Cy5.5, PE-Cy7, PE-Texas Red, and APC-Cy7.

Other fluorophores include, *inter alia*, Alexa Fluor® 350, Alexa Fluor® 488, Alexa Fluor® 532, Alexa Fluor® 546, Alexa Fluor® 568, Alexa Fluor® 594, Alexa  
20 Fluor® 647 (monoclonal antibody labeling kits available from Molecular Probes, Inc., Eugene, OR, USA), BODIPY dyes, such as BODIPY 493/503, BODIPY FL, BODIPY R6G, BODIPY 530/550, BODIPY TMR, BODIPY 558/568, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY TR, BODIPY 630/650, BODIPY 650/665, Cascade Blue, Cascade Yellow, Dansyl, lissamine  
25 rhodamine B, Marina Blue, Oregon Green 488, Oregon Green 514, Pacific Blue, rhodamine 6G, rhodamine green, rhodamine red, tetramethylrhodamine, Texas Red (available from Molecular Probes, Inc., Eugene, OR, USA), and Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7, all of which are also useful for fluorescently labeling the antibodies of the present invention.

30 For secondary detection using labeled avidin, streptavidin, captavidin or neutravidin, the antibodies of the present invention can usefully be labeled with biotin.

When the antibodies of the present invention are used, *e.g.*, for Western blotting applications, they can usefully be labeled with radioisotopes, such as  $^{33}\text{P}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^3\text{H}$ , and  $^{125}\text{I}$ .

As another example, when the antibodies of the present invention are used for radioimmunotherapy, the label can usefully be  $^{228}\text{Th}$ ,  $^{227}\text{Ac}$ ,  $^{225}\text{Ac}$ ,  $^{223}\text{Ra}$ ,  $^{213}\text{Bi}$ ,  $^{212}\text{Pb}$ ,  $^{212}\text{Bi}$ ,  $^{211}\text{At}$ ,  $^{203}\text{Pb}$ ,  $^{194}\text{Os}$ ,  $^{188}\text{Re}$ ,  $^{186}\text{Re}$ ,  $^{153}\text{Sm}$ ,  $^{149}\text{Tb}$ ,  $^{131}\text{I}$ ,  $^{125}\text{I}$ ,  $^{111}\text{In}$ ,  $^{105}\text{Rh}$ ,  $^{99\text{m}}\text{Tc}$ ,  $^{97}\text{Ru}$ ,  $^{90}\text{Y}$ ,  $^{90}\text{Sr}$ ,  $^{88}\text{Y}$ ,  $^{72}\text{Se}$ ,  $^{67}\text{Cu}$ , or  $^{47}\text{Sc}$ .

As another example, when the antibodies of the present invention are to be used for *in vivo* diagnostic use, they can be rendered detectable by conjugation to MRI contrast agents, such as gadolinium diethylenetriaminepentaacetic acid (DTPA), Lauffer *et al.*, *Radiology* 207(2): 529-38 (1998), or by radioisotopic labeling.

As would be understood, use of the labels described above is not restricted to the application for which they are mentioned.

The antibodies of the present invention, including fragments and derivatives thereof, can also be conjugated to toxins, in order to target the toxin's ablative action to cells that display and/or express the proteins of the present invention. Commonly, the antibody in such immunotoxins is conjugated to *Pseudomonas* exotoxin A, diphtheria toxin, shiga toxin A, anthrax toxin lethal factor, or ricin. See Hall (ed.), Immunotoxin Methods and Protocols (Methods in Molecular Biology, vol. 166), Humana Press (2000); and Frankel *et al.* (eds.), Clinical Applications of Immunotoxins, Springer-Verlag (1998), the disclosures of which are incorporated herein by reference in their entireties.

The antibodies of the present invention can usefully be attached to a substrate, and it is, therefore, another aspect of the invention to provide antibodies that bind specifically to one or more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, or the binding of which can be competitively inhibited by one or more of the proteins and protein fragments of the present invention or one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, attached to a substrate.

Substrates can be porous or nonporous, planar or nonplanar.

For example, the antibodies of the present invention can usefully be conjugated to filtration media, such as NHS-activated Sepharose or CNBr-activated Sepharose for purposes of immunoaffinity chromatography.

For example, the antibodies of the present invention can usefully be attached to  
5 paramagnetic microspheres, typically by biotin-streptavidin interaction, which microspheres can then be used for isolation of cells that express or display the proteins of the present invention. As another example, the antibodies of the present invention can usefully be attached to the surface of a microtiter plate for ELISA.

As noted above, the antibodies of the present invention can be produced in  
10 prokaryotic and eukaryotic cells. It is, therefore, another aspect of the present invention to provide cells that express the antibodies of the present invention, including hybridoma cells, B cells, plasma cells, and host cells recombinantly modified to express the antibodies of the present invention.

In yet a further aspect, the present invention provides aptamers evolved to bind  
15 specifically to one or more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, or the binding of which can be competitively inhibited by one or more of the proteins and protein fragments of the present invention or one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present  
20 invention.

In sum, one of skill in the art, provided with the teachings of this invention, has available a variety of methods which may be used to alter the biological properties of the antibodies of this invention including methods which would increase or decrease the stability or half-life, immunogenicity, toxicity, affinity or yield of a given antibody  
25 molecule, or to alter it in any other way that may render it more suitable for a particular application.

#### Transgenic Animals and Cells

In another aspect, the invention provides transgenic cells and non-human  
30 organisms comprising nucleic acid molecules of the invention. In a preferred embodiment, the transgenic cells and non-human organisms comprise a nucleic acid molecule encoding an LSP. In a preferred embodiment, the LSP comprises an amino

acid sequence selected from SEQ ID NO: 143 through 277, or a fragment, mutein, homologous protein or allelic variant thereof. In another preferred embodiment, the transgenic cells and non-human organism comprise an LSNA of the invention, preferably an LSNA comprising a nucleotide sequence selected from the group consisting of SEQ  
5 ID NO: 1 through 142, or a part, substantially similar nucleic acid molecule, allelic variant or hybridizing nucleic acid molecule thereof.

In another embodiment, the transgenic cells and non-human organisms have a targeted disruption or replacement of the endogenous orthologue of the human LSG. The transgenic cells can be embryonic stem cells or somatic cells. The transgenic non-human  
10 organisms can be chimeric, nonchimeric heterozygotes, and nonchimeric homozygotes. Methods of producing transgenic animals are well-known in the art. *See, e.g., Hogan et al., Manipulating the Mouse Embryo: A Laboratory Manual*, 2d ed., Cold Spring Harbor Press (1999); Jackson *et al.*, *Mouse Genetics and Transgenics: A Practical Approach*, Oxford University Press (2000); and Pinkert, *Transgenic Animal Technology: A*  
15 *Laboratory Handbook*, Academic Press (1999).

Any technique known in the art may be used to introduce a nucleic acid molecule of the invention into an animal to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection. (*see, e.g., Paterson et al., Appl. Microbiol. Biotechnol.* 40: 691-698 (1994); Carver *et al.*, *Biotechnology* 11:  
20 1263-1270 (1993); Wright *et al.*, *Biotechnology* 9: 830-834 (1991); and U.S. Patent 4,873,191 (1989 retrovirus-mediated gene transfer into germ lines, blastocysts or embryos (*see, e.g., Van der Putten et al., Proc. Natl. Acad. Sci., USA* 82: 6148-6152 (1985)); gene targeting in embryonic stem cells (*see, e.g., Thompson et al., Cell* 56: 313-321 (1989)); electroporation of cells or embryos (*see, e.g., Lo, 1983, Mol. Cell. Biol.*  
25 3: 1803-1814 (1983)); introduction using a gene gun (*see, e.g., Ulmer et al., Science* 259: 1745-49 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated gene transfer (*see, e.g., Lavitrano et al., Cell* 57: 717-723 (1989)).

Other techniques include, for example, nuclear transfer into enucleated oocytes of  
30 nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (*see, e.g., Campell et al., Nature* 380: 64-66 (1996); Wilmut *et al., Nature* 385: 810-813 (1997)). The present invention provides for transgenic animals that carry the transgene (*i.e., a*

nucleic acid molecule of the invention) in all their cells, as well as animals which carry the transgene in some, but not all their cells, i. e., mosaic animals or chimeric animals.

The transgene may be integrated as a single transgene or as multiple copies, such as in concatamers, e. g., head-to-head tandems or head-to-tail tandems. The transgene  
5 may also be selectively introduced into and activated in a particular cell type by following, e.g., the teaching of Lasko *et al. et al.*, *Proc. Natl. Acad. Sci. USA* 89: 6232-6236 (1992). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

10 Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using  
15 techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse transcriptase-PCR (RT-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

20 Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels  
25 because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is  
30 appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of



the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

Methods for creating a transgenic animal with a disruption of a targeted gene are also well-known in the art. In general, a vector is designed to comprise some nucleotide sequences homologous to the endogenous targeted gene. The vector is introduced into a cell so that it may integrate, via homologous recombination with chromosomal sequences, into the endogenous gene, thereby disrupting the function of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type. *See, e.g., Gu et al., Science* 265: 103-106 (1994). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. *See, e.g., Smithies et al., Nature* 317: 230-234 (1985); Thomas *et al., Cell* 51: 503-512 (1987); Thompson *et al., Cell* 5: 313-321 (1989).

In one embodiment, a mutant, non-functional nucleic acid molecule of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous nucleic acid sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention *in vivo*. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene. *See, e.g., Thomas, supra* and Thompson, *supra*. However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (*e.g., knockouts*) are administered to a patient *in vivo*. Such cells may be obtained from an animal or patient or an MHC

compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (*e.g.*, lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt  
5 the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, *e.g.*, by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc.

10 The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, *e.g.*, in the circulation, or intraperitoneally.

15 Alternatively, the cells can be incorporated into a matrix and implanted in the body, *e.g.*, genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. *See, e.g.*, U.S. Patents 5,399,349 and 5,460,959, each of which is incorporated by reference herein in its entirety.

20 When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well-known techniques which prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the  
25 introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such  
30 conditions and/or disorders.

Computer Readable Means

A further aspect of the invention relates to a computer readable means for storing the nucleic acid and amino acid sequences of the instant invention. In a preferred embodiment, the invention provides a computer readable means for storing SEQ ID NO: 1 through 142 and SEQ ID NO: 143 through 277 as described herein, as the complete set of sequences or in any combination. The records of the computer readable means can be accessed for reading and display and for interface with a computer system for the application of programs allowing for the location of data upon a query for data meeting certain criteria, the comparison of sequences, the alignment or ordering of sequences meeting a set of criteria, and the like.

The nucleic acid and amino acid sequences of the invention are particularly useful as components in databases useful for search analyses as well as in sequence analysis algorithms. As used herein, the terms "nucleic acid sequences of the invention" and "amino acid sequences of the invention" mean any detectable chemical or physical characteristic of a polynucleotide or polypeptide of the invention that is or may be reduced to or stored in a computer readable form. These include, without limitation, chromatographic scan data or peak data, photographic data or scan data therefrom, and mass spectrographic data.

This invention provides computer readable media having stored thereon sequences of the invention. A computer readable medium may comprise one or more of the following: a nucleic acid sequence comprising a sequence of a nucleic acid sequence of the invention; an amino acid sequence comprising an amino acid sequence of the invention; a set of nucleic acid sequences wherein at least one of said sequences comprises the sequence of a nucleic acid sequence of the invention; a set of amino acid sequences wherein at least one of said sequences comprises the sequence of an amino acid sequence of the invention; a data set representing a nucleic acid sequence comprising the sequence of one or more nucleic acid sequences of the invention; a data set representing a nucleic acid sequence encoding an amino acid sequence comprising the sequence of an amino acid sequence of the invention; a set of nucleic acid sequences wherein at least one of said sequences comprises the sequence of a nucleic acid sequence of the invention; a set of amino acid sequences wherein at least one of said sequences comprises the sequence of an amino acid sequence of the invention; a data set

representing a nucleic acid sequence comprising the sequence of a nucleic acid sequence of the invention; a data set representing a nucleic acid sequence encoding an amino acid sequence comprising the sequence of an amino acid sequence of the invention. The computer readable medium can be any composition of matter used to store information or  
5 data, including, for example, commercially available floppy disks, tapes, hard drives, compact disks, and video disks.

Also provided by the invention are methods for the analysis of character sequences, particularly genetic sequences. Preferred methods of sequence analysis include, for example, methods of sequence homology analysis, such as identity and  
10 similarity analysis, RNA structure analysis, sequence assembly, cladistic analysis, sequence motif analysis, open reading frame determination, nucleic acid base calling, and sequencing chromatogram peak analysis.

A computer-based method is provided for performing nucleic acid sequence identity or similarity identification. This method comprises the steps of providing a  
15 nucleic acid sequence comprising the sequence of a nucleic acid of the invention in a computer readable medium; and comparing said nucleic acid sequence to at least one nucleic acid or amino acid sequence to identify sequence identity or similarity.

A computer-based method is also provided for performing amino acid homology identification, said method comprising the steps of: providing an amino acid sequence  
20 comprising the sequence of an amino acid of the invention in a computer readable medium; and comparing said an amino acid sequence to at least one nucleic acid or an amino acid sequence to identify homology.

A computer-based method is still further provided for assembly of overlapping nucleic acid sequences into a single nucleic acid sequence, said method comprising the  
25 steps of: providing a first nucleic acid sequence comprising the sequence of a nucleic acid of the invention in a computer readable medium; and screening for at least one overlapping region between said first nucleic acid sequence and a second nucleic acid sequence.

#### Diagnostic Methods for Lung Cancer

30

The present invention also relates to quantitative and qualitative diagnostic assays and methods for detecting, diagnosing, monitoring, staging and predicting cancers by

comparing expression of an LSNA or an LSP in a human patient that has or may have lung cancer, or who is at risk of developing lung cancer, with the expression of an LSNA or an LSP in a normal human control. For purposes of the present invention, "expression of an LSNA" or "LSNA expression" means the quantity of LSG mRNA that can be measured by any method known in the art or the level of transcription that can be measured by any method known in the art in a cell, tissue, organ or whole patient. Similarly, the term "expression of an LSP" or "LSP expression" means the amount of LSP that can be measured by any method known in the art or the level of translation of an LSG LSNA that can be measured by any method known in the art.

10 The present invention provides methods for diagnosing lung cancer in a patient, in particular squamous cell carcinoma, by analyzing for changes in levels of LSNA or LSP in cells, tissues, organs or bodily fluids compared with levels of LSNA or LSP in cells, tissues, organs or bodily fluids of preferably the same type from a normal human control, wherein an increase, or decrease in certain cases, in levels of an LSNA or LSP in the patient versus the normal human control is associated with the presence of lung cancer or with a predilection to the disease. In another preferred embodiment, the present invention provides methods for diagnosing lung cancer in a patient by analyzing changes in the structure of the mRNA of an LSG compared to the mRNA from a normal control. These changes include, without limitation, aberrant splicing, alterations in polyadenylation and/or alterations in 5' nucleotide capping. In yet another preferred embodiment, the present invention provides methods for diagnosing lung cancer in a patient by analyzing changes in an LSP compared to an LSP from a normal control. These changes include, e.g., alterations in glycosylation and/or phosphorylation of the LSP or subcellular LSP localization.

25 In a preferred embodiment, the expression of an LSNA is measured by determining the amount of an mRNA that encodes an amino acid sequence selected from SEQ ID NO: 143 through 277, a homolog, an allelic variant, or a fragment thereof. In a more preferred embodiment, the LSNA expression that is measured is the level of expression of an LSNA mRNA selected from SEQ ID NO: 1 through 142, or a hybridizing nucleic acid, homologous nucleic acid or allelic variant thereof, or a part of any of these nucleic acids. LSNA expression may be measured by any method known in the art, such as those described *supra*, including measuring mRNA expression by

Northern blot, quantitative or qualitative reverse transcriptase PCR (RT-PCR), microarray, dot or slot blots or *in situ* hybridization. *See, e.g.,* Ausubel (1992), *supra*; Ausubel (1999), *supra*; Sambrook (1989), *supra*; and Sambrook (2001), *supra*. LSNA transcription may be measured by any method known in the art including using a reporter  
5 gene hooked up to the promoter of an LSG of interest or doing nuclear run-off assays. Alterations in mRNA structure, *e.g.,* aberrant splicing variants, may be determined by any method known in the art, including, RT-PCR followed by sequencing or restriction analysis. As necessary, LSNA expression may be compared to a known control, such as normal lung nucleic acid, to detect a change in expression.

10 In another preferred embodiment, the expression of an LSP is measured by determining the level of an LSP having an amino acid sequence selected from the group consisting of SEQ ID NO: 143 through 277, a homolog, an allelic variant, or a fragment thereof. Such levels are preferably determined in at least one of cells, tissues, organs and/or bodily fluids, including determination of normal and abnormal levels. Thus, for  
15 instance, a diagnostic assay in accordance with the invention for diagnosing over- or underexpression of LSNA or LSP compared to normal control bodily fluids, cells, or tissue samples may be used to diagnose the presence of lung cancer. The expression level of an LSP may be determined by any method known in the art, such as those described *supra*. In a preferred embodiment, the LSP expression level may be  
20 determined by radioimmunoassays, competitive-binding assays, ELISA, Western blot, FACS, immunohistochemistry, immunoprecipitation, proteomic approaches: two-dimensional gel electrophoresis (2D electrophoresis) and non-gel-based approaches such as mass spectrometry or protein interaction profiling. *See, e.g.,* Harlow (1999), *supra*; Ausubel (1992), *supra*; and Ausubel (1999), *supra*. Alterations in the LSP  
25 structure may be determined by any method known in the art, including, *e.g.,* using antibodies that specifically recognize phosphoserine, phosphothreonine or phosphotyrosine residues, two-dimensional polyacrylamide gel electrophoresis (2D PAGE) and/or chemical analysis of amino acid residues of the protein. *Id.*

In a preferred embodiment, a radioimmunoassay (RIA) or an ELISA is used. An  
30 antibody specific to an LSP is prepared if one is not already available. In a preferred embodiment, the antibody is a monoclonal antibody. The anti-LSP antibody is bound to a solid support and any free protein binding sites on the solid support are blocked with a

protein such as bovine serum albumin. A sample of interest is incubated with the antibody on the solid support under conditions in which the LSP will bind to the anti-LSP antibody. The sample is removed, the solid support is washed to remove unbound material, and an anti-LSP antibody that is linked to a detectable reagent (a radioactive substance for RIA and an enzyme for ELISA) is added to the solid support and incubated under conditions in which binding of the LSP to the labeled antibody will occur. After binding, the unbound labeled antibody is removed by washing. For an ELISA, one or more substrates are added to produce a colored reaction product that is based upon the amount of an LSP in the sample. For an RIA, the solid support is counted for radioactive decay signals by any method known in the art. Quantitative results for both RIA and ELISA typically are obtained by reference to a standard curve.

Other methods to measure LSP levels are known in the art. For instance, a competition assay may be employed wherein an anti-LSP antibody is attached to a solid support and an allocated amount of a labeled LSP and a sample of interest are incubated with the solid support. The amount of labeled LSP detected which is attached to the solid support can be correlated to the quantity of an LSP in the sample.

Of the proteomic approaches, 2D PAGE is a well-known technique. Isolation of individual proteins from a sample such as serum is accomplished using sequential separation of proteins by isoelectric point and molecular weight. Typically, polypeptides are first separated by isoelectric point (the first dimension) and then separated by size using an electric current (the second dimension). In general, the second dimension is perpendicular to the first dimension. Because no two proteins with different sequences are identical on the basis of both size and charge, the result of 2D PAGE is a roughly square gel in which each protein occupies a unique spot. Analysis of the spots with chemical or antibody probes, or subsequent protein microsequencing can reveal the relative abundance of a given protein and the identity of the proteins in the sample.

Expression levels of an LSNA can be determined by any method known in the art, including PCR and other nucleic acid methods, such as ligase chain reaction (LCR) and nucleic acid sequence based amplification (NASBA), can be used to detect malignant cells for diagnosis and monitoring of various malignancies. For example, reverse-transcriptase PCR (RT-PCR) is a powerful technique which can be used to detect the presence of a specific mRNA population in a complex mixture of thousands of other

mRNA species. In RT-PCR, an mRNA species is first reverse transcribed to complementary DNA (cDNA) with use of the enzyme reverse transcriptase; the cDNA is then amplified as in a standard PCR reaction.

Hybridization to specific DNA molecules (*e.g.*, oligonucleotides) arrayed on a solid support can be used to both detect the expression of and quantitate the level of expression of one or more LSNAs of interest. In this approach, all or a portion of one or more LSNAs is fixed to a substrate. A sample of interest, which may comprise RNA, *e.g.*, total RNA or polyA-selected mRNA, or a complementary DNA (cDNA) copy of the RNA is incubated with the solid support under conditions in which hybridization will occur between the DNA on the solid support and the nucleic acid molecules in the sample of interest. Hybridization between the substrate-bound DNA and the nucleic acid molecules in the sample can be detected and quantitated by several means, including, without limitation, radioactive labeling or fluorescent labeling of the nucleic acid molecule or a secondary molecule designed to detect the hybrid.

The above tests can be carried out on samples derived from a variety of cells, bodily fluids and/or tissue extracts such as homogenates or solubilized tissue obtained from a patient. Tissue extracts are obtained routinely from tissue biopsy and autopsy material. Bodily fluids useful in the present invention include blood, urine, saliva or any other bodily secretion or derivative thereof. By blood it is meant to include whole blood, plasma, serum or any derivative of blood. In a preferred embodiment, the specimen tested for expression of LSNA or LSP includes, without limitation, lung tissue, fluid obtained by bronchial alveolar lavage (BAL), sputum, lung cells grown in cell culture, blood, serum, lymph node tissue and lymphatic fluid. In another preferred embodiment, especially when metastasis of a primary lung cancer is known or suspected, specimens include, without limitation, tissues from brain, bone, bone marrow, liver, adrenal glands and colon. In general, the tissues may be sampled by biopsy, including, without limitation, needle biopsy, *e.g.*, transthoracic needle aspiration, cervical mediastinoscopy, endoscopic lymph node biopsy, video-assisted thoracoscopy, exploratory thoracotomy, bone marrow biopsy and bone marrow aspiration. See Scott, *supra* and Franklin, pp. 529-570, in Kane, *supra*. For early and inexpensive detection, assaying for changes in LSNAs or LSPs in cells in sputum samples may be particularly useful. Methods of obtaining and analyzing sputum samples is disclosed in Franklin, *supra*.



All the methods of the present invention may optionally include determining the expression levels of one or more other cancer markers in addition to determining the expression level of an LSNA or LSP. In many cases, the use of another cancer marker will decrease the likelihood of false positives or false negatives. In one embodiment, the one or more other cancer markers include other LSNA or LSPs as disclosed herein. Other cancer markers useful in the present invention will depend on the cancer being tested and are known to those of skill in the art. In a preferred embodiment, at least one other cancer marker in addition to a particular LSNA or LSP is measured. In a more preferred embodiment, at least two other additional cancer markers are used. In an even more preferred embodiment, at least three, more preferably at least five, even more preferably at least ten additional cancer markers are used.

#### *Diagnosing*

In one aspect, the invention provides a method for determining the expression levels and/or structural alterations of one or more LSNAs and/or LSPs in a sample from a patient suspected of having lung cancer. In general, the method comprises the steps of obtaining the sample from the patient, determining the expression level or structural alterations of an LSNA and/or LSP and then ascertaining whether the patient has lung cancer from the expression level of the LSNA or LSP. In general, if high expression relative to a control of an LSNA or LSP is indicative of lung cancer, a diagnostic assay is considered positive if the level of expression of the LSNA or LSP is at least two times higher, and more preferably are at least five times higher, even more preferably at least ten times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control. In contrast, if low expression relative to a control of an LSNA or LSP is indicative of lung cancer, a diagnostic assay is considered positive if the level of expression of the LSNA or LSP is at least two times lower, more preferably are at least five times lower, even more preferably at least ten times lower than in preferably the same cells, tissues or bodily fluid of a normal human control. The normal human control may be from a different patient or from uninvolved tissue of the same patient.

The present invention also provides a method of determining whether lung cancer has metastasized in a patient. One may identify whether the lung cancer has metastasized by measuring the expression levels and/or structural alterations of one or more LSNAs and/or LSPs in a variety of tissues. The presence of an LSNA or LSP in a certain tissue

at levels higher than that of corresponding noncancerous tissue (e.g., the same tissue from another individual) is indicative of metastasis if high level expression of an LSNA or LSP is associated with lung cancer. Similarly, the presence of an LSNA or LSP in a tissue at levels lower than that of corresponding noncancerous tissue is indicative of metastasis if low level expression of an LSNA or LSP is associated with lung cancer. Further, the presence of a structurally altered LSNA or LSP that is associated with lung cancer is also indicative of metastasis.

In general, if high expression relative to a control of an LSNA or LSP is indicative of metastasis, an assay for metastasis is considered positive if the level of expression of the LSNA or LSP is at least two times higher, and more preferably are at least five times higher, even more preferably at least ten times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control. In contrast, if low expression relative to a control of an LSNA or LSP is indicative of metastasis, an assay for metastasis is considered positive if the level of expression of the LSNA or LSP is at least two times lower, more preferably are at least five times lower, even more preferably at least ten times lower than in preferably the same cells, tissues or bodily fluid of a normal human control.

The LSNA or LSP of this invention may be used as element in an array or a multi-analyte test to recognize expression patterns associated with lung cancers or other lung related disorders. In addition, the sequences of either the nucleic acids or proteins may be used as elements in a computer program for pattern recognition of lung disorders.

### *Staging*

The invention also provides a method of staging lung cancer in a human patient. The method comprises identifying a human patient having lung cancer and analyzing cells, tissues or bodily fluids from such human patient for expression levels and/or structural alterations of one or more LSNAs or LSPs. First, one or more tumors from a variety of patients are staged according to procedures well-known in the art, and the expression level of one or more LSNAs or LSPs is determined for each stage to obtain a standard expression level for each LSNA and LSP. Then, the LSNA or LSP expression levels are determined in a biological sample from a patient whose stage of cancer is not known. The LSNA or LSP expression levels from the patient are then compared to the

standard expression level. By comparing the expression level of the LSNAs and LSPs from the patient to the standard expression levels, one may determine the stage of the tumor. The same procedure may be followed using structural alterations of an LSNA or LSP to determine the stage of a lung cancer.

## 5 *Monitoring*

Further provided is a method of monitoring lung cancer in a human patient. One may monitor a human patient to determine whether there has been metastasis and, if there has been, when metastasis began to occur. One may also monitor a human patient to determine whether a preneoplastic lesion has become cancerous. One may also monitor  
10 a human patient to determine whether a therapy, *e.g.*, chemotherapy, radiotherapy or surgery, has decreased or eliminated the lung cancer. The method comprises identifying a human patient that one wants to monitor for lung cancer, periodically analyzing cells, tissues or bodily fluids from such human patient for expression levels of one or more LSNAs or LSPs, and comparing the LSNA or LSP levels over time to those LSNA or  
15 LSP expression levels obtained previously. Patients may also be monitored by measuring one or more structural alterations in an LSNA or LSP that are associated with lung cancer.

If increased expression of an LSNA or LSP is associated with metastasis, treatment failure, or conversion of a preneoplastic lesion to a cancerous lesion, then  
20 detecting an increase in the expression level of an LSNA or LSP indicates that the tumor is metastasizing, that treatment has failed or that the lesion is cancerous, respectively. One having ordinary skill in the art would recognize that if this were the case, then a decreased expression level would be indicative of no metastasis, effective therapy or failure to progress to a neoplastic lesion. If decreased expression of an LSNA or LSP is  
25 associated with metastasis, treatment failure, or conversion of a preneoplastic lesion to a cancerous lesion, then detecting an decrease in the expression level of an LSNA or LSP indicates that the tumor is metastasizing, that treatment has failed or that the lesion is cancerous, respectively. In a preferred embodiment, the levels of LSNAs or LSPs are determined from the same cell type, tissue or bodily fluid as prior patient samples.  
30 Monitoring a patient for onset of lung cancer metastasis is periodic and preferably is done on a quarterly basis, but may be done more or less frequently.

The methods described herein can further be utilized as prognostic assays to identify subjects having or at risk of developing a disease or disorder associated with increased or decreased expression levels of an LSNA and/or LSP. The present invention provides a method in which a test sample is obtained from a human patient and one or more LSNA and/or LSPs are detected. The presence of higher (or lower) LSNA or LSP levels as compared to normal human controls is diagnostic for the human patient being at risk for developing cancer, particularly lung cancer. The effectiveness of therapeutic agents to decrease (or increase) expression or activity of one or more LSNA and/or LSPs of the invention can also be monitored by analyzing levels of expression of the LSNA and/or LSPs in a human patient in clinical trials or in *in vitro* screening assays such as in human cells. In this way, the gene expression pattern can serve as a marker, indicative of the physiological response of the human patient or cells, as the case may be, to the agent being tested.

#### *Detection of Genetic Lesions or Mutations*

The methods of the present invention can also be used to detect genetic lesions or mutations in an LSG, thereby determining if a human with the genetic lesion is susceptible to developing lung cancer or to determine what genetic lesions are responsible, or are partly responsible, for a person's existing lung cancer. Genetic lesions can be detected, for example, by ascertaining the existence of a deletion, insertion and/or substitution of one or more nucleotides from the LSGs of this invention, a chromosomal rearrangement of LSG, an aberrant modification of LSG (such as of the methylation pattern of the genomic DNA), or allelic loss of an LSG. Methods to detect such lesions in the LSG of this invention are known to those having ordinary skill in the art following the teachings of the specification.

#### 25 Methods of Detecting Noncancerous Lung Diseases

The invention also provides a method for determining the expression levels and/or structural alterations of one or more LSNA and/or LSPs in a sample from a patient suspected of having or known to have a noncancerous lung disease. In general, the method comprises the steps of obtaining a sample from the patient, determining the expression level or structural alterations of an LSNA and/or LSP, comparing the expression level or structural alteration of the LSNA or LSP to a normal lung control,

and then ascertaining whether the patient has a noncancerous lung disease. In general, if high expression relative to a control of an LSNA or LSP is indicative of a particular noncancerous lung disease, a diagnostic assay is considered positive if the level of expression of the LSNA or LSP is at least two times higher, and more preferably are at least five times higher, even more preferably at least ten times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control. In contrast, if low expression relative to a control of an LSNA or LSP is indicative of a noncancerous lung disease, a diagnostic assay is considered positive if the level of expression of the LSNA or LSP is at least two times lower, more preferably are at least five times lower, even more preferably at least ten times lower than in preferably the same cells, tissues or bodily fluid of a normal human control. The normal human control may be from a different patient or from uninvolved tissue of the same patient.

One having ordinary skill in the art may determine whether an LSNA and/or LSP is associated with a particular noncancerous lung disease by obtaining lung tissue from a patient having a noncancerous lung disease of interest and determining which LSNAs and/or LSPs are expressed in the tissue at either a higher or a lower level than in normal lung tissue. In another embodiment, one may determine whether an LSNA or LSP exhibits structural alterations in a particular noncancerous lung disease state by obtaining lung tissue from a patient having a noncancerous lung disease of interest and determining the structural alterations in one or more LSNAs and/or LSPs relative to normal lung tissue.

#### Methods for Identifying Lung Tissue

In another aspect, the invention provides methods for identifying lung tissue. These methods are particularly useful in, *e.g.*, forensic science, lung cell differentiation and development, and in tissue engineering.

In one embodiment, the invention provides a method for determining whether a sample is lung tissue or has lung tissue-like characteristics. The method comprises the steps of providing a sample suspected of comprising lung tissue or having lung tissue-like characteristics, determining whether the sample expresses one or more LSNAs and/or LSPs, and, if the sample expresses one or more LSNAs and/or LSPs, concluding that the sample comprises lung tissue. In a preferred embodiment, the LSNA encodes a

- polypeptide having an amino acid sequence selected from SEQ ID NO: 143 through 277, or a homolog, allelic variant or fragment thereof. In a more preferred embodiment, the LSNA has a nucleotide sequence selected from SEQ ID NO: 1 through 142, or a hybridizing nucleic acid, an allelic variant or a part thereof. Determining whether a sample expresses an LSNA can be accomplished by any method known in the art. Preferred methods include hybridization to microarrays, Northern blot hybridization, and quantitative or qualitative RT-PCR. In another preferred embodiment, the method can be practiced by determining whether an LSP is expressed. Determining whether a sample expresses an LSP can be accomplished by any method known in the art.
- 10 Preferred methods include Western blot, ELISA, RIA and 2D PAGE. In one embodiment, the LSP has an amino acid sequence selected from SEQ ID NO: 143 through 277, or a homolog, allelic variant or fragment thereof. In another preferred embodiment, the expression of at least two LSNAs and/or LSPs is determined. In a more preferred embodiment, the expression of at least three, more preferably four and even
- 15 more preferably five LSNAs and/or LSPs are determined.

- In one embodiment, the method can be used to determine whether an unknown tissue is lung tissue. This is particularly useful in forensic science, in which small, damaged pieces of tissues that are not identifiable by microscopic or other means are recovered from a crime or accident scene. In another embodiment, the method can be
- 20 used to determine whether a tissue is differentiating or developing into lung tissue. This is important in monitoring the effects of the addition of various agents to cell or tissue culture, *e.g.*, in producing new lung tissue by tissue engineering. These agents include, *e.g.*, growth and differentiation factors, extracellular matrix proteins and culture medium. Other factors that may be measured for effects on tissue development and differentiation
- 25 include gene transfer into the cells or tissues, alterations in pH, aqueous:air interface and various other culture conditions.

#### Methods for Producing and Modifying Lung Tissue

- In another aspect, the invention provides methods for producing engineered lung
- 30 tissue or cells. In one embodiment, the method comprises the steps of providing cells, introducing an LSNA or an LSG into the cells, and growing the cells under conditions in which they exhibit one or more properties of lung tissue cells. In a preferred

-105-

embodiment, the cells are pluripotent. As is well-known in the art, normal lung tissue comprises a large number of different cell types. Thus, in one embodiment, the engineered lung tissue or cells comprises one of these cell types. In another embodiment, the engineered lung tissue or cells comprises more than one lung cell type. Further, the culture conditions of the cells or tissue may require manipulation in order to achieve full differentiation and development of the lung cell tissue. Methods for manipulating culture conditions are well-known in the art.

Nucleic acid molecules encoding one or more LSPs are introduced into cells, preferably pluripotent cells. In a preferred embodiment, the nucleic acid molecules encode LSPs having amino acid sequences selected from SEQ ID NO: 143 through 277, or homologous proteins, analogs, allelic variants or fragments thereof. In a more preferred embodiment, the nucleic acid molecules have a nucleotide sequence selected from SEQ ID NO: 1 through 142, or hybridizing nucleic acids, allelic variants or parts thereof. In another highly preferred embodiment, an LSG is introduced into the cells. Expression vectors and methods of introducing nucleic acid molecules into cells are well-known in the art and are described in detail, *supra*.

Artificial lung tissue may be used to treat patients who have lost some or all of their lung function.

#### Pharmaceutical Compositions

In another aspect, the invention provides pharmaceutical compositions comprising the nucleic acid molecules, polypeptides, antibodies, antibody derivatives, antibody fragments, agonists, antagonists, and inhibitors of the present invention. In a preferred embodiment, the pharmaceutical composition comprises an LSNA or part thereof. In a more preferred embodiment, the LSNA has a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 through 142, a nucleic acid that hybridizes thereto, an allelic variant thereof, or a nucleic acid that has substantial sequence identity thereto. In another preferred embodiment, the pharmaceutical composition comprises an LSP or fragment thereof. In a more preferred embodiment, the LSP having an amino acid sequence that is selected from the group consisting of SEQ ID NO: 143 through 277, a polypeptide that is homologous thereto, a fusion protein comprising all or a portion of the polypeptide, or an analog or derivative thereof. In another preferred embodiment, the

pharmaceutical composition comprises an anti-LSP antibody, preferably an antibody that specifically binds to an LSP having an amino acid that is selected from the group consisting of SEQ ID NO: 143 through 277, or an antibody that binds to a polypeptide that is homologous thereto, a fusion protein comprising all or a portion of the  
5 polypeptide, or an analog or derivative thereof.

Such a composition typically contains from about 0.1 to 90% by weight of a therapeutic agent of the invention formulated in and/or with a pharmaceutically acceptable carrier or excipient.

Pharmaceutical formulation is a well-established art, and is further described in  
10 Gennaro (ed.), Remington: The Science and Practice of Pharmacy, 20<sup>th</sup> ed., Lippincott, Williams & Wilkins (2000); Ansel *et al.*, Pharmaceutical Dosage Forms and Drug Delivery Systems, 7<sup>th</sup> ed., Lippincott Williams & Wilkins (1999); and Kibbe (ed.), Handbook of Pharmaceutical Excipients American Pharmaceutical Association, 3<sup>rd</sup> ed. (2000), the disclosures of which are incorporated herein by reference in their entireties,  
15 and thus need not be described in detail herein.

Briefly, formulation of the pharmaceutical compositions of the present invention will depend upon the route chosen for administration. The pharmaceutical compositions utilized in this invention can be administered by various routes including both enteral and parenteral routes, including oral, intravenous, intramuscular, subcutaneous, inhalation,  
20 topical, sublingual, rectal, intra-arterial, intramedullary, intrathecal, intraventricular, transmucosal, transdermal, intranasal, intraperitoneal, intrapulmonary, and intrauterine.

Oral dosage forms can be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Solid formulations of the compositions for oral administration can contain  
25 suitable carriers or excipients, such as carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, or microcrystalline cellulose; gums including arabic and tragacanth; proteins such as gelatin and collagen; inorganics, such as kaolin, calcium  
30 carbonate, dicalcium phosphate, sodium chloride; and other agents such as acacia and alginic acid.



-107-

Agents that facilitate disintegration and/or solubilization can be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate, microcrystalline cellulose, corn starch, sodium starch glycolate, and alginic acid.

- 5           Tablet binders that can be used include acacia, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone (Povidone™), hydroxypropyl methylcellulose, sucrose, starch and ethylcellulose.

Lubricants that can be used include magnesium stearates, stearic acid, silicone fluid, talc, waxes, oils, and colloidal silica.

- 10           Fillers, agents that facilitate disintegration and/or solubilization, tablet binders and lubricants, including the aforementioned, can be used singly or in combination.

- Solid oral dosage forms need not be uniform throughout. For example, dragee cores can be used in conjunction with suitable coatings, such as concentrated sugar solutions, which can also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
- 15

- Oral dosage forms of the present invention include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.
- 20

- Additionally, dyestuffs or pigments can be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, *i.e.*, dosage.
- 25

- Liquid formulations of the pharmaceutical compositions for oral (enteral) administration are prepared in water or other aqueous vehicles and can contain various suspending agents such as methylcellulose, alginates, tragacanth, pectin, kelgin, carrageenan, acacia, polyvinylpyrrolidone, and polyvinyl alcohol. The liquid formulations can also include solutions, emulsions, syrups and elixirs containing, together with the active compound(s), wetting agents, sweeteners, and coloring and flavoring agents.
- 30

The pharmaceutical compositions of the present invention can also be formulated for parenteral administration. Formulations for parenteral administration can be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions.

For intravenous injection, water soluble versions of the compounds of the present invention are formulated in, or if provided as a lyophilate, mixed with, a physiologically acceptable fluid vehicle, such as 5% dextrose ("D5"), physiologically buffered saline, 0.9% saline, Hanks' solution, or Ringer's solution. Intravenous formulations may include carriers, excipients or stabilizers including, without limitation, calcium, human serum albumin, citrate, acetate, calcium chloride, carbonate, and other salts.

10 Intramuscular preparations, *e.g.* a sterile formulation of a suitable soluble salt form of the compounds of the present invention, can be dissolved and administered in a pharmaceutical excipient such as Water-for-Injection, 0.9% saline, or 5% glucose solution. Alternatively, a suitable insoluble form of the compound can be prepared and administered as a suspension in an aqueous base or a pharmaceutically acceptable oil  
15 base, such as an ester of a long chain fatty acid (*e.g.*, ethyl oleate), fatty oils such as sesame oil, triglycerides, or liposomes.

Parenteral formulations of the compositions can contain various carriers such as vegetable oils, dimethylacetamide, dimethylformamide, ethyl lactate, ethyl carbonate, isopropyl myristate, ethanol, polyols (glycerol, propylene glycol, liquid polyethylene  
20 glycol, and the like).

Aqueous injection suspensions can also contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Non-lipid polycationic amino polymers can also be used for delivery. Optionally, the suspension can also contain suitable stabilizers or agents that increase the solubility of  
25 the compounds to allow for the preparation of highly concentrated solutions.

Pharmaceutical compositions of the present invention can also be formulated to permit injectable, long-term, deposition. Injectable depot forms may be made by forming microencapsulated matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature  
30 of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot

injectable formulations are also prepared by entrapping the drug in microemulsions that are compatible with body tissues.

The pharmaceutical compositions of the present invention can be administered topically.

5           For topical use the compounds of the present invention can also be prepared in suitable forms to be applied to the skin, or mucus membranes of the nose and throat, and can take the form of lotions, creams, ointments, liquid sprays or inhalants, drops, tinctures, lozenges, or throat paints. Such topical formulations further can include chemical compounds such as dimethylsulfoxide (DMSO) to facilitate surface penetration  
10 of the active ingredient. In other transdermal formulations, typically in patch-delivered formulations, the pharmaceutically active compound is formulated with one or more skin penetrants, such as 2-N-methyl-pyrrolidone (NMP) or Azone. A topical semi-solid ointment formulation typically contains a concentration of the active ingredient from about 1 to 20%, *e.g.*, 5 to 10%, in a carrier such as a pharmaceutical cream base.

15           For application to the eyes or ears, the compounds of the present invention can be presented in liquid or semi-liquid form formulated in hydrophobic or hydrophilic bases as ointments, creams, lotions, paints or powders.

          For rectal administration the compounds of the present invention can be administered in the form of suppositories admixed with conventional carriers such as  
20 cocoa butter, wax or other glyceride.

          Inhalation formulations can also readily be formulated. For inhalation, various powder and liquid formulations can be prepared. For aerosol preparations, a sterile formulation of the compound or salt form of the compound may be used in inhalers, such as metered dose inhalers, and nebulizers. Aerosolized forms may be especially useful for  
25 treating respiratory disorders.

          Alternatively, the compounds of the present invention can be in powder form for reconstitution in the appropriate pharmaceutically acceptable carrier at the time of delivery.

          The pharmaceutically active compound in the pharmaceutical compositions of the  
30 present invention can be provided as the salt of a variety of acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acid. Salts

tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms.

After pharmaceutical compositions have been prepared, they are packaged in an appropriate container and labeled for treatment of an indicated condition.

5       The active compound will be present in an amount effective to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

A "therapeutically effective dose" refers to that amount of active ingredient, for example LSP polypeptide, fusion protein, or fragments thereof, antibodies specific for  
10   LSP, agonists, antagonists or inhibitors of LSP, which ameliorates the signs or symptoms of the disease or prevents progression thereof; as would be understood in the medical arts, cure, although desired, is not required.

The therapeutically effective dose of the pharmaceutical agents of the present invention can be estimated initially by *in vitro* tests, such as cell culture assays, followed  
15   by assay in model animals, usually mice, rats, rabbits, dogs, or pigs. The animal model can also be used to determine an initial preferred concentration range and route of administration.

For example, the ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population) can be determined in  
20   one or more cell culture of animal model systems. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as LD50/ED50. Pharmaceutical compositions that exhibit large therapeutic indices are preferred.

The data obtained from cell culture assays and animal studies are used in formulating an initial dosage range for human use, and preferably provide a range of  
25   circulating concentrations that includes the ED50 with little or no toxicity. After administration, or between successive administrations, the circulating concentration of active agent varies within this range depending upon pharmacokinetic factors well-known in the art, such as the dosage form employed, sensitivity of the patient, and the route of administration.

30       The exact dosage will be determined by the practitioner, in light of factors specific to the subject requiring treatment. Factors that can be taken into account by the practitioner include the severity of the disease state, general health of the subject, age,

-111-

weight, gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions can be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.

5        Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Where the therapeutic agent is a protein or antibody of the present invention, the therapeutic protein or antibody agent typically is administered at a daily dosage of 0.01 mg to 30 mg/kg of body weight of the patient (*e.g.*, 1 mg/kg to 5 mg/kg). The pharmaceutical formulation can be  
10 administered in multiple doses per day, if desired, to achieve the total desired daily dose.

Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells,  
15 conditions, locations, etc.

Conventional methods, known to those of ordinary skill in the art of medicine, can be used to administer the pharmaceutical formulation(s) of the present invention to the patient. The pharmaceutical compositions of the present invention can be administered alone, or in combination with other therapeutic agents or interventions.

## 20    Therapeutic Methods

The present invention further provides methods of treating subjects having defects in a gene of the invention, *e.g.*, in expression, activity, distribution, localization, and/or solubility, which can manifest as a disorder of lung function. As used herein,  
25 "treating" includes all medically-acceptable types of therapeutic intervention, including palliation and prophylaxis (prevention) of disease. The term "treating" encompasses any improvement of a disease, including minor improvements. These methods are discussed below.

### *Gene Therapy and Vaccines*

30        The isolated nucleic acids of the present invention can also be used to drive *in vivo* expression of the polypeptides of the present invention. *In vivo* expression can be driven from a vector, typically a viral vector, often a vector based upon a replication

incompetent retrovirus, an adenovirus, or an adeno-associated virus (AAV), for purpose of gene therapy. *In vivo* expression can also be driven from signals endogenous to the nucleic acid or from a vector, often a plasmid vector, such as pVAX1 (Invitrogen, Carlsbad, CA, USA), for purpose of "naked" nucleic acid vaccination, as further  
5 described in U.S. Patents 5,589,466; 5,679,647; 5,804,566; 5,830,877; 5,843,913; 5,880,104; 5,958,891; 5,985,847; 6,017,897; 6,110,898; and 6,204,250, the disclosures of which are incorporated herein by reference in their entireties. For cancer therapy, it is preferred that the vector also be tumor-selective. *See, e.g., Doronin et al., J. Virol.* 75: 3314-24 (2001).

10 In another embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising a nucleic acid of the present invention is administered. The nucleic acid can be delivered in a vector that drives expression of an LSP, fusion protein, or fragment thereof, or without such vector. Nucleic acid compositions that can drive expression of an LSP are  
15 administered, for example, to complement a deficiency in the native LSP, or as DNA vaccines. Expression vectors derived from virus, replication deficient retroviruses, adenovirus, adeno-associated (AAV) virus, herpes virus, or vaccinia virus can be used as can plasmids. *See, e.g., Cid-Arregui, supra.* In a preferred embodiment, the nucleic acid molecule encodes an LSP having the amino acid sequence of SEQ ID NO: 143 through  
20 277, or a fragment, fusion protein, allelic variant or homolog thereof.

In still other therapeutic methods of the present invention, pharmaceutical compositions comprising host cells that express an LSP, fusions, or fragments thereof can be administered. In such cases, the cells are typically autologous, so as to circumvent xenogeneic or allotypic rejection, and are administered to complement  
25 defects in LSP production or activity. In a preferred embodiment, the nucleic acid molecules in the cells encode an LSP having the amino acid sequence of SEQ ID NO: 143 through 277, or a fragment, fusion protein, allelic variant or homolog thereof.

#### *Antisense Administration*

Antisense nucleic acid compositions, or vectors that drive expression of an LSG  
30 antisense nucleic acid, are administered to downregulate transcription and/or translation of an LSG in circumstances in which excessive production, or production of aberrant protein, is the pathophysiologic basis of disease.

Antisense compositions useful in therapy can have a sequence that is complementary to coding or to noncoding regions of an LSG. For example, oligonucleotides derived from the transcription initiation site, *e.g.*, between positions -10 and +10 from the start site, are preferred.

5 Catalytic antisense compositions, such as ribozymes, that are capable of sequence-specific hybridization to LSG transcripts, are also useful in therapy. *See, e.g.*, Phylactou, *Adv. Drug Deliv. Rev.* 44(2-3): 97-108 (2000); Phylactou *et al.*, *Hum. Mol. Genet.* 7(10): 1649-53 (1998); Rossi, *Ciba Found. Symp.* 209: 195-204 (1997); and Sigurdsson *et al.*, *Trends Biotechnol.* 13(8): 286-9 (1995), the disclosures of which are  
10 incorporated herein by reference in their entireties.

Other nucleic acids useful in the therapeutic methods of the present invention are those that are capable of triplex helix formation in or near the LSG genomic locus. Such triplexing oligonucleotides are able to inhibit transcription. *See, e.g.*, Intody *et al.*, *Nucleic Acids Res.* 28(21): 4283-90 (2000); McGuffie *et al.*, *Cancer Res.* 60(14): 3790-9  
15 (2000), the disclosures of which are incorporated herein by reference. Pharmaceutical compositions comprising such triplex forming oligos (TFOs) are administered in circumstances in which excessive production, or production of aberrant protein, is a pathophysiologic basis of disease.

In a preferred embodiment, the antisense molecule is derived from a nucleic acid  
20 molecule encoding an LSP, preferably an LSP comprising an amino acid sequence of SEQ ID NO: 143 through 277, or a fragment, allelic variant or homolog thereof. In a more preferred embodiment, the antisense molecule is derived from a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1 through 142, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

#### 25 *Polypeptide Administration*

In one embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising an LSP, a fusion protein, fragment, analog or derivative thereof is administered to a subject with a clinically-significant LSP defect.

30 Protein compositions are administered, for example, to complement a deficiency in native LSP. In other embodiments, protein compositions are administered as a vaccine to elicit a humoral and/or cellular immune response to LSP. The immune response can

be used to modulate activity of LSP or, depending on the immunogen, to immunize against aberrant or aberrantly expressed forms, such as mutant or inappropriately expressed isoforms. In yet other embodiments, protein fusions having a toxic moiety are administered to ablate cells that aberrantly accumulate LSP.

5        In a preferred embodiment, the polypeptide is an LSP comprising an amino acid sequence of SEQ ID NO: 143 through 277, or a fusion protein, allelic variant, homolog, analog or derivative thereof. In a more preferred embodiment, the polypeptide is encoded by a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1  
10        through 142, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

#### *Antibody, Agonist and Antagonist Administration*

In another embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising an antibody (including fragment or derivative thereof) of the present invention is  
15        administered. As is well-known, antibody compositions are administered, for example, to antagonize activity of LSP, or to target therapeutic agents to sites of LSP presence and/or accumulation. In a preferred embodiment, the antibody specifically binds to an LSP comprising an amino acid sequence of SEQ ID NO: 143 through 277, or a fusion protein, allelic variant, homolog, analog or derivative thereof. In a more preferred  
20        embodiment, the antibody specifically binds to an LSP encoded by a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1 through 142, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

The present invention also provides methods for identifying modulators which bind to an LSP or have a modulatory effect on the expression or activity of an LSP.  
25        Modulators which decrease the expression or activity of LSP (antagonists) are believed to be useful in treating lung cancer. Such screening assays are known to those of skill in the art and include, without limitation, cell-based assays and cell-free assays. Small molecules predicted via computer imaging to specifically bind to regions of an LSP can also be designed, synthesized and tested for use in the imaging and treatment of lung  
30        cancer. Further, libraries of molecules can be screened for potential anticancer agents by assessing the ability of the molecule to bind to the LSPs identified herein. Molecules identified in the library as being capable of binding to an LSP are key candidates for



-115-

further evaluation for use in the treatment of lung cancer. In a preferred embodiment, these molecules will downregulate expression and/or activity of an LSP in cells.

In another embodiment of the therapeutic methods of the present invention, a pharmaceutical composition comprising a non-antibody antagonist of LSP is  
5 administered. Antagonists of LSP can be produced using methods generally known in the art. In particular, purified LSP can be used to screen libraries of pharmaceutical agents, often combinatorial libraries of small molecules, to identify those that specifically bind and antagonize at least one activity of an LSP.

In other embodiments a pharmaceutical composition comprising an agonist of an  
10 LSP is administered. Agonists can be identified using methods analogous to those used to identify antagonists.

In a preferred embodiment, the antagonist or agonist specifically binds to and antagonizes or agonizes, respectively, an LSP comprising an amino acid sequence of SEQ ID NO: 143 through 277, or a fusion protein, allelic variant, homolog, analog or  
15 derivative thereof. In a more preferred embodiment, the antagonist or agonist specifically binds to and antagonizes or agonizes, respectively, an LSP encoded by a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1 through 142, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

#### *Targeting Lung Tissue*

20 The invention also provides a method in which a polypeptide of the invention, or an antibody thereto, is linked to a therapeutic agent such that it can be delivered to the lung or to specific cells in the lung. In a preferred embodiment, an anti-LSP antibody is linked to a therapeutic agent and is administered to a patient in need of such therapeutic agent. The therapeutic agent may be a toxin, if lung tissue needs to be selectively  
25 destroyed. This would be useful for targeting and killing lung cancer cells. In another embodiment, the therapeutic agent may be a growth or differentiation factor, which would be useful for promoting lung cell function.

In another embodiment, an anti-LSP antibody may be linked to an imaging agent that can be detected using, *e.g.*, magnetic resonance imaging, CT or PET. This would be  
30 useful for determining and monitoring lung function, identifying lung cancer tumors, and identifying noncancerous lung diseases.

## EXAMPLES

### Example 1: Gene Expression analysis

LSGs were identified by a systematic analysis of gene expression data in the LIFESEQ® Gold database available from Incyte Genomics Inc (Palo Alto, CA) using the data mining software package CLASP™ (Candidate Lead Automatic Search Program). CLASP™ is a set of algorithms that interrogate Incyte's database to identify genes that are both specific to particular tissue types as well as differentially expressed in tissues from patients with cancer. LifeSeq® Gold contains information about which genes are expressed in various tissues in the body and about the dynamics of expression in both normal and diseased states. CLASP™ first sorts the LifeSeq® Gold database into defined tissue types, such as breast, ovary and prostate. Whereas over half of the diseased samples in the LifeSeq® Gold database are cancer-related, there is considerable variability in the number of patient samples across different cancers. CLASP™ categorizes each tissue sample by disease state. Disease states include "healthy," "cancer," "associated with cancer," "other disease" and "other." Categorizing the disease states filters out data that might otherwise impair our ability to identify tissue and cancer-specific molecular targets. CLASP™ then performs a simultaneous parallel search for genes that are expressed both (1) selectively in the defined tissue type compared to other tissue types and (2) differentially in the "cancer" disease state compared to the other disease states affecting the same, or different, tissues. This sorting is accomplished by using mathematical and statistical filters that specify the minimum change in expression levels and the minimum frequency that the differential expression pattern must be observed across the tissue samples for the gene to be considered statistically significant. The CLASP™ algorithm quantifies the relative abundance of a particular gene in each tissue type and in each disease state.

To find the LSGs of this invention, the following specific CLASP™ profiles were utilized: detectable expression only in cancer tissue (CLASP 2), differential expression in cancer tissue (CLASP 5), and tissue-specific expression (CLASP 1). cDNA libraries were divided into 60 unique tissue types (early versions of LifeSeq® had 48 tissue types). Genes were grouped into "gene bins," where each bin is a cluster of sequences grouped together where they share a common contig. The expression level for each gene

bin was calculated for each tissue type. Differential expression significance was calculated with rigorous statistical significant testing taking into account variations in sample size and relative gene abundance in different libraries and within each library (for the equations used to determine statistically significant expression see Audic and  
5 Claverie "The significance of digital gene expression profiles," Genome Res 7(10): 986-995 (1997), including Equation 1 on page 987 and Equation 2 on page 988, the contents of which are incorporated by reference). Differently expressed tissue-specific genes were selected based on the percentage abundance level in the targeted tissue versus all the other tissues (tissue-specificity). The expression levels for each gene in normal tissue  
10 libraries was compared with the expression level in tissue libraries associated with tumor or disease (cancer-specificity). The results were analyzed for statistical significance.

The selection of the target genes meeting the rigorous CLASP™ profile criteria were as follows:

- 15 (a) CLASP 2: detectable expression only in cancer tissue: To qualify as a CLASP 2H (High) candidate, a gene must exhibit detectable expression in tumor tissues and undetectable expression in libraries from normal individuals and libraries from normal tissue obtained from diseased patients. In addition, such a gene must also exhibit further specificity for lung tumor tissues.
- 20 (b) CLASP 5: differential expression in cancer tissue: To qualify as a CLASP 5H (High) candidate, a gene must be differentially expressed in tumor libraries in the target tissue compared to normal libraries for all tissues. Only if the gene exhibits cancer-specific differential expression with a 90% of confidence level is it selected as a CLASP 5H lead.
- 25 (c) CLASP 1: tissue-specific expression: To qualify as a CLASP 1H (High) candidate, a gene must exhibit statistically significant tissue-specific expression. At first, the percentage abundance level in each gene in each tissue was calculated to identify the tissue with the highest expression percentage level. If the gene shows expression in more than four tissue types, the candidate is considered CLASP 1H candidate only if it exhibits a five-fold  
30 absolute abundance in the target tissue compared with the secondary tissue and a 1.5-fold relative abundance in the target tissue compared with

-118-

secondary tissue. If the candidate gene shows expression in less than 4 tissues, three situations are considered for prioritization of the candidate.

- a. If there are less than 3 tumor libraries for the target tissue, the candidate is considered a high priority (1H) candidate only if it exhibits expression in at least one tumor library, otherwise, it is only a medium priority (M) candidate and not considered further.
- b. If there are 3 or 4 tumor libraries for the target tissue and the candidate shows expression in at least one tumor library, the candidate is considered a high priority (1H) candidate only if it exhibits a higher percentage expression in the tumor tissues compared to the normal tissues. Otherwise, it is only a medium (M) priority candidate and not considered further.
- c. If there are more than 4 tumor libraries of the tissue of interest, the candidate exhibits expression in less than 40% of tumor libraries and the percentage abundance in tumor is 3 fold greater than in normal, the candidate is considered a 1H candidate. If the candidate exhibits expression percentage less than 0.00001, it is considered a low (L) priority candidate. Otherwise, it is considered a medium (M) priority candidate.

20 The CLASP scores for SEQ ID NO: 1 through 142 are listed below:

DEX0241_1	CLASP 5 H
DEX0241_2	CLASP 5 H
DEX0241_4	CLASP 2 H
DEX0241_5	CLASP 2 H
25 DEX0241_6	CLASP 2 H
DEX0241_7	CLASP 5 H 1 H
DEX0241_8	CLASP 5 H 1 H
DEX0241_9	CLASP 2 H
DEX0241_10	CLASP 2 H
30 DEX0241_11	CLASP 2 H
DEX0241_12	CLASP 2 H
DEX0241_13	CLASP 2 H
DEX0241_14	CLASP 2 H
DEX0241_15	CLASP 2 H 1 H
35 DEX0241_16	CLASP 2 H
DEX0241_17	CLASP 2 H
DEX0241_18	CLASP 2 H 1 H
DEX0241_19	CLASP 2 H 1 H

-119-

	DEX0241_20	CLASP 5 H
	DEX0241_21	CLASP 5 H
	DEX0241_22	CLASP 2 H
	DEX0241_23	CLASP 2 H
5	DEX0241_24	CLASP 5 H
	DEX0241_25	CLASP 5 H
	DEX0241_26	CLASP 2 H
	DEX0241_27	CLASP 2 H 1 H
	DEX0241_28	CLASP 2 H
10	DEX0241_29	CLASP 2 H
	DEX0241_30	CLASP 2 H 1 H
	DEX0241_31	CLASP 2 H 1 H
	DEX0241_32	CLASP 2 H
	DEX0241_33	CLASP 2 H
15	DEX0241_34	CLASP 5 H
	DEX0241_35	CLASP 5 H
	DEX0241_36	CLASP 2 H 1 H
	DEX0241_37	CLASP 2 H
	DEX0241_38	CLASP 2 H
20	DEX0241_39	CLASP 2 H
	DEX0241_40	CLASP 5 H
	DEX0241_41	CLASP 5 H
	DEX0241_42	CLASP 5 H 1 H
	DEX0241_43	CLASP 2 H
25	DEX0241_44	CLASP 2 H
	DEX0241_45	CLASP 2 H
	DEX0241_47	CLASP 2 H
	DEX0241_48	CLASP 2 H
	DEX0241_49	CLASP 5 H 1 H
30	DEX0241_50	CLASP 2 H
	DEX0241_53	CLASP 2 H
	DEX0241_54	CLASP 2 H
	DEX0241_56	CLASP 2 H
	DEX0241_57	CLASP 2 H
35	DEX0241_58	CLASP 2 H
	DEX0241_61	CLASP 2 H
	DEX0241_62	CLASP 2 H
	DEX0241_63	CLASP 2 H
	DEX0241_64	CLASP 2 H
40	DEX0241_65	CLASP 2 H
	DEX0241_66	CLASP 2 H
	DEX0241_67	CLASP 2 H
	DEX0241_68	CLASP 2 H
	DEX0241_69	CLASP 2 H
45	DEX0241_70	CLASP 2 H
	DEX0241_71	CLASP 2 H
	DEX0241_72	CLASP 2 H
	DEX0241_73	CLASP 2 H
	DEX0241_74	CLASP 2 H

-120-

	DEX0241_75	CLASP 2 H
	DEX0241_76	CLASP 2 H
	DEX0241_77	CLASP 2 H
	DEX0241_80	CLASP 2 H
5	DEX0241_81	CLASP 2 H
	DEX0241_82	CLASP 2 H
	DEX0241_83	CLASP 1 H
	DEX0241_84	CLASP 2 H
	DEX0241_85	CLASP 2 H
10	DEX0241_86	CLASP 5 H 1 H
	DEX0241_87	CLASP 5 H 1 H
	DEX0241_88	CLASP 2 H
	DEX0241_89	CLASP 2 H
	DEX0241_90	CLASP 2 H
15	DEX0241_91	CLASP 2 H
	DEX0241_92	CLASP 2 H
	DEX0241_93	CLASP 2 H
	DEX0241_94	CLASP 2 H
	DEX0241_95	CLASP 2 H
20	DEX0241_96	CLASP 2 H
	DEX0241_97	CLASP 2 H
	DEX0241_98	CLASP 2 H
	DEX0241_99	CLASP 2 H
	DEX0241_101	CLASP 5 H 1 H
25	DEX0241_102	CLASP 1 H
	DEX0241_103	CLASP 1 H
	DEX0241_104	CLASP 5 H 1 H
	DEX0241_105	CLASP 2 H
	DEX0241_108	CLASP 2 H
30	DEX0241_109	CLASP 2 H
	DEX0241_110	CLASP 5 H
	DEX0241_113	CLASP 5 H
	DEX0241_114	CLASP 5 H
	DEX0241_115	CLASP 2 H
35	DEX0241_116	CLASP 2 H
	DEX0241_117	CLASP 2 H
	DEX0241_118	CLASP 2 H
	DEX0241_121	CLASP 2 H
	DEX0241_122	CLASP 2 H
40	DEX0241_124	CLASP 2 H
	DEX0241_125	CLASP 5 H
	DEX0241_126	CLASP 5 H
	DEX0241_127	CLASP 2 H
	DEX0241_128	CLASP 2 H
45	DEX0241_129	CLASP 5 H 1 H
	DEX0241_130	CLASP 5 H 1 H
	DEX0241_131	CLASP 2 H
	DEX0241_132	CLASP 2 H
	DEX0241_133	CLASP 2 H

-121-

	DEX0241_135	CLASP	2	H
	DEX0241_137	CLASP	2	H 1 H
	DEX0241_138	CLASP	2	H 1 H
	DEX0241_139	CLASP	1	H
5	DEX0241_142	CLASP	2	H

### Example 2: Relative Quantitation of Gene Expression

Real-Time quantitative PCR with fluorescent Taqman probes is a quantitation detection system utilizing the 5'-3' nuclease activity of Taq DNA polymerase. The method uses an internal fluorescent oligonucleotide probe (Taqman) labeled with a 5' reporter dye and a downstream, 3' quencher dye. During PCR, the 5'-3' nuclease activity of Taq DNA polymerase releases the reporter, whose fluorescence can then be detected by the laser detector of the Model 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA). Amplification of an endogenous control is used to standardize the amount of sample RNA added to the reaction and normalize for Reverse Transcriptase (RT) efficiency. Either cyclophilin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), ATPase, or 18S ribosomal RNA (rRNA) is used as this endogenous control. To calculate relative quantitation between all the samples studied, the target RNA levels for one sample were used as the basis for comparative results (calibrator). Quantitation relative to the "calibrator" can be obtained using the standard curve method or the comparative method (User Bulletin #2: ABI PRISM 7700 Sequence Detection System).

The tissue distribution and the level of the target gene are evaluated for every sample in normal and cancer tissues. Total RNA is extracted from normal tissues, cancer tissues, and from cancers and the corresponding matched adjacent tissues. Subsequently, first strand cDNA is prepared with reverse transcriptase and the polymerase chain reaction is done using primers and Taqman probes specific to each target gene. The results are analyzed using the ABI PRISM 7700 Sequence Detector. The absolute numbers are relative levels of expression of the target gene in a particular tissue compared to the calibrator tissue.

One of ordinary skill can design appropriate primers. The relative levels of expression of the LSNA versus normal tissues and other cancer tissues can then be determined. All the values are compared to normal thymus (calibrator). These RNA

-122-

samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

The relative levels of expression of the LSNA in pairs of matching samples and 1 cancer and 1 normal/normal adjacent of tissue may also be determined. All the values are compared to normal thymus (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.

In the analysis of matching samples, the LSNAs that show a high degree of tissue specificity for the tissue of interest. These results confirm the tissue specificity results obtained with normal pooled samples.

Further, the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual are compared. This comparison provides an indication of specificity for the cancer stage (e.g. higher levels of mRNA expression in the cancer sample compared to the normal adjacent).

Altogether, the high level of tissue specificity, plus the mRNA overexpression in matching samples tested are indicative of SEQ ID NO: 1 through 142 being a diagnostic marker for cancer.

Sequences	Gene ID	ddx QPCR lung code	SEQ ID NO:
DEX0241_84	206814	Lng179	84

Table 1. The absolute numbers are relative levels of expression of Lng179 in 24 normal different tissues. All the values are compared to normal brain (calibrator). These RNA samples are commercially pools, originated by pooling samples of a particular tissue from different individuals.

Tissue	NORMAL
Adrenal Gland	0.00
Bladder	0.12
Brain	1.00
Cervix	0.00
Colon	0.00
Endometrium	0.14
Esophagus	0.00
Heart	0.00
Kidney	0.03
Liver	0.00



-123-

Lung	0.72
Mammary Gland	0.04
Muscle	0.00
Ovary	0.09
Pancreas	0.41
Prostate	0.00
Rectum	0.00
Small Intestine	0.03
Spleen	0.17
Stomach	0.00
Testis	0.64
Thymus	0.12
Trachea	0.11
Uterus	0.11

0=negative

The relative levels of expression in Table 1 show that Lng179 mRNA expression is relatively higher in lung compared with most other normal tissues analyzed.

- 5 The absolute numbers in Table 1 were obtained analyzing pools of samples of a particular tissue from different individuals. They can not be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 2.

- 10 Table 2. The absolute numbers are relative levels of expression of Lng179 in 20 pairs of matching samples. All the values are compared to normal brain (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.

Sample ID	Cancer Type	Tissue	CANCER	MATCHING NORMAL ADJACENT
Lng 60L	Adenocarcinoma	Lung 1	0.01	0.00
Lng AC66	Adenocarcinoma	Lung 2	0.13	0.06
Lng AC69	Adenocarcinoma	Lung 3	0.11	0.00
Lng AC94	Adenocarcinoma	Lung 4	0.00	0.00
Lng AC11	Adenocarcinoma	Lung 5	0.18	0.00
Lng AC32	Adenocarcinoma	Lung 6	0.00	0.04
Lng 223L	Adenocarcinoma	Lung 7	0.11	0.00
Lng SQ45	Squamous cell carcinoma	Lung 8	0.15	1.35
Lng SQ16	Squamous cell carcinoma	Lung 9	0.04	0.00
Lng SQ79	Squamous cell carcinoma	Lung 10	0.62	0.16
Bld46XK		Bladder 1	0.00	0.00
BldTR14		Bladder 2	0.22	0.09

-124-

ClnAS43		Colon 1	0.00	0.00
ClnAS45		Colon 2	0.00	0.01
ClnAS46		Colon 3	0.03	0.02
ClnAS67		Colon 4	0.00	0.05
ClnAS89		Colon 5	0.01	0.31
Liv94Xa		Liver 1	0.00	0.00
Tst647T		Testis 1	0.38	0.18
Utr135XO		Uterus 1	0.15	0.11

0= Negative

In the analysis of matching samples, higher expression of lng179 is detected in lung samples showing a high degree of tissue specificity for lung tissue. These results confirm the tissue specificity results obtained with normal pooled samples (Table 1).

- 5 Furthermore, we compared the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual. This comparison provides an indication of specificity for the cancer stage (e.g. higher levels of mRNA expression in the cancer sample compared to the normal adjacent). Table 2 shows overexpression of Lng179 in 10 lung cancer tissues compared with their respective normal adjacent (lung samples # 1, 2, 3, 5, 7, 9, and 10). There is overexpression in the cancer tissue for 70% of the lung matching samples tested (7 out of total of 10 lung matching samples).

Altogether, the high level of tissue specificity, plus the mRNA differential expression in the lung matching samples tested are believed to make Lng179 a good marker for diagnosing, monitoring, staging, imaging and treating lung cancer.

15

#### Primers Used for QPCR Expression Analysis

Primer Probe Oligo	Start From	End To	QueryLength	SbjctDescript
Lng179For	69	93	25	DEX0241_84 (SEQ ID NO:84)
Lng179Rev	218	193	26	DEX0241_84 (SEQ ID NO:84)
Lng179Probe	94	128	35	DEX0241_84 (SEQ ID NO:84)

#### Example 2B: Custom Microarray Experiment

- Custom oligonucleotide microarrays were provided by Agilent Technologies, Inc. (Palo Alto, CA). The microarrays were fabricated by Agilent using their technology for the *in-situ* synthesis of 60mer oligonucleotides (Hughes, et al. 2001, Nature Biotechnology 19:342-347). The 60mer microarray probes were designed by Agilent,

from gene sequences provided by diaDexus, using Agilent proprietary algorithms. Whenever possible two different 60mers were designed for each gene of interest.

All microarray experiments were two-color experiments and were preformed using Agilent-recommended protocols and reagents. Briefly, each microarray was  
5 hybridized with cRNAs synthesized from polyA+ RNA, isolated from cancer and normal tissues, labeled with fluorescent dyes Cyanine3 and Cyanine5 (NEN Life Science Products, Inc., Boston, MA) using a linear amplification method (Agilent). In each experiment the experimental sample was polyA+ RNA isolated from cancer tissue from a single individual and the reference sample was a pool of polyA+ RNA isolated from  
10 normal tissues of the same organ as the cancerous tissue (*i.e.* normal lung tissue in experiments with lung cancer samples). Hybridizations were carried out at 60°C, overnight using Agilent *in-situ* hybridization buffer. Following washing, arrays were scanned with a GenePix 4000B Microarray Scanner (Axon Instruments, Inc., Union City, CA). The resulting images were analyzed with GenePix Pro 3.0 Microarray Acquisition  
15 and Analysis Software (Axon). A total of 29 experiments comparing the expression patterns of lung cancer derived polyA+ RNA (15 squamous cell carcinomas, 14 adenocarcinomas) to polyA+ RNA isolated from a pool of 12 normal lung tissues were analyzed.

Data normalization and expression profiling were done with Expressionist  
20 software from GeneData Inc. (Daly City, CA/Basel, Switzerland). Gene expression analysis was performed using only experiments that meet certain quality criteria. The quality criteria that experiments must meet are a combination of evaluations performed by the Expressionist software and evaluations performed manually using raw and normalized data. To evaluate raw data quality, detection limits (the mean signal for a replicated negative control + 2 Standard Deviations (SD)) for each channel were  
25 calculated. The detection limit is a measure of non-specific hybridization. Arrays with poor detection limits were not analyzed and the experiments were repeated. To evaluate normalized data quality, positive control elements included in the array were utilized. These array features should have a mean ratio of 1 (no differential expression). If these  
30 features have a mean ratio of greater than 1.5-fold up or down, the experiments were not analyzed further and were repeated. In addition to traditional scatter plots demonstrating the distribution of signal in each experiment, the Expressionist software also has

minimum thresholding criteria that employ user defined parameters to identify quality data. Only those features that meet the threshold criteria were included in the filtering and analyses carried out by Expressionist. The thresholding settings employed require a minimum area percentage of 60% [(% pixels > background + 2SD)-(% pixels saturated)],  
 5 and a minimum signal to noise ratio of 2.0 in both channels. By these criteria, very low expressors and saturated features were not included in analysis.

Relative expression data was collected from Expressionist based on filtering and clustering analyses. Up- and down- regulated genes were identified using criteria for percentage of valid values obtained, and the percentage of experiments in which the gene  
 10 is up- or down-regulated. These criteria were set independently for each data set, depending on the size and the nature of the data set. The results for the statistically significant upregulated and downregulated genes are shown in Table 1. The first three columns of the table contain information about the sequence itself (Oligo ID, Parent ID, and Patent#), the next 3 columns show the results obtained. '%valid' indicates the  
 15 percentage of 29 unique experiments total in which a valid expression value was obtained, '%up' indicates the percentage of 29 experiments in which up-regulation of at least 2.5-fold was observed, and '%down' indicates the percentage of the 29 experiments in which down-regulation of at least 2.5-fold was observed. The last column in Table 1 describes the location of the microarray probe (oligo) relative to the parent sequence.  
 20 Additional sequences were examined but the data was inconclusive.

Table 1. Sensitivity data for DEX0241 series microarray features.

Oligo ID	Parent ID	Patent #	Sensitivity of up and down regulation			Oligo Seq location
			% valid	% up	% down	
4176	2881	DEX0241_49 (SEQ ID NO:49)	62%	0%	48%	564-623
4177	2881	DEX0241_49 (SEQ ID NO:49)	45%	0%	31%	554-613
7140	1950	DEX0241_100 (SEQ ID NO:100)	86%	0%	79%	1342-1401

-127-

7141	1950	DEX0241_100 (SEQ ID NO:100)	93%	0%	86%	1246- 1305
------	------	--------------------------------	-----	----	-----	---------------

**Example 3: Protein Expression**

The LSNA is amplified by polymerase chain reaction (PCR) and the amplified DNA fragment encoding the LSNA is subcloned in pET-21d for expression in *E. coli*. In addition to the LSNA coding sequence, codons for two amino acids, Met-Ala, flanking the NH<sub>2</sub>-terminus of the coding sequence of LSNA, and six histidines, flanking the COOH-terminus of the coding sequence of LSNA, are incorporated to serve as initiating Met/restriction site and purification tag, respectively.

An over-expressed protein band of the appropriate molecular weight may be observed on a Coomassie blue stained polyacrylamide gel. This protein band is confirmed by Western blot analysis using monoclonal antibody against 6X Histidine tag.

Large-scale purification of LSP was achieved using cell paste generated from 6-liter bacterial cultures, and purified using immobilized metal affinity chromatography (IMAC). Soluble fractions that had been separated from total cell lysate were incubated with a nickle chelating resin. The column was packed and washed with five column volumes of wash buffer. LSP was eluted stepwise with various concentration imidazole buffers.

**Example 4: Protein Fusions**

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector. For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 2, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced. If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second

signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. *See, e. g.*, WO 96/34891.

#### **Example 5: Production of an Antibody from a Polypeptide**

- 5        In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential
- 10    amino acids, about 1,000 U/ml of penicillin, and about 100, µg/ml of streptomycin. The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP20), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT
- 15    medium, and then cloned by limiting dilution as described by Wands *et al.*, *Gastroenterology* 80: 225-232 (1981).

- The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide. Alternatively, additional antibodies capable of binding to the polypeptide can be
- 20    produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the
- 25    hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies. Using the Jameson-Wolf methods the following epitopes were predicted. (Jameson and
- 30    Wolf, *CABIOS*, 4(1), 181-186, 1988, the contents of which are incorporated by reference).

Examples of post-translational modifications (PTMs) of the LSP of this invention are listed below. In addition, antibodies that specifically bind such post-translational modifications may be useful as a diagnostic or as therapeutic. Using the ProSite database (Bairoch et al., Nucleic Acids Res. 25(1):217-221 (1997), the contents of which are incorporated by reference), the following PTMs were predicted for the LSPs of the invention ([http://npsa-pbil.ibcp.fr/cgi-bin/npsa\\_automat.pl?page=npsa\\_prosite.html](http://npsa-pbil.ibcp.fr/cgi-bin/npsa_automat.pl?page=npsa_prosite.html) most recently accessed October 23, 2001).

	DEX0241_143	Ck2_Phospho_Site 16-19;38-41; Myristyl 50-55;
	DEX0241_144	Ck2_Phospho_Site 16-19;38-41; Myristyl 50-55;
10	DEX0241_145	Myristyl 5-10;
	DEX0241_146	Pkc_Phospho_Site 2-4;
	DEX0241_147	Myristyl 26-31; Pkc_Phospho_Site 75-77;
	DEX0241_149	Amidation 3-6; Camp_Phospho_Site 8-11; Ck2_Phospho_Site 12-15;17-20;51-54;93-96;155-158; Myristyl 156-161;
15		Pkc_Phospho_Site 12-14;34-36;101-103;117-119;
	DEX0241_150	Asn_Glycosylation 23-26;141-144;187-190; Camp_Phospho_Site 246-249; Ck2_Phospho_Site 5-8;15-18;27-30;32-35;43-46;53-56;95-98;217-220; Myristyl 139-144;288-293; Pkc_Phospho_Site 103-105;119-121;174-176;222-224;245-247;249-251;308-310;
20	DEX0241_152	Myristyl 4-9;
	DEX0241_153	Ck2_Phospho_Site 8-11; Myb_1 7-15;
	DEX0241_154	Leucine_Zipper 69-90; Myristyl 77-82;
	DEX0241_155	Asn_Glycosylation 23-26; Ck2_Phospho_Site 11-14; Myristyl 48-53; Pkc_Phospho_Site 18-20;25-27;
25	DEX0241_156	Amidation 33-36; Ck2_Phospho_Site 4-7;20-23; Myristyl 40-45;54-59;69-74;70-75;78-83;
	DEX0241_157	Ck2_Phospho_Site 28-31; Myristyl 51-56;58-63;
	DEX0241_158	Ck2_Phospho_Site 42-45; Pkc_Phospho_Site 7-9;23-25;
	DEX0241_159	Amidation 43-46; Asn_Glycosylation 6-9; Pkc_Phospho_Site 95-97; Tyr_Phospho_Site 70-77;
30	DEX0241_160	Myristyl 65-70; Pkc_Phospho_Site 75-77;
	DEX0241_161	Ck2_Phospho_Site 31-34;
	DEX0241_162	Ck2_Phospho_Site 34-37;
	DEX0241_163	Pkc_Phospho_Site 7-9;14-16;
35	DEX0241_164	Asn_Glycosylation 18-21;31-34;
	DEX0241_166	Camp_Phospho_Site 10-13; Ck2_Phospho_Site 9-12; Myristyl 33-38; Pkc_Phospho_Site 9-11;37-39; Tyr_Phospho_Site 10-17;11-17;
	DEX0241_167	Pkc_Phospho_Site 26-28;
40	DEX0241_168	Ck2_Phospho_Site 66-69; Myristyl 23-28;72-77;
		Pkc_Phospho_Site 11-13;36-38;73-75;76-78;
	DEX0241_169	Camp_Phospho_Site 17-20; Ck2_Phospho_Site 3-6;
	DEX0241_170	Amidation 89-92; Ck2_Phospho_Site 84-87; Myristyl 81-86;101-106; Pkc_Phospho_Site 7-9; Prokar_Lipoprotein 38-48;50-60;52-62;
45		

	DEX0241_171	Camp_Phospho_Site 13-16; Ck2_Phospho_Site 21-24;56-59; Myristyl 27-32;31-36;41-46;47-52;
	DEX0241_172	Ck2_Phospho_Site 63-66; Myristyl 12-17;64-69;
5	DEX0241_173	Pkc_Phospho_Site 76-78; Prokar_Lipoprotein 17-27; Ck2_Phospho_Site 63-66; Myristyl 12-17;64-69;
	DEX0241_174	Pkc_Phospho_Site 76-78; Prokar_Lipoprotein 17-27; Asn_Glycosylation 56-59; Myristyl 7-12; Tyr_Phospho_Site 32-40;
10	DEX0241_175	Asn_Glycosylation 56-59; Myristyl 7-12; Tyr_Phospho_Site 32-40;
	DEX0241_176	Ck2_Phospho_Site 30-33; Glycosaminoglycan 26-29; Myristyl 49-54;50-55;
	DEX0241_177	Asn_Glycosylation 20-23; Ck2_Phospho_Site 52-55; Glycosaminoglycan 48-51; Myristyl 71-76;72-77;
15	DEX0241_179	Myristyl 34-39;
	DEX0241_180	Asn_Glycosylation 10-13;
	DEX0241_181	Myristyl 17-22;32-37;44-49;
	DEX0241_182	Ck2_Phospho_Site 5-8;
20	DEX0241_183	Ck2_Phospho_Site 23-26;52-55;54-57; Pkc_Phospho_Site 48-50;83-85;
	DEX0241_184	Asn_Glycosylation 32-35; Pkc_Phospho_Site 7-9;
	DEX0241_186	Amidation 24-27; Ck2_Phospho_Site 54-57; Myristyl 70-75; Pkc_Phospho_Site 4-6;24-26;
	DEX0241_188	Tyr_Phospho_Site 21-28;
25	DEX0241_189	Ck2_Phospho_Site 18-21;
	DEX0241_190	Asn_Glycosylation 21-24; Pkc_Phospho_Site 31-33;
	DEX0241_191	Pkc_Phospho_Site 7-9;51-53;
	DEX0241_192	Pkc_Phospho_Site 21-23;
	DEX0241_193	Asn_Glycosylation 30-33;
30	DEX0241_194	Asn_Glycosylation 30-33;
	DEX0241_195	Myristyl 23-28; Pkc_Phospho_Site 62-64;
	DEX0241_196	Asn_Glycosylation 70-73; Myristyl 25-30; Pkc_Phospho_Site 45-47;
	DEX0241_197	Ck2_Phospho_Site 2-5;19-22;26-29; Pkc_Phospho_Site 19-21;34-36;
35	DEX0241_198	Ck2_Phospho_Site 2-5;19-22;26-29; Pkc_Phospho_Site 19-21;34-36;
	DEX0241_199	Myristyl 14-19;37-42; Pkc_Phospho_Site 69-71;
	DEX0241_200	Asn_Glycosylation 58-61; Ck2_Phospho_Site 38-41; Myristyl 50-55;54-59; Pkc_Phospho_Site 60-62;
40	DEX0241_201	Asn_Glycosylation 299-302;345-348;435-438; Camp_Phospho_Site 398-401; Ck2_Phospho_Site 42-45;64-67;130-133;165-168;178-181;187-190;195-198;240-243;286-289;301-304;315-318;365-368;419-422;430-433;454-457;477-480; Myristyl 184-189;402-407; Pkc_Phospho_Site 130-132;138-140;465-467;
45	DEX0241_202	Myristyl 41-46; Pkc_Phospho_Site 27-29;
	DEX0241_203	Myristyl 41-46; Pkc_Phospho_Site 27-29;



	DEX0241_204	Camp_Phospho_Site 35-38; Ck2_Phospho_Site 4-7;23-26; Pkc_Phospho_Site 33-35;47-49;
	DEX0241_205	Ck2_Phospho_Site 7-10;
	DEX0241_206	Pkc_Phospho_Site 7-9;57-59;
5	DEX0241_207	Pkc_Phospho_Site 7-9;57-59;
	DEX0241_210	Myristyl 44-49; Pkc_Phospho_Site 9-11;23-25; Prokar_Lipoprotein 54-64;
	DEX0241_211	Asn_Glycosylation 15-18;43-46;
	DEX0241_212	Asn_Glycosylation 17-20;
10	DEX0241_213	Ck2_Phospho_Site 17-20;36-39;59-62; Myristyl 43-48; Pkc_Phospho_Site 17-19;26-28;
	DEX0241_215	Asn_Glycosylation 4-7; Ck2_Phospho_Site 37-40;
	DEX0241_216	Pkc_Phospho_Site 13-15;
	DEX0241_218	Ck2_Phospho_Site 14-17; Pkc_Phospho_Site 10-12;14-16;
15	DEX0241_219	Pkc_Phospho_Site 80-82;
	DEX0241_220	Myristyl 18-23;
	DEX0241_221	Asn_Glycosylation 304-307;617-620;623-626;643-646;686-689; Cadherin 93-103;198-208;309-319; Camp_Phospho_Site 527-530; Ck2_Phospho_Site 109-112;128-131;130-133;233-236;235- 238;248-251;457-460;530-533;593-596;654-657;668-671;727- 730;758-761; Egf_1 506-517; Glycosaminoglycan 438-441;452- 455;658-661; Myristyl 117-122;121-126;138-143;296-301;370- 375;434-439;435-440;436-441;437-442;439-444;440-445;453- 458;454-459;511-516;512-517;513-518;514-519;555-560;601- 606;618-623;742-747;767-772; Pkc_Phospho_Site 5-7;26-28;55- 57;109-111;130-132;155-157;192-194;235-237;387-389;576- 578;654-656;673-675;697-699; Tyr_Phospho_Site 339-345;
20		
	DEX0241_222	Camp_Phospho_Site 3-6; Ck2_Phospho_Site 14-17; Pkc_Phospho_Site 6-8;30-32; Tyr_Phospho_Site 41-48;
30	DEX0241_223	Ck2_Phospho_Site 42-45; Myristyl 10-15; Pkc_Phospho_Site 35- 37; Prokar_Lipoprotein 12-22;
	DEX0241_224	Pkc_Phospho_Site 32-34;
	DEX0241_225	Asn_Glycosylation 13-16; Pkc_Phospho_Site 59-61;
	DEX0241_226	Asn_Glycosylation 18-21;
35	DEX0241_227	Amidation 14-17; Asn_Glycosylation 10-13; Ck2_Phospho_Site 25-28; Pkc_Phospho_Site 9-11;
	DEX0241_228	Camp_Phospho_Site 11-14;25-28; Ck2_Phospho_Site 14-17; Myristyl 52-57; Pkc_Phospho_Site 14-16;
	DEX0241_229	Amidation 34-37;
40	DEX0241_230	Ck2_Phospho_Site 11-14;
	DEX0241_232	Ck2_Phospho_Site 21-24; Myristyl 19-24;
	DEX0241_235	Asn_Glycosylation 32-35; Pkc_Phospho_Site 34-36;
	DEX0241_236	Asn_Glycosylation 86-89; Camp_Phospho_Site 42-45; Ck2_Phospho_Site 82-85;105-108; Myristyl 49-54;51-56;63-68; Pkc_Phospho_Site 128-130;
45	DEX0241_237	Camp_Phospho_Site 28-31;69-72;316-319; Ck2_Phospho_Site 5- 8;46-49;191-194;208-211;270-273;304-307;361-364;381-384; Myristyl 78-83;90-95;97-102;168-173;174-179;197-202;278-

		283;297-302;299-304;310-315;318-323;321-326;368-373;376-381; Pkc_Phospho_Site 210-212;214-216;311-313;
	DEX0241_238	Myristyl 45-50; Pkc_Phospho_Site 51-53;
	DEX0241_239	Myristyl 45-50; Pkc_Phospho_Site 51-53;
5	DEX0241_240	Asn_Glycosylation 27-30;63-66; Ck2_Phospho_Site 39-42; Pkc_Phospho_Site 46-48;
	DEX0241_241	Asn_Glycosylation 27-30;63-66; Ck2_Phospho_Site 39-42; Pkc_Phospho_Site 46-48;
10	DEX0241_242	Asn_Glycosylation 25-28; Myristyl 30-35; Pkc_Phospho_Site 27-29;
	DEX0241_243	Pkc_Phospho_Site 67-69; Tyr_Phospho_Site 31-39;
	DEX0241_244	Myristyl 14-19;18-23;78-83;
	DEX0241_245	Pkc_Phospho_Site 7-9;
	DEX0241_246	Myristyl 4-9;5-10;
15	DEX0241_247	Myristyl 31-36;
	DEX0241_248	Myristyl 20-25;96-101; Pkc_Phospho_Site 13-15;
	DEX0241_250	Myristyl 44-49;
	DEX0241_251	Myristyl 28-33;
	DEX0241_256	Myristyl 54-59;85-90; Pkc_Phospho_Site 74-76;
20	DEX0241_257	Amidation 84-87; Myristyl 54-59;103-108; Pkc_Phospho_Site 74-76;84-86;
	DEX0241_258	Ck2_Phospho_Site 13-16; Myristyl 5-10;
	DEX0241_259	Myristyl 42-47;
	DEX0241_260	Pkc_Phospho_Site 29-31;
25	DEX0241_261	Asn_Glycosylation 21-24;
	DEX0241_262	Ck2_Phospho_Site 2-5;3-6;17-20; Myristyl 9-14;
	DEX0241_263	Ck2_Phospho_Site 12-15; Myristyl 17-22; Pkc_Phospho_Site 64-66;
	DEX0241_264	Asn_Glycosylation 62-65; Myristyl 60-65; Pkc_Phospho_Site 28-30;
30	DEX0241_265	Amidation 12-15; Pkc_Phospho_Site 3-5;
	DEX0241_266	Asn_Glycosylation 42-45; Ck2_Phospho_Site 17-20; Pkc_Phospho_Site 50-52;55-57;
	DEX0241_267	Ck2_Phospho_Site 51-54; Pkc_Phospho_Site 15-17;
35	DEX0241_268	Ck2_Phospho_Site 35-38; Pkc_Phospho_Site 24-26;
	DEX0241_269	Myristyl 12-17; Pkc_Phospho_Site 48-50;
	DEX0241_270	Camp_Phospho_Site 11-14; Pkc_Phospho_Site 16-18;
	DEX0241_271	Asn_Glycosylation 70-73; Ck2_Phospho_Site 72-75; Pkc_Phospho_Site 15-17;51-53;56-58;72-74;
40	DEX0241_272	Myristyl 33-38;
	DEX0241_273	Asn_Glycosylation 8-11;15-18;35-38;
	DEX0241_274	Asn_Glycosylation 16-19;
	DEX0241_276	Ck2_Phospho_Site 67-70;210-213; Glycosaminoglycan 121-124; Myristyl 197-202; Pkc_Phospho_Site 28-30;111-113;165-167;204-206;229-231;241-243; Rgd 206-208; Tyr_Phospho_Site 155-163;
45		
	DEX0241_277	Ck2_Phospho_Site 13-16;

**Example 6: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide**

RNA is isolated from individual patients or from a family of individuals that have a phenotype of interest. cDNA is then generated from these RNA samples using  
5 protocols known in the art. *See*, Sambrook (2001), *supra*. The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO: 1 through 142. Suggested PCR conditions consist of 35 cycles at 95°C for 30 seconds; 60-120 seconds at 52-58°C; and 60-120 seconds at 70°C, using buffer solutions described in Sidransky *et al.*, *Science* 252(5006): 706-9 (1991). *See also* Sidransky *et al.*,  
10 *Science* 278(5340): 1054-9 (1997).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations are then  
15 cloned and sequenced to validate the results of the direct sequencing. PCR products is cloned into T-tailed vectors as described in Holton *et al.*, *Nucleic Acids Res.*, 19: 1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements may also be determined. Genomic clones are  
20 nick-translated with digoxigenin deoxyuridine 5' triphosphate (Boehringer Mannheim), and FISH is performed as described in Johnson *et al.*, *Methods Cell Biol.* 35: 73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium  
25 iodide, producing a combination of C-and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. *Id.* Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical  
30 Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and

translocations. These alterations are used as a diagnostic marker for an associated disease.

**Example 7: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample**

- 5           Antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10  $\mu\text{g/ml}$ . The antibodies are either monoclonal or polyclonal and are produced by the method described above. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced. The
- 10       coated wells are then incubated for  $> 2$  hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbound polypeptide. Next, 50  $\mu\text{l}$  of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature.
- 15       The plates are again washed three times with deionized or distilled water to remove unbound conjugate. 75  $\mu\text{l}$  of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution are added to each well and incubated 1 hour at room temperature.

- The reaction is measured by a microtiter plate reader. A standard curve is
- 20       prepared, using serial dilutions of a control sample, and polypeptide concentrations are plotted on the X-axis (log scale) and fluorescence or absorbance on the Y-axis (linear scale). The concentration of the polypeptide in the sample is calculated using the standard curve.

**Example 8: Formulating a Polypeptide**

- 25       The secreted polypeptide composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the secreted polypeptide alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for
- 30       purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of secreted polypeptide administered parenterally per dose will be in the range of about 1 ,  $\mu\text{g/kg/day}$  to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the secreted polypeptide is typically administered at a dose rate of about 1  $\mu\text{g/kg/hour}$  to about 50 mg/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Pharmaceutical compositions containing the secreted protein of the invention are administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

The secreted polypeptide is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semipermeable polymer matrices in the form of shaped articles, e. g., films, or microcapsules. Sustained-release matrices include polylactides (U. S. Pat. No.3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al., Biopolymers 22: 547-556 (1983)), poly (2-hydroxyethyl methacrylate) (R. Langer et al., J. Biomed. Mater. Res. 15: 167-277 (1981), and R. Langer, Chem. Tech. 12: 98-105 (1982)), ethylene vinyl acetate (R. Langer et al.) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988). Sustained-release compositions also include liposomally entrapped polypeptides. Liposomes containing the secreted polypeptide are prepared by methods known per se: DE Epstein et al., Proc. Natl. Acad. Sci. USA 82: 3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA 77: 4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U. S. Pat. Nos. 4,485,045 and 4,544,545; and

EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.

5           For parenteral administration, in one embodiment, the secreted polypeptide is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, I. e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.

10           For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides. Generally, the formulations are prepared by contacting the polypeptide uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more  
15           preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

          The carrier suitably contains minor amounts of additives such as substances that  
20           enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e. g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic  
25           polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

30           The secreted polypeptide is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about

-137-

3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any polypeptide to be used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e. g., 0.2  
5 micron membranes). Therapeutic polypeptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Polypeptides ordinarily will be stored in unit or multi-dose containers, for example, sealed ampules or vials, as an aqueous solution or as a lyophilized formulation  
10 for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1 % (w/v) aqueous polypeptide solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized polypeptide using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or more  
15 containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container (s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the polypeptides of the  
20 present invention may be employed in conjunction with other therapeutic compounds.

**Example 9: Method of Treating Decreased Levels of the Polypeptide**

It will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the secreted form.  
25 Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a pharmaceutical composition comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily  
30 dose 0.1-100 µg/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided above.

**Example 10: Method of Treating Increased Levels of the Polypeptide**

Antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer.

5 For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided above.

**10 Example 11: Method of Treatment Using Gene Therapy**

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a  
15 tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e. g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37°C for approximately one  
20 week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks. pMV-7 (Kirschmeier, P. T. et al., DNA, 7: 219-25 (1988)), flanked by the long terminal repeats of the Moloney murine  
25 sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set  
30 forth in Example 1. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the



presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB 101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

5       The amphotropic pA317 or GP+aml2 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are  
10       now referred to as producer cells).

      Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is  
15       removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media.

      If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently  
20       infected, the fibroblasts are analyzed to determine whether protein is produced.

      The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

#### **Example 12: Method of Treatment Using Gene Therapy-*In Vivo***

      Another aspect of the present invention is using *in vivo* gene therapy methods to  
25       treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide.

      The polynucleotide of the present invention may be operatively linked to a promoter or any other genetic elements necessary for the expression of the polypeptide  
30       by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO 90/11092, WO 98/11779; U. S. Patent 5,693,622; 5,705,151; 5,580,859; Tabata H. et al. (1997) Cardiovasc. Res. 35 (3): 470-479, Chao J et

al. (1997) Pharmacol. Res. 35 (6): 517-522, Wolff J. A. (1997) Neuromuscul. Disord. 7 (5): 314-318, Schwartz B. et al. (1996) Gene Ther. 3 (5): 405-411, Tsurumi Y. et al. (1996) Circulation 94 (12): 3281-3290 (incorporated herein by reference).

The polynucleotide constructs may be delivered by any method that delivers  
5 injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell,  
10 including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P. L. et al. (1995) Ann. NY Acad. Sci. 772: 126-139 and Abdallah B. et al. (1995) Biol. Cell 85 (1): 1-7) which can be prepared by methods well known to those skilled in the art.

15 The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target  
20 cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow,  
25 thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue  
30 ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They

may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin  
5 fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 µg/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and  
10 more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the  
15 parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

20 The dose response effects of injected polynucleotide in muscle *in vivo* is determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps  
25 muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute,  
30 approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

After an appropriate incubation time (e. g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that quadriceps from different  
5 mice are harvested at different times. Persistence of DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice.

The results of the above experimentation in mice can be use to extrapolate proper dosages and other treatment parameters in humans and other animals using naked DNA.

#### 10 **Example 13: Transgenic Animals**

The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, e. g., baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific  
15 embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

Any technique known in the art may be used to introduce the transgene (i. e., polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection  
20 (Paterson et al., Appl. Microbiol. Biotechnol. 40: 691-698 (1994); Carver et al., Biotechnology (NY) 11: 1263-1270 (1993); Wright et al., Biotechnology (NY) 9: 830-834 (1991); and Hoppe et al., U. S. Patent 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci., USA 82: 6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson et  
25 al., Cell 56: 313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell. Biol. 3: 1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, e. g., Ulmer et al., Science 259: 1745 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm mediated gene transfer (Lavitrano et al., Cell 57: 717-723  
30 (1989); etc. For a review of such techniques, see Gordon, "Transgenic Animals," Intl. Rev. Cytol. 115: 171-229 (1989), which is incorporated by reference herein in its entirety.

-143-

Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., Nature 380: 64-66 (1996); Wilmut et al., Nature 385: 810813 (1997)).

5       The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, I. e., mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, e. g., head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a  
10 particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., Proc. Natl. Acad. Sci. USA 89: 6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous  
15 gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus  
20 inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., Science 265: 103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant  
25 gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples  
30 obtained from the animal, in situ hybridization analysis, and reverse transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated

immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

#### **Example 14: Knock-Out Animals**

Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (E. g., see Smithies et al., Nature 317: 230-234 (1985); Thomas & Capecchi, Cell 51: 503-512 (1987); Thompson et al., Cell 5: 313-321 (1989); each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention *in vivo*. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications

-145-

to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (e. g., see Thomas & Capecchi 1987 and Thompson 1989, supra). However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (e. g., knockouts) are administered to a patient *in vivo*. Such cells may be obtained from the patient (I. e., animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (e. g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, e. g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc.

The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e. g., in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, e. g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U. S. Patent 5,399,349; and Mulligan & Wilson, U. S. Patent 5,460,959 each of which is incorporated by reference herein in its entirety).

When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For example, the

cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include,  
5 but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

All patents, patent publications, and other published references mentioned herein  
10 are hereby incorporated by reference in their entireties as if each had been individually and specifically incorporated by reference herein. While preferred illustrative embodiments of the present invention are described, one skilled in the art will appreciate that the present invention can be practiced by other than the described embodiments, which are presented for purposes of illustration only and not by way of limitation. The  
15 present invention is limited only by the claims that follow.



-147-

## CLAIMS

We claim:

1. An isolated nucleic acid molecule comprising
  - (a) a nucleic acid molecule comprising a nucleic acid sequence that encodes  
5 an amino acid sequence of SEQ ID NO: 143 through 277;
  - (b) a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID  
NO: 1 through 142;
  - (c) a nucleic acid molecule that selectively hybridizes to the nucleic acid  
molecule of (a) or (b); or
  - 10 (d) a nucleic acid molecule having at least 60% sequence identity to the nucleic  
acid molecule of (a) or (b).
2. The nucleic acid molecule according to claim 1, wherein the nucleic acid  
molecule is a cDNA.
- 15 3. The nucleic acid molecule according to claim 1, wherein the nucleic acid  
molecule is genomic DNA.
4. The nucleic acid molecule according to claim 1, wherein the nucleic acid  
20 molecule is a mammalian nucleic acid molecule.
5. The nucleic acid molecule according to claim 4, wherein the nucleic acid  
molecule is a human nucleic acid molecule.
- 25 6. A method for determining the presence of a lung specific nucleic acid  
(LSNA) in a sample, comprising the steps of:
  - (a) contacting the sample with the nucleic acid molecule according to claim 1  
under conditions in which the nucleic acid molecule will selectively hybridize to a lung  
specific nucleic acid; and
  - 30 (b) detecting hybridization of the nucleic acid molecule to a LSNA in the  
sample, wherein the detection of the hybridization indicates the presence of a LSNA in  
the sample.

7. A vector comprising the nucleic acid molecule of claim 1.

8. A host cell comprising the vector according to claim 7.

5

9. A method for producing a polypeptide encoded by the nucleic acid molecule according to claim 1, comprising the steps of (a) providing a host cell comprising the nucleic acid molecule operably linked to one or more expression control sequences, and (b) incubating the host cell under conditions in which the polypeptide is produced.

10

10. A polypeptide encoded by the nucleic acid molecule according to claim 1.

11. An isolated polypeptide selected from the group consisting of:

(a) a polypeptide comprising an amino acid sequence with at least 60%

15 sequence identity to of SEQ ID NO: 143 through 277 ; or

(b) a polypeptide comprising an amino acid sequence encoded by a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1 through 142.

12. An antibody or fragment thereof that specifically binds to the polypeptide  
20 according to claim 11.

13. A method for determining the presence of a lung specific protein in a sample, comprising the steps of:

(a) contacting the sample with the antibody according to claim 12 under  
25 conditions in which the antibody will selectively bind to the lung specific protein; and  
(b) detecting binding of the antibody to a lung specific protein in the sample, wherein the detection of binding indicates the presence of a lung specific protein in the sample.

30 14. A method for diagnosing and monitoring the presence and metastases of lung cancer in a patient, comprising the steps of:

-149-

(a) determining an amount of the nucleic acid molecule of claim 1 or a polypeptide of claim 6 in a sample of a patient; and

(b) comparing the amount of the determined nucleic acid molecule or the polypeptide in the sample of the patient to the amount of the lung specific marker in a normal control; wherein a difference in the amount of the nucleic acid molecule or the polypeptide in the sample compared to the amount of the nucleic acid molecule or the polypeptide in the normal control is associated with the presence of lung cancer.

15. A kit for detecting a risk of cancer or presence of cancer in a patient, said kit comprising a means for determining the presence the nucleic acid molecule of claim 1 or a polypeptide of claim 6 in a sample of a patient.

16. A method of treating a patient with lung cancer, comprising the step of administering a composition according to claim 12 to a patient in need thereof, wherein said administration induces an immune response against the lung cancer cell expressing the nucleic acid molecule or polypeptide.

17. A vaccine comprising the polypeptide or the nucleic acid encoding the polypeptide of claim 11.

20

## SEQUENCE LISTING

<110> Recipon, Herve  
Sun, Yongming  
Liu, Chenghua  
Chen, Sei-Yu  
Turner, Leah  
diaDexus, Inc.

<120> Compositions and Methods Relating to Lung Specific  
Genes and Proteins

<130> DEX-0242

<140>

<141>

<150> 60/242,998

<151> 2001-10-25

<160> 277

<170> PatentIn Ver. 2.1

<210> 1

<211> 898

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (124)..(185)

<223> a, c, g or t

<400> 1

tttaaagaat agctcgtgta tatgattttt taaaaaaaaa tctaccaaatt caaataaaga 60  
agtcctggga gttcacccgg tgttttctac agaaccaagg tattcatatt gagatccttc 120  
aatnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 180  
nnnnngtgaa atggagatat tcaacaaagc accctgtggg gattagatga gattgcacat 240  
ctgactgcct agagtatagt aaggggtcac tgtttctctc tctactcctca ggaaaatttg 300  
attgaacaag gatagaaact ttgattctag ggacagaagg tcttcagaag tctttgaggc 360  
cagagggcct gtcatagaac tgcagtgtag gttcattaaa acgctgtcat cctaattgtt 420  
atccacagta tctaatagat ttaaaaggaa gacaatatgg cacagactat ttcggaaacc 480  
tatgccatt ctgccaagag gatatcgcta ttgggtgtca gactatttca cttataagg 540  
ttcttttttc cttaagtcac aaagattaac atttactaaa aatttgaggg tccattaatg 600  
gactcccaca tggctttcct ctttcctttg agctggattc attttcactg agtcccagat 660  
cctgcacatc tgacaattgc ttcagacctt ggacatgctt gaattatttt atgcaaatca 720  
tttgaaaagg caaagtacca ctgttctttc ttgagtttct tcgtaaaactg gtntctaatt 780

tatctgctgc tttttctcga tccaatttgt gcctatgtct tactatagat tctttggaaa 840  
 taaagaaata aagaatata ctgtagctat tttgttaaac taagaatgtt ttaaaata 898

<210> 2

<211> 1047

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (125)..(186)

<223> a, c, g or t

<400> 2

tttaaagaat agctcgtgta tatgattttt taaaacaaaa atctaccaa tcaaataaag 60  
 aagtcctggg agttcacccg gtgttttcta cagaaccaag gtattcatat tgagatcctt 120  
 caatnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 180  
 nnnnnngtga aatggagata ttcaacaaag caccctgtgg ggattagatg agattgcaca 240  
 tctgactgcc tagagtatag taaggggtca ctgtttcctc ttcactcctc aggaaaattt 300  
 gattgaacaa ggatagaaac tttgattcta gggacagaag gtcttcagaa gtctttgagg 360  
 ccagagggcc tgcatagaa ctgcagtgtg gggttcattaa aacgctgtca tcctaattgtt 420  
 tatccacagt atctaataga tttaaaagga agacaatatg gcacagacta tttcggaaac 480  
 ctatgcccat tctgccaaga ggatatcgct attggtgggc agactatttc acttataagg 540  
 tttctttttt ccttaagtca taaagattaa catttactaa aaatttgagg gtccattaat 600  
 ggactcccac atggctttcc tctttccttt gagctggatt cattttcact gagtcccgag 660  
 tctgcacat ctgacaattg cttcagacct tggacatgct tgaattattt tatgcaaadc 720  
 atttgaaaag gcaaagtaac actgttcttt cttgagtttc ttcgtaaaact ggtttctaata 780  
 ttatctgctg ctttttctcg atccaatttg tgcctatgtc ttactataga ttttttgga 840  
 ataaagaaat aaagaatata tctgtagcta tttgtttaa ctaagaatgt tttaaaatat 900  
 tttattgtaa aataaaattc cttgtttctc tcagaaataa aaaaattttt ttttattttt 960  
 gtattaattt tttttatta tttttatttt attaaaatat gggggcctga agttttttcc 1020  
 cttgtgggg gggttatttt tctggaa 1047

<210> 3

<211> 538

<212> DNA

<213> Homo sapiens

<400> 3

gtccataacc ttctttattc tgggaccaag ctggagagat gagtctctat ctgtggaaga 60  
 ccttggaaga cccactcag ggtgtttctg aaagggatct cacatggatt gagccataac 120  
 cttagaccaaa gagaagccag atttgctagg agaaagtcct gtcagcatag tcaaacactt 180  
 aggaggagta aaaagggtgta tttttctgca tagatgggtg gatcacattt ttatcaatta 240  
 atctgcaccc tagggacaaa gagttaacat ttgaattttt ctcagtaaga atctactcct 300  
 cagggaaagt tagcgtttga aaaactctaa ctagaaatcc actttccaga ggctgtctca 360  
 gcaagtgcct aagtatctag actagaaatt cccttcataa gcatgaggag tgctggaagt 420

gatttttcat tggatgaaatg ggtgggttttc aagttatgta gatggactgg agatattttt 480  
 cctctactct tgcatagaaga aatatgtctt aatgtagata gactggagat atttttcc 538

<210> 4

<211> 303

<212> DNA

<213> Homo sapiens

<400> 4

ctccatctca aaaaacaaag ggatcaaggt cagatgaggt caagagaaga ctgaggaact 60  
 gtgccagact gaggaagatg aaggagacat gacatttaat gtttctgaac tggatccttt 120  
 cctatgaaac tactggaaca actggcatac ttgaatggaa tttgttgatt agatggtagc 180  
 aatgtatcag tggtaatcac ccgactttga tgagcgtaac acggtgatgc agtaaaatgt 240  
 atttgtttct agaaaataca caccatcgtg gccgggcacg gtggctcata cctataatcc 300  
 cag 303

<210> 5

<211> 519

<212> DNA

<213> Homo sapiens

<400> 5

gtacgacgtg gcgcagtctt ggctcactgc aacagccacc tcccgggttc aagcgattct 60  
 cctgcctcag tctcctgagt agctgggatt aataggcgcc tgacaccaca cctgggtaat 120  
 ttttgtattt ttagtagaga cagggtttca tcatgttgge caggatggta ttgaactcct 180  
 gacctcgtga tctgcctgcc tcggcctccc aaagtgcctg gattataggt atgagccacc 240  
 gtgcccggcc acgatgggtg gtatttttcta gaaacaaata cattttactg catcaccgta 300  
 ttacgctcat caaagtcggg tgattaccac tgatacattg ctaccatcta atcaacaaat 360  
 tccattcaag tatgccagtt gttccagtag ttcatagga aaggatccag ttcagaaaca 420  
 ttaaatgtca tgtctccttc atcttctcga gtctggcaca gttcctcagt cttctcttga 480  
 cctcatctga ccttgatccc tttgtttttt gagatggag 519

<210> 6

<211> 781

<212> DNA

<213> Homo sapiens

<400> 6

tatgaaggta gatgccatat atgtttacct tgccactgta tttctactgt cttacattgc 60  
 tcctaacgta tatcatgagc tcttaaatat ttgttgaaga aatgaactag cgtattttga 120  
 taactataat gtgtgaagcc cctggttgag tctgttgac actggaatta aggggttaaa 180  
 aaccttttcc cttgctgctt gagaatctga tctttggttt agccacctag ctctgttacc 240  
 ctggaaacca ggtaagagct taggcattca caatattgct aagcaacact gcttacggta 300  
 aaaatgatcc ttggttggtg aactgcattc gaaccaggaa gaaatatgaa tgagctgtaa 360  
 atgtctgata ggacactttg gccttcctcg aatgcagttt cttcttgga accctacaaa 420

ctatatcaag aattgttaca agagatactg gctgcttaag gcaggaggct tcttctgagc 480  
 cagggcagct cccgtacctc cctgatgtgg agcttaggct ttgtacctgg aactacgtcg 540  
 tgtggggaga caacagtccc cagaaaggta tgtgagctgt catttgtgca aacatgcaga 600  
 gccccgtctg agaggaattc ttgatgctgc cctgctggca agctggcaag aaatgtggcc 660  
 tgtggtagcc ttgtgagtcc acatgttttag ttaacttaaa aagacccttg gtggccacta 720  
 aacacacctt atttcattta atgctcgcaa caactttgag agacaggaaa taccattttc 780  
 c 781

<210> 7

<211> 996

<212> DNA

<213> Homo sapiens

<400> 7

tcatagaagc cagggaaaagg aaggagctgg ccggtggagg gtgctcctga ccaggagtca 60  
 aacttctttc actgaccttc ttggacaaag cggccaagggt agaactggca gactgggagc 120  
 taaaaggggg aggaaaagga ctcaaatcgc atggtctcct cagtcctggt gagagatttg 180  
 tcctgcagaa cggcattggc tgcagctttc agtttttagga tggctgaata ccggagacaa 240  
 gctgcagggtg gtggttgagt ttggcaacca cttacctga ttccatataa aacggttact 300  
 tggagtgtat tggtcattct gttcctgctt ctcggccaac ttcctggcca gaacactgag 360  
 ctgctgggcg tgggtgggaag gcggggaaaa ggagaggttt cgagccaacg tttacggggg 420  
 actccactct gccattagcc gtggctgcag catcgagttt gagggaaacca gcctccagca 480  
 gccgcctcaa attgctgctc aggggcttgt tggagcctgg gtcacgtca cacaagaag 540  
 aactcccgg ggaaagggtga tcttgacact gcagtgagtc tcgcaggacc tactgtcca 600  
 gtgccaccag ctccaacgtg tggctgctgg gagtctgct tccaaggag gtgtccgggg 660  
 acgtggactg ctccctggat ccggtcctcc agagacaact tatagttctc ctggacttcc 720  
 ccataggatg cttctgacgg agtctctgaa gaggttccat accagtgttc tcttctactg 780  
 agctctccct ccgcctcttc ctgcctacta acatgtgagg gaaggcgtt gggctgctcc 840  
 tgcttctctc tgggcatttt ccccttttc tcacattctc ctcttggtt aatgtgagat 900  
 caaataacac ccccgtaggg gcagagaggc agacactggc aggagcgggg aggtagttag 960  
 ggggcgggcg ggcgggcagg ggaaaccctt ctccgg 996

<210> 8

<211> 1678

<212> DNA

<213> Homo sapiens

<400> 8

atgctgctca gtgactgtca ctgttggcag cgggcagcgg agaggcaagt tccaggaggt 60  
 accggacaca ggatgaagcg ggctgcatct tcccaggag taaaacaatc catgaaatgc 120  
 actggacttt acgacgtgcc ccgaagcatg tttgtactgt cctccaactg gttacttcag 180  
 ccagttacca actgttccag aaaaggagcc aagacaaagg agacacgttt tatccgtgga 240  
 cccaaaactc tggcgccagt cacggactgg gaaggcagcc ttccttggt gtttaatcat 300  
 tgcagggctg cctctctgat tattcacca cgtttcaaag gtgtcagacc acgcagggac 360  
 gcctgcctta gtccttcacc cttagtggca agtcccgtt tcctggggca ggggcaacac 420  
 gctttaaaag gattagagcc tgttatcact cacctgctac agcatggcct tttaaagact 480

ataaactctc cttacaatac ccccatTTtTa cctgtcctaa aaccagacaa gccttttaca 540  
 gttagttcag gatctgcgcc ttatcaacca aattgTTTTg cctatccacc ccgtgatgtt 600  
 agtaggcagg aagaggcgga gggagagctc agtgaaggag aacctggta tggaaactct 660  
 tcagagactc cgtcagaagc atcctatggg gaagtccagg agaactataa gttgtctctg 720  
 gaggaccgga tccaggagca gtccacgtcc ccggacacct ccttggaag cagactccc 780  
 agcagccaca cgttgagct ggtggcactg gacagtgagg tctgcgaga ctactgcag 840  
 tgtcaagatc acctttcccc gggagtgtct tctttgtgtg acgatgacct aggtccaac 900  
 aagccctga gcagcaattt gaggcggtg ctggaggtg gttccctcaa actcgatgct 960  
 gcagccacgg ctaatggcag agtggagtcc cccgtaaagc ttggtcgaa cctctcctt 1020  
 tccccgcctt cccaccacgc ccagcagctc agtgttctgg ccaggaagt ggccgagaag 1080  
 caggaacaga atgaccaata cactccaagt aaccgttTtTa tatggaatca aggtaagtgg 1140  
 ttgcaaaact caaccaccac ctgcagcttg tctccgatt cagccatcct aaaactgaaa 1200  
 gctgcagcca atgccgttct gcaggacaaa tctctacca ggactgagga gaccatgca 1260  
 tttgagctct tttctcccc cttttagctc ccagtctgcc agttctacct tggccgctt 1320  
 gtccaagaag gtcagtgaag gaagtttgac tctgggtcag gagcaccctc caccggccag 1380  
 ctcttctctt tccctggctt ctatgacctc ctacgcggcc cttctgaagg aggtggccgc 1440  
 aagggctgcg ggcagtcttc tggctgagaa atcatcgctg ctgcctgagg accctctacc 1500  
 gccccgcct tcagagaaga aaccagaaaa agtactccg ccacctccac cgcacacctc 1560  
 accacctcca ccaccaccac cacaatccct ggaattatta ttactcccag ttcctaaggg 1620  
 aagagtttct aaacctcca attcaggtat ggcattcttt ctttcaatca tcgtgtaa 1678

&lt;210&gt; 9

&lt;211&gt; 659

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 9

cccacgtgaa tgcccagatc ctgcccattc aaagcctgat atcattggca tccctgttgt 60  
 gaagacatcc tggaccgcct caactgaatc aggtttctag cccaactccg attgctctta 120  
 aaggcactat ccttttccgt cttctttacc agactctgtg ctcccagtag gcaggatgca 180  
 gtctaactta agaaaacacc cagggaggag cctccaggct actgacattc agaagaggtt 240  
 tctttttctc tcttctctct gtccgtaact tctaattgag cactaaatgt acagggtgcta 300  
 agacaaaaggc tttccacaaa tctctcctt tctcaattgc cccaggggtt aagcaccctg 360  
 tactccaaag gtcccacctt tggtgaaaag cagagctcac tggaagggtg tgttctagac 420  
 tcccatggaa acctgaaatg ctgttgactc tcagcctgta ccattggtac cccatttctg 480  
 agcagcagca gagaattcgt cactggatgt gtgactcca gcctccactc tcagggcagg 540  
 attcaggggtg acccagaagt ttgttttaga aataaacctg ttaatatctt taacacatta 600  
 agtttcaata aattagagaa aacaggctat aaaaatggca taatgtgaca aaaacccaa 659

&lt;210&gt; 10

&lt;211&gt; 947

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 10

acacggctcg tgtctgtgaa caaaatcgca tctgcagccc tctacagttt gcacgggttt 60



```

tccagctttg atacctacat catctttagt ggtagttact actgcccccc atttacaggt 120
gagaaaaactg gggctcagga aggcagttag aaactggaag tcagccacgt gtcaggacag 180
gagcctggat ttggcccaca tctttggctt tggttttgca cacagctgct gctgggagct 240
ggggccaggg caggcagggtg cctcctctct ggcctcagcc tcgtgggaaa gcttgggcct 300
cagggtggagt gaggatgtct tgggtgcac ttctcgtctc ggctcttga cccagcaggg 360
gtcggagggg gatttcttaa gggagggggc tttttcagaa atggacaggg actttcggga 420
ccatggctgc ccacctcagt gaagtctgag gggagttcct ggaaggcatt tccatctgtc 480
catgtgttct aagtcagtgg acaattaagt ccagaaacct cctggactta aaaagcaagc 540
accgccagga tccctggggc tgcagacagc ctggggggtt ttggagggtt ggctcctcag 600
gcacccatga aggaagggtg cctgggggtc gtattcagac ccaaagccc gcagggaccc 660
tcagggtgcc tttatctact catgtctcca cacacttgct ggcagagctg ggacaagtca 720
ctaaccctct gtgtgacctc tgattcgcca tggaaaaaag agtgaataga ataaatcatt 780
tattcccagg gtaggttctt ggggtggcag tgccgagctt gggtagtct ccacccttc 840
gatttaggag ccgatgccct ggtgcggatc tctcctctga gctgagcgtc ctccactaag 900
tcaggcacag agcacgtgca gcatagggcc ggtgtccagg cccacc 947

```

&lt;210&gt; 11

&lt;211&gt; 577

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 11

```

gtaactttac agtgttttcg ctacagagcc gaaacttcaa gtccctttt tgccagcaga 60
gtttgggttg cggctgctgg aaaacttgat ggcactgaa atctcttggc ctgtgcatga 120
ggaagagtgg atccagcttc ttgtcttggc tctctgttct ctgaatgcct tgtactttt 180
gcttttctat cttaccattt ttttttgggt tgccttctact gtgaataata tattttctc 240
tttccttgcc cttgcttttt tggctgacag aaaatgggtg atgcacaccg tgggtgcagt 300
gagggtcttg tgcctgctac gtgggcagct tccacctgtg gctggcttat tgggctactt 360
ggagccacag aatcattgct gagctccgat tgccagaga gtccaggcc attgggggtc 420
ctctctagc tggggaatct taagtccagc ttttgggatg tcatcctccc gtggagggg 480
agctcatgaa agtccaagggt tcgagtcttc ctcccagag ggctaccctg taatgccgtg 540
ggggggtgtg tgtggggggg tggcaaggga agctctg 577

```

&lt;210&gt; 12

&lt;211&gt; 3725

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 12

```

gtcttgcctc ttaattgtaa ctttacagtg ttttcgctca cgagccgaaa cttcaagttc 60
cctttttgcc agcagagttt gggttgcggc cgctggaaaa cttgatgcgc actgaaatct 120
cttggctctg gcatgaggaa gagggtatcc agcttcttgt cttggctctc tgttctctga 180
atgccttgta ctttttgctt ttctatctta ccattttttt ttggtttgct ttcactgtga 240
ataatatatt ttcacttttc cttgcccttg cttttttggc tgacagaaaa tgggtgaatgc 300
acaccgtggg tgcagtgagg gcttgggtgc tgctacgtgg gcagcttcca cctgtggctg 360
gcttattggg ctacttgagg ccacagaatc attgctgagc tccgatgtgc cagagagtcc 420

```

caggccattg gggtcactct tctagctggg gaatcttaag tccagctttt gggatgtcat 480  
 cctcccgtgg agggggagct catgaaagtc caagggtcga gtcttcctcc ccagagggct 540  
 accctgtaat gccgtggggg ggtgtgtgtg ggggggtggc aagggaagct ctgtcagcct 600  
 tggctatggc tgatgccagt caggggcata gacacctgtt tggtctcccc tccctgccac 660  
 aaacgttgag gactgtgaac attatgtcac tgtgacctgc ttacaatggg aactaagcgt 720  
 taggcagaag gggttgagga ggggggagac ataggctctt ctgtaatagt atgagtgtcg 780  
 acatgggtgtt ctttcccctc ccttttagct attgaaacaa tccacccggg agagtgaaca 840  
 gcttgagggtt gatcctggcc tgtgataaga gccagggtcag tatacttgtt agggacatgt 900  
 gagagacctc cccgccacac tgcagcattc acagcacctt tccctggacct cctgtcacct 960  
 cgcagggtcag ggagttatgt cccctgggaa cccagggtt gtccagagct acccacagtt 1020  
 gtctgcactt ccaggtagcc cgattttggg gttctaggat gtttcatctc ctgggggggt 1080  
 aatcaaatcc ctggaagagg acaagaaaga ctgaggtagg aataaagttc ttttaaacct 1140  
 caagggtgcc cattgcaggt tatcaaaact cacttggtga accctgaaga gggagatggg 1200  
 tttggtggaa atggtttccc cacttgccctt tttggcctct tttatgatgc ttccaaggaa 1260  
 tcttgaattc agcacagtca aaaccaaact caggatcttc tcttgccaaa agcagtcctt 1320  
 tcccagggcc ccttctgggt gtctggcacc gatatttgaa cactcattgc cataagccag 1380  
 aaatatagaa ggcgatctgt gtacccctc tctgttagca tccataccta gtccacctcc 1440  
 aagttctgaa aaatctctcc agctcttcac ttgaatctgc ctgccttctg ccaactgccct 1500  
 ggtccaagtc accatctgct catgactgaa cttagagtag ccttcgtctg gccacacctt 1560  
 atctgctctg actcacctct agtgctttct ccattcttct gccatcctgg tcttttcaga 1620  
 gccataacat ttgcttgtea ccttatttat gaaaaaccaa ccacttggtg gccttctgtt 1680  
 gctcttggga cagatcttca tgtggccac aaggctctgt gcagcccagc tttgtctccc 1740  
 tgccagcctt gtcttacaca ccgtgtgtc catcgatatc gtacgtggc cataccctag 1800  
 cagttgcctt cctatcctca actacatcac atgctttctg gcctcaggac ctttgcacat 1860  
 gctgtttatg ctacttggag tgttttggtc ctttcttcac cctcagccac tccctctgga 1920  
 ctgcactcca cagggcagaa gctgaggatg ttcagaagcc caaacggagt tggctgcctt 1980  
 gtgggaccca agcgagttgt aaacattctg gcttcagatg taaatcaaag gcagagccct 2040  
 gagttttagg gcagagaatt ccttctatca gctctgcagt gagccctcac aggcagactc 2100  
 gggcccaaat atagcctagg tgctgtttat gtatttgaaa gtatttaagg ctggtccttc 2160  
 tgtcatcggg cctccaaagt cttttattac attttgggac tgtggtatat agagttccaa 2220  
 atttctttct cccctagagc aaatggtttc agtttactgt aatgcataat aaacatgtaa 2280  
 acataaatag gcacacttca gaccagggtt tccctgtagc ttagctttct ctgctaaggc 2340  
 ccccttcag gtttttgggt cgggtgtgtc ccagggtatg ctcagactcg cccttcatca 2400  
 cctctcctt ggcctgcgag gcggtcatgg cttcttcgtg actcatcttc gtggcactgg 2460  
 ggattgcagg gaggcaggt gatgtcctt tccagtcaca aggctggact gccaaaecgaa 2520  
 ctgcacagat tcctttccag tgccccaagc tgaaggaaag cgtgatcagg aagcaggcag 2580  
 cagacgtatt tgaaccaga catgctcgag cccctccctg agcaggtgtg aaattatgta 2640  
 tgcagctcca tagctccact gaggattctg aagtgatcct ctgcacgaca cttcccggaa 2700  
 ataagtggaa aagcttactg catgactgaa aagtacgtat cagtcctgca cccctaggat 2760  
 tgccctggac tcttgtctaa actgtttgtt gttgatacca gcctcagaag ctggatgcct 2820  
 ttaagccatg gctagtgtgt ttaaccgatc ccttttatga agatcttgta agcgcgtggt 2880  
 aatagcccac tatgcttttt aactgaacca gcagagcaaa catagttaat ggagagacat 2940  
 ttttgtcatt ccttggcctc tgtttatttg caaaaacgag taaagtgtta cctgcaagtg 3000  
 gttcagtgcg tgccgggggt tcaggctgca ggtatgtgag cttgttcaag gcttgtcctg 3060  
 cccacgcagc agtttgagag cccagagggt cgaacgctgg ggcctgttg gaagcgggtg 3120  
 gtggatgaag ccaccagga gtcccttctc tccctgtcac ctatagggt tgcacactt 3180  
 tttaaaggag cactggcccg aggcctagaa aaacagccat gtgggtgggt aagaatcaca 3240  
 aagacattgc aagtcagtc taactgtctc tccaagatgg tcttgaattt gacaagggtga 3300

```

tgaagagttg gtgctggcag gtttaagaaa acaaacacaa aaccaggttg ggggtgctgat 3360
ttagtgccctt gctgcctttt cagatccctc ccctgaactg ctggcacctg atgtttgagc 3420
tatttttgta cctgtctctt ctcaaactag atgataagtg gcctcagggc agggactaca 3480
tactcctgag agctgcttga gctcgagggtg tttattttcc tcagtaagca ttttttttca 3540
ggagcatgac ttggctcaaa aaaacaaaaa gaaaaagaa accctccctt caatttacct 3600
gtgtctaaac tttgggtgaat tattctccca tctgccttct gggcagagga gaaatgtgga 3660
atgcatacaag ttcaaggctt tggatttaa gagctggctt taaaggttgc catgttaaca 3720
attgt 3725

```

&lt;210&gt; 13

&lt;211&gt; 1299

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 13

```

tacacctaaa tattaatatc tagaaattat aaatatcacc agaggacatt aacatatatc 60
aatttttagt taagagtcac aaggcctttc ttttccacga gcaaattcat tttgcaccat 120
tacgataaac ataacaatct catcaggact tcttcatacg tcttcccttt ctcatccact 180
gttacgggtc ataaagcaca aagacatttg aacaaagcag cctgtggctg gaactgcagt 240
tttttctttt ggcaaagaaa gctactgacc ctggtcacc ccataccctaa agtgactgtc 300
agaatacaga tagctcccta accatgctct cctactctag ggacaatgct gaggggtctt 360
aggaaagtgt ttataccctg acccaatgat tccccttcta gagtcaatcc ttcaagaact 420
agccagaatt aaaacaaaga tcaatcatc aagcttacta tagcttgatt ttttttcagc 480
tcagataaaa tcagaaacaa cagtaatgtc tacattgaga aaattgccaa gtaaattaga 540
atatctaatt attgaatata caggtaaagc tttccctggc tcactttcta agggctctga 600
attggtctct gacttactta gactatgtcc ttagattctc tagcctctaa aagctaattg 660
tctacacatt ctcatgtttc ttttcaagct tcctggagtc tggggatact catcgaagaa 720
taaattggatc tggaaaggtc ccagggtctc tgcacgagga ggacctggta agactagaaa 780
cctgtttggc aagccaggga agtgagatc catatccatg tgcaaaataa gctaagactc 840
ccttccacag gggatgcagg tctgcaaaca atatgatgca tttagggaaa tgcttttctt 900
ccttaattgg aacctagact atattatttc tgagaacgga catctgaatg atacatatca 960
taaccagtaa ttacctgtac tctgcattgg tatatggcaa tcttgagggtg actaaactga 1020
agagagttac agcttacttt ttgccttttg gttagatata aaatgtcata ttccaatcct 1080
gtggaagacc tccaggagta ctgatcttgg ctgagtaact cagaacttag gagatattgt 1140
gctggaaatg acgtactgta gggactgctt gactggggaa gagaatatgg aaaggggttt 1200
ccgcaaaaaca caggagtaaa gattcacccg tgcaggtttg aaggagagata cttctttttc 1260
agagcaggga gatcaaagga aagtgggtca agccttacc 1299

```

&lt;210&gt; 14

&lt;211&gt; 2005

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 14

```

gggtatggag ttctgccctg aaggcagaac tgggcagatt ctctggactc ccactgaagg 60
ggagggccca ggcttgggga agaagggttc caggggtcac atccttacat tcacattcat 120

```

tgccttcttc caatctcagg agacacagaa agtggctggg acgacactgc tgtgggtcaat 180  
 gacctctcat ccacatcacc gggcactgaa tcaggctctc agtctcctct gacaccagat 240  
 ggtaaaccga atcccaaggg cattaagaag tcttggggaa aaatccgaag aactcagtc 300  
 ggaaatttct aactgacac gctggggatg gcagagtttc gacgaggtgg gctccgggca 360  
 accgcagggc caggactctc taggaccagg gacttcaagg gacagaaaag gtaaggcttg 420  
 acccactttc ctttgatctc cctgctctga aaaagaagta tctcccttca aacctgcacg 480  
 ggtgaatctt tactcctgtg ttttgcggaa acccctttcc atattctctt cccagtcaa 540  
 gcagtcccta cagtacgtca tttccagcac aatatctcct aagttctgag ttactcagcc 600  
 aagatcagta ctcttgagg tctccacag gattggaata tgacatttta tatctaacca 660  
 aaaggcaaaa agtaagctgt aactctcttc agtttagtca cctcaagatt gccatatacc 720  
 aatgcagagt acaggttaatt actggttatg atatgtatca ttcagatgtc cgttctcaga 780  
 aataatatag tctaggttcc aattaaggaa gaaaagcatt tccctaaatg catcatattg 840  
 tttgcagacc tgcacccctt gtggaaggga gtcttagctt attttgcaca tggatatgat 900  
 actgcacttc cctggcttgc caaacagggt tctagtctta ccaggctctc ctctgtcatg 960  
 agacctggga cctttccaga tccatttatt ctctgatgag tatccccaga ctccaggaag 1020  
 cttgaaaaga aacatgagaa tgtgtagacc attagctttt agaggctaga gaactaagg 1080  
 acatagtcta agtaagtcag agaccaatcc agagccctta gaaagtgagc cagggaagc 1140  
 tttacctgta tattcaataa ttagatattc taatttactt ggcaattttc tcaatgtaga 1200  
 cattactgtt gtttctgatt tatctgagct gaaaaaaat caagctatag taagcttgaa 1260  
 tgattgatct ttgttttaatt tctggctagt tcttgaagga ttgactctag aagggggaatc 1320  
 attgggtcag ggtataaaaa ctttcctaag acccctcagc attgtcccta gagtaggaga 1380  
 gcatgggttag ggagctatct gtattctgac agtcacttta ggggtatggg tgaccaggg 1440  
 cagtagcttt ctttgccaaa ggaaaaaact gcagttccag ccacaggctg ctttgttcaa 1500  
 atgtctttgt gctttatgaa ccgtaacagt ggatgagaaa ggggaagcgt atgaagaagt 1560  
 cctgatgaga ttgttatgtt tatcgtaatg gtgcaaaatg aatttgctcg tggaaaagaa 1620  
 aggccttggt actcttaact agaaattgat atatgttaat gtcctctggt gatattttata 1680  
 atttctagat attaataattt aggtgtagct ttaaaactgt tggtgtagt attctttagg 1740  
 aaaagtactt tgatactgaa agcctccagc cccaaccttt ttttgttcaa taaaacaatt 1800  
 gatttttttt taaatatgat atttgataac attgtgtagg cactctctct cagattatgg 1860  
 atgaacacat tttattttct ttcttctccc aggtaaagt ttacagagtt acattccagt 1920  
 cagcactgct ggacagagtg cgctattac acccacatcc ttgtcagcat tgagtagtta 1980  
 aatttttctt tttcaaagtt ttcta 2005

&lt;210&gt; 15

&lt;211&gt; 667

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 15

caaatattta tctctggatc gagaaggagg aagggtcttg gaacccagc ctggctcagc 60  
 cctgcctggg agggggggga ggaggaagg gacgggggag ggtgcagccc ctgagaggac 120  
 aggaacaggg ctgggagtc tgcacacccg ggttcaaatc ccagctctgc caccaccag 180  
 ggcagggtcc tcatgcccct gtgcctctgt gtcctccctg gaaacatggt cctaagacca 240  
 ccctgacgtc tcagggcaaa tgaaggttca gtgcctggaa cagggttaga gtccagctat 300  
 ggccgcctct atgccaggca ctgggcaagc gtttgtgatc ctgcagggaa gaaggcaaca 360  
 ggtagcaggt atttctatta gagaaaaaaa aggcgtgcag ggagaaggc tcacggggta 420  
 acctacagag ctctgaggag ctggcagcac cggggaatgg gacattcagc acacctcctg 480

cagaggggtca aataaatcga tcaatatgcc cccgacgact agacgcacag cagcgctctc 540  
 ctggtttcac aggccactc accctaaggg aaaaatggct gggccgccac atggggaaca 600  
 ggatgcaaaa ttcagaactc aaattcagag catctttttt tttctttttg agacgagctc 660  
 ctctctg 667

<210> 16

<211> 615

<212> DNA

<213> Homo sapiens

<400> 16

ggttttttag attaacataa gatatttcgt tgttttttct tctgagatga gaaccattag 60  
 taagaattga aacgttttaa aatgttgatt ttttttcttt gaggactaaa cagaatggta 120  
 gcaaggatca aatcagagaa accaggggaa agtaaaactac tagaaatctt ggtaattttg 180  
 accagaaggg tagaagtga agtgatgaaa tgtggaaagt tctggaagcc ttttgaaagt 240  
 aaagctgaaa gtatttgctg ttacatttaa cttgagtgag gtgaagacag tgttacagga 300  
 tatatccaca ttttctgacc tgaacaacta aaggctctgaa tttcttgagg tgaagaatac 360  
 tattaataaa aagtttttagg tcatagggaa tcaagatact tttttggaca ttttaatttt 420  
 gagatgttga gtgaaaatca aagtagaata ttgaatatgc agtttgatat acactttcaa 480  
 aatttgagaa ataaatttgagg agtagaacat ggatctttta agcatgtgac aaaatgatac 540  
 tactcttgaa gtacaaaaat agattctagt tacataagtc tttagaattc aggagctaga 600  
 aaaaaaaaaa aaggg 615

<210> 17

<211> 1108

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (300)

<223> a, c, g or t

<400> 17

gaattttaac aatgttccag atttattaat ttaaaaagtg gccattcatg ctatgcatat 60  
 tttagggact gaagcatcaa cagtgaacaa aaaaaccagt ctgtgtcttc cagactttac 120  
 atatgaatga gagaaagcat aaagtatgta cacattaaaa aaattatatt tcaaaaagtc 180  
 atgaattcta cagagaaaaa cgaaccaag taagtggtag agggcaggtg gatgagtggtg 240  
 gggcgcagca gtgggtgttt tctttcctag cctctgtga taataatata tatataaacn 300  
 aagactagaa ggaagggagg aacaagtcac atgggtgtat aaggaaaggc actctagaag 360  
 aagataaata aatgtaacat tcaaaagtc tgccatcttt gtgcattaaa ggagaggaaa 420  
 agtgctctgt gttgatgtat ttcagaaaaa gaggaggaaa atggtagaaa atgagatcaa 480  
 gtaggtcact gaagggtttt tagattaaca taagatattt cgttgttttt tcttctgaga 540  
 tgagaacat tagtaagaat tgaaacgttt taaaatgttg attttttttc tttgaggact 600  
 aaacagaatg gtagcaagga tcaaatcaga gaaaccaggg aacagtaaac tactagaaat 660  
 cttggaatt ttgaccagaa gggtagaagt gaaagtgatg aaatgtggaa agttctggaa 720

gccttttgaa agtaaagctg aaagtatttg ctgttacatt taacttgagt gaggtgaaga 780  
 cagtgttaca ggatatatcc acattttctg acctgaacaa cttaaaggctct gaatttcctg 840  
 aggtgaagaa tactattaaa taaaagtttt aggtcatagg gaatcaagat acttttttgg 900  
 acattttaat tttgagatgt tgagtgaata tcaaagtaga atattgaata tgcagtttga 960  
 tatacacttt caaaatttga gaaataaatt tgggagtaaa catggatctt taaagcatgt 1020  
 gacaaaatga tactactctt gaagtacaaa aatagattct agttacataa gtcttttagaa 1080  
 ttcaggagct agaaaaaaaa aaaaaggg 1108

<210> 18

<211> 552

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (454)..(480)

<223> a, c, g or t

<400> 18

caggatatta agtgatatct aacaaaaatc atttccaaa ttcattgttac agtggttcct 60  
 ggttttagctg gaattcaggg aacgacacta ggagtgtttt gtaatcagaa gaatccagca 120  
 tcagacagtc cgaccagaca ggaaattgat ttgtcagtct tacacttaaa aacttaatag 180  
 tggagaaaca gtattggatt gtctatgttc aatttcacag caatttcctg gcattagtgt 240  
 aaggaacaca aagctatgtg tacttttggc gttgatatta ttttaagctgg tattctaagc 300  
 ttatgagcat aaattcttta ttgtttttcg caagtatata catatttgta tgcccttgta 360  
 gatacatatg taggcatata cattacatgt acataaatat gtaggcatac acattacata 420  
 tgcataatata aatacatgaa tacatatata tacnnnnnnn nnnnnnnnnn nnnnnnnnnn 480  
 ctttttaciaa ttgattaatg gccaagatgc cactgcaatg cagtgaggaa tatgatgggt 540  
 ctgcatccat tg 552

<210> 19

<211> 307

<212> DNA

<213> Homo sapiens

<400> 19

tatacaacca gaataataac taacatttct aaaactgaca ataataccaa gtacgcagct 60  
 gcagcaactg aactcagaaa catttctggg aggaatacaa attgtcacia taacttttga 120  
 aactgtata gcagtatctt ccaaacctaa acattacagg gatccaatga tctagcactt 180  
 ccacccagaa tgcatacaca agtacatatg ttcactgaaa gtcaagtgca agaacgttca 240  
 aaagagccaa aactagaagc aacacatatg tttatcaaca gtagagatga taaaatatat 300  
 ttggata 307

<210> 20

<211> 602

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 20

```

gggacaagaa agactaagaa aatggctgtg tgctgttggt tcagttttga atattgtctc 60
attgctttct aataatttag ctcttggtta tatcaacaaa gttaaataaat cataatgttt 120
tggtctgaac ccaaagtagc ttccaatgtg attaatatac cctaaggaaa tatacaatgt 180
aagtggtaac caacaaatgg gtcttcatat tgttggtgct ttggaatcct tagaggtaaa 240
aagtatttta tccgtctttt aaatgatgaa ctaaatactt ttcaaattt ggcttcatag 300
agtgtataaa ccatatgaaa atccaaatta acataatatg ttctctccag aaataaactg 360
tacaatgtgg acttaacgtg gcaggggtgg ccacttgcaa acatgacctg agcaatgaga 420
aattgaattc aggaaattta gttttctttt cttttctctt tttctctctg cctttttggg 480
acaactttcc attgagggag ataaaatatt caggaaaaaa tactctaagg agtcaaagaa 540
atttggttaa atgagtaaca ttaatctttg tgttgagact gaattttgct gataaaaatc 600
tg                                                    602

```

&lt;210&gt; 21

&lt;211&gt; 934

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 21

```

gggacaagaa agactaagaa aatggctgtg tgctgttggt tcagttttga atattgtctc 60
attgctttct aataatttag ctcttggtta tatcaacaaa gttaaataaat cataatgttt 120
tggtctgaac ccaaagtagc ttccaatgtg attaatatac cctaaggaaa tatacaatgt 180
aagtggtaac caacaaatgg gtcttcatat tgttggtgct ttggaatcct tagaggtaaa 240
aagtatttta tccgtctttt aaatgatgaa ctaaatactt ttcaaattt ggcttcatag 300
agtgtataaa ccatatgaaa atccaaatta acataatatg ttctctccag aaataaactg 360
tacaatgtgg acttaacgtg gcaggggtgg ccacttgcaa acatgacctg agcaatgaga 420
aattgaattc aggaaattta gttttctttt cttttctctt tttctctctg cctttttggg 480
acaactttcc attgagggag ataaaatatt caggaaaaaa tactctaagg agtcaaagaa 540
aatttggtta aatgagtaaa cattaaatct ttgtgttgag actgaatttt gcatgataaa 600
aatctgcttt ttgggttgga ggaacggtgc gttgcactgc tctcatggga caattgtgta 660
atattttggc acgaaaatgg gttatcagac accaaagaat tgtgtacctc agaaaagcca 720
aagtaacaat tggtttgagg tgaaaggaaa atctaagtga tgaaattcag agtctggaag 780
agaatatgtt ggtgtttgat tgggtgtagt gggaagaatt tctttgccta ggagtacttc 840
attatctaaa tggttgttgt atatgtttca tcctaaaata cttttaagtt ggaatgtgca 900
tgcaattcaa gtttatcttc ttgaaatctg gtaa                                                    934

```

&lt;210&gt; 22

&lt;211&gt; 568

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 22

```

tgatcttggt actcttttag ctctaagagg tgaacattat agccttttgg gaataaggta 60

```

```

cactgcctac atttcagtgt gtaattttac aaacctctcc atatggcttg ccctaaaatt 120
ttaatatatg tcctaaaggg caaatgtagc ataaaccaga ttatggtact ttggcacaag 180
cttttcactc acgagctgaa tgctaactaa gttacaaact taattttgct ttttcataatt 240
ttttgaactt gttttggccc catgaaatgc tttgatatct ggaattttct tccactgttt 300
catttcgctg tgaatcagtc tgaatttaga tccattatgt ggatatatga gaacgtcagc 360
aatggtctct tttagaaagg cctgaattcg tggaacaaag aattaggcta tgcctgatg 420
gtgattttct tctatagaat ttctttatat tgggcctgag tgagctttag aagtgaagac 480
ctggagagta tttcagattg tctctagctt cagtgtatcc acagcactag tgaattgtta 540
ctctaattccc gaaccagcag gatcagca 568

```

&lt;210&gt; 23

&lt;211&gt; 969

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (610)..(712)

&lt;223&gt; a, c, g or t

&lt;400&gt; 23

```

tgatcttggt actcttttag ctctaagagg tgaacattat agccttttgg gaataaggta 60
cactgcctac atttcagtgt gtaattttac aaacctctcc atatggcttg ccctaaaatt 120
ttaatatatg tcctaaaggg caaatgtagc ataaaccaga ttatggtact ttggcacaag 180
cttttcactc acgagctgaa tgctaactaa gttacaaact taattttgct ttttcataatt 240
ttttgaactt gttttggccc catgaaatgc tttgatatct ggaattttct tccactgttt 300
catttcgctg tgaatcagtc tgaatttaga tccattatgt ggatatatga gaacgtcagc 360
aatggtctct tttagaaagg cctgaattcg tggaacaaag aattaggcta tgcctgatg 420
gtgattttct tctatagaat ttctttatat tgggcctgag tgagctttag aagtgaagac 480
ctggagagta tttcagattg tctctagctt cagtgtatcc acagcactag tgaattgtta 540
ctctaattccc gaaccagcag gatcagcctc cctgagagtt tgcagaaat gcaaattctc 600
tggtatttgn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 660
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnattctaac 720
ccacgattgt gtttactggt ggccctcaaa ccatagctta ggaatctaag aacttcaaga 780
aaattttgag ccttaattct taaagcagtt attgaatctg tgggtcaaac gagaaaagga 840
gtacttgaaa cctagagttg cgttttcact tgagaagaca cactttggaa acacctatcc 900
aacagactac aaatataggc tattaaatta aaaatctggt ttcaaaataa taccactta 960
ggttggttaa 969

```

&lt;210&gt; 24

&lt;211&gt; 870

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 24

```

cacgaagcta agttttcaac tcacaaactc ttggtgataa aagaactaaa ggatgttctt 60

```



```

cagtaaagag aaaaataaat gcagaaagaa gtggaatact aaagcaaaga gtgttataat 120
atgagctaaa gctaatatgc ttcaaaagct agaactaaat cttagcaata ataatatggt 180
attaaagatg taaatgtgtg ctaaagtcct tgttttgagt agaaaagata cagatgaatg 240
ttatagactt ttaaaaaata tatatttaa taagtatgtt aaatataagg gtatccagta 300
tagtaataga aatatagaaa tagaaggtag aagtccttaa tcagtagggg aaagagaaaa 360
gataggtaat attttaaatg ctttctctcc attcaataga gggcaggaaa gaagataaaa 420
agaagcaaag gaaaaacatg gaaataggaa atacaaaata aaatatgtaa gtagtataa 480
tataaattaa tctacaaagc cagagagata gtcagattat ccttccatat gctgttttca 540
aagtaacact gaaagataaa aaaatacaag tataagacag gaaaaatttt ctcttggtta 600
ccaccaagtg aaagctggca gcatgaacat catttgaaac atgaacatgt ttttgcttaa 660
aaacagcaaa tgacagaaat atatgtctca cttataaata aggaacaatc catgaagatg 720
atataaaatg actctagata ctgaaaatat actctcaaaa tatataaac aaaaccgaca 780
gaattatcaa gaaatagcat atccacagtc agtggtgcag attttaacac acctctctta 840
gaaaccagta tatcaaaaaa aaaaaaaagg
870

```

&lt;210&gt; 25

&lt;211&gt; 3795

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 25

```

cctttttttt ttttttgata tactggtttc taagagaggt gtgttataat ctgcaacact 60
gactgtggat atgctatttc ttgataattc tgtcggtttt gttttatata ttttgagagt 120
atattttcag tatctagagt cattttatat catcttcatg gattgttcct tatttataag 180
tgagacatat atttctgtca tttgctgttt ttaagcaaaa acatgttcat gtttcaaatg 240
atgttcatgc tgccagcttt cacttggttg taaccaagag aaaatttttc ctgtcttata 300
cttgattttt tttatctttc agtgttactt tgaaaacagc atatggaagg ataactgac 360
tatctctctg gctttgtaga ttaatttata ttatgactac ttacatattt tttttgtat 420
ttcctatttc catgtttttc ctttgcttct ttttatcttc tttcctgcc tctattgaat 480
ggagtgaag catttaaaat attacctatc ttttctctt cccctactga ttaaggactt 540
gtaccttcta tttctatatt tctattacta tactggatac ccttataatt aacatactta 600
tttaaatata ttttttttaa aagtctataa cattcatctg tatcttttct actcaaaaca 660
aggacttttag cacacattta catctttaat accatattat tattgctaag atttagttct 720
agcttttgaa gcatattagc ttttagctcat attttaacac tctttgcttt agtattccac 780
ttctttctgc atttattttt ctctttactg aagaacatcc tttagttctt ttatcaccia 840
gagtttggtg gttgaaaact tagcttcgtg tatctgaaga tgtgtttatt ttgctccac 900
tctgtatata aaccactgta tgaaactgga agctcacagt ttttttcta cagcactttg 960
aagatactag tcagttttct ggtatctact gttgccaaag cctactgcca atttgactac 1020
cattccatta ttcagaattt tttcttatac ttgtattcag aatttcagat tttctcttta 1080
tcattaattt cctacgattt tattatcatg tatgtagttg tggatttatc tatctgtgt 1140
tacatatggc agcattttct attttgaaga ctgagcttca tttctgaaaa aattcttagc 1200
tgcagttatt gttattatta ttgccacttt tttattcatt cttttttctc ctttgcaact 1260
cctagcagat gtatgttaga gcttctcagg tcatctttca tgtccatctt tctctttcat 1320
tttcttctaa ctctctctaa actgcattct gaaagatttt ctgagttcta tttcctaatt 1380
ctgtaatttt ctcttaagct atagaaagta tgtgcagtct aactgttctt ttacttcaat 1440
attgtattta taatattttt cacttcaaga tgtctaaacg cttctttctc acagctttct 1500
cttcttggtt cattatctgt tcttcattct gtaaaatcta acttcttctg tacatatatt 1560

```

gagaatttta acttattttt aaactctcac cagattgttc ttcttttctc aggtataaat 1620  
 tctctcattt gttgggttct cttgactgct ttttcatgat cttaggtttt actgggttct 1680  
 ttgtaatggt ttgggggctc aatttttatg ataactaaaa aatgtaagta cctgtatcta 1740  
 tagggcagtt ttaagttgcc tcagcttaaa tctgataatg tgccaacctt gaaccagacc 1800  
 ttaagttggt agctctgggt cttctttcct cctaggtagc ccagttctga attttttagcc 1860  
 caaaaagtatt ttgggtccaa gtcctatcct gagtggttct ctgcgcttgc ttgtgactgc 1920  
 caattcttct ttaacttctg tcaggaacaa gcagcttatt cctggctgtg acactgctgg 1980  
 gataagttag attagcccag ctccattttg tattgtgctc ttgggtcctg ggttcatgca 2040  
 cagacaggat cattgcaaaa aaacctgggc ccaattgccc atatccattc atagcacccc 2100  
 ccgatccctt gccatcatag tggttttctt attactggcc caaagagact tttctttctt 2160  
 atttttaaga ataactatgt attttttaaa acctttaaaa atatttatgc ataatttctc 2220  
 tgtttttgaa tgagaggaat aagattcagg agtattcact ctgccaccct gacctagaag 2280  
 tcccagagta gctttcactt ttgaaataac agcagttcaa ttttctgat ctccagtc 2340  
 tgtaaacatt agcatatata ctcaaagtc aaacttgaat aagctgtagt agagacaaat 2400  
 ttccattatt tggaatttgt ttacattgaa ataaataata gatgtactag gaaatcagaa 2460  
 atggaaggaa gatgacttta aaagggttaa gaaacttggg acagcagcag actttactgt 2520  
 aaatcttatg tacaaactoc accactgctt cccataaatg gaatcagact gagcaaagaa 2580  
 gagggtagct tccacagcac cagaaagagc cactgcagcc agcagagtcc tgtaataagt 2640  
 accaacctgc actcctgcac ctggaagaca gccatcagct tagtggaag aatgctggac 2700  
 tggaattca gaaatgttct agttcatttt ctaccactaa gtcattgtac agcttaggct 2760  
 aagccaggcc ctcttttggg ccccagggtt tccatctgta aaataagaga gttgggctag 2820  
 aacaacttct aatgtacctt ccagaaataa ttttctgta ccttaacagt ttggtacttt 2880  
 ataagtaggc tgagtcctcc attcttcagc ttgctcagaa ataactctgc aggtaaaaga 2940  
 agaaaataat gtgtttctga aatcagtttt caaatcaaat gaaagaatca ccagatgcat 3000  
 atttttgttt gatcaccact ctacaaagga atagcctggg agctggatga agtttctgtg 3060  
 tgggtgtaca cacaatctaa gttttaaata gaaaaagcaa accaaccag accaaaacaa 3120  
 aaacctcca cacaagtccc agacgcaaca aatggtgaag gttcttttct acaaacatgt 3180  
 ctgtttctaa tagctgagaa gacaaaaaaa gaaaaaatg tatcaaactg ccaagatata 3240  
 tgtgtagata aagaaaaaac taaggagcat gcagcaaagt tacaggatat gagagatttg 3300  
 actctgcaca ctgcaaagtc tgtacaatta gaaatttcat gtgaacagaa atgtaggga 3360  
 gncaatgaga aaagaaagaa taaaattgga gttcactaa atggaagtta agagtggatt 3420  
 aataattttt aaattgaggc caggcacagt ggttcacgcc tgtaatccca gccccatgtc 3480  
 attactataa aacagatagg cattatattt gaatttttac ctttttcatt tcatcttcaa 3540  
 atgccttctc caaatactta tatctctga tgagtttatt gaagacctaa aaaaaaaca 3600  
 accattaaat attagggtcaa ccaaaaagac acagaagtag gtaatagaaa ctactataa 3660  
 tgacaccata gatctataat aataaaagt tatagttaaa caggctcaca ctgtaataa 3720  
 agaactataa gcatttcaaa gatgctatca tgacctaggg gaacaaatat gatcaaatg 3780  
 tacacgtaag ataag 3795

&lt;210&gt; 26

&lt;211&gt; 618

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 26

aaaatattta agaggcattt aagagcaaat caatgagatt tggagattaa tttttgtaga 60  
 aggtgaggga aaaggaggca tcaagggtga tcccaagtg gtgggttagg caaaaggatg 120

```

aataatagat ggatgctacc tcccttttcc ccacgcagaa ataaagggaa aggagagggc 180
ctgggtgggt ggatcagcag gcagacaggt gagtgtgagg ggacaatcag gagggaggtc 240
caccctgaaa tcagatatgt cagtccactt aggtttccaa caattgactc tgaactcctg 300
gaatctgtgt ccagcatctc tgatgctgtt gggtcatcta aaagtggcaa atattcctgc 360
acatttgtcc ccgaatcctc aaattaaatg tcaccttctc agacagatct tcccacacca 420
cctaagctct tctcctaccc cacactgatt ccccaccatt gcactcttcc atcttcctc 480
acagcaagta ccatgtttgc taatttatat ttacctgttt gctttcttgt ttcttatctg 540
actccccact agtcattcag cactgtaagg tcaggggttg tatgttggtc ccactccaga 600
tctacacagt gacagtca                                     618

```

&lt;210&gt; 27

&lt;211&gt; 451

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 27

```

ggtaccatgt atccccacca tccaggacca gccagatgac atcaggggtgc ggagaggcag 60
ttaggcctcc cctcattgta tagcagagtc ttgttttaat gaaaaagtcc cactttcttc 120
cccgactgaa actcccttaa gtccatataa gtcactgtgg atggagaggt actgttaccg 180
tagctgtgtg tgtactgaag gggcacctct acaaccgaca gtggccagaa gtgagaaaat 240
aaaatggaga gtagtctaga aacatgtgcc tcatccaacc cactccgcct gaaaaaaact 300
tccttccttt ctcaagagac acctgggcgc cttttcattc tccctaccac gtggccaaat 360
gtcacaaact aatgcttaag ttctgaagtt taccaggtta gagacggaat cattgatgac 420
atztatgtgt tcaactcaaaa caaacgaacg g                                     451

```

&lt;210&gt; 28

&lt;211&gt; 573

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 28

```

ggaactgcct cttctctgct ggacagagtc taccaggctc cctctgcctt gccctgccat 60
aggggtggaca tgtgaccac ctagccagta agattgtcca ctctctaat tcatgggcag 120
aaggacaagg acagtcagag tctcccggtt gcctcctgcc acgcattcct gctccccacc 180
cccaatctat gcgtttgccc ttcccgctt ttggccctca ggagctgtct tggttcctgc 240
ccttgcccag gcctgttttt ccagccttcc caccaatttt ctgagctcct gtgggtgtgc 300
ctatcttgtg tgggttttgt tttggctttt aaatgagcaa aggcagaatg agggtgccat 360
gagcacagat gaggcttttg ggaaacgccc cccttcatt gcactgttgg aaggagagtgt 420
agaggctgct gtgtttcctg gggccggcca ccttgacacc gtgcctgcat gcacgcagcc 480
ccccagcacg cttcttcacc agccagcctg agtgcagggc cctggccagc cttgccggga 540
ggaaatgccca gccccggtt cttaagcct cag                                     573

```

&lt;210&gt; 29

&lt;211&gt; 643

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 29

tagcacagcc ctttaccag ttccctggga agcctgggtg gagaggccgg agcaaaggtc 60  
 tggggctgaa catgccttaa ctggagcctg gcctgetcca gggccccgt ggggagggtgc 120  
 agggccggga gggagggagt cctgaagagg cttgcaattt ccctggtgca cagccccact 180  
 gcaggccctt caggaaacgt ccctggagggc tgtgagettg gcccaccca gcccatctca 240  
 gcccctcag ctgccggcca gccagctcc actcccagtt cggtgccaag cctttccagc 300  
 ccgetccagc ccacgcagct ctctctctc tgaactctca catacccata attacaactg 360  
 accatatttt ccaaagcaga aatcaagaaa ccactaaata aaggatttct gggctacttc 420  
 tgagtgtcag aggcagcctg ggaggtgaag tttggatgca gaggtattca aatctctgag 480  
 acacgttgat agttttttgc gatgactact atatctatca tattttatta ataagtcaaa 540  
 gccatcctag gaaatgtgtg ttgggcacat gccaccata ccactgttaa ctgttgacgt 600  
 ggacacttta gcctggcagt tctagctgt gtggcctggg caa 643

&lt;210&gt; 30

&lt;211&gt; 761

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 30

ccctgccaca ctcagaggac ccaaaagagg cctcagtggg gatctgggta gaataaaaaga 60  
 ggcagtagca caccaagtca ccaacatggc ccagacatt ccacaccctt accctgtaag 120  
 tctctttta agacttctc taactcatga ttgctctccc agacagacac acggccacca 180  
 gctgcactec tatttccagc cactcagctg gctttgcaag cctgccagga gcacagatat 240  
 ggtctccct tattctgtca ctaagctgtc cttgtcacct tgggacacca gctgcctaga 300  
 aggcagacaa tgaatggagg ccaagcactg tctgtgctgg ggacactgtg ctgggggagc 360  
 gttccaccct gggacaagca aagacaggca gaataaagc tagagatagg cagagttttc 420  
 aatggagaca ccaggggaca gactgggtct gtaagggaca ggagggaagc aaggactgtt 480  
 gaagcaagga cggttggttc cctctctaac ctgcacagta ttccactcac tccctgtaac 540  
 tagaagagac agccgcgaaa ccagtatcct aggcgaaggg tagctgctgt ccttagccac 600  
 acccggtaga acagcagcca gaaaaggggc ccagagcctc cagcaggcca aagccatgtt 660  
 tccatgggat ggcaaggta gcaatatccc aggtcagcc agaaagtcct gtggcagcac 720  
 catgtctgga gagagaccga gagaagaatg ttggacagag a 761

&lt;210&gt; 31

&lt;211&gt; 1658

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 31

cacatctgag gtttcagaga gagggagaac ttttcatgtc agagccgagg aggttgact 60  
 gacttgggaa tggcagttga tgacagggat tctggctttg aaatgcattc tcttagagat 120  
 gcaatggttc agtaacaagg gactctagga tgatcaaagg agatttgagt gaagggaac 180  
 cattccattc agtggaatcc tccatctgac ctccattaca cagatggacg aaagtgagtc 240  
 tcacagagaa cctagcactt gcccgaagtt atagactgaa tcagaagcaa tgctgagact 300

```

aaaaccaagt ctccaactc ctaaccatgg gatggatggg agaggcaccg cgagtctgat 360
gtttctgctg gggatgacct ccacccact gatttagagg ctgtgggagg gtctggggca 420
gggtgctggg gaagcctgcc aggcctcagct tgcagccctc cagccagagc tcttcctgtg 480
gccccactca cagaagggca ttacctgcta gttagcatag cctccacact tctgggggtg 540
ttatggaaac caaacctgga ggggaaggga ggaagggcag agaggagggt ggcaattcct 600
gcagtcacta acggcgtggg cttcaccatc tcaagataag ggaggggcag gaagaaggct 660
tccttgcagt ggggctgggt atgggatagg attctcaacc accacccttt gctctttctg 720
cccctgtctg ctgtccagct gtctgcctct ggccagcagc ttagccatca ctgaaggagc 780
agactggctt ggaggagggt tttgccagcc tgagaggggc aaagctctga cccctcacgt 840
gacccacac ttgccacctc tgcaactggc cctgtgtcat accaagcatt cctccagccc 900
tgccacactc agaggaccca aaaggagcct cagtggggat ctgggtagaa taaaaggagg 960
agtagcacac caagtcacca acatggcccc agacattcca cacccttacc ctgtaagtcc 1020
tcttttaaga cttcctctaa ctcattgatt ctctcccaga cagacacacg gccaccagct 1080
gcactcctat ttccagccac tcagctgget ttgcaagcct gccaggagca cagatatggt 1140
cctcccttat tctgtcacta agctgtcctt gtcaccttgg gacaccagct gcctagaagg 1200
cagacaatga atggaggcca agcactgtct gtgctgggga cactgtgctg ggggagggtt 1260
ccaccctggg acaagcaaag acaggcagaa tataagctag agataggcag agttttcaat 1320
ggagacacca ggggacagac tgggtctgta agggacagga ggggaagcaag gactgttgaa 1380
gcaaggacgg ttggttcctt ctctaacctg cacagtattc cactcactcc ctgtaactag 1440
aagagacagc cgcgaaacca gtatcctagg caagggttag ctgctgtcct tagccacacc 1500
cggtagaaca gcagccagaa aaggggcccc gagcctccag caggccaaag ccatgtttcc 1560
atgggatggc aaggtcagca atatccagg ctcagccaga aagtcctgtg gcagaccat 1620
gtctggagag agaccgagag aagaatgttg gacagaga 1658

```

&lt;210&gt; 32

&lt;211&gt; 627

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 32

```

gtgaagggtc acatcattat ttccctcaag gtcttttgtg caaagtaatt ggcacagggc 60
agctaactat gtggcaggag acaaggctat acttcgctgt ctaaatgaga acaattccca 120
tctgactgat attaatttgt attttagtca aggcctctgc tgagaaacaa gaactaagg 180
agcagcaaaa atctcttctt actttacttg ggtacctgtg aagtccactt gggatagtga 240
aggagaaatc cgcattcctc tccctgggtg gtgtgagacc cagtgaccac cacaccatct 300
tgatgacaaa tcacgcacatc tcagaggcct acctccttct ccgtaatgtc ttggagctaa 360
ctggtctcat cgtgtcccag atcttcagtt caaactcttc cccaagtctg gactgctttc 420
tatctctcta attcacacac ccagatattt ttcttttgac agccaacaca aaccctattg 480
cttgagaaat ctgctccaat taccctgaga ttcaaactct gattcagctg tgatgctgga 540
cagctaaccg aaatttgctg agccccaata tcctaattta gaaaatgaaa tactaatatt 600
taagatatgt ggcttttgag gattatg 627

```

&lt;210&gt; 33

&lt;211&gt; 1212

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 33

```

tttatgcttc caccaaaggt tttgggtaga aagaagatat ttttgatata taatatcata 60
gtactataat tttaaaacta gcttttcaga caaatgtgtc cactcaggca caggtaccgt 120
ggacccccaa agcaggagat gcttcacact acctcaatga agccaccgtc accactactc 180
actcactgaa cagatatatta ctgggcatac actacatact aggtgacttt ctaaccacgt 240
gctactccaa gtgtgggtcca tggaaacagaa ccagaccatg gactgtttgt tactgggtctg 300
ctacaagata agtacaaaaa tgaagagtaa gcatctagaa acatagcata aatgacactg 360
ccattttaatc agtgggtctca tttcgctgga cagagtatag acaagctcag gagttgtcac 420
actactgtgg tgagttactg tggtgtgtgt ccaggcacat gccatgctgt ctagcctttg 480
taagacatgg aagcaagga gtgataaaat cacatgtacg ttttaggcag atgccttctg 540
cctaaagatg aggaaaggac aagaaggagg gtgtgaact acattgtgaa gggtcacatc 600
attattttccc tcaaggtctt ttgtgcaaag taattggcac agggcagcta actatgtggc 660
aggagacaag gctatacttc gctgtctaaa tgagaacaat tcccatctga ctgatattaa 720
tttgtatttt agtcaaggcc tctgtgaga aacaagaact aaggtagcag caaaaatctc 780
ttcttacttt acttgggtac ctgtgaagtc cacttgggat agtgaaggag aaatccgcat 840
tcctctccct ggtgagtgtg agaccagtg accaccacac catcttgatg acaaatcacg 900
catcatcaga ggctacctc cttctcgtg atgtcttgga gctaactggt ctcatcgtgt 960
cccagatctt cagttcaaac tcttcccaa gtctggactg ctttctatct ctctaattca 1020
cacaccaga tatttttctt ttgacagcca acacaaaccc cattgcttga gaaatctgct 1080
ccaattaccc tgagattcaa atcttgattc agctgtgatg ctggacagct aacccaaatt 1140
tgctgagccc caatatccta atttagaaaa tgaatacta atatttaaga tatgtggctt 1200
ttgaggatta tg                                     1212

```

&lt;210&gt; 34

&lt;211&gt; 447

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 34

```

ggctgtcccc cccaaaaaag tttatatatg taatgtataa acataaaata gtgattaccg 60
aattgtcttc tagaaaagtc ttaagtgtca aaatcttaaa tgccattctc cttgtcccca 120
cagttctaca ttttgaaatc tattctaagg aaagaagata agtgtgtaga tatccagacg 180
tgtgtggagg tcggggctgc attatttata aaaggagtag ttgttaaacc tgctggcatt 240
tctgcactgt ggcacacctc atgtgtagac aggcagaagt gtgcagtgtg agagggaag 300
gcggggtctg gagcagtcct cggggcactc ctggttttaa gtacatgggt ctctaaggta 360
accatcagag gtgaggagac ggggtacact tttcttttat acatgggtgg attgtagaga 420
ttcttttggt aagcgtgtat tactttt                                     447

```

&lt;210&gt; 35

&lt;211&gt; 1078

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 35

```

ggctgtcccc cccaaaaaag tttatatatg taatgtataa acataaaata gtgattaccg 60

```

```

aattgctctc tagaaaagtc ttaagtgtca aaatcttaaa tgccattctc cttgtcccca 120
cagttctaca ttttgaaatc tattctaagg aaagaagata agtgtgtaga tatccagacg 180
tgtgtggagg tcggggctgc attatttata aaaggagtag ttgttaaacc tgctggcatt 240
tctgcactgt ggcacacctc atgtgtagac aggcagaagt gtgcagtgtg agaggggaaag 300
gtgggggtctg gagcagtcctc cggggccactc ctgggttttaa gtacatgggt ctctaaggta 360
accatcagag gtgaggagac ggggtacact tttcttttat acatgggtgt attgtagaga 420
ttcttttggt aagcgtgtat tactttttta cagtagtaat ttgaaaacat ttagatatct 480
tcattggaaa gaaaagtact ctttaagtc tggcaagt gataaatatg ctttgcaata 540
gaagaattta ggggcatttg tttttctaac tcacatgtaa gctcttcaag gtggggactg 600
accctcgggg tctgagcggg gctctgttac agcccatcct acaaacagtc tcccaggttt 660
ccatccagaa gcaggtttgt acctctcatt cccttgcttg aaaccctggc atgactttcc 720
tgtattctta ggatcctaag gtctcagggt ccctggaagg cctgcctgat cctggcctct 780
gttttaccag cctcatctga tagcacttgc tgtgtttgtg gagtttcagc tgccacctgc 840
tttactttct agctctctct aagtccctt tgacctcggg gcctttgcac aactgttcc 900
ccttccttgg aatggcctcc ctttaccttc ctcttctcca gcccctcagt tcatgctcat 960
cctctcatcc tttgatcccc tgtaaactt agcctaatag cttttttcct cttttctaac 1020
agcatcccat tgtgcaattt caggaaggag ctcatgtga ccttagttgt ttaatgcc 1078

```

&lt;210&gt; 36

&lt;211&gt; 424

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 36

```

aagatagtca catgggttac taagaatcag gtagacaaga aatgaaacaa gaatcttaaa 60
ttttgttttt gacatcaaaa ctctcttca tctaatttt taccagaaa ccaatatgt 120
aacaattga gaatgaaatg ctttctctaa agccagttga gagggccaaa tcccagaaa 180
ttcatcctct acccaagtac ccaaagtacc tatgaatata ttcaaaaac cacttcaata 240
aaacaattaa atgaatatac aaactgacat acagaaagggt agtgatgtca tcagatataa 300
actgcttgca gaaaggcagt tccattaaat tcacactaca gttcaaagag ttccttggtc 360
agcttatgaa cagactcatc tgaaattcaa tgtttgaagg atcgactggg tgcagtggct 420
caca 424

```

&lt;210&gt; 37

&lt;211&gt; 860

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 37

```

tgtgccttgg gccttggcca ctcatattgg gccctagaat atttatttct tcaaacattc 60
tacagagttt gactctttct tgttgacact agtcagcttg agacgtgcaa ttatttactg 120
gcaatcttaa agtcaaaaat accaggatct aagacaaagg tagctaaaac tgaatcacia 180
tcaaactgac ttcataatta atgctttaat caggaaagtc tcagcatatt ccttaagata 240
ctcaagcact cacgtcaaga aaatttctct aaataaacc tgtaaagttt gccattgttc 300
ctagccacat ttttctggtg tttctaatag atcatttgtt ctagaaaaca cttagaatct 360
gaaacccaaa gggtgagcat gtagacttca tgaaagccca atcccctaaa acctgaaatg 420

```

```

cccaggaatt ttctcaattt gagtaaaaag atttactgtt caagttatgt aaaaccaa 480
cctgtgaatt tgacttttga aagaattaca gtcacacagc aaaattcact ttaagatgca 540
atgcaaccca caccatgaat ctgttaattc tgtctttgtc aaactaccca aaaaatcaat 600
ttgtctttct tgttattgca ggaaatagag gtttatgcct cattaatcag aaggggagca 660
gtttaggagc agttatttac taagcccttt aagttatact agacagacca ttttaaaatc 720
acagtatcat tttagaaaaa tacagtccaa atagcaagtt tagggtagca atcatttaaa 780
atgtaataga gatgagtaca catagacaca ctcacaacct taacactgag cttgaggaaa 840
gtatqaagct tgctcatttt                                     860

```

&lt;210&gt; 38

&lt;211&gt; 272

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 38

```

cattttgact gtctttacag aaaaagttaa ttgaccctgt gtgtagataa gaaatcattg 60
tgacctgagt gagaatatta gtcaatgtaa ctcttcaagg taatgaaaag agtactgagc 120
tatgatttaa acttaactgc agagaagtct agcatattcc agttatcagc agtgtagcat 180
gataactaaa ttacttgacc tttcagaatc ttagttttct caattgttaa atgaacatac 240
tgatactatt ctactcactt cacagtctta aa                                     272

```

&lt;210&gt; 39

&lt;211&gt; 207

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 39

```

ctgagcctgt cgggtgcatca ggagcagtgc actgcacagc gagatccggg ccagctggaa 60
gggagggggg ttgcagaggt gccggagcca gatggaaccc tgtggtgcct ggggaggaa 120
ttggattttg gattgagggg cagccggcac gtgcagtggc agcagtttgg gcaaggaggt 180
gatgaactga gttgcttttt gttgaga                                     207

```

&lt;210&gt; 40

&lt;211&gt; 134

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 40

```

gtgtgagcta ccaccactgg cagttaagaa ttttaacaat ttgtcaatga aacaagaatc 60
tcaattagag tctttatata caatctgtac tgttgaatt ttcaaataaa tattgtaaag 120
aaaattaaca aaac                                     134

```

&lt;210&gt; 41

&lt;211&gt; 546



&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 41

```

ccaatgaata caaagcagag atttaagaag ttgaaagaca gattttacag ggtgaacaaa 60
gttacagttc tgactagaa ggaatgaaga tggaaatctc ccatctaact caggagttac 120
atcagcgaga tatcactatt gcttccacca aaggttcttc ctcagacatg gaaaagcgac 180
tcagagcaga gatgcaaaag gcagaagaca aagcagtaga gcataaggag attttggatc 240
agctggagtc actcaaatta gaaaatcgtc atctttctga aatgggtgatg aaattggaat 300
tgggtttaca tgagagatgg gggtttacca tgttgccag tctggttttg aacttcggga 360
ttcaagcaat ccgccagcct cagcgtccca aagtgtgga attacaagtg tgagctacca 420
ccactggcag ttaagaattt taacaatttg tcaatgaaac aagaatctca attagagtct 480
ttatatacaa tctgtactgt tggaaatttc aaataaatat tgtaaagaaa attaaaaaaa 540
aaaaaa: 546

```

&lt;210&gt; 42

&lt;211&gt; 1134

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (538)..(585)

&lt;223&gt; a, c, g or t

&lt;400&gt; 42

```

agttcatggg cttgaggggtg tggttaattgt atttaggtcc tgtgaaaagg cagaagccct 60
agtaaacaac ctaggctttc attgagaacc ctgagtctag gtgaatcaga aataaaacat 120
aggtagtgaa gccaaaactc aaataatttc agattagtgc ccctagccta gatgtctgcc 180
tgaagccaga ataaaaatc tctttggagg aagatgcttt tcccagaaac tcaggttatc 240
actgtagttt ttcattgtact atatctgtca gtcagtagaa ataatagaca catcacatga 300
gaagaccaga tatgattaaa aaaaacaata aaaaataaac aaattggata tacctacaag 360
agatccagat aatagataat caaatatggc cctaccata actgtgatta atatgtttca 420
aggattaaaa gataagattg aaaactctgc cagagaactg aaaattgtaa ataagaccaa 480
atggaccttc tggaactgan aaatacaatt actgcagtta aaatctaaat gagtgaannn 540
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnatggc tgcataaatg 600
aattaatgac taaaaccatt gaatgtgtac ttacaatggg tgaattttat gctgtgtaaa 660
ttgtacttta aaaattaagc tttaaaaaaa ccaaatgaat tgggtcaata gagtagatgc 720
aattgaggag agagttagtg aaccagaaga taaagcagaa gaaaatatca acaataaagc 780
atthtgaggc ttttagatgg aaaataaata tcagattgtg aaagacatat taaatatggc 840
ggaaaggcct aatatatgtg taactggagg ttcagcngga gaggagagag aaagtgggac 900
ataaaaaata attggaaaaa aatagctgag atagttctaa aactaacaaa tcacacaaag 960
ccacagaatc cagaagccct agggcaccaa gcaggataag tacaagatt caacatagta 1020
aaatttctga taacaaagct aacgagaaca acatagggac aacatggtaa catthataaa 1080
agaaaaagag aaaagctgaa aagcatcatg gttggggagt gggtagctct tate 1134

```

<210> 43  
 <211> 161  
 <212> DNA  
 <213> Homo sapiens

<400> 43  
 atgtgcttat ttctagtata tgtgctgctg aagcgagcag taaaatgtgc ttatttctat 60  
 taatgaattc tttattataa aagtgggtaca ttattacaaa agtagtaaat gtttattaag 120  
 attagaaaca aattctaatt atacagaaga gtacttactg a 161

<210> 44  
 <211> 413  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> unsure  
 <222> (220)..(221)  
 <223> a, c, g or t

<400> 44  
 agctcactgc agcttcaaac tccaaagctg aagcaatctt eccacctcag cctctcaagt 60  
 agctgggact acaggcagac gccaccaggc caggccaatt tttgtatttt ttgtagagac 120  
 gaggtttcgc catattgccc aggctggtct cgaactcctg agctcaagtg atccaaccac 180  
 ctcatcctcc caaagtgtg ggattatagg cgtgacactn ngtgctgggt ctgagtaagt 240  
 actcttctgt ataattagaa tttgtttcta atcttaataa acatttacta cttttgtaat 300  
 aatgtaccac ttttataata aagaattcat taatagaaat aagcacattt tactgtctgc 360  
 ttcagcagca catatactag aaataagcac attttataat atagaagata tat 413

<210> 45  
 <211> 470  
 <212> DNA  
 <213> Homo sapiens

<400> 45  
 atcaaagtgc gagaccaaga tattgcgaga tggaagtgat ggtaatggaa agaacaatga 60  
 tgaccttgga agagatactg tgaggaatta acaagaggtc aaatagaaat aaatcaaagg 120  
 gctgacaggt agcactgagg tgagtaagca caaattaaca cagtttcatg gctttctcca 180  
 gcaaagctca tcagcaaaaag ccagagactc tgggagtacc cagggtttaga gaacatgcct 240  
 atggaatcag tttacaatgt ctttaaattc agttaaccgc tttcctccta aaatatcttt 300  
 aaaatattct ttctccatgc tattagtatt cagaattaaa atgttggttac tgatgtcaaa 360  
 gcaaagagaa taaactacgg agaaattaac tcttcatttc cagatacaga aggacctgat 420  
 tttgtagaga ccaccaactc aatagtttgg agcaggagtt ggcaaactac 470

<210> 46

&lt;211&gt; 410

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 46

```

ccctcctgtg tcttttaaaa cagcatcacc ttccccccat gtttccctt ctccccagat 60
ccattccact tagtctcacc agttcagttt tccttcatct gtctatttta ctggaagaca 120
gaactgtgtg atgattaaga ccctgggtatt ggagccaaac acagctaaat ctgacttacc 180
acagcactta ctaagttact tggctctact gagoctcagt tctctaataa aatgaggata 240
atatctacct tttgtagtta tggttaaggat ttaaagctg atgcctgtgc ccgggatatg 300
gtagacacta cttacattgc tgcatgatt ctattgtatt actcagtact ctatcttctc 360
cttcatacac ttcctttgcc aataatgaca aaaataatca cagcttatgt 410

```

&lt;210&gt; 47

&lt;211&gt; 411

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (254) .. (276)

&lt;223&gt; a, c, g or t

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (333)

&lt;223&gt; a, c, g or t

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (393)

&lt;223&gt; a, c, g or t

&lt;400&gt; 47

```

gtctaacttc agtgcattgc aacacatcag atatgggttaa atgtaggagt ttataatgat 60
actttaaaga gagaaatcta gtcctaatt gcttgatctt ctctctggta attattaggg 120
agattaagag tcacaagtac aagaagccac agagaaacag gcatagtcta gaagggcagt 180
gtatcccatg cccatagctg tgccctgccc atggcccatt aaacagcggc catgagacct 240
tttctgttg tacnnnnnnn nnnnnnnnnn nnnnnngtct tcaccagcgg ggaagctgca 300
gtcctacttt gtctgttctt actgtgctgg aangtttaac atatgggatt taattgtggg 360
tttatctcca aattttttaa ttatacagat gcntcttgac atacaatggc g 411

```

&lt;210&gt; 48

&lt;211&gt; 1022

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (254) .. (276)

&lt;223&gt; a, c, g or t

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (333)

&lt;223&gt; a, c, g or t

&lt;400&gt; 48

```

gtctaacttc agtgcattgc aacacatcag atatggttaa atgtaggagt ttataatgat 60
actttaaaga gagaaatcta gtccctaatt gcttgatctt ctctctggta attattaggg 120
agattaagag tcacaagtag aagaagccac agagaaacag gcatagtcta gaagggcagt 180
gtatcccatg cccatagctg tgccctgccc atggcccatt aaacagcggc catgagacct 240
tttctgttg tacnnnnnnn nnnnnnnnnn nnnnnngtct tcaccagcgg ggaagctgca 300
gtcctacttt gtctgttctt actgtgctgg aangtttaac atatgggatt taattgtggg 360
tttatctcca aattttttta ttatacagat gcgtcttgac atacaatggc gttatgtccc 420
aataaactca ttgtaggttg tagatattgt aagttgaaaa tgcatccaat acacctaccc 480
tactgaacat catagcttag cctagtctac cttaaatgtg cttagaacat ttacattagc 540
ctacagtctg gcaaaagcat ataacacaaa gcctatttta taataaagtg ttgaatagct 600
catgtaattt attgaatatg gttctaaaaa tgaacagcag gatggttgca tgggtattca 660
aagtatggtt tctactgaat gcaagtggct ttctcaccaa cataaaatca aaaaaaaaaa 720
aaaaaaaaat ccttgtagct atcaggagac ttcagtgact taaatgcaag attgaattcc 780
agtgtctctt gcgctctttc tatccctgtg tcccctatgt ataactataa taagtgcac 840
caggaaaatg ttatgagagt ataaaacagg gattaaaaat aatttggggg taaaaggagt 900
gggtcataaa tacttcccag ggaagatgac atttatacta ggccatgaat gatgtaagat 960
ttaacaggc attcatgggg gtggggcagg cattccaggc ttagggaaca ataggagcaa 1020
aa

```

&lt;210&gt; 49

&lt;211&gt; 631

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 49

```

gcaatcatat tcagcctgaa gtgaaaggat tgacctgtct cgttgcctgt tgcaccctcc 60
tgagctgatt aggaaacctt actttccacc aaagggctac cgcagtgtct ggaaacagca 120
cctcccctac ttctcctgt tgctttgggg aggccatgcc aggtgtgctt gatgccctct 180
gccatactg aatataccag tgctggcttc cggaattagg ggcaataggc agagacatga 240
gcggggtgct tgtgagaagg gagaaagcaa aaaccggag ggagaattgt ggggaagaca 300
tttacaatt gactgatttt tcttatacat tttcaagagt cctgattttc agttttttta 360
aacattactt taaaaaaacc aatgcatttc aaagttgatt acaaaatgat tttaaactcc 420
tggaatttac ccaaattttg tttacttaaa ttatagatga tcttaatatg ctattatttt 480
aaaaaacat atcctactct attgtaatgt attatcagtt taaaaaatta ggaaactgcc 540
tatttcactt ttttaattta aagcacatat caaagatcat ggcaaaaaag gaggggctca 600

```

ataaatgtta gcccttcagt tgcttcaaaa g

631

&lt;210&gt; 50

&lt;211&gt; 797

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 50

tgtgtagctt ccatgtttcc tgtattaaca atgctaattg gagaagcgat taatttatgt 60  
aaactttaca tttttatgca aatgaagctg atatttatta gagctaaaac aattatactg 120  
gcacttagtg gagtaacctt gtgtgcctgg gaaatgttag aggagagcag ttgatgttcc 180  
actaatacct ctgctgtaaa caaatatgca tttatgccac tttttagaat ttaaagacaa 240  
aaagaagagc tcggagagca ttgctggaga ttgcttatta ggggtgataa cctgaaataa 300  
ctcctgattg gcaggcgagc cttggcctta caatTTTTTT gtgaaagaaa gatagccttt 360  
cttgatagaa tgtaataaac aaaatgataa aaaatgaaat gctaattgca ttttaaagag 420  
gtcttttgaa aaaaaatttt taatagttgg ttgtattgtt actgagagaa ctggtatgct 480  
aatgactgac tacctagatg attttgcatt aatataataa ccattacctg ccttagtgct 540  
ttgtacagta ttgtggcaaa atagctaanc cttaaaggagt tatacaaaaa gcagaattcc 600  
ataatgaaac agaattttac tttccacata aatagcatgc cttttttttt ttttttttta 660  
agaccgaaat attatatcag aagtgtgttt tctttcctgt atgatagtta cttgcatggt 720  
acctggttg ttcattttgt tttgtttttt taataccagg agaaagaagc ttctaacttt 780  
tctgttgcca tacacgt 797

&lt;210&gt; 51

&lt;211&gt; 527

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 51

ggatggagga agggcagttg cgaaagtggg ggaaaaggag atccagcaga gcatggcaca 60  
ttctcaggca aatcagattt ttttttcctt tttaaagagc ccttcaaaaa gattgatggt 120  
ctgaacattt atttccttca cacttttcac ataatcatgt accccttagt tcatggaagg 180  
ccttcaagta tttctagggg ccaagtacac cttgtcagag cgcagaagct acacagtcag 240  
actaatgaat catctcagaa catttttcctt agactttggg tatacctcta cagaaatcac 300  
tggtatgttat taagcctttt tagtttttaa atatttcaaa tgatttattt atatgtgtag 360  
aattcgtttc cttaagattt tcttctatat ggtcttaaata gatcctcata acagccctca 420  
caatgaaaca agtgaggatg tggtatccac atttctaaat gactgagatt atgtgatttg 480  
tctaagggtca cacagtatta gagtcaggac ttgctgccat ttttctt 527

&lt;210&gt; 52

&lt;211&gt; 579

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 52

```

ggatggagga agggcagttg cgaaagtggg ggaaaaggag atccagcaga gcatggcaca 60
ttctcaggca aatcagattt tttttttcct tttaaagagc acatacaaaa gattgatggg 120
ctgaacattt atttccttca cacttttcac ataatcatgt accccttagt tcatggaagg 180
cettcaagta tttctagggg ccaagtacac cttgtcagag cgcagaagct acacagtcag 240
actaatgaat catctcagaa cattttcctt agactttggg tatacctcta cagaaatcac 300
tggatgttat taagcctttt tagtttttaa atatttcaaa tgatttattt atatgtgtag 360
aattcgtttc cttaagattt tcttctatat tgtcttaa at gactcctcata acagccctca 420
caatgaaaca agtgaggat tgttatccac atttctaaat gactgagatt atgtgatttg 480
tctaaggta cacagtatta gagtcaggac ttgctgccat ttttcttttc tgtaaattcc 540
ttgttctttc tgccacttca agctgcatta tatatcatt 579

```

&lt;210&gt; 53

&lt;211&gt; 1033

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (108)..(144)

&lt;223&gt; a, c, g or t

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (193)

&lt;223&gt; a, c, g or t

&lt;400&gt; 53

```

ttcatgtttc tgtgtttcca taaacttggt ggtcttcacc caaggacaaa attaccctag 60
ggcaagactt tttgtttatc ttggtaacaa ttaggttttg gttttagnnn nnnnnnnnnn 120
nnnnnnnnnn nnnnnnnnnn nnnnggataa agaatgtata gctctataaa tgactgttaa 180
aaggatatta tcnattgttt agattttgtt tttttgtttt ttaaggaaaa gttgacaagg 240
ggtaaaaggg ttatcaaaca agaactttgt catcatatat agcattatat tatttaattg 300
acaaccagac aattagcttc tttttatcag catgatattc cagtgtactc aaaccccgag 360
cacagcaact acagtacagg aaagggccat gtaactaatt gagtcactga atttatgtaa 420
agtccttag aacacaaaca tgtatgttcc agcaagcagt acaaaattgg gcagggtgag 480
catattacaa aaatgggcaa agaagcaata ttaattggcc ctagagaaca ttaggcctt 540
tgtttagtgc ttgtgactgg aatactttac acttttatag ttggggaaaa agcagcaata 600
acctctgcc aagaaagtctt attgattcat gggcttaaca ttatagaaat gttgcttggt 660
ctctgtaggg ctgattctag tagaacaag gaatggcagt ctgatgagct aagacacatc 720
agagatccta cagtgcagat gatgacacag aatctttttc tcttatagac aactgacttt 780
tggcttattt taagtgattt gtcagacttt taagtacttc atctggtttt tttttcccc 840
tttcatttga taccatcaca gattggatgt ggcttatagc aatggtagcc tagtgtagag 900
agagatacat atatatgtag aatttggaaat gccaaagtaa ganttnaaat gtaattttag 960
taaggaaggg aatgctccat taacatttat nccagttgat aattataaag aatattaaga 1020
acagtatagg gaa 1033

```

<210> 54  
 <211> 403  
 <212> DNA  
 <213> Homo sapiens

<400> 54  
 cgaactcctg gttgcccttt tctttcatag ttccccagtg ggagccctct atgtgtggta 60  
 aagacactgg ggagtagggg acagttagcc cagaaaggct tttctgagga agagggagggt 120  
 ggaaccgact agttgggagg ggaatctgta gtcctagaga gtttatgaga actgccaac 180  
 agtgcaccca aagacatgag cacctcgag ccctggaatc tgggccacat aaatttggtg 240  
 ggatccaggc tttgcaaaa agagctgggt gatgtcatt cctgctccac ttcctatccc 300  
 agcgcgccag agagctgtct ccccaaacca aaggcaaggg aaggttacaa agttccctat 360  
 acctggcctt gaatgcaagt tccctctgtg gtccagctcg agc 403

<210> 55  
 <211> 360  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> unsure  
 <222> (58)..(289)  
 <223> a, c, g or t

<400> 55  
 ttattaccag agatgacagg tccatttgtg gtagttccct gaagaccttc tagtgggnnn 60  
 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 120  
 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 180  
 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 240  
 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnna agttttaaaa 300  
 agaaacagaa aaaatacaga ataaagctta cagaataagg atataaagaa aatatttttt 360

<210> 56  
 <211> 247  
 <212> DNA  
 <213> Homo sapiens

<400> 56  
 tgtctgattc caaagcccat gctttctcca aacttaccat gttggctgaa gagaaggaga 60  
 tctgagaagc ccagagagac tctcattct taactaagg ggaagaagct tctctgttac 120  
 tggccccatt tcatctgtg aacccatgg gtccttacat gtagggtgcc cattcatccc 180  
 catttgctg gaacagtccc actctatgtc tgtcatagtg tcagtatggc agtattgtta 240  
 aaattcc 247

<210> 57

&lt;211&gt; 250

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 57

```

gectgtctga ttccaaagcc catgctttct ccaaacttac catgttggt gaagagaagg 60
agatctgaga agcccagaga gactctcact tcttaactaa gggggaagaa gcttctctgt 120
tactggcccc atttcatctg ctgaacccat ggtgtcctta catgtagggt gccattcat 180
ccccatttgc ctggaacagt cccactctat gtctgtcata gtgtcagtat ggcagtattg 240
ttaaaattcc                                     250

```

&lt;210&gt; 58

&lt;211&gt; 598

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 58

```

gggctggaga aatcactagc agggaggagc cctgaggttg ccgaggggga tcggagctac 60
ttcccaaggc gcctacaccg cccgtagact gggaaactac ggtcacaaag ggtcagcgca 120
ttccccaagg tcccagagcc acacgcagca tggctggcat ttgaaagtca aagcagagga 180
agcaggcagg tggctcttgt tgaactggct tccagagtct gtgttgggca gagagatcct 240
tccccgagag tggagtggcc tcgtgctcac ctgggttcag cgtcaagggt cacctggaat 300
cacctgcact cttgtccttg accaaggcag ggtgggttagc catgggctga tagccttgga 360
gagcctgatt cagccttttg gtagagctgg gtcagtccag cctcagggcc atcactcacc 420
cgaagcattg tggtaacctg cctgcccctg gagaccccgg gtgtggggca gggtgaccgt 480
ggtggagagt gggagctggc agaggtaagg aggcacacag tcatgccaca gcaccagagc 540
tcagggcgcc tgagaagcaa ggtcatagcg tctgttctt ggaccccgtc agtctcca 598

```

&lt;210&gt; 59

&lt;211&gt; 594

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 59

```

gccctgtctg aagggggcgtg tgggtttgca ctcagcatct gtctcccag aattctggcc 60
ggctcaccca ggccgggggc tctgtaggct ccaggttatt gccagaggc ctgagtccat 120
gaatggatcc aggacagtgg ggaggctggg cagctccagt gcctgcttg ctcattgcac 180
attgttggtc tgtttacctg gggggccctt tgccttagca catgtgtgac ctctgtgatc 240
ggttagagtc ctgcgggaaa ccagtcctag tcaggagag tctggggccc tttcccaca 300
gggctctgtt ctcaaagtcc catagctggg tgaccaatgt agatgcagg cccatgcctt 360
gccaggagg cctggctcct gggagcccag aaaataccag tgggagatgg gaggtatgg 420
ggggcagcct ggctaggggt gatatggggc agagataggg aagaggctct tcctggaagg 480
catggggcac cttcaggggt ctagggggct aggggacctg aagcctaggc ccaagccaga 540
ccctgacctt gtacctcca tccccacagg acatcaacaa tgctggggc tgct 594

```



&lt;210&gt; 60

&lt;211&gt; 2848

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 60

```

gccctgtctg aaggggctg tgggtttgca ctcagcatct gtcctcccag aattctggcc 60
ggctcaccca ggccgggggc tctgtaggct ccaggttatt gccagaggc ctgagtcacat 120
gaatggatcc aggacagtgg ggaggctggg cagctccagt gcctgcttgc ctcattgcac 180
attgttggtc tgtttacctg gggggccctt tgcttagca catgtgtgac ctctgtgatc 240
ggttagagtc ctgcgggaaa ccagtcctag tcagggagag tctggggccc tttccccaca 300
gggctctgtt ctcaaagtc catagctggg tgaccaatgt agatgcaggc cccatgcctt 360
gccagaggag cctggctcct gggagcccag aaaataccag tgggagatgg gaggtatggg 420
ggggcagcct ggctaggggt gatatggggc agagataggg aagaggctct tcctggaagg 480
catggggcac cttcaggggt ctagggggct aggggacctg aagcctaggc ccaagccaga 540
ccctgaccct gtacctccca tccccacagg acatcaacaa tgcttggggc tgctggaggc 600
aggtggagaa gggctatgag gagtgggtgc tgaatgagat ccggaggctg gagcgactgg 660
accacctggc agagaagttc cggcagaagg cctccatcca cgaggcctgg actgacggga 720
aggaagccat gctgaagcac cgggactacg agacggccac actatcgga atcaaagccc 780
tcattcgcaa gcacgaggcc ttcgagagcg acctgcctga gcaccaggac cgcgcggagc 840
agatcgccgc cattgcccag gagctcaacg agctggatta ctacgactcc cacaatgtca 900
acaccgggtg ccagaagatc tgtgaccagt gggacgcctt cggtctctg acacatagtc 960
gcagggaagc cctggagaaa acagagaagc agctggaggc catcgaccag ctgcacctgg 1020
aatacgccaa gcgcgcggcc cccttcaaca actggatgga gagegccaatg gaggacctcc 1080
aggacatgtt categtccat accatcgagg agattgaggg cctgatctca gcccatgacc 1140
agttcaagtc caccctgccg gacgcccgat agggagcgcg aggccatcct ggccatccac 1200
aaggaggccc agaggatcgc tgagagcaac cacatcaagc tgcgggcag caaccctac 1260
accaccgtca ccccgcaaat catcaactcc aagtgggaga aggtgcagca gctggtgcca 1320
aaacgggacc atgccctcct ggaggagcag agcaagcagc agtccaacga gcacctgccc 1380
cgccagttcg ccagccaggc caatgttgtg gggccctgga tccagaccaa gatggaggag 1440
atcgggcgca tctccattga gatgaacggg acctggagg accagctgag ccacctgaag 1500
cagtatgaac gcagcatcgt ggactacaag cccaacctgg acctgctgga gcagcagcac 1560
cagctcatcc aggaggccct catcttcgac aacaagcaca ccaactatac catggagcac 1620
atccgcgtgg gctgggagca gctgctcacc accattgccc gcaccatcaa cgagggtggag 1680
aaccagatcc tcaccgcga cgccaagggc atcagccagg agcagatgca ggagttccgg 1740
gcgtccttca accacttga caagaagcag acaggcagca tggactccga tgacttcagg 1800
gctctgttta tctccacagg atacagcctg ggtgaggccg agttcaaccg catcatgagc 1860
ctggtcgacc ccaaccatag cggccttgtg acctccaag cttcatcga cttcatgtcg 1920
cgggagacca ccgacacgga cacggctgac caggtcatcg ctctctcaa ggtcttagca 1980
ggggacaaga acttcatcac agctgaggag ctgcggagag agctgcccc cgaccaggcc 2040
gagtactgca tcgcccgcgt ggccgcatat caggggcctg acgcccgtgc cgggtgccc 2100
gactacaagt cttctccac ggccttgtat ggcgagagcg acctgtgagg cccagagac 2160
ctgacceaac acccccagc gctccagga ggggcctggg cagccccaca gtccattcc 2220
tccactctgt atctatgaa agcactctct gcagtcctcc ggggtgggtg ggtgggtggg 2280
cagggagggg ctggggcagg ctctctctc tctctctttg tgggttggcc aggaggttcc 2340
ccgaccagg ttggggagac ttggggccag cgcttctggt ctggtaaata tgtatgatgt 2400
gttgtgtctt tttaaccaag gaggggccag tggattccca cagcacaacc ggtcccttcc 2460
atgccctggg atgcctcacc acaccagggt ctcttccttt gctctgaggt cccttcaagg 2520

```

```

cctccccaat ccaggccaaa gcccctgtg cctgtgccag gaactgcctg ggccatgcca 2580
gggccagcag agggcgccac caccacctga cggctgggga cccaccagc ccctctcccc 2640
tctctgtccc agactcactt gccattgcca ggagatggcc ccaaccaagc aaccccgtt 2700
ttgcagcaga ggagctgagt tggcagaccg gggccccctg aacggaccca tccaacagcc 2760
ggcctgctta gtcggctcac ggtctcaaga attgctagaa ccaaaaaaaaa agggacaaga 2820
gcaaaaacga agacgaaaca acagggggg 2848

```

&lt;210&gt; 61

&lt;211&gt; 572

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 61

```

accctgggta atggtggaga cgaggggttc cagcctcctg gtcctgtcc cattcactgc 60
atcatcgccct gcaatgacag ctctgtcggg ccacggccca tgcaacagca gcagaggggc 120
ccaacagtct aatgaaaagg cccatactt gaagtcagaa aatttgggtcc cagtccctggc 180
tctcttgaga attcactatg tggcctgggtg tgggacagaa aaatctacat aaggacagaa 240
ttctattttc tgaagcaaaa aacagtcgag gggctacat aagatttttt tcagcagttc 300
agttgcaaga gatgttaggc atctcctaca actcacacct gtcaaagaca taccagga 360
gatgttcagc gttttcacat ttaggtgctg aacaacccta tatagctgtc tatatcttga 420
cctatttccc tgacttcctt ggtggttgac cttggtcagt tccggccttg ctgacacctg 480
gtctccatgg ctgggtatat ctctaagtta tcttgtttcc aggtcagccc tgtttcctgt 540
aacaataat tctttccctt cagtgcagcag aa 572

```

&lt;210&gt; 62

&lt;211&gt; 650

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 62

```

accctgggta atggtggaga cgaggggttc cagcctcctg gtcctgtcc cattcactgc 60
atcatcgccct gcaatgacag ctctgtcggg ccacggccca tgcaacagca gcagaggggc 120
ccaacagtct aatgaaaagg cccatactt gaagtcagaa aatttgggtcc cagtccctggc 180
tctcttgaga attcactatg tggcctgggtg tgggacagaa aaatctacat aaggacagaa 240
ttctattttc tgaagcaaaa aacagtcgag gggctacat aagatttttt tcagcagttc 300
agttgcaaga gatgttaggc atctcctaca actcacacct gtcaaagaca taccagga 360
gatgttcagc gttttcacat ttaggtgctg aacaacccta tatagctgtc tatatcttga 420
cctatttccc tgacttcctt ggtggttgac cttggtcagt tccggccttg ctgacacctg 480
gtctccatgg ctgggtatat ctctaagtta tcttgtttcc aggtcagccc ctgtttcctg 540
taacaaataa ttctttcccc tcagtgcagc gaagtaatgg nctcatctgg cctgatccag 600
catttgggga gaagccggtg aaagagggca tctaagagat atgtttaatg 650

```

&lt;210&gt; 63

&lt;211&gt; 591

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 63

```

acaaggtag ttgggatttt aatcatggtt tcagtttaaa ggcaaagggt taatcatggt 60
ttcggtttaa agatcatgcc gttcagttag ccctttgtta tgatctaaag gtgtttgaca 120
gcttgaaatc caaaaggagg tcaactgagg tatggagagc tccacatatt gggctaaaag 180
ccagtcacat ttagcatttt ggaaagttat gtgaaaaatt gatatcgtct gttgtaaaac 240
tgaagcaatt gccaagcttg tccattgttc ttttgactg aattaactca ctcttaataa 300
aaggaccgac acagggcctt acacgggttg tctttgtgca gggcccacct gtgtatcttg 360
ctctgatggt tgtctttgct catagctcaa tgatgctgat taaatgagtt taagtgtgct 420
ggacagtgtt gcacaaacta ggccatttgt gtgtcttttc tctttctctt cctttgtaga 480
ttataaattc agcctgtatt ctaacaaaag attttcattc cagaatttaa ggcagtgttc 540
ttctctcaaa atgatattgc ctcacagatg gtctagggcc agccagtgga t 591

```

&lt;210&gt; 64

&lt;211&gt; 542

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 64

```

ctcaactagc attaacattg gaggtcaatt ttggtattga acataaatgt gagattaaag 60
ttgaagggcc cagatatctc tcagagatga ctacaaccac gggagatgtc tctgttttgt 120
tttcccatgc atgtaaattc aagtatctat aaacagcatg ggccaaaagg cagtcattgaa 180
gaggtcacag gacaaagctt ttcactttag catacactgc tataataatc aaacttatgt 240
gacctgagtg cttcccagga attattattg atttatgtgc caaaatattg atacagtccc 300
tgaggaagcc tcaaagcata ataagtgtta cttcagacac aagcttcagg actccttaac 360
aattcctgcg tgtctaattg gctagctcct caggctgact gcccttttcc tgtttccaga 420
caaatcttcc ctaaaactca tggtcagatt aattttcttc aaatacagtt tacctcaaca 480
actttccatc accgcgctcg agccgattcg gctcgagggc gattgatgaa ccaggcgggt 540
ga 542

```

&lt;210&gt; 65

&lt;211&gt; 586

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 65

```

aaattctttt tgacatctct cagggttata ttttttctt ttaactcata tgtcaccatt 60
aggtttttaa aatcctttta aatattttat ttctagtgtt ccttggagtt ccctttttcc 120
tccttttttg ggaaagtttt gaaaatgttt tgtttttgtg tatgaaaaga atagctcacc 180
aaggaagaag gggagtgttt ttggtgaaat aggaagaag tctgaaactg taggagagga 240
ggggaatatg gccgtgata aaaagcacta gaggaggggg gaaatactct tccataggaa 300
ggcttccagc tacaaagatt tgaagacatt tttctgggga agtaaaacac taaatcagca 360
ttattttcca aagcccagaa aataacttaa tagattgttt ttaaattact gttttaattc 420
agcttgtaga gatattctga atagttcatg tagaatatct tactattttg cagatacttt 480
tgtataaata gttgccagtg agaaatgttg caactgtgtc ttttcaaatg aagtaaatag 540

```

gagagctagt atagcgctg aaagaagtaa gtgagttata ttgtac

586

<210> 66  
<211> 858  
<212> DNA  
<213> Homo sapiens

<400> 66  
gtcaaaattc tttttgacat ctctcagggt tatatttttt tcctttaact catatgtcac 60  
cattaggttt ttaaaatcct tttaaatatt ttatttctag tgtaccttg agttcccttt 120  
ttcctccttt ttggggaaag ttttgaaaat gttttgtttt tgtgtatgaa aagaatagct 180  
caccaaggaa gaaggggagt gtttttggtg aaataggaaa gaagtctgaa actgtaggag 240  
aggaggggaa tatggccgct gataaaaagc actagaggag gggggaaata ctctccata 300  
ggaaggcttc cagctacaaa gatttgaaga ctttttctg gggaaagtaa aactaaatc 360  
agcattattt tccaaagccc agaaaataac ttaatagatt gtttttaaat tactgtttta 420  
attcagcttg tgaagatatt ctgaatagtt catgtagaat atcttactat ttgcagata 480  
cttttgata aatagttgcc agtgagaaat gttgcaactg tgtcttttca aatgaagtaa 540  
ataggagagc tagtatagcg cctgaaagaa gtaagttagt tatattgtaa cttcttgctc 600  
tacctcaggg taagcactcc ttttagcatt tattaactc tcattatttg tagagaaatt 660  
atntagatgt aggttgagta ttcctaactc gaaaatctga aacacaagat gctctaaaat 720  
tcaaacagg atgctcaaag gagatacttg tttgagcatt tcagacttca gattttcaga 780  
ttagggatgc tgaactggta agtataatgc agatattcca aaatctggaa gaaaaaaaaa 840  
aaaaaaaaat gagcggtc 858

<210> 67  
<211> 593  
<212> DNA  
<213> Homo sapiens

<400> 67  
gtgcctttta tgctcatatg caagttttaa cacaatatga atctccatt ctcttaaact 60  
agaggctaaa aagaggacca ggtgttcaca cagaacttg cagatgatgt tggccagttt 120  
gaacgtggag aggattgaaa atggctgagt agggaggat gctgagcggg gcttgggcct 180  
ctagcagctg ctaattttat agaatgcgct aaaataaacc ttgtggatag atcttgctc 240  
agccttttct atctctggtc cttggacaga gaattgttta agtcatttca tgtttattga 300  
gttatttttg ttaatcatca gtacagattg cctctaagtg gtttttgcac ctttttttta 360  
ttatcgcttg gtcacataac ttctcggaac ctgagtttcc ttatttaata ctctcaagg 420  
tgaatattaa atcatatgaa caggatttgc aaactataaa gcaatgctat gcatgtaagg 480  
tgtcttttat ttgccagtta ctgagctttt aagggcaa atgtctactca atacttggtt 540  
tactgtgtta ggattccatt agggaagcag aacccttata aatattgtgg aat 593

<210> 68  
<211> 578  
<212> DNA  
<213> Homo sapiens

&lt;400&gt; 68

```

gggaacagaa gagagaaaac aaacactggc ttcactaaag agacaaaagc tgaagcaaag 60
ttgggattgg tccacagccc agggcggaac tcactgtgtc ccgagagtac cctgccacac 120
agtgcctgcg tgtgcctctc catcaccag atggaagaga acgtgttccg aaaggcagag 180
caaacaacag agcctcaaag ctgttataac gggccctcgc cttgggggtc ctagcaagtc 240
aatgacaaaa agcaccctct cgggagcaca ctggagagct gcagtcagcc tacggctatc 300
caacacactt gtttttccat aatcacggga aacctctgct taaagatggg ggattgaact 360
cacatattta tctcctttct caccagaaac cgtactaaaa cgaagggatt ttttttttaa 420
ggcaciaaat acaatgacaa aataacagga agagagatgg tggagcacgc atcatcttg 480
gggaacctga agaatccaac agccaaaagc agggcagccg gagagcagga cagggtgaaa 540
ctgactgaaa aggccagga aagccagtga cccacctg 578

```

&lt;210&gt; 69

&lt;211&gt; 730

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 69

```

gggaacagaa gagagaaaac aaacactggc ttcactaaag agacaaaagc tgaagcaaag 60
ttgggattgg tccacagccc agggcggaac tcactgtgtc ccgagagtac cctgccacac 120
agtgcctgcg tgtgcctctc catcaccag atggaagaga acgtgttccg aaaggcagag 180
caaacaacag agcctcaaag ctgttataac gggccctcgc cttgggggtc ctagcaagtc 240
aatgacaaaa agcaccctct cgggagcaca ctggagagct gcagtcagcc tacggctatc 300
caacacactt gtttttccat aatcacggga aacctctgct taaagatggg ggattgaact 360
cacatattta tctcctttct caccagaaac cgtactaaaa cgaagggatt ttttttttaa 420
ggcaciaaat acaatgacaa aataacagga agagagatgg tggagcacgc atcatcttg 480
gggaacctga agaatccaac agccaaaagc agggcagccg gagagcagga cagggtgaaa 540
ctgactgaga aggccagga aagccagtga cccacctgct gcacccgaa gaactgcca 600
gaagctcagg ccctggagggt gctgagcggc tctggaagtg tgggcaagggt gacagtgaag 660
agagctgaac tgtttgaaag tctctttcag aagcaatgag ctcaccccg cacaactcg 720
ccagttacgc 730

```

&lt;210&gt; 70

&lt;211&gt; 408

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 70

```

ggggcttgtg gttaccgatg gaaacctgga gaagtgtgcg ggctacatca ttctttcttt 60
caacagactc ggagtgtctg ccctgggcca ggaactctgc ctgacctccc agatgagggtg 120
tgtgtctaga acctttcctt gggaagggaa ggagagggct ggggtatggg ggagcctgga 180
catgaaaaag aactaccctc tgacagtaac atttcctct acttattcaa ggtctgtatg 240
tgccagacgg tgcctagcac tttgtataca ttagcttacc cgggtctcac aaacatctct 300
gagatgggca ttacagttca atttcagac atcgtgtcaa aagccaaacc caagcctgtc 360
tgaccagag cctgtgccct tcacacagac tggttaatat aaatctga 408

```

<210> 71  
<211> 430  
<212> DNA  
<213> Homo sapiens

<400> 71  
ggggcttggtg gttacgatg gaaacctgga gaagtgtgcg ggctacatca ttctttcttt 60  
caacagactc ggagtgtctg ccctgggcca ggaactctgc ctgacctccc agatgagggtg 120  
tgtgtctaga accgttccct tgggaaggga aggagagggc tggggtatgg gggagcctgg 180  
acatgaaaaa ggactaccct ctgacagtaa catttccct ctacttattc aagggtctgta 240  
tgtgcccaga cggtgccctag caccttgtat acattagctt atcccgggtgc tcacaaacca 300  
tctctgagat gggccattac cagtgtccaa atttccagac atcgtgtcca aaagcccaac 360  
ccaagcctgt ctgcaccacg agcctgtgcc ccttcaacac caagaactgg ttaaataatt 420  
aaaatctgaa 430

<210> 72  
<211> 239  
<212> DNA  
<213> Homo sapiens

<400> 72  
tgggagacaa acataccctc ctgaccttgg ggaagtgttt tccctgctct tgtgtccaag 60  
ggggagtgtg caggactgtt agaaatgagg gatgggcctc catttggccc accatgggccc 120  
aaatctccag agctggagag tagtaatttc tcccccttgg gagtgggtgtt gattctcttc 180  
tctctagagc tcaagtcctg ggctagcagc tggagaacag gactctgagg gactttcat 239

<210> 73  
<211> 333  
<212> DNA  
<213> Homo sapiens

<400> 73  
tgggagacaa acataccctc ctgaccttgg ggaagtgttt tccctgctct tgtgtccaag 60  
ggggagtgtg caggactgtt agaaatgagg gatgggcctc catttggccc accatgggccc 120  
aaatctccag agctggagag tagtaatttc tcccccttgg gagtgggtgtt gattctcttc 180  
tctctagagc tcaaggtcct gggctagcag ctggagaaca ggactctgag ggactttcat 240  
ccagccatgc attcaggac ccagtgagg tgatgggcca gctgcacacc ctacagaatc 300  
tgggctgagt gtgaagagg acaactggtg ccc 333

<210> 74  
<211> 636  
<212> DNA  
<213> Homo sapiens

&lt;400&gt; 74

```

ggtactccca atattagagt ctgctttata caatataaga gaatagtaac tattcaagta 60
cttgtaaga gtataaaaag gagaaaatga ttgttcttca cttagagaag tacataatgt 120
agcgaaggat acaaaaacaa atataaaaga aagaatataa aaataagtgc agctataaat 180
attataaaac aaattataag aggagttttt tagcatttat tctatgttaa aagttttaca 240
ttaatgtgtt tgaagtttat tttatttctc agtaactctc tgaggaagct acttaatgaa 300
taataaaact gagacttgga actattaagt tttttgcccc tatagctctc aagttgagaa 360
ctgagattta aagctgggtcc atgggagaac aaagtttttc ctcttctgc aacattactt 420
ggggcataaa aaagcaagag gctagttggt atggatgagg ttttatagag aaggcttttc 480
agggaaaatg aaacttgaag aacaaaacaa taagagatat aagaagttga acctccttgc 540
tttgactatt tgtgggaagt gggaagatta tagattattc aggaatatta gaggtaaaat 600
tcagttattc agcaatattt gttgagtgtg tactga 636

```

&lt;210&gt; 75

&lt;211&gt; 244

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 75

```

ggattatattt tttttcactt tgaaatgctt aagaacagcc tcagtaaaat gtttatatcc 60
taggcagtga atgatttgat ctctatagga atgagctggt tgttatcata tcagaatttg 120
gggtaagct acagatgcta atataggac atagaagatt tttccctc aaaattagtt 180
aagattagca aatagcatta aggcagttaa cttgatgaa atacctagca gaaatgggtg 240
atgt 244

```

&lt;210&gt; 76

&lt;211&gt; 359

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 76

```

ggattatattt tttttcactt tgaaatgctt aagaacagcc tcagtaaaat gtttatatcc 60
taggcagtga atgatttgat ctctatagga atgagctggt tgttatcata tcagaatttg 120
gggtaagct acagatgcta atataggac atagaagatt tttccctca aaattagtta 180
agattagcaa atagcattaa ggcagttaac cttgatgaaa tacctagcaa gaaatgggtg 240
atgttatcct ggaactgcta ttctcctccc atctcttctc tcagcatttg ccatccaaac 300
catttggaag ctttgggtgct tgatgcattg cagtattttt ttttctttt ctttgagaa 359

```

&lt;210&gt; 77

&lt;211&gt; 142

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 77

cagtgcggga ccagccgagc ctctgcaggt gggcacaggc tgetgcggct ttctcccag 60  
gcagttcttg gagcttctgt ctgcagagca cccacccac agcctcagag agtggggcga 120  
ctgtggagtg ggggtctctg ca 142

<210> 78  
<211> 72  
<212> DNA  
<213> Homo sapiens

<400> 78  
ctgaatgaca gagcaagact ctctctctct caaaaaaaaa cagagagaga gagtttagag 60  
accaggcaca gt 72

<210> 79  
<211> 529  
<212> DNA  
<213> Homo sapiens

<220>  
<221> unsure  
<222> (234) .. (388)  
<223> a, c, g or t

<400> 79  
gtttttataa agcctgaaac tcacagaatt ggaagtctga gtgacacaga tatgttaaca 60  
gaataacca attgtttctc aacaatggaa agatgtggga tccagagagc agtttttgct 120  
tttgtttctg ctatcaagt actgccctcc atgtgataaa attggagagg tgaactgaga 180  
gttcttcatt acaaatacag ctgactttat tgcttactga attttgatac tgannnnnnn 240  
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 300  
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 360  
nnnnnnnnnn nnnnnnnnnn nnnnnnnnag taccagaatg ctaaccaagg caatctgact 420  
tggttcactt ggctcttggt agccccacaa tggaagggt ctgtccatta cttgctgaca 480  
agaacaagac ctcaacata cacggcactc aagaatatc tgttgatgg 529

<210> 80  
<211> 567  
<212> DNA  
<213> Homo sapiens

<220>  
<221> unsure  
<222> (12)  
<223> a, c, g or t

<220>



<221> unsure  
<222> (34)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (46)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (101)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (107)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (137)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (140)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (202)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (210)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (237)  
<223> a, c, g or t

<400> 80  
atcaagtga gntccctca atgaatgaga tggnaactga actgantctc agggttaacc 60  
aggttgaggaga ataaagtgtg gcgtgttcta ggcagagggg ncaacantgt gatcacaagc 120  
agagaggggaa ggaaacnacn tggtgtgcag aaggaattat gagcacttag gtgttgctgg 180

agcttaaagc tgaataggaa gnactaattn tgtagccaga gataattggc aaaggtngaa 240  
 tcatgaaggc ccgtgtttgc caggtgaaga catatttgtt acacacagct tgttattttc 300  
 attattgttg tattgcattht tggattggag ctgtctgac aggttttgtt tttagacaaa 360  
 tccttctatc agcagtgggg aaggtggatt tcaggggatg aattctgaag catgaagacc 420  
 agtcagatgg ccgttgcagc agttcaggca aggacaatga ggcctaaatt aagactgcga 480  
 gggtaggatg ggggaagaga aactagagtc aagaaatagg tggttttaaa aagaagtatt 540  
 tagagggtaa aaagaatact aactggc 567

<210> 81

<211> 4158

<212> DNA

<213> Homo sapiens

<400> 81

atgagccacg gcgcccggcc cttaagaagt cttaaagtca tctatgatgg gctaattggca 60  
 ctcttcacga caagcctgat tgcactgtta agctccagag gaaaaaatgt ggctatagag 120  
 tatattaaaa tacatacaat tgaaaaggaa gatgttcatt tttgcaagca gaagattacc 180  
 aacagaatgc taaaattaaa gttggactat gaagagagcc cagtgtacca agtgtacgtg 240  
 caagccaagg acctggggcc caacgccgtg cctgcgcact gcaaggatgat agtgcgagta 300  
 ctggatgcta atgacaacgc gccagagatc agcttcagca ccgtgaagga agcggtagt 360  
 gagggcgagg cgccgggcac tgtggtggcc cttttcagcg tgactgaccg cgactcagag 420  
 gagaatgggc aggtgcagtg cgagctactg ggagacgtgc ctttcgcct caagtcttcc 480  
 tttagaatt actacacat cgttaccgaa gccccctgg accgagaggc gggggactcc 540  
 tacaccctga ctgtagtggc tcgggaccgg ggcgagcctg cgctctccac cagtaagtgc 600  
 atccaggtag aagtgtcgga tgtgaacgac aacgcgcgc gtttcagcca gccggtctac 660  
 gacgtgtatg tgactgaaaa caacgtgcct ggcgcctaca tctacgcgtg gagcgccacc 720  
 gaccgggatg agggcgccaa cgccagcctt gcctactcta tcctcgagt ccagatccag 780  
 ggcatgagcg tcttcacctt cgtttctatc aactctgaga acggctactt gtacgccctg 840  
 cgctccttcg actatgagca gctgaaggac ttcagttttc aggtggaagc ccgggacgct 900  
 ggcagccccc aggcgctggc tggtaacgcc actgtcaaca tcctcatagt ggatcaaaat 960  
 gacaacgcc ctgccatcgt ggcgcctcta ccaggcgca acgggactcc agcgcgtag 1020  
 gtgctgcccc gctcggcgga gccgggttac ctgctcacc gcgtggccgc cgtggacgcg 1080  
 gacgacggcg agaacgccc gctcacttac agcatcgtgc gtggcaacga aatgaacctc 1140  
 ttctgcatgg actggcgac cggggagctg cgacagcac gccagatccc ggccaagcgc 1200  
 gacccccagc ggccttatga gctggtgatc gaggtgcgcg accatgggca gccgcccctt 1260  
 tcctccaccg ccaccctggt ggttcagctg gtggatggcg ccgtggagcc ccaggcggg 1320  
 ggcgggagcg gaggcggagg gtcaggagag caccagcgcc ccagtcgctc tggcgggcg 1380  
 gaaacctcgc tagacctcac cctcatcctc atcatcgct tgggctcgtt gtccttcac 1440  
 ttctgctgg ccattgatc gctggccgtg cgttgccaaa aagagaagaa gctcaacatc 1500  
 tatacttgct tggccagcga ttgctgcctc tgctgctgct gctgcggtgg cggaggttcg 1560  
 acctgctgtg gccgccaagc ccgggcgcgc aagaagaaac tcagcaagtc agacatcatg 1620  
 ctggtgcaga gctccaatgt acccagtaac ccggcccagg tgccgataga ggagtcggg 1680  
 ggctttggct ccaccacca caaccagaat tactgctatc aggtatgcct gacccctgag 1740  
 tccgccaaga ccgacctgat gtttcttaag ccttcagacc cttcgcggag tacggacact 1800  
 gagcacaacc cctgcggggc catcgtcacc gggtacacc accagcagcc tgatatcatc 1860  
 tccaacggaa gcattttgtc caacgagact aaacaccagc gagcagagct cagctatcta 1920  
 gttgacagac ctcgcccagt taacagttct gcattccagg aagccgacat agtaagctct 1980

```

aaggacagtg gtcattggaga cagtgaacag ggagatagtg atcatgatgc caccaaccgt 2040
gcccagtcag ctggtatgga tctcttctcc aattgcactg aggaatgtaa agctctgggc 2100
cactcagatc ggtgctggat gccttctttt gtcccttctg atggacgcca ggctgctgat 2160
tatecgagca atctgcatgt tcttggcatg gactctgttc cagacactga ggtgtttgaa 2220
actccagaag cccagcctgg ggcagagcgg tctttttcca cctttggcaa agagaaggcc 2280
cttcacagca ctctggagag gaaggagctg gatggactgc tgactaatac gcgagcgct 2340
tacaaccac catatttgag tgatccacct gcctcagcct cccaaagtgc tgggattaca 2400
ggcgtgagcc accacatccg gccagttagt attcttttta cctctaaaat acttcttttt 2460
aaaaccacct atttcttgac tctagtcttct ctcccccac ctcaccctcg cagtcttaat 2520
ttaggcctca ttgtccttgc ctgaactgct gcaacggcca tctgactggt cttcatgctt 2580
cagaattcat accctgaaat ccaccttccc cactgctgat agaaggattt gtctaaaaca 2640
caaacctgat cagacagctc caatccaaaa tgcaatacaa caataatgaa aataacaagc 2700
tgtgtgtaca caatatgtct tcacctggca aacacgggcc ttcattgatc aacctttgcc 2760
aattatctct ggctacataa ttagtacttc ctattccagc ttttaagctcc agcaacacct 2820
aagtgtctcat aattccttct gcacaccatg ttgtttcctt cctctctgct tgtgatcaca 2880
ctgttgctcc ctctgcctag aacacgccac cctttattct ccaacctggt taacctgaga 2940
ttcagttcag ttgccatctc attcattgag ggagtcttcc ttgatgatga aggaaggatt 3000
aggtgtctcg actcagtgtt cctgtgatac gtagtaataa tctactgtcat tgtaatctac 3060
attgcttcaa aattgtttat gtgtctacct cctgtttcca gcaacaaatc attcctaaac 3120
tctatggctt aactcaacag tcatttattt tgctcacaaa ctgggaaagg gcacagtggg 3180
gatggatgac tgatgacttg tctctgtttc atgtagcatt aactggggca gctctcctgg 3240
aactggagaa tccacctcca agatggctca ttcatacagc tgacaagttg gttcctctct 3300
gcttgggtct ttaggcttca tcacagcatg gtagctgggt tccaagagtg agcatacaag 3360
gagacaggaa gtggacgtg ctaggttctt aaggtctggg cccagaaact gatacaatgc 3420
gtcatttctg ccatattcta ttggcaggca gttacagagc tcagatccaa gtggaagggg 3480
cagagtccca cttgctaatt agaagagtgt caaataattt tgggggacat gttgtaaaac 3540
aactatattc ctttacgtgc ccatgagctc tttcaggact cagctggcat ggcatttggt 3600
tgctgaatga aaggattcat tcccggacca aactgcttcc atagaacgtc acagtctcag 3660
tcatttgcac caaggagggt gattccagac aactcagtca catcaattag caaggaggatt 3720
aaggctcaaa ggaaattagg cttaaagtct tatagcatgt tagaaatggg aagaatttac 3780
aagccaatca aattatagtc ctttattaaa aaaaaaaaaa ctgaggtaaa cagataaaaag 3840
aaaaagcaaa gaacccatgt gggtcagtta tataaaaaat ggcagtgatt caggatttgc 3900
tatatatggt gaagtacatg ctatttactt gttcaatttc tttcttttag caagttaaag 3960
ctaattaaac ttcagaatct gaatgagcat ggtaattttt ctttcttgta aaaggggaca 4020
ctatttactt ttgtaaattg ggtcccgttt acagctacca ttgttaattc actatttgat 4080
gacgcaccat ttcttggtaa aatgttttgt ggcacactaa tgactcaaat cctatgcact 4140
gacatgcac cagccatt

```

4158

&lt;210&gt; 82

&lt;211&gt; 270

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 82

```

caagaacaat tttttgcatt gtcattcatt atgtataaga gacgaagttg taaaatagcc 60
cccatagaat cagaattaga gaacctggaa gagtgtgctc taaccaatgc accatttttc 120
agcaaagcac attttttttt tctacaaacg aaactcttgg aacaagtaga ctacactttc 180

```

tgtcattccc atgtatggaa gaataaaaaat ggccacaagt tatttgcagc tccttacgtc 240  
 aagagttgga gtccattggc tgggtgtggt 270

<210> 83  
 <211> 612  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> unsure  
 <222> (349)..(456)  
 <223> a, c, g or t

<400> 83  
 caaaacaaaa caaaactgac cactacattt agctgcgtgg agggaaactgt taagttttgt 60  
 tgaagtgcag gagacaaaaa cctaaatgga gtgggagaga aattggagac agaaagaacc 120  
 cttcagaggt ctgttgtaaa aggatgcaaa gaaacaggga actagaaggg attgtggggg 180  
 ccaaaggaga aataccagca cgtttgtatg ttgtcaataa tgtttcagta gaaaggtaaa 240  
 aattgagaca agagagaaga aagtgtagct ggctagtcca acatcctaga atagccaaga 300  
 agggatggga catagtgc aaactaggctg cccaaagcag agttttcann nnnnnnnnnn 360  
 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 420  
 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnaact ccaagaattt gcgtttctag 480  
 caagttcccg gatgattcta ttgctagcta ggtcccagaa acctcatatt tggagaacca 540  
 ctgtatcaaa aggagggaag acagaaaaga tgagtatata cattagtaca aatgctgaac 600  
 acctgggtta tc 612

<210> 84  
 <211> 342  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> unsure  
 <222> (268)  
 <223> a, c, g or t

<400> 84  
 gtttcagttt catcccacag gtgttgctat tgttatttta tggttcagtt caaaatattt 60  
 tctcaatacc attgactctg tctctgtgtt attcaggctt gtttttacag ttctttattg 120  
 atttctatct taaatgcact gtagtaaaaa atgacaatta tttcaatttt caaaatttct 180  
 tgagttgctt tataactaag tatgtgggtg actgtgggtga tgtgtctgct ttcaaaaaac 240  
 tgtacattct gattttggtc gtgtgtgtnct gtacatatta attgcgtcat ttttacatca 300  
 tgttattcac gtttcctata tccttaactt ttctcttgct ag 342

<210> 85

<211> 1035  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> unsure  
 <222> (97)..(179)  
 <223> a, c, g or t

<400> 85  
 attttctgtc ttattttgct gtcctttttc taacttcttg aaaagggatt ttcagctcaa 60  
 gacttttcag actcttctaa tacacttact tatggcnnnn nnnnnnnnnn nnnnnnnnnn 120  
 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 180  
 tcaataccat tgactctgtc tctgtgttat tcaggcttgt ttttacagtt ctttattgat 240  
 ttctatcttaaatgcactgt agtaaaaaat gacaattatt tcaattttca aaatttcttg 300  
 agttgcttta taactaagta tgtggttgac tgtggtgatg tgtctgcttt caaaaaactg 360  
 tacattctga ttttggtcgt gttgttctgt acatattaat tgcgtcattt ttacatcatg 420  
 ttattcacgt ttctatatc cttaattttt ctcttgctag tcttaacgat tagtgagaaa 480  
 gtcctgttaa aattacccaa tatgaccagg cattttttt ctttgtaatt ctgtcacttc 540  
 actttgtttc atatgtattt ttcattaggt acttataaat tttaaattta aaacacattt 600  
 cctttttaga ctcaagaagtc atctaagact ctttctttc attcctttta tatcccatca 660  
 gtcataattta aaagatatct atatgtaaac tgacgtcaat agacatgatg taaaagaagg 720  
 ggggtggtct ggtaaagcta aagtaactcc actatgagag tgcattaact atgggggaaa 780  
 tactttctat attgcagaac acatatttgg tggtagctag cctcacatcg ccaccggaa 840  
 aagtctgcat atattgaatt tggaatggat caaactgcac tgagtgcaaa attgtaaatt 900  
 gcatcttata taaatgtttt agaactagat gatggagcag atgggatcta ttaagagaac 960  
 ggggtgccag atgactgacc ataaacatgc tttttaataa agactctgct gagagattaa 1020  
 ctcataaaaa aaaaa 1035

<210> 86  
 <211> 662  
 <212> DNA  
 <213> Homo sapiens

<400> 86  
 aaagaacaag acaaaggaat tcagagcttt caagaaccaa gtatgtcagg atagttgtgg 60  
 aaaacagatc tttttctcat tttctttgag atgaagatag gcaacatttg ctgcccatta 120  
 aataccttaa aagtatacag gtgtatctgc aggattcttt ttgctgcttt taaatagtat 180  
 attgttttaa aaggctctgt tttatcttgc ctttacaatt atatagactt ttattgacta 240  
 gctgatcata tagggcctta gtatagacta ccatattcgc cagcatttaa gaaatagtcc 300  
 ccttccctcc aggagagtat ttatctggta ctcccatatt atggattgaa ggatgagaca 360  
 agagactgag tattgctaatt agttctgtgt gagcctgcag tgtaagtaa aacctattga 420  
 gtgcacaaaa aatcatggtt acaattacta caaatagag aaaccaccta ggttaccaag 480  
 atgtcaaata atggattaat ggaagaaagt aatgtacctc cttggtagcc tacataatcc 540  
 accttaattt gttatttctt atttaactat tttgctatgt ctttaagaaat gtatattaag 600  
 tgaaaatgga tgcataaaaa taataaaaga gaaatgtata tatacaagct acatgaaaat 660  
 ac 662

<210> 87  
<211> 884  
<212> DNA  
<213> Homo sapiens

<400> 87  
tcatttctga attcttcctt cttcatttct ggactttaca gctatgaaag aacaagacaa 60  
aggaattcag agctttcaag aaccaagtat gtcaggatag ttgtggaaaa cagatcctttt 120  
tctcattttc ttgagatga agataggcaa catttgctgc ccattaaata ccttaaaagt 180  
atacagggtg atctgcagga ttctttttgc tgctttttaa tagtatattg ttttaaaagg 240  
tctgttttta tcttgccctt acaattatat agacttttat tgactagctg atcatatagg 300  
gccttagtat agactacat attcgccagc atttaagaaa tagtcccctt ccctccagga 360  
gagtatttat ctgggtactcc catattatgg attgaaggat gagacaagag actgagtatt 420  
gctaatagtt ctgtgtgagc ctgcagtgtt aagtaaaacc tattgagtgc acaaaaaaat 480  
catgttacaa ttactacaaa atagagaaac cacctaggtt accaagatgt caaataatgg 540  
attaatggaa gaaagtaatg tacctccttg gtagcctaca taatccacct taatttgta 600  
tttcttattt aactattttg ctatgtctta agaaatgtat attaagtga aatggatgca 660  
taaaaaataaa aaaagagaaa tgtatatata caagctacat gaaaattggc cctgggaata 720  
aatcaagaaa ttcaaccaac aaggctacca gttatttagt aaataccaaa gagatagggtg 780  
gatgtagcag taccgaatat cacagtaaga tatgagtagg tagttccact ccctcctacc 840  
caactcagtt ttattagaaa attcccgtg ccaaaggggc aagg 884

<210> 88  
<211> 528  
<212> DNA  
<213> Homo sapiens

<400> 88  
caccactggg tgcttgggca gttacccacg gtggacaaag ggcaagagcg ctgggttttg 60  
agtcagatag atgtgctctg ccctcccgcc tccagggtcg ggctcccagg ttggtgtg 120  
atccagagag ttgtgagga gaggtaaaat gtgtgtgaaa gttcttggtg aacacccagc 180  
cactatatat tatgagtggg agcaccta atctctta atatttcagg tgccatattg 240  
ggtcacctc actaaagacc cttcaagagg gttttcctcc aatagcccca gtattaacat 300  
tggtctggcc ttattatttg tatctaattg ggtagactt tcccttccat gctgagaaaa 360  
agttgtcttt aagagaatgt gctgaacaat caggggccag aaaggcaaca acgaatattt 420  
tgcattgcaa gaaggaggca aaagaggaag tggaattgta cccaaatatg cttataatag 480  
gtgttatttt agctgagctt gtaaggcctc caggagggca ggtatta 528

<210> 89  
<211> 1282  
<212> DNA  
<213> Homo sapiens

<400> 89

```

gttacttatt tcattctgat cacattttcc agtacaaata catggagggtc ccaagtgcc 60
aagttacaaa aaaaaaaca cagttcctgg tccagtttgg gaagacatgt agggactttt 120
tctttaaaca cttgggacca agtggggagt aagcctgcat tgaggagggt gaccagttg 180
ctaagagacg gggaggccag ccaggatgaa aacttggcct gtataatctg tggtcaccac 240
tgggtgcctg ggagttaccc acggtggaca aagggaaga gcgctggttt tggagtcaga 300
tagatgtgct ctgccctccc gcctccaggg ctgggctccc aggttggctg tggatccaga 360
gagttgtgag ggagaggtaa aatgtgtgtg aaagtctctg gtaaaccacc agccactata 420
tattatgagt ggtagcacct aatctcctta atgatatttc aggtgccata ttgggtcatc 480
ctcactaaag acccttcaag agggttttcc tccaatagcc ccagtattaa cattggtctg 540
gccttattat ttgtatctaa tggggttaga ctttcccttc catgctgaga aaaagttgtc 600
tttaagagaa tgtgctgaac aatcagggcc cagaaaggca acaacgaata ttttgcagtc 660
caagaaggag gcaaaaggag aagtggaatt gtacccaaat aatgcttata ataggtgtta 720
ttttagctga gctgtaagct ccaggagggc aggttattaa tatattgagg tgttggctga 780
gcactgtggc tactcctat aatctcaaca ctttgggagg ccaaggtggg aggatgactt 840
gagaccagga gttcgagacc agcctgggca acatagcaag acctcgtctc tacacataat 900
ttaaaaaaat aggcattgta gcgtgcgcct gtgattccca actactcaag aggctgaaga 960
aggatcaccg gagactggga ggtcaaggct gcagtgaact gtgtttgcac cactgcactc 1020
cagcctgggg gacagagcat gaccctgtct caaaaaacaa acaaaaaaag aagcggaaga 1080
agaggaagaa gaggaagaag aggaagaaga ggaagaagag gaagaggaag aggaagaaga 1140
agagaagaaa gaaaggaaga agaagaagaa agaagaagaa gaagaagaag aagaagaaga 1200
agaagaagaa gaagaagaag aagaagaaga agaagaagaa agaaagaaag aaagaaagaa 1260
agagggagga ctctacaaat aa 1282

```

<210> 90

<211> 286

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (259)

<223> a, c, g or t

<220>

<221> unsure

<222> (263) .. (264)

<223> a, c, g or t

<220>

<221> unsure

<222> (268)

<223> a, c, g or t

<220>

<221> unsure

<222> (271)

<223> a, c, g or t

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (277)

&lt;223&gt; a, c, g or t

&lt;400&gt; 90

```

gctcgagggc aggtgaataa caggcaatgg aaatgcatgg aaatgcattt gtgagcacag 60
ttttggaacg attaaagcat tttatttagg taatagagtc ttctgtctta tttttctagt 120
agaggaaatt tagtttatgc tacaatatca agatatctga ttaataccat gcatctctga 180
aggatgtatt ggtttcttat ttcttttaat tgagagagtt gttgaatgat ttaatagaac 240
tttgaattt tcaaaaaana aannaaanta nattaanaaa attttt 286

```

&lt;210&gt; 91

&lt;211&gt; 644

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 91

```

acagtgggaa atgcagttat tctgtagcat acaggttagg taaagtttct ttcttctgtt 60
tctagagctt gtaaacatag gagcgattgg aatagtttaa gcaaagtcaa agtgagaaaa 120
tatgcagtgc cagaagcttg tgtgagggag tggaaatttt tgcacaaaag ccagaatttg 180
actagataat acttttcaaa ttgtggtccc tgcagtggca ttacatggga acctggtata 240
aaagcaaatt attgggtctc aactaaaatc cactgaatca aaaaccttag ggggtttttg 300
agcccagaga tccatgtttt aacaagcccc tcagtgattt tgttatgcat taaactttga 360
gaaccactgg actaaattat gttgggtttt caatggcagg tgaataacag gcaatggaaa 420
tgcattggaa tgcatttggt agcacagttt tggaaacgatt aaagcatttt atttaggtaa 480
tagagtcctc tgtcttattt ttctagtaga ggaatttttag tttatgctac aatatcaaga 540
tatctgattt aatccatgca tctctgaagg atgtattggt ttcttatttc ttttaattga 600
gagagttggt gaatgattta atagaacttt ggaattttca aaaa 644

```

&lt;210&gt; 92

&lt;211&gt; 870

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 92

```

cttacttcag ctgcaaatta cttatattaa taaagtagga tctatcaaat tagagaaatg 60
atatatggca tcattgggat tttcatattt aatacaattt atcatttttc tggctctgaca 120
ttaagcgatt tatttggaat ttttccctt atgacaaaat ttatcaatca atggtaactc 180
ctttagtacc ttggtcattt gatgaggtgt tttctagggg atttggtcgt tcttagtata 240
taattcagct attttcagtc agatccaatc tttagatata aaaatatatc atttgattaa 300
tggtagttag aagaggggtga aagcggtagt gtttatcaga ttctactcct tctcgctctt 360
aggacggcct catctgacag cctcctgact aattatggcc acttgttact acttctctgt 420
gttccaagtg cgtaaaacac atgcaagggt ccaacaatga gaagtcactc tctccagcca 480
ggatttcctt cattgtgttg gcacaacgaa tcaaaattaa tgtataatgt tcattttttt 540

```



```

agaactctcc ggtctttgaa ctttcctctt tgaaataaaa atttctcttc tgcccattgt 600
gaattagagc ctcatctcca cataaagcat ttgtatttgc ttttagtgat ttaatactgc 660
tttttagttt tgctttatct gtactaacca atagtcatag ctttttgact ccttttgact 720
tttacatttg ttgttaattt cagtatctca agtggattta tgttaccatt tcaaataagg 780
agtttatata gcccgggcaa tgtaagggtg ttttaataaa ccaaaggaca aaaattaagt 840
aaacttgaaa gaatgtcaac tgaatatctt 870

```

&lt;210&gt; 93

&lt;211&gt; 499

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 93

```

ggcagccaag cacaatagcc atacactaca caaggcaaca tcttcctcag gggttattct 60
tcttttaaag gaagtagtgc agccttcctg ttggttgcc tctcaattac actttactag 120
gttctgccct ttctacagtc tttctactta gttaacgtag ttctcctagg ccacaatgct 180
tttaccacat acaacatctg tttaacagtg gttatttatt caagagctgt tatctctttg 240
acataagctg gaaggtagga ggcattgggtg acttttctct gggatttcag tattagatat 300
gtccttggtg gccatatttt ccacagtgtt tacaaattag acaaactcagg gtttctgggt 360
ggctaggaag gtgagagttg atgaatgtga gagagaaata aaacaaactg gcagaaggaa 420
ggagaggtta aagaaatcct gttcatttca aaggcttgct tgattctctg gccgtgtatt 480
ctatgaaaca tccttgaat 499

```

&lt;210&gt; 94

&lt;211&gt; 654

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 94

```

ggcagccaag cacaatagcc atacactaca caaggcaaca tcttcctcag gggttattct 60
tcttttaaag gaagtagtgc agccttcctg ttggttgcc tctcaattac actttactag 120
gttctgccct ttctacagtc tttctactta gttaacgtag ttctcctagg ccacaatgct 180
tttaccacat acaacatctg tttaacagtg gttatttatt caagagctgt tatctctttg 240
acataagctg gaaggtagga ggcattgggtg acttttctct gggatttcag tattagatat 300
gtccttggtg gccatatttt ccacagtgtt tacaaattag acaaactcagg gtttctgggt 360
ggctaggaag gtgagagttg atgaatgtga gagagaaata aaacaaactg gcagaaggaa 420
ggagaggtta aagaaatcct gttcatttca aaggcttgct tgattctctg gccgtgtatt 480
ctatgaaaca tccttgaatc ctgggtttct taagttggct ggagtgggct gctgtaattt 540
gagggttaaga aaagtccaaa ttaataact atccctccag tgagctgcaa atattattca 600
tatatactat aaataaactg ggtgataagt tgggtttaat taatgatatt ccaa 654

```

&lt;210&gt; 95

&lt;211&gt; 431

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 95

```

gtttgagcca ctgtgtccag cctgaaagtt cttgactcaa gtggtgggaa acacataatt 60
tgagccttta tgaactctaa aatctatatt gtcagctaca tgattttact tgcaattgca 120
ttgacacaga tctattcatt gaacatttaa gaattgtctt ttcatacatat cgtatatctc 180
atatatatga gagaacatct tttagtaaac tttacaagtg gtctttctttt tacatattaa 240
catgttgatg aatgttaaag tagcaaagac tcaagccctt accatactaa tgttttcttct 300
tttcaagaca gatctttatg ggcagaaaca cagaaatgga agtagcagat ttaagaagaa 360
ctgattcaga ctttgaactt gtatgacctt atattttattg atttatttga gtcataagat 420
ttctgggttt t 431

```

&lt;210&gt; 96

&lt;211&gt; 616

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (15)

&lt;223&gt; a, c, g or t

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (61)

&lt;223&gt; a, c, g or t

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (191)

&lt;223&gt; a, c, g or t

&lt;400&gt; 96

```

ccaggggtcc ggttngtttt cctgtgtgct ggttcggggc catggctgcc aacggcaact 60
nccctggggg cacagagtag gtttcctgtg agctggtcgg ggccatggct tgccgccttg 120
caattgcccc tgggggcaac agacttaggt tttcatgtga gcttggtcgg ggccatggct 180
gccgcgggca nctgcccctg gggcaacaga gtagggtttc tgtgagctgg tcggggccat 240
ggctgccgcc tgcacctgcc cgggggcaca gagtaggttt cctgtgtgct ggtcggggcc 300
atggctgcc cgggcacctg cctgggggca cagagtaggt ttcctgtgag ttggtcgggg 360
ccacggctgc cgctgcact gccctggggc acagactagg tttcatgtga gctggtcggg 420
gccatggctg ccgccggcac ctgccctggg gcacagagta ggtttcgtgt tgcttggaac 480
attaaggcgt aattttgatt cagtttttcc taaagaagca ttttgattt ttatggcttt 540
tgcagttcgg gagaaagctt ctctattttg gatgcatttc agaaggcgt tctattaaac 600
atgaatctgc aaacag 616

```

&lt;210&gt; 97

&lt;211&gt; 1636

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 97

```

ctgtttgcag attcatgttt aatagaacgc ctttctgaaa tgcattccaaa atagagaagc 60
tttctcccg actgcaaaag ccataaaaat gcaaaatgct tctttaggaa aaactgaatc 120
aaaattacgc cttaatgttc caagcaacac gaaacctact ctgtgccccca gggcaggtgc 180
cggcggcagc catggccccg accagctcac atgaaacctc gtctgtgcc cagggcagtg 240
caggcggcag cegtggcccc gaccaactca caggaaacct actctgtgcc ccagggcagg 300
tgccggtggc agccatggcc cggaccagca cacaggaaac ctactctgtg ccccggggca 360
ggtgcaggcg gcagccatgg ccccgaccag ctacacaggaa acctactctg tgccccgggg 420
caggtgcagg cagcagccat ggccccgacc agctcacagg aaacctagtc tgtgccccag 480
ggcagtgtag gcggcagccg tggccccgac cagctcacag gaaacctact ctgtgccccca 540
gggcaggtgc cgggtggcagc cgtggccccg accagctcac aggaaacctc ctctgtgccc 600
cagggcaggt gccggcggca gccgtggccc cgaccagctc acaggaaacc tactctgtgc 660
cctgggtcag ggacagtgcc ggccgcagcc gtggccccga ccagccccca ccagcctcag 720
ttgttctcga tctgtccag gtccagctcc cagcggggcc cgggggaaga cgccctcctc 780
cccgaactg tccccatcac ggggtgcccc gctgtcctct cgggagccat cactggtcac 840
cgactcccta gaggccaca gggggagcct ggcacctgga gtctcttga cttcaggcac 900
tgcttctggc agcaaagctg cacccccacc ccaggagggg ctgatgactg agctcgagtc 960
ctgtggaggc aggacagcca caggacctg cctgcccact ggctcagaaa gaccctcctc 1020
tcggctgcca gggccctgcc cgagtgtggg gcactcccag gccctgggcc agcgggaagca 1080
gttccgggag actgcgcagg ccaggaaagc ccagggtggc tgggagcccc ggtcagctga 1140
aatagaactg gagaaacaag aagcttgccc ggggcccccg gcaagcaagg gggagcggca 1200
ggctcctgga gtgggaagtg gggctcctgg tccccacca actggaatct tccctccact 1260
cccaggaggt ggggcaggca gagccagccc agcagaggcc cccggaagcg tcaggaaaca 1320
caggaaaggc agccggggca cagggaactc ccacactccc caccctgccc accccatcgg 1380
ccccatccac cccgtgcacc ctgtctaccc catctacgt cacttccctc tgactctca 1440
actttcccg ctctgacct tggaggagct gaactccggc ctggccagct gtctgcagtg 1500
tgggaccctg tgctcctcca cgtgggagcc ccagggtgcc cgctcagtg ggatctgtac 1560
cctgccccctc acagagatct accatgcaga gacctcagac ttgcgtggga cctcggcagg 1620
ccccctgggtc cattga 1636

```

&lt;210&gt; 98

&lt;211&gt; 638

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 98

```

gcagagatta tctcagagag ctctttgacc atttaattta taaataattc tacttgtgtt 60
ttctttctac tttcactagt tttctctttc cactttttaa aaatgttgtg tttcttattc 120
agggttttgt tttggactgt aatattttat agaaatttta ggattacttt cataaaaatt 180
tcttaatact tcagagctaa ttcaagaaac ctgtgtgcat taacgtcagg aagttaactg 240
tcccacataa ttgccttgga gttgttctga attgttgatt atggtctcaa ataattatct 300
gacaggtttt tgggtaggaa tttttctgct gccacacact gttcctgttg agaattgaga 360
ggtacatttc ggactttata tttttatgaa acatttgga gggtgggggt gtggatgcca 420
ggtttctaaa tccagaaaaa tgtattttgt tagactatga gtatccctaa tctttaacat 480

```

gggttaattg gatggtgggg agtatttgc ttgatttcct gtgtataact caccgatggg 540  
 ttccattgt ttgattttct tcgcggatag gtttttcaga ttacaattag tctaaattag 600  
 ctggtgcggt ggacatgact gtaatccag cacgttga 638

<210> 99

<211> 1253

<212> DNA

<213> Homo sapiens

<400> 99

aaggtactgc ctaaagggtg tcatcttaaa tagcaactgc tgtttttcac tcataagttt 60  
 ggatgtatgt agcaaataat gtaggttttc tattgagatt tttggataaa ctattatttt 120  
 ttctaataga gtgataagat attctctact ttgctctcat tctgaaaatc agctaccatg 180  
 aatattataa cttacatctg ttatcttgc tccagcatagt aatatttaaa gtgattaaag 240  
 gaaacaaatg ttacacctcc aaaagatgca ttcattttat tcatttatat aaaaaaactg 300  
 cacgtttaat atatacattt tgagtgaagt cattgttaat taagggatgt tacagcccct 360  
 tttgtactat gaagagactt tatgattttc tttctgttaa gggtagtatt tacataaaaa 420  
 ataatttcat caaaccagag agaggccaac agacattaca tgtcatctca ggtggttcca 480  
 agcagagatt atctcagaga gctctttgac catttaattt ataaataatt ctacttgtgt 540  
 tttctttcta ctttccactag ttttctcttt ccacttttaa aaaatgttgt gtttcttatt 600  
 cagggttttg ttttggactg taatatttta tagaaatttt aggattactt tcataaaaaat 660  
 ttcttaatac ttcagagcta attcaagaaa cctgtgtgca ttaacgtcag gaagttaaact 720  
 gtcccacata attgccttgg agttgttctg aattgttgat tatggtctca aataattatc 780  
 tgacaggttt ttggttagga atttttctgc tgccacacac tgttcctgtt gagaatgtag 840  
 aggtacattt cggactttat atttttctga aacatttgga aggttgggtt ggtggatgcc 900  
 aggtttctaa atccagaaaa atgtattttg ttagactatg agtatcccta atctttaaca 960  
 tgggttaatt ggatggtggg gagtatttgc tttgatttcc tgtgtataac tcaccgatgg 1020  
 gtttccattg tttgattttc ttcgcggata ggtttttcag attacaatta gtctaaatta 1080  
 gcctggtgag gtggcacatg actgtaatcc cagcactttg aggaaggcta aggcaagcgg 1140  
 atcgcttgag ctcgaattca agaccagcct gggcaacatg gcgaaaccct gtctctacca 1200  
 aaaaaacctc atgccgaatt cttgcctcgg ggccaaatcc ctatgtggac aat 1253

<210> 100

<211> 1479

<212> DNA

<213> Homo sapiens

<400> 100

gtctttggta gaattctatg attctaaagt gctgtgacta caagtgtgga cagggtgtaat 60  
 cactttacct ctacactgcc cgctgcatgc tgacactgcc tttcatatgg tgggcattca 120  
 acagcaacat tcctgtggag tatagatggc tatgactaag gtagtgtaag tgggtggtcct 180  
 tataaaatat gctctgcttg ccttagggga aaatagttcc ttaaaaacgt tctcatccaa 240  
 ctctcagtg ttaagatata taaacaaaag tgaccacatc tatacacaac agtaatgaca 300  
 cctgaaagaa ttttttaaca gataaagaac agtactccca tgggtatgta accaaccaac 360  
 taggaaggag agactttaaa attgacaaca tcccagagat gttatattct aagttatgaa 420  
 tgtgctgccc ttgaagaaaa atcagctttc tcatattact cacatatata tattattaca 480

```

taacaatgtg ttaaattgga ctacagtga tcaaagagtt attgcagctt ctgaagggtga 540
cagactttta actttcagat attgcttaat gcctgggaaa ccctgggaac cacgccaagt 600
caatttaacc aagcttttgc tttttagcca gctgtgatgg tggtttctac atagtctgga 660
taaataccaag aatactttca tggccctagt gaaatttgc tttttgaaat tattaggaaa 720
acgaaataca cattatgaaa cttctatcac tcctaaagaa aggggaaaac ctattaanaa 780
tgaagctctt atttactaat gcatttctat ttcaggagca tttggctaaa ctggggacaa 840
aaaacaaaaa cttgttctta attaacaaaa gaactagaaa gaagctcata tgaaagcacc 900
accttgtgtt cagtaagctt caggatagct ctgttgacag cagggcattt agagagtccc 960
aagtatagtc atgtatcact ggggagggaa gaatctttga ggacatctag tttacaatct 1020
ttattatttt tcaggtgtag aaaagagatt aaagatcata gaagtcagaa taaatttgta 1080
aaagttctca tagtcaaac agctaagtaa tggcattgcc cagactccaa aatcctgacc 1140
agaatataaa tcaccaattg ttggtttaa ggggttattt gtgaatcatt ttccaaaaaa 1200
agaagtacac tttttgtgtt acttaccatt tcaaagaaac ttattcttca agaccatttc 1260
agatttctt aggaatgtat gtgttaccca taattgacca cttcaaactt gtaagaaaaa 1320
aaatgttatg gtcattttgt ttttttaga gacaaagtat ttctaactta ggtttgcata 1380
caaccttgag gctgtgagat cattagtcaa ttgctttaat tataagccct gttttttttt 1440
aatctaaaaa actaataaac atctataagg ttaaaaaaa 1479

```

<210> 101

<211> 2313

<212> DNA

<213> Homo sapiens

<400> 101

```

gtactctcga tgttgaatgg gagccagctg attaggagag ttaatgagag ctacaataga 60
cttgttttaa aagaatagga caaggcaaac actaactcga caagtattca acaagaatgt 120
ccttagataa ccttagaata tatcacttta tacagcattg tattttaaga tacaaaaatt 180
ggagatagtt ctcaagcatc tttccagtc tgcttgtaa tcttagccca agataggttc 240
aataatggat ttttaagtcct cctaggcggt ggagtgaac ttaacaaaca ccaatcagga 300
cttttattag taagaagaaa actaggaaaag ctgttgtttt ataacattaa tggctgcta 360
cttttaactt tgatttttca tggatttttt aaaagtaatt tcaagtgtaa gagacaattt 420
aggcaaatca taacatattt tatcagagac tgtgcacaaa gggcactttt aggtagcttc 480
atttccaca gggtctatac ataaatcatg aggtgttacg agaattttgg tccaggaatc 540
agaaaagtgt ggaatttaca atcacctaaa gcaatatgac ttaagaaaaa tctgttacct 600
cccatcatct ccctttccca tcctgttaac atttgggtgt gatagattta gataagttga 660
cattagtata gatactttac tattataaga gggtgtcttt ggtagaattc tatgattcta 720
aagtgtctgt actacaagtg tggacaggtg taatcacttt acctctacac tgcccgtctc 780
atgctgacac tgcctttcat atggtgggca ttcaacagca acattcctgt ggagtataga 840
tggctatgac taaggtagtg taagtgggtg tccttataaa atatgctctg cttgccttag 900
gggaaaatag ttccttaaaa acgttctcat ccaactcctc agtggttaaga tatctaaaca 960
aaagtgacca catctataca caacagtaat gacacctgaa agaatttttt aacagataaa 1020
gaacagtact cccatgggtta tgtaaccaac caactaggaa ggagagactt taaaattgac 1080
aacatcccag agatgttata tcctaagtta tgaatgtgct gccgttgaag aaaaatcagc 1140
tttctcatat tactcacata tatatattat tacataacaa tgtgttaaat tggactacag 1200
tgaatcaaag agttattgca gcttctgaag gtgacagact ttttaactttc agatattgct 1260
taatgcctgg gaaacccctg gaaccacgcc aagtcaattt aaccaagctt ttgcttttta 1320
gccagctgtg atggtgggtt ctacatagtc tggataaatc caagaatact ttcattggccc 1380

```

```

tagtgaaatt tgcctttttg aaattattag gaaaacgaaa tacacattat gaaacttcta 1440
tcactcctaa agaaagggga aaacctatta aaaatgaagc tcttatttac taatgcattt 1500
ctatttcagg agcatttggc taaactgggg acaaaaaaca aaaacttggt ctttaattaac 1560
aaaagaacta gaaagaagct catatgaaag caccaccttg tggtcagtaa gcttcaggat 1620
agctctgttg acagcagggc atttagagag tccaagtat agtcagtat cactggggag 1680
ggaagaatct ttgaggacat ctagtttaca atctttatta tttttcaggt gtagaaaaga 1740
gattaaagat catagaagtc agaataaatt tgtaaaagtt ctcatagtca aaacagctaa 1800
gtaatggcat tgcccagact ccaaaatcct gaccagaata taaatcacca attgttggtt 1860
taaaggggtt atttgtgaat cattttccaa aaaaagaagt acactttttg tgttacttac 1920
catttcaaag aaacttattc ttcaagacca tttcagattt ccttaggaat gtatgtgtta 1980
cccataattg accacttcaa acttgtaaga aaaaaaatgt tatgggtcatt ttgttatttt 2040
tagagacaaa gtatttctaa tctaggtttg catacaacct tgaggctgtg agatcattag 2100
tcaattgctt taattataag ccctgttttt tttttaaatc taaaaactaa taaacatcta 2160
taagaattat aacagattat tttcttcatt aaattacttt gtaatcaagt tctagattaa 2220
atgtttaaac atgcattaaa ggattagttc tatctcaaaa gacaaaataa aactcgaggg 2280
gggctccgta ccctattctg ccgatagtga ctt 2313

```

<210> 102

<211> 217

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (138) .. (154)

<223> a, c, g or t

<220>

<221> unsure

<222> (159)

<223> a, c, g or t

<220>

<221> unsure

<222> (172)

<223> a, c, g or t

<220>

<221> unsure

<222> (182)

<223> a, c, g or t

<220>

<221> unsure

<222> (188)

<223> a, c, g or t

<220>  
 <221> unsure  
 <222> (190)  
 <223> a, c, g or t

<220>  
 <221> unsure  
 <222> (192)  
 <223> a, c, g or t

<220>  
 <221> unsure  
 <222> (198)  
 <223> a, c, g or t

<400> 102  
 agaaatggca aacttctctt aaaacttgcc acacaaagat tatttttcct tctctgtctg 60  
 cacctgagat ctcacactca atttatccat tgctgaaatc tgtggcaaag ctaccctga 120  
 tcgagagatt ccatctcnnn nnnnnnnnnn nnnngtcant tttaaaggct ancatccaag 180  
 anttggngn gnatgtgngc atgtttatat ttagaag 217

<210> 103  
 <211> 667  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> unsure  
 <222> (231)..(542)  
 <223> a, c, g or t

<400> 103  
 acacaaaagc gtattgtggg ggagaaacgc cagcaaaagg aacacagaga aagatcttaa 60  
 agtttctactg cttaaaggat ttattacata acacggccac cttttgccag ccagaccaa 120  
 ccgaaagagc aatggctgta tttctgaaag tagcattctg tccggccgaa atatggtaat 180  
 gagattttaa aagatttttt taaaggagct caatgggtta aagtcagctt nnnnnnnnnn 240  
 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 300  
 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 360  
 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 420  
 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 480  
 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 540  
 ncttctctt aaaacttgcc acacaaagat tatttttcct tctctgtctg cacctgagat 600  
 ctcacactca atttatccat tgctgaaatc tgtggcaaag ctaccctga tcgagagatt 660  
 ccatctc 667

<210> 104

<211> 451  
 <212> DNA  
 <213> Homo sapiens

<400> 104  
 ataacattct agaaataaat tgtttaatat aaaatacact aatatataat aatgtattac 60  
 ctaacatatg attatatata actataatgt gtactgtttt acatatatat ttccaaagta 120  
 tactataaat gcacttccgc actttgctct ttttactaaa tatatcttgg aaatcatcct 180  
 ttattcgtac ataaaaagct tcatagtcc tttttatggc tgcaaaatgt tccagcttat 240  
 ggatggactg attctctatc gagcaacatt aagatttgtt cctattttac tattcctaata 300  
 tttgctgaag tgaatttctt ttgccatgtg atttccacag gtgtatata gtacgtaata 360  
 tagtactagt agaaagtaga attgctagat caaagagtat gtgccttgta attttgatga 420  
 tattgtgaaa tctcttcac agaagttgtt g 451

<210> 105  
 <211> 852  
 <212> DNA  
 <213> Homo sapiens

<400> 105  
 ggacggagtc tcaggtcagg aactgcagtc atctcctttg ctgggtttca gcatttccct 60  
 ccttgggaat ctacttctat ctgcaggttt tttatacctt atgttcacct ttggttgtat 120  
 ggaagtcgtt ctcttactgt ttaatccaac ctccagtgc agaagtagaa ttaactaaaa 180  
 cacaagttag gctccatgct agccaagaac tcagtttttc ttggtctgca gatgagggga 240  
 tgttcagtat cctaacctgt tctctggtca caggatggtg tttctctggg tgtggctcac 300  
 gagcctccca tcttagaatc ttctaggagc cgggaagtgt gcaagctcta gagccctact 360  
 ccggacttgt tgaatctgaa tgtgttagtg ctggggctca ggacctgtga taggaaagtc 420  
 acagaaagca tagatctgct tgaagaaact gctgcagcct ccattcattt ctttcttcat 480  
 cttccaggcc atgacttcga actttgttag gatccaacct gcaggagat ttcatgtcag 540  
 ttcagtcaca cacacantca ccactagca tcgctgtatc caatatcttc tctggatgtc 600  
 aggagagtc tgtgctggcg ctcaaggacc tcagggtcta gttgaaggaa tgaagtgtgc 660  
 tcatattaaa agaaaagtag caatgcaaag caaagaaggc caagtgcaa tgtgcagtgt 720  
 aaacttgatt ttaagggagg ggagaggctt tggccttggc caggatccca aggaaggagc 780  
 tgaagacatg gaattggagg cagtgagaaa ggtggtcttt ncagaggag cagtgttgac 840  
 aaggeccctg ta 852

<210> 106  
 <211> 456  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> unsure  
 <222> (84) .. (129)  
 <223> a, c, g or t



```

<400> 106
taggttactt tctctactaa tagtctttcc agaaatcttt catatttcat ggggttattt 60
ggggattcag aaagccaccc agannnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 120
nnnnnnnnnc actgcatttt aggaagggtga gaatttagag aagagaacac cacttggaat 180
ccctgcttag cgggtgaatgt gaaagtagac atagtgggtt cccttttctc aagtgactgg 240
gtcttacttc aagtaaatta gacatttctt ggagatcagg ggttgtgtat tttcacttct 300
ctatatagcc atagtactct ttaagagttc actaactacg tgtaaataatgg gaactcatga 360
tggttaacaa tagctcagtg gagatgttct acagttattt catacatgct actttgaagt 420
agctcagctt attttgtgaa gtgagtgtat gtgcca 456

```

```

<210> 107
<211> 501
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> unsure
<222> (393)
<223> a, c, g or t

```

```

<400> 107
cacagaacgt catagggagt agtgcacccat ctgggataca aaacaagggtc ctaagctagg 60
attgtggatc acaacggatg aatccaggat ctagtttcta gtgatacaag agagggactt 120
ggttatgaat aactagataa aatcttagtg cctgaaacta ggtcacaata tcagagcagg 180
atcagcagaa tgactgatcc tactgagcag ataagctacc agtctgaggc ttctaaaaat 240
tcctccagta tagagcacca gcccaggccc tgaggccaag ataagattcc aggtggaact 300
tcatggttcc aggtggccaa agggctggag ggctttgcct gaaaagatca ctgcagatag 360
tatttgagaa aattactcaa aaccagcctt ggntatatct taggcaagaa ggaaagtatt 420
ttaaagact ttgtgaattt gtttcagttc acttgttttt tgtggagtac attttactca 480
tctgatacac aaacttcata g 501

```

```

<210> 108
<211> 377
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> unsure
<222> (317)
<223> a, c, g or t

```

```

<220>
<221> unsure
<222> (333)
<223> a, c, g or t

```

<220>  
<221> unsure  
<222> (341)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (369)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (374)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (354) .. (355)  
<223> a, c, g or t

<400> 108  
actgtgcctg gcctgttctt taaaatatga gataatatat ctgttgatg gatgcctaaa 60  
agtgggaattg cttgggtcaaa gaaatgtttt tttagttgcc ctctatagag actgtaccaa 120  
ttaacagaat aggagtcttg ctgcatggga tattgttaag acttgggtggg cctttgttaa 180  
tataagagaa aattgggtggc ctttcagaat ttaagtagta tttttgtaga tacatattta 240  
agagtgattt ttgtgtgtga actgtttatt ttttgtcatt tattctattt gattgtgggt 300  
tatctcattg attgtangaa ctctttgcct tcnttttctt ncgatctgac aaannttttc 360  
ttttcatgng gatntcc 377

<210> 109  
<211> 884  
<212> DNA  
<213> Homo sapiens

<220>  
<221> unsure  
<222> (108)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (140)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (300)

<223> a, c, g or t

<400> 109

```

aactgaggtc cagaggagct tgggtgcctt gcccgaggtc acacagcttg tgagtgcctgg 60
ttggagctga ggaaacgtga gaaaattggt gtccccaagc tgtgaagntg ccacatgggg 120
gccagataaa attattcttn ttcttttttag agatagggtc tcaccatcat tcagggtgta 180
gtacagtggc gcaatcatgg ctactgccca cctccaactc ctgggcttaa gggatcctcc 240
cacctcagcc tcctgagtag ctgggtctac aggccagtgc caccatgggt ggctaatttn 300
taaaagtttt tattttccat agagattggg ctttgccatt ttgccaggc tggctctgaa 360
ctcgtgggct gaagcaatcc ggctccgtca acctccaaa gccctgggat tacaggcgtg 420
agccactgtg cctggcctgt tctttaaaat atgagataat atatctgttg gatggatgcc 480
taaaagtgga attgcttggt caaagaaatg ttttttttagt tgccctctat agagactgta 540
ccaattaaca gaataggagt cttgctgcat gggatattgt taagacttgg tgggcctttg 600
ttaatataag agaaaattgg tggcctttca gaatttaagt agtatttttg tagatacata 660
tttaagagtg atttttgtgt gtgaactgtt tattttttgt catttattct atttgattgt 720
ggtttatctc attgattgta ggagctcttt gccttcattt tattacgata tgacaaaaat 780
tttcttttca taggatatca ttgtttttgg tatttttttc ccccatatgg tgtcttcttt 840
tcttaaaaaa aaatcctcgt gccgaatgta tcgtcgaggc cagt 884

```

<210> 110

<211> 471

<212> DNA

<213> Homo sapiens

<400> 110

```

ggctccattgg tgagtgaag gtcattatgt ggtatatgac tatatttcca ggctggggtg 60
agggagaggt acacagggat tcttgggtta agaaatcttt atattctcat cttctcttaa 120
aagccaagag ccctgtagga taattttcat agaaccagt gtctcaggct ccagactcta 180
gatactttaa atactataat aatttattat atgcaaaaaa aaccctcatt taacttttagc 240
taatttataa agcagtccta gcaattcatt tttgtttggt agctatata agggaatgcc 300
tttgtcaaaa ggaaaattac tgtggtgtcc cagcataacc aaggcatttg atcactgtgt 360
tcagtagtga ttttagagtg atgctgtctg ataaggtagc tgatttttta ctttaagtct 420
tgtttactat gataataaca gttaatatatt attattttta ctagatattg t 471

```

<210> 111

<211> 233

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (96)..(121)

<223> a, c, g or t

<400> 111

```

aatatagggg tgatgaagcc agctcttgct acatatattc ttactaaat atttaacaga 60

```

```

attgaatggt cactgatgtg ttagagttga aggtgnnnnn nnnnnnnnnn nnnnnnnnnn 120
ngcaagatat gtccaagtat gcatggttgt tttctataat gtgtatgttg agtatatctc 180
tattatctgt gttgggggta gaactaactg ttttgggccca ctttattgag ttt      233

```

&lt;210&gt; 112

&lt;211&gt; 771

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (342)..(410)

&lt;223&gt; a, c, g or t

&lt;400&gt; 112

```

ttaaggcaat aaaagcatta tttgggataa ataaggtaat taggtaatga taaaaagaac 60
taagtaggaa gatagtaaca atttcaaact tctactcagt tcataaaata gccttaattt 120
ttaaagcac aacttgacaa aactgtaaga acttttcaaa tgtacaacaa aggtggaaga 180
acttaatat tttctcaata attgatagat caggaagaca aaataaaagt aagtaaataa 240
ttatctgaat agagttaaca agctacctaa tacaaacata aataattatt cagcacattt 300
tagggagcat tgtctatgat ctagacactt ctctaatac tnnnnnnnnn nnnnnnnnnn 360
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn taatagacaa 420
caataagtaa ctgataaata tatgatatgc taaatggtga aaaatgccat gaagaaaaat 480
aaagcagatt aaaggaggta aggagatgca aaatggtagg gaggagggtt gctattttac 540
atattcagtg atcagggatg cttaaactcat aagattatat ttgaggagag acctgaaaga 600
agtaaagggt gagccatgtg agaagaatgt cccaggcaga aggaacagca gttaaaaagc 660
cctgatgcaa gaatgtgctt ggcctatttg agaaacagca agactagttt gcctggagta 720
gagtgaggaa cggggaaagt tgaagaagat gttaccaggg aacatgcgga g      771

```

&lt;210&gt; 113

&lt;211&gt; 453

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 113

```

cgtttaactga tcatccaaat acaatcctaa agatatatca gaagctttat tttggtacaa 60
agtcataaga atcaaaactt ttttaacctt tcacattagg tatcaacagt aattgtttga 120
gatactttta tatcaattct gttactga gccttttagt atactaagag aatgcagaag 180
aagttatagg aaaacgaatc ttactgaaa ctagtattat ataactttga attagatgtt 240
taaaaaactt tatagcttga tataaaatga gttgaaaatt attatttaatt aggaagcagc 300
attagatttt tgtcacctgt tttcagataa tatttctagt ctatgtatgt tatttaattt 360
ttacactttg gccattgtt tattttcctt aaggaattca tcaaatgcaa tgaaatttga 420
ataaaattga tcatagcaat aaataatttt taa      453

```

&lt;210&gt; 114

&lt;211&gt; 810

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 114

```

caagaatcat aacataaagg gattcatgct tagaaaaaat ccataaactc ccttctaaat 60
attgagacac tccaggcttc ttccagacaa ataacttcta attattccat atttttcaag 120
ttattaacca agataaagaa tctctcagtt agtggggaaa atgaaaatta ttaagaatag 180
aattgtcttc tgacttttaa aacaatttag actttaaaac atgaacgttt actcaggctg 240
gtgatactct agttgttagt ataccatact tgaagatata atcaagatca ctatagttgt 300
atatattctc tatttttata tgtaaagtgt aacttagttc aagtattttt gcttgtatcg 360
ttaactgata atcaaataca atcctaaaga tatatcagaa gctttatttt ggtacaaagt 420
cataagaatc aaaacttttt taaccattca cattaggtat caacagtaat tgtttgagat 480
acttttatat caattctggt aactgagcc ttttagtcata ctaagagaat gcagaagaag 540
ttataggaaa acgaatcttc actgaaacta gtattatata atcttgaatt agatgtttta 600
aaaactttat agcttgatat aaaatgagtt gaaaattatt atttaatagg aagcagcatt 660
agatttttgt cacctgtttt cagataatat ttctagtcta tgtatgttat ttaattttta 720
cactttggcc cattgtttat ttctcttaag gaattcatca aatgcaatga aatttgaata 780
aaattgatca tagcaataaa taatttttaa 810

```

&lt;210&gt; 115

&lt;211&gt; 155

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 115

```

ctctaactct aggagtaaca gccgctccta acatctgctc ttctatgtg ctttagagtt 60
ctctctgctt attagccaat tctcattac tccaatcccc catcaccaa tagagttgat 120
aactctttac agtaaaactat cctgttgat attgt 155

```

&lt;210&gt; 116

&lt;211&gt; 160

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 116

```

ctctaactct aggagtaaca gccgctccta acatctgctc ttctatgtg ctttagagtt 60
ctctctgctt attagccaat tctcattac tccaatcccc catcaccaa tagagttgat 120
aactctttac agtaaaactat cctgttgat attgtaaaag 160

```

&lt;210&gt; 117

&lt;211&gt; 553

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 117

```

accacgtccg gccctcttc tcttaattta aatgttttct tcagcaaaca gtatcctagg 60
agcattgtct atatgggccg gaatgtcctg gctgcccac gaggtgtct gtagataccc 120
tttgctgtct tcagtgccaa gtgaacatcg cagagatctg ccttgtgtct ccctgcaccc 180
ctggctgcag gggagctcct gctgcctcct ctggagctgg tgggggcctc actgccatcc 240
ttggatccct tcctgccgtc agcctgctgt cctcagtgca ctgggaggag ggggtgcgct 300
gtggttgtgt tgagccttca taggtgtcct ctggtgggct tagaatggg gttcttaatc 360
ccccccagta tgtggataga attcaggggt ctgtgaacat ggatgaggaa aaaataacat 420
tattatttat tactaatgta gctaaaatat gtagtgtgac ctttgattat aaatgtagac 480
aataaacctc acagcattag aaaggcctgt gactaccac ataacaaaca agcacattgt 540
tgtccctgaa ccc 553

```

&lt;210&gt; 118

&lt;211&gt; 593

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 118

```

accacgtccg gccctcttc tcttaattta aatgttttct tcagcaaaca gtatcctagg 60
agcattgtct ataggggccg gaatgtcctg gctgcccac gaggtgtct gtagataccc 120
tttgctgtct tcagtgccaa gtgaacatcg cagagatctg ccttgtgtct ccctgcaccc 180
ctggctgcag gggagctcct gctgcctcct ctggagctgg tgggggcctc actgccatcc 240
ttggatccct tcctgccgtc agcctgctgt tcctcagtg actgggagga ggggtgcgc 300
tgtggttgtg ttgagccttc ataggtgtcc tctgtgggc ttagaatgg ggttcttaat 360
ccccccagt atgtggatag aattcagggg tctgtgaaca tggatgagga aaaaataaca 420
ttattattta ttactaatgt agctaaaata tgtagtgtga ctttgatta taaatgtaga 480
caataaacct cacagcatta gaaaggcctg tgactacca cataacaaac aagcacatgt 540
agtccctgaa cccaaaaaaa aaaaaaaaaa aaaagatctt taattaagcg gtc 593

```

&lt;210&gt; 119

&lt;211&gt; 94

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 119

```

ttaaaatttt taaaaaata aaaagaaat cttgtgactt tatccccagt ggaaatcaca 60
ggtatttcat atgaagttat agttactgct gata 94

```

&lt;210&gt; 120

&lt;211&gt; 82

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 120

```

gaaaaaagcc attctgcaac atgaaagtc aaggtgctga ttagcagct gcagcaagtt 60

```

atcaagaata tctaactaag at

82

&lt;210&gt; 121

&lt;211&gt; 431

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 121

gcagtgttca ggacaggggg ataagctgag gccttagcaa tcaggagagg catcgtggag 60  
 ggggtggccc tgagcagtcc caactgccac cagcccagag ggcacatcaa taccagtgat 120  
 aaaaagcatc ttctcctcgc cttcatgaga ggggctggag tggactcagc tcccaccag 180  
 cccaccaccc aagctggcat cattggccag ggcacaaccc acgtagctct cagcagtggc 240  
 cctgggctgc tccttgctgg acaggatagg ctaagggttg taaaggaaaa ggggaaggag 300  
 aaccaggtaa caatccata agcagggtac cagcgcactc atcacaacag aggcaaaagg 360  
 ctgtcatggg ggcatctgat tccgaattga cctgtttcta atggcttccg tgtttccttt 420  
 cttttccagc a 431

&lt;210&gt; 122

&lt;211&gt; 750

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 122

agacaaaacc caagaatcag cttcctcttc cttcattact cttgcatggg tgttggtctt 60  
 aattttctcca tctagttagg cagtcctttg ctttttattg cttgtttatt gatgacattt 120  
 gccatttgta gcaatagtaa tagaatcatc tatatatattg tggccttggt gaatgtagaa 180  
 aaaggatagt ggcattttct aattgtgtaa cctataaca ccttgacggg ggactacagt 240  
 tcatatgctg gaccttttgt gttgttcat ggcgtgtggg ttgetttaat atacttagca 300  
 cattgtccta attgccatcc ttttggggag ggctatatat ccaagcta atggtagcat 360  
 ttttgtttta acatagagct gaccaagggt agacgtaagt gttgttcatt ttcgccta 420  
 actaataaaa ttacctaatt gttgaagctt ggagcttgaa tctaggcatt ttatgtcatt 480  
 tcaagtacac ctagtattt taaagcataa atatcctact atcctcaaca actttagaac 540  
 aaaaataaat attttaacaa gaaaaagca tgccatgaca agctgtaact taataaagaa 600  
 agacaaggaa tggctcttat agaccgagaa aaaataggtc ctcagatata tttatagcaa 660  
 aggaaagtta ggaagttaaa aaacagtgga ctcccccccc ccgcaaaaaa ctcacaacct 720  
 atatattggt tatcacaagc tgttttagtg 750

&lt;210&gt; 123

&lt;211&gt; 55

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 123

ctaatagcct gctgttgact gaaagcctta ctgatagcaa aaccagttga ttaac 55

<210> 124  
 <211> 450  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> unsure  
 <222> (384)..(386)  
 <223> a, c, g or t

<220>  
 <221> unsure  
 <222> (396)  
 <223> a, c, g or t

<220>  
 <221> unsure  
 <222> (398)  
 <223> a, c, g or t

<220>  
 <221> unsure  
 <222> (405)  
 <223> a, c, g or t

<400> 124  
 taattatttg catgaaataa atcatcagtt gaaacttact atattaaaaa acataaaaaat 60  
 aagccctttt ttacacaca ccagtgcctt gaaaaactgg cttgccaaat tcaaaatggc 120  
 aaaattaata aaatgagtag ctaagcattt tatttgcaat tgtatctttg catttatttt 180  
 tagagcataa tcgagaaata tatttattga ttccctaaagg aaatgtttac tttccctttat 240  
 ctggtaatta cggaaacaaa ttgcctgggc acatttgaaa taaatgaatc anatttgagt 300  
 caatgtgtta tagataacta aagttacatg attgcaattt attcacagag tgttttttta 360  
 aaaaaatcat tgaagtgact ggannnaatg tacttnantg aaatnttaaa aaatggagaa 420  
 gagtctcagc atgaagtgtc gaaggcttct 450

<210> 125  
 <211> 398  
 <212> DNA  
 <213> Homo sapiens

<400> 125  
 gtcttctagc tcccggacct gagegttctt gccttgcttt ctctctttcc tctcatttat 60  
 gctatttctg gcgtgtcatc actggcttac ccattatgta agctttaagt gaaaaaatca 120  
 gatgttattt tcatgagctc tgagggcact tctgcatttg ttctcatttg actcttctga 180  
 agcctggaga tgcacaggaa ggcagtttcc actgcagatg agcagcatgg aggaggcttt 240  
 tggaagtgaa atgaattgtc caaggtccag aggtgaggag ctgggaccag gcctcacagg 300



cttctgttct gtggctcctgt cccgtccctg gttctgctc taccagggtg gtgccttcta 360  
gttccttcct aaccaacaag tgtgggagggc tgggtgtg 398

<210> 126

<211> 658

<212> DNA

<213> Homo sapiens

<400> 126

gattttattg ttgatgggaa atgacaccaa atgtcatttc aggaataaat aaccatggca 60  
gttctaataaa cttggcacia atatatgagt tgcgctgaga ctggggtagc tccatccttt 120  
atccatggag attggcaagt gacaactcct gtcctggctc cttcgtgcat tccccattt 180  
gtgaggaagc gagagggggc ctcctgtctg tgcccccatg cctgtgtcac tgcctctctt 240  
ttcaccacgc gtgttgtctt ctagctcccg gacctgagcg ttcttgctt gctttctctc 300  
tttctctca tttatgctat ttctggcgtg tcatcactgg cttaccatt atgtaagctt 360  
taagtgaata aatcagatgt tattttcatg agctctgagg gcacttctgc atttgctctc 420  
atttgactct tctgaagcct ggagatgcac aggaaggcag ttccactgc agatgagcag 480  
catggaggag gcttttgaa gtgaaatgaa ttgtccaagg tccagagggtg aggagctggg 540  
accaggctc acaggcttct gttctgtggt cctgtcccg cctgggttc tgctctatcc 600  
agggtgtgcc ttctagttcc ttctaacca acaagtgtgaggaggctgggt gtgggtggc 658

<210> 127

<211> 430

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (142)

<223> a, c, g or t

<220>

<221> unsure

<222> (152)

<223> a, c, g or t

<220>

<221> unsure

<222> (167)


<223> a, c, g or t

<220>

<221> unsure

<222> (171)

<223> a, c, g or t



## COMPOSITIONS AND METHODS RELATING TO LUNG SPECIFIC GENES AND PROTEINS

This application claims the benefit of priority from U.S. Provisional Application  
5 Serial No. 60/242,998 filed October 25, 2000, which is herein incorporated by reference  
in its entirety.

### FIELD OF THE INVENTION

The present invention relates to newly identified nucleic acid molecules and  
10 polypeptides present in normal and neoplastic lung cells, including fragments, variants  
and derivatives of the nucleic acids and polypeptides. The present invention also relates  
to antibodies to the polypeptides of the invention, as well as agonists and antagonists of  
the polypeptides of the invention. The invention also relates to compositions comprising  
the nucleic acids, polypeptides, antibodies, variants, derivatives, agonists and antagonists  
15 of the invention and methods for the use of these compositions. These uses include  
identifying, diagnosing, monitoring, staging, imaging and treating lung cancer and non-  
cancerous disease states in lung, identifying lung tissue and monitoring and identifying  
and/or designing agonists and antagonists of polypeptides of the invention. The uses also  
include gene therapy, production of transgenic animals and cells, and production of  
20 engineered lung tissue for treatment and research.

### BACKGROUND OF THE INVENTION

Throughout the last hundred years, the incidence of lung cancer has steadily  
increased, so much so that now in many countries, it is the most common cancer. In fact,  
lung cancer is the second most prevalent type of cancer for both men and women in the  
25 United States and is the most common cause of cancer death in both sexes. Lung cancer  
deaths have increased ten-fold in both men and women since 1930, primarily due to an  
increase in cigarette smoking, but also due to an increased exposure to arsenic, asbestos,  
chromates, chloromethyl ethers, nickel, polycyclic aromatic hydrocarbons and other  
agents. See Scott, Lung Cancer: A Guide to Diagnosis and Treatment, Addicus Books  
30 (2000) and Alberg *et al.*, in Kane *et al.* (eds.) Biology of Lung Cancer, pp. 11-52, Marcel  
Dekker, Inc. (1998). Lung cancer may result from a primary tumor originating in the

lung or a secondary tumor which has spread from another organ such as the bowel or breast. Although there are over a dozen types of lung cancer, over 90% fall into two categories: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). *See* Scott, *supra*. About 20-25% of all lung cancers are characterized as SCLC, while 70-  
5 80% are diagnosed as NSCLC. *Id.* A rare type of lung cancer is mesothelioma, which is generally caused by exposure to asbestos, and which affects the pleura of the lung. Lung cancer is usually diagnosed or screened for by chest x-ray, CAT scans, PET scans, or by sputum cytology. A diagnosis of lung cancer is usually confirmed by biopsy of the tissue. *Id.*

10 SCLC tumors are highly metastatic and grow quickly. By the time a patient has been diagnosed with SCLC, the cancer has usually already spread to other parts of the body, including lymph nodes, adrenals, liver, bone, brain and bone marrow. *See* Scott, *supra*; Van Houtte *et al.* (eds.), Progress and Perspective in the Treatment of Lung Cancer, Springer-Verlag (1999). Because the disease has usually spread to such an  
15 extent that surgery is not an option, the current treatment of choice is chemotherapy plus chest irradiation. *See* Van Houtte, *supra*. The stage of disease is a principal predictor of long-term survival. Less than 5% of patients with extensive disease that has spread beyond one lung and surrounding lymph nodes, live longer than two years. *Id.* However, the probability of five-year survival is three to four times higher if the disease  
20 is diagnosed and treated when it is still in a limited stage, i.e., not having spread beyond one lung. *Id.*

NSCLC is generally divided into three types: squamous cell carcinoma, adenocarcinoma and large cell carcinoma. Both squamous cell cancer and adenocarcinoma develop from the cells that line the airways; however, adenocarcinoma  
25 develops from the goblet cells that produce mucus. Large cell lung cancer has been thus named because the cells look large and rounded when viewed microscopically, and generally are considered relatively undifferentiated. *See* Yesner, Atlas of Lung Cancer, Lippincott-Raven (1998).

Secondary lung cancer is a cancer initiated elsewhere in the body that has spread  
30 to the lungs. Cancers that metastasize to the lung include, but are not limited to, breast cancer, melanoma, colon cancer and Hodgkin's lymphoma. Treatment for secondary lung cancer may depend upon the source of the original cancer. In other words, a lung

cancer that originated from breast cancer may be more responsive to breast cancer treatments and a lung cancer that originated from the colon cancer may be more responsive to colon cancer treatments.

The stage of a cancer indicates how far it has spread and is an important indicator of the prognosis. In addition, staging is important because treatment is often decided according to the stage of a cancer. SCLC is divided into two stages: limited disease, *i.e.*, cancer that can only be seen in one lung and in nearby lymph nodes; and extensive disease, *i.e.*, cancer that has spread outside the lung to the chest or to other parts of the body. For most patients with SCLC, the disease has already progressed to lymph nodes or elsewhere in the body at the time of diagnosis. *See Scott, supra.* Even if spreading is not apparent on the scans, it is likely that some cancer cells may have spread away and traveled through the bloodstream or lymph system. In general, chemotherapy with or without radiotherapy is often the preferred treatment. The initial scans and tests done at first will be used later to see how well a patient is responding to treatment.

In contrast, non-small cell cancer may be divided into four stages. Stage I is highly localized cancer with no cancer in the lymph nodes. Stage II cancer has spread to the lymph nodes at the top of the affected lung. Stage III cancer has spread near to where the cancer started. This can be to the chest wall, the covering of the lung (pleura), the middle of the chest (mediastinum) or other lymph nodes. Stage IV cancer has spread to another part of the body. Stage I-III cancer is usually treated with surgery, with or without chemotherapy. Stage IV cancer is usually treated with chemotherapy and/or palliative care.

A number of chromosomal and genetic abnormalities have been observed in lung cancer. In NSCLC, chromosomal aberrations have been described on 3p, 9p, 11p, 15p and 17p, and chromosomal deletions have been seen on chromosomes 7, 11, 13 and 19. *See Skarin (ed.), Multimodality Treatment of Lung Cancer*, Marcel Dekker, Inc. (2000); Gemmill *et al.*, pp. 465-502, in Kane, *supra*; Bailey-Wilson *et al.*, pp. 53-98, in Kane, *supra*. Chromosomal abnormalities have been described on 1p, 3p, 5q, 6q, 8q, 13q and 17p in SCLC. *Id.* The loss of the short arm of chromosome 3p has also been seen in greater than 90% of SCLC tumors and approximately 50% of NSCLC tumors. *Id.*

A number of oncogenes and tumor suppressor genes have been implicated in lung cancer. *See Mabry*, pp. 391-412, in Kane, *supra* and Sclafani *et al.*, pp. 295-316, in

Kane, *supra*. In both SCLC and NSCLC, the p53 tumor suppressor gene is mutated in over 50% of lung cancers. See Yesner, *supra*. Another tumor suppressor gene, FHIT, which is found on chromosome 3p, is mutated by tobacco smoke. *Id.*; Skarin, *supra*. In addition, more than 95% of SCLCs and approximately 20-60% of NSCLCs have an  
5 absent or abnormal retinoblastoma (Rb) protein, another tumor suppressor gene. The *ras* oncogene (particularly K-*ras*) is mutated in 20-30% of NSCLC specimens and the *c-erbB2* oncogene is expressed in 18% of stage 2 NSCLC and 60% of stage 4 NSCLC specimens. See Van Houtte, *supra*. Other tumor suppressor genes that are found in a region of chromosome 9, specifically in the region of 9p21, are deleted in many cancer  
10 cells, including p16<sup>INK4A</sup> and p15<sup>INK4B</sup>. See Bailey-Wilson, *supra*; Sclafani *et al.*, *supra*. These tumor suppressor genes may also be implicated in lung cancer pathogenesis.

In addition, many lung cancer cells produce growth factors that may act in an autocrine fashion on lung cancer cells. See Siegfried *et al.*, pp. 317-336, in Kane, *supra*; Moody, pp. 337-370, in Kane, *supra* and Heasley *et al.*, 371-390, in Kane, *supra*. In  
15 SCLC, many tumor cells produce gastrin-releasing peptide (GRP), which is a proliferative growth factor for these cells. See Skarin, *supra*. Many NSCLC tumors express epidermal growth factor (EGF) receptors, allowing NSCLC cells to proliferate in response to EGF. Insulin-like growth factor (IGF-I) is elevated in greater than 95% of SCLC and greater than 80% of NSCLC tumors; it is thought to function as an autocrine  
20 growth factor. *Id.* Finally, stem cell factor (SCF, also known as steel factor or kit ligand) and c-Kit (a proto-oncoprotein tyrosine kinase receptor for SCF) are both expressed at high levels in SCLC, and thus may form an autocrine loop that increases proliferation. *Id.*

Although the majority of lung cancer cases are attributable to cigarette smoking,  
25 most smokers do not develop lung cancer. Epidemiological evidence has suggested that susceptibility to lung cancer may be inherited in a Mendelian fashion, and thus have an inherited genetic component. Bailey-Wilson, *supra*. Thus, it is thought that certain allelic variants at some genetic loci may affect susceptibility to lung cancer. *Id.* One way to identify which allelic variants are likely to be involved in lung cancer susceptibility, as  
30 well as susceptibility to other diseases, is to look at allelic variants of genes that are highly expressed in lung.

The lung is susceptible to a number of other debilitating diseases as well, including, without limitation, emphysema, pneumonia, cystic fibrosis and asthma. *See* Stockley (ed.), Molecular Biology of the Lung, Volume I: Emphysema and Infection, Birkhauser Verlag (1999), hereafter Stockley I, and Stockley (ed.), Molecular Biology of the Lung, Volume II: Asthma and Cancer, Birkhauser Verlag (1999), hereafter Stockley II. The cause of many these disorders is still not well understood and there are few, if any, good treatment options for many of these noncancerous lung disorders. Thus, there also remains a need for understanding of various noncancerous lung disorders and for identify treatments for these diseases.

10       The development and differentiation of the lung tissue during embryonic development is also very important. All of the epithelial cells of the respiratory tract, including those of the lung and bronchi, are derived from the primitive endodermal cells that line the embryonic outpouching. *See* Yesner, *supra*. During embryonic development, multipotent endodermal stem cells differentiate into many different types  
15 of specialized cells, which include ciliated cells for moving inhaled particles, goblet cells for producing mucus, Kulchitsky's cells for endocrine function, and Clara cells and type II pneumocytes for secreting surfactant protein. *Id.* Improper development and differentiation may cause respiratory disorders and distress in infants, particularly in premature infants, whose lungs cannot produce sufficient surfactant when they are born.  
20 Further, some lung cancer cells, particularly small cell carcinomas, appear multipotent, and can spontaneously differentiate into a number of cell types, including small cell carcinoma, adenocarcinoma and squamous cell carcinoma. *Id.* Thus, a better understanding of lung development and differentiation may help facilitate understanding of lung cancer initiation and progression.

25       Accordingly, there is a great need for more sensitive and accurate methods for predicting whether a person is likely to develop lung cancer, for diagnosing lung cancer, for monitoring the progression of the disease, for staging the lung cancer, for determining whether the lung cancer has metastasized and for imaging the lung cancer. There is also a need for better treatment of lung cancer. There is also a great need for diagnosing and  
30 treating noncancerous lung disorders such as emphysema, pneumonia, lung infection, pulmonary fibrosis, cystic fibrosis and asthma. There is also a need for compositions and methods of using compositions that are capable of identifying lung tissue for forensic

purposes and for determining whether a particular cell or tissue exhibits lung-specific characteristics.

#### SUMMARY OF THE INVENTION

5       The present invention solves these and other needs in the art by providing nucleic acid molecules and polypeptides as well as antibodies, agonists and antagonists, thereto that may be used to identify, diagnose, monitor, stage, image and treat lung cancer and non-cancerous disease states in lung; identify and monitor lung tissue; and identify and design agonists and antagonists of polypeptides of the invention. The invention also  
10 provides gene therapy, methods for producing transgenic animals and cells, and methods for producing engineered lung tissue for treatment and research.

Accordingly, one object of the invention is to provide nucleic acid molecules that are specific to lung cells, lung tissue and/or the lung organ. These lung specific nucleic acids (LSNAs) may be a naturally-occurring cDNA, genomic DNA, RNA, or a fragment  
15 of one of these nucleic acids, or may be a non-naturally-occurring nucleic acid molecule. If the LSNA is genomic DNA, then the LSNA is a lung specific gene (LSG). In a preferred embodiment, the nucleic acid molecule encodes a polypeptide that is specific to lung. In a more preferred embodiment, the nucleic acid molecule encodes a polypeptide that comprises an amino acid sequence of SEQ ID NO: 143 through 277. In another  
20 highly preferred embodiment, the nucleic acid molecule comprises a nucleic acid sequence of SEQ ID NO: 1 through 142. By nucleic acid molecule, it is also meant to be inclusive of sequences that selectively hybridize or exhibit substantial sequence similarity to a nucleic acid molecule encoding an LSP, or that selectively hybridize or exhibit substantial sequence similarity to an LSNA, as well as allelic variants of a nucleic  
25 acid molecule encoding an LSP, and allelic variants of an LSNA. Nucleic acid molecules comprising a part of a nucleic acid sequence that encodes an LSP or that comprises a part of a nucleic acid sequence of an LSNA are also provided.

A related object of the present invention is to provide a nucleic acid molecule comprising one or more expression control sequences controlling the transcription and/or  
30 translation of all or a part of an LSNA. In a preferred embodiment, the nucleic acid molecule comprises one or more expression control sequences controlling the



transcription and/or translation of a nucleic acid molecule that encodes all or a fragment of an LSP.

Another object of the invention is to provide vectors and/or host cells comprising a nucleic acid molecule of the instant invention. In a preferred embodiment, the nucleic acid molecule encodes all or a fragment of an LSP. In another preferred embodiment, the nucleic acid molecule comprises all or a part of an LSNA.

Another object of the invention is to provide methods for using the vectors and host cells comprising a nucleic acid molecule of the instant invention to recombinantly produce polypeptides of the invention.

Another object of the invention is to provide a polypeptide encoded by a nucleic acid molecule of the invention. In a preferred embodiment, the polypeptide is an LSP. The polypeptide may comprise either a fragment or a full-length protein as well as a mutant protein (mutin), fusion protein, homologous protein or a polypeptide encoded by an allelic variant of an LSP.

Another object of the invention is to provide an antibody that specifically binds to a polypeptide of the instant invention..

Another object of the invention is to provide agonists and antagonists of the nucleic acid molecules and polypeptides of the instant invention.

Another object of the invention is to provide methods for using the nucleic acid molecules to detect or amplify nucleic acid molecules that have similar or identical nucleic acid sequences compared to the nucleic acid molecules described herein. In a preferred embodiment, the invention provides methods of using the nucleic acid molecules of the invention for identifying, diagnosing, monitoring, staging, imaging and treating lung cancer and non-cancerous disease states in lung. In another preferred embodiment, the invention provides methods of using the nucleic acid molecules of the invention for identifying and/or monitoring lung tissue. The nucleic acid molecules of the instant invention may also be used in gene therapy, for producing transgenic animals and cells, and for producing engineered lung tissue for treatment and research.

The polypeptides and/or antibodies of the instant invention may also be used to identify, diagnose, monitor, stage, image and treat lung cancer and non-cancerous disease states in lung. The invention provides methods of using the polypeptides of the invention to identify and/or monitor lung tissue, and to produce engineered lung tissue.

The agonists and antagonists of the instant invention may be used to treat lung cancer and non-cancerous disease states in lung and to produce engineered lung tissue.

Yet another object of the invention is to provide a computer readable means of storing the nucleic acid and amino acid sequences of the invention. The records of the computer readable means can be accessed for reading and displaying of sequences for  
5 comparison, alignment and ordering of the sequences of the invention to other sequences.

### DETAILED DESCRIPTION OF THE INVENTION

#### Definitions and General Techniques

Unless otherwise defined herein, scientific and technical terms used in connection  
10 with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Generally, nomenclatures used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, genetics and protein and nucleic acid  
15 chemistry and hybridization described herein are those well-known and commonly used in the art. The methods and techniques of the present invention are generally performed according to conventional methods well-known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. *See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press (1989) and*  
20 *Sambrook et al., Molecular Cloning: A Laboratory Manual, 3d ed., Cold Spring Harbor Press (2001); Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates (1992, and Supplements to 2000); Ausubel et al., Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular*  
25 *Biology – 4<sup>th</sup> Ed., Wiley & Sons (1999); Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1990); and Harlow and Lane, Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1999); each of which is incorporated herein by reference in its entirety.*

Enzymatic reactions and purification techniques are performed according to  
30 manufacturer's specifications, as commonly accomplished in the art or as described herein. The nomenclatures used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and

pharmaceutical chemistry described herein are those well-known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.

The following terms, unless otherwise indicated, shall be understood to have the following meanings:

A "nucleic acid molecule" of this invention refers to a polymeric form of nucleotides and includes both sense and antisense strands of RNA, cDNA, genomic DNA, and synthetic forms and mixed polymers of the above. A nucleotide refers to a ribonucleotide, deoxynucleotide or a modified form of either type of nucleotide. A "nucleic acid molecule" as used herein is synonymous with "nucleic acid" and "polynucleotide." The term "nucleic acid molecule" usually refers to a molecule of at least 10 bases in length, unless otherwise specified. The term includes single- and double-stranded forms of DNA. In addition, a polynucleotide may include either or both naturally-occurring and modified nucleotides linked together by naturally-occurring and/or non-naturally occurring nucleotide linkages.

The nucleic acid molecules may be modified chemically or biochemically or may contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those of skill in the art. Such modifications include, for example, labels, methylation, substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as uncharged linkages (*e.g.*, methyl phosphonates, phosphotriesters, phosphoramidates, carbamates, etc.), charged linkages (*e.g.*, phosphorothioates, phosphorodithioates, etc.), pendent moieties (*e.g.*, polypeptides), intercalators (*e.g.*, acridine, psoralen, etc.), chelators, alkylators, and modified linkages (*e.g.*, alpha anomeric nucleic acids, etc.) The term "nucleic acid molecule" also includes any topological conformation, including single-stranded, double-stranded, partially duplexed, triplexed, hairpinned, circular and padlocked conformations. Also included are synthetic molecules that mimic polynucleotides in their ability to bind to a designated sequence via hydrogen bonding and other chemical interactions. Such molecules are known in the art and include, for example, those in which peptide linkages substitute for phosphate linkages in the backbone of the molecule.

A "gene" is defined as a nucleic acid molecule that comprises a nucleic acid sequence that encodes a polypeptide and the expression control sequences that surround

the nucleic acid sequence that encodes the polypeptide. For instance, a gene may comprise a promoter, one or more enhancers, a nucleic acid sequence that encodes a polypeptide, downstream regulatory sequences and, possibly, other nucleic acid sequences involved in regulation of the expression of an RNA. As is well-known in the art, eukaryotic genes usually contain both exons and introns. The term "exon" refers to a nucleic acid sequence found in genomic DNA that is bioinformatically predicted and/or experimentally confirmed to contribute a contiguous sequence to a mature mRNA transcript. The term "intron" refers to a nucleic acid sequence found in genomic DNA that is predicted and/or confirmed to not contribute to a mature mRNA transcript, but rather to be "spliced out" during processing of the transcript.

A nucleic acid molecule or polypeptide is "derived" from a particular species if the nucleic acid molecule or polypeptide has been isolated from the particular species, or if the nucleic acid molecule or polypeptide is homologous to a nucleic acid molecule or polypeptide isolated from a particular species.

An "isolated" or "substantially pure" nucleic acid or polynucleotide (*e.g.*, an RNA, DNA or a mixed polymer) is one which is substantially separated from other cellular components that naturally accompany the native polynucleotide in its natural host cell, *e.g.*, ribosomes, polymerases, or genomic sequences with which it is naturally associated. The term embraces a nucleic acid or polynucleotide that (1) has been removed from its naturally occurring environment, (2) is not associated with all or a portion of a polynucleotide in which the "isolated polynucleotide" is found in nature, (3) is operatively linked to a polynucleotide which it is not linked to in nature, (4) does not occur in nature as part of a larger sequence or (5) includes nucleotides or internucleoside bonds that are not found in nature. The term "isolated" or "substantially pure" also can be used in reference to recombinant or cloned DNA isolates, chemically synthesized polynucleotide analogs, or polynucleotide analogs that are biologically synthesized by heterologous systems. The term "isolated nucleic acid molecule" includes nucleic acid molecules that are integrated into a host cell chromosome at a heterologous site, recombinant fusions of a native fragment to a heterologous sequence, recombinant vectors present as episomes or as integrated into a host cell chromosome.

A "part" of a nucleic acid molecule refers to a nucleic acid molecule that comprises a partial contiguous sequence of at least 10 bases of the reference nucleic acid

molecule. Preferably, a part comprises at least 15 to 20 bases of a reference nucleic acid molecule. In theory, a nucleic acid sequence of 17 nucleotides is of sufficient length to occur at random less frequently than once in the three gigabase human genome, and thus to provide a nucleic acid probe that can uniquely identify the reference sequence in a nucleic acid mixture of genomic complexity. A preferred part is one that comprises a nucleic acid sequence that can encode at least 6 contiguous amino acid sequences (fragments of at least 18 nucleotides) because they are useful in directing the expression or synthesis of peptides that are useful in mapping the epitopes of the polypeptide encoded by the reference nucleic acid. *See, e.g., Geysen et al., Proc. Natl. Acad. Sci. USA* 81:3998-4002 (1984); and United States Patent Nos. 4,708,871 and 5,595,915, the disclosures of which are incorporated herein by reference in their entireties. A part may also comprise at least 25, 30, 35 or 40 nucleotides of a reference nucleic acid molecule, or at least 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400 or 500 nucleotides of a reference nucleic acid molecule. A part of a nucleic acid molecule may comprise no other nucleic acid sequences. Alternatively, a part of a nucleic acid may comprise other nucleic acid sequences from other nucleic acid molecules.

The term "oligonucleotide" refers to a nucleic acid molecule generally comprising a length of 200 bases or fewer. The term often refers to single-stranded deoxyribonucleotides, but it can refer as well to single- or double-stranded ribonucleotides, RNA:DNA hybrids and double-stranded DNAs, among others. Preferably, oligonucleotides are 10 to 60 bases in length and most preferably 12, 13, 14, 15, 16, 17, 18, 19 or 20 bases in length. Other preferred oligonucleotides are 25, 30, 35, 40, 45, 50, 55 or 60 bases in length. Oligonucleotides may be single-stranded, *e.g.* for use as probes or primers, or may be double-stranded, *e.g.* for use in the construction of a mutant gene. Oligonucleotides of the invention can be either sense or antisense oligonucleotides. An oligonucleotide can be derivatized or modified as discussed above for nucleic acid molecules.

Oligonucleotides, such as single-stranded DNA probe oligonucleotides, often are synthesized by chemical methods, such as those implemented on automated oligonucleotide synthesizers. However, oligonucleotides can be made by a variety of other methods, including *in vitro* recombinant DNA-mediated techniques and by expression of DNAs in cells and organisms. Initially, chemically synthesized DNAs

typically are obtained without a 5' phosphate. The 5' ends of such oligonucleotides are not substrates for phosphodiester bond formation by ligation reactions that employ DNA ligases typically used to form recombinant DNA molecules. Where ligation of such oligonucleotides is desired, a phosphate can be added by standard techniques, such as those that employ a kinase and ATP. The 3' end of a chemically synthesized oligonucleotide generally has a free hydroxyl group and, in the presence of a ligase, such as T4 DNA ligase, readily will form a phosphodiester bond with a 5' phosphate of another polynucleotide, such as another oligonucleotide. As is well-known, this reaction can be prevented selectively, where desired, by removing the 5' phosphates of the other polynucleotide(s) prior to ligation.

The term "naturally-occurring nucleotide" referred to herein includes naturally-occurring deoxyribonucleotides and ribonucleotides. The term "modified nucleotides" referred to herein includes nucleotides with modified or substituted sugar groups and the like. The term "nucleotide linkages" referred to herein includes nucleotides linkages such as phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoraniladate, phosphoroamidate, and the like. See e.g., LaPlanche *et al. Nucl. Acids Res.* 14:9081-9093 (1986); Stein *et al. Nucl. Acids Res.* 16:3209-3221 (1988); Zon *et al. Anti-Cancer Drug Design* 6:539-568 (1991); Zon *et al.*, in Eckstein (ed.) Oligonucleotides and Analogues: A Practical Approach, pp. 87-108, Oxford University Press (1991); United States Patent No. 5,151,510; Uhlmann and Peyman *Chemical Reviews* 90:543 (1990), the disclosures of which are hereby incorporated by reference.

Unless specified otherwise, the left hand end of a polynucleotide sequence in sense orientation is the 5' end and the right hand end of the sequence is the 3' end. In addition, the left hand direction of a polynucleotide sequence in sense orientation is referred to as the 5' direction, while the right hand direction of the polynucleotide sequence is referred to as the 3' direction. Further, unless otherwise indicated, each nucleotide sequence is set forth herein as a sequence of deoxyribonucleotides. It is intended, however, that the given sequence be interpreted as would be appropriate to the polynucleotide composition: for example, if the isolated nucleic acid is composed of RNA, the given sequence intends ribonucleotides, with uridine substituted for thymidine.

The term "allelic variant" refers to one of two or more alternative naturally-occurring forms of a gene, wherein each gene possesses a unique nucleotide sequence. In a preferred embodiment, different alleles of a given gene have similar or identical biological properties.

5       The term "percent sequence identity" in the context of nucleic acid sequences refers to the residues in two sequences which are the same when aligned for maximum correspondence. The length of sequence identity comparison may be over a stretch of at least about nine nucleotides, usually at least about 20 nucleotides, more usually at least about 24 nucleotides, typically at least about 28 nucleotides, more typically at least about  
10   32 nucleotides, and preferably at least about 36 or more nucleotides. There are a number of different algorithms known in the art which can be used to measure nucleotide sequence identity. For instance, polynucleotide sequences can be compared using FASTA, Gap or Bestfit, which are programs in Wisconsin Package Version 10.0, Genetics Computer Group (GCG), Madison, Wisconsin. FASTA, which includes, *e.g.*,  
15   the programs FASTA2 and FASTA3, provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences (Pearson, *Methods Enzymol.* 183: 63-98 (1990); Pearson, *Methods Mol. Biol.* 132: 185-219 (2000); Pearson, *Methods Enzymol.* 266: 227-258 (1996); Pearson, *J. Mol. Biol.* 276: 71-84 (1998); herein incorporated by reference). Unless otherwise specified, default  
20   parameters for a particular program or algorithm are used. For instance, percent sequence identity between nucleic acid sequences can be determined using FASTA with its default parameters (a word size of 6 and the NOPAM factor for the scoring matrix) or using Gap with its default parameters as provided in GCG Version 6.1, herein incorporated by reference.

25       A reference to a nucleic acid sequence encompasses its complement unless otherwise specified. Thus, a reference to a nucleic acid molecule having a particular sequence should be understood to encompass its complementary strand, with its complementary sequence. The complementary strand is also useful, *e.g.*, for antisense therapy, hybridization probes and PCR primers.

30       In the molecular biology art, researchers use the terms "percent sequence identity", "percent sequence similarity" and "percent sequence homology"

interchangeably. In this application, these terms shall have the same meaning with respect to nucleic acid sequences only.

The term "substantial similarity" or "substantial sequence similarity," when referring to a nucleic acid or fragment thereof, indicates that, when optimally aligned  
5 with appropriate nucleotide insertions or deletions with another nucleic acid (or its complementary strand), there is nucleotide sequence identity in at least about 50%, more preferably 60% of the nucleotide bases, usually at least about 70%, more usually at least about 80%, preferably at least about 90%, and more preferably at least about 95-98% of the nucleotide bases, as measured by any well-known algorithm of sequence identity,  
10 such as FASTA, BLAST or Gap, as discussed above.

Alternatively, substantial similarity exists when a nucleic acid or fragment thereof hybridizes to another nucleic acid, to a strand of another nucleic acid, or to the complementary strand thereof, under selective hybridization conditions. Typically, selective hybridization will occur when there is at least about 55% sequence identity,  
15 preferably at least about 65%, more preferably at least about 75%, and most preferably at least about 90% sequence identity, over a stretch of at least about 14 nucleotides, more preferably at least 17 nucleotides, even more preferably at least 20, 25, 30, 35, 40, 50, 60, 70, 80, 90 or 100 nucleotides.

Nucleic acid hybridization will be affected by such conditions as salt  
20 concentration, temperature, solvents, the base composition of the hybridizing species, length of the complementary regions, and the number of nucleotide base mismatches between the hybridizing nucleic acids, as will be readily appreciated by those skilled in the art. "Stringent hybridization conditions" and "stringent wash conditions" in the context of nucleic acid hybridization experiments depend upon a number of different  
25 physical parameters. The most important parameters include temperature of hybridization, base composition of the nucleic acids, salt concentration and length of the nucleic acid. One having ordinary skill in the art knows how to vary these parameters to achieve a particular stringency of hybridization. In general, "stringent hybridization" is performed at about 25°C below the thermal melting point ( $T_m$ ) for the specific DNA  
30 hybrid under a particular set of conditions. "Stringent washing" is performed at temperatures about 5°C lower than the  $T_m$  for the specific DNA hybrid under a particular set of conditions. The  $T_m$  is the temperature at which 50% of the target sequence



hybridizes to a perfectly matched probe. See Sambrook (1989), *supra*, p. 9.51, hereby incorporated by reference.

The  $T_m$  for a particular DNA-DNA hybrid can be estimated by the formula:

$$T_m = 81.5^{\circ}\text{C} + 16.6 (\log_{10}[\text{Na}^+]) + 0.41 (\text{fraction G} + \text{C}) - 0.63 (\% \text{ formamide}) - (600/l)$$

5 where  $l$  is the length of the hybrid in base pairs.

The  $T_m$  for a particular RNA-RNA hybrid can be estimated by the formula:

$$T_m = 79.8^{\circ}\text{C} + 18.5 (\log_{10}[\text{Na}^+]) + 0.58 (\text{fraction G} + \text{C}) + 11.8 (\text{fraction G} + \text{C})^2 - 0.35 (\% \text{ formamide}) - (820/l).$$

The  $T_m$  for a particular RNA-DNA hybrid can be estimated by the formula:

10  $T_m = 79.8^{\circ}\text{C} + 18.5 (\log_{10}[\text{Na}^+]) + 0.58 (\text{fraction G} + \text{C}) + 11.8 (\text{fraction G} + \text{C})^2 - 0.50 (\% \text{ formamide}) - (820/l).$

In general, the  $T_m$  decreases by 1-1.5°C for each 1% of mismatch between two nucleic acid sequences. Thus, one having ordinary skill in the art can alter hybridization and/or washing conditions to obtain sequences that have higher or lower degrees of  
15 sequence identity to the target nucleic acid. For instance, to obtain hybridizing nucleic acids that contain up to 10% mismatch from the target nucleic acid sequence, 10-15°C would be subtracted from the calculated  $T_m$  of a perfectly matched hybrid, and then the hybridization and washing temperatures adjusted accordingly. Probe sequences may also hybridize specifically to duplex DNA under certain conditions to form triplex or other  
20 higher order DNA complexes. The preparation of such probes and suitable hybridization conditions are well-known in the art.

An example of stringent hybridization conditions for hybridization of complementary nucleic acid sequences having more than 100 complementary residues on a filter in a Southern or Northern blot or for screening a library is 50% formamide/6X  
25 SSC at 42°C for at least ten hours and preferably overnight (approximately 16 hours). Another example of stringent hybridization conditions is 6X SSC at 68°C without formamide for at least ten hours and preferably overnight. An example of moderate stringency hybridization conditions is 6X SSC at 55°C without formamide for at least ten hours and preferably overnight. An example of low stringency hybridization conditions  
30 for hybridization of complementary nucleic acid sequences having more than 100 complementary residues on a filter in a Southern or Northern blot or for screening a library is 6X SSC at 42°C for at least ten hours. Hybridization conditions to identify

nucleic acid sequences that are similar but not identical can be identified by experimentally changing the hybridization temperature from 68°C to 42°C while keeping the salt concentration constant (6X SSC), or keeping the hybridization temperature and salt concentration constant (*e.g.* 42°C and 6X SSC) and varying the formamide concentration from 50% to 0%. Hybridization buffers may also include blocking agents to lower background. These agents are well-known in the art. *See* Sambrook *et al.* (1989), *supra*, pages 8.46 and 9.46-9.58, herein incorporated by reference. *See also* Ausubel (1992), *supra*, Ausubel (1999), *supra*, and Sambrook (2001), *supra*.

Wash conditions also can be altered to change stringency conditions. An example of stringent wash conditions is a 0.2x SSC wash at 65°C for 15 minutes (*see* Sambrook (1989), *supra*, for SSC buffer). Often the high stringency wash is preceded by a low stringency wash to remove excess probe. An exemplary medium stringency wash for duplex DNA of more than 100 base pairs is 1x SSC at 45°C for 15 minutes. An exemplary low stringency wash for such a duplex is 4x SSC at 40°C for 15 minutes. In general, signal-to-noise ratio of 2x or higher than that observed for an unrelated probe in the particular hybridization assay indicates detection of a specific hybridization.

As defined herein, nucleic acid molecules that do not hybridize to each other under stringent conditions are still substantially similar to one another if they encode polypeptides that are substantially identical to each other. This occurs, for example, when a nucleic acid molecule is created synthetically or recombinantly using high codon degeneracy as permitted by the redundancy of the genetic code.

Hybridization conditions for nucleic acid molecules that are shorter than 100 nucleotides in length (*e.g.*, for oligonucleotide probes) may be calculated by the formula:  $T_m = 81.5^{\circ}\text{C} + 16.6(\log_{10}[\text{Na}^+]) + 0.41(\text{fraction G+C}) - (600/\text{N})$ , wherein N is change length and the  $[\text{Na}^+]$  is 1 M or less. *See* Sambrook (1989), *supra*, p. 11.46. For hybridization of probes shorter than 100 nucleotides, hybridization is usually performed under stringent conditions (5-10°C below the  $T_m$ ) using high concentrations (0.1-1.0 pmol/ml) of probe. *Id.* at p. 11.45. Determination of hybridization using mismatched probes, pools of degenerate probes or "guessmers," as well as hybridization solutions and methods for empirically determining hybridization conditions are well-known in the art. *See, e.g.*, Ausubel (1999), *supra*; Sambrook (1989), *supra*, pp. 11.45-11.57.

The term "digestion" or "digestion of DNA" refers to catalytic cleavage of the DNA with a restriction enzyme that acts only at certain sequences in the DNA. The various restriction enzymes referred to herein are commercially available and their reaction conditions, cofactors and other requirements for use are known and routine to the skilled artisan. For analytical purposes, typically, 1 µg of plasmid or DNA fragment is digested with about 2 units of enzyme in about 20 µl of reaction buffer. For the purpose of isolating DNA fragments for plasmid construction, typically 5 to 50 µg of DNA are digested with 20 to 250 units of enzyme in proportionately larger volumes. Appropriate buffers and substrate amounts for particular restriction enzymes are described in standard laboratory manuals, such as those referenced below, and they are specified by commercial suppliers. Incubation times of about 1 hour at 37°C are ordinarily used, but conditions may vary in accordance with standard procedures, the supplier's instructions and the particulars of the reaction. After digestion, reactions may be analyzed, and fragments may be purified by electrophoresis through an agarose or polyacrylamide gel, using well-known methods that are routine for those skilled in the art.

The term "ligation" refers to the process of forming phosphodiester bonds between two or more polynucleotides, which most often are double-stranded DNAs. Techniques for ligation are well-known to the art and protocols for ligation are described in standard laboratory manuals and references, such as, *e.g.*, Sambrook (1989), *supra*.

Genome-derived "single exon probes," are probes that comprise at least part of an exon ("reference exon") and can hybridize detectably under high stringency conditions to transcript-derived nucleic acids that include the reference exon but do not hybridize detectably under high stringency conditions to nucleic acids that lack the reference exon. Single exon probes typically further comprise, contiguous to a first end of the exon portion, a first intronic and/or intergenic sequence that is identically contiguous to the exon in the genome, and may contain a second intronic and/or intergenic sequence that is identically contiguous to the exon in the genome. The minimum length of genome-derived single exon probes is defined by the requirement that the exonic portion be of sufficient length to hybridize under high stringency conditions to transcript-derived nucleic acids, as discussed above. The maximum length of genome-derived single exon probes is defined by the requirement that the probes contain portions of no more than one

exon. The single exon probes may contain priming sequences not found in contiguity with the rest of the probe sequence in the genome, which priming sequences are useful for PCR and other amplification-based technologies.

The term "microarray" or "nucleic acid microarray" refers to a substrate-bound  
5 collection of plural nucleic acids, hybridization to each of the plurality of bound nucleic acids being separately detectable. The substrate can be solid or porous, planar or non-planar, unitary or distributed. Microarrays or nucleic acid microarrays include all the devices so called in Schena (ed.), DNA Microarrays: A Practical Approach (Practical Approach Series), Oxford University Press (1999); *Nature Genet.* 21(1)(suppl.):1 - 60  
10 (1999); Schena (ed.), Microarray Biochip: Tools and Technology, Eaton Publishing Company/BioTechniques Books Division (2000). These microarrays include substrate-bound collections of plural nucleic acids in which the plurality of nucleic acids are disposed on a plurality of beads, rather than on a unitary planar substrate, as is described, *inter alia*, in Brenner *et al.*, *Proc. Natl. Acad. Sci. USA* 97(4):1665-1670 (2000).

15 The term "mutated" when applied to nucleic acid molecules means that nucleotides in the nucleic acid sequence of the nucleic acid molecule may be inserted, deleted or changed compared to a reference nucleic acid sequence. A single alteration may be made at a locus (a point mutation) or multiple nucleotides may be inserted, deleted or changed at a single locus. In addition, one or more alterations may be made at  
20 any number of loci within a nucleic acid sequence. In a preferred embodiment, the nucleic acid molecule comprises the wild type nucleic acid sequence encoding an LSP or is an LSNA. The nucleic acid molecule may be mutated by any method known in the art including those mutagenesis techniques described *infra*.

The term "error-prone PCR" refers to a process for performing PCR under  
25 conditions where the copying fidelity of the DNA polymerase is low, such that a high rate of point mutations is obtained along the entire length of the PCR product. *See, e.g.*, Leung *et al.*, *Technique* 1: 11-15 (1989) and Caldwell *et al.*, *PCR Methods Applic.* 2: 28-33 (1992).

The term "oligonucleotide-directed mutagenesis" refers to a process which  
30 enables the generation of site-specific mutations in any cloned DNA segment of interest. *See, e.g.*, Reidhaar-Olson *et al.*, *Science* 241: 53-57 (1988).

The term "assembly PCR" refers to a process which involves the assembly of a PCR product from a mixture of small DNA fragments. A large number of different PCR reactions occur in parallel in the same vial, with the products of one reaction priming the products of another reaction.

- 5       The term "sexual PCR mutagenesis" or "DNA shuffling" refers to a method of error-prone PCR coupled with forced homologous recombination between DNA molecules of different but highly related DNA sequence *in vitro*, caused by random fragmentation of the DNA molecule based on sequence similarity, followed by fixation of the crossover by primer extension in an error-prone PCR reaction. *See, e.g., Stemmer,*  
10 *Proc. Natl. Acad. Sci. U.S.A.* 91: 10747-10751 (1994). DNA shuffling can be carried out between several related genes ("Family shuffling").

- The term "*in vivo* mutagenesis" refers to a process of generating random mutations in any cloned DNA of interest which involves the propagation of the DNA in a strain of bacteria such as *E. coli* that carries mutations in one or more of the DNA repair  
15 pathways. These "mutator" strains have a higher random mutation rate than that of a wild-type parent. Propagating the DNA in a mutator strain will eventually generate random mutations within the DNA.

- The term "cassette mutagenesis" refers to any process for replacing a small region of a double-stranded DNA molecule with a synthetic oligonucleotide "cassette" that  
20 differs from the native sequence. The oligonucleotide often contains completely and/or partially randomized native sequence.

- The term "recursive ensemble mutagenesis" refers to an algorithm for protein engineering (protein mutagenesis) developed to produce diverse populations of phenotypically related mutants whose members differ in amino acid sequence. This  
25 method uses a feedback mechanism to control successive rounds of combinatorial cassette mutagenesis. *See, e.g., Arkin et al., Proc. Natl. Acad. Sci. U.S.A.* 89: 7811-7815 (1992).

- The term "exponential ensemble mutagenesis" refers to a process for generating combinatorial libraries with a high percentage of unique and functional mutants, wherein  
30 small groups of residues are randomized in parallel to identify, at each altered position, amino acids which lead to functional proteins. *See, e.g., Delegrave et al., Biotechnology Research* 11: 1548-1552 (1993); Arnold, *Current Opinion in Biotechnology* 4: 450-455

(1993). Each of the references mentioned above are hereby incorporated by reference in its entirety.

“Operatively linked” expression control sequences refers to a linkage in which the expression control sequence is contiguous with the gene of interest to control the gene of interest, as well as expression control sequences that act in *trans* or at a distance to control the gene of interest.

The term “expression control sequence” as used herein refers to polynucleotide sequences which are necessary to affect the expression of coding sequences to which they are operatively linked. Expression control sequences are sequences which control the transcription, post-transcriptional events and translation of nucleic acid sequences. Expression control sequences include appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (*e.g.*, ribosome binding sites); sequences that enhance protein stability; and when desired, sequences that enhance protein secretion. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include the promoter, ribosomal binding site, and transcription termination sequence. The term “control sequences” is intended to include, at a minimum, all components whose presence is essential for expression, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences.

The term “vector,” as used herein, is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a “plasmid”, which refers to a circular double-stranded DNA loop into which additional DNA segments may be ligated. Other vectors include cosmids, bacterial artificial chromosomes (BAC) and yeast artificial chromosomes (YAC). Another type of vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome. Viral vectors that infect bacterial cells are referred to as bacteriophages. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication). Other vectors can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable

of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "recombinant expression vectors" (or simply, "expression vectors"). In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" may  
5 be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include other forms of expression vectors that serve equivalent functions.

The term "recombinant host cell" (or simply "host cell"), as used herein, is intended to refer to a cell into which an expression vector has been introduced. It should  
10 be understood that such terms are intended to refer not only to the particular subject cell but to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term "host cell" as used herein.

15 As used herein, the phrase "open reading frame" and the equivalent acronym "ORF" refer to that portion of a transcript-derived nucleic acid that can be translated in its entirety into a sequence of contiguous amino acids. As so defined, an ORF has length, measured in nucleotides, exactly divisible by 3. As so defined, an ORF need not encode the entirety of a natural protein.

20 As used herein, the phrase "ORF-encoded peptide" refers to the predicted or actual translation of an ORF.

As used herein, the phrase "degenerate variant" of a reference nucleic acid sequence intends all nucleic acid sequences that can be directly translated, using the standard genetic code, to provide an amino acid sequence identical to that translated from  
25 the reference nucleic acid sequence.

The term "polypeptide" encompasses both naturally-occurring and non-naturally-occurring proteins and polypeptides, polypeptide fragments and polypeptide mutants, derivatives and analogs. A polypeptide may be monomeric or polymeric. Further, a polypeptide may comprise a number of different modules within a single polypeptide  
30 each of which has one or more distinct activities. A preferred polypeptide in accordance with the invention comprises an LSP encoded by a nucleic acid molecule of the instant invention, as well as a fragment, mutant, analog and derivative thereof.

The term "isolated protein" or "isolated polypeptide" is a protein or polypeptide that by virtue of its origin or source of derivation (1) is not associated with naturally associated components that accompany it in its native state, (2) is free of other proteins from the same species (3) is expressed by a cell from a different species, or (4) does not occur in nature. Thus, a polypeptide that is chemically synthesized or synthesized in a cellular system different from the cell from which it naturally originates will be "isolated" from its naturally associated components. A polypeptide or protein may also be rendered substantially free of naturally associated components by isolation, using protein purification techniques well-known in the art.

10 A protein or polypeptide is "substantially pure," "substantially homogeneous" or "substantially purified" when at least about 60% to 75% of a sample exhibits a single species of polypeptide. The polypeptide or protein may be monomeric or multimeric. A substantially pure polypeptide or protein will typically comprise about 50%, 60%, 70%, 80% or 90% W/W of a protein sample, more usually about 95%, and preferably will be over 99% pure. Protein purity or homogeneity may be indicated by a number of means well-known in the art, such as polyacrylamide gel electrophoresis of a protein sample, followed by visualizing a single polypeptide band upon staining the gel with a stain well-known in the art. For certain purposes, higher resolution may be provided by using HPLC or other means well-known in the art for purification.

20 The term "polypeptide fragment" as used herein refers to a polypeptide of the instant invention that has an amino-terminal and/or carboxy-terminal deletion compared to a full-length polypeptide. In a preferred embodiment, the polypeptide fragment is a contiguous sequence in which the amino acid sequence of the fragment is identical to the corresponding positions in the naturally-occurring sequence. Fragments typically are at least 5, 6, 7, 8, 9 or 10 amino acids long, preferably at least 12, 14, 16 or 18 amino acids long, more preferably at least 20 amino acids long, more preferably at least 25, 30, 35, 40 or 45, amino acids, even more preferably at least 50 or 60 amino acids long, and even more preferably at least 70 amino acids long.

A "derivative" refers to polypeptides or fragments thereof that are substantially similar in primary structural sequence but which include, *e.g.*, *in vivo* or *in vitro* chemical and biochemical modifications that are not found in the native polypeptide. Such modifications include, for example, acetylation, acylation, ADP-ribosylation, amidation,



-23-

covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. Other modification include, *e.g.*, labeling with radionuclides, and various enzymatic modifications, as will be readily appreciated by those skilled in the art. A variety of methods for labeling polypeptides and of substituents or labels useful for such purposes are well-known in the art, and include radioactive isotopes such as  $^{125}\text{I}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ , and  $^3\text{H}$ , ligands which bind to labeled antiligands (*e.g.*, antibodies), fluorophores, chemiluminescent agents, enzymes, and antiligands which can serve as specific binding pair members for a labeled ligand. The choice of label depends on the sensitivity required, ease of conjugation with the primer, stability requirements, and available instrumentation. Methods for labeling polypeptides are well-known in the art. *See* Ausubel (1992), *supra*; Ausubel (1999), *supra*, herein incorporated by reference.

20       The term "fusion protein" refers to polypeptides of the instant invention comprising polypeptides or fragments coupled to heterologous amino acid sequences. Fusion proteins are useful because they can be constructed to contain two or more desired functional elements from two or more different proteins. A fusion protein comprises at least 10 contiguous amino acids from a polypeptide of interest, more preferably at least 20 or 30 amino acids, even more preferably at least 40, 50 or 60 amino acids, yet more preferably at least 75, 100 or 125 amino acids. Fusion proteins can be produced recombinantly by constructing a nucleic acid sequence which encodes the polypeptide or a fragment thereof in frame with a nucleic acid sequence encoding a different protein or peptide and then expressing the fusion protein. Alternatively, a fusion protein can be produced chemically by crosslinking the polypeptide or a fragment thereof to another protein.

The term "analog" refers to both polypeptide analogs and non-peptide analogs. The term "polypeptide analog" as used herein refers to a polypeptide of the instant invention that is comprised of a segment of at least 25 amino acids that has substantial identity to a portion of an amino acid sequence but which contains non-natural amino acids or non-natural inter-residue bonds. In a preferred embodiment, the analog has the same or similar biological activity as the native polypeptide. Typically, polypeptide analogs comprise a conservative amino acid substitution (or insertion or deletion) with respect to the naturally-occurring sequence. Analogs typically are at least 20 amino acids long, preferably at least 50 amino acids long or longer, and can often be as long as a full-length naturally-occurring polypeptide.

The term "non-peptide analog" refers to a compound with properties that are analogous to those of a reference polypeptide of the instant invention. A non-peptide compound may also be termed a "peptide mimetic" or a "peptidomimetic." Such compounds are often developed with the aid of computerized molecular modeling. Peptide mimetics that are structurally similar to useful peptides may be used to produce an equivalent effect. Generally, peptidomimetics are structurally similar to a paradigm polypeptide (*i.e.*, a polypeptide that has a desired biochemical property or pharmacological activity), but have one or more peptide linkages optionally replaced by a linkage selected from the group consisting of: --CH<sub>2</sub>NH--, --CH<sub>2</sub>S--, --CH<sub>2</sub>-CH<sub>2</sub>--, --CH=CH--(cis and trans), --COCH<sub>2</sub>--, --CH(OH)CH<sub>2</sub>--, and --CH<sub>2</sub>SO--, by methods well-known in the art. Systematic substitution of one or more amino acids of a consensus sequence with a D-amino acid of the same type (*e.g.*, D-lysine in place of L-lysine) may also be used to generate more stable peptides. In addition, constrained peptides comprising a consensus sequence or a substantially identical consensus sequence variation may be generated by methods known in the art (Rizo *et al.*, *Ann. Rev. Biochem.* 61:387-418 (1992), incorporated herein by reference). For example, one may add internal cysteine residues capable of forming intramolecular disulfide bridges which cyclize the peptide.

A "polypeptide mutant" or "mutein" refers to a polypeptide of the instant invention whose sequence contains substitutions, insertions or deletions of one or more amino acids compared to the amino acid sequence of a native or wild-type protein. A mutein may have one or more amino acid point substitutions, in which a single amino

acid at a position has been changed to another amino acid, one or more insertions and/or deletions, in which one or more amino acids are inserted or deleted, respectively, in the sequence of the naturally-occurring protein, and/or truncations of the amino acid sequence at either or both the amino or carboxy termini. Further, a mutein may have the same or different biological activity as the naturally-occurring protein. For instance, a mutein may have an increased or decreased biological activity. A mutein has at least 50% sequence similarity to the wild type protein, preferred is 60% sequence similarity, more preferred is 70% sequence similarity. Even more preferred are muteins having 80%, 85% or 90% sequence similarity to the wild type protein. In an even more preferred embodiment, a mutein exhibits 95% sequence identity, even more preferably 97%, even more preferably 98% and even more preferably 99%. Sequence similarity may be measured by any common sequence analysis algorithm, such as Gap or Bestfit.

Preferred amino acid substitutions are those which: (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for forming protein complexes, (4) alter binding affinity or enzymatic activity, and (5) confer or modify other physicochemical or functional properties of such analogs. For example, single or multiple amino acid substitutions (preferably conservative amino acid substitutions) may be made in the naturally-occurring sequence (preferably in the portion of the polypeptide outside the domain(s) forming intermolecular contacts. In a preferred embodiment, the amino acid substitutions are moderately conservative substitutions or conservative substitutions. In a more preferred embodiment, the amino acid substitutions are conservative substitutions. A conservative amino acid substitution should not substantially change the structural characteristics of the parent sequence (e.g., a replacement amino acid should not tend to disrupt a helix that occurs in the parent sequence, or disrupt other types of secondary structure that characterizes the parent sequence). Examples of art-recognized polypeptide secondary and tertiary structures are described in Creighton (ed.), Proteins, Structures and Molecular Principles, W. H. Freeman and Company (1984); Branden *et al.* (ed.), Introduction to Protein Structure, Garland Publishing (1991); Thornton *et al.*, *Nature* 354:105-106 (1991), each of which are incorporated herein by reference.

As used herein, the twenty conventional amino acids and their abbreviations follow conventional usage. See Golub *et al.* (eds.), Immunology - A Synthesis 2<sup>nd</sup> Ed.,

Sinauer Associates (1991), which is incorporated herein by reference. Stereoisomers (e.g., D-amino acids) of the twenty conventional amino acids, unnatural amino acids such as -, -disubstituted amino acids, N-alkyl amino acids, and other unconventional amino acids may also be suitable components for polypeptides of the present invention.

- 5 Examples of unconventional amino acids include: 4-hydroxyproline,  $\gamma$ -carboxyglutamate, -N,N,N-trimethyllysine, -N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, s-N-methylarginine, and other similar amino acids and imino acids (e.g., 4-hydroxyproline). In the polypeptide notation used herein, the lefthand direction is the amino terminal direction and the right hand
- 10 direction is the carboxy-terminal direction, in accordance with standard usage and convention.

- A protein has "homology" or is "homologous" to a protein from another organism if the encoded amino acid sequence of the protein has a similar sequence to the encoded amino acid sequence of a protein of a different organism and has a similar biological
- 15 activity or function. Alternatively, a protein may have homology or be homologous to another protein if the two proteins have similar amino acid sequences and have similar biological activities or functions. Although two proteins are said to be "homologous," this does not imply that there is necessarily an evolutionary relationship between the proteins. Instead, the term "homologous" is defined to mean that the two proteins have
- 20 similar amino acid sequences and similar biological activities or functions. In a preferred embodiment, a homologous protein is one that exhibits 50% sequence similarity to the wild type protein, preferred is 60% sequence similarity, more preferred is 70% sequence similarity. Even more preferred are homologous proteins that exhibit 80%, 85% or 90% sequence similarity to the wild type protein. In a yet more preferred embodiment, a
- 25 homologous protein exhibits 95%, 97%, 98% or 99% sequence similarity.

- When "sequence similarity" is used in reference to proteins or peptides, it is recognized that residue positions that are not identical often differ by conservative amino acid substitutions. In a preferred embodiment, a polypeptide that has "sequence similarity" comprises conservative or moderately conservative amino acid substitutions.
- 30 A "conservative amino acid substitution" is one in which an amino acid residue is substituted by another amino acid residue having a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). In general, a conservative amino

acid substitution will not substantially change the functional properties of a protein. In cases where two or more amino acid sequences differ from each other by conservative substitutions, the percent sequence identity or degree of similarity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well-known to those of skill in the art. *See, e.g., Pearson, Methods Mol. Biol.* 24: 307-31 (1994), herein incorporated by reference.

For instance, the following six groups each contain amino acids that are conservative substitutions for one another:

- 1) Serine (S), Threonine (T);
- 2) Aspartic Acid (D), Glutamic Acid (E);
- 3) Asparagine (N), Glutamine (Q);
- 4) Arginine (R), Lysine (K);
- 5) Isoleucine (I), Leucine (L), Methionine (M), Alanine (A), Valine (V), and
- 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

Alternatively, a conservative replacement is any change having a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet *et al., Science* 256: 1443-45 (1992), herein incorporated by reference. A "moderately conservative" replacement is any change having a nonnegative value in the PAM250 log-likelihood matrix.

Sequence similarity for polypeptides, which is also referred to as sequence identity, is typically measured using sequence analysis software. Protein analysis software matches similar sequences using measures of similarity assigned to various substitutions, deletions and other modifications, including conservative amino acid substitutions. For instance, GCG contains programs such as "Gap" and "Bestfit" which can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from different species of organisms or between a wild type protein and a mutant thereof. *See, e.g., GCG Version 6.1. Other programs include FASTA, discussed supra.*

A preferred algorithm when comparing a sequence of the invention to a database containing a large number of sequences from different organisms is the computer program BLAST, especially blastp or tblastn. *See, e.g., Altschul et al., J. Mol. Biol.* 215: 403-410 (1990); Altschul *et al., Nucleic Acids Res.* 25:3389-402 (1997); herein incorporated by reference. Preferred parameters for blastp are:

-28-

Expectation value: 10 (default)  
Filter: seg (default)  
Cost to open a gap: 11 (default)  
Cost to extend a gap: 1 (default)  
5 Max. alignments: 100 (default)  
Word size: 11 (default)  
No. of descriptions: 100 (default)  
Penalty Matrix: BLOSUM62

The length of polypeptide sequences compared for homology will generally be at  
10 least about 16 amino acid residues, usually at least about 20 residues, more usually at  
least about 24 residues, typically at least about 28 residues, and preferably more than  
about 35 residues. When searching a database containing sequences from a large number  
of different organisms, it is preferable to compare amino acid sequences.

Database searching using amino acid sequences can be measured by algorithms  
15 other than blastp are known in the art. For instance, polypeptide sequences can be  
compared using FASTA, a program in GCG Version 6.1. FASTA (*e.g.*, FASTA2 and  
FASTA3) provides alignments and percent sequence identity of the regions of the best  
overlap between the query and search sequences (Pearson (1990), *supra*; Pearson (2000),  
*supra*. For example, percent sequence identity between amino acid sequences can be  
20 determined using FASTA with its default or recommended parameters (a word size of 2  
and the PAM250 scoring matrix), as provided in GCG Version 6.1, herein incorporated  
by reference.

An "antibody" refers to an intact immunoglobulin, or to an antigen-binding  
portion thereof that competes with the intact antibody for specific binding to a molecular  
25 species, *e.g.*, a polypeptide of the instant invention. Antigen-binding portions may be  
produced by recombinant DNA techniques or by enzymatic or chemical cleavage of  
intact antibodies. Antigen-binding portions include, *inter alia*, Fab, Fab', F(ab')<sub>2</sub>, Fv,  
dAb, and complementarity determining region (CDR) fragments, single-chain antibodies  
(scFv), chimeric antibodies, diabodies and polypeptides that contain at least a portion of  
30 an immunoglobulin that is sufficient to confer specific antigen binding to the  
polypeptide. An Fab fragment is a monovalent fragment consisting of the VL, VH, CL  
and CH1 domains; an F(ab')<sub>2</sub> fragment is a bivalent fragment comprising two Fab

fragments linked by a disulfide bridge at the hinge region; an Fd fragment consists of the VH and CH1 domains; an Fv fragment consists of the VL and VH domains of a single arm of an antibody; and a dAb fragment consists of a VH domain. *See, e.g., Ward et al., Nature* 341: 544-546 (1989).

5 By "bind specifically" and "specific binding" is here intended the ability of the antibody to bind to a first molecular species in preference to binding to other molecular species with which the antibody and first molecular species are admixed. An antibody is said specifically to "recognize" a first molecular species when it can bind specifically to that first molecular species.

10 A single-chain antibody (scFv) is an antibody in which a VL and VH region are paired to form a monovalent molecule via a synthetic linker that enables them to be made as a single protein chain. *See, e.g., Bird et al., Science* 242: 423-426 (1988); Huston *et al., Proc. Natl. Acad. Sci. USA* 85: 5879-5883 (1988). Diabodies are bivalent, bispecific antibodies in which VH and VL domains are expressed on a single polypeptide chain, but  
15 using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen binding sites. *See e.g., Holliger et al., Proc. Natl. Acad. Sci. USA* 90: 6444-6448 (1993); Poljak *et al., Structure* 2: 1121-1123 (1994). One or more CDRs may be incorporated into a molecule either covalently or noncovalently to make it  
20 an immunoadhesin. An immunoadhesin may incorporate the CDR(s) as part of a larger polypeptide chain, may covalently link the CDR(s) to another polypeptide chain, or may incorporate the CDR(s) noncovalently. The CDRs permit the immunoadhesin to specifically bind to a particular antigen of interest. A chimeric antibody is an antibody that contains one or more regions from one antibody and one or more regions from one  
25 or more other antibodies.

An antibody may have one or more binding sites. If there is more than one binding site, the binding sites may be identical to one another or may be different. For instance, a naturally-occurring immunoglobulin has two identical binding sites, a single-chain antibody or Fab fragment has one binding site, while a "bispecific" or  
30 "bifunctional" antibody has two different binding sites.

An "isolated antibody" is an antibody that (1) is not associated with naturally-associated components, including other naturally-associated antibodies, that accompany

it in its native state, (2) is free of other proteins from the same species, (3) is expressed by a cell from a different species, or (4) does not occur in nature. It is known that purified proteins, including purified antibodies, may be stabilized with non-naturally-associated components. The non-naturally-associated component may be a protein, such as albumin (*e.g.*, BSA) or a chemical such as polyethylene glycol (PEG).

A "neutralizing antibody" or "an inhibitory antibody" is an antibody that inhibits the activity of a polypeptide or blocks the binding of a polypeptide to a ligand that normally binds to it. An "activating antibody" is an antibody that increases the activity of a polypeptide.

10 The term "epitope" includes any protein determinant capable of specifically binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three-dimensional structural characteristics, as well as specific charge characteristics. An antibody is said to specifically bind an antigen when  
15 the dissociation constant is less than  $1 \mu\text{M}$ , preferably less than  $100 \text{ nM}$  and most preferably less than  $10 \text{ nM}$ .

The term "patient" as used herein includes human and veterinary subjects.

Throughout this specification and claims, the word "comprise," or variations such as "comprises" or "comprising," will be understood to imply the inclusion of a stated  
20 integer or group of integers but not the exclusion of any other integer or group of integers.

The term "lung specific" refers to a nucleic acid molecule or polypeptide that is expressed predominantly in the lung as compared to other tissues in the body. In a preferred embodiment, a "lung specific" nucleic acid molecule or polypeptide is  
25 expressed at a level that is 5-fold higher than any other tissue in the body. In a more preferred embodiment, the "lung specific" nucleic acid molecule or polypeptide is expressed at a level that is 10-fold higher than any other tissue in the body, more preferably at least 15-fold, 20-fold, 25-fold, 50-fold or 100-fold higher than any other tissue in the body. Nucleic acid molecule levels may be measured by nucleic acid  
30 hybridization, such as Northern blot hybridization, or quantitative PCR. Polypeptide levels may be measured by any method known to accurately quantitate protein levels, such as Western blot analysis.



Nucleic Acid Molecules, Regulatory Sequences, Vectors, Host Cells and Recombinant Methods of Making Polypeptides

*Nucleic Acid Molecules*

5           One aspect of the invention provides isolated nucleic acid molecules that are specific to the lung or to lung cells or tissue or that are derived from such nucleic acid molecules. These isolated lung specific nucleic acids (LSNAs) may comprise a cDNA, a genomic DNA, RNA, or a fragment of one of these nucleic acids, or may be a non-naturally-occurring nucleic acid molecule. In a preferred embodiment, the nucleic acid  
10 molecule encodes a polypeptide that is specific to lung, a lung-specific polypeptide (LSP). In a more preferred embodiment, the nucleic acid molecule encodes a polypeptide that comprises an amino acid sequence of SEQ ID NO: 143 through 277. In another highly preferred embodiment, the nucleic acid molecule comprises a nucleic acid sequence of SEQ ID NO: 1 through 142.

15           An LSNA may be derived from a human or from another animal. In a preferred embodiment, the LSNA is derived from a human or other mammal. In a more preferred embodiment, the LSNA is derived from a human or other primate. In an even more preferred embodiment, the LSNA is derived from a human.

          By "nucleic acid molecule" for purposes of the present invention, it is also meant  
20 to be inclusive of nucleic acid sequences that selectively hybridize to a nucleic acid molecule encoding an LSNA or a complement thereof. The hybridizing nucleic acid molecule may or may not encode a polypeptide or may not encode an LSP. However, in a preferred embodiment, the hybridizing nucleic acid molecule encodes an LSP. In a more preferred embodiment, the invention provides a nucleic acid molecule that  
25 selectively hybridizes to a nucleic acid molecule that encodes a polypeptide comprising an amino acid sequence of SEQ ID NO: 143 through 277. In an even more preferred embodiment, the invention provides a nucleic acid molecule that selectively hybridizes to a nucleic acid molecule comprising the nucleic acid sequence of SEQ ID NO: 1 through 142.

30           In a preferred embodiment, the nucleic acid molecule selectively hybridizes to a nucleic acid molecule encoding an LSP under low stringency conditions. In a more preferred embodiment, the nucleic acid molecule selectively hybridizes to a nucleic acid molecule encoding an LSP under moderate stringency conditions. In a more preferred

embodiment, the nucleic acid molecule selectively hybridizes to a nucleic acid molecule encoding an LSP under high stringency conditions. In an even more preferred embodiment, the nucleic acid molecule hybridizes under low, moderate or high stringency conditions to a nucleic acid molecule encoding a polypeptide comprising an amino acid sequence of SEQ ID NO: 143 through 277. In a yet more preferred embodiment, the nucleic acid molecule hybridizes under low, moderate or high stringency conditions to a nucleic acid molecule comprising a nucleic acid sequence selected from SEQ ID NO: 1 through 142. In a preferred embodiment of the invention, the hybridizing nucleic acid molecule may be used to express recombinantly a polypeptide of the invention.

By "nucleic acid molecule" as used herein it is also meant to be inclusive of sequences that exhibits substantial sequence similarity to a nucleic acid encoding an LSP or a complement of the encoding nucleic acid molecule. In a preferred embodiment, the nucleic acid molecule exhibits substantial sequence similarity to a nucleic acid molecule encoding human LSP. In a more preferred embodiment, the nucleic acid molecule exhibits substantial sequence similarity to a nucleic acid molecule encoding a polypeptide having an amino acid sequence of SEQ ID NO: 143 through 277. In a preferred embodiment, the similar nucleic acid molecule is one that has at least 60% sequence identity with a nucleic acid molecule encoding an LSP, such as a polypeptide having an amino acid sequence of SEQ ID NO: 143 through 277, more preferably at least 70%, even more preferably at least 80% and even more preferably at least 85%. In a more preferred embodiment, the similar nucleic acid molecule is one that has at least 90% sequence identity with a nucleic acid molecule encoding an LSP, more preferably at least 95%, more preferably at least 97%, even more preferably at least 98%, and still more preferably at least 99%. In another highly preferred embodiment, the nucleic acid molecule is one that has at least 99.5%, 99.6%, 99.7%, 99.8% or 99.9% sequence identity with a nucleic acid molecule encoding an LSP.

In another preferred embodiment, the nucleic acid molecule exhibits substantial sequence similarity to an LSNA or its complement. In a more preferred embodiment, the nucleic acid molecule exhibits substantial sequence similarity to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1 through 142. In a preferred embodiment, the nucleic acid molecule is one that has at least 60% sequence identity

with an LSNA, such as one having a nucleic acid sequence of SEQ ID NO: 1 through 142, more preferably at least 70%, even more preferably at least 80% and even more preferably at least 85%. In a more preferred embodiment, the nucleic acid molecule is one that has at least 90% sequence identity with an LSNA, more preferably at least 95%,  
5 more preferably at least 97%, even more preferably at least 98%, and still more preferably at least 99%. In another highly preferred embodiment, the nucleic acid molecule is one that has at least 99.5%, 99.6%, 99.7%, 99.8% or 99.9% sequence identity with an LSNA.

A nucleic acid molecule that exhibits substantial sequence similarity may be one  
10 that exhibits sequence identity over its entire length to an LSNA or to a nucleic acid molecule encoding an LSP, or may be one that is similar over only a part of its length. In this case, the part is at least 50 nucleotides of the LSNA or the nucleic acid molecule encoding an LSP, preferably at least 100 nucleotides, more preferably at least 150 or 200 nucleotides, even more preferably at least 250 or 300 nucleotides, still more preferably at  
15 least 400 or 500 nucleotides.

The substantially similar nucleic acid molecule may be a naturally-occurring one that is derived from another species, especially one derived from another primate, wherein the similar nucleic acid molecule encodes an amino acid sequence that exhibits significant sequence identity to that of SEQ ID NO: 143 through 277 or demonstrates  
20 significant sequence identity to the nucleotide sequence of SEQ ID NO: 1 through 142. The similar nucleic acid molecule may also be a naturally-occurring nucleic acid molecule from a human, when the LSNA is a member of a gene family. The similar nucleic acid molecule may also be a naturally-occurring nucleic acid molecule derived from a non-primate, mammalian species, including without limitation, domesticated  
25 species, *e.g.*, dog, cat, mouse, rat, rabbit, hamster, cow, horse and pig; and wild animals, *e.g.*, monkey, fox, lions, tigers, bears, giraffes, zebras, etc. The substantially similar nucleic acid molecule may also be a naturally-occurring nucleic acid molecule derived from a non-mammalian species, such as birds or reptiles. The naturally-occurring substantially similar nucleic acid molecule may be isolated directly from humans or other  
30 species. In another embodiment, the substantially similar nucleic acid molecule may be one that is experimentally produced by random mutation of a nucleic acid molecule. In another embodiment, the substantially similar nucleic acid molecule may be one that is

experimentally produced by directed mutation of an LSNA. Further, the substantially similar nucleic acid molecule may or may not be an LSNA. However, in a preferred embodiment, the substantially similar nucleic acid molecule is an LSNA.

By "nucleic acid molecule" it is also meant to be inclusive of allelic variants of an LSNA or a nucleic acid encoding an LSP. For instance, single nucleotide polymorphisms (SNPs) occur frequently in eukaryotic genomes. In fact, more than 1.4 million SNPs have already identified in the human genome, International Human Genome Sequencing Consortium, *Nature* 409: 860-921 (2001). Thus, the sequence determined from one individual of a species may differ from other allelic forms present within the population. Additionally, small deletions and insertions, rather than single nucleotide polymorphisms, are not uncommon in the general population, and often do not alter the function of the protein. Further, amino acid substitutions occur frequently among natural allelic variants, and often do not substantially change protein function.

In a preferred embodiment, the nucleic acid molecule comprising an allelic variant is a variant of a gene, wherein the gene is transcribed into an mRNA that encodes an LSP. In a more preferred embodiment, the gene is transcribed into an mRNA that encodes an LSP comprising an amino acid sequence of SEQ ID NO: 143 through 277. In another preferred embodiment, the allelic variant is a variant of a gene, wherein the gene is transcribed into an mRNA that is an LSNA. In a more preferred embodiment, the gene is transcribed into an mRNA that comprises the nucleic acid sequence of SEQ ID NO: 1 through 142. In a preferred embodiment, the allelic variant is a naturally-occurring allelic variant in the species of interest. In a more preferred embodiment, the species of interest is human.

By "nucleic acid molecule" it is also meant to be inclusive of a part of a nucleic acid sequence of the instant invention. The part may or may not encode a polypeptide, and may or may not encode a polypeptide that is an LSP. However, in a preferred embodiment, the part encodes an LSP. In one aspect, the invention comprises a part of an LSNA. In a second aspect, the invention comprises a part of a nucleic acid molecule that hybridizes or exhibits substantial sequence similarity to an LSNA. In a third aspect, the invention comprises a part of a nucleic acid molecule that is an allelic variant of an LSNA. In a fourth aspect, the invention comprises a part of a nucleic acid molecule that encodes an LSP. A part comprises at least 10 nucleotides, more preferably at least 15,

17, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400 or 500 nucleotides. The maximum size of a nucleic acid part is one nucleotide shorter than the sequence of the nucleic acid molecule encoding the full-length protein.

By "nucleic acid molecule" it is also meant to be inclusive of sequence that  
5 encoding a fusion protein, a homologous protein, a polypeptide fragment, a mutein or a polypeptide analog, as described below.

Nucleotide sequences of the instantly-described nucleic acids were determined by sequencing a DNA molecule that had resulted, directly or indirectly, from at least one enzymatic polymerization reaction (e.g., reverse transcription and/or polymerase chain  
10 reaction) using an automated sequencer (such as the MegaBACE™ 1000, Molecular Dynamics, Sunnyvale, CA, USA). Further, all amino acid sequences of the polypeptides of the present invention were predicted by translation from the nucleic acid sequences so determined, unless otherwise specified.

In a preferred embodiment of the invention, the nucleic acid molecule contains  
15 modifications of the native nucleic acid molecule. These modifications include nonnative internucleoside bonds, post-synthetic modifications or altered nucleotide analogues. One having ordinary skill in the art would recognize that the type of modification that can be made will depend upon the intended use of the nucleic acid molecule. For instance, when the nucleic acid molecule is used as a hybridization probe,  
20 the range of such modifications will be limited to those that permit sequence-discriminating base pairing of the resulting nucleic acid. When used to direct expression of RNA or protein *in vitro* or *in vivo*, the range of such modifications will be limited to those that permit the nucleic acid to function properly as a polymerization substrate. When the isolated nucleic acid is used as a therapeutic agent, the modifications will be  
25 limited to those that do not confer toxicity upon the isolated nucleic acid.

In a preferred embodiment, isolated nucleic acid molecules can include nucleotide analogues that incorporate labels that are directly detectable, such as radiolabels or fluorophores, or nucleotide analogues that incorporate labels that can be visualized in a subsequent reaction, such as biotin or various haptens. In a more preferred embodiment,  
30 the labeled nucleic acid molecule may be used as a hybridization probe.

Common radiolabeled analogues include those labeled with  $^{33}\text{P}$ ,  $^{32}\text{P}$ , and  $^{35}\text{S}$ , such as  $^{-32}\text{P}$ -dATP,  $^{-32}\text{P}$ -dCTP,  $^{-32}\text{P}$ -dGTP,  $^{-32}\text{P}$ -dTTP,  $^{-32}\text{P}$ -3'dATP,  $^{-32}\text{P}$ -ATP,  $^{-32}\text{P}$ -CTP,  $^{-32}\text{P}$ -GTP,  $^{-32}\text{P}$ -UTP,  $^{-35}\text{S}$ -dATP,  $\alpha$ - $^{35}\text{S}$ -GTP,  $\alpha$ - $^{33}\text{P}$ -dATP, and the like.

Commercially available fluorescent nucleotide analogues readily incorporated into the nucleic acids of the present invention include Cy3-dCTP, Cy3-dUTP, Cy5-dCTP, Cy3-dUTP (Amersham Pharmacia Biotech, Piscataway, New Jersey, USA), fluorescein-12-dUTP, tetramethylrhodamine-6-dUTP, Texas Red®-5-dUTP, Cascade Blue®-7-dUTP, BODIPY® FL-14-dUTP, BODIPY® TMR-14-dUTP, BODIPY® TR-14-dUTP, Rhodamine Green™-5-dUTP, Oregon Green® 488-5-dUTP, Texas Red®-12-dUTP, BODIPY® 630/650-14-dUTP, BODIPY® 650/665-14-dUTP, Alexa Fluor® 488-5-dUTP, Alexa Fluor® 532-5-dUTP, Alexa Fluor® 568-5-dUTP, Alexa Fluor® 594-5-dUTP, Alexa Fluor® 546-14-dUTP, fluorescein-12-UTP, tetramethylrhodamine-6-UTP, Texas Red®-5-UTP, Cascade Blue®-7-UTP, BODIPY® FL-14-UTP, BODIPY® TMR-14-UTP, BODIPY® TR-14-UTP, Rhodamine Green™-5-UTP, Alexa Fluor® 488-5-UTP, Alexa Fluor® 546-14-UTP (Molecular Probes, Inc. Eugene, OR, USA). One may also custom synthesize nucleotides having other fluorophores. See Henegariu *et al.*, *Nature Biotechnol.* 18: 345-348 (2000), the disclosure of which is incorporated herein by reference in its entirety.

Haptens that are commonly conjugated to nucleotides for subsequent labeling include biotin (biotin-11-dUTP, Molecular Probes, Inc., Eugene, OR, USA; biotin-21-UTP, biotin-21-dUTP, Clontech Laboratories, Inc., Palo Alto, CA, USA), digoxigenin (DIG-11-dUTP, alkali labile, DIG-11-UTP, Roche Diagnostics Corp., Indianapolis, IN, USA), and dinitrophenyl (dinitrophenyl-11-dUTP, Molecular Probes, Inc., Eugene, OR, USA).

Nucleic acid molecules can be labeled by incorporation of labeled nucleotide analogues into the nucleic acid. Such analogues can be incorporated by enzymatic polymerization, such as by nick translation, random priming, polymerase chain reaction (PCR), terminal transferase tailing, and end-filling of overhangs, for DNA molecules, and *in vitro* transcription driven, *e.g.*, from phage promoters, such as T7, T3, and SP6, for RNA molecules. Commercial kits are readily available for each such labeling approach. Analogues can also be incorporated during automated solid phase chemical synthesis. Labels can also be incorporated after nucleic acid synthesis, with the 5' phosphate and 3'

hydroxyl providing convenient sites for post-synthetic covalent attachment of detectable labels.

Other post-synthetic approaches also permit internal labeling of nucleic acids. For example, fluorophores can be attached using a cisplatin reagent that reacts with the N7 of guanine residues (and, to a lesser extent, adenine bases) in DNA, RNA, and PNA to provide a stable coordination complex between the nucleic acid and fluorophore label (Universal Linkage System) (available from Molecular Probes, Inc., Eugene, OR, USA and Amersham Pharmacia Biotech, Piscataway, NJ, USA); see Alers *et al.*, *Genes, Chromosomes & Cancer* 25: 301- 305 (1999); Jelsma *et al.*, *J. NIH Res.* 5: 82 (1994); Van Belkum *et al.*, *BioTechniques* 16: 148-153 (1994), incorporated herein by reference. As another example, nucleic acids can be labeled using a disulfide-containing linker (FastTag™ Reagent, Vector Laboratories, Inc., Burlingame, CA, USA) that is photo- or thermally-coupled to the target nucleic acid using aryl azide chemistry; after reduction, a free thiol is available for coupling to a hapten, fluorophore, sugar, affinity ligand, or other marker.

One or more independent or interacting labels can be incorporated into the nucleic acid molecules of the present invention. For example, both a fluorophore and a moiety that in proximity thereto acts to quench fluorescence can be included to report specific hybridization through release of fluorescence quenching or to report exonucleotidic excision. See, e.g., Tyagi *et al.*, *Nature Biotechnol.* 14: 303-308 (1996); Tyagi *et al.*, *Nature Biotechnol.* 16: 49-53 (1998); Sokol *et al.*, *Proc. Natl. Acad. Sci. USA* 95: 11538-11543 (1998); Kostrikis *et al.*, *Science* 279: 1228-1229 (1998); Marras *et al.*, *Genet. Anal.* 14: 151-156 (1999); U. S. Patent 5,846,726; 5,925,517; 5,925,517; 5,723,591 and 5,538,848; Holland *et al.*, *Proc. Natl. Acad. Sci. USA* 88: 7276-7280 (1991); Heid *et al.*, *Genome Res.* 6(10): 986-94 (1996); Kuimelis *et al.*, *Nucleic Acids Symp. Ser.* (37): 255-6 (1997); the disclosures of which are incorporated herein by reference in their entireties.

Nucleic acid molecules of the invention may be modified by altering one or more native phosphodiester internucleoside bonds to more nuclease-resistant, internucleoside bonds. See Hartmann *et al.* (eds.), Manual of Antisense Methodology: Perspectives in Antisense Science, Kluwer Law International (1999); Stein *et al.* (eds.), Applied Antisense Oligonucleotide Technology, Wiley-Liss (1998); Chadwick *et al.* (eds.),

Oligonucleotides as Therapeutic Agents - Symposium No. 209, John Wiley & Son Ltd (1997); the disclosures of which are incorporated herein by reference in their entireties. Such altered internucleoside bonds are often desired for antisense techniques or for targeted gene correction. See Gamper *et al.*, *Nucl. Acids Res.* 28(21): 4332-4339 (2000),  
5 the disclosure of which is incorporated herein by reference in its entirety.

Modified oligonucleotide backbones include, without limitation, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including  
10 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Representative United States patents that teach the preparation of the above  
15 phosphorus-containing linkages include, but are not limited to, U. S. Patents 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050, the disclosures of which are incorporated herein by  
20 reference in their entireties. In a preferred embodiment, the modified internucleoside linkages may be used for antisense techniques.

Other modified oligonucleotide backbones do not include a phosphorus atom, but have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or  
25 more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and  
30 methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH<sub>2</sub> component parts. Representative U.S. patents that teach the preparation of the above backbones include, but are not limited to, U.S.



Patent 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437 and 5,677,439; the disclosures of which are incorporated herein by reference in their entireties.

In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage are replaced with novel groups, such as peptide nucleic acids (PNA). In PNA compounds, the phosphodiester backbone of the nucleic acid is replaced with an amide-containing backbone, in particular by repeating N-(2-aminoethyl) glycine units linked by amide bonds. Nucleobases are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone, typically by methylene carbonyl linkages. PNA can be synthesized using a modified peptide synthesis protocol. PNA oligomers can be synthesized by both Fmoc and tBoc methods. Representative U.S. patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Patent 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Automated PNA synthesis is readily achievable on commercial synthesizers (see, e.g., "PNA User's Guide," Rev. 2, February 1998, Perseptive Biosystems Part No. 60138, Applied Biosystems, Inc., Foster City, CA).

PNA molecules are advantageous for a number of reasons. First, because the PNA backbone is uncharged, PNA/DNA and PNA/RNA duplexes have a higher thermal stability than is found in DNA/DNA and DNA/RNA duplexes. The  $T_m$  of a PNA/DNA or PNA/RNA duplex is generally 1°C higher per base pair than the  $T_m$  of the corresponding DNA/DNA or DNA/RNA duplex (in 100 mM NaCl). Second, PNA molecules can also form stable PNA/DNA complexes at low ionic strength, under conditions in which DNA/DNA duplex formation does not occur. Third, PNA also demonstrates greater specificity in binding to complementary DNA because a PNA/DNA mismatch is more destabilizing than DNA/DNA mismatch. A single mismatch in mixed a PNA/DNA 15-mer lowers the  $T_m$  by 8–20°C (15°C on average). In the corresponding DNA/DNA duplexes, a single mismatch lowers the  $T_m$  by 4–16°C (11°C on average). Because PNA probes can be significantly shorter than DNA probes, their specificity is greater. Fourth, PNA oligomers are resistant to degradation by enzymes, and the lifetime of these compounds is extended both *in vivo* and *in vitro* because nucleases and proteases

do not recognize the PNA polyamide backbone with nucleobase sidechains. *See, e.g.,* Ray *et al.*, *FASEB J.* 14(9): 1041-60 (2000); Nielsen *et al.*, *Pharmacol Toxicol.* 86(1): 3-7 (2000); Larsen *et al.*, *Biochim Biophys Acta.* 1489(1): 159-66 (1999); Nielsen, *Curr. Opin. Struct. Biol.* 9(3): 353-7 (1999), and Nielsen, *Curr. Opin. Biotechnol.* 10(1): 71-5  
5 (1999), the disclosures of which are incorporated herein by reference in their entireties.

Nucleic acid molecules may be modified compared to their native structure throughout the length of the nucleic acid molecule or can be localized to discrete portions thereof. As an example of the latter, chimeric nucleic acids can be synthesized that have discrete DNA and RNA domains and that can be used for targeted gene repair and  
10 modified PCR reactions, as further described in U.S. Patents 5,760,012 and 5,731,181, Misra *et al.*, *Biochem.* 37: 1917-1925 (1998); and Finn *et al.*, *Nucl. Acids Res.* 24: 3357-3363 (1996), the disclosures of which are incorporated herein by reference in their entireties.

Unless otherwise specified, nucleic acids of the present invention can include any  
15 topological conformation appropriate to the desired use; the term thus explicitly comprehends, among others, single-stranded, double-stranded, triplexed, quadruplexed, partially double-stranded, partially-triplexed, partially-quadruplexed, branched, hairpinned, circular, and padlocked conformations. Padlock conformations and their utilities are further described in Banér *et al.*, *Curr. Opin. Biotechnol.* 12: 11-15 (2001);  
20 Escude *et al.*, *Proc. Natl. Acad. Sci. USA* 14: 96(19):10603-7 (1999); Nilsson *et al.*, *Science* 265(5181): 2085-8 (1994), the disclosures of which are incorporated herein by reference in their entireties. Triplex and quadruplex conformations, and their utilities, are reviewed in Praseuth *et al.*, *Biochim. Biophys. Acta.* 1489(1): 181-206 (1999); Fox, *Curr. Med. Chem.* 7(1): 17-37 (2000); Kochetkova *et al.*, *Methods Mol. Biol.* 130: 189-201  
25 (2000); Chan *et al.*, *J. Mol. Med.* 75(4): 267-82 (1997), the disclosures of which are incorporated herein by reference in their entireties.

#### *Methods for Using Nucleic Acid Molecules as Probes and Primers*

The isolated nucleic acid molecules of the present invention can be used as  
30 hybridization probes to detect, characterize, and quantify hybridizing nucleic acids in, and isolate hybridizing nucleic acids from, both genomic and transcript-derived nucleic acid samples. When free in solution, such probes are typically, but not invariably,

detectably labeled; bound to a substrate, as in a microarray, such probes are typically, but not invariably unlabeled.

In one embodiment, the isolated nucleic acids of the present invention can be used as probes to detect and characterize gross alterations in the gene of an LSNA, such as deletions, insertions, translocations, and duplications of the LSNA genomic locus through fluorescence *in situ* hybridization (FISH) to chromosome spreads. *See, e.g.,* Andreeff *et al.* (eds.), Introduction to Fluorescence In Situ Hybridization: Principles and Clinical Applications, John Wiley & Sons (1999), the disclosure of which is incorporated herein by reference in its entirety. The isolated nucleic acids of the present invention can be used as probes to assess smaller genomic alterations using, *e.g.*, Southern blot detection of restriction fragment length polymorphisms. The isolated nucleic acid molecules of the present invention can be used as probes to isolate genomic clones that include the nucleic acid molecules of the present invention, which thereafter can be restriction mapped and sequenced to identify deletions, insertions, translocations, and substitutions (single nucleotide polymorphisms, SNPs) at the sequence level.

In another embodiment, the isolated nucleic acid molecules of the present invention can be used as probes to detect, characterize, and quantify LSNA in, and isolate LSNA from, transcript-derived nucleic acid samples. In one aspect, the isolated nucleic acid molecules of the present invention can be used as hybridization probes to detect, characterize by length, and quantify mRNA by Northern blot of total or poly-A<sup>+</sup>- selected RNA samples. In another aspect, the isolated nucleic acid molecules of the present invention can be used as hybridization probes to detect, characterize by location, and quantify mRNA by *in situ* hybridization to tissue sections. *See, e.g.,* Schvarczacher *et al.*, In Situ Hybridization, Springer-Verlag New York (2000), the disclosure of which is incorporated herein by reference in its entirety. In another preferred embodiment, the isolated nucleic acid molecules of the present invention can be used as hybridization probes to measure the representation of clones in a cDNA library or to isolate hybridizing nucleic acid molecules acids from cDNA libraries, permitting sequence level characterization of mRNAs that hybridize to LSNAs, including, without limitations, identification of deletions, insertions, substitutions, truncations, alternatively spliced forms and single nucleotide polymorphisms. In yet another preferred embodiment, the nucleic acid molecules of the instant invention may be used in microarrays.

All of the aforementioned probe techniques are well within the skill in the art, and are described at greater length in standard texts such as Sambrook (2001), *supra*; Ausubel (1999), *supra*; and Walker *et al.* (eds.), The Nucleic Acids Protocols Handbook, Humana Press (2000), the disclosures of which are incorporated herein by reference in  
5 their entirety.

Thus, in one embodiment, a nucleic acid molecule of the invention may be used as a probe or primer to identify or amplify a second nucleic acid molecule that selectively hybridizes to the nucleic acid molecule of the invention. In a preferred embodiment, the probe or primer is derived from a nucleic acid molecule encoding an LSP. In a more  
10 preferred embodiment, the probe or primer is derived from a nucleic acid molecule encoding a polypeptide having an amino acid sequence of SEQ ID NO: 143 through 277. In another preferred embodiment, the probe or primer is derived from an LSNA. In a more preferred embodiment, the probe or primer is derived from a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1 through 142.

15 In general, a probe or primer is at least 10 nucleotides in length, more preferably at least 12, more preferably at least 14 and even more preferably at least 16 or 17 nucleotides in length. In an even more preferred embodiment, the probe or primer is at least 18 nucleotides in length, even more preferably at least 20 nucleotides and even more preferably at least 22 nucleotides in length. Primers and probes may also be longer  
20 in length. For instance, a probe or primer may be 25 nucleotides in length, or may be 30, 40 or 50 nucleotides in length. Methods of performing nucleic acid hybridization using oligonucleotide probes are well-known in the art. *See, e.g.*, Sambrook *et al.*, 1989, *supra*, Chapter 11 and pp. 11.31-11.32 and 11.40-11.44, which describes radiolabeling of short probes, and pp. 11.45-11.53, which describe hybridization conditions for oligonucleotide  
25 probes, including specific conditions for probe hybridization (pp. 11.50-11.51).

Methods of performing primer-directed amplification are also well-known in the art. Methods for performing the polymerase chain reaction (PCR) are compiled, *inter alia*, in McPherson, PCR Basics: From Background to Bench, Springer Verlag (2000); Innis *et al.* (eds.), PCR Applications: Protocols for Functional Genomics, Academic  
30 Press (1999); Gelfand *et al.* (eds.), PCR Strategies, Academic Press (1998); Newton *et al.*, PCR, Springer-Verlag New York (1997); Burke (ed.), PCR: Essential Techniques, John Wiley & Son Ltd (1996); White (ed.), PCR Cloning Protocols: From Molecular

Cloning to Genetic Engineering, Vol. 67, Humana Press (1996); McPherson *et al.* (eds.), PCR 2: A Practical Approach, Oxford University Press, Inc. (1995); the disclosures of which are incorporated herein by reference in their entireties. Methods for performing RT-PCR are collected, *e.g.*, in Siebert *et al.* (eds.), Gene Cloning and Analysis by RT-PCR, Eaton Publishing Company/Bio Techniques Books Division, 1998; Siebert (ed.), PCR Technique: RT-PCR, Eaton Publishing Company/ BioTechniques Books (1995); the disclosure of which is incorporated herein by reference in its entirety.

PCR and hybridization methods may be used to identify and/or isolate allelic variants, homologous nucleic acid molecules and fragments of the nucleic acid molecules of the invention. PCR and hybridization methods may also be used to identify, amplify and/or isolate nucleic acid molecules that encode homologous proteins, analogs, fusion protein or muteins of the invention. The nucleic acid primers of the present invention can be used to prime amplification of nucleic acid molecules of the invention, using transcript-derived or genomic DNA as template.

The nucleic acid primers of the present invention can also be used, for example, to prime single base extension (SBE) for SNP detection (*See, e.g.*, U.S. Patent 6,004,744, the disclosure of which is incorporated herein by reference in its entirety).

Isothermal amplification approaches, such as rolling circle amplification, are also now well-described. *See, e.g.*, Schweitzer *et al.*, *Curr. Opin. Biotechnol.* 12(1): 21-7 (2001); U.S. Patents 5,854,033 and 5,714,320; and international patent publications WO 97/19193 and WO 00/15779, the disclosures of which are incorporated herein by reference in their entireties. Rolling circle amplification can be combined with other techniques to facilitate SNP detection. *See, e.g.*, Lizardi *et al.*, *Nature Genet.* 19(3): 225-32 (1998).

Nucleic acid molecules of the present invention may be bound to a substrate either covalently or noncovalently. The substrate can be porous or solid, planar or non-planar, unitary or distributed. The bound nucleic acid molecules may be used as hybridization probes, and may be labeled or unlabeled. In a preferred embodiment, the bound nucleic acid molecules are unlabeled.

In one embodiment, the nucleic acid molecule of the present invention is bound to a porous substrate, *e.g.*, a membrane, typically comprising nitrocellulose, nylon, or positively-charged derivatized nylon. The nucleic acid molecule of the present invention

can be used to detect a hybridizing nucleic acid molecule that is present within a labeled nucleic acid sample, *e.g.*, a sample of transcript-derived nucleic acids. In another embodiment, the nucleic acid molecule is bound to a solid substrate, including, without limitation, glass, amorphous silicon, crystalline silicon or plastics. Examples of plastics include, without limitation, polymethylacrylic, polyethylene, polypropylene, polyacrylate, polymethylmethacrylate, polyvinylchloride, polytetrafluoroethylene, polystyrene, polycarbonate, polyacetal, polysulfone, celluloseacetate, cellulosenitrate, nitrocellulose, or mixtures thereof. The solid substrate may be any shape, including rectangular, disk-like and spherical. In a preferred embodiment, the solid substrate is a microscope slide or slide-shaped substrate.

The nucleic acid molecule of the present invention can be attached covalently to a surface of the support substrate or applied to a derivatized surface in a chaotropic agent that facilitates denaturation and adherence by presumed noncovalent interactions, or some combination thereof. The nucleic acid molecule of the present invention can be bound to a substrate to which a plurality of other nucleic acids are concurrently bound, hybridization to each of the plurality of bound nucleic acids being separately detectable. At low density, *e.g.* on a porous membrane, these substrate-bound collections are typically denominated macroarrays; at higher density, typically on a solid support, such as glass, these substrate bound collections of plural nucleic acids are colloquially termed microarrays. As used herein, the term microarray includes arrays of all densities. It is, therefore, another aspect of the invention to provide microarrays that include the nucleic acids of the present invention.

#### *Expression Vectors, Host Cells and Recombinant Methods of Producing Polypeptides*

Another aspect of the present invention relates to vectors that comprise one or more of the isolated nucleic acid molecules of the present invention, and host cells in which such vectors have been introduced.

The vectors can be used, *inter alia*, for propagating the nucleic acids of the present invention in host cells (cloning vectors), for shuttling the nucleic acids of the present invention between host cells derived from disparate organisms (shuttle vectors), for inserting the nucleic acids of the present invention into host cell chromosomes (insertion vectors), for expressing sense or antisense RNA transcripts of the nucleic acids of the present invention *in vitro* or within a host cell, and for expressing polypeptides

encoded by the nucleic acids of the present invention, alone or as fusions to heterologous polypeptides (expression vectors). Vectors of the present invention will often be suitable for several such uses.

Vectors are by now well-known in the art, and are described, *inter alia*, in Jones  
5 *et al.* (eds.), Vectors: Cloning Applications: Essential Techniques (Essential Techniques Series), John Wiley & Son Ltd. (1998); Jones *et al.* (eds.), Vectors: Expression Systems: Essential Techniques (Essential Techniques Series), John Wiley & Son Ltd. (1998); Gacesa *et al.*, Vectors: Essential Data, John Wiley & Sons Ltd. (1995); Cid-Arregui (eds.), Viral Vectors: Basic Science and Gene Therapy, Eaton Publishing Co. (2000);  
10 Sambrook (2001), *supra*; Ausubel (1999), *supra*; the disclosures of which are incorporated herein by reference in their entireties. Furthermore, an enormous variety of vectors are available commercially. Use of existing vectors and modifications thereof being well within the skill in the art, only basic features need be described here.

Nucleic acid sequences may be expressed by operatively linking them to an  
15 expression control sequence in an appropriate expression vector and employing that expression vector to transform an appropriate unicellular host. Expression control sequences are sequences which control the transcription, post-transcriptional events and translation of nucleic acid sequences. Such operative linking of a nucleic sequence of this invention to an expression control sequence, of course, includes, if not already part  
20 of the nucleic acid sequence, the provision of a translation initiation codon, ATG or GTG, in the correct reading frame upstream of the nucleic acid sequence.

A wide variety of host/expression vector combinations may be employed in expressing the nucleic acid sequences of this invention. Useful expression vectors, for example, may consist of segments of chromosomal, non-chromosomal and synthetic  
25 nucleic acid sequences.

In one embodiment, prokaryotic cells may be used with an appropriate vector. Prokaryotic host cells are often used for cloning and expression. In a preferred embodiment, prokaryotic host cells include *E. coli*, *Pseudomonas*, *Bacillus* and *Streptomyces*. In a preferred embodiment, bacterial host cells are used to express the  
30 nucleic acid molecules of the instant invention. Useful expression vectors for bacterial hosts include bacterial plasmids, such as those from *E. coli*, *Bacillus* or *Streptomyces*, including pBluescript, pGEX-2T, pUC vectors, col E1, pCR1, pBR322, pMB9 and their

derivatives, wider host range plasmids, such as RP4, phage DNAs, *e.g.*, the numerous derivatives of phage lambda, *e.g.*, NM989,  $\lambda$ GT10 and  $\lambda$ GT11, and other phages, *e.g.*, M13 and filamentous single-stranded phage DNA. Where *E. coli* is used as host, selectable markers are, analogously, chosen for selectivity in gram negative bacteria: *e.g.*,  
5 typical markers confer resistance to antibiotics, such as ampicillin, tetracycline, chloramphenicol, kanamycin, streptomycin and zeocin; auxotrophic markers can also be used.

In other embodiments, eukaryotic host cells, such as yeast, insect, mammalian or plant cells, may be used. Yeast cells, typically *S. cerevisiae*, are useful for eukaryotic  
10 genetic studies, due to the ease of targeting genetic changes by homologous recombination and the ability to easily complement genetic defects using recombinantly expressed proteins. Yeast cells are useful for identifying interacting protein components, *e.g.* through use of a two-hybrid system. In a preferred embodiment, yeast cells are useful for protein expression. Vectors of the present invention for use in yeast will  
15 typically, but not invariably, contain an origin of replication suitable for use in yeast and a selectable marker that is functional in yeast. Yeast vectors include Yeast Integrating plasmids (*e.g.*, YIp5) and Yeast Replicating plasmids (the YRp and YEplac series plasmids), Yeast Centromere plasmids (the YCp series plasmids), Yeast Artificial Chromosomes (YACs) which are based on yeast linear plasmids, denoted YLp, pGPD-2,  
20 2 $\mu$  plasmids and derivatives thereof, and improved shuttle vectors such as those described in Gietz *et al.*, *Gene*, 74: 527-34 (1988) (YIplac, YEplac and YCplac). Selectable markers in yeast vectors include a variety of auxotrophic markers, the most common of which are (in *Saccharomyces cerevisiae*) URA3, HIS3, LEU2, TRP1 and LYS2, which complement specific auxotrophic mutations, such as *ura3-52*, *his3-D1*,  
25 *leu2-D1*, *trp1-D1* and *lys2-201*.

Insect cells are often chosen for high efficiency protein expression. Where the host cells are from *Spodoptera frugiperda*, *e.g.*, Sf9 and Sf21 cell lines, and expresSFTM cells (Protein Sciences Corp., Meriden, CT, USA)), the vector replicative strategy is typically based upon the baculovirus life cycle. Typically, baculovirus transfer vectors  
30 are used to replace the wild-type AcMNPV polyhedrin gene with a heterologous gene of interest. Sequences that flank the polyhedrin gene in the wild-type genome are positioned 5' and 3' of the expression cassette on the transfer vectors. Following co-



transfection with AcMNPV DNA, a homologous recombination event occurs between these sequences resulting in a recombinant virus carrying the gene of interest and the polyhedrin or p10 promoter. Selection can be based upon visual screening for lacZ fusion activity.

5 In another embodiment, the host cells may be mammalian cells, which are particularly useful for expression of proteins intended as pharmaceutical agents, and for screening of potential agonists and antagonists of a protein or a physiological pathway. Mammalian vectors intended for autonomous extrachromosomal replication will typically include a viral origin, such as the SV40 origin (for replication in cell lines  
10 expressing the large T-antigen, such as COS1 and COS7 cells), the papillomavirus origin, or the EBV origin for long term episomal replication (for use, *e.g.*, in 293-EBNA cells, which constitutively express the EBV EBNA-1 gene product and adenovirus E1A). Vectors intended for integration, and thus replication as part of the mammalian chromosome, can, but need not, include an origin of replication functional in mammalian  
15 cells, such as the SV40 origin. Vectors based upon viruses, such as adenovirus, adeno-associated virus, vaccinia virus, and various mammalian retroviruses, will typically replicate according to the viral replicative strategy. Selectable markers for use in mammalian cells include resistance to neomycin (G418), blasticidin, hygromycin and to zeocin, and selection based upon the purine salvage pathway using HAT medium.

20 Expression in mammalian cells can be achieved using a variety of plasmids, including pSV2, pBC12BI, and p91023, as well as lytic virus vectors (*e.g.*, vaccinia virus, adeno virus, and baculovirus), episomal virus vectors (*e.g.*, bovine papillomavirus), and retroviral vectors (*e.g.*, murine retroviruses). Useful vectors for insect cells include baculoviral vectors and pVL 941.

25 Plant cells can also be used for expression, with the vector replicon typically derived from a plant virus (*e.g.*, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) and selectable markers chosen for suitability in plants.

It is known that codon usage of different host cells may be different. For example, a plant cell and a human cell may exhibit a difference in codon preference for  
30 encoding a particular amino acid. As a result, human mRNA may not be efficiently translated in a plant, bacteria or insect host cell. Therefore, another embodiment of this invention is directed to codon optimization. The codons of the nucleic acid molecules of

the invention may be modified to resemble, as much as possible, genes naturally contained within the host cell without altering the amino acid sequence encoded by the nucleic acid molecule.

Any of a wide variety of expression control sequences may be used in these  
5 vectors to express the DNA sequences of this invention. Such useful expression control sequences include the expression control sequences associated with structural genes of the foregoing expression vectors. Expression control sequences that control transcription include, *e.g.*, promoters, enhancers and transcription termination sites. Expression control sequences in eukaryotic cells that control post-transcriptional events include  
10 splice donor and acceptor sites and sequences that modify the half-life of the transcribed RNA, *e.g.*, sequences that direct poly(A) addition or binding sites for RNA-binding proteins. Expression control sequences that control translation include ribosome binding sites, sequences which direct targeted expression of the polypeptide to or within particular cellular compartments, and sequences in the 5' and 3' untranslated regions that  
15 modify the rate or efficiency of translation.

Examples of useful expression control sequences for a prokaryote, *e.g.*, *E. coli*, will include a promoter, often a phage promoter, such as phage lambda pL promoter, the *trc* promoter, a hybrid derived from the *trp* and *lac* promoters, the bacteriophage T7 promoter (in *E. coli* cells engineered to express the T7 polymerase), the TAC or TRC  
20 system, the major operator and promoter regions of phage lambda, the control regions of fd coat protein, or the *araBAD* operon. Prokaryotic expression vectors may further include transcription terminators, such as the *aspA* terminator, and elements that facilitate translation, such as a consensus ribosome binding site and translation termination codon, Schomer *et al.*, *Proc. Natl. Acad. Sci. USA* 83: 8506-8510 (1986).

25 Expression control sequences for yeast cells, typically *S. cerevisiae*, will include a yeast promoter, such as the *CYC1* promoter, the *GAL1* promoter, the *GAL10* promoter, *ADH1* promoter, the promoters of the yeast  $\alpha$ -mating system, or the *GPD* promoter, and will typically have elements that facilitate transcription termination, such as the transcription termination signals from the *CYC1* or *ADH1* gene.

30 Expression vectors useful for expressing proteins in mammalian cells will include a promoter active in mammalian cells. These promoters include those derived from mammalian viruses, such as the enhancer-promoter sequences from the immediate early

gene of the human cytomegalovirus (CMV), the enhancer-promoter sequences from the Rous sarcoma virus long terminal repeat (RSV LTR), the enhancer-promoter from SV40 or the early and late promoters of adenovirus. Other expression control sequences include the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the  
5 promoters of acid phosphatase. Other expression control sequences include those from the gene comprising the LSNA of interest. Often, expression is enhanced by incorporation of polyadenylation sites, such as the late SV40 polyadenylation site and the polyadenylation signal and transcription termination sequences from the bovine growth hormone (BGH) gene, and ribosome binding sites. Furthermore, vectors can include  
10 introns, such as intron II of rabbit  $\beta$ -globin gene and the SV40 splice elements.

Preferred nucleic acid vectors also include a selectable or amplifiable marker gene and means for amplifying the copy number of the gene of interest. Such marker genes are well-known in the art. Nucleic acid vectors may also comprise stabilizing sequences (*e.g.*, ori- or ARS-like sequences and telomere-like sequences), or may  
15 alternatively be designed to favor directed or non-directed integration into the host cell genome. In a preferred embodiment, nucleic acid sequences of this invention are inserted in frame into an expression vector that allows high level expression of an RNA which encodes a protein comprising the encoded nucleic acid sequence of interest. Nucleic acid cloning and sequencing methods are well-known to those of skill in the art and are  
20 described in an assortment of laboratory manuals, including Sambrook (1989), *supra*, Sambrook (2000), *supra*; and Ausubel (1992), *supra*, Ausubel (1999), *supra*. Product information from manufacturers of biological, chemical and immunological reagents also provide useful information.

Expression vectors may be either constitutive or inducible. Inducible vectors  
25 include either naturally inducible promoters, such as the trc promoter, which is regulated by the lac operon, and the pL promoter, which is regulated by tryptophan, the MMTV-LTR promoter, which is inducible by dexamethasone, or can contain synthetic promoters and/or additional elements that confer inducible control on adjacent promoters. Examples of inducible synthetic promoters are the hybrid Plac/ara-1 promoter and the  
30 PLtetO-1 promoter. The PLtetO-1 promoter takes advantage of the high expression levels from the PL promoter of phage lambda, but replaces the lambda repressor sites with two copies of operator 2 of the Tn10 tetracycline resistance operon, causing this promoter to

be tightly repressed by the Tet repressor protein and induced in response to tetracycline (Tc) and Tc derivatives such as anhydrotetracycline. Vectors may also be inducible because they contain hormone response elements, such as the glucocorticoid response element (GRE) and the estrogen response element (ERE), which can confer hormone inducibility where vectors are used for expression in cells having the respective hormone receptors. To reduce background levels of expression, elements responsive to ecdysone, an insect hormone, can be used instead, with coexpression of the ecdysone receptor.

In one aspect of the invention, expression vectors can be designed to fuse the expressed polypeptide to small protein tags that facilitate purification and/or visualization. Tags that facilitate purification include a polyhistidine tag that facilitates purification of the fusion protein by immobilized metal affinity chromatography, for example using NiNTA resin (Qiagen Inc., Valencia, CA, USA) or TALON™ resin (cobalt immobilized affinity chromatography medium, Clontech Labs, Palo Alto, CA, USA). The fusion protein can include a chitin-binding tag and self-excising intein, permitting chitin-based purification with self-removal of the fused tag (IMPACT™ system, New England Biolabs, Inc., Beverly, MA, USA). Alternatively, the fusion protein can include a calmodulin-binding peptide tag, permitting purification by calmodulin affinity resin (Stratagene, La Jolla, CA, USA), or a specifically excisable fragment of the biotin carboxylase carrier protein, permitting purification of *in vivo* biotinylated protein using an avidin resin and subsequent tag removal (Promega, Madison, WI, USA). As another useful alternative, the proteins of the present invention can be expressed as a fusion protein with glutathione-S-transferase, the affinity and specificity of binding to glutathione permitting purification using glutathione affinity resins, such as Glutathione-Superflow Resin (Clontech Laboratories, Palo Alto, CA, USA), with subsequent elution with free glutathione. Other tags include, for example, the Xpress epitope, detectable by anti-Xpress antibody (Invitrogen, Carlsbad, CA, USA), a myc tag, detectable by anti-myc tag antibody, the V5 epitope, detectable by anti-V5 antibody (Invitrogen, Carlsbad, CA, USA), FLAG® epitope, detectable by anti-FLAG® antibody (Stratagene, La Jolla, CA, USA), and the HA epitope.

For secretion of expressed proteins, vectors can include appropriate sequences that encode secretion signals, such as leader peptides. For example, the pSecTag2 vectors (Invitrogen, Carlsbad, CA, USA) are 5.2 kb mammalian expression vectors that

carry the secretion signal from the V-J2-C region of the mouse Ig kappa-chain for efficient secretion of recombinant proteins from a variety of mammalian cell lines.

Expression vectors can also be designed to fuse proteins encoded by the heterologous nucleic acid insert to polypeptides that are larger than purification and/or  
5 identification tags. Useful fusion proteins include those that permit display of the encoded protein on the surface of a phage or cell, fusion to intrinsically fluorescent proteins, such as those that have a green fluorescent protein (GFP)-like chromophore, fusions to the IgG Fc region, and fusion proteins for use in two hybrid systems.

Vectors for phage display fuse the encoded polypeptide to, *e.g.*, the gene III  
10 protein (pIII) or gene VIII protein (pVIII) for display on the surface of filamentous phage, such as M13. *See* Barbas *et al.*, Phage Display: A Laboratory Manual, Cold Spring Harbor Laboratory Press (2001); Kay *et al.* (eds.), Phage Display of Peptides and Proteins: A Laboratory Manual, Academic Press, Inc., (1996); Abelson *et al.* (eds.), Combinatorial Chemistry (Methods in Enzymology, Vol. 267) Academic Press (1996).  
15 Vectors for yeast display, *e.g.* the pYD1 yeast display vector (Invitrogen, Carlsbad, CA, USA), use the  $\alpha$ -agglutinin yeast adhesion receptor to display recombinant protein on the surface of *S. cerevisiae*. Vectors for mammalian display, *e.g.*, the pDisplay™ vector (Invitrogen, Carlsbad, CA, USA), target recombinant proteins using an N-terminal cell surface targeting signal and a C-terminal transmembrane anchoring domain of platelet  
20 derived growth factor receptor.

A wide variety of vectors now exist that fuse proteins encoded by heterologous nucleic acids to the chromophore of the substrate-independent, intrinsically fluorescent green fluorescent protein from *Aequorea victoria* ("GFP") and its variants. The GFP-like chromophore can be selected from GFP-like chromophores found in naturally occurring  
25 proteins, such as *A. victoria* GFP (GenBank accession number AAA27721), *Renilla reniformis* GFP, FP583 (GenBank accession no. AF168419) (DsRed), FP593 (AF272711), FP483 (AF168420), FP484 (AF168424), FP595 (AF246709), FP486 (AF168421), FP538 (AF168423), and FP506 (AF168422), and need include only so much of the native protein as is needed to retain the chromophore's intrinsic  
30 fluorescence. Methods for determining the minimal domain required for fluorescence are known in the art. *See* Li *et al.*, *J. Biol. Chem.* 272: 28545-28549 (1997). Alternatively, the GFP-like chromophore can be selected from GFP-like chromophores modified from

those found in nature. The methods for engineering such modified GFP-like chromophores and testing them for fluorescence activity, both alone and as part of protein fusions, are well-known in the art. See Heim *et al.*, *Curr. Biol.* 6: 178-182 (1996) and Palm *et al.*, *Methods Enzymol.* 302: 378-394 (1999), incorporated herein by reference in its entirety. A variety of such modified chromophores are now commercially available and can readily be used in the fusion proteins of the present invention. These include EGFP ("enhanced GFP"), EBFP ("enhanced blue fluorescent protein"), BFP2, EYFP ("enhanced yellow fluorescent protein"), ECFP ("enhanced cyan fluorescent protein") or Citrine. EGFP (*see, e.g.* Cormack *et al.*, *Gene* 173: 33-38 (1996); United States Patent Nos. 6,090,919 and 5,804,387) is found on a variety of vectors, both plasmid and viral, which are available commercially (Clontech Labs, Palo Alto, CA, USA); EBFP is optimized for expression in mammalian cells whereas BFP2, which retains the original jellyfish codons, can be expressed in bacteria (*see, e.g.* Heim *et al.*, *Curr. Biol.* 6: 178-182 (1996) and Cormack *et al.*, *Gene* 173: 33-38 (1996)). Vectors containing these blue-shifted variants are available from Clontech Labs (Palo Alto, CA, USA). Vectors containing EYFP, ECFP (*see, e.g.* Heim *et al.*, *Curr. Biol.* 6: 178-182 (1996); Miyawaki *et al.*, *Nature* 388: 882-887 (1997)) and Citrine (*see, e.g.* Heikal *et al.*, *Proc. Natl. Acad. Sci. USA* 97: 11996-12001 (2000)) are also available from Clontech Labs. The GFP-like chromophore can also be drawn from other modified GFPs, including those described in U.S. Patents 6,124,128; 6,096,865; 6,090,919; 6,066,476; 6,054,321; 6,027,881; 5,968,750; 5,874,304; 5,804,387; 5,777,079; 5,741,668; and 5,625,048, the disclosures of which are incorporated herein by reference in their entireties. See also Conn (ed.), Green Fluorescent Protein (Methods in Enzymology, Vol. 302), Academic Press, Inc. (1999). The GFP-like chromophore of each of these GFP variants can usefully be included in the fusion proteins of the present invention.

Fusions to the IgG Fc region increase serum half life of protein pharmaceutical products through interaction with the FcRn receptor (also denominated the FcRp receptor and the Brambell receptor, FcRb), further described in International Patent Application Nos. WO 97/43316, WO 97/34631, WO 96/32478, WO 96/18412.

For long-term, high-yield recombinant production of the proteins, protein fusions, and protein fragments of the present invention, stable expression is preferred. Stable

expression is readily achieved by integration into the host cell genome of vectors having selectable markers, followed by selection of these integrants. Vectors such as pUB6/V5-His A, B, and C (Invitrogen, Carlsbad, CA, USA) are designed for high-level stable expression of heterologous proteins in a wide range of mammalian tissue types and cell lines. pUB6/V5-His uses the promoter/enhancer sequence from the human ubiquitin C gene to drive expression of recombinant proteins: expression levels in 293, CHO, and NIH3T3 cells are comparable to levels from the CMV and human EF-1a promoters. The *bsd* gene permits rapid selection of stably transfected mammalian cells with the potent antibiotic blasticidin.

Replication incompetent retroviral vectors, typically derived from Moloney murine leukemia virus, also are useful for creating stable transfectants having integrated provirus. The highly efficient transduction machinery of retroviruses, coupled with the availability of a variety of packaging cell lines such as RetroPack™ PT 67, EcoPack2™-293, AmphiPack-293, and GP2-293 cell lines (all available from Clontech Laboratories, Palo Alto, CA, USA), allow a wide host range to be infected with high efficiency; varying the multiplicity of infection readily adjusts the copy number of the integrated provirus.

Of course, not all vectors and expression control sequences will function equally well to express the nucleic acid sequences of this invention. Neither will all hosts function equally well with the same expression system. However, one of skill in the art may make a selection among these vectors, expression control sequences and hosts without undue experimentation and without departing from the scope of this invention. For example, in selecting a vector, the host must be considered because the vector must be replicated in it. The vector's copy number, the ability to control that copy number, the ability to control integration, if any, and the expression of any other proteins encoded by the vector, such as antibiotic or other selection markers, should also be considered. The present invention further includes host cells comprising the vectors of the present invention, either present episomally within the cell or integrated, in whole or in part, into the host cell chromosome. Among other considerations, some of which are described above, a host cell strain may be chosen for its ability to process the expressed protein in the desired fashion. Such post-translational modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation,

and acylation, and it is an aspect of the present invention to provide LSPs with such post-translational modifications.

Polypeptides of the invention may be post-translationally modified. Post-translational modifications include phosphorylation of amino acid residues serine, threonine and/or tyrosine, N-linked and/or O-linked glycosylation, methylation, acetylation, prenylation, methylation, acetylation, arginylation, ubiquitination and racemization. One may determine whether a polypeptide of the invention is likely to be post-translationally modified by analyzing the sequence of the polypeptide to determine if there are peptide motifs indicative of sites for post-translational modification. There are a number of computer programs that permit prediction of post-translational modifications. See, e.g., [www.expasy.org](http://www.expasy.org) (accessed August 31, 2001), which includes PSORT, for prediction of protein sorting signals and localization sites, SignalP, for prediction of signal peptide cleavage sites, MITOPROT and Predotar, for prediction of mitochondrial targeting sequences, NetOGlyc, for prediction of type O-glycosylation sites in mammalian proteins, big-PI Predictor and DGPI, for prediction of prenylation-anchor and cleavage sites, and NetPhos, for prediction of Ser, Thr and Tyr phosphorylation sites in eukaryotic proteins. Other computer programs, such as those included in GCG, also may be used to determine post-translational modification peptide motifs.

General examples of types of post-translational modifications may be found in web sites such as the Delta Mass database <http://www.abrf.org/ABRF/Research/Committees/deltamass/deltamass.html> (accessed October 19, 2001); "GlycoSuiteDB: a new curated relational database of glycoprotein glycan structures and their biological sources" Cooper et al. *Nucleic Acids Res.* 29; 332-335 (2001) and <http://www.glycosuite.com/> (accessed October 19, 2001); "O-GLYCBASE version 4.0: a revised database of O-glycosylated proteins" Gupta et al. *Nucleic Acids Research*, 27: 370-372 (1999) and <http://www.cbs.dtu.dk/databases/OGLYCBASE/> (accessed October 19, 2001); "PhosphoBase, a database of phosphorylation sites: release 2.0.", Kreegipuu et al. *Nucleic Acids Res* 27(1):237-239 (1999) and <http://www.cbs.dtu.dk/databases/PhosphoBase/> (accessed October 19, 2001); or <http://pir.georgetown.edu/pirwww/search/textresid.html> (accessed October 19, 2001).



Tumorigenesis is often accompanied by alterations in the post-translational modifications of proteins. Thus, in another embodiment, the invention provides polypeptides from cancerous cells or tissues that have altered post-translational modifications compared to the post-translational modifications of polypeptides from normal cells or tissues. A number of altered post-translational modifications are known. One common alteration is a change in phosphorylation state, wherein the polypeptide from the cancerous cell or tissue is hyperphosphorylated or hypophosphorylated compared to the polypeptide from a normal tissue, or wherein the polypeptide is phosphorylated on different residues than the polypeptide from a normal cell. Another common alteration is a change in glycosylation state, wherein the polypeptide from the cancerous cell or tissue has more or less glycosylation than the polypeptide from a normal tissue, and/or wherein the polypeptide from the cancerous cell or tissue has a different type of glycosylation than the polypeptide from a noncancerous cell or tissue. Changes in glycosylation may be critical because carbohydrate-protein and carbohydrate-carbohydrate interactions are important in cancer cell progression, dissemination and invasion. See, e.g., Barchi, *Curr. Pharm. Des.* 6: 485-501 (2000), Verma, *Cancer Biochem. Biophys.* 14: 151-162 (1994) and Dennis et al., *Bioessays* 5: 412-421 (1999).

Another post-translational modification that may be altered in cancer cells is prenylation. Prenylation is the covalent attachment of a hydrophobic prenyl group (either farnesyl or geranylgeranyl) to a polypeptide. Prenylation is required for localizing a protein to a cell membrane and is often required for polypeptide function. For instance, the Ras superfamily of GTPase signaling proteins must be prenylated for function in a cell. See, e.g., Prendergast et al., *Semin. Cancer Biol.* 10: 443-452 (2000) and Khwaja et al., *Lancet* 355: 741-744 (2000).

Other post-translation modifications that may be altered in cancer cells include, without limitation, polypeptide methylation, acetylation, arginylation or racemization of amino acid residues. In these cases, the polypeptide from the cancerous cell may exhibit either increased or decreased amounts of the post-translational modification compared to the corresponding polypeptides from noncancerous cells.

Other polypeptide alterations in cancer cells include abnormal polypeptide cleavage of proteins and aberrant protein-protein interactions. Abnormal polypeptide cleavage may be cleavage of a polypeptide in a cancerous cell that does not usually occur

in a normal cell, or a lack of cleavage in a cancerous cell, wherein the polypeptide is cleaved in a normal cell. Aberrant protein-protein interactions may be either covalent cross-linking or non-covalent binding between proteins that do not normally bind to each other. Alternatively, in a cancerous cell, a protein may fail to bind to another protein to which it is bound in a noncancerous cell. Alterations in cleavage or in protein-protein interactions may be due to over- or underproduction of a polypeptide in a cancerous cell compared to that in a normal cell, or may be due to alterations in post-translational modifications (see above) of one or more proteins in the cancerous cell. See, e.g., Henschen-Edman, *Ann. N.Y. Acad. Sci.* 936: 580-593 (2001).

Alterations in polypeptide post-translational modifications, as well as changes in polypeptide cleavage and protein-protein interactions, may be determined by any method known in the art. For instance, alterations in phosphorylation may be determined by using anti-phosphoserine, anti-phosphothreonine or anti-phosphotyrosine antibodies or by amino acid analysis. Glycosylation alterations may be determined using antibodies specific for different sugar residues, by carbohydrate sequencing, or by alterations in the size of the glycoprotein, which can be determined by, e.g., SDS polyacrylamide gel electrophoresis (PAGE). Other alterations of post-translational modifications, such as prenylation, racemization, methylation, acetylation and arginylation, may be determined by chemical analysis, protein sequencing, amino acid analysis, or by using antibodies specific for the particular post-translational modifications. Changes in protein-protein interactions and in polypeptide cleavage may be analyzed by any method known in the art including, without limitation, non-denaturing PAGE (for non-covalent protein-protein interactions), SDS PAGE (for covalent protein-protein interactions and protein cleavage), chemical cleavage, protein sequencing or immunoassays.

In another embodiment, the invention provides polypeptides that have been post-translationally modified. In one embodiment, polypeptides may be modified enzymatically or chemically, by addition or removal of a post-translational modification. For example, a polypeptide may be glycosylated or deglycosylated enzymatically. Similarly, polypeptides may be phosphorylated using a purified kinase, such as a MAP kinase (e.g., p38, ERK, or JNK) or a tyrosine kinase (e.g., Src or erbB2). A polypeptide may also be modified through synthetic chemistry. Alternatively, one may isolate the polypeptide of interest from a cell or tissue that expresses the polypeptide with the

desired post-translational modification. In another embodiment, a nucleic acid molecule encoding the polypeptide of interest is introduced into a host cell that is capable of post-translationally modifying the encoded polypeptide in the desired fashion. If the polypeptide does not contain a motif for a desired post-translational modification, one  
5 may alter the post-translational modification by mutating the nucleic acid sequence of a nucleic acid molecule encoding the polypeptide so that it contains a site for the desired post-translational modification. Amino acid sequences that may be post-translationally modified are known in the art. See, e.g., the programs described above on the website [www.expasy.org](http://www.expasy.org). The nucleic acid molecule is then be introduced into a host cell that is  
10 capable of post-translationally modifying the encoded polypeptide. Similarly, one may delete sites that are post-translationally modified by either mutating the nucleic acid sequence so that the encoded polypeptide does not contain the post-translational modification motif, or by introducing the native nucleic acid molecule into a host cell that is not capable of post-translationally modifying the encoded polypeptide.

15 In selecting an expression control sequence, a variety of factors should also be considered. These include, for example, the relative strength of the sequence, its controllability, and its compatibility with the nucleic acid sequence of this invention, particularly with regard to potential secondary structures. Unicellular hosts should be selected by consideration of their compatibility with the chosen vector, the toxicity of the  
20 product coded for by the nucleic acid sequences of this invention, their secretion characteristics, their ability to fold the polypeptide correctly, their fermentation or culture requirements, and the ease of purification from them of the products coded for by the nucleic acid sequences of this invention.

The recombinant nucleic acid molecules and more particularly, the expression  
25 vectors of this invention may be used to express the polypeptides of this invention as recombinant polypeptides in a heterologous host cell. The polypeptides of this invention may be full-length or less than full-length polypeptide fragments recombinantly expressed from the nucleic acid sequences according to this invention. Such polypeptides include analogs, derivatives and muteins that may or may not have  
30 biological activity.

Vectors of the present invention will also often include elements that permit *in vitro* transcription of RNA from the inserted heterologous nucleic acid. Such vectors

typically include a phage promoter, such as that from T7, T3, or SP6, flanking the nucleic acid insert. Often two different such promoters flank the inserted nucleic acid, permitting separate *in vitro* production of both sense and antisense strands.

Transformation and other methods of introducing nucleic acids into a host cell  
5 (e.g., conjugation, protoplast transformation or fusion, transfection, electroporation, liposome delivery, membrane fusion techniques, high velocity DNA-coated pellets, viral infection and protoplast fusion) can be accomplished by a variety of methods which are well-known in the art (*See, for instance, Ausubel, supra, and Sambrook et al., supra*). Bacterial, yeast, plant or mammalian cells are transformed or transfected with an  
10 expression vector, such as a plasmid, a cosmid, or the like, wherein the expression vector comprises the nucleic acid of interest. Alternatively, the cells may be infected by a viral expression vector comprising the nucleic acid of interest. Depending upon the host cell, vector, and method of transformation used, transient or stable expression of the polypeptide will be constitutive or inducible. One having ordinary skill in the art will be  
15 able to decide whether to express a polypeptide transiently or stably, and whether to express the protein constitutively or inducibly.

A wide variety of unicellular host cells are useful in expressing the DNA sequences of this invention. These hosts may include well-known eukaryotic and prokaryotic hosts, such as strains of, fungi, yeast, insect cells such as *Spodoptera*  
20 *frugiperda* (SF9), animal cells such as CHO, as well as plant cells in tissue culture. Representative examples of appropriate host cells include, but are not limited to, bacterial cells, such as *E. coli*, *Caulobacter crescentus*, *Streptomyces* species, and *Salmonella typhimurium*; yeast cells, such as *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Pichia pastoris*, *Pichia methanolica*; insect cell lines, such as those from  
25 *Spodoptera frugiperda*, e.g., Sf9 and Sf21 cell lines, and expresSF™ cells (Protein Sciences Corp., Meriden, CT, USA), *Drosophila* S2 cells, and *Trichoplusia ni* High Five® Cells (Invitrogen, Carlsbad, CA, USA); and mammalian cells. Typical mammalian cells include BHK cells, BSC 1 cells, BSC 40 cells, BMT 10 cells, VERO cells, COS1 cells, COS7 cells, Chinese hamster ovary (CHO) cells, 3T3 cells, NIH 3T3  
30 cells, 293 cells, HEPG2 cells, HeLa cells, L cells, MDCK cells, HEK293 cells, WI38 cells, murine ES cell lines (e.g., from strains 129/SV, C57/BL6, DBA-1, 129/SVJ), K562 cells, Jurkat cells, and BW5147 cells. Other mammalian cell lines are well-known and

readily available from the American Type Culture Collection (ATCC) (Manassas, VA, USA) and the National Institute of General Medical Sciences (NIGMS) Human Genetic Cell Repository at the Coriell Cell Repositories (Camden, NJ, USA). Cells or cell lines derived from lung are particularly preferred because they may provide a more native  
5 post-translational processing. Particularly preferred are human lung cells.

Particular details of the transfection, expression and purification of recombinant proteins are well documented and are understood by those of skill in the art. Further details on the various technical aspects of each of the steps used in recombinant production of foreign genes in bacterial cell expression systems can be found in a number  
10 of texts and laboratory manuals in the art. See, e.g., Ausubel (1992), *supra*, Ausubel (1999), *supra*, Sambrook (1989), *supra*, and Sambrook (2001), *supra*, herein incorporated by reference.

Methods for introducing the vectors and nucleic acids of the present invention into the host cells are well-known in the art; the choice of technique will depend  
15 primarily upon the specific vector to be introduced and the host cell chosen.

Nucleic acid molecules and vectors may be introduced into prokaryotes, such as *E. coli*, in a number of ways. For instance, phage lambda vectors will typically be packaged using a packaging extract (e.g., Gigapack® packaging extract, Stratagene, La Jolla, CA, USA), and the packaged virus used to infect *E. coli*.

20 Plasmid vectors will typically be introduced into chemically competent or electrocompetent bacterial cells. *E. coli* cells can be rendered chemically competent by treatment, e.g., with  $\text{CaCl}_2$ , or a solution of  $\text{Mg}^{2+}$ ,  $\text{Mn}^{2+}$ ,  $\text{Ca}^{2+}$ ,  $\text{Rb}^+$  or  $\text{K}^+$ , dimethyl sulfoxide, dithiothreitol, and hexamine cobalt (III), Hanahan, *J. Mol. Biol.* 166(4):557-80 (1983), and vectors introduced by heat shock. A wide variety of chemically competent  
25 strains are also available commercially (e.g., Epicurian Coli® XL10-Gold® Ultracompetent Cells (Stratagene, La Jolla, CA, USA); DH5 competent cells (Clontech Laboratories, Palo Alto, CA, USA); and TOP10 Chemically Competent *E. coli* Kit (Invitrogen, Carlsbad, CA, USA)). Bacterial cells can be rendered electrocompetent, that is, competent to take up exogenous DNA by electroporation, by various pre-pulse  
30 treatments; vectors are introduced by electroporation followed by subsequent outgrowth in selected media. An extensive series of protocols is provided online in Electroprotocols

(BioRad, Richmond, CA, USA) ([http://www.biorad.com/LifeScience/pdf/New\\_Gene\\_Pulser.pdf](http://www.biorad.com/LifeScience/pdf/New_Gene_Pulser.pdf)).

Vectors can be introduced into yeast cells by spheroplasting, treatment with lithium salts, electroporation, or protoplast fusion. Spheroplasts are prepared by the  
5 action of hydrolytic enzymes such as snail-gut extract, usually denoted Glusulase, or Zymolyase, an enzyme from *Arthrobacter luteus*, to remove portions of the cell wall in the presence of osmotic stabilizers, typically 1 M sorbitol. DNA is added to the spheroplasts, and the mixture is co-precipitated with a solution of polyethylene glycol (PEG) and  $\text{Ca}^{2+}$ . Subsequently, the cells are resuspended in a solution of sorbitol, mixed  
10 with molten agar and then layered on the surface of a selective plate containing sorbitol.

For lithium-mediated transformation, yeast cells are treated with lithium acetate, which apparently permeabilizes the cell wall, DNA is added and the cells are co-precipitated with PEG. The cells are exposed to a brief heat shock, washed free of PEG and lithium acetate, and subsequently spread on plates containing ordinary selective  
15 medium. Increased frequencies of transformation are obtained by using specially-prepared single-stranded carrier DNA and certain organic solvents. Schiestl *et al.*, *Curr. Genet.* 16(5-6): 339-46 (1989).

For electroporation, freshly-grown yeast cultures are typically washed, suspended in an osmotic protectant, such as sorbitol, mixed with DNA, and the cell suspension  
20 pulsed in an electroporation device. Subsequently, the cells are spread on the surface of plates containing selective media. Becker *et al.*, *Methods Enzymol.* 194: 182-187 (1991). The efficiency of transformation by electroporation can be increased over 100-fold by using PEG, single-stranded carrier DNA and cells that are in late log-phase of growth. Larger constructs, such as YACs, can be introduced by protoplast fusion.

25 Mammalian and insect cells can be directly infected by packaged viral vectors, or transfected by chemical or electrical means. For chemical transfection, DNA can be coprecipitated with  $\text{CaPO}_4$  or introduced using liposomal and nonliposomal lipid-based agents. Commercial kits are available for  $\text{CaPO}_4$  transfection (CalPhos™ Mammalian Transfection Kit, Clontech Laboratories, Palo Alto, CA, USA), and lipid-mediated  
30 transfection can be practiced using commercial reagents, such as LIPOFECTAMINE™ 2000, LIPOFECTAMINE™ Reagent, CELLFECTIN® Reagent, and LIPOFECTIN® Reagent (Invitrogen, Carlsbad, CA, USA), DOTAP Liposomal Transfection Reagent,

FuGENE 6, X-tremeGENE Q2, DOSPER, (Roche Molecular Biochemicals, Indianapolis, IN USA), Effectene™, PolyFect®, Superfect® (Qiagen, Inc., Valencia, CA, USA).

Protocols for electroporating mammalian cells can be found online in Electroprotocols (Bio-Rad, Richmond, CA, USA) (<http://www.bio-rad.com/LifeScience/pdf/>

- 5 New\_Gene\_Pulser.pdf); Norton *et al.* (eds.), Gene Transfer Methods: Introducing DNA into Living Cells and Organisms, BioTechniques Books, Eaton Publishing Co. (2000); incorporated herein by reference in its entirety. Other transfection techniques include transfection by particle bombardment and microinjection. *See, e.g.,* Cheng *et al.*, *Proc. Natl. Acad. Sci. USA* 90(10): 4455-9 (1993); Yang *et al.*, *Proc. Natl. Acad. Sci. USA*  
10 87(24): 9568-72 (1990).

Production of the recombinantly produced proteins of the present invention can optionally be followed by purification.

- Purification of recombinantly expressed proteins is now well by those skilled in the art. *See, e.g.,* Thorner *et al.* (eds.), Applications of Chimeric Genes and Hybrid  
15 Proteins, Part A: Gene Expression and Protein Purification (Methods in Enzymology, Vol. 326), Academic Press (2000); Harbin (ed.), Cloning, Gene Expression and Protein Purification : Experimental Procedures and Process Rationale, Oxford Univ. Press (2001); Marshak *et al.*, Strategies for Protein Purification and Characterization: A Laboratory Course Manual, Cold Spring Harbor Laboratory Press (1996); and Roe (ed.),  
20 Protein Purification Applications, Oxford University Press (2001); the disclosures of which are incorporated herein by reference in their entireties, and thus need not be detailed here.

- Briefly, however, if purification tags have been fused through use of an expression vector that appends such tags, purification can be effected, at least in part, by  
25 means appropriate to the tag, such as use of immobilized metal affinity chromatography for polyhistidine tags. Other techniques common in the art include ammonium sulfate fractionation, immunoprecipitation, fast protein liquid chromatography (FPLC), high performance liquid chromatography (HPLC), and preparative gel electrophoresis.

#### Polypeptides

- 30 Another object of the invention is to provide polypeptides encoded by the nucleic acid molecules of the instant invention. In a preferred embodiment, the polypeptide is a lung specific polypeptide (LSP). In an even more preferred embodiment, the polypeptide

is derived from a polypeptide comprising the amino acid sequence of SEQ ID NO: 143 through 277. A polypeptide as defined herein may be produced recombinantly, as discussed *supra*, may be isolated from a cell that naturally expresses the protein, or may be chemically synthesized following the teachings of the specification and using methods well-known to those having ordinary skill in the art.

In another aspect, the polypeptide may comprise a fragment of a polypeptide, wherein the fragment is as defined herein. In a preferred embodiment, the polypeptide fragment is a fragment of an LSP. In a more preferred embodiment, the fragment is derived from a polypeptide comprising the amino acid sequence of SEQ ID NO: 143 through 277. A polypeptide that comprises only a fragment of an entire LSP may or may not be a polypeptide that is also an LSP. For instance, a full-length polypeptide may be lung-specific, while a fragment thereof may be found in other tissues as well as in lung. A polypeptide that is not an LSP, whether it is a fragment, analog, mutein, homologous protein or derivative, is nevertheless useful, especially for immunizing animals to prepare anti-LSP antibodies. However, in a preferred embodiment, the part or fragment is an LSP. Methods of determining whether a polypeptide is an LSP are described *infra*.

Fragments of at least 6 contiguous amino acids are useful in mapping B cell and T cell epitopes of the reference protein. See, e.g., Geysen *et al.*, *Proc. Natl. Acad. Sci. USA* 81: 3998-4002 (1984) and U.S. Patents 4,708,871 and 5,595,915, the disclosures of which are incorporated herein by reference in their entireties. Because the fragment need not itself be immunogenic, part of an immunodominant epitope, nor even recognized by native antibody, to be useful in such epitope mapping, all fragments of at least 6 amino acids of the proteins of the present invention have utility in such a study.

Fragments of at least 8 contiguous amino acids, often at least 15 contiguous amino acids, are useful as immunogens for raising antibodies that recognize the proteins of the present invention. See, e.g., Lerner, *Nature* 299: 592-596 (1982); Shinnick *et al.*, *Annu. Rev. Microbiol.* 37: 425-46 (1983); Sutcliffe *et al.*, *Science* 219: 660-6 (1983), the disclosures of which are incorporated herein by reference in their entireties. As further described in the above-cited references, virtually all 8-mers, conjugated to a carrier, such as a protein, prove immunogenic, meaning that they are capable of eliciting antibody for the conjugated peptide; accordingly, all fragments of at least 8 amino acids of the proteins of the present invention have utility as immunogens.



Fragments of at least 8, 9, 10 or 12 contiguous amino acids are also useful as competitive inhibitors of binding of the entire protein, or a portion thereof, to antibodies (as in epitope mapping), and to natural binding partners, such as subunits in a multimeric complex or to receptors or ligands of the subject protein; this competitive inhibition  
5 permits identification and separation of molecules that bind specifically to the protein of interest, U.S. Patents 5,539,084 and 5,783,674, incorporated herein by reference in their entireties.

The protein, or protein fragment, of the present invention is thus at least 6 amino acids in length, typically at least 8, 9, 10 or 12 amino acids in length, and often at least 15  
10 amino acids in length. Often, the protein of the present invention, or fragment thereof, is at least 20 amino acids in length, even 25 amino acids, 30 amino acids, 35 amino acids, or 50 amino acids or more in length. Of course, larger fragments having at least 75 amino acids, 100 amino acids, or even 150 amino acids are also useful, and at times preferred.

One having ordinary skill in the art can produce fragments of a polypeptide by truncating the nucleic acid molecule, *e.g.*, an LSNA, encoding the polypeptide and then expressing it recombinantly. Alternatively, one can produce a fragment by chemically synthesizing a portion of the full-length polypeptide. One may also produce a fragment by enzymatically cleaving either a recombinant polypeptide or an isolated naturally-  
20 occurring polypeptide. Methods of producing polypeptide fragments are well-known in the art. *See, e.g.*, Sambrook (1989), *supra*; Sambrook (2001), *supra*; Ausubel (1992), *supra*; and Ausubel (1999), *supra*. In one embodiment, a polypeptide comprising only a fragment of polypeptide of the invention, preferably an LSP, may be produced by chemical or enzymatic cleavage of a polypeptide. In a preferred embodiment, a  
25 polypeptide fragment is produced by expressing a nucleic acid molecule encoding a fragment of the polypeptide, preferably an LSP, in a host cell.

By "polypeptides" as used herein it is also meant to be inclusive of mutants, fusion proteins, homologous proteins and allelic variants of the polypeptides specifically exemplified.

30 A mutant protein, or mutein, may have the same or different properties compared to a naturally-occurring polypeptide and comprises at least one amino acid insertion, duplication, deletion, rearrangement or substitution compared to the amino acid sequence

of a native protein. Small deletions and insertions can often be found that do not alter the function of the protein. In one embodiment, the mutein may or may not be lung-specific. In a preferred embodiment, the mutein is lung-specific. In a preferred embodiment, the mutein is a polypeptide that comprises at least one amino acid insertion, duplication, deletion, rearrangement or substitution compared to the amino acid sequence of SEQ ID NO: 143 through 277. In a more preferred embodiment, the mutein is one that exhibits at least 50% sequence identity, more preferably at least 60% sequence identity, even more preferably at least 70%, yet more preferably at least 80% sequence identity to an LSP comprising an amino acid sequence of SEQ ID NO: 143 through 277. In yet a more preferred embodiment, the mutein exhibits at least 85%, more preferably 90%, even more preferably 95% or 96%, and yet more preferably at least 97%, 98%, 99% or 99.5% sequence identity to an LSP comprising an amino acid sequence of SEQ ID NO: 143 through 277.

A mutein may be produced by isolation from a naturally-occurring mutant cell, tissue or organism. A mutein may be produced by isolation from a cell, tissue or organism that has been experimentally mutagenized. Alternatively, a mutein may be produced by chemical manipulation of a polypeptide, such as by altering the amino acid residue to another amino acid residue using synthetic or semi-synthetic chemical techniques. In a preferred embodiment, a mutein may be produced from a host cell comprising an altered nucleic acid molecule compared to the naturally-occurring nucleic acid molecule. For instance, one may produce a mutein of a polypeptide by introducing one or more mutations into a nucleic acid sequence of the invention and then expressing it recombinantly. These mutations may be targeted, in which particular encoded amino acids are altered, or may be untargeted, in which random encoded amino acids within the polypeptide are altered. Muteins with random amino acid alterations can be screened for a particular biological activity or property, particularly whether the polypeptide is lung-specific, as described below. Multiple random mutations can be introduced into the gene by methods well-known to the art, *e.g.*, by error-prone PCR, shuffling, oligonucleotide-directed mutagenesis, assembly PCR, sexual PCR mutagenesis, *in vivo* mutagenesis, cassette mutagenesis, recursive ensemble mutagenesis, exponential ensemble mutagenesis and site-specific mutagenesis. Methods of producing muteins with targeted or random amino acid alterations are well-known in the art. *See, e.g.*,

Sambrook (1989), *supra*; Sambrook (2001), *supra*; Ausubel (1992), *supra*; and Ausubel (1999), U.S. Patent 5,223,408, and the references discussed *supra*, each herein incorporated by reference.

By "polypeptide" as used herein it is also meant to be inclusive of polypeptides homologous to those polypeptides exemplified herein. In a preferred embodiment, the polypeptide is homologous to an LSP. In an even more preferred embodiment, the polypeptide is homologous to an LSP selected from the group having an amino acid sequence of SEQ ID NO: 143 through 277. In a preferred embodiment, the homologous polypeptide is one that exhibits significant sequence identity to an LSP. In a more preferred embodiment, the polypeptide is one that exhibits significant sequence identity to an comprising an amino acid sequence of SEQ ID NO: 143 through 277. In an even more preferred embodiment, the homologous polypeptide is one that exhibits at least 50% sequence identity, more preferably at least 60% sequence identity, even more preferably at least 70%, yet more preferably at least 80% sequence identity to an LSP comprising an amino acid sequence of SEQ ID NO: 143 through 277. In a yet more preferred embodiment, the homologous polypeptide is one that exhibits at least 85%, more preferably 90%, even more preferably 95% or 96%, and yet more preferably at least 97% or 98% sequence identity to an LSP comprising an amino acid sequence of SEQ ID NO: 143 through 277. In another preferred embodiment, the homologous polypeptide is one that exhibits at least 99%, more preferably 99.5%, even more preferably 99.6%, 99.7%, 99.8% or 99.9% sequence identity to an LSP comprising an amino acid sequence of SEQ ID NO: 143 through 277. In a preferred embodiment, the amino acid substitutions are conservative amino acid substitutions as discussed above.

In another embodiment, the homologous polypeptide is one that is encoded by a nucleic acid molecule that selectively hybridizes to an LSNA. In a preferred embodiment, the homologous polypeptide is encoded by a nucleic acid molecule that hybridizes to an LSNA under low stringency, moderate stringency or high stringency conditions, as defined herein. In a more preferred embodiment, the LSNA is selected from the group consisting of SEQ ID NO: 1 through 142. In another preferred embodiment, the homologous polypeptide is encoded by a nucleic acid molecule that hybridizes to a nucleic acid molecule that encodes an LSP under low stringency, moderate stringency or high stringency conditions, as defined herein. In a more preferred

embodiment, the LSP is selected from the group consisting of SEQ ID NO: 143 through 277.

The homologous polypeptide may be a naturally-occurring one that is derived from another species, especially one derived from another primate, such as chimpanzee, gorilla, rhesus macaque, baboon or gorilla, wherein the homologous polypeptide comprises an amino acid sequence that exhibits significant sequence identity to that of SEQ ID NO: 143 through 277. The homologous polypeptide may also be a naturally-occurring polypeptide from a human, when the LSP is a member of a family of polypeptides. The homologous polypeptide may also be a naturally-occurring polypeptide derived from a non-primate, mammalian species, including without limitation, domesticated species, *e.g.*, dog, cat, mouse, rat, rabbit, guinea pig, hamster, cow, horse, goat or pig. The homologous polypeptide may also be a naturally-occurring polypeptide derived from a non-mammalian species, such as birds or reptiles. The naturally-occurring homologous protein may be isolated directly from humans or other species. Alternatively, the nucleic acid molecule encoding the naturally-occurring homologous polypeptide may be isolated and used to express the homologous polypeptide recombinantly. In another embodiment, the homologous polypeptide may be one that is experimentally produced by random mutation of a nucleic acid molecule and subsequent expression of the nucleic acid molecule. In another embodiment, the homologous polypeptide may be one that is experimentally produced by directed mutation of one or more codons to alter the encoded amino acid of an LSP. Further, the homologous protein may or may not encode polypeptide that is an LSP. However, in a preferred embodiment, the homologous polypeptide encodes a polypeptide that is an LSP.

Relatedness of proteins can also be characterized using a second functional test, the ability of a first protein competitively to inhibit the binding of a second protein to an antibody. It is, therefore, another aspect of the present invention to provide isolated proteins not only identical in sequence to those described with particularity herein, but also to provide isolated proteins ("cross-reactive proteins") that competitively inhibit the binding of antibodies to all or to a portion of various of the isolated polypeptides of the present invention. Such competitive inhibition can readily be determined using immunoassays well-known in the art.

As discussed above, single nucleotide polymorphisms (SNPs) occur frequently in eukaryotic genomes, and the sequence determined from one individual of a species may differ from other allelic forms present within the population. Thus, by "polypeptide" as used herein it is also meant to be inclusive of polypeptides encoded by an allelic variant of a nucleic acid molecule encoding an LSP. In a preferred embodiment, the polypeptide is encoded by an allelic variant of a gene that encodes a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO: 143 through 277. In a yet more preferred embodiment, the polypeptide is encoded by an allelic variant of a gene that has the nucleic acid sequence selected from the group consisting of SEQ ID NO: 1 through 142.

In another embodiment, the invention provides polypeptides which comprise derivatives of a polypeptide encoded by a nucleic acid molecule according to the instant invention. In a preferred embodiment, the polypeptide is an LSP. In a preferred embodiment, the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO: 143 through 277, or is a mutein, allelic variant, homologous protein or fragment thereof. In a preferred embodiment, the derivative has been acetylated, carboxylated, phosphorylated, glycosylated or ubiquitinated. In another preferred embodiment, the derivative has been labeled with, *e.g.*, radioactive isotopes such as  $^{125}\text{I}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ , and  $^3\text{H}$ . In another preferred embodiment, the derivative has been labeled with fluorophores, chemiluminescent agents, enzymes, and antiligands that can serve as specific binding pair members for a labeled ligand.

Polypeptide modifications are well-known to those of skill and have been described in great detail in the scientific literature. Several particularly common modifications, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, for instance, are described in most basic texts, such as, for instance Creighton, Protein Structure and Molecular Properties, 2nd ed., W. H. Freeman and Company (1993). Many detailed reviews are available on this subject, such as, for example, those provided by Wold, in Johnson (ed.), Posttranslational Covalent Modification of Proteins, pgs. 1-12, Academic Press (1983); Seifter *et al.*, *Meth. Enzymol.* 182: 626-646 (1990) and Rattan *et al.*, *Ann. N.Y. Acad. Sci.* 663: 48-62 (1992).

-68-

It will be appreciated, as is well-known and as noted above, that polypeptides are not always entirely linear. For instance, polypeptides may be branched as a result of ubiquitination, and they may be circular, with or without branching, generally as a result of posttranslation events, including natural processing event and events brought about by human manipulation which do not occur naturally. Circular, branched and branched circular polypeptides may be synthesized by non-translation natural process and by entirely synthetic methods, as well. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. In fact, blockage of the amino or carboxyl group in a polypeptide, or both, by a covalent modification, is common in naturally occurring and synthetic polypeptides and such modifications may be present in polypeptides of the present invention, as well. For instance, the amino terminal residue of polypeptides made in *E. coli*, prior to proteolytic processing, almost invariably will be N-formylmethionine.

Useful post-synthetic (and post-translational) modifications include conjugation to detectable labels, such as fluorophores. A wide variety of amine-reactive and thiol-reactive fluorophore derivatives have been synthesized that react under nondenaturing conditions with N-terminal amino groups and epsilon amino groups of lysine residues, on the one hand, and with free thiol groups of cysteine residues, on the other.

Kits are available commercially that permit conjugation of proteins to a variety of amine-reactive or thiol-reactive fluorophores: Molecular Probes, Inc. (Eugene, OR, USA), *e.g.*, offers kits for conjugating proteins to Alexa Fluor 350, Alexa Fluor 430, Fluorescein-EX, Alexa Fluor 488, Oregon Green 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, and Texas Red-X.

A wide variety of other amine-reactive and thiol-reactive fluorophores are available commercially (Molecular Probes, Inc., Eugene, OR, USA), including Alexa Fluor® 350, Alexa Fluor® 488, Alexa Fluor® 532, Alexa Fluor® 546, Alexa Fluor® 568, Alexa Fluor® 594, Alexa Fluor® 647 (monoclonal antibody labeling kits available from Molecular Probes, Inc., Eugene, OR, USA), BODIPY dyes, such as BODIPY 493/503, BODIPY FL, BODIPY R6G, BODIPY 530/550, BODIPY TMR, BODIPY 558/568, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY TR, BODIPY 630/650, BODIPY 650/665, Cascade Blue, Cascade Yellow, Dansyl, lissamine rhodamine B, Marina Blue, Oregon Green 488, Oregon Green 514,

Pacific Blue, rhodamine 6G, rhodamine green, rhodamine red, tetramethylrhodamine, Texas Red (available from Molecular Probes, Inc., Eugene, OR, USA).

The polypeptides of the present invention can also be conjugated to fluorophores, other proteins, and other macromolecules, using bifunctional linking reagents. Common homobifunctional reagents include, *e.g.*, APG, AEDP, B'ASED, BMB, BMDB, BMH, BMOE, BM[PEO]3, BM[PEO]4, BS3, BSOCOES, DFDNB, DMA, DMP, DMS, DPDPB, DSG, DSP (Lomant's Reagent), DSS, DST, DTBP, DTME, DTSSP, EGS, HBVS, Sulfo-BSOCOES, Sulfo-DST, Sulfo-EGS (all available from Pierce, Rockford, IL, USA); common heterobifunctional cross-linkers include ABH, AMAS, ANB-NOS, APDP, ASBA, BMPA, BMPH, BMPS, EDC, EMCA, EMCH, EMCS, KMUA, KMUH, GMBS, LC-SMCC, LC-SPDP, MBS, M2C2H, MPBH, MSA, NHS-ASA, PDPH, PMPI, SADP, SAED, SAND, SANPAH, SASD, SATP, SBAP, SFAD, SIA, SIAB, SMCC, SMPB, SMPH, SMPT, SPDP, Sulfo-EMCS, Sulfo-GMBS, Sulfo-HSAB, Sulfo-KMUS, Sulfo-LC-SPDP, Sulfo-MBS, Sulfo-NHS-LC-ASA, Sulfo-SADP, Sulfo-SANPAH, Sulfo-SIAB, Sulfo-SMCC, Sulfo-SMPB, Sulfo-LC-SMPT, SVSB, TFCS (all available from Pierce, Rockford, IL, USA).

The polypeptides, fragments, and fusion proteins of the present invention can be conjugated, using such cross-linking reagents, to fluorophores that are not amine- or thiol-reactive. Other labels that usefully can be conjugated to the polypeptides, fragments, and fusion proteins of the present invention include radioactive labels, echosonographic contrast reagents, and MRI contrast agents.

The polypeptides, fragments, and fusion proteins of the present invention can also usefully be conjugated using cross-linking agents to carrier proteins, such as KLH, bovine thyroglobulin, and even bovine serum albumin (BSA), to increase immunogenicity for raising anti-LSP antibodies.

The polypeptides, fragments, and fusion proteins of the present invention can also usefully be conjugated to polyethylene glycol (PEG); PEGylation increases the serum half-life of proteins administered intravenously for replacement therapy. Delgado *et al.*, *Crit. Rev. Ther. Drug Carrier Syst.* 9(3-4): 249-304 (1992); Scott *et al.*, *Curr. Pharm. Des.* 4(6): 423-38 (1998); DeSantis *et al.*, *Curr. Opin. Biotechnol.* 10(4): 324-30 (1999), incorporated herein by reference in their entireties. PEG monomers can be attached to the protein directly or through a linker, with PEGylation using PEG monomers activated

with tresyl chloride (2,2,2-trifluoroethanesulphonyl chloride) permitting direct attachment under mild conditions.

In yet another embodiment, the invention provides analogs of a polypeptide encoded by a nucleic acid molecule according to the instant invention. In a preferred embodiment, the polypeptide is an LSP. In a more preferred embodiment, the analog is derived from a polypeptide having part or all of the amino acid sequence of SEQ ID NO: 143 through 277. In a preferred embodiment, the analog is one that comprises one or more substitutions of non-natural amino acids or non-native inter-residue bonds compared to the naturally-occurring polypeptide. In general, the non-peptide analog is structurally similar to an LSP, but one or more peptide linkages is replaced by a linkage selected from the group consisting of --CH<sub>2</sub>NH--, --CH<sub>2</sub>S--, --CH<sub>2</sub>-CH<sub>2</sub>-, --CH=CH--(cis and trans), --COCH<sub>2</sub>--, --CH(OH)CH<sub>2</sub>-- and --CH<sub>2</sub>SO--. In another embodiment, the non-peptide analog comprises substitution of one or more amino acids of an LSP with a D-amino acid of the same type or other non-natural amino acid in order to generate more stable peptides. D-amino acids can readily be incorporated during chemical peptide synthesis: peptides assembled from D-amino acids are more resistant to proteolytic attack; incorporation of D-amino acids can also be used to confer specific three-dimensional conformations on the peptide. Other amino acid analogues commonly added during chemical synthesis include ornithine, norleucine, phosphorylated amino acids (typically phosphoserine, phosphothreonine, phosphotyrosine), L-malonyltyrosine, a non-hydrolyzable analog of phosphotyrosine (*see, e.g., Kole et al., Biochem. Biophys. Res. Com.* 209: 817-821 (1995)), and various halogenated phenylalanine derivatives.

Non-natural amino acids can be incorporated during solid phase chemical synthesis or by recombinant techniques, although the former is typically more common. Solid phase chemical synthesis of peptides is well established in the art. Procedures are described, inter alia, in Chan *et al.* (eds.), Fmoc Solid Phase Peptide Synthesis: A Practical Approach (Practical Approach Series), Oxford Univ. Press (March 2000); Jones, Amino Acid and Peptide Synthesis (Oxford Chemistry Primers, No 7), Oxford Univ. Press (1992); and Bodanszky, Principles of Peptide Synthesis (Springer Laboratory), Springer Verlag (1993); the disclosures of which are incorporated herein by reference in their entireties.



-71-

- Amino acid analogues having detectable labels are also usefully incorporated during synthesis to provide derivatives and analogs. Biotin, for example can be added using biotinoyl-(9-fluorenylmethoxycarbonyl)-L-lysine (FMOC biocytin) (Molecular Probes, Eugene, OR, USA). Biotin can also be added enzymatically by incorporation
- 5 into a fusion protein of a *E. coli* BirA substrate peptide. The FMOC and *t*BOC derivatives of dabcyL-L-lysine (Molecular Probes, Inc., Eugene, OR, USA) can be used to incorporate the dabcyL chromophore at selected sites in the peptide sequence during synthesis. The aminonaphthalene derivative EDANS, the most common fluorophore for pairing with the dabcyL quencher in fluorescence resonance energy transfer (FRET)
- 10 systems, can be introduced during automated synthesis of peptides by using EDANS-FMOC-L-glutamic acid or the corresponding *t*BOC derivative (both from Molecular Probes, Inc., Eugene, OR, USA). Tetramethylrhodamine fluorophores can be incorporated during automated FMOC synthesis of peptides using (FMOC)-TMR-L-lysine (Molecular Probes, Inc. Eugene, OR, USA).
- 15 Other useful amino acid analogues that can be incorporated during chemical synthesis include aspartic acid, glutamic acid, lysine, and tyrosine analogues having allyl side-chain protection (Applied Biosystems, Inc., Foster City, CA, USA); the allyl side chain permits synthesis of cyclic, branched-chain, sulfonated, glycosylated, and phosphorylated peptides.
- 20 A large number of other FMOC-protected non-natural amino acid analogues capable of incorporation during chemical synthesis are available commercially, including, *e.g.*, Fmoc-2-aminobicyclo[2.2.1]heptane-2-carboxylic acid, Fmoc-3-endo-aminobicyclo[2.2.1]heptane-2-endo-carboxylic acid, Fmoc-3-exo-aminobicyclo[2.2.1]heptane-2-exo-carboxylic acid, Fmoc-3-endo-amino-
- 25 bicyclo[2.2.1]hept-5-ene-2-endo-carboxylic acid, Fmoc-3-exo-amino-bicyclo[2.2.1]hept-5-ene-2-exo-carboxylic acid, Fmoc-cis-2-amino-1-cyclohexanecarboxylic acid, Fmoc-trans-2-amino-1-cyclohexanecarboxylic acid, Fmoc-1-amino-1-cyclopentanecarboxylic acid, Fmoc-cis-2-amino-1-cyclopentanecarboxylic acid, Fmoc-1-amino-1-cyclopropanecarboxylic acid, Fmoc-D-2-amino-4-(ethylthio)butyric acid, Fmoc-L-2-
- 30 amino-4-(ethylthio)butyric acid, Fmoc-L-buthionine, Fmoc-S-methyl-L-Cysteine, Fmoc-2-aminobenzoic acid (anthranillic acid), Fmoc-3-aminobenzoic acid, Fmoc-4-aminobenzoic acid, Fmoc-2-aminobenzophenone-2'-carboxylic acid, Fmoc-N-(4-

- aminobenzoyl)- $\beta$ -alanine, Fmoc-2-amino-4,5-dimethoxybenzoic acid, Fmoc-4-aminohippuric acid, Fmoc-2-amino-3-hydroxybenzoic acid, Fmoc-2-amino-5-hydroxybenzoic acid, Fmoc-3-amino-4-hydroxybenzoic acid, Fmoc-4-amino-3-hydroxybenzoic acid, Fmoc-4-amino-2-hydroxybenzoic acid, Fmoc-5-amino-2-hydroxybenzoic acid, Fmoc-2-amino-3-methoxybenzoic acid, Fmoc-4-amino-3-methoxybenzoic acid, Fmoc-2-amino-3-methylbenzoic acid, Fmoc-2-amino-5-methylbenzoic acid, Fmoc-2-amino-6-methylbenzoic acid, Fmoc-3-amino-2-methylbenzoic acid, Fmoc-3-amino-4-methylbenzoic acid, Fmoc-4-amino-3-methylbenzoic acid, Fmoc-3-amino-2-naphtoic acid, Fmoc-D,L-3-amino-3-phenylpropionic acid, Fmoc-L-Methyldopa, Fmoc-2-amino-4,6-dimethyl-3-pyridinecarboxylic acid, Fmoc-D,L-amino-2-thiophenacetic acid, Fmoc-4-(carboxymethyl)piperazine, Fmoc-4-carboxypiperazine, Fmoc-4-(carboxymethyl)homopiperazine, Fmoc-4-phenyl-4-piperidinecarboxylic acid, Fmoc-L-1,2,3,4-tetrahydronorharman-3-carboxylic acid, Fmoc-L-thiazolidine-4-carboxylic acid,
- all available from The Peptide Laboratory (Richmond, CA, USA).

Non-natural residues can also be added biosynthetically by engineering a suppressor tRNA, typically one that recognizes the UAG stop codon, by chemical aminoacylation with the desired unnatural amino acid. Conventional site-directed mutagenesis is used to introduce the chosen stop codon UAG at the site of interest in the protein gene. When the acylated suppressor tRNA and the mutant gene are combined in an *in vitro* transcription/translation system, the unnatural amino acid is incorporated in response to the UAG codon to give a protein containing that amino acid at the specified position. Liu *et al.*, *Proc. Natl Acad. Sci. USA* 96(9): 4780-5 (1999); Wang *et al.*, *Science* 292(5516): 498-500 (2001).

## 25 *Fusion Proteins*

The present invention further provides fusions of each of the polypeptides and fragments of the present invention to heterologous polypeptides. In a preferred embodiment, the polypeptide is an LSP. In a more preferred embodiment, the polypeptide that is fused to the heterologous polypeptide comprises part or all of the amino acid sequence of SEQ ID NO: 143 through 277, or is a mutein, homologous polypeptide, analog or derivative thereof. In an even more preferred embodiment, the nucleic acid molecule encoding the fusion protein comprises all or part of the nucleic

acid sequence of SEQ ID NO: 1 through 142, or comprises all or part of a nucleic acid sequence that selectively hybridizes or is homologous to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1 through 142.

5 The fusion proteins of the present invention will include at least one fragment of the protein of the present invention, which fragment is at least 6, typically at least 8, often at least 15, and usefully at least 16, 17, 18, 19, or 20 amino acids long. The fragment of the protein of the present to be included in the fusion can usefully be at least 25 amino acids long, at least 50 amino acids long, and can be at least 75, 100, or even 150 amino acids long. Fusions that include the entirety of the proteins of the present invention have  
10 particular utility.

The heterologous polypeptide included within the fusion protein of the present invention is at least 6 amino acids in length, often at least 8 amino acids in length, and usefully at least 15, 20, and 25 amino acids in length. Fusions that include larger polypeptides, such as the IgG Fc region, and even entire proteins (such as GFP  
15 chromophore-containing proteins) are particularly useful.

As described above in the description of vectors and expression vectors of the present invention, which discussion is incorporated here by reference in its entirety, heterologous polypeptides to be included in the fusion proteins of the present invention can usefully include those designed to facilitate purification and/or visualization of  
20 recombinantly-expressed proteins. *See, e.g., Ausubel, Chapter 16, (1992), supra.* Although purification tags can also be incorporated into fusions that are chemically synthesized, chemical synthesis typically provides sufficient purity that further purification by HPLC suffices; however, visualization tags as above described retain their utility even when the protein is produced by chemical synthesis, and when so  
25 included render the fusion proteins of the present invention useful as directly detectable markers of the presence of a polypeptide of the invention.

As also discussed above, heterologous polypeptides to be included in the fusion proteins of the present invention can usefully include those that facilitate secretion of recombinantly expressed proteins — into the periplasmic space or extracellular milieu for  
30 prokaryotic hosts, into the culture medium for eukaryotic cells — through incorporation of secretion signals and/or leader sequences. For example, a His<sup>6</sup> tagged protein can be purified on a Ni affinity column and a GST fusion protein can be purified on a

glutathione affinity column. Similarly, a fusion protein comprising the Fc domain of IgG can be purified on a Protein A or Protein G column and a fusion protein comprising an epitope tag such as myc can be purified using an immunoaffinity column containing an anti-c-myc antibody. It is preferable that the epitope tag be separated from the protein encoded by the essential gene by an enzymatic cleavage site that can be cleaved after purification. See also the discussion of nucleic acid molecules encoding fusion proteins that may be expressed on the surface of a cell.

Other useful protein fusions of the present invention include those that permit use of the protein of the present invention as bait in a yeast two-hybrid system. See Bartel *et al.* (eds.), The Yeast Two-Hybrid System, Oxford University Press (1997); Zhu *et al.*, Yeast Hybrid Technologies, Eaton Publishing (2000); Fields *et al.*, *Trends Genet.* 10(8): 286-92 (1994); Mendelsohn *et al.*, *Curr. Opin. Biotechnol.* 5(5): 482-6 (1994); Luban *et al.*, *Curr. Opin. Biotechnol.* 6(1): 59-64 (1995); Allen *et al.*, *Trends Biochem. Sci.* 20(12): 511-6 (1995); Drees, *Curr. Opin. Chem. Biol.* 3(1): 64-70 (1999); Topcu *et al.*, *Pharm. Res.* 17(9): 1049-55 (2000); Fashena *et al.*, *Gene* 250(1-2): 1-14 (2000); ; Colas *et al.*, (1996) Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. *Nature* 380, 548-550; Norman, T. *et al.*, (1999) Genetic selection of peptide inhibitors of biological pathways. *Science* 285, 591-595, Fabbri *et al.*, (1999) Inhibition of mammalian cell proliferation by genetically selected peptide aptamers that functionally antagonize E2F activity. *Oncogene* 18, 4357-4363; Xu *et al.*, (1997) Cells that register logical relationships among proteins. *Proc Natl Acad Sci U S A.* 94, 12473-12478; Yang, *et al.*, (1995) Protein-peptide interactions analyzed with the yeast two-hybrid system. *Nuc. Acids Res.* 23, 1152-1156; Kolonin *et al.*, (1998) Targeting cyclin-dependent kinases in *Drosophila* with peptide aptamers. *Proc Natl Acad Sci U S A* 95, 14266-14271; Cohen *et al.*, (1998) An artificial cell-cycle inhibitor isolated from a combinatorial library. *Proc Natl Acad Sci U S A* 95, 14272-14277; Uetz, P.; Giot, L.; al, e.; Fields, S.; Rothberg, J. M. (2000) A comprehensive analysis of protein-protein interactions in *Saccharomyces cerevisiae*. *Nature* 403, 623-627; Ito, *et al.*, (2001) A comprehensive two-hybrid analysis to explore the yeast protein interactome. *Proc Natl Acad Sci U S A* 98, 4569-4574, the disclosures of which are incorporated herein by reference in their entireties. Typically, such fusion is to either *E. coli* LexA or yeast

GAL4 DNA binding domains. Related bait plasmids are available that express the bait fused to a nuclear localization signal.

Other useful fusion proteins include those that permit display of the encoded protein on the surface of a phage or cell, fusions to intrinsically fluorescent proteins, such as green fluorescent protein (GFP), and fusions to the IgG Fc region, as described above, which discussion is incorporated here by reference in its entirety.

The polypeptides and fragments of the present invention can also usefully be fused to protein toxins, such as *Pseudomonas* exotoxin A, *diphtheria* toxin, *shiga* toxin A, *anthrax* toxin lethal factor, ricin, in order to effect ablation of cells that bind or take up the proteins of the present invention.

Fusion partners include, *inter alia*, myc, hemagglutinin (HA), GST, immunoglobulins,  $\beta$ -galactosidase, biotin trpE, protein A,  $\beta$ -lactamase,  $\alpha$ -amylase, maltose binding protein, alcohol dehydrogenase, polyhistidine (for example, six histidine at the amino and/or carboxyl terminus of the polypeptide), lacZ, green fluorescent protein (GFP), yeast  $\alpha$ -mating factor, GAL4 transcription activation or DNA binding domain, luciferase, and serum proteins such as ovalbumin, albumin and the constant domain of IgG. See, e.g., Ausubel (1992), *supra* and Ausubel (1999), *supra*. Fusion proteins may also contain sites for specific enzymatic cleavage, such as a site that is recognized by enzymes such as Factor XIII, trypsin, pepsin, or any other enzyme known in the art. Fusion proteins will typically be made by either recombinant nucleic acid methods, as described above, chemically synthesized using techniques well-known in the art (e.g., a Merrifield synthesis), or produced by chemical cross-linking.

Another advantage of fusion proteins is that the epitope tag can be used to bind the fusion protein to a plate or column through an affinity linkage for screening binding proteins or other molecules that bind to the LSP.

As further described below, the isolated polypeptides, muteins, fusion proteins, homologous proteins or allelic variants of the present invention can readily be used as specific immunogens to raise antibodies that specifically recognize LSPs, their allelic variants and homologues. The antibodies, in turn, can be used, *inter alia*, specifically to assay for the polypeptides of the present invention, particularly LSPs, e.g. by ELISA for detection of protein fluid samples, such as serum, by immunohistochemistry or laser scanning cytometry, for detection of protein in tissue samples, or by flow cytometry, for

detection of intracellular protein in cell suspensions, for specific antibody-mediated isolation and/or purification of LSPs, as for example by immunoprecipitation, and for use as specific agonists or antagonists of LSPs.

- One may determine whether polypeptides including muteins, fusion proteins, homologous proteins or allelic variants are functional by methods known in the art. For instance, residues that are tolerant of change while retaining function can be identified by altering the protein at known residues using methods known in the art, such as alanine scanning mutagenesis, Cunningham *et al.*, *Science* 244(4908): 1081-5 (1989); transposon linker scanning mutagenesis, Chen *et al.*, *Gene* 263(1-2): 39-48 (2001); combinations of homolog- and alanine-scanning mutagenesis, Jin *et al.*, *J. Mol. Biol.* 226(3): 851-65 (1992); combinatorial alanine scanning, Weiss *et al.*, *Proc. Natl. Acad. Sci USA* 97(16): 8950-4 (2000), followed by functional assay. Transposon linker scanning kits are available commercially (New England Biolabs, Beverly, MA, USA, catalog. no. E7-102S; EZ::TN™ In-Frame Linker Insertion Kit, catalogue no. EZI04KN, Epicentre Technologies Corporation, Madison, WI, USA).

- Purification of the polypeptides including fragments, homologous polypeptides, muteins, analogs, derivatives and fusion proteins is well-known and within the skill of one having ordinary skill in the art. See, e.g., Scopes, Protein Purification, 2d ed. (1987). Purification of recombinantly expressed polypeptides is described above. Purification of chemically-synthesized peptides can readily be effected, e.g., by HPLC.

- Accordingly, it is an aspect of the present invention to provide the isolated proteins of the present invention in pure or substantially pure form in the presence of absence of a stabilizing agent. Stabilizing agents include both proteinaceous or non-proteinaceous material and are well-known in the art. Stabilizing agents, such as albumin and polyethylene glycol (PEG) are known and are commercially available.

- Although high levels of purity are preferred when the isolated proteins of the present invention are used as therapeutic agents, such as in vaccines and as replacement therapy, the isolated proteins of the present invention are also useful at lower purity. For example, partially purified proteins of the present invention can be used as immunogens to raise antibodies in laboratory animals.

In preferred embodiments, the purified and substantially purified proteins of the present invention are in compositions that lack detectable ampholytes, acrylamide monomers, bis-acrylamide monomers, and polyacrylamide.

The polypeptides, fragments, analogs, derivatives and fusions of the present invention can usefully be attached to a substrate. The substrate can be porous or solid,  
5 planar or non-planar; the bond can be covalent or noncovalent.

For example, the polypeptides, fragments, analogs, derivatives and fusions of the present invention can usefully be bound to a porous substrate, commonly a membrane, typically comprising nitrocellulose, polyvinylidene fluoride (PVDF), or cationically  
10 derivatized, hydrophilic PVDF; so bound, the proteins, fragments, and fusions of the present invention can be used to detect and quantify antibodies, *e.g.* in serum, that bind specifically to the immobilized protein of the present invention.

As another example, the polypeptides, fragments, analogs, derivatives and fusions of the present invention can usefully be bound to a substantially nonporous substrate,  
15 such as plastic, to detect and quantify antibodies, *e.g.* in serum, that bind specifically to the immobilized protein of the present invention. Such plastics include polymethylacrylic, polyethylene, polypropylene, polyacrylate, polymethylmethacrylate, polyvinylchloride, polytetrafluoroethylene, polystyrene, polycarbonate, polyacetal, polysulfone, celluloseacetate, cellulosenitrate, nitrocellulose, or mixtures thereof; when  
20 the assay is performed in a standard microtiter dish, the plastic is typically polystyrene.

The polypeptides, fragments, analogs, derivatives and fusions of the present invention can also be attached to a substrate suitable for use as a surface enhanced laser desorption ionization source; so attached, the protein, fragment, or fusion of the present invention is useful for binding and then detecting secondary proteins that bind with  
25 sufficient affinity or avidity to the surface-bound protein to indicate biologic interaction there between. The proteins, fragments, and fusions of the present invention can also be attached to a substrate suitable for use in surface plasmon resonance detection; so attached, the protein, fragment, or fusion of the present invention is useful for binding and then detecting secondary proteins that bind with sufficient affinity or avidity to the  
30 surface-bound protein to indicate biological interaction there between.

### Antibodies

In another aspect, the invention provides antibodies, including fragments and derivatives thereof, that bind specifically to polypeptides encoded by the nucleic acid molecules of the invention, as well as antibodies that bind to fragments, muteins, derivatives and analogs of the polypeptides. In a preferred embodiment, the antibodies are specific for a polypeptide that is an LSP, or a fragment, mutein, derivative, analog or fusion protein thereof. In a more preferred embodiment, the antibodies are specific for a polypeptide that comprises SEQ ID NO: 143 through 277, or a fragment, mutein, derivative, analog or fusion protein thereof.

The antibodies of the present invention can be specific for linear epitopes, discontinuous epitopes, or conformational epitopes of such proteins or protein fragments, either as present on the protein in its native conformation or, in some cases, as present on the proteins as denatured, as, *e.g.*, by solubilization in SDS. New epitopes may be also due to a difference in post translational modifications (PTMs) in disease versus normal tissue. For example, a particular site on a LSP may be glycosylated in cancerous cells, but not glycosylated in normal cells or visa versa. In addition, alternative splice forms of a LSP may be indicative of cancer. Differential degradation of the C or N-terminus of a LSP may also be a marker or target for anticancer therapy. For example, a LSP may be N-terminal degraded in cancer cells exposing new epitopes to which antibodies may selectively bind for diagnostic or therapeutic uses.

As is well-known in the art, the degree to which an antibody can discriminate as among molecular species in a mixture will depend, in part, upon the conformational relatedness of the species in the mixture; typically, the antibodies of the present invention will discriminate over adventitious binding to non-LSP polypeptides by at least 2-fold, more typically by at least 5-fold, typically by more than 10-fold, 25-fold, 50-fold, 75-fold, and often by more than 100-fold, and on occasion by more than 500-fold or 1000-fold. When used to detect the proteins or protein fragments of the present invention, the antibody of the present invention is sufficiently specific when it can be used to determine the presence of the protein of the present invention in samples derived from human lung.

Typically, the affinity or avidity of an antibody (or antibody multimer, as in the case of an IgM pentamer) of the present invention for a protein or protein fragment of the present invention will be at least about  $1 \times 10^{-6}$  molar (M), typically at least about  $5 \times 10^{-7}$



<sup>7</sup> M,  $1 \times 10^{-7}$  M, with affinities and avidities of at least  $1 \times 10^{-8}$  M,  $5 \times 10^{-9}$  M,  $1 \times 10^{-10}$  M and up to  $1 \times 10^{-13}$  M proving especially useful.

The antibodies of the present invention can be naturally-occurring forms, such as IgG, IgM, IgD, IgE, IgY, and IgA, from any avian, reptilian, or mammalian species.

5 Human antibodies can, but will infrequently, be drawn directly from human donors or human cells. In this case, antibodies to the proteins of the present invention will typically have resulted from fortuitous immunization, such as autoimmune immunization, with the protein or protein fragments of the present invention. Such antibodies will typically, but will not invariably, be polyclonal. In addition, individual  
10 polyclonal antibodies may be isolated and cloned to generate monoclonals.

Human antibodies are more frequently obtained using transgenic animals that express human immunoglobulin genes, which transgenic animals can be affirmatively immunized with the protein immunogen of the present invention. Human Ig-transgenic mice capable of producing human antibodies and methods of producing human  
15 antibodies therefrom upon specific immunization are described, *inter alia*, in U.S. Patents 6,162,963; 6,150,584; 6,114,598; 6,075,181; 5,939,598; 5,877,397; 5,874,299; 5,814,318; 5,789,650; 5,770,429; 5,661,016; 5,633,425; 5,625,126; 5,569,825; 5,545,807; 5,545,806, and 5,591,669, the disclosures of which are incorporated herein by reference in their entireties. Such antibodies are typically monoclonal, and are typically  
20 produced using techniques developed for production of murine antibodies.

Human antibodies are particularly useful, and often preferred, when the antibodies of the present invention are to be administered to human beings as *in vivo* diagnostic or therapeutic agents, since recipient immune response to the administered antibody will often be substantially less than that occasioned by administration of an  
25 antibody derived from another species, such as mouse.

IgG, IgM, IgD, IgE, IgY, and IgA antibodies of the present invention can also be obtained from other species, including mammals such as rodents (typically mouse, but also rat, guinea pig, and hamster) lagomorphs, typically rabbits, and also larger mammals, such as sheep, goats, cows, and horses, and other egg laying birds or reptiles  
30 such as chickens or alligators. For example, avian antibodies may be generated using techniques described in WO 00/29444, published 25 May 2000, the contents of which are hereby incorporated in their entirety. In such cases, as with the transgenic human-

antibody-producing non-human mammals, fortuitous immunization is not required, and the non-human mammal is typically affirmatively immunized, according to standard immunization protocols, with the protein or protein fragment of the present invention.

As discussed above, virtually all fragments of 8 or more contiguous amino acids of the proteins of the present invention can be used effectively as immunogens when conjugated to a carrier, typically a protein such as bovine thyroglobulin, keyhole limpet hemocyanin, or bovine serum albumin, conveniently using a bifunctional linker such as those described elsewhere above, which discussion is incorporated by reference here.

Immunogenicity can also be conferred by fusion of the polypeptide and fragments of the present invention to other moieties. For example, peptides of the present invention can be produced by solid phase synthesis on a branched polylysine core matrix; these multiple antigenic peptides (MAPs) provide high purity, increased avidity, accurate chemical definition and improved safety in vaccine development. Tam *et al.*, *Proc. Natl. Acad. Sci. USA* 85: 5409-5413 (1988); Posnett *et al.*, *J. Biol. Chem.* 263: 1719-1725 (1988).

Protocols for immunizing non-human mammals or avian species are well-established in the art. See Harlow *et al.* (eds.), Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory (1998); Coligan *et al.* (eds.), Current Protocols in Immunology, John Wiley & Sons, Inc. (2001); Zola, Monoclonal Antibodies: Preparation and Use of Monoclonal Antibodies and Engineered Antibody Derivatives (Basics: From Background to Bench), Springer Verlag (2000); Gross M, Speck *J.Dtsch. Tierarztl. Wochenschr.* 103: 417-422 (1996), the disclosures of which are incorporated herein by reference. Immunization protocols often include multiple immunizations, either with or without adjuvants such as Freund's complete adjuvant and Freund's incomplete adjuvant, and may include naked DNA immunization (Moss, *Semin. Immunol.* 2: 317-327 (1990)).

Antibodies from non-human mammals and avian species can be polyclonal or monoclonal, with polyclonal antibodies having certain advantages in immunohistochemical detection of the proteins of the present invention and monoclonal antibodies having advantages in identifying and distinguishing particular epitopes of the proteins of the present invention. Antibodies from avian species may have particular advantage in detection of the proteins of the present invention, in human serum or tissues (Viking *et al.*, *Biosens. Bioelectron.* 13: 1257-1262 (1998)).

Following immunization, the antibodies of the present invention can be produced using any art-accepted technique. Such techniques are well-known in the art, Coligan, *supra*; Zola, *supra*; Howard *et al.* (eds.), Basic Methods in Antibody Production and Characterization, CRC Press (2000); Harlow, *supra*; Davis (ed.), Monoclonal Antibody  
5 Protocols, Vol. 45, Humana Press (1995); Delves (ed.), Antibody Production: Essential Techniques, John Wiley & Son Ltd (1997); Kenney, Antibody Solution: An Antibody Methods Manual, Chapman & Hall (1997), incorporated herein by reference in their entireties, and thus need not be detailed here.

Briefly, however, such techniques include, *inter alia*, production of monoclonal  
10 antibodies by hybridomas and expression of antibodies or fragments or derivatives thereof from host cells engineered to express immunoglobulin genes or fragments thereof. These two methods of production are not mutually exclusive: genes encoding antibodies specific for the proteins or protein fragments of the present invention can be cloned from hybridomas and thereafter expressed in other host cells. Nor need the two  
15 necessarily be performed together: *e.g.*, genes encoding antibodies specific for the proteins and protein fragments of the present invention can be cloned directly from B cells known to be specific for the desired protein, as further described in U.S. Patent 5,627,052, the disclosure of which is incorporated herein by reference in its entirety, or from antibody-displaying phage.

20 Recombinant expression in host cells is particularly useful when fragments or derivatives of the antibodies of the present invention are desired.

Host cells for recombinant production of either whole antibodies, antibody fragments, or antibody derivatives can be prokaryotic or eukaryotic.

Prokaryotic hosts are particularly useful for producing phage displayed antibodies  
25 of the present invention.

The technology of phage-displayed antibodies, in which antibody variable region fragments are fused, for example, to the gene III protein (pIII) or gene VIII protein (pVIII) for display on the surface of filamentous phage, such as M13, is by now well-established. *See, e.g.*, Sidhu, *Curr. Opin. Biotechnol.* 11(6): 610-6 (2000); Griffiths *et al.*, *Curr. Opin. Biotechnol.* 9(1): 102-8 (1998); Hoogenboom *et al.*, *Immunotechnology*,  
30 4(1): 1-20 (1998); Rader *et al.*, *Current Opinion in Biotechnology* 8: 503-508 (1997); Aujame *et al.*, *Human Antibodies* 8: 155-168 (1997); Hoogenboom, *Trends in*

*Biotechnol.* 15: 62-70 (1997); de Kruif *et al.*, 17: 453-455 (1996); Barbas *et al.*, *Trends in Biotechnol.* 14: 230-234 (1996); Winter *et al.*, *Ann. Rev. Immunol.* 433-455 (1994).

Techniques and protocols required to generate, propagate, screen (pan), and use the antibody fragments from such libraries have recently been compiled. *See, e.g.*, Barbas  
5 (2001), *supra*; Kay, *supra*; Abelson, *supra*, the disclosures of which are incorporated herein by reference in their entireties.

Typically, phage-displayed antibody fragments are scFv fragments or Fab fragments; when desired, full length antibodies can be produced by cloning the variable regions from the displaying phage into a complete antibody and expressing the full length  
10 antibody in a further prokaryotic or a eukaryotic host cell.

Eukaryotic cells are also useful for expression of the antibodies, antibody fragments, and antibody derivatives of the present invention.

For example, antibody fragments of the present invention can be produced in *Pichia pastoris* and in *Saccharomyces cerevisiae*. *See, e.g.*, Takahashi *et al.*, *Biosci.*  
15 *Biotechnol. Biochem.* 64(10): 2138-44 (2000); Freyre *et al.*, *J. Biotechnol.* 76(2-3): 157-63 (2000); Fischer *et al.*, *Biotechnol. Appl. Biochem.* 30 (Pt 2): 117-20 (1999); Pennell *et al.*, *Res. Immunol.* 149(6): 599-603 (1998); Eldin *et al.*, *J. Immunol. Methods.* 201(1): 67-75 (1997); Frenken *et al.*, *Res. Immunol.* 149(6): 589-99 (1998); Shusta *et al.*, *Nature Biotechnol.* 16(8): 773-7 (1998), the disclosures of which are incorporated herein  
20 by reference in their entireties.

Antibodies, including antibody fragments and derivatives, of the present invention can also be produced in insect cells. *See, e.g.*, Li *et al.*, *Protein Expr. Purif.* 21(1): 121-8 (2001); Ailor *et al.*, *Biotechnol. Bioeng.* 58(2-3): 196-203 (1998); Hsu *et al.*, *Biotechnol. Prog.* 13(1): 96-104 (1997); Edelman *et al.*, *Immunology* 91(1): 13-9 (1997);  
25 and Nesbit *et al.*, *J. Immunol. Methods* 151(1-2): 201-8 (1992), the disclosures of which are incorporated herein by reference in their entireties.

Antibodies and fragments and derivatives thereof of the present invention can also be produced in plant cells, particularly maize or tobacco, Giddings *et al.*, *Nature Biotechnol.* 18(11): 1151-5 (2000); Gaviñondo *et al.*, *Biotechniques* 29(1): 128-38 (2000);  
30 Fischer *et al.*, *J. Biol. Regul. Homeost. Agents* 14(2): 83-92 (2000); Fischer *et al.*, *Biotechnol. Appl. Biochem.* 30 (Pt 2): 113-6 (1999); Fischer *et al.*, *Biol. Chem.* 380(7-8): 825-39 (1999); Russell, *Curr. Top. Microbiol. Immunol.* 240: 119-38 (1999); and Ma *et*

*al.*, *Plant Physiol.* 109(2): 341-6 (1995), the disclosures of which are incorporated herein by reference in their entireties.

Antibodies, including antibody fragments and derivatives, of the present invention can also be produced in transgenic, non-human, mammalian milk. *See, e.g.*

5 Pollock *et al.*, *J. Immunol Methods.* 231: 147-57 (1999); Young *et al.*, *Res. Immunol.* 149: 609-10 (1998); Limonta *et al.*, *Immunotechnology* 1: 107-13 (1995), the disclosures of which are incorporated herein by reference in their entireties.

Mammalian cells useful for recombinant expression of antibodies, antibody fragments, and antibody derivatives of the present invention include CHO cells, COS  
10 cells, 293 cells, and myeloma cells.

Verma *et al.*, *J. Immunol. Methods* 216(1-2):165-81 (1998), herein incorporated by reference, review and compare bacterial, yeast, insect and mammalian expression systems for expression of antibodies.

Antibodies of the present invention can also be prepared by cell free translation,  
15 as further described in Merk *et al.*, *J. Biochem.* (Tokyo) 125(2): 328-33 (1999) and Ryabova *et al.*, *Nature Biotechnol.* 15(1): 79-84 (1997), and in the milk of transgenic animals, as further described in Pollock *et al.*, *J. Immunol. Methods* 231(1-2): 147-57 (1999), the disclosures of which are incorporated herein by reference in their entireties.

The invention further provides antibody fragments that bind specifically to one or  
20 more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, or the binding of which can be competitively inhibited by one or more of the proteins and protein fragments of the present invention or one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention.

25 Among such useful fragments are Fab, Fab', Fv, F(ab)'<sub>2</sub>, and single chain Fv (scFv) fragments. Other useful fragments are described in Hudson, *Curr. Opin. Biotechnol.* 9(4): 395-402 (1998).

It is also an aspect of the present invention to provide antibody derivatives that bind specifically to one or more of the proteins and protein fragments of the present  
30 invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, or the binding of which can be competitively inhibited by one or more of the proteins and protein fragments of the present invention or

one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention.

Among such useful derivatives are chimeric, primatized, and humanized antibodies; such derivatives are less immunogenic in human beings, and thus more  
5 suitable for *in vivo* administration, than are unmodified antibodies from non-human mammalian species. Another useful derivative is PEGylation to increase the serum half life of the antibodies.

Chimeric antibodies typically include heavy and/or light chain variable regions (including both CDR and framework residues) of immunoglobulins of one species,  
10 typically mouse, fused to constant regions of another species, typically human. See, e.g., United States Patent No. 5,807,715; Morrison *et al.*, *Proc. Natl. Acad. Sci USA* 81(21): 6851-5 (1984); Sharon *et al.*, *Nature* 309(5966): 364-7 (1984); Takeda *et al.*, *Nature* 314(6010): 452-4 (1985), the disclosures of which are incorporated herein by reference in their entireties. Primatized and humanized antibodies typically include heavy and/or  
15 light chain CDRs from a murine antibody grafted into a non-human primate or human antibody V region framework, usually further comprising a human constant region, Riechmann *et al.*, *Nature* 332(6162): 323-7 (1988); Co *et al.*, *Nature* 351(6326): 501-2 (1991); United States Patent Nos. 6,054,297; 5,821,337; 5,770,196; 5,766,886; 5,821,123; 5,869,619; 6,180,377; 6,013,256; 5,693,761; and 6,180,370, the disclosures of  
20 which are incorporated herein by reference in their entireties.

Other useful antibody derivatives of the invention include heteromeric antibody complexes and antibody fusions, such as diabodies (bispecific antibodies), single-chain diabodies, and intrabodies.

It is contemplated that the nucleic acids encoding the antibodies of the present  
25 invention can be operably joined to other nucleic acids forming a recombinant vector for cloning or for expression of the antibodies of the invention. The present invention includes any recombinant vector containing the coding sequences, or part thereof, whether for eukaryotic transduction, transfection or gene therapy. Such vectors may be prepared using conventional molecular biology techniques, known to those with skill in  
30 the art, and would comprise DNA encoding sequences for the immunoglobulin V-regions including framework and CDRs or parts thereof, and a suitable promoter either with or without a signal sequence for intracellular transport. Such vectors may be transduced or

transfected into eukaryotic cells or used for gene therapy (Marasco et al., *Proc. Natl. Acad. Sci. (USA)* 90: 7889-7893 (1993); Duan et al., *Proc. Natl. Acad. Sci. (USA)* 91: 5075-5079 (1994), by conventional techniques, known to those with skill in the art.

The antibodies of the present invention, including fragments and derivatives thereof, can usefully be labeled. It is, therefore, another aspect of the present invention to provide labeled antibodies that bind specifically to one or more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, or the binding of which can be competitively inhibited by one or more of the proteins and protein fragments of the present invention or one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention.

The choice of label depends, in part, upon the desired use.

For example, when the antibodies of the present invention are used for immunohistochemical staining of tissue samples, the label is preferably an enzyme that catalyzes production and local deposition of a detectable product.

Enzymes typically conjugated to antibodies to permit their immunohistochemical visualization are well-known, and include alkaline phosphatase,  $\beta$ -galactosidase, glucose oxidase, horseradish peroxidase (HRP), and urease. Typical substrates for production and deposition of visually detectable products include o-nitrophenyl-beta-D-galactopyranoside (ONPG); o-phenylenediamine dihydrochloride (OPD); p-nitrophenyl phosphate (PNPP); p-nitrophenyl-beta-D-galactopyranoside (PNPG); 3',3'-diaminobenzidine (DAB); 3-amino-9-ethylcarbazole (AEC); 4-chloro-1-naphthol (CN); 5-bromo-4-chloro-3-indolyl-phosphate (BCIP); ABTS®; BlueGal; iodonitrotetrazolium (INT); nitroblue tetrazolium chloride (NBT); phenazine methosulfate (PMS); phenolphthalein monophosphate (PMP); tetramethyl benzidine (TMB); tetranitroblue tetrazolium (TNBT); X-Gal; X-Gluc; and X-Glucoside.

Other substrates can be used to produce products for local deposition that are luminescent. For example, in the presence of hydrogen peroxide ( $H_2O_2$ ), horseradish peroxidase (HRP) can catalyze the oxidation of cyclic diacylhydrazides, such as luminol. Immediately following the oxidation, the luminol is in an excited state (intermediate reaction product), which decays to the ground state by emitting light. Strong enhancement of the light emission is produced by enhancers, such as phenolic

compounds. Advantages include high sensitivity, high resolution, and rapid detection without radioactivity and requiring only small amounts of antibody. See, e.g., Thorpe *et al.*, *Methods Enzymol.* 133: 331-53 (1986); Kricka *et al.*, *J. Immunoassay* 17(1): 67-83 (1996); and Lundqvist *et al.*, *J. Biolumin. Chemilumin.* 10(6): 353-9 (1995), the  
5 disclosures of which are incorporated herein by reference in their entireties. Kits for such enhanced chemiluminescent detection (ECL) are available commercially.

The antibodies can also be labeled using colloidal gold.

As another example, when the antibodies of the present invention are used, e.g., for flow cytometric detection, for scanning laser cytometric detection, or for fluorescent  
10 immunoassay, they can usefully be labeled with fluorophores.

There are a wide variety of fluorophore labels that can usefully be attached to the antibodies of the present invention.

For flow cytometric applications, both for extracellular detection and for intracellular detection, common useful fluorophores can be fluorescein isothiocyanate  
15 (FITC), allophycocyanin (APC), R-phycoerythrin (PE), peridinin chlorophyll protein (PerCP), Texas Red, Cy3, Cy5, fluorescence resonance energy tandem fluorophores such as PerCP-Cy5.5, PE-Cy5, PE-Cy5.5, PE-Cy7, PE-Texas Red, and APC-Cy7.

Other fluorophores include, *inter alia*, Alexa Fluor® 350, Alexa Fluor® 488, Alexa Fluor® 532, Alexa Fluor® 546, Alexa Fluor® 568, Alexa Fluor® 594, Alexa  
20 Fluor® 647 (monoclonal antibody labeling kits available from Molecular Probes, Inc., Eugene, OR, USA), BODIPY dyes, such as BODIPY 493/503, BODIPY FL, BODIPY R6G, BODIPY 530/550, BODIPY TMR, BODIPY 558/568, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY TR, BODIPY 630/650, BODIPY 650/665, Cascade Blue, Cascade Yellow, Dansyl, lissamine  
25 rhodamine B, Marina Blue, Oregon Green 488, Oregon Green 514, Pacific Blue, rhodamine 6G, rhodamine green, rhodamine red, tetramethylrhodamine, Texas Red (available from Molecular Probes, Inc., Eugene, OR, USA), and Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7, all of which are also useful for fluorescently labeling the antibodies of the present invention.

30 For secondary detection using labeled avidin, streptavidin, captavidin or neutravidin, the antibodies of the present invention can usefully be labeled with biotin.



When the antibodies of the present invention are used, *e.g.*, for Western blotting applications, they can usefully be labeled with radioisotopes, such as  $^{33}\text{P}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^3\text{H}$ , and  $^{125}\text{I}$ .

As another example, when the antibodies of the present invention are used for radioimmunotherapy, the label can usefully be  $^{228}\text{Th}$ ,  $^{227}\text{Ac}$ ,  $^{225}\text{Ac}$ ,  $^{223}\text{Ra}$ ,  $^{213}\text{Bi}$ ,  $^{212}\text{Pb}$ ,  $^{212}\text{Bi}$ ,  $^{211}\text{At}$ ,  $^{203}\text{Pb}$ ,  $^{194}\text{Os}$ ,  $^{188}\text{Re}$ ,  $^{186}\text{Re}$ ,  $^{153}\text{Sm}$ ,  $^{149}\text{Tb}$ ,  $^{131}\text{I}$ ,  $^{125}\text{I}$ ,  $^{111}\text{In}$ ,  $^{105}\text{Rh}$ ,  $^{99\text{m}}\text{Tc}$ ,  $^{97}\text{Ru}$ ,  $^{90}\text{Y}$ ,  $^{90}\text{Sr}$ ,  $^{88}\text{Y}$ ,  $^{72}\text{Se}$ ,  $^{67}\text{Cu}$ , or  $^{47}\text{Sc}$ .

As another example, when the antibodies of the present invention are to be used for *in vivo* diagnostic use, they can be rendered detectable by conjugation to MRI contrast agents, such as gadolinium diethylenetriaminepentaacetic acid (DTPA), Lauffer *et al.*, *Radiology* 207(2): 529-38 (1998), or by radioisotopic labeling.

As would be understood, use of the labels described above is not restricted to the application for which they are mentioned.

The antibodies of the present invention, including fragments and derivatives thereof, can also be conjugated to toxins, in order to target the toxin's ablative action to cells that display and/or express the proteins of the present invention. Commonly, the antibody in such immunotoxins is conjugated to *Pseudomonas* exotoxin A, diphtheria toxin, shiga toxin A, anthrax toxin lethal factor, or ricin. See Hall (ed.), Immunotoxin Methods and Protocols (Methods in Molecular Biology, vol. 166), Humana Press (2000); and Frankel *et al.* (eds.), Clinical Applications of Immunotoxins, Springer-Verlag (1998), the disclosures of which are incorporated herein by reference in their entireties.

The antibodies of the present invention can usefully be attached to a substrate, and it is, therefore, another aspect of the invention to provide antibodies that bind specifically to one or more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, or the binding of which can be competitively inhibited by one or more of the proteins and protein fragments of the present invention or one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, attached to a substrate.

Substrates can be porous or nonporous, planar or nonplanar.

For example, the antibodies of the present invention can usefully be conjugated to filtration media, such as NHS-activated Sepharose or CNBr-activated Sepharose for purposes of immunoaffinity chromatography.

For example, the antibodies of the present invention can usefully be attached to  
5 paramagnetic microspheres, typically by biotin-streptavidin interaction, which microspheres can then be used for isolation of cells that express or display the proteins of the present invention. As another example, the antibodies of the present invention can usefully be attached to the surface of a microtiter plate for ELISA.

As noted above, the antibodies of the present invention can be produced in  
10 prokaryotic and eukaryotic cells. It is, therefore, another aspect of the present invention to provide cells that express the antibodies of the present invention, including hybridoma cells, B cells, plasma cells, and host cells recombinantly modified to express the antibodies of the present invention.

In yet a further aspect, the present invention provides aptamers evolved to bind  
15 specifically to one or more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, or the binding of which can be competitively inhibited by one or more of the proteins and protein fragments of the present invention or one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present  
20 invention.

In sum, one of skill in the art, provided with the teachings of this invention, has available a variety of methods which may be used to alter the biological properties of the antibodies of this invention including methods which would increase or decrease the stability or half-life, immunogenicity, toxicity, affinity or yield of a given antibody  
25 molecule, or to alter it in any other way that may render it more suitable for a particular application.

#### Transgenic Animals and Cells

In another aspect, the invention provides transgenic cells and non-human  
30 organisms comprising nucleic acid molecules of the invention. In a preferred embodiment, the transgenic cells and non-human organisms comprise a nucleic acid molecule encoding an LSP. In a preferred embodiment, the LSP comprises an amino

acid sequence selected from SEQ ID NO: 143 through 277, or a fragment, mutein, homologous protein or allelic variant thereof. In another preferred embodiment, the transgenic cells and non-human organism comprise an LSNA of the invention, preferably an LSNA comprising a nucleotide sequence selected from the group consisting of SEQ  
5 ID NO: 1 through 142, or a part, substantially similar nucleic acid molecule, allelic variant or hybridizing nucleic acid molecule thereof.

In another embodiment, the transgenic cells and non-human organisms have a targeted disruption or replacement of the endogenous orthologue of the human LSG. The transgenic cells can be embryonic stem cells or somatic cells. The transgenic non-human  
10 organisms can be chimeric, nonchimeric heterozygotes, and nonchimeric homozygotes. Methods of producing transgenic animals are well-known in the art. *See, e.g., Hogan et al., Manipulating the Mouse Embryo: A Laboratory Manual*, 2d ed., Cold Spring Harbor Press (1999); Jackson *et al.*, *Mouse Genetics and Transgenics: A Practical Approach*, Oxford University Press (2000); and Pinkert, *Transgenic Animal Technology: A*  
15 *Laboratory Handbook*, Academic Press (1999).

Any technique known in the art may be used to introduce a nucleic acid molecule of the invention into an animal to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection. (*see, e.g., Paterson et al., Appl. Microbiol. Biotechnol.* 40: 691-698 (1994); Carver *et al.*, *Biotechnology* 11:  
20 1263-1270 (1993); Wright *et al.*, *Biotechnology* 9: 830-834 (1991); and U.S. Patent 4,873,191 (1989 retrovirus-mediated gene transfer into germ lines, blastocysts or embryos (*see, e.g., Van der Putten et al., Proc. Natl. Acad. Sci., USA* 82: 6148-6152 (1985)); gene targeting in embryonic stem cells (*see, e.g., Thompson et al., Cell* 56: 313-321 (1989)); electroporation of cells or embryos (*see, e.g., Lo, 1983, Mol. Cell. Biol.*  
25 3: 1803-1814 (1983)); introduction using a gene gun (*see, e.g., Ulmer et al., Science* 259: 1745-49 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated gene transfer (*see, e.g., Lavitrano et al., Cell* 57: 717-723 (1989)).

Other techniques include, for example, nuclear transfer into enucleated oocytes of  
30 nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (*see, e.g., Campell et al., Nature* 380: 64-66 (1996); Wilmut *et al.*, *Nature* 385: 810-813 (1997)). The present invention provides for transgenic animals that carry the transgene (*i.e., a*

nucleic acid molecule of the invention) in all their cells, as well as animals which carry the transgene in some, but not all their cells, i. e., mosaic animals or chimeric animals.

The transgene may be integrated as a single transgene or as multiple copies, such as in concatamers, e. g., head-to-head tandems or head-to-tail tandems. The transgene  
5 may also be selectively introduced into and activated in a particular cell type by following, e.g., the teaching of Lasko *et al. et al.*, *Proc. Natl. Acad. Sci. USA* 89: 6232-6236 (1992). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

10 Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using  
15 techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse transcriptase-PCR (RT-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

20 Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels  
25 because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is  
30 appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of

the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

Methods for creating a transgenic animal with a disruption of a targeted gene are also well-known in the art. In general, a vector is designed to comprise some nucleotide sequences homologous to the endogenous targeted gene. The vector is introduced into a cell so that it may integrate, via homologous recombination with chromosomal sequences, into the endogenous gene, thereby disrupting the function of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type. *See, e.g., Gu et al., Science* 265: 103-106 (1994). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. *See, e.g., Smithies et al., Nature* 317: 230-234 (1985); Thomas *et al., Cell* 51: 503-512 (1987); Thompson *et al., Cell* 5: 313-321 (1989).

In one embodiment, a mutant, non-functional nucleic acid molecule of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous nucleic acid sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention *in vivo*. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene. *See, e.g., Thomas, supra* and Thompson, *supra*. However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (*e.g., knockouts*) are administered to a patient *in vivo*. Such cells may be obtained from an animal or patient or an MHC

compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (*e.g.*, lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt  
5 the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, *e.g.*, by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc.

10 The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, *e.g.*, in the circulation, or intraperitoneally.

15 Alternatively, the cells can be incorporated into a matrix and implanted in the body, *e.g.*, genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. *See, e.g.*, U.S. Patents 5,399,349 and 5,460,959, each of which is incorporated by reference herein in its entirety.

20 When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well-known techniques which prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the  
25 introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such  
30 conditions and/or disorders.

Computer Readable Means

A further aspect of the invention relates to a computer readable means for storing the nucleic acid and amino acid sequences of the instant invention. In a preferred embodiment, the invention provides a computer readable means for storing SEQ ID NO: 1 through 142 and SEQ ID NO: 143 through 277 as described herein, as the complete set of sequences or in any combination. The records of the computer readable means can be accessed for reading and display and for interface with a computer system for the application of programs allowing for the location of data upon a query for data meeting certain criteria, the comparison of sequences, the alignment or ordering of sequences meeting a set of criteria, and the like.

The nucleic acid and amino acid sequences of the invention are particularly useful as components in databases useful for search analyses as well as in sequence analysis algorithms. As used herein, the terms "nucleic acid sequences of the invention" and "amino acid sequences of the invention" mean any detectable chemical or physical characteristic of a polynucleotide or polypeptide of the invention that is or may be reduced to or stored in a computer readable form. These include, without limitation, chromatographic scan data or peak data, photographic data or scan data therefrom, and mass spectrographic data.

This invention provides computer readable media having stored thereon sequences of the invention. A computer readable medium may comprise one or more of the following: a nucleic acid sequence comprising a sequence of a nucleic acid sequence of the invention; an amino acid sequence comprising an amino acid sequence of the invention; a set of nucleic acid sequences wherein at least one of said sequences comprises the sequence of a nucleic acid sequence of the invention; a set of amino acid sequences wherein at least one of said sequences comprises the sequence of an amino acid sequence of the invention; a data set representing a nucleic acid sequence comprising the sequence of one or more nucleic acid sequences of the invention; a data set representing a nucleic acid sequence encoding an amino acid sequence comprising the sequence of an amino acid sequence of the invention; a set of nucleic acid sequences wherein at least one of said sequences comprises the sequence of a nucleic acid sequence of the invention; a set of amino acid sequences wherein at least one of said sequences comprises the sequence of an amino acid sequence of the invention; a data set

representing a nucleic acid sequence comprising the sequence of a nucleic acid sequence of the invention; a data set representing a nucleic acid sequence encoding an amino acid sequence comprising the sequence of an amino acid sequence of the invention. The computer readable medium can be any composition of matter used to store information or ,  
5 data, including, for example, commercially available floppy disks, tapes, hard drives, compact disks, and video disks.

Also provided by the invention are methods for the analysis of character sequences, particularly genetic sequences. Preferred methods of sequence analysis include, for example, methods of sequence homology analysis, such as identity and  
10 similarity analysis, RNA structure analysis, sequence assembly, cladistic analysis, sequence motif analysis, open reading frame determination, nucleic acid base calling, and sequencing chromatogram peak analysis.

A computer-based method is provided for performing nucleic acid sequence identity or similarity identification. This method comprises the steps of providing a  
15 nucleic acid sequence comprising the sequence of a nucleic acid of the invention in a computer readable medium; and comparing said nucleic acid sequence to at least one nucleic acid or amino acid sequence to identify sequence identity or similarity.

A computer-based method is also provided for performing amino acid homology identification, said method comprising the steps of: providing an amino acid sequence  
20 comprising the sequence of an amino acid of the invention in a computer readable medium; and comparing said an amino acid sequence to at least one nucleic acid or an amino acid sequence to identify homology.

A computer-based method is still further provided for assembly of overlapping nucleic acid sequences into a single nucleic acid sequence, said method comprising the  
25 steps of: providing a first nucleic acid sequence comprising the sequence of a nucleic acid of the invention in a computer readable medium; and screening for at least one overlapping region between said first nucleic acid sequence and a second nucleic acid sequence.

#### Diagnostic Methods for Lung Cancer

30

The present invention also relates to quantitative and qualitative diagnostic assays and methods for detecting, diagnosing, monitoring, staging and predicting cancers by



comparing expression of an LSNA or an LSP in a human patient that has or may have lung cancer, or who is at risk of developing lung cancer, with the expression of an LSNA or an LSP in a normal human control. For purposes of the present invention, "expression of an LSNA" or "LSNA expression" means the quantity of LSG mRNA that can be measured by any method known in the art or the level of transcription that can be measured by any method known in the art in a cell, tissue, organ or whole patient. Similarly, the term "expression of an LSP" or "LSP expression" means the amount of LSP that can be measured by any method known in the art or the level of translation of an LSG LSNA that can be measured by any method known in the art.

10       The present invention provides methods for diagnosing lung cancer in a patient, in particular squamous cell carcinoma, by analyzing for changes in levels of LSNA or LSP in cells, tissues, organs or bodily fluids compared with levels of LSNA or LSP in cells, tissues, organs or bodily fluids of preferably the same type from a normal human control, wherein an increase, or decrease in certain cases, in levels of an LSNA or LSP in the patient versus the normal human control is associated with the presence of lung cancer or with a predilection to the disease. In another preferred embodiment, the present invention provides methods for diagnosing lung cancer in a patient by analyzing changes in the structure of the mRNA of an LSG compared to the mRNA from a normal control. These changes include, without limitation, aberrant splicing, alterations in polyadenylation and/or alterations in 5' nucleotide capping. In yet another preferred embodiment, the present invention provides methods for diagnosing lung cancer in a patient by analyzing changes in an LSP compared to an LSP from a normal control. These changes include, *e.g.*, alterations in glycosylation and/or phosphorylation of the LSP or subcellular LSP localization.

25       In a preferred embodiment, the expression of an LSNA is measured by determining the amount of an mRNA that encodes an amino acid sequence selected from SEQ ID NO: 143 through 277, a homolog, an allelic variant, or a fragment thereof. In a more preferred embodiment, the LSNA expression that is measured is the level of expression of an LSNA mRNA selected from SEQ ID NO: 1 through 142, or a hybridizing nucleic acid, homologous nucleic acid or allelic variant thereof, or a part of any of these nucleic acids. LSNA expression may be measured by any method known in the art, such as those described *supra*, including measuring mRNA expression by

Northern blot, quantitative or qualitative reverse transcriptase PCR (RT-PCR), microarray, dot or slot blots or *in situ* hybridization. *See, e.g.,* Ausubel (1992), *supra*; Ausubel (1999), *supra*; Sambrook (1989), *supra*; and Sambrook (2001), *supra*. LSNA transcription may be measured by any method known in the art including using a reporter gene hooked up to the promoter of an LSG of interest or doing nuclear run-off assays. Alterations in mRNA structure, *e.g.,* aberrant splicing variants, may be determined by any method known in the art, including, RT-PCR followed by sequencing or restriction analysis. As necessary, LSNA expression may be compared to a known control, such as normal lung nucleic acid, to detect a change in expression.

10 In another preferred embodiment, the expression of an LSP is measured by determining the level of an LSP having an amino acid sequence selected from the group consisting of SEQ ID NO: 143 through 277, a homolog, an allelic variant, or a fragment thereof. Such levels are preferably determined in at least one of cells, tissues, organs and/or bodily fluids, including determination of normal and abnormal levels. Thus, for instance, a diagnostic assay in accordance with the invention for diagnosing over- or underexpression of LSNA or LSP compared to normal control bodily fluids, cells, or tissue samples may be used to diagnose the presence of lung cancer. The expression level of an LSP may be determined by any method known in the art, such as those described *supra*. In a preferred embodiment, the LSP expression level may be determined by radioimmunoassays, competitive-binding assays, ELISA, Western blot, FACS, immunohistochemistry, immunoprecipitation, proteomic approaches: two-dimensional gel electrophoresis (2D electrophoresis) and non-gel-based approaches such as mass spectrometry or protein interaction profiling. *See, e.g.,* Harlow (1999), *supra*; Ausubel (1992), *supra*; and Ausubel (1999), *supra*. Alterations in the LSP structure may be determined by any method known in the art, including, *e.g.,* using antibodies that specifically recognize phosphoserine, phosphothreonine or phosphotyrosine residues, two-dimensional polyacrylamide gel electrophoresis (2D PAGE) and/or chemical analysis of amino acid residues of the protein. *Id.*

25 In a preferred embodiment, a radioimmunoassay (RIA) or an ELISA is used. An antibody specific to an LSP is prepared if one is not already available. In a preferred embodiment, the antibody is a monoclonal antibody. The anti-LSP antibody is bound to a solid support and any free protein binding sites on the solid support are blocked with a

protein such as bovine serum albumin. A sample of interest is incubated with the antibody on the solid support under conditions in which the LSP will bind to the anti-LSP antibody. The sample is removed, the solid support is washed to remove unbound material, and an anti-LSP antibody that is linked to a detectable reagent (a radioactive substance for RIA and an enzyme for ELISA) is added to the solid support and incubated under conditions in which binding of the LSP to the labeled antibody will occur. After binding, the unbound labeled antibody is removed by washing. For an ELISA, one or more substrates are added to produce a colored reaction product that is based upon the amount of an LSP in the sample. For an RIA, the solid support is counted for radioactive decay signals by any method known in the art. Quantitative results for both RIA and ELISA typically are obtained by reference to a standard curve.

Other methods to measure LSP levels are known in the art. For instance, a competition assay may be employed wherein an anti-LSP antibody is attached to a solid support and an allocated amount of a labeled LSP and a sample of interest are incubated with the solid support. The amount of labeled LSP detected which is attached to the solid support can be correlated to the quantity of an LSP in the sample.

Of the proteomic approaches, 2D PAGE is a well-known technique. Isolation of individual proteins from a sample such as serum is accomplished using sequential separation of proteins by isoelectric point and molecular weight. Typically, polypeptides are first separated by isoelectric point (the first dimension) and then separated by size using an electric current (the second dimension). In general, the second dimension is perpendicular to the first dimension. Because no two proteins with different sequences are identical on the basis of both size and charge, the result of 2D PAGE is a roughly square gel in which each protein occupies a unique spot. Analysis of the spots with chemical or antibody probes, or subsequent protein microsequencing can reveal the relative abundance of a given protein and the identity of the proteins in the sample.

Expression levels of an LSNA can be determined by any method known in the art, including PCR and other nucleic acid methods, such as ligase chain reaction (LCR) and nucleic acid sequence based amplification (NASBA), can be used to detect malignant cells for diagnosis and monitoring of various malignancies. For example, reverse-transcriptase PCR (RT-PCR) is a powerful technique which can be used to detect the presence of a specific mRNA population in a complex mixture of thousands of other

mRNA species. In RT-PCR, an mRNA species is first reverse transcribed to complementary DNA (cDNA) with use of the enzyme reverse transcriptase; the cDNA is then amplified as in a standard PCR reaction.

Hybridization to specific DNA molecules (*e.g.*, oligonucleotides) arrayed on a solid support can be used to both detect the expression of and quantitate the level of expression of one or more LSNAs of interest. In this approach, all or a portion of one or more LSNAs is fixed to a substrate. A sample of interest, which may comprise RNA, *e.g.*, total RNA or polyA-selected mRNA, or a complementary DNA (cDNA) copy of the RNA is incubated with the solid support under conditions in which hybridization will occur between the DNA on the solid support and the nucleic acid molecules in the sample of interest. Hybridization between the substrate-bound DNA and the nucleic acid molecules in the sample can be detected and quantitated by several means, including, without limitation, radioactive labeling or fluorescent labeling of the nucleic acid molecule or a secondary molecule designed to detect the hybrid.

The above tests can be carried out on samples derived from a variety of cells, bodily fluids and/or tissue extracts such as homogenates or solubilized tissue obtained from a patient. Tissue extracts are obtained routinely from tissue biopsy and autopsy material. Bodily fluids useful in the present invention include blood, urine, saliva or any other bodily secretion or derivative thereof. By blood it is meant to include whole blood, plasma, serum or any derivative of blood. In a preferred embodiment, the specimen tested for expression of LSNA or LSP includes, without limitation, lung tissue, fluid obtained by bronchial alveolar lavage (BAL), sputum, lung cells grown in cell culture, blood, serum, lymph node tissue and lymphatic fluid. In another preferred embodiment, especially when metastasis of a primary lung cancer is known or suspected, specimens include, without limitation, tissues from brain, bone, bone marrow, liver, adrenal glands and colon. In general, the tissues may be sampled by biopsy, including, without limitation, needle biopsy, *e.g.*, transthoracic needle aspiration, cervical mediastinoscopy, endoscopic lymph node biopsy, video-assisted thoracoscopy, exploratory thoracotomy, bone marrow biopsy and bone marrow aspiration. *See Scott, supra* and Franklin, pp. 529-570, in Kane, *supra*. For early and inexpensive detection, assaying for changes in LSNAs or LSPs in cells in sputum samples may be particularly useful. Methods of obtaining and analyzing sputum samples is disclosed in Franklin, *supra*.

All the methods of the present invention may optionally include determining the expression levels of one or more other cancer markers in addition to determining the expression level of an LSNA or LSP. In many cases, the use of another cancer marker will decrease the likelihood of false positives or false negatives. In one embodiment, the one or more other cancer markers include other LSNA or LSPs as disclosed herein. Other cancer markers useful in the present invention will depend on the cancer being tested and are known to those of skill in the art. In a preferred embodiment, at least one other cancer marker in addition to a particular LSNA or LSP is measured. In a more preferred embodiment, at least two other additional cancer markers are used. In an even more preferred embodiment, at least three, more preferably at least five, even more preferably at least ten additional cancer markers are used.

#### *Diagnosing*

In one aspect, the invention provides a method for determining the expression levels and/or structural alterations of one or more LSNAs and/or LSPs in a sample from a patient suspected of having lung cancer. In general, the method comprises the steps of obtaining the sample from the patient, determining the expression level or structural alterations of an LSNA and/or LSP and then ascertaining whether the patient has lung cancer from the expression level of the LSNA or LSP. In general, if high expression relative to a control of an LSNA or LSP is indicative of lung cancer, a diagnostic assay is considered positive if the level of expression of the LSNA or LSP is at least two times higher, and more preferably are at least five times higher, even more preferably at least ten times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control. In contrast, if low expression relative to a control of an LSNA or LSP is indicative of lung cancer, a diagnostic assay is considered positive if the level of expression of the LSNA or LSP is at least two times lower, more preferably are at least five times lower, even more preferably at least ten times lower than in preferably the same cells, tissues or bodily fluid of a normal human control. The normal human control may be from a different patient or from uninvolved tissue of the same patient.

The present invention also provides a method of determining whether lung cancer has metastasized in a patient. One may identify whether the lung cancer has metastasized by measuring the expression levels and/or structural alterations of one or more LSNAs and/or LSPs in a variety of tissues. The presence of an LSNA or LSP in a certain tissue

at levels higher than that of corresponding noncancerous tissue (*e.g.*, the same tissue from another individual) is indicative of metastasis if high level expression of an LSNA or LSP is associated with lung cancer. Similarly, the presence of an LSNA or LSP in a tissue at levels lower than that of corresponding noncancerous tissue is indicative of metastasis if low level expression of an LSNA or LSP is associated with lung cancer. Further, the presence of a structurally altered LSNA or LSP that is associated with lung cancer is also indicative of metastasis.

In general, if high expression relative to a control of an LSNA or LSP is indicative of metastasis, an assay for metastasis is considered positive if the level of expression of the LSNA or LSP is at least two times higher, and more preferably are at least five times higher, even more preferably at least ten times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control. In contrast, if low expression relative to a control of an LSNA or LSP is indicative of metastasis, an assay for metastasis is considered positive if the level of expression of the LSNA or LSP is at least two times lower, more preferably are at least five times lower, even more preferably at least ten times lower than in preferably the same cells, tissues or bodily fluid of a normal human control.

The LSNA or LSP of this invention may be used as element in an array or a multi-analyte test to recognize expression patterns associated with lung cancers or other lung related disorders. In addition, the sequences of either the nucleic acids or proteins may be used as elements in a computer program for pattern recognition of lung disorders.

### *Staging*

The invention also provides a method of staging lung cancer in a human patient. The method comprises identifying a human patient having lung cancer and analyzing cells, tissues or bodily fluids from such human patient for expression levels and/or structural alterations of one or more LSNAs or LSPs. First, one or more tumors from a variety of patients are staged according to procedures well-known in the art, and the expression level of one or more LSNAs or LSPs is determined for each stage to obtain a standard expression level for each LSNA and LSP. Then, the LSNA or LSP expression levels are determined in a biological sample from a patient whose stage of cancer is not known. The LSNA or LSP expression levels from the patient are then compared to the

standard expression level. By comparing the expression level of the LSNAs and LSPs from the patient to the standard expression levels, one may determine the stage of the tumor. The same procedure may be followed using structural alterations of an LSNA or LSP to determine the stage of a lung cancer.

## 5 *Monitoring*

Further provided is a method of monitoring lung cancer in a human patient. One may monitor a human patient to determine whether there has been metastasis and, if there has been, when metastasis began to occur. One may also monitor a human patient to determine whether a preneoplastic lesion has become cancerous. One may also monitor  
10 a human patient to determine whether a therapy, e.g., chemotherapy, radiotherapy or surgery, has decreased or eliminated the lung cancer. The method comprises identifying a human patient that one wants to monitor for lung cancer, periodically analyzing cells, tissues or bodily fluids from such human patient for expression levels of one or more LSNAs or LSPs, and comparing the LSNA or LSP levels over time to those LSNA or  
15 LSP expression levels obtained previously. Patients may also be monitored by measuring one or more structural alterations in an LSNA or LSP that are associated with lung cancer.

If increased expression of an LSNA or LSP is associated with metastasis, treatment failure, or conversion of a preneoplastic lesion to a cancerous lesion, then  
20 detecting an increase in the expression level of an LSNA or LSP indicates that the tumor is metastasizing, that treatment has failed or that the lesion is cancerous, respectively. One having ordinary skill in the art would recognize that if this were the case, then a decreased expression level would be indicative of no metastasis, effective therapy or failure to progress to a neoplastic lesion. If decreased expression of an LSNA or LSP is  
25 associated with metastasis, treatment failure, or conversion of a preneoplastic lesion to a cancerous lesion, then detecting an decrease in the expression level of an LSNA or LSP indicates that the tumor is metastasizing, that treatment has failed or that the lesion is cancerous, respectively. In a preferred embodiment, the levels of LSNAs or LSPs are determined from the same cell type, tissue or bodily fluid as prior patient samples.  
30 Monitoring a patient for onset of lung cancer metastasis is periodic and preferably is done on a quarterly basis, but may be done more or less frequently.

The methods described herein can further be utilized as prognostic assays to identify subjects having or at risk of developing a disease or disorder associated with increased or decreased expression levels of an LSNA and/or LSP. The present invention provides a method in which a test sample is obtained from a human patient and one or more LSNA and/or LSPs are detected. The presence of higher (or lower) LSNA or LSP levels as compared to normal human controls is diagnostic for the human patient being at risk for developing cancer, particularly lung cancer. The effectiveness of therapeutic agents to decrease (or increase) expression or activity of one or more LSNA and/or LSPs of the invention can also be monitored by analyzing levels of expression of the LSNA and/or LSPs in a human patient in clinical trials or in *in vitro* screening assays such as in human cells. In this way, the gene expression pattern can serve as a marker, indicative of the physiological response of the human patient or cells, as the case may be, to the agent being tested.

#### *Detection of Genetic Lesions or Mutations*

The methods of the present invention can also be used to detect genetic lesions or mutations in an LSG, thereby determining if a human with the genetic lesion is susceptible to developing lung cancer or to determine what genetic lesions are responsible, or are partly responsible, for a person's existing lung cancer. Genetic lesions can be detected, for example, by ascertaining the existence of a deletion, insertion and/or substitution of one or more nucleotides from the LSGs of this invention; a chromosomal rearrangement of LSG, an aberrant modification of LSG (such as of the methylation pattern of the genomic DNA), or allelic loss of an LSG. Methods to detect such lesions in the LSG of this invention are known to those having ordinary skill in the art following the teachings of the specification.

#### 25 Methods of Detecting Noncancerous Lung Diseases

The invention also provides a method for determining the expression levels and/or structural alterations of one or more LSNA and/or LSPs in a sample from a patient suspected of having or known to have a noncancerous lung disease. In general, the method comprises the steps of obtaining a sample from the patient, determining the expression level or structural alterations of an LSNA and/or LSP, comparing the expression level or structural alteration of the LSNA or LSP to a normal lung control,



and then ascertaining whether the patient has a noncancerous lung disease. In general, if high expression relative to a control of an LSNA or LSP is indicative of a particular noncancerous lung disease, a diagnostic assay is considered positive if the level of expression of the LSNA or LSP is at least two times higher, and more preferably are at least five times higher, even more preferably at least ten times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control. In contrast, if low expression relative to a control of an LSNA or LSP is indicative of a noncancerous lung disease, a diagnostic assay is considered positive if the level of expression of the LSNA or LSP is at least two times lower, more preferably are at least five times lower, even more preferably at least ten times lower than in preferably the same cells, tissues or bodily fluid of a normal human control. The normal human control may be from a different patient or from uninvolved tissue of the same patient.

One having ordinary skill in the art may determine whether an LSNA and/or LSP is associated with a particular noncancerous lung disease by obtaining lung tissue from a patient having a noncancerous lung disease of interest and determining which LSNAs and/or LSPs are expressed in the tissue at either a higher or a lower level than in normal lung tissue. In another embodiment, one may determine whether an LSNA or LSP exhibits structural alterations in a particular noncancerous lung disease state by obtaining lung tissue from a patient having a noncancerous lung disease of interest and determining the structural alterations in one or more LSNAs and/or LSPs relative to normal lung tissue.

#### Methods for Identifying Lung Tissue

In another aspect, the invention provides methods for identifying lung tissue. These methods are particularly useful in, e.g., forensic science, lung cell differentiation and development, and in tissue engineering.

In one embodiment, the invention provides a method for determining whether a sample is lung tissue or has lung tissue-like characteristics. The method comprises the steps of providing a sample suspected of comprising lung tissue or having lung tissue-like characteristics, determining whether the sample expresses one or more LSNAs and/or LSPs, and, if the sample expresses one or more LSNAs and/or LSPs, concluding that the sample comprises lung tissue. In a preferred embodiment, the LSNA encodes a

- polypeptide having an amino acid sequence selected from SEQ ID NO: 143 through 277, or a homolog, allelic variant or fragment thereof. In a more preferred embodiment, the LSNA has a nucleotide sequence selected from SEQ ID NO: 1 through 142, or a hybridizing nucleic acid, an allelic variant or a part thereof. Determining whether a sample expresses an LSNA can be accomplished by any method known in the art. Preferred methods include hybridization to microarrays, Northern blot hybridization, and quantitative or qualitative RT-PCR. In another preferred embodiment, the method can be practiced by determining whether an LSP is expressed. Determining whether a sample expresses an LSP can be accomplished by any method known in the art.
- 10 Preferred methods include Western blot, ELISA, RIA and 2D PAGE. In one embodiment, the LSP has an amino acid sequence selected from SEQ ID NO: 143 through 277, or a homolog, allelic variant or fragment thereof. In another preferred embodiment, the expression of at least two LSNAs and/or LSPs is determined. In a more preferred embodiment, the expression of at least three, more preferably four and even
- 15 more preferably five LSNAs and/or LSPs are determined.

- In one embodiment, the method can be used to determine whether an unknown tissue is lung tissue. This is particularly useful in forensic science, in which small, damaged pieces of tissues that are not identifiable by microscopic or other means are recovered from a crime or accident scene. In another embodiment, the method can be
- 20 used to determine whether a tissue is differentiating or developing into lung tissue. This is important in monitoring the effects of the addition of various agents to cell or tissue culture, *e.g.*, in producing new lung tissue by tissue engineering. These agents include, *e.g.*, growth and differentiation factors, extracellular matrix proteins and culture medium. Other factors that may be measured for effects on tissue development and differentiation
- 25 include gene transfer into the cells or tissues, alterations in pH, aqueous:air interface and various other culture conditions.

#### Methods for Producing and Modifying Lung Tissue

- In another aspect, the invention provides methods for producing engineered lung
- 30 tissue or cells. In one embodiment, the method comprises the steps of providing cells, introducing an LSNA or an LSG into the cells, and growing the cells under conditions in which they exhibit one or more properties of lung tissue cells. In a preferred

embodiment, the cells are pluripotent. As is well-known in the art, normal lung tissue comprises a large number of different cell types. Thus, in one embodiment, the engineered lung tissue or cells comprises one of these cell types. In another embodiment, the engineered lung tissue or cells comprises more than one lung cell type. Further, the culture conditions of the cells or tissue may require manipulation in order to achieve full differentiation and development of the lung cell tissue. Methods for manipulating culture conditions are well-known in the art.

Nucleic acid molecules encoding one or more LSPs are introduced into cells, preferably pluripotent cells. In a preferred embodiment, the nucleic acid molecules encode LSPs having amino acid sequences selected from SEQ ID NO: 143 through 277, or homologous proteins, analogs, allelic variants or fragments thereof. In a more preferred embodiment, the nucleic acid molecules have a nucleotide sequence selected from SEQ ID NO: 1 through 142, or hybridizing nucleic acids, allelic variants or parts thereof. In another highly preferred embodiment, an LSG is introduced into the cells. Expression vectors and methods of introducing nucleic acid molecules into cells are well-known in the art and are described in detail, *supra*.

Artificial lung tissue may be used to treat patients who have lost some or all of their lung function.

#### Pharmaceutical Compositions

In another aspect, the invention provides pharmaceutical compositions comprising the nucleic acid molecules, polypeptides, antibodies, antibody derivatives, antibody fragments, agonists, antagonists, and inhibitors of the present invention. In a preferred embodiment, the pharmaceutical composition comprises an LSNA or part thereof. In a more preferred embodiment, the LSNA has a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 through 142, a nucleic acid that hybridizes thereto, an allelic variant thereof, or a nucleic acid that has substantial sequence identity thereto. In another preferred embodiment, the pharmaceutical composition comprises an LSP or fragment thereof. In a more preferred embodiment, the LSP having an amino acid sequence that is selected from the group consisting of SEQ ID NO: 143 through 277, a polypeptide that is homologous thereto, a fusion protein comprising all or a portion of the polypeptide, or an analog or derivative thereof. In another preferred embodiment, the

pharmaceutical composition comprises an anti-LSP antibody, preferably an antibody that specifically binds to an LSP having an amino acid that is selected from the group consisting of SEQ ID NO: 143 through 277, or an antibody that binds to a polypeptide that is homologous thereto, a fusion protein comprising all or a portion of the polypeptide, or an analog or derivative thereof.

Such a composition typically contains from about 0.1 to 90% by weight of a therapeutic agent of the invention formulated in and/or with a pharmaceutically acceptable carrier or excipient.

Pharmaceutical formulation is a well-established art, and is further described in Gennaro (ed.), Remington: The Science and Practice of Pharmacy, 20<sup>th</sup> ed., Lippincott, Williams & Wilkins (2000); Ansel *et al.*, Pharmaceutical Dosage Forms and Drug Delivery Systems, 7<sup>th</sup> ed., Lippincott Williams & Wilkins (1999); and Kibbe (ed.), Handbook of Pharmaceutical Excipients American Pharmaceutical Association, 3<sup>rd</sup> ed. (2000), the disclosures of which are incorporated herein by reference in their entireties, and thus need not be described in detail herein.

Briefly, formulation of the pharmaceutical compositions of the present invention will depend upon the route chosen for administration. The pharmaceutical compositions utilized in this invention can be administered by various routes including both enteral and parenteral routes, including oral, intravenous, intramuscular, subcutaneous, inhalation, topical, sublingual, rectal, intra-arterial, intramedullary, intrathecal, intraventricular, transmucosal, transdermal, intranasal, intraperitoneal, intrapulmonary, and intrauterine.

Oral dosage forms can be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Solid formulations of the compositions for oral administration can contain suitable carriers or excipients, such as carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, or microcrystalline cellulose; gums including arabic and tragacanth; proteins such as gelatin and collagen; inorganics, such as kaolin, calcium carbonate, dicalcium phosphate, sodium chloride; and other agents such as acacia and alginic acid.

Agents that facilitate disintegration and/or solubilization can be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate, microcrystalline cellulose, corn starch, sodium starch glycolate, and alginic acid.

- 5        Tablet binders that can be used include acacia, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone (Povidone™), hydroxypropyl methylcellulose, sucrose, starch and ethylcellulose.

Lubricants that can be used include magnesium stearates, stearic acid, silicone fluid, talc, waxes, oils, and colloidal silica.

- 10       Fillers, agents that facilitate disintegration and/or solubilization, tablet binders and lubricants, including the aforementioned, can be used singly or in combination.

- Solid oral dosage forms need not be uniform throughout. For example, dragee cores can be used in conjunction with suitable coatings, such as concentrated sugar solutions, which can also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
- 15

- Oral dosage forms of the present invention include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.
- 20

- Additionally, dyestuffs or pigments can be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, *i.e.*, dosage.
- 25

- Liquid formulations of the pharmaceutical compositions for oral (enteral) administration are prepared in water or other aqueous vehicles and can contain various suspending agents such as methylcellulose, alginates, tragacanth, pectin, kelgin, carrageenan, acacia, polyvinylpyrrolidone, and polyvinyl alcohol. The liquid formulations can also include solutions, emulsions, syrups and elixirs containing, together with the active compound(s), wetting agents, sweeteners, and coloring and flavoring agents.
- 30

The pharmaceutical compositions of the present invention can also be formulated for parenteral administration. Formulations for parenteral administration can be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions.

For intravenous injection, water soluble versions of the compounds of the present invention are formulated in, or if provided as a lyophilate, mixed with, a physiologically acceptable fluid vehicle, such as 5% dextrose ("D5"), physiologically buffered saline, 0.9% saline, Hanks' solution, or Ringer's solution. Intravenous formulations may include carriers, excipients or stabilizers including, without limitation, calcium, human serum albumin, citrate, acetate, calcium chloride, carbonate, and other salts.

10 Intramuscular preparations, *e.g.* a sterile formulation of a suitable soluble salt form of the compounds of the present invention, can be dissolved and administered in a pharmaceutical excipient such as Water-for-Injection, 0.9% saline, or 5% glucose solution. Alternatively, a suitable insoluble form of the compound can be prepared and administered as a suspension in an aqueous base or a pharmaceutically acceptable oil  
15 base, such as an ester of a long chain fatty acid (*e.g.*, ethyl oleate), fatty oils such as sesame oil, triglycerides, or liposomes.

Parenteral formulations of the compositions can contain various carriers such as vegetable oils, dimethylacetamide, dimethylformamide, ethyl lactate, ethyl carbonate, isopropyl myristate, ethanol, polyols (glycerol, propylene glycol, liquid polyethylene glycol, and the like).

Aqueous injection suspensions can also contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Non-lipid polycationic amino polymers can also be used for delivery. Optionally, the suspension can also contain suitable stabilizers or agents that increase the solubility of  
25 the compounds to allow for the preparation of highly concentrated solutions.

Pharmaceutical compositions of the present invention can also be formulated to permit injectable, long-term, deposition. Injectable depot forms may be made by forming microencapsulated matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature  
30 of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot

injectable formulations are also prepared by entrapping the drug in microemulsions that are compatible with body tissues.

The pharmaceutical compositions of the present invention can be administered topically.

5        For topical use the compounds of the present invention can also be prepared in suitable forms to be applied to the skin, or mucus membranes of the nose and throat, and can take the form of lotions, creams, ointments, liquid sprays or inhalants, drops, tinctures, lozenges, or throat paints. Such topical formulations further can include chemical compounds such as dimethylsulfoxide (DMSO) to facilitate surface penetration  
10 of the active ingredient. In other transdermal formulations, typically in patch-delivered formulations, the pharmaceutically active compound is formulated with one or more skin penetrants, such as 2-N-methyl-pyrrolidone (NMP) or Azone. A topical semi-solid ointment formulation typically contains a concentration of the active ingredient from about 1 to 20%, *e.g.*, 5 to 10%, in a carrier such as a pharmaceutical cream base.

15        For application to the eyes or ears, the compounds of the present invention can be presented in liquid or semi-liquid form formulated in hydrophobic or hydrophilic bases as ointments, creams, lotions, paints or powders.

For rectal administration the compounds of the present invention can be administered in the form of suppositories admixed with conventional carriers such as  
20 cocoa butter, wax or other glyceride.

Inhalation formulations can also readily be formulated. For inhalation, various powder and liquid formulations can be prepared. For aerosol preparations, a sterile formulation of the compound or salt form of the compound may be used in inhalers, such as metered dose inhalers, and nebulizers. Aerosolized forms may be especially useful for  
25 treating respiratory disorders.

Alternatively, the compounds of the present invention can be in powder form for reconstitution in the appropriate pharmaceutically acceptable carrier at the time of delivery.

The pharmaceutically active compound in the pharmaceutical compositions of the  
30 present invention can be provided as the salt of a variety of acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acid. Salts

tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms.

After pharmaceutical compositions have been prepared, they are packaged in an appropriate container and labeled for treatment of an indicated condition.

- 5       The active compound will be present in an amount effective to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

- A "therapeutically effective dose" refers to that amount of active ingredient, for example LSP polypeptide, fusion protein, or fragments thereof, antibodies specific for  
10   LSP, agonists, antagonists or inhibitors of LSP, which ameliorates the signs or symptoms of the disease or prevents progression thereof; as would be understood in the medical arts, cure, although desired, is not required.

- The therapeutically effective dose of the pharmaceutical agents of the present invention can be estimated initially by *in vitro* tests, such as cell culture assays, followed  
15   by assay in model animals, usually mice, rats, rabbits, dogs, or pigs. The animal model can also be used to determine an initial preferred concentration range and route of administration.

- For example, the ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population) can be determined in  
20   one or more cell culture of animal model systems. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as LD50/ED50. Pharmaceutical compositions that exhibit large therapeutic indices are preferred.

- The data obtained from cell culture assays and animal studies are used in formulating an initial dosage range for human use, and preferably provide a range of  
25   circulating concentrations that includes the ED50 with little or no toxicity. After administration, or between successive administrations, the circulating concentration of active agent varies within this range depending upon pharmacokinetic factors well-known in the art, such as the dosage form employed, sensitivity of the patient, and the route of administration.

- 30       The exact dosage will be determined by the practitioner, in light of factors specific to the subject requiring treatment. Factors that can be taken into account by the practitioner include the severity of the disease state, general health of the subject, age,



weight, gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions can be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.

5        Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Where the therapeutic agent is a protein or antibody of the present invention, the therapeutic protein or antibody agent typically is administered at a daily dosage of 0.01 mg to 30 mg/kg of body weight of the patient (*e.g.*, 1 mg/kg to 5 mg/kg). The pharmaceutical formulation can be  
10 administered in multiple doses per day, if desired, to achieve the total desired daily dose.

Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells,  
15 conditions, locations, etc.

Conventional methods, known to those of ordinary skill in the art of medicine, can be used to administer the pharmaceutical formulation(s) of the present invention to the patient. The pharmaceutical compositions of the present invention can be administered alone, or in combination with other therapeutic agents or interventions.

## 20    Therapeutic Methods

The present invention further provides methods of treating subjects having defects in a gene of the invention, *e.g.*, in expression, activity, distribution, localization, and/or solubility, which can manifest as a disorder of lung function. As used herein,  
25 "treating" includes all medically-acceptable types of therapeutic intervention, including palliation and prophylaxis (prevention) of disease. The term "treating" encompasses any improvement of a disease, including minor improvements. These methods are discussed below.

### *Gene Therapy and Vaccines*

30        The isolated nucleic acids of the present invention can also be used to drive *in vivo* expression of the polypeptides of the present invention. *In vivo* expression can be driven from a vector, typically a viral vector, often a vector based upon a replication

incompetent retrovirus, an adenovirus, or an adeno-associated virus (AAV), for purpose of gene therapy. *In vivo* expression can also be driven from signals endogenous to the nucleic acid or from a vector, often a plasmid vector, such as pVAX1 (Invitrogen, Carlsbad, CA, USA), for purpose of "naked" nucleic acid vaccination, as further  
5 described in U.S. Patents 5,589,466; 5,679,647; 5,804,566; 5,830,877; 5,843,913; 5,880,104; 5,958,891; 5,985,847; 6,017,897; 6,110,898; and 6,204,250, the disclosures of which are incorporated herein by reference in their entireties. For cancer therapy, it is preferred that the vector also be tumor-selective. *See, e.g., Doronin et al., J. Virol.* 75: 3314-24 (2001).

10 In another embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising a nucleic acid of the present invention is administered. The nucleic acid can be delivered in a vector that drives expression of an LSP, fusion protein, or fragment thereof, or without such vector. Nucleic acid compositions that can drive expression of an LSP are  
15 administered, for example, to complement a deficiency in the native LSP, or as DNA vaccines. Expression vectors derived from virus, replication deficient retroviruses, adenovirus, adeno-associated (AAV) virus, herpes virus, or vaccinia virus can be used as can plasmids. *See, e.g., Cid-Arregui, supra.* In a preferred embodiment, the nucleic acid molecule encodes an LSP having the amino acid sequence of SEQ ID NO: 143 through  
20 277, or a fragment, fusion protein, allelic variant or homolog thereof.

In still other therapeutic methods of the present invention, pharmaceutical compositions comprising host cells that express an LSP, fusions, or fragments thereof can be administered. In such cases, the cells are typically autologous, so as to circumvent xenogeneic or allotypic rejection, and are administered to complement  
25 defects in LSP production or activity. In a preferred embodiment, the nucleic acid molecules in the cells encode an LSP having the amino acid sequence of SEQ ID NO: 143 through 277, or a fragment, fusion protein, allelic variant or homolog thereof.

#### *Antisense Administration*

Antisense nucleic acid compositions, or vectors that drive expression of an LSG  
30 antisense nucleic acid, are administered to downregulate transcription and/or translation of an LSG in circumstances in which excessive production, or production of aberrant protein, is the pathophysiologic basis of disease.

Antisense compositions useful in therapy can have a sequence that is complementary to coding or to noncoding regions of an LSG. For example, oligonucleotides derived from the transcription initiation site, *e.g.*, between positions -10 and +10 from the start site, are preferred.

5 Catalytic antisense compositions, such as ribozymes, that are capable of sequence-specific hybridization to LSG transcripts, are also useful in therapy. *See, e.g.*, Phylactou, *Adv. Drug Deliv. Rev.* 44(2-3): 97-108 (2000); Phylactou *et al.*, *Hum. Mol. Genet.* 7(10): 1649-53 (1998); Rossi, *Ciba Found. Symp.* 209: 195-204 (1997); and Sigurdsson *et al.*, *Trends Biotechnol.* 13(8): 286-9 (1995), the disclosures of which are  
10 incorporated herein by reference in their entireties.

Other nucleic acids useful in the therapeutic methods of the present invention are those that are capable of triplex helix formation in or near the LSG genomic locus. Such triplexing oligonucleotides are able to inhibit transcription. *See, e.g.*, Intody *et al.*, *Nucleic Acids Res.* 28(21): 4283-90 (2000); McGuffie *et al.*, *Cancer Res.* 60(14): 3790-9  
15 (2000), the disclosures of which are incorporated herein by reference. Pharmaceutical compositions comprising such triplex forming oligos (TFOs) are administered in circumstances in which excessive production, or production of aberrant protein, is a pathophysiologic basis of disease.

In a preferred embodiment, the antisense molecule is derived from a nucleic acid  
20 molecule encoding an LSP, preferably an LSP comprising an amino acid sequence of SEQ ID NO: 143 through 277, or a fragment, allelic variant or homolog thereof. In a more preferred embodiment, the antisense molecule is derived from a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1 through 142, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

#### 25 *Polypeptide Administration*

In one embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising an LSP, a fusion protein, fragment, analog or derivative thereof is administered to a subject with a clinically-significant LSP defect.

30 Protein compositions are administered, for example, to complement a deficiency in native LSP. In other embodiments, protein compositions are administered as a vaccine to elicit a humoral and/or cellular immune response to LSP. The immune response can

be used to modulate activity of LSP or, depending on the immunogen, to immunize against aberrant or aberrantly expressed forms, such as mutant or inappropriately expressed isoforms. In yet other embodiments, protein fusions having a toxic moiety are administered to ablate cells that aberrantly accumulate LSP.

5        In a preferred embodiment, the polypeptide is an LSP comprising an amino acid sequence of SEQ ID NO: 143 through 277, or a fusion protein, allelic variant, homolog, analog or derivative thereof. In a more preferred embodiment, the polypeptide is encoded by a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1  
10        through 142, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

#### *Antibody, Agonist and Antagonist Administration*

In another embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising an antibody (including fragment or derivative thereof) of the present invention is  
15        administered. As is well-known, antibody compositions are administered, for example, to antagonize activity of LSP, or to target therapeutic agents to sites of LSP presence and/or accumulation. In a preferred embodiment, the antibody specifically binds to an LSP comprising an amino acid sequence of SEQ ID NO: 143 through 277, or a fusion protein, allelic variant, homolog, analog or derivative thereof. In a more preferred  
20        embodiment, the antibody specifically binds to an LSP encoded by a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1 through 142, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

The present invention also provides methods for identifying modulators which bind to an LSP or have a modulatory effect on the expression or activity of an LSP.  
25        Modulators which decrease the expression or activity of LSP (antagonists) are believed to be useful in treating lung cancer. Such screening assays are known to those of skill in the art and include, without limitation, cell-based assays and cell-free assays. Small molecules predicted via computer imaging to specifically bind to regions of an LSP can also be designed, synthesized and tested for use in the imaging and treatment of lung  
30        cancer. Further, libraries of molecules can be screened for potential anticancer agents by assessing the ability of the molecule to bind to the LSPs identified herein. Molecules identified in the library as being capable of binding to an LSP are key candidates for

-115-

further evaluation for use in the treatment of lung cancer. In a preferred embodiment, these molecules will downregulate expression and/or activity of an LSP in cells.

In another embodiment of the therapeutic methods of the present invention, a pharmaceutical composition comprising a non-antibody antagonist of LSP is  
5 administered. Antagonists of LSP can be produced using methods generally known in the art. In particular, purified LSP can be used to screen libraries of pharmaceutical agents, often combinatorial libraries of small molecules, to identify those that specifically bind and antagonize at least one activity of an LSP.

In other embodiments a pharmaceutical composition comprising an agonist of an  
10 LSP is administered. Agonists can be identified using methods analogous to those used to identify antagonists.

In a preferred embodiment, the antagonist or agonist specifically binds to and antagonizes or agonizes, respectively, an LSP comprising an amino acid sequence of SEQ ID NO: 143 through 277, or a fusion protein, allelic variant, homolog, analog or  
15 derivative thereof. In a more preferred embodiment, the antagonist or agonist specifically binds to and antagonizes or agonizes, respectively, an LSP encoded by a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1 through 142, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

#### *Targeting Lung Tissue*

20 The invention also provides a method in which a polypeptide of the invention, or an antibody thereto, is linked to a therapeutic agent such that it can be delivered to the lung or to specific cells in the lung. In a preferred embodiment, an anti-LSP antibody is linked to a therapeutic agent and is administered to a patient in need of such therapeutic agent. The therapeutic agent may be a toxin, if lung tissue needs to be selectively  
25 destroyed. This would be useful for targeting and killing lung cancer cells. In another embodiment, the therapeutic agent may be a growth or differentiation factor, which would be useful for promoting lung cell function.

In another embodiment, an anti-LSP antibody may be linked to an imaging agent that can be detected using, e.g., magnetic resonance imaging, CT or PET. This would be  
30 useful for determining and monitoring lung function, identifying lung cancer tumors, and identifying noncancerous lung diseases.

## EXAMPLES

### Example 1: Gene Expression analysis

LSGs were identified by a systematic analysis of gene expression data in the LIFESEQ® Gold database available from Incyte Genomics Inc (Palo Alto, CA) using the data mining software package CLASP™ (Candidate Lead Automatic Search Program). CLASP™ is a set of algorithms that interrogate Incyte's database to identify genes that are both specific to particular tissue types as well as differentially expressed in tissues from patients with cancer. LifeSeq® Gold contains information about which genes are expressed in various tissues in the body and about the dynamics of expression in both normal and diseased states. CLASP™ first sorts the LifeSeq® Gold database into defined tissue types, such as breast, ovary and prostate. Whereas over half of the diseased samples in the LifeSeq® Gold database are cancer-related, there is considerable variability in the number of patient samples across different cancers. CLASP™ categorizes each tissue sample by disease state. Disease states include "healthy," "cancer," "associated with cancer," "other disease" and "other." Categorizing the disease states filters out data that might otherwise impair our ability to identify tissue and cancer-specific molecular targets. CLASP™ then performs a simultaneous parallel search for genes that are expressed both (1) selectively in the defined tissue type compared to other tissue types and (2) differentially in the "cancer" disease state compared to the other disease states affecting the same, or different, tissues. This sorting is accomplished by using mathematical and statistical filters that specify the minimum change in expression levels and the minimum frequency that the differential expression pattern must be observed across the tissue samples for the gene to be considered statistically significant. The CLASP™ algorithm quantifies the relative abundance of a particular gene in each tissue type and in each disease state.

To find the LSGs of this invention, the following specific CLASP™ profiles were utilized: detectable expression only in cancer tissue (CLASP 2), differential expression in cancer tissue (CLASP 5), and tissue-specific expression (CLASP 1). cDNA libraries were divided into 60 unique tissue types (early versions of LifeSeq® had 48 tissue types). Genes were grouped into "gene bins," where each bin is a cluster of sequences grouped together where they share a common contig. The expression level for each gene

bin was calculated for each tissue type. Differential expression significance was calculated with rigorous statistical significant testing taking into account variations in sample size and relative gene abundance in different libraries and within each library (for the equations used to determine statistically significant expression see Audic and Claverie "The significance of digital gene expression profiles," Genome Res 7(10): 986-995 (1997), including Equation 1 on page 987 and Equation 2 on page 988, the contents of which are incorporated by reference). Differently expressed tissue-specific genes were selected based on the percentage abundance level in the targeted tissue versus all the other tissues (tissue-specificity). The expression levels for each gene in normal tissue libraries was compared with the expression level in tissue libraries associated with tumor or disease (cancer-specificity). The results were analyzed for statistical significance.

The selection of the target genes meeting the rigorous CLASP™ profile criteria were as follows:

- (a) CLASP 2: detectable expression only in cancer tissue: To qualify as a CLASP 2H (High) candidate, a gene must exhibit detectable expression in tumor tissues and undetectable expression in libraries from normal individuals and libraries from normal tissue obtained from diseased patients. In addition, such a gene must also exhibit further specificity for lung tumor tissues.
- (b) CLASP 5: differential expression in cancer tissue: To qualify as a CLASP 5H (High) candidate, a gene must be differentially expressed in tumor libraries in the target tissue compared to normal libraries for all tissues. Only if the gene exhibits cancer-specific differential expression with a 90% of confidence level is it selected as a CLASP 5H lead.
- (c) CLASP 1: tissue-specific expression: To qualify as a CLASP 1H (High) candidate, a gene must exhibit statistically significant tissue-specific expression. At first, the percentage abundance level in each gene in each tissue was calculated to identify the tissue with the highest expression percentage level. If the gene shows expression in more than four tissue types, the candidate is considered CLASP 1H candidate only if it exhibits a five-fold absolute abundance in the target tissue compared with the secondary tissue and a 1.5-fold relative abundance in the target tissue compared with

secondary tissue. If the candidate gene shows expression in less than 4 tissues, three situations are considered for prioritization of the candidate.

- a. If there are less than 3 tumor libraries for the target tissue, the candidate is considered a high priority (1H) candidate only if it exhibits expression in at least one tumor library, otherwise, it is only a medium priority (M) candidate and not considered further.
- b. If there are 3 or 4 tumor libraries for the target tissue and the candidate shows expression in at least one tumor library, the candidate is considered a high priority (1H) candidate only if it exhibits a higher percentage expression in the tumor tissues compared to the normal tissues. Otherwise, it is only a medium (M) priority candidate and not considered further.
- c. If there are more than 4 tumor libraries of the tissue of interest, the candidate exhibits expression in less than 40% of tumor libraries and the percentage abundance in tumor is 3 fold greater than in normal, the candidate is considered a 1H candidate. If the candidate exhibits expression percentage less than 0.00001, it is considered a low (L) priority candidate. Otherwise, it is considered a medium (M) priority candidate.

20 The CLASP scores for SEQ ID NO: 1 through 142 are listed below:

	DEX0241_1	CLASP 5 H
	DEX0241_2	CLASP 5 H
	DEX0241_4	CLASP 2 H
	DEX0241_5	CLASP 2 H
25	DEX0241_6	CLASP 2 H
	DEX0241_7	CLASP 5 H 1 H
	DEX0241_8	CLASP 5 H 1 H
	DEX0241_9	CLASP 2 H
	DEX0241_10	CLASP 2 H
30	DEX0241_11	CLASP 2 H
	DEX0241_12	CLASP 2 H
	DEX0241_13	CLASP 2 H
	DEX0241_14	CLASP 2 H
	DEX0241_15	CLASP 2 H 1 H
35	DEX0241_16	CLASP 2 H
	DEX0241_17	CLASP 2 H
	DEX0241_18	CLASP 2 H 1 H
	DEX0241_19	CLASP 2 H 1 H



-119-

	DEX0241_20	CLASP 5 H
	DEX0241_21	CLASP 5 H
	DEX0241_22	CLASP 2 H
	DEX0241_23	CLASP 2 H
5	DEX0241_24	CLASP 5 H
	DEX0241_25	CLASP 5 H
	DEX0241_26	CLASP 2 H
	DEX0241_27	CLASP 2 H 1 H
	DEX0241_28	CLASP 2 H
10	DEX0241_29	CLASP 2 H
	DEX0241_30	CLASP 2 H 1 H
	DEX0241_31	CLASP 2 H 1 H
	DEX0241_32	CLASP 2 H
	DEX0241_33	CLASP 2 H
15	DEX0241_34	CLASP 5 H
	DEX0241_35	CLASP 5 H
	DEX0241_36	CLASP 2 H 1 H
	DEX0241_37	CLASP 2 H
	DEX0241_38	CLASP 2 H
20	DEX0241_39	CLASP 2 H
	DEX0241_40	CLASP 5 H
	DEX0241_41	CLASP 5 H
	DEX0241_42	CLASP 5 H 1 H
	DEX0241_43	CLASP 2 H
25	DEX0241_44	CLASP 2 H
	DEX0241_45	CLASP 2 H
	DEX0241_47	CLASP 2 H
	DEX0241_48	CLASP 2 H
	DEX0241_49	CLASP 5 H 1 H
30	DEX0241_50	CLASP 2 H
	DEX0241_53	CLASP 2 H
	DEX0241_54	CLASP 2 H
	DEX0241_56	CLASP 2 H
	DEX0241_57	CLASP 2 H
35	DEX0241_58	CLASP 2 H
	DEX0241_61	CLASP 2 H
	DEX0241_62	CLASP 2 H
	DEX0241_63	CLASP 2 H
	DEX0241_64	CLASP 2 H
40	DEX0241_65	CLASP 2 H
	DEX0241_66	CLASP 2 H
	DEX0241_67	CLASP 2 H
	DEX0241_68	CLASP 2 H
	DEX0241_69	CLASP 2 H
45	DEX0241_70	CLASP 2 H
	DEX0241_71	CLASP 2 H
	DEX0241_72	CLASP 2 H
	DEX0241_73	CLASP 2 H
	DEX0241_74	CLASP 2 H

	DEX0241_75	CLASP 2 H
	DEX0241_76	CLASP 2 H
	DEX0241_77	CLASP 2 H
	DEX0241_80	CLASP 2 H
5	DEX0241_81	CLASP 2 H
	DEX0241_82	CLASP 2 H
	DEX0241_83	CLASP 1 H
	DEX0241_84	CLASP 2 H
	DEX0241_85	CLASP 2 H
10	DEX0241_86	CLASP 5 H 1 H
	DEX0241_87	CLASP 5 H 1 H
	DEX0241_88	CLASP 2 H
	DEX0241_89	CLASP 2 H
	DEX0241_90	CLASP 2 H
15	DEX0241_91	CLASP 2 H
	DEX0241_92	CLASP 2 H
	DEX0241_93	CLASP 2 H
	DEX0241_94	CLASP 2 H
	DEX0241_95	CLASP 2 H
20	DEX0241_96	CLASP 2 H
	DEX0241_97	CLASP 2 H
	DEX0241_98	CLASP 2 H
	DEX0241_99	CLASP 2 H
	DEX0241_101	CLASP 5 H 1 H
25	DEX0241_102	CLASP 1 H
	DEX0241_103	CLASP 1 H
	DEX0241_104	CLASP 5 H 1 H
	DEX0241_105	CLASP 2 H
	DEX0241_108	CLASP 2 H
30	DEX0241_109	CLASP 2 H
	DEX0241_110	CLASP 5 H
	DEX0241_113	CLASP 5 H
	DEX0241_114	CLASP 5 H
	DEX0241_115	CLASP 2 H
35	DEX0241_116	CLASP 2 H
	DEX0241_117	CLASP 2 H
	DEX0241_118	CLASP 2 H
	DEX0241_121	CLASP 2 H
	DEX0241_122	CLASP 2 H
40	DEX0241_124	CLASP 2 H
	DEX0241_125	CLASP 5 H
	DEX0241_126	CLASP 5 H
	DEX0241_127	CLASP 2 H
	DEX0241_128	CLASP 2 H
45	DEX0241_129	CLASP 5 H 1 H
	DEX0241_130	CLASP 5 H 1 H
	DEX0241_131	CLASP 2 H
	DEX0241_132	CLASP 2 H
	DEX0241_133	CLASP 2 H

-121-

	DEX0241_135	CLASP 2 H
	DEX0241_137	CLASP 2 H 1 H
	DEX0241_138	CLASP 2 H 1 H
	DEX0241_139	CLASP 1 H
5	DEX0241_142	CLASP 2 H

### Example 2: Relative Quantitation of Gene Expression

Real-Time quantitative PCR with fluorescent Taqman probes is a quantitation detection system utilizing the 5'-3' nuclease activity of Taq DNA polymerase. The method uses an internal fluorescent oligonucleotide probe (Taqman) labeled with a 5' reporter dye and a downstream, 3' quencher dye. During PCR, the 5'-3' nuclease activity of Taq DNA polymerase releases the reporter, whose fluorescence can then be detected by the laser detector of the Model 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA). Amplification of an endogenous control is used to standardize the amount of sample RNA added to the reaction and normalize for Reverse Transcriptase (RT) efficiency. Either cyclophilin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), ATPase, or 18S ribosomal RNA (rRNA) is used as this endogenous control. To calculate relative quantitation between all the samples studied, the target RNA levels for one sample were used as the basis for comparative results (calibrator). Quantitation relative to the "calibrator" can be obtained using the standard curve method or the comparative method (User Bulletin #2: ABI PRISM 7700 Sequence Detection System).

The tissue distribution and the level of the target gene are evaluated for every sample in normal and cancer tissues. Total RNA is extracted from normal tissues, cancer tissues, and from cancers and the corresponding matched adjacent tissues. Subsequently, first strand cDNA is prepared with reverse transcriptase and the polymerase chain reaction is done using primers and Taqman probes specific to each target gene. The results are analyzed using the ABI PRISM 7700 Sequence Detector. The absolute numbers are relative levels of expression of the target gene in a particular tissue compared to the calibrator tissue.

One of ordinary skill can design appropriate primers. The relative levels of expression of the LSNA versus normal tissues and other cancer tissues can then be determined. All the values are compared to normal thymus (calibrator). These RNA

samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

The relative levels of expression of the LSNA in pairs of matching samples and 1 cancer and 1 normal/normal adjacent of tissue may also be determined. All the values are compared to normal thymus (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.

In the analysis of matching samples, the LSNAs that show a high degree of tissue specificity for the tissue of interest. These results confirm the tissue specificity results obtained with normal pooled samples.

Further, the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual are compared. This comparison provides an indication of specificity for the cancer stage (*e.g.* higher levels of mRNA expression in the cancer sample compared to the normal adjacent).

Altogether, the high level of tissue specificity, plus the mRNA overexpression in matching samples tested are indicative of SEQ ID NO: 1 through 142 being a diagnostic marker for cancer.

Sequences	Gene ID	ddx QPCR lung code	SEQ ID NO:
DEX0241_84	206814	Lng179	84

Table 1. The absolute numbers are relative levels of expression of Lng179 in 24 normal different tissues. All the values are compared to normal brain (calibrator). These RNA samples are commercially pools, originated by pooling samples of a particular tissue from different individuals.

Tissue	NORMAL
Adrenal Gland	0.00
Bladder	0.12
Brain	1.00
Cervix	0.00
Colon	0.00
Endometrium	0.14
Esophagus	0.00
Heart	0.00
Kidney	0.03
Liver	0.00

-123-

Lung	0.72
Mammary Gland	0.04
Muscle	0.00
Ovary	0.09
Pancreas	0.41
Prostate	0.00
Rectum	0.00
Small Intestine	0.03
Spleen	0.17
Stomach	0.00
Testis	0.64
Thymus	0.12
Trachea	0.11
Uterus	0.11

0=negative

The relative levels of expression in Table 1 show that Lng179 mRNA expression is relatively higher in lung compared with most other normal tissues analyzed.

- 5 The absolute numbers in Table 1 were obtained analyzing pools of samples of a particular tissue from different individuals. They can not be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 2.

10 Table 2. The absolute numbers are relative levels of expression of Lng179 in 20 pairs of matching samples. All the values are compared to normal brain (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.

Sample ID	Cancer Type	Tissue	CANCER	MATCHING NORMAL ADJACENT
Lng 60L	Adenocarcinoma	Lung 1	0.01	0.00
Lng AC66	Adenocarcinoma	Lung 2	0.13	0.06
Lng AC69	Adenocarcinoma	Lung 3	0.11	0.00
Lng AC94	Adenocarcinoma	Lung 4	0.00	0.00
Lng AC11	Adenocarcinoma	Lung 5	0.18	0.00
Lng AC32	Adenocarcinoma	Lung 6	0.00	0.04
Lng 223L	Adenocarcinoma	Lung 7	0.11	0.00
Lng SQ45	Squamous cell carcinoma	Lung 8	0.15	1.35
Lng SQ16	Squamous cell carcinoma	Lung 9	0.04	0.00
Lng SQ79	Squamous cell carcinoma	Lung 10	0.62	0.16
Bld46XK		Bladder 1	0.00	0.00
BldTR14		Bladder 2	0.22	0.09

-124-

ClnAS43		Colon 1	0.00	0.00
ClnAS45		Colon 2	0.00	0.01
ClnAS46		Colon 3	0.03	0.02
ClnAS67		Colon 4	0.00	0.05
ClnAS89		Colon 5	0.01	0.31
Liv94Xa		Liver 1	0.00	0.00
Tst647T		Testis 1	0.38	0.18
Utr135XO		Uterus 1	0.15	0.11

0= Negative

In the analysis of matching samples, higher expression of lng179 is detected in lung samples showing a high degree of tissue specificity for lung tissue. These results confirm the tissue specificity results obtained with normal pooled samples (Table 1).

- 5 Furthermore, we compared the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual. This comparison provides an indication of specificity for the cancer stage (e.g. higher levels of mRNA expression in the cancer sample compared to the normal adjacent). Table 2 shows overexpression of lng179 in 10 lung cancer tissues compared with their respective normal adjacent (lung
- 10 samples # 1, 2, 3, 5, 7, 9, and 10). There is overexpression in the cancer tissue for 70% of the lung matching samples tested (7 out of total of 10 lung matching samples).

Altogether, the high level of tissue specificity, plus the mRNA differential expression in the lung matching samples tested are believed to make lng179 a good marker for diagnosing, monitoring, staging, imaging and treating lung cancer.

15

#### Primers Used for QPCR Expression Analysis

Primer Probe Oligo	Start From	End To	QueryLength	SbjctDescript
Lng179For	69	93	25	DEX0241_84 (SEQ ID NO:84)
Lng179Rev	218	193	26	DEX0241_84 (SEQ ID NO:84)
Lng179Probe	94	128	35	DEX0241_84 (SEQ ID NO:84)

#### Example 2B: Custom Microarray Experiment

- Custom oligonucleotide microarrays were provided by Agilent Technologies, Inc.
- 20 (Palo Alto, CA). The microarrays were fabricated by Agilent using their technology for the *in-situ* synthesis of 60mer oligonucleotides (Hughes, et al. 2001, Nature Biotechnology 19:342-347). The 60mer microarray probes were designed by Agilent,

from gene sequences provided by diaDexus, using Agilent proprietary algorithms. Whenever possible two different 60mers were designed for each gene of interest.

All microarray experiments were two-color experiments and were preformed using Agilent-recommended protocols and reagents. Briefly, each microarray was  
5 hybridized with cRNAs synthesized from polyA+ RNA, isolated from cancer and normal tissues, labeled with fluorescent dyes Cyanine3 and Cyanine5 (NEN Life Science Products, Inc., Boston, MA) using a linear amplification method (Agilent). In each experiment the experimental sample was polyA+ RNA isolated from cancer tissue from a single individual and the reference sample was a pool of polyA+ RNA isolated from  
10 normal tissues of the same organ as the cancerous tissue (*i.e.* normal lung tissue in experiments with lung cancer samples). Hybridizations were carried out at 60°C, overnight using Agilent *in-situ* hybridization buffer. Following washing, arrays were scanned with a GenePix 4000B Microarray Scanner (Axon Instruments, Inc., Union City, CA). The resulting images were analyzed with GenePix Pro 3.0 Microarray Acquisition  
15 and Analysis Software (Axon). A total of 29 experiments comparing the expression patterns of lung cancer derived polyA+ RNA (15 squamous cell carcinomas, 14 adenocarcinomas) to polyA+ RNA isolated from a pool of 12 normal lung tissues were analyzed.

Data normalization and expression profiling were done with Expressionist  
20 software from GeneData Inc. (Daly City, CA/Basel, Switzerland). Gene expression analysis was performed using only experiments that meet certain quality criteria. The quality criteria that experiments must meet are a combination of evaluations performed by the Expressionist software and evaluations performed manually using raw and normalized data. To evaluate raw data quality, detection limits (the mean signal for a  
25 replicated negative control + 2 Standard Deviations (SD)) for each channel were calculated. The detection limit is a measure of non-specific hybridization. Arrays with poor detection limits were not analyzed and the experiments were repeated. To evaluate normalized data quality, positive control elements included in the array were utilized. These array features should have a mean ratio of 1 (no differential expression). If these  
30 features have a mean ratio of greater than 1.5-fold up or down, the experiments were not analyzed further and were repeated. In addition to traditional scatter plots demonstrating the distribution of signal in each experiment, the Expressionist software also has

- minimum thresholding criteria that employ user defined parameters to identify quality data. Only those features that meet the threshold criteria were included in the filtering and analyses carried out by Expressionist. The thresholding settings employed require a minimum area percentage of 60% [(% pixels > background + 2SD)-( % pixels saturated)],
- 5 and a minimum signal to noise ratio of 2.0 in both channels. By these criteria, very low expressors and saturated features were not included in analysis.

- Relative expression data was collected from Expressionist based on filtering and clustering analyses. Up- and down- regulated genes were identified using criteria for percentage of valid values obtained, and the percentage of experiments in which the gene
- 10 is up- or down-regulated. These criteria were set independently for each data set, depending on the size and the nature of the data set. The results for the statistically significant upregulated and downregulated genes are shown in Table 1. The first three columns of the table contain information about the sequence itself (Oligo ID, Parent ID, and Patent#), the next 3 columns show the results obtained. '%valid' indicates the
- 15 percentage of 29 unique experiments total in which a valid expression value was obtained, '%up' indicates the percentage of 29 experiments in which up-regulation of at least 2.5-fold was observed, and '%down' indicates the percentage of the 29 experiments in which down-regulation of at least 2.5-fold was observed. The last column in Table 1 describes the location of the microarray probe (oligo) relative to the parent sequence.
- 20 Additional sequences were examined but the data was inconclusive.

Table 1. Sensitivity data for DEX0241 series microarray features.

Oligo ID	Parent ID	Patent #	Sensitivity of up and down regulation			Oligo Seq location
			% valid	% up	% down	
4176	2881	DEX0241_49 (SEQ ID NO:49)	62%	0%	48%	564-623
4177	2881	DEX0241_49 (SEQ ID NO:49)	45%	0%	31%	554-613
7140	1950	DEX0241_100 (SEQ ID NO:100)	86%	0%	79%	1342-1401



-127-

7141	1950	DEX0241_100 (SEQ ID NO:100)	93%	0%	86%	1246- 1305
------	------	--------------------------------	-----	----	-----	---------------

**Example 3: Protein Expression**

The LSNA is amplified by polymerase chain reaction (PCR) and the amplified DNA fragment encoding the LSNA is subcloned in pET-21d for expression in *E. coli*. In addition to the LSNA coding sequence, codons for two amino acids, Met-Ala, flanking the NH<sub>2</sub>-terminus of the coding sequence of LSNA, and six histidines, flanking the COOH-terminus of the coding sequence of LSNA, are incorporated to serve as initiating Met/restriction site and purification tag, respectively.

An over-expressed protein band of the appropriate molecular weight may be observed on a Coomassie blue stained polyacrylamide gel. This protein band is confirmed by Western blot analysis using monoclonal antibody against 6X Histidine tag.

Large-scale purification of LSP was achieved using cell paste generated from 6-liter bacterial cultures, and purified using immobilized metal affinity chromatography (IMAC). Soluble fractions that had been separated from total cell lysate were incubated with a nickle chelating resin. The column was packed and washed with five column volumes of wash buffer. LSP was eluted stepwise with various concentration imidazole buffers.

**Example 4: Protein Fusions**

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector. For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 2, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced. If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second

signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. *See, e. g.*, WO 96/34891.

#### Example 5: Production of an Antibody from a Polypeptide

5 In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential  
10 amino acids, about 1,000 U/ml of penicillin, and about 100, µg/ml of streptomycin. The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP20), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT  
15 medium, and then cloned by limiting dilution as described by Wands *et al.*, *Gastroenterology* 80: 225-232 (1981).

The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide. Alternatively, additional antibodies capable of binding to the polypeptide can be  
20 produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the  
25 hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies. Using the Jameson-Wolf methods the following epitopes were predicted. (Jameson and  
30 Wolf, CABIOS, 4(1), 181-186, 1988, the contents of which are incorporated by reference).

Examples of post-translational modifications (PTMs) of the LSP of this invention are listed below. In addition, antibodies that specifically bind such post-translational modifications may be useful as a diagnostic or as therapeutic. Using the ProSite database (Bairoch et al., Nucleic Acids Res. 25(1):217-221 (1997), the contents of which are incorporated by reference), the following PTMs were predicted for the LSPs of the invention ([http://npsa-pbil.ibcp.fr/cgi-bin/npsa\\_automat.pl?page=npsa\\_prosite.html](http://npsa-pbil.ibcp.fr/cgi-bin/npsa_automat.pl?page=npsa_prosite.html) most recently accessed October 23, 2001).

	DEX0241_143	Ck2_Phospho_Site 16-19;38-41; Myristyl 50-55;
	DEX0241_144	Ck2_Phospho_Site 16-19;38-41; Myristyl 50-55;
10	DEX0241_145	Myristyl 5-10;
	DEX0241_146	Pkc_Phospho_Site 2-4;
	DEX0241_147	Myristyl 26-31; Pkc_Phospho_Site 75-77;
	DEX0241_149	Amidation 3-6; Camp_Phospho_Site 8-11; Ck2_Phospho_Site 12-15;17-20;51-54;93-96;155-158; Myristyl 156-161;
15		Pkc_Phospho_Site 12-14;34-36;101-103;117-119;
	DEX0241_150	Asn_Glycosylation 23-26;141-144;187-190; Camp_Phospho_Site 246-249; Ck2_Phospho_Site 5-8;15-18;27-30;32-35;43-46;53-56;95-98;217-220; Myristyl 139-144;288-293; Pkc_Phospho_Site 103-105;119-121;174-176;222-224;245-247;249-251;308-310;
20	DEX0241_152	Myristyl 4-9;
	DEX0241_153	Ck2_Phospho_Site 8-11; Myb_1 7-15;
	DEX0241_154	Leucine_Zipper 69-90; Myristyl 77-82;
	DEX0241_155	Asn_Glycosylation 23-26; Ck2_Phospho_Site 11-14; Myristyl 48-53; Pkc_Phospho_Site 18-20;25-27;
25	DEX0241_156	Amidation 33-36; Ck2_Phospho_Site 4-7;20-23; Myristyl 40-45;54-59;69-74;70-75;78-83;
	DEX0241_157	Ck2_Phospho_Site 28-31; Myristyl 51-56;58-63;
	DEX0241_158	Ck2_Phospho_Site 42-45; Pkc_Phospho_Site 7-9;23-25;
	DEX0241_159	Amidation 43-46; Asn_Glycosylation 6-9; Pkc_Phospho_Site 95-97; Tyr_Phospho_Site 70-77;
30	DEX0241_160	Myristyl 65-70; Pkc_Phospho_Site 75-77;
	DEX0241_161	Ck2_Phospho_Site 31-34;
	DEX0241_162	Ck2_Phospho_Site 34-37;
	DEX0241_163	Pkc_Phospho_Site 7-9;14-16;
35	DEX0241_164	Asn_Glycosylation 18-21;31-34;
	DEX0241_166	Camp_Phospho_Site 10-13; Ck2_Phospho_Site 9-12; Myristyl 33-38; Pkc_Phospho_Site 9-11;37-39; Tyr_Phospho_Site 10-17;11-17;
	DEX0241_167	Pkc_Phospho_Site 26-28;
40	DEX0241_168	Ck2_Phospho_Site 66-69; Myristyl 23-28;72-77;
		Pkc_Phospho_Site 11-13;36-38;73-75;76-78;
	DEX0241_169	Camp_Phospho_Site 17-20; Ck2_Phospho_Site 3-6;
	DEX0241_170	Amidation 89-92; Ck2_Phospho_Site 84-87; Myristyl 81-86;101-106; Pkc_Phospho_Site 7-9; Prokar_Lipoprotein 38-48;50-60;52-62;
45		

	DEX0241_171	Camp_Phospho_Site 13-16; Ck2_Phospho_Site 21-24;56-59; Myristyl 27-32;31-36;41-46;47-52;
	DEX0241_172	Ck2_Phospho_Site 63-66; Myristyl 12-17;64-69;
5	DEX0241_173	Pkc_Phospho_Site 76-78; Prokar_Lipoprotein 17-27; Ck2_Phospho_Site 63-66; Myristyl 12-17;64-69;
	DEX0241_174	Pkc_Phospho_Site 76-78; Prokar_Lipoprotein 17-27; Asn_Glycosylation 56-59; Myristyl 7-12; Tyr_Phospho_Site 32-40;
10	DEX0241_175	Asn_Glycosylation 56-59; Myristyl 7-12; Tyr_Phospho_Site 32-40;
	DEX0241_176	Ck2_Phospho_Site 30-33; Glycosaminoglycan 26-29; Myristyl 49-54;50-55;
	DEX0241_177	Asn_Glycosylation 20-23; Ck2_Phospho_Site 52-55; Glycosaminoglycan 48-51; Myristyl 71-76;72-77;
15	DEX0241_179	Myristyl 34-39;
	DEX0241_180	Asn_Glycosylation 10-13;
	DEX0241_181	Myristyl 17-22;32-37;44-49;
	DEX0241_182	Ck2_Phospho_Site 5-8;
20	DEX0241_183	Ck2_Phospho_Site 23-26;52-55;54-57; Pkc_Phospho_Site 48-50;83-85;
	DEX0241_184	Asn_Glycosylation 32-35; Pkc_Phospho_Site 7-9;
	DEX0241_186	Amidation 24-27; Ck2_Phospho_Site 54-57; Myristyl 70-75; Pkc_Phospho_Site 4-6;24-26;
	DEX0241_188	Tyr_Phospho_Site 21-28;
25	DEX0241_189	Ck2_Phospho_Site 18-21;
	DEX0241_190	Asn_Glycosylation 21-24; Pkc_Phospho_Site 31-33;
	DEX0241_191	Pkc_Phospho_Site 7-9;51-53;
	DEX0241_192	Pkc_Phospho_Site 21-23;
	DEX0241_193	Asn_Glycosylation 30-33;
30	DEX0241_194	Asn_Glycosylation 30-33;
	DEX0241_195	Myristyl 23-28; Pkc_Phospho_Site 62-64;
	DEX0241_196	Asn_Glycosylation 70-73; Myristyl 25-30; Pkc_Phospho_Site 45-47;
35	DEX0241_197	Ck2_Phospho_Site 2-5;19-22;26-29; Pkc_Phospho_Site 19-21;34-36;
	DEX0241_198	Ck2_Phospho_Site 2-5;19-22;26-29; Pkc_Phospho_Site 19-21;34-36;
	DEX0241_199	Myristyl 14-19;37-42; Pkc_Phospho_Site 69-71;
40	DEX0241_200	Asn_Glycosylation 58-61; Ck2_Phospho_Site 38-41; Myristyl 50-55;54-59; Pkc_Phospho_Site 60-62;
	DEX0241_201	Asn_Glycosylation 299-302;345-348;435-438; Camp_Phospho_Site 398-401; Ck2_Phospho_Site 42-45;64-67;130-133;165-168;178-181;187-190;195-198;240-243;286-289;301-304;315-318;365-368;419-422;430-433;454-457;477-480; Myristyl 184-189;402-407; Pkc_Phospho_Site 130-132;138-140;465-467;
45	DEX0241_202	Myristyl 41-46; Pkc_Phospho_Site 27-29;
	DEX0241_203	Myristyl 41-46; Pkc_Phospho_Site 27-29;

-131-

	DEX0241_204	Camp_Phospho_Site 35-38; Ck2_Phospho_Site 4-7;23-26; Pkc_Phospho_Site 33-35;47-49;
	DEX0241_205	Ck2_Phospho_Site 7-10;
	DEX0241_206	Pkc_Phospho_Site 7-9;57-59;
5	DEX0241_207	Pkc_Phospho_Site 7-9;57-59;
	DEX0241_210	Myristyl 44-49; Pkc_Phospho_Site 9-11;23-25; Prokar_Lipoprotein 54-64;
	DEX0241_211	Asn_Glycosylation 15-18;43-46;
	DEX0241_212	Asn_Glycosylation 17-20;
10	DEX0241_213	Ck2_Phospho_Site 17-20;36-39;59-62; Myristyl 43-48; Pkc_Phospho_Site 17-19;26-28;
	DEX0241_215	Asn_Glycosylation 4-7; Ck2_Phospho_Site 37-40;
	DEX0241_216	Pkc_Phospho_Site 13-15;
	DEX0241_218	Ck2_Phospho_Site 14-17; Pkc_Phospho_Site 10-12;14-16;
15	DEX0241_219	Pkc_Phospho_Site 80-82;
	DEX0241_220	Myristyl 18-23;
	DEX0241_221	Asn_Glycosylation 304-307;617-620;623-626;643-646;686-689; Cadherin 93-103;198-208;309-319; Camp_Phospho_Site 527-530; Ck2_Phospho_Site 109-112;128-131;130-133;233-236;235- 238;248-251;457-460;530-533;593-596;654-657;668-671;727- 730;758-761; Egf_1 506-517; Glycosaminoglycan 438-441;452- 455;658-661; Myristyl 117-122;121-126;138-143;296-301;370- 375;434-439;435-440;436-441;437-442;439-444;440-445;453- 458;454-459;511-516;512-517;513-518;514-519;555-560;601- 606;618-623;742-747;767-772; Pkc_Phospho_Site 5-7;26-28;55- 57;109-111;130-132;155-157;192-194;235-237;387-389;576- 578;654-656;673-675;697-699; Tyr_Phospho_Site 339-345;
20		
25		
	DEX0241_222	Camp_Phospho_Site 3-6; Ck2_Phospho_Site 14-17; Pkc_Phospho_Site 6-8;30-32; Tyr_Phospho_Site 41-48;
30	DEX0241_223	Ck2_Phospho_Site 42-45; Myristyl 10-15; Pkc_Phospho_Site 35- 37; Prokar_Lipoprotein 12-22;
	DEX0241_224	Pkc_Phospho_Site 32-34;
	DEX0241_225	Asn_Glycosylation 13-16; Pkc_Phospho_Site 59-61;
	DEX0241_226	Asn_Glycosylation 18-21;
35	DEX0241_227	Amidation 14-17; Asn_Glycosylation 10-13; Ck2_Phospho_Site 25-28; Pkc_Phospho_Site 9-11;
	DEX0241_228	Camp_Phospho_Site 11-14;25-28; Ck2_Phospho_Site 14-17; Myristyl 52-57; Pkc_Phospho_Site 14-16;
	DEX0241_229	Amidation 34-37;
40	DEX0241_230	Ck2_Phospho_Site 11-14;
	DEX0241_232	Ck2_Phospho_Site 21-24; Myristyl 19-24;
	DEX0241_235	Asn_Glycosylation 32-35; Pkc_Phospho_Site 34-36;
	DEX0241_236	Asn_Glycosylation 86-89; Camp_Phospho_Site 42-45; Ck2_Phospho_Site 82-85;105-108; Myristyl 49-54;51-56;63-68; Pkc_Phospho_Site 128-130;
45	DEX0241_237	Camp_Phospho_Site 28-31;69-72;316-319; Ck2_Phospho_Site 5- 8;46-49;191-194;208-211;270-273;304-307;361-364;381-384; Myristyl 78-83;90-95;97-102;168-173;174-179;197-202;278-

		283;297-302;299-304;310-315;318-323;321-326;368-373;376-381; Pkc_Phospho_Site 210-212;214-216;311-313;
	DEX0241_238	Myristyl 45-50; Pkc_Phospho_Site 51-53;
	DEX0241_239	Myristyl 45-50; Pkc_Phospho_Site 51-53;
5	DEX0241_240	Asn_Glycosylation 27-30;63-66; Ck2_Phospho_Site 39-42; Pkc_Phospho_Site 46-48;
	DEX0241_241	Asn_Glycosylation 27-30;63-66; Ck2_Phospho_Site 39-42; Pkc_Phospho_Site 46-48;
	DEX0241_242	Asn_Glycosylation 25-28; Myristyl 30-35; Pkc_Phospho_Site 27-29;
10	DEX0241_243	Pkc_Phospho_Site 67-69; Tyr_Phospho_Site 31-39;
	DEX0241_244	Myristyl 14-19;18-23;78-83;
	DEX0241_245	Pkc_Phospho_Site 7-9;
	DEX0241_246	Myristyl 4-9;5-10;
15	DEX0241_247	Myristyl 31-36;
	DEX0241_248	Myristyl 20-25;96-101; Pkc_Phospho_Site 13-15;
	DEX0241_250	Myristyl 44-49;
	DEX0241_251	Myristyl 28-33;
	DEX0241_256	Myristyl 54-59;85-90; Pkc_Phospho_Site 74-76;
20	DEX0241_257	Amidation 84-87; Myristyl 54-59;103-108; Pkc_Phospho_Site 74-76;84-86;
	DEX0241_258	Ck2_Phospho_Site 13-16; Myristyl 5-10;
	DEX0241_259	Myristyl 42-47;
	DEX0241_260	Pkc_Phospho_Site 29-31;
25	DEX0241_261	Asn_Glycosylation 21-24;
	DEX0241_262	Ck2_Phospho_Site 2-5;3-6;17-20; Myristyl 9-14;
	DEX0241_263	Ck2_Phospho_Site 12-15; Myristyl 17-22; Pkc_Phospho_Site 64-66;
	DEX0241_264	Asn_Glycosylation 62-65; Myristyl 60-65; Pkc_Phospho_Site 28-30;
30	DEX0241_265	Amidation 12-15; Pkc_Phospho_Site 3-5;
	DEX0241_266	Asn_Glycosylation 42-45; Ck2_Phospho_Site 17-20; Pkc_Phospho_Site 50-52;55-57;
	DEX0241_267	Ck2_Phospho_Site 51-54; Pkc_Phospho_Site 15-17;
35	DEX0241_268	Ck2_Phospho_Site 35-38; Pkc_Phospho_Site 24-26;
	DEX0241_269	Myristyl 12-17; Pkc_Phospho_Site 48-50;
	DEX0241_270	Camp_Phospho_Site 11-14; Pkc_Phospho_Site 16-18;
	DEX0241_271	Asn_Glycosylation 70-73; Ck2_Phospho_Site 72-75; Pkc_Phospho_Site 15-17;51-53;56-58;72-74;
40	DEX0241_272	Myristyl 33-38;
	DEX0241_273	Asn_Glycosylation 8-11;15-18;35-38;
	DEX0241_274	Asn_Glycosylation 16-19;
	DEX0241_276	Ck2_Phospho_Site 67-70;210-213; Glycosaminoglycan 121-124; Myristyl 197-202; Pkc_Phospho_Site 28-30;111-113;165-167;204-206;229-231;241-243; Rgd 206-208; Tyr_Phospho_Site 155-163;
45		
	DEX0241_277	Ck2_Phospho_Site 13-16;

**Example 6: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide**

RNA is isolated from individual patients or from a family of individuals that have a phenotype of interest. cDNA is then generated from these RNA samples using  
5 protocols known in the art. *See*, Sambrook (2001), *supra*. The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO: 1 through 142. Suggested PCR conditions consist of 35 cycles at 95°C for 30 seconds; 60-120 seconds at 52-58°C; and 60-120 seconds at 70°C, using buffer solutions described in Sidransky *et al.*, *Science* 252(5006): 706-9 (1991). *See also* Sidransky *et al.*,  
10 *Science* 278(5340): 1054-9 (1997).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations are then  
15 cloned and sequenced to validate the results of the direct sequencing. PCR products is cloned into T-tailed vectors as described in Holton *et al.*, *Nucleic Acids Res.*, 19: 1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements may also be determined. Genomic clones are  
20 nick-translated with digoxigenin deoxyuridine 5' triphosphate (Boehringer Mannheim), and FISH is performed as described in Johnson *et al.*, *Methods Cell Biol.* 35: 73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium  
25 iodide, producing a combination of C-and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. *Id.* Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical  
30 Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and

translocations. These alterations are used as a diagnostic marker for an associated disease.

**Example 7: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample**

- 5           Antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 µg/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described above. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced. The
- 10   coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbound polypeptide. Next, 50 µl of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature.
- 15   The plates are again washed three times with deionized or distilled water to remove unbound conjugate. 75 µl of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution are added to each well and incubated 1 hour at room temperature.

- The reaction is measured by a microtiter plate reader. A standard curve is
- 20   prepared, using serial dilutions of a control sample, and polypeptide concentrations are plotted on the X-axis (log scale) and fluorescence or absorbance on the Y-axis (linear scale). The concentration of the polypeptide in the sample is calculated using the standard curve.

**Example 8: Formulating a Polypeptide**

- 25           The secreted polypeptide composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the secreted polypeptide alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for
- 30   purposes herein is thus determined by such considerations.



As a general proposition, the total pharmaceutically effective amount of secreted polypeptide administered parenterally per dose will be in the range of about 1 ,  $\mu\text{g/kg/day}$  to 10  $\text{mg/kg/day}$  of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01  $\text{mg/kg/day}$ , and most preferably for humans between about 0.01 and 1  $\text{mg/kg/day}$  for the hormone. If given continuously, the secreted polypeptide is typically administered at a dose rate of about 1  $\mu\text{g/kg/hour}$  to about 50  $\text{mg/kg/hour}$ , either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Pharmaceutical compositions containing the secreted protein of the invention are administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

The secreted polypeptide is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semipermeable polymer matrices in the form of shaped articles, e. g., films, or microcapsules. Sustained-release matrices include polylactides (U. S. Pat. No.3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al., Biopolymers 22: 547-556 (1983)), poly (2-hydroxyethyl methacrylate) (R. Langer et al., J. Biomed. Mater. Res. 15: 167-277 (1981), and R. Langer, Chem. Tech. 12: 98-105 (1982)), ethylene vinyl acetate (R. Langer et al.) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988). Sustained-release compositions also include liposomally entrapped polypeptides. Liposomes containing the secreted polypeptide are prepared by methods known per se: DE Epstein et al., Proc. Natl. Acad. Sci. USA 82: 3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA 77: 4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U. S. Pat. Nos. 4,485,045 and 4,544,545; and

EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.

5           For parenteral administration, in one embodiment, the secreted polypeptide is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, I. e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.

10           For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides. Generally, the formulations are prepared by contacting the polypeptide uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more  
15           preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

          The carrier suitably contains minor amounts of additives such as substances that  
20           enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e. g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic  
25           polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

30           The secreted polypeptide is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about

<220>  
 <221> unsure  
 <222> (183)  
 <223> a, c, g or t

<220>  
 <221> unsure  
 <222> (195)  
 <223> a, c, g or t

<220>  
 <221> unsure  
 <222> (241)  
 <223> a, c, g or t

<220>  
 <221> unsure  
 <222> (243)  
 <223> a, c, g or t

<220>  
 <221> unsure  
 <222> (283)  
 <223> a, c, g or t

<220>  
 <221> unsure  
 <222> (296)  
 <223> a, c, g or t

<220>  
 <221> unsure  
 <222> (315)  
 <223> a, c, g or t

<400> 127  
 cagaaaatat ttggccagaa gaaataaagt atgaccta tagaatccag aagcgtaagc 60  
 atagcactaa atgatgcct taggcctgat cttcaagcca gtcatactgt ataacgtaag 120  
 atttgagccg gtgtcggtat cntcagacat gnaggaggaa gtgattnaac natgaacagt 180  
 tgnaaagtgg cagcngttag gacaacccaa attgtttt caagagaaaa caatccacac 240  
 ntnaaaaaaa aaattggggc ctttttctt ttgtcctggc ttntgtcttg gccacnttgg 300  
 ccacatagtg ttgtntgtta aatataataa aactcattag ggcagtcctt cattaaaaat 360  
 ggcacagct ctgaaactc actatttaag cttaaaggac tacatattca tgatagagtc 420  
 gāgatgcccg 430

<210> 128  
 <211> 113

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 128

tacaaaacaa aaatgatcag tgagaagcta ggtggcgta aatgcccgga caaaaagggg 60  
 ttaggtctgc agcgctatac tcagatgtaa cttacagatg caactagcgg aaa 113

&lt;210&gt; 129

&lt;211&gt; 689

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 129

cacaactcta gaaggtgcct gtcacaccgt tttgtatgaa aggtgcctcc tagagtatag 60  
 ctgtacagta gactcatttt tgatataaga agggataaag cacacttgac agatgatata 120  
 aaaatgtaaa agaaaagaag tgtctgtttt agaaggaagc tgtatgagat aataggccaa 180  
 ggtaggggtg gtggtagcca tgggtgtaaa aataggatca cttaatctag attacttaat 240  
 cagtaagttg attccagggg ccagtgggaa ttgctgaaag tttcatctga atacatggaa 300  
 tttttagcag tgattagggg aatgggtgctg gtatttatag ccatgaactt attacttgaa 360  
 agcatcctag ggaaccaagt cttaatcaag gggcagttct tccaagtagt ggttgaggaa 420  
 gttgggtatg ctttccaaaa cttctttcct cactaaagat tgcagatata ctctgtaagt 480  
 gacttcacag aatatactca attgtcatat ttttaatttac atgtttcttc tgattatagg 540  
 tcccacgtga ttataagttc tgagatcaag ggtcatcttt gtgggggtgt gtgtgtgcac 600  
 ttaaaatttt tatgtgctgg taatagttat cttgtggata ttttaagaaat aggaatgtgt 660  
 gccatatttt aaatacacct tatatgcaa 689

&lt;210&gt; 130

&lt;211&gt; 1901

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (1582)..(1837)

&lt;223&gt; a, c, g or t

&lt;400&gt; 130

tcttttaaac tgtctttacc ttgctcccat taatattcac atttaaggta accgctttca 60  
 taaaaacatc actgaataac tcccctgggt cctgtcagtc cagcattatt ctcaccattt 120  
 atagagtttc aaatattggt aaactgtagt ggctatcttg cttttatgta ttttgggttt 180  
 atgcacattt cctccacaga ataggaattg ttttcggtat tgttctctat ctcttctcca 240  
 agtacctagt cagcaacccc ccatgggtgc tcagtaaata ttgaatgatt atacttaacc 300  
 tcccttcata gtcagacta ttccatgaac aatttatgga cataaaaaac tatgccagta 360  
 gacatttaag gatatttttt atgggtgacta tggaaattgc ctggttacia atttatatat 420  
 agagtcagta acattgataa aaacataaca aattactgtt tcatggaact catgaggcat 480  
 taagaggctt atttagtttt gtttagatac aaggtagtgt cttccaaaac attgttactt 540

```

caaaatTTTT gtagctgctc cagttgaaca ctatattaaa atgcacattt ttgaggacat 600
attcttgaaa ttaggaatgt aatttttaag aattaaacag aggaccagaa atagatctga 660
ggagtttatc agagctgctt ccttgacaaa ctctagaagg tgctgtcac acctttttgt 720
atgaaagggtg cctcctagag tataactgta cagtagactc atttttgata taagaaggga 780
taaagcacac ttaacagatg atatcaaaat gtaaaagaaa agaagtgtct gttttagaag 840
gaagctgtat gagataatag gcaaagggtta ggggtggtgg agcaatgggt gtaaaaatag 900
gatcacttaa tctagattac ttaatcagta agttgattcc aggggccagt ggggaattgct 960
gaaagtttca tctgaataca tgggaatTTTT agcagtgatt aggggaatgg tgctggtatt 1020
tatagccatg aacttattac ttgaaagcat ctaggggacc caagtcttaa tcaaggggca 1080
gttcttccaa gtagtggttg aggaagttgg gtatgctttc caaaacttct ttcctcacta 1140
aagattgcag atatactctg taagtgactt cacagaatat actcaattgt catattttta 1200
tttcatgtt tcttctgatt atagggtcca cgtgattata agttctgaga tcaagggtca 1260
tctttgtggg ggtgtgtgtg tgcacttaaa atttttatgt gctggtaata gttatcttgt 1320
ggatatttaa gaaataggaa tgtgtgccat attttaata caccttatat gcaaaaattt 1380
taatgtaatt taagtatatc gcaaaaaata aatagcgggt ggtattcaca ctgcagagga 1440
ttggcaagtc tttttactat acttcaaaca attgttggca gaaatccgcc tcatgcactg 1500
tattgaataa tttgaaacat tagcatttaa ctaatccaaa gctaagataa agagattttg 1560
aggtgaggtg ataaatatat gnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn 1620
nnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn 1680
nnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn 1740
nnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn 1800
nnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnttt aataggtata ttttcgattc 1860
atgattgaat ccatgataat ggaaccatt gatatggagg g 1901

```

&lt;210&gt; 131

&lt;211&gt; 436

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 131

```

gctcgagtaa ggcattcaat aatgtctttt tgcttccgat tctagctgta taacataggt 60
aaatctctta aattctcaga acttcaattc atttatatgt aaagtgagga gttgtaccat 120
attggtagtt attaacatgt actgtactta tgaatcagtc tgaaaatctt gctaaactgc 180
atattctgag cttttcttaa tttttttttg ttttctcgga aacgctgatt ctctaggtct 240
tggttggagt ccaggatatc gcaaattaaa taagcacttg aagtgatagt atctgagtg 300
ccgtaggcaa atgttaggag aactgaatca gatgttcttt gaaagatttt catggttcta 360
aaatgttctg atttaaaatc cacaaagaaa aaaagcattg aaaatgaatc agcaaactag 420
atgtaattaa agcttc 436

```

&lt;210&gt; 132

&lt;211&gt; 498

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (434)

&lt;223&gt; a, c, g or t

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (488)

&lt;223&gt; a, c, g or t

&lt;400&gt; 132

```

gaaaaaaagt ggaaacattt ttttaaataca agatttataaa aaaaattaca tttgtgatag 60
gtagaaaaca atctgtcaca cactgctttt ggtagttgtg taagtttgta caacctacca 120
aaatgtaaat ctgacagtat acatcaaagc cttatgatgg tcggcagtcc atcgaggaat 180
ctattctatg ttgtacaatc aaggcgact atgatattta ttgcagaaca gagagaaata 240
gcatatacat tgctagttaa ttgattaaat aaagcatgat tccttcaaaa attgagtaat 300
atgacattaa aaaccacaat ttcaaactat atttaagaag atacaaataa ttctttatta 360
ttacttttac tctcaggaat gtgtttgagt gatgcatctc caggcatcaa gtgagtaatc 420
caatattgaa gaanattaaa attttocaca aagtcacctt tctagaagaa tgtgtcata 480
tcttttgnac agaaatga 498

```

&lt;210&gt; 133

&lt;211&gt; 422

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 133

```

tagaggagga aatcagggtt gcttaggaat gttacataat gtattctgat ttgagttaa 60
taaaaaaatc attatttgct catacatcag atgaagaaac ctgggaagat gaaatgtggc 120
ttgagtgagt gggtaactgg atgaacgagt gattgagttg tcaactgttg gttagcggc 180
atggtgaaca cgaaggagg catctggga tatgccat agctctgttc ttggccagca 240
cttgtaaaag acatttttaa caatgacata aatcagggtc ttggtggcac acttatcaa 300
tatataaatg tcccaaagct caggggatg gtgaatgtaa gatgacagaa ttaacacttc 360
ccaattattt ccaaccaggc tagaatgaat acttagccaa agtcataaa ataacattca 420
ct 422

```

&lt;210&gt; 134

&lt;211&gt; 441

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (307)

&lt;223&gt; a, c, g or t

&lt;400&gt; 134

```

tagtacataa aactgaaatg gcccaaaaaa catgaaaaga tgcccaactg tttattcttc 60

```

```

agtctcattt tttgctcatt tcttttcctt tgctttacta tagtaaaagt gactccagtc 120
cctacattaa attttgattt tgaatttttg catcttttcc ataaacttct tttctacagt 180
gttttttaat tcaaagtac gtgtcttcat cttctctttt tttctcctgt agtttctttt 240
attcgaggtt attttaatga aggcaccaag gttcctgggt aatctcatgc tggtgatat 300
ttttttntaa catttaatat aaaatttttc acacataggc aaatttgaaa tgtttgcaat 360
gaaatttttt atacctgcca cctagctatt accatgaata ttttagtata cttgctttat 420
cacatatctg gtccatttat c 441

```

&lt;210&gt; 135

&lt;211&gt; 499

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 135

```

tagcttccct aacatgccag tctacagttt actccaaatc ccaccaggag aagccacttt 60
aaaaatacct gataaattaa aattcattaa tttaattcta ttaagtcttg ttagtcctat 120
cattgtgccc attgctgaca caataccaaa tttacacagt tgcagtgcc gccatgagtc 180
aagaaaatgg ggtctaatac ttcctgccac cttagtatcg aattattctg aaaaagaagt 240
ggatgtactg atagatggaa agatcgaaat gattttttta ggagagattt tcttgcgctc 300
atgataaaat aatcctggtg gaatagatat tgtatccatg cctcctcaag tacagggtcc 360
caaagtcaag gccagacagt aagccaagtg ctatagaaat ttgtggtagt ggtacaatta 420
gcaatacata ataaatttga gctcttagga tgggttaaaga atttgaggga aaaaacttaa 480
aaccacctct taaaagcaa 499

```

&lt;210&gt; 136

&lt;211&gt; 701

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 136

```

ctccttgagg atttccatat aacgctagcc ttgatattct ggcccacacc atttgtaga 60
aagaagaatg attgttcttt actgagtaag agaactacag agaccaatgg attcaagtag 120
tggaacagct ttaatatgta acccatacct gtaccaatgg gtattggttc tctagctcac 180
ctttaggctg actagtatgc ctatgctgga tgttcaatcg cgggattaga cgggattgag 240
ctttatttag tatctctatt agtcactatg agctataatc ttttagcccc tggatcatta 300
tgaagtgcac caagaataag atacagtggg tcccaaggac tggatatcat agctaaccac 360
ctcagatggc taaaatacta ttcttgattt ttatacctag tatttttggc ttgctttata 420
atgggagtag tcattctggg aatctgatct tctaaatgaa agacaacttt atgcctatat 480
tatttctatc ctgccaaga tatgtaccaa acttgatttc tggggtttct gtgggattat 540
acatttttct tggactttct ccccttttac tgaagaagtg atttttctaa aagacaccaa 600
tcaacttttc tttttctgt agggaggatg gtggtggtga ggtgttcttt gcaaggaggg 660
tagacaatga gatgaattgc actgaactag tgtaaagaa t 701

```

&lt;210&gt; 137

&lt;211&gt; 274

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 137

```

gtaaaaacct aaatgcccaa taataggaat taaactggta aaataatatt gtcatttttaa 60
taatcagata aaatgatata gatgaatatt caatgacacg agaagatatt tataaatatt 120
ttattataaa aactattttta attgggttaca ttatatgtcg ctatgccttc agagtagaga 180
gaagtgcacg tttcaacaca aactgaaaaa tttgtaagat aatggctgct atttctaggc 240
ctgtaaaaat tcattttacc aaagaaaatc atag                                274

```

&lt;210&gt; 138

&lt;211&gt; 352

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 138

```

gtaaaaacct aaatgcccaa taataggaat taaactggta aaataatatt gtcatttttaa 60
taatcagata aaatgatata gatgaatatt caatgacacg agaagatatt tataaatatt 120
ttattataaa aactattttta attgggttaca ttatatgtcg ctatgccttc agagtagaga 180
gaagtgcacg tttcaacaca aactgaaaaa tttgtaagat aatggctgct atttctaggc 240
ctgtaaaaat tcattttacc aaagaaaatc atagtttttt tttttttttc tggagatgga 300
gtttcgtctt tgttgcccag gctggagtac ctcgcccgcg accacgctaa gc          352

```

&lt;210&gt; 139

&lt;211&gt; 647

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (318)..(552)

&lt;223&gt; a, c, g or t

&lt;400&gt; 139

```

acagattcat ctgttatact cgtatagatt gaaactgac tactgttaag tcaacaataa 60
cgaaggggag gacattgcag aaaactatga gaaggatctc aattttgcaa attatacatg 120
tatacacaca tctctacat ctattctctg tgagcatttg tttctgttaa tatgtagatc 180
aagttctagg cacagaaagt tctagaagta tctattaaca gttgggttg agttaagtaa 240
ataacttact ttctaaccac atttttcatt gatatgcgtt gtgaattttt tatactttgt 300
gtgtgtgtgt atacacacnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 360
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 420
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 480
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 540
nnnnnnnnnn nnaaacaatg aaaattaggt agtatgattt ttctaacat atgagagtta 600
gagaaaaggc ttgatctca gaacaccctc tttgacagcc gggtgca                    647

```



<210> 140  
<211> 334  
<212> DNA  
<213> Homo sapiens

<220>  
<221> unsure  
<222> (44)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (214)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (300)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (306)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (308)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (315)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (320)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (323)  
<223> a, c, g or t

<400> 140  
tgctacagaa catggcttca attaagagtg aattcagttt tttnttatta aagtcataac 60

```

ttacgtgcca cttttatggt attctggact ttgggcagtg tgatttatta tgtctgtccc 120
tccattgaag tgtcactaac tttgtcaaaa atacctttca ctaattagag gtgccagaat 180
ttttatactc gctactcagg aattgggtcac ttcnataatc tgaattacta taaccttggg 240
cctcttttca tgaacagctt gagccactga cattctgttg tctaggtgat tacgtgaagn 300
ttctangnta taatntggan acnagtcacc agtc 334

```

<210> 141

<211> 990

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (105)

<223> a, c, g or t

<220>

<221> unsure

<222> (116)..(117)

<223> a, c, g or t

<220>

<221> unsure

<222> (132)

<223> a, c, g or t

<220>

<221> unsure

<222> (143)

<223> a, c, g or t

<400> 141

```

ggccgatggg ggcatgcagt ttgtcttctg ggaactgctt tccagctggt tggctatgag 60
gaaaacgcag tccaatctct acagcatctc ttgaagttta tgtcnagtaa taaganngca 120
gcagatgata anagtgtagc aanagcagca cagagtttct tccaacgatt ggaactgggc 180
gatatgcaag cactttcact gtggcaaaaa ttctgggact tgagcattga agagtacatt 240
cgggtttaca agcgtctggg agtatatttt gatgaatatt caggagaatc attttatcgt 300
gaaaaatctc aagaggtctt aaagtgtctg gagagtaaag gactcctact gaaaacaata 360
aaaggaacgg ctgtagtaga tctctctggg aatggcgacc cctcctcaat ttgtactgta 420
atgcgaagtg atgggacttc tctctatgca accagagatc ttgcagctgc tatagatcga 480
atggacaagt ataattttga tacaatgata tatgtgacag ataaaggaca aaaaaagcat 540
tttcagcaag tattccaaat gctgaagatc atgggatatg actgggcaga aagggtgccag 600
cacgtgccct ttggagtagt acaggggaatg aagactcgaa gaggagatgt cactttctcg 660
gaagatgttt taaatgagat tcaattaagg atgctacaga acatggcttc aattaagagt 720
gaattcagtt ttttcttatt aaagtcataa cttacgtgcc acttttatgt tattctggac 780
tttgggcagt gtgatttatt atgtctgtcc ctccattgaa gtgtcactaa ctttgtcaaa 840
aatacctttc actaattaga ggtgccagaa tttttatact cgctactcag gaattggtca 900

```

cttcaataat ctgaattact ataaccttgg tcctcttttc atgaacagct tgagccactg 960  
 acattctggt gtctaggtga ttacgtgaag 990

<210> 142  
 <211> 195  
 <212> DNA  
 <213> Homo sapiens

<400> 142  
 ccaaaatcct atcatttttaa caagtacaac taccctatnt ccctcagaat gtagcattgc 60  
 ctctgggttg ctgtggatcc tgtattggac cactcagctg tagagtcctg tgggatcaa 120  
 gcttcaagga gacccatcat gcatgttttag ggccagtcc aggtgtcctt gacatgacac 180  
 taaacctcca ttcc 195

<210> 143  
 <211> 57  
 <212> PRT  
 <213> Homo sapiens

<400> 143  
 Met Asn Leu His Cys Ser Ser Met Thr Gly Pro Leu Ala Ser Lys Thr  
 1 5 10 15  
 Ser Glu Asp Leu Leu Ser Leu Glu Ser Lys Phe Leu Ser Leu Phe Asn  
 20 25 30  
 Gln Ile Phe Leu Arg Ser Glu Glu Glu Thr Val Thr Pro Tyr Tyr Thr  
 35 40 45  
 Leu Gly Ser Gln Met Cys Asn Leu Ile  
 50 55

<210> 144  
 <211> 57  
 <212> PRT  
 <213> Homo sapiens

<400> 144  
 Met Asn Leu His Cys Ser Ser Met Thr Gly Pro Leu Ala Ser Lys Thr  
 1 5 10 15  
 Ser Glu Asp Leu Leu Ser Leu Glu Ser Lys Phe Leu Ser Leu Phe Asn  
 20 25 30  
 Gln Ile Phe Leu Arg Ser Glu Glu Glu Thr Val Thr Pro Tyr Tyr Thr

35

40

45

Leu Gly Ser Gln Met Cys Asn Leu Ile  
 50 55

&lt;210&gt; 145

&lt;211&gt; 45

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 145

Met Arg Ser Ala Gly Ser Asp Phe Ser Leu Val Lys Trp Val Val Phe  
 1 5 10 15

Lys Leu Cys Arg Trp Thr Gly Asp Ile Phe Pro Leu Leu Leu His Glu  
 20 25 30

Glu Ile Cys Leu Asn Val Asp Arg Leu Glu Ile Phe Phe  
 35 40 45

&lt;210&gt; 146

&lt;211&gt; 30

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 146

Met Ser His Arg Ala Arg Pro Arg Trp Cys Val Phe Ser Arg Asn Lys  
 1 5 10 15

Tyr Ile Leu Leu His His Arg Ile Thr Leu Ile Lys Val Gly  
 20 25 30

&lt;210&gt; 147

&lt;211&gt; 85

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 147

Gly Ala Val Leu Ala His Cys Asn Ser His Leu Pro Gly Ser Ser Asp  
 1 5 10 15

Ser Pro Ala Ser Val Ser Ala Val Ala Gly Ile Asn Gly Ala Ala His  
 20 25 30

His Thr Trp Leu Ile Phe Val Phe Leu Val Glu Thr Gly Phe His His

35                      40                      45  
 Val Gly Gln Asp Gly Ile Glu Leu Leu Thr Ser Asp Leu Pro Ala Ser  
     50                      55                      60  
 Ala Ser Gln Ser Ala Gly Ile Ile Gly Met Ser His Arg Ala Arg Pro  
     65                      70                      75                      80  
 Arg Trp Cys Val Phe  
                             85

&lt;210&gt; 148

&lt;211&gt; 47

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 148

Met Pro Lys Leu Leu Pro Gly Phe Gln Gly Asn Arg Ala Arg Trp Leu  
     1                      5                      10                      15

Asn Gln Arg Ser Asp Ser Gln Ala Ala Arg Glu Lys Val Phe Asn Pro  
                             20                      25                      30

Leu Ile Pro Val Cys Asn Arg Arg Asn Gln Gly Leu His Thr Leu  
                             35                      40                      45

&lt;210&gt; 149

&lt;211&gt; 166

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 149

Met Leu Val Gly Arg Lys Arg Arg Arg Glu Ser Ser Val Lys Glu Asn  
     1                      5                      10                      15

Thr Gly Met Glu Thr Leu Gln Arg Leu Arg Gln Lys His Pro Met Gly  
                             20                      25                      30

Lys Ser Arg Arg Thr Ile Ser Cys Leu Trp Arg Thr Gly Ser Arg Glu  
                             35                      40                      45

Gln Ser Thr Ser Pro Asp Thr Ser Leu Gly Ser Thr Thr Pro Ser Ser  
     50                      55                      60

His Thr Leu Glu Leu Val Ala Leu Asp Ser Glu Val Leu Arg Asp Ser  
     65                      70                      75                      80

Leu Gln Cys Gln Asp His Leu Ser Pro Gly Val Ser Ser Leu Cys Asp  
                             85                            90                            95

Asp Asp Pro Gly Ser Asn Lys Pro Leu Ser Ser Asn Leu Arg Arg Leu  
                             100                            105                            110

Leu Glu Ala Gly Ser Leu Lys Leu Asp Ala Ala Ala Thr Ala Asn Gly  
                             115                            120                            125

Arg Val Glu Ser Pro Val Asn Val Gly Ser Lys Pro Leu Leu Phe Pro  
                             130                            135                            140

Ala Phe Pro Pro Arg Pro Ala Ala Gln Cys Ser Gly Gln Glu Val Gly  
                             145                            150                            155                            160

Arg Glu Ala Gly Thr Glu  
                             165

<210> 150

<211> 352

<212> PRT

<213> Homo sapiens

<400> 150

Pro Arg Asp Val Ser Arg Gln Glu Glu Ala Glu Gly Glu Leu Ser Glu  
                             1                            5                            10                            15

Gly Glu His Trp Tyr Gly Asn Ser Ser Glu Thr Pro Ser Glu Ala Ser  
                             20                            25                            30

Tyr Gly Glu Val Gln Glu Asn Tyr Lys Leu Ser Leu Glu Asp Arg Ile  
                             35                            40                            45

Gln Glu Gln Ser Thr Ser Pro Asp Thr Ser Leu Gly Ser Thr Thr Pro  
                             50                            55                            60

Ser Ser His Thr Leu Glu Leu Val Ala Leu Asp Ser Glu Val Leu Arg  
                             65                            70                            75                            80

Asp Ser Leu Gln Cys Gln Asp His Leu Ser Pro Gly Val Ser Ser Leu  
                             85                            90                            95

Cys Asp Asp Asp Pro Gly Ser Asn Lys Pro Leu Ser Ser Asn Leu Arg  
                             100                            105                            110

Arg Leu Leu Glu Ala Gly Ser Leu Lys Leu Asp Ala Ala Ala Thr Ala

115	120	125
Asn Gly Arg Val Glu Ser Pro Val Asn Val Gly Ser Asn Leu Ser Phe		
130	135	140
Ser Pro Pro Ser His His Ala Gln Gln Leu Ser Val Leu Ala Arg Lys		
145	150	155 160
Leu Ala Glu Lys Gln Glu Gln Asn Asp Gln Tyr Thr Pro Ser Asn Arg		
165	170	175
Phe Ile Trp Asn Gln Gly Lys Trp Leu Pro Asn Ser Thr Thr Thr Cys		
180	185	190
Ser Leu Ser Pro Asp Ser Ala Ile Leu Lys Leu Lys Ala Ala Ala Asn		
195	200	205
Ala Val Leu Gln Asp Lys Ser Leu Thr Arg Thr Glu Glu Thr Met Arg		
210	215	220
Phe Glu Ser Phe Ser Ser Pro Phe Ser Ser Gln Ser Ala Ser Ser Thr		
225	230	235 240
Leu Ala Ala Leu Ser Lys Lys Val Ser Glu Arg Ser Leu Thr Pro Gly		
245	250	255
Gln Glu His Pro Pro Pro Ala Ser Ser Phe Leu Ser Leu Ala Ser Met		
260	265	270
Thr Ser Ser Ala Ala Leu Leu Lys Glu Val Ala Ala Arg Ala Ala Gly		
275	280	285
Ser Leu Leu Ala Glu Lys Ser Ser Leu Leu Pro Glu Asp Pro Leu Pro		
290	295	300
Pro Pro Pro Ser Glu Lys Lys Pro Glu Lys Val Thr Pro Pro Pro Pro		
305	310	315 320
Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Gln Ser Leu Glu Leu		
325	330	335
Leu Leu Leu Pro Val Pro Lys Gly Arg Val Ser Lys Pro Ser Asn Ser		
340	345	350

<210> 151  
 <211> 67  
 <212> PRT  
 <213> Homo sapiens

<400> 151  
 Met Gly Tyr Gln Trp Tyr Arg Leu Arg Val Asn Ser Ile Ser Gly Phe  
           1                  5                  10                  15  
 His Gly Ser Leu Glu Gln His Leu Pro Val Ser Ser Ala Phe His Gln  
                   20                  25                  30  
 Arg Trp Asp Leu Trp Ser Thr Gly Cys Leu Thr Pro Gly Ala Ile Glu  
                   35                  40                  45  
 Lys Gly Glu Asp Leu Trp Lys Ala Phe Val Leu Ala Pro Val His Leu  
                   50                  55                  60  
 Val Leu Asn  
           65

<210> 152  
 <211> 52  
 <212> PRT  
 <213> Homo sapiens

<400> 152  
 Met Lys Glu Gly Val Leu Gly Ser Val Phe Arg Pro Lys Cys Pro Gln  
           1                  5                  10                  15  
 Gly Pro Ser Gly Cys Leu Tyr Leu Leu Met Ser Pro His Thr Cys Trp  
                   20                  25                  30  
 Gln Ser Trp Asp Lys Ser Leu Thr Leu Cys Val Thr Ser Asp Ser Pro  
                   35                  40                  45  
 Trp Lys Lys Glu  
           50

<210> 153  
 <211> 63  
 <212> PRT  
 <213> Homo sapiens

<400> 153  
 Met Arg Thr Glu Ile Ser Trp Ser Val His Glu Glu Glu Trp Ile Gln



1                      5                      10                      15  
 Leu Leu Val Leu Ala Leu Cys Ser Leu Asn Ala Leu Tyr Phe Leu Leu  
                     20                      25                      30  
 Phe Tyr Leu Thr Ile Phe Phe Trp Phe Ala Phe Thr Val Asn Asn Ile  
                     35                      40                      45  
 Phe Ser Ser Phe Leu Ala Leu Ala Phe Leu Ala Asp Arg Lys Trp  
                     50                      55                      60

&lt;210&gt; 154

&lt;211&gt; 98

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 154

Met Lys Asn Gln Pro Leu Gly Gly Leu Leu Leu Leu Gly Gln Ile  
 1                      5                      10                      15  
 Phe Met Trp Pro Thr Arg Leu Cys Ala Ala Gln Leu Cys Leu Pro Ala  
                     20                      25                      30  
 Ser Leu Val Leu His Thr Val Leu Ser Ile Val Ser Val Ala Trp Pro  
                     35                      40                      45  
 Tyr Pro Ser Ser Cys Leu Pro Ile Leu Asn Tyr Ile Thr Cys Phe Leu  
                     50                      55                      60  
 Ala Ser Gly Pro Leu His Met Leu Phe Met Leu Leu Gly Val Phe Cys  
                     65                      70                      75                      80  
 Ser Phe Leu His Pro Gln Pro Leu Pro Leu Asp Cys Thr Pro Gln Gly  
                     85                      90                      95

Arg Ser

&lt;210&gt; 155

&lt;211&gt; 57

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 155

Met Val Tyr Thr Phe Ser Cys Phe Phe Ser Ser Phe Leu Glu Ser Gly  
 1                      5                      10                      15

Asp Thr His Arg Arg Ile Asn Gly Ser Gly Lys Val Pro Gly Leu Met  
 20 25 30

His Glu Glu Asp Leu Val Arg Leu Glu Thr Cys Leu Ala Ser Gln Gly  
 35 40 45

Ser Ala Val Ser Tyr Pro Cys Ala Lys  
 50 55

<210> 156

<211> 89

<212> PRT

<213> Homo sapiens

<400> 156

Asp Thr Glu Ser Gly Trp Asp Asp Thr Ala Val Val Asn Asp Leu Ser  
 1 5 10 15

Ser Thr Ser Ser Gly Thr Glu Ser Gly Pro Gln Ser Pro Leu Thr Pro  
 20 25 30

Asp Gly Lys Arg Asn Pro Lys Gly Ile Lys Lys Ser Trp Gly Lys Ile  
 35 40 45

Arg Arg Thr Gln Ser Gly Asn Phe Tyr Thr Asp Thr Leu Gly Met Ala  
 50 55 60

Glu Phe Arg Arg Gly Gly Leu Arg Ala Thr Ala Gly Pro Gly Leu Ser  
 65 70 75 80

Arg Thr Arg Asp Phe Lys Gly Gln Lys  
 85

<210> 157

<211> 65

<212> PRT

<213> Homo sapiens

<400> 157

Met Ser His Ser Pro Val Leu Pro Ala Pro Gln Ser Ser Val Gly Tyr  
 1 5 10 15

Pro Val Arg Pro Ser Pro Cys Thr Pro Phe Phe Ser Leu Ile Glu Ile  
 20 25 30

Pro Ala Thr Cys Cys Leu Leu Pro Cys Arg Ile Thr Asn Ala Cys Pro  
35 40 45

Val Pro Gly Ile Glu Ala Ala Ile Ala Gly Leu Leu Pro Cys Ser Arg  
50 55 60

His  
65

<210> 158

<211> 51

<212> PRT

<213> Homo sapiens

<400> 158

Met Val Ala Arg Ile Lys Ser Glu Lys Pro Gly Asn Ser Lys Leu Leu  
1 5 10 15

Glu Ile Leu Val Ile Leu Thr Arg Arg Val Glu Val Lys Val Met Lys  
20 25 30

Cys Gly Lys Phe Trp Lys Pro Phe Glu Ser Lys Ala Glu Ser Ile Cys  
35 40 45

Cys Tyr Ile  
50

<210> 159

<211> 116

<212> PRT

<213> Homo sapiens

<220>

<221> UNSURE

<222> (33)

<400> 159

Met Ala Gly Leu Leu Asn Val Thr Phe Ile Tyr Leu Leu Leu Glu Cys  
1 5 10 15

Leu Ser Leu Tyr Thr His Val Thr Cys Ser Ser Leu Pro Ser Ser Leu  
20 25 30

Xaa Leu Tyr Ile Tyr Tyr Tyr His Arg Gly Leu Gly Lys Lys Thr Pro  
35 40 45

Thr Ala Ala Pro His Thr His Pro Pro Ala Leu Tyr His Leu Leu Gly  
 50 55 60

Phe Val Phe Leu Cys Arg Ile His Asp Phe Leu Lys Tyr Asn Phe Phe  
 65 70 75 80

Asn Val Tyr Ile Leu Tyr Ala Phe Ser His Ser Tyr Val Lys Ser Gly  
 85 90 95

Arg His Arg Leu Val Phe Leu Phe Thr Val Asp Ala Ser Val Pro Lys  
 100 105 110

Ile Cys Ile Ala  
 115

<210> 160

<211> 81

<212> PRT

<213> Homo sapiens

<220>

<221> UNSURE

<222> (23)..(31)

<400> 160

Met Gln Asn His His Ile Pro His Cys Ile Ala Val Ala Ser Trp Pro  
 1 5 10 15

Leu Ile Asn Cys Lys Lys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Val  
 20 25 30

Tyr Ile Cys Ile His Val Phe Ile Tyr Ala Tyr Val Met Tyr Met Pro  
 35 40 45

Thr Tyr Leu Cys Thr Cys Asn Val Tyr Ala Tyr Ile Cys Ile Tyr Lys  
 50 55 60

Gly Ile Gln Ile Cys Ile Tyr Leu Arg Lys Thr Ile Lys Asn Leu Cys  
 65 70 75 80

Ser

<210> 161

<211> 39

<212> PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 161

Met His Thr Gln Val His Met Phe Thr Glu Ser Gln Val Gln Glu Arg

1

5

10

15

Ser Lys Glu Pro Lys Leu Glu Ala Thr His Met Phe Ile Asn Ser Arg

20

25

30

Asp Asp Lys Ile Tyr Leu Asp

35

&lt;210&gt; 162

&lt;211&gt; 40

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 162

Met Phe Ala Ser Gly Pro Pro Cys His Val Lys Ser Thr Leu Tyr Ser

1

5

10

15

Leu Phe Leu Glu Arg Thr Tyr Tyr Val Asn Leu Asp Phe His Met Val

20

25

30

Ile Thr Leu Tyr Glu Ala Asn Ile

35

40

&lt;210&gt; 163

&lt;211&gt; 73

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 163

Met Gln Asn Ser Val Ser Thr Gln Arg Phe Asn Val Tyr Ser Phe Lys

1

5

10

15

Gln Ile Ser Phe Asp Ser Leu Glu Tyr Phe Phe Leu Asn Ile Leu Ser

20

25

30

Pro Ser Met Glu Ser Cys Pro Lys Lys Ala Glu Arg Lys Glu Lys Lys

35

40

45

Lys Arg Lys Leu Asn Phe Leu Asn Ser Ile Ser His Cys Leu Gly His

50

55

60

Val Cys Lys Trp Pro Thr Leu Pro Arg

65

70

&lt;210&gt; 164

&lt;211&gt; 37

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 164

Met Lys Cys Phe Asp Ile Trp Asn Phe Leu Pro Leu Phe His Phe Ala

1

5

10

15

Val Asn Gln Ser Glu Phe Arg Ser Ile Met Trp Ile Tyr Glu Asn Val

20

25

30

Ser Asn Gly Leu Phe

35

&lt;210&gt; 165

&lt;211&gt; 55

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (8)..(42)

&lt;400&gt; 165

Met Gln Ile Leu Trp Leu Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

1

5

10

15

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

20

25

30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ser Asn Pro Arg Leu Cys

35

40

45

Leu Leu Val Ala Leu Lys Pro

50

55

&lt;210&gt; 166

&lt;211&gt; 48

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 166

Met Cys Ala Lys Val Leu Val Leu Ser Arg Lys Asp Thr Asp Glu Cys  
 1 5 10 15

Tyr Arg Leu Leu Lys Asn Ile Tyr Leu Asn Lys Tyr Val Lys Tyr Lys  
 20 25 30

Gly Ile Gln Tyr Ser Asn Arg Asn Ile Glu Ile Glu Gly Thr Ser Pro  
 35 40 45

<210> 167

<211> 95

<212> PRT

<213> Homo sapiens

<400> 167

Met Cys Leu Phe Cys Ser His Ser Val Tyr Lys Pro Leu Tyr Glu Thr  
 1 5 10 15

Gly Ser Ser Gln Leu Phe Phe Tyr Ser Thr Leu Lys Ile Leu Val Ser  
 20 25 30

Phe Leu Val Ser Thr Val Ala Lys Ala Tyr Cys Gln Phe Asp Tyr His  
 35 40 45

Ser Ile Ile Gln Asn Phe Phe Leu Tyr Leu Tyr Ser Glu Phe Gln Ile  
 50 55 60

Phe Ser Leu Ser Leu Ile Ser Tyr Asp Phe Ile Ile Met Tyr Val Val  
 65 70 75 80

Val Asp Leu Ser Ile Leu Cys Tyr Ile Trp Gln His Phe Leu Phe  
 85 90 95

<210> 168

<211> 89

<212> PRT

<213> Homo sapiens

<400> 168

Met Asn Asn Arg Trp Met Leu Pro Pro Phe Ser Pro Arg Arg Asn Lys  
 1 5 10 15

Gly Lys Gly Glu Gly Leu Gly Gly Trp Ile Ser Arg Gln Thr Gly Glu

20 25 30  
 Cys Glu Gly Thr Ile Arg Arg Glu Val His Pro Glu Ile Arg Tyr Val  
 35 40 45  
 Ser Pro Leu Arg Phe Pro Thr Ile Asp Ser Glu Leu Leu Glu Ser Val  
 50 55 60  
 Ser Ser Ile Ser Asp Ala Val Gly Ser Ser Lys Ser Gly Lys Tyr Ser  
 65 70 75 80  
 Cys Thr Phe Val Pro Glu Ser Ser Asn  
 85

<210> 169  
 <211> 42  
 <212> PRT  
 <213> Homo sapiens

<400> 169  
 Met Glu Ser Ser Leu Glu Thr Cys Ala Ser Ser Asn Pro Leu Arg Leu  
 1 5 10 15  
 Lys Lys Thr Ser Phe Leu Ser Gln Glu Thr Pro Gly Arg Leu Phe Ile  
 20 25 30  
 Leu Pro Thr Thr Trp Pro Asn Ala His Asn  
 35 40

<210> 170  
 <211> 132  
 <212> PRT  
 <213> Homo sapiens

<400> 170  
 Met Gly Arg Arg Thr Arg Thr Val Arg Val Ser Arg Leu Pro Pro Ala  
 1 5 10 15  
 Thr His Ser Cys Ser Pro Pro Pro Ile Tyr Ala Leu Ala Leu Pro Ala  
 20 25 30  
 Phe Trp Pro Ser Gly Ala Val Leu Val Pro Ala Leu Ala Gln Ala Cys  
 35 40 45  
 Phe Ser Ser Leu Pro Thr Asn Phe Leu Ser Ser Cys Gly Cys Ala Tyr  
 50 55 60



Leu Val Trp Val Trp Phe Trp Leu Leu Asn Glu Gln Arg Gln Asn Glu  
65 70 75 80

Gly Ala Met Ser Thr Asp Glu Ala Phe Gly Lys Arg Pro Pro Ser Ile  
85 90 95

Ala Leu Leu Glu Gly Ser Val Glu Ala Ala Val Phe Pro Gly Ala Gly  
100 105 110

His Leu Asp Thr Val Pro Ala Cys Thr Gln Pro Pro Ser Thr Leu Leu  
115 120 125

His Gln Pro Ala  
130

<210> 171

<211> 121

<212> PRT

<213> Homo sapiens

<400> 171

Met Val Ser Cys Asn Tyr Gly Tyr Val Arg Val Gln Arg Arg Glu Ser  
1 5 10 15

Cys Val Gly Trp Ser Gly Leu Glu Arg Leu Gly Thr Glu Leu Gly Val  
20 25 30

Glu Leu Gly Trp Pro Ala Ala Glu Gly Ala Glu Met Gly Trp Gly Gly  
35 40 45

Pro Ser Ser Gln Pro Pro Gly Thr Phe Pro Glu Gly Pro Ala Val Gly  
50 55 60

Leu Cys Thr Arg Glu Ile Ala Ser Leu Phe Arg Thr Pro Ser Leu Pro  
65 70 75 80

Ala Leu His Leu Pro Thr Gly Ala Leu Glu Gln Ala Arg Leu Gln Leu  
85 90 95

Arg His Val Gln Pro Gln Thr Phe Ala Pro Ala Ser Pro Pro Arg Leu  
100 105 110

Pro Arg Glu Leu Gly Lys Gly Leu Cys  
115 120

&lt;210&gt; 172

&lt;211&gt; 107

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 172

Met Val Leu Pro Gln Asp Phe Leu Ala Glu Pro Gly Ile Leu Leu Thr  
 1 5 10 15

Leu Pro Ser His Gly Asn Met Ala Leu Ala Cys Trp Arg Leu Trp Ala  
 20 25 30

Pro Phe Leu Ala Ala Val Leu Pro Gly Val Ala Lys Asp Ser Ser Tyr  
 35 40 45

Pro Leu Pro Arg Ile Leu Val Ser Arg Leu Ser Leu Leu Val Thr Gly  
 50 55 60

Ser Glu Trp Asn Thr Val Gln Val Arg Glu Gly Thr Asn Arg Pro Cys  
 65 70 75 80

Phe Asn Ser Pro Cys Phe Pro Pro Val Pro Tyr Arg Pro Ser Leu Ser  
 85 90 95

Pro Gly Val Ser Ile Glu Asn Ser Ala Tyr Leu  
 100 105

&lt;210&gt; 173

&lt;211&gt; 107

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 173

Met Val Leu Pro Gln Asp Phe Leu Ala Glu Pro Gly Ile Leu Leu Thr  
 1 5 10 15

Leu Pro Ser His Gly Asn Met Ala Leu Ala Cys Trp Arg Leu Trp Ala  
 20 25 30

Pro Phe Leu Ala Ala Val Leu Pro Gly Val Ala Lys Asp Ser Ser Tyr  
 35 40 45

Pro Leu Pro Arg Ile Leu Val Ser Arg Leu Ser Leu Leu Val Thr Gly  
 50 55 60

Ser Glu Trp Asn Thr Val Gln Val Arg Glu Gly Thr Asn Arg Pro Cys  
 65 70 75 80

Phe Asn Ser Pro Cys Phe Pro Pro Val Pro Tyr Arg Pro Ser Leu Ser  
                                     85                                    90                                    95

Pro Gly Val Ser Ile Glu Asn Ser Ala Tyr Leu  
                                     100                                    105

<210> 174

<211> 65

<212> PRT

<213> Homo sapiens

<400> 174

Met Val Trp Trp Ser Leu Gly Leu Thr Leu Thr Arg Glu Arg Asn Ala  
       1                                    5                                    10                                    15

Asp Phe Ser Phe Thr Ile Pro Ser Gly Leu His Arg Tyr Pro Ser Lys  
                                     20                                    25                                    30

Val Arg Arg Asp Phe Cys Cys Tyr Leu Ser Ser Cys Phe Ser Ala Glu  
                                     35                                    40                                    45

Ala Leu Thr Lys Ile Gln Ile Asn Ile Ser Gln Met Gly Ile Val Leu  
                                     50                                    55                                    60

Ile

65

<210> 175

<211> 65

<212> PRT

<213> Homo sapiens

<400> 175

Met Val Trp Trp Ser Leu Gly Leu Thr Leu Thr Arg Glu Arg Asn Ala  
       1                                    5                                    10                                    15

Asp Phe Ser Phe Thr Ile Pro Ser Gly Leu His Arg Tyr Pro Ser Lys  
                                     20                                    25                                    30

Val Arg Arg Asp Phe Cys Cys Tyr Leu Ser Ser Cys Phe Ser Ala Glu  
                                     35                                    40                                    45

Ala Leu Thr Lys Ile Gln Ile Asn Ile Ser Gln Met Gly Ile Val Leu  
                                     50                                    55                                    60

Ile  
65

<210> 176  
<211> 92  
<212> PRT  
<213> Homo sapiens

<400> 176  
Met Tyr Lys Arg Lys Val Tyr Pro Val Ser Ser Pro Leu Met Val Thr  
1 5 10 15  
Leu Glu Thr His Val Leu Lys Thr Arg Ser Gly Pro Gly Thr Ala Pro  
20 25 30  
Asp Pro Ala Phe Pro Ser Tyr Thr Ala His Phe Cys Leu Ser Thr His  
35 40 45  
Gly Gly Cys His Ser Ala Glu Met Pro Ala Gly Leu Thr Ser Thr Pro  
50 55 60  
Phe Ile Asn Asn Ala Ala Pro Thr Ser Thr His Val Trp Ile Ser Thr  
65 70 75 80  
His Leu Ser Ser Phe Leu Arg Ile Asp Phe Lys Met  
85 90

<210> 177  
<211> 114  
<212> PRT  
<213> Homo sapiens

<400> 177  
Met Phe Ser Asn Tyr Tyr Cys Lys Lys Val Ile His Ala Tyr Gln Lys  
1 5 10 15  
Asn Leu Tyr Asn Thr Thr Met Tyr Lys Arg Lys Val Tyr Pro Val Ser  
20 25 30  
Ser Pro Leu Met Val Thr Leu Glu Thr His Val Leu Lys Thr Arg Ser  
35 40 45  
Gly Pro Gly Thr Ala Pro Asp Pro Thr Phe Pro Ser Tyr Thr Ala His  
50 55 60  
Phe Cys Leu Ser Thr His Gly Gly Cys His Ser Ala Glu Met Pro Ala

PCT/US01/45541

```

<210> 178
<211> 47
<212> PRT
<213> Homo sapiens

<400> 178
Met Glu Leu Pro Phe Cys Lys Gln Phe Ile Ser Asp Asp Ile Thr Thr
 1             5             10             15
Phe Leu Tyr Val Ser Leu Tyr Ile His Leu Ile Val Leu Leu Lys Trp
      20             25             30
Phe Leu Lys Cys Ile His Arg Tyr Phe Gly Tyr Leu Gly Arg Gly
      35             40             45

```

```

<210> 179
<211> 42
<212> PRT
<213> Homo sapiens

<400> 179
Met Asn Leu Leu Ile Leu Ser Leu Ser Asn Tyr Pro Lys Asn Gln Phe
  1                      5                      10                      15
Val Phe Leu Val Ile Ala Gly Asn Arg Gly Leu Cys Leu Ile Asn Gln
      20                      25                      30
Lys Gly Ser Ser Leu Gly Ala Val Ile Tyr
      35                      40

```

```
<210> 180
<211> 24
<212> PRT
<213> Homo sapiens
```

&lt;400&gt; 180

Met Lys Arg Val Leu Ser Tyr Asp Leu Asn Leu Thr Ala Glu Lys Ser  
1 5 10 15

Ser Ile Phe Gln Leu Ser Ala Val  
20

&lt;210&gt; 181

&lt;211&gt; 69

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 181

Met Ser Leu Ser Val His Gln Glu Gln Cys Thr Ala Gln Arg Asp Pro  
1 5 10 15

Gly Gln Leu Glu Gly Arg Gly Phe Ala Glu Val Pro Glu Pro Asp Gly  
20 25 30

Thr Leu Trp Cys Leu Gly Arg Asn Leu Asp Phe Gly Leu Arg Gly Ser  
35 40 45

Arg His Val Gln Trp Gln Gln Phe Gly Gln Gly Gly Asp Glu Leu Ser  
50 55 60

Cys Phe Leu Leu Arg  
65

&lt;210&gt; 182

&lt;211&gt; 20

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 182

Met Lys Gln Glu Ser Gln Leu Glu Ser Leu Tyr Thr Ile Cys Thr Val  
1 5 10 15

Gly Ile Phe Lys  
20

&lt;210&gt; 183

&lt;211&gt; 136

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 183

Asn Glu Tyr Lys Ala Glu Ile Ala Glu Val Glu Arg Gln Ile Leu Gln  
 1 5 10 15

Gly Glu Gln Ser Tyr Ser Ser Ala Leu Glu Gly Met Lys Met Glu Ile  
 20 25 30

Ser His Leu Thr Gln Glu Leu His Gln Arg Asp Ile Thr Ile Ala Ser  
 35 40 45

Thr Lys Gly Ser Ser Ser Asp Met Glu Lys Arg Leu Arg Ala Glu Met  
 50 55 60

Gln Lys Ala Glu Asp Lys Ala Val Glu His Lys Glu Ile Leu Asp Gln  
 65 70 75 80

Leu Glu Ser Leu Lys Leu Glu Asn Arg His Leu Ser Glu Met Val Met  
 85 90 95

Lys Leu Glu Leu Gly Leu His Glu Arg Trp Gly Phe Thr Met Leu Ser  
 100 105 110

Ser Leu Val Leu Asn Phe Gly Ile Gln Ala Ile Arg Gln Pro Gln Arg  
 115 120 125

Pro Lys Val Leu Glu Leu Gln Val  
 130 135

&lt;210&gt; 184

&lt;211&gt; 47

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 184

Met Cys Asn Trp Arg Phe Ser Xaa Arg Gly Glu Arg Lys Trp Asp Ile  
 1 5 10 15

Lys Asn Asn Trp Lys Lys Ile Ala Glu Ile Val Leu Lys Leu Thr Asn  
 20 25 30

His Thr Lys Pro Gln Asn Pro Glu Ala Leu Gly His Gln Ala Gly  
 35 40 45

&lt;210&gt; 185

&lt;211&gt; 30

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 185

Met Tyr His Phe Tyr Asn Lys Glu Phe Ile Asn Arg Asn Lys His Ile  
 1 5 10 15

Leu Leu Leu Ala Ser Ala Ala His Ile Leu Glu Ile Ser Thr  
 20 25 30

&lt;210&gt; 186

&lt;211&gt; 86

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 186

Ala His Cys Ser Phe Lys Leu Gln Ser Ala Ser Asn Leu Pro Thr Ser  
 1 5 10 15

Ala Ser Gln Val Ala Gly Thr Thr Gly Arg Arg His Gln Ala Arg Pro  
 20 25 30

Ile Phe Val Phe Phe Val Glu Thr Arg Phe Arg His Ile Ala Gln Ala  
 35 40 45

Gly Leu Glu Leu Leu Ser Ser Ser Asp Pro Thr Thr Ser Ser Ser Gln  
 50 55 60

Ser Ala Gly Ile Ile Gly Val Thr Ala Ala Ala Gly Ser Gln Ala Val  
 65 70 75 80

Leu Phe Cys Ile Ile Arg  
 85

&lt;210&gt; 187

&lt;211&gt; 40

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 187

Met Phe Ser Lys Pro Gly Tyr Ser Gln Ser Leu Trp Leu Leu Leu Met  
 1 5 10 15

Ser Phe Ala Gly Glu Ser His Glu Thr Val Leu Ile Cys Ala Tyr Ser  
 20 25 30



&lt;400&gt; 190

Met Val Leu Lys Val Asn Ser Arg Met Val Ala Trp Val Phe Lys Val  
1 5 10 15

Trp Phe Leu Leu Asn Ala Ser Gly Phe Leu Thr Asn Ile Lys Ser Lys  
20 25 30

Lys Lys Lys Lys Asn Leu Leu Val Ala Ile Arg Arg Leu Gln  
35 40 45

&lt;210&gt; 191

&lt;211&gt; 96

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 191

Met Ser Ser Pro Gln Phe Ser Leu Arg Val Phe Ala Phe Ser Leu Leu  
1 5 10 15

Thr Ser Thr Pro Leu Met Ser Leu Pro Ile Ala Pro Asn Ser Gly Ser  
20 25 30

Gln His Trp Tyr Ile Gln Val Trp Gln Arg Ala Ser Ser Thr Pro Gly  
35 40 45

Met Ala Ser Pro Lys Gln Gln Glu Glu Val Gly Glu Val Leu Phe Pro  
50 55 60

Ser Thr Ala Val Ala Leu Trp Trp Lys Val Arg Phe Pro Asn Gln Leu  
65 70 75 80

Arg Arg Val Gln Gln Ala Thr Arg Gln Val Asn Pro Phe Thr Ser Gly  
85 90 95

&lt;210&gt; 192

&lt;211&gt; 54

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (24)

Pro Gln Cys Tyr Leu Ser Ala Leu  
35 40

<210> 188  
<211> 59  
<212> PRT  
<213> Homo sapiens

<400> 188  
Met Arg Ile Ile Ser Thr Phe Cys Ser Tyr Gly Lys Asp Leu Lys Ala  
1 5 10 15

Asp Ala Cys Ala Arg Asp Met Val Asp Thr Thr Tyr Ile Ala Val Met  
20 25 30

Ile Leu Leu Tyr Tyr Ser Val Leu Tyr Leu Leu Leu His Thr Leu Pro  
35 40 45

Leu Pro Ile Met Thr Lys Ile Ile Thr Ala Tyr  
50 55

<210> 189  
<211> 35  
<212> PRT  
<213> Homo sapiens

<220>  
<221> UNSURE  
<222> (8)..(15)

<400> 189  
Met Arg Pro Phe Pro Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Val  
1 5 10 15

Phe Thr Ser Gly Glu Ala Ala Val Leu Leu Cys Leu Phe Leu Leu Cys  
20 25 30

Trp Xaa Val  
35

<210> 190  
<211> 46  
<212> PRT  
<213> Homo sapiens

&lt;400&gt; 192

Met Leu Phe Met Trp Lys Val Lys Phe Cys Phe Ile Met Glu Phe Cys  
 1 5 10 15

Phe Leu Tyr Asn Ser Phe Arg Xaa Ser Tyr Phe Ala Thr Ile Leu Tyr  
 20 25 30

Lys Ala Leu Arg Gln Val Met Val Ile Ile Leu Met Gln Asn His Leu  
 35 40 45

Gly Ser Gln Ser Leu Ala  
 50

&lt;210&gt; 193

&lt;211&gt; 57

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 193

Met Tyr Pro Leu Val His Gly Arg Pro Ser Ser Ile Ser Arg Gly Gln  
 1 5 10 15

Val His Leu Val Arg Ala Gln Lys Leu His Ser Gln Thr Asn Glu Ser  
 20 25 30

Ser Gln Asn Ile Phe Leu Arg Leu Trp Val Tyr Leu Tyr Arg Asn His  
 35 40 45

Trp Met Leu Leu Ser Leu Phe Ser Phe  
 50 55

&lt;210&gt; 194

&lt;211&gt; 57

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 194

Met Tyr Pro Leu Val His Gly Arg Pro Ser Ser Ile Ser Arg Gly Gln  
 1 5 10 15

Val His Leu Val Arg Ala Gln Lys Leu His Ser Gln Thr Asn Glu Ser  
 20 25 30

Ser Gln Asn Ile Phe Leu Arg Leu Trp Val Tyr Leu Tyr Arg Asn His  
 35 40 45

Trp Met Leu Leu Ser Leu Phe Ser Phe  
50 55

<210> 195

<211> 91

<212> PRT

<213> Homo sapiens

<400> 195

Met Gly Lys Glu Ala Ile Leu Ile Gly Pro Arg Glu His Val Gly Leu  
1 5 10 15

Cys Leu Val Leu Val Thr Gly Ile Leu Tyr Thr Phe Ile Val Gly Glu  
20 25 30

Lys Ala Ala Ile Thr Ser Ala Met Lys Val Leu Leu Ile His Gly Leu  
35 40 45

Asn Ile Ile Glu Met Leu Leu Val Leu Cys Arg Ala Asp Ser Ser Arg  
50 55 60

Thr Lys Glu Trp Gln Ser Asp Glu Leu Arg His Ile Arg Asp Pro Thr  
65 70 75 80

Val Gln Met Met Thr Gln Asn Leu Phe Leu Leu  
85 90

<210> 196

<211> 79

<212> PRT

<213> Homo sapiens

<400> 196

Met Arg Thr Ala Gln Gln Cys Ile Gln Arg His Glu His Leu Ala Ala  
1 5 10 15

Leu Glu Ser Gly Pro His Lys Phe Gly Gly Ile Gln Ala Leu Pro Lys  
20 25 30

Arg Ala Gly Gly Cys Ser Phe Leu Leu His Phe Leu Ser Gln Arg Pro  
35 40 45

Arg Glu Leu Ser Pro Gln Thr Lys Gly Lys Gly Arg Leu Gln Ser Ser  
50 55 60

Leu Tyr Leu Ala Leu Asn Ala Ser Ser Leu Cys Gly Pro Ala Arg

65

70

75

&lt;210&gt; 197

&lt;211&gt; 40

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 197

Met Thr Asp Ile Glu Trp Asp Cys Ser Arg Gln Met Gly Met Asn Gly

1

5

10

15

His Pro Thr Cys Lys Asp Thr Met Gly Ser Ala Asp Glu Met Gly Pro

20

25

30

Val Thr Glu Lys Leu Leu Pro Pro

35

40

&lt;210&gt; 198

&lt;211&gt; 40

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 198

Met Thr Asp Ile Glu Trp Asp Cys Ser Arg Gln Met Gly Met Asn Gly

1

5

10

15

His Pro Thr Cys Lys Asp Thr Met Gly Ser Ala Asp Glu Met Gly Pro

20

25

30

Val Thr Glu Lys Leu Leu Pro Pro

35

40

&lt;210&gt; 199

&lt;211&gt; 76

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 199

Met Thr Leu Leu Leu Arg Arg Pro Glu Leu Trp Cys Cys Gly Met Thr

1

5

10

15

Val Cys Leu Leu Thr Ser Ala Ser Ser His Ser Pro Pro Arg Ser Pro

20

25

30

Cys Pro Thr Pro Gly Val Ser Arg Gly Arg Gln Val Thr Thr Met Leu

35

40

45

Arg Val Ser Asp Gly Pro Glu Ala Gly Leu Thr Gln Leu Tyr Pro Lys  
 50 55 60

Ala Glu Ser Gly Ser Pro Arg Leu Ser Ala His Gly  
 65 70 75

&lt;210&gt; 200

&lt;211&gt; 78

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 200

Met Cys Asp Leu Cys Asp Arg Leu Glu Ser Cys Gly Lys Pro Val Leu  
 1 5 10 15

Val Arg Glu Ser Leu Gly Pro Phe Pro His Arg Ala Leu Phe Ser Lys  
 20 25 30

Ser His Ser Trp Val Thr Asn Val Asp Ala Gly Pro Met Pro Cys Pro  
 35 40 45

Gly Gly Leu Ala Pro Gly Ser Pro Glu Asn Thr Ser Gly Arg Trp Glu  
 50 55 60

Val Trp Trp Gly Ser Leu Ala Arg Val Asp Met Gly Gln Arg  
 65 70 75

&lt;210&gt; 201

&lt;211&gt; 525

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 201

Asp Ile Asn Asn Ala Trp Gly Cys Leu Glu Gln Val Glu Lys Gly Tyr  
 1 5 10 15

Glu Glu Trp Leu Leu Asn Glu Ile Arg Arg Leu Glu Arg Leu Asp His  
 20 25 30

Leu Ala Glu Lys Phe Arg Gln Lys Ala Ser Ile His Glu Ala Trp Thr  
 35 40 45

Asp Gly Lys Glu Ala Met Leu Lys His Arg Asp Tyr Glu Thr Ala Thr  
 50 55 60

Leu Ser Asp Ile Lys Ala Leu Ile Arg Lys His Glu Ala Phe Glu Ser  
 65 70 75 80  
 Asp Leu Pro Glu His Gln Asp Arg Ala Glu Gln Ile Ala Ala Ile Ala  
 85 90 95  
 Gln Glu Leu Asn Glu Leu Asp Tyr Tyr Asp Ser His Asn Val Asn Thr  
 100 105 110  
 Arg Cys Gln Lys Ile Cys Asp Gln Trp Asp Ala Leu Gly Ser Leu Thr  
 115 120 125  
 His Ser Arg Arg Glu Ala Leu Glu Lys Thr Glu Lys Gln Leu Glu Ala  
 130 135 140  
 Ile Asp Gln Leu His Leu Glu Tyr Ala Lys Arg Ala Ala Pro Phe Asn  
 145 150 155 160  
 Asn Trp Met Glu Ser Ala Met Glu Asp Leu Gln Asp Met Phe Ile Val  
 165 170 175  
 His Thr Ile Glu Glu Ile Glu Gly Leu Ile Ser Ala His Asp Gln Phe  
 180 185 190  
 Lys Ser Thr Leu Pro Asp Ala Asp Arg Glu Arg Glu Ala Ile Leu Ala  
 195 200 205  
 Ile His Lys Glu Ala Gln Arg Ile Ala Glu Ser Asn His Ile Lys Leu  
 210 215 220  
 Ser Gly Ser Asn Pro Tyr Thr Thr Val Thr Pro Gln Ile Ile Asn Ser  
 225 230 235 240  
 Lys Trp Glu Lys Val Gln Gln Leu Val Pro Lys Arg Asp His Ala Leu  
 245 250 255  
 Leu Glu Glu Gln Ser Lys Gln Gln Ser Asn Glu His Leu Arg Arg Gln  
 260 265 270  
 Phe Ala Ser Gln Ala Asn Val Val Gly Pro Trp Ile Gln Thr Lys Met  
 275 280 285  
 Glu Glu Ile Gly Arg Ile Ser Ile Glu Met Asn Gly Thr Leu Glu Asp  
 290 295 300  
 Gln Leu Ser His Leu Lys Gln Tyr Glu Arg Ser Ile Val Asp Tyr Lys  
 305 310 315 320

Pro Asn Leu Asp Leu Leu Glu Gln Gln His Gln Leu Ile Gln Glu Ala  
325 330 335

Leu Ile Phe Asp Asn Lys His Thr Asn Tyr Thr Met Glu His Ile Arg  
340 345 350

Val Gly Trp Glu Gln Leu Leu Thr Thr Ile Ala Arg Thr Ile Asn Glu  
355 360 365

Val Glu Asn Gln Ile Leu Thr Arg Asp Ala Lys Gly Ile Ser Gln Glu  
370 375 380

Gln Met Gln Glu Phe Arg Ala Ser Phe Asn His Phe Asp Lys Lys Gln  
385 390 395 400

Thr Gly Ser Met Asp Ser Asp Asp Phe Arg Ala Leu Leu Ile Ser Thr  
405 410 415

Gly Tyr Ser Leu Gly Glu Ala Glu Phe Asn Arg Ile Met Ser Leu Val  
420 425 430

Asp Pro Asn His Ser Gly Leu Val Thr Phe Gln Ala Phe Ile Asp Phe  
435 440 445

Met Ser Arg Glu Thr Thr Asp Thr Asp Thr Ala Asp Gln Val Ile Ala  
450 455 460

Ser Phe Lys Val Leu Ala Gly Asp Lys Asn Phe Ile Thr Ala Glu Glu  
465 470 475 480

Leu Arg Arg Glu Leu Pro Pro Asp Gln Ala Glu Tyr Cys Ile Ala Arg  
485 490 495

Met Ala Pro Tyr Gln Gly Pro Asp Ala Val Pro Gly Ala Leu Asp Tyr  
500 505 510

Lys Ser Phe Ser Thr Ala Leu Tyr Gly Glu Ser Asp Leu  
515 520 525

<210> 202

<211> 83

<212> PRT

<213> Homo sapiens

<400> 202

Met Trp Pro Gly Val Gly Gln Lys Asn Leu His Lys Asp Arg Ile Leu



1                      5                      10                      15  
 Phe Ser Glu Ala Lys Asn Ser Arg Gly Ala Thr Ile Arg Phe Phe Ser  
                     20                      25                      30  
 Ala Val Gln Leu Gln Glu Met Leu Gly Ile Ser Tyr Asn Ser His Leu  
                     35                      40                      45  
 Ser Lys Thr Tyr Pro Gly Arg Cys Ser Ala Phe Ser His Leu Gly Ala  
                     50                      55                      60  
 Glu Gln Pro Tyr Ile Ala Val Tyr Ile Leu Thr Tyr Phe Pro Asp Phe  
                     65                      70                      75                      80  
 Leu Gly Gly

<210> 203  
 <211> 83  
 <212> PRT  
 <213> Homo sapiens

<400> 203  
 Met Trp Pro Gly Val Gly Gln Lys Asn Leu His Lys Asp Arg Ile Leu  
                     1                      5                      10                      15  
 Phe Ser Glu Ala Lys Asn Ser Arg Gly Ala Thr Ile Arg Phe Phe Ser  
                     20                      25                      30  
 Ala Val Gln Leu Gln Glu Met Leu Gly Ile Ser Tyr Asn Ser His Leu  
                     35                      40                      45  
 Ser Lys Thr Tyr Pro Gly Arg Cys Ser Ala Phe Ser His Leu Gly Ala  
                     50                      55                      60  
 Glu Gln Pro Tyr Ile Ala Val Tyr Ile Leu Thr Tyr Phe Pro Asp Phe  
                     65                      70                      75                      80  
 Leu Gly Gly

<210> 204  
 <211> 62  
 <212> PRT  
 <213> Homo sapiens

WO 02/062945

PCT/US01/45541

<400> 204

Met Ser Leu Ser Val Leu Asp Ser Val Ala Gln Thr Arg Pro Phe Val  
1 5 10 15

Cys Leu Phe Ser Phe Ser Ser Phe Val Asp Tyr Lys Phe Ser Leu Tyr  
20 25 30

Ser Asn Lys Arg Phe Ser Phe Gln Asn Leu Arg Gln Cys Ser Ser Leu  
35 40 45

Lys Met Ile Leu Pro His Arg Trp Ser Arg Ala Ser Gln Trp  
50 55 60

<210> 205

<211> 36

<212> PRT

<213> Homo sapiens

<400> 205

Met Cys Gln Asn Ile Asp Thr Val Pro Glu Glu Ala Ser Lys His Asn  
1 5 10 15

Lys Cys Tyr Phe Arg His Lys Leu Gln Asp Ser Leu Thr Ile Pro Ala  
20 25 30

Cys Leu Ile Gly  
35

<210> 206

<211> 78

<212> PRT

<213> Homo sapiens

<400> 206

Met Ser Ser Asn Leu Cys Ser Trp Lys Pro Ser Tyr Gly Arg Val Phe  
1 5 10 15

Pro Pro Ser Ser Ser Ala Phe Tyr Gln Arg Pro Tyr Ser Pro Pro Leu  
20 25 30

Leu Gln Phe Gln Thr Ser Phe Leu Phe His Gln Lys His Ser Pro Ser  
35 40 45

Ser Leu Val Ser Tyr Ser Phe His Thr Gln Lys Gln Asn Ile Phe Lys  
50 55 60

Thr Phe Pro Lys Lys Glu Glu Lys Gly Asn Ser Lys Val His  
65 70 75

<210> 207

<211> 78

<212> PRT

<213> Homo sapiens

<400> 207

Met Ser Ser Asn Leu Cys Ser Trp Lys Pro Ser Tyr Gly Arg Val Phe  
1 5 10 15

Pro Pro Ser Ser Ser Ala Phe Tyr Gln Arg Pro Tyr Ser Pro Pro Leu  
20 25 30

Leu Gln Phe Gln Thr Ser Phe Leu Phe His Gln Lys His Ser Pro Ser  
35 40 45

Ser Leu Val Ser Tyr Ser Phe His Thr Gln Lys Gln Asn Ile Phe Lys  
50 55 60

Thr Phe Pro Lys Lys Glu Glu Lys Gly Asn Ser Lys Val His  
65 70 75

<210> 208

<211> 15

<212> PRT

<213> Homo sapiens

<400> 208

Met Phe Ile Glu Leu Phe Trp Leu Ile Ile Ser Thr Asp Cys Leu  
1 5 10 15

<210> 209

<211> 47

<212> PRT

<213> Homo sapiens

<400> 209

Met Glu Arg His Thr Gln Ala Leu Cys Gly Arg Val Leu Ser Gly His  
1 5 10 15

Ser Glu Phe Arg Pro Gly Leu Trp Thr Asn Pro Asn Phe Ala Ser Ala  
20 25 30

Phe Val Ser Leu Val Lys Pro Val Phe Val Phe Ser Leu Leu Phe  
                   35                  40                  45

<210> 210

<211> 77

<212> PRT

<213> Homo sapiens

<400> 210

Met Ser Ser Leu Leu Leu Lys Glu Thr Phe Lys Gln Phe Ser Ser Leu  
       1                  5                  10                  15

His Cys His Leu Ala His Thr Ser Arg Ala Ala Gln His Leu Gln Gly  
                   20                  25                  30

Leu Ser Phe Trp Ala Val Leu Arg Asp Ala Ala Gly Gly Ser Leu Ala  
                   35                  40                  45

Phe Leu Gly Leu Leu Ser Gln Phe Pro Pro Val Leu Leu Ser Gly Cys  
                   50                  55                  60

Pro Ala Phe Gly Cys Trp Ile Leu Gln Val Pro Gln Arg  
       65                  70                  75

<210> 211

<211> 78

<212> PRT

<213> Homo sapiens

<400> 211

Met Gly Glu Pro Gly His Glu Lys Glu Leu Pro Ser Asp Ser Asn Ile  
       1                  5                  10                  15

Ser Leu Tyr Leu Phe Lys Val Cys Met Cys Gln Thr Val Pro Ser Thr  
                   20                  25                  30

Leu Tyr Thr Leu Ala Tyr Pro Val Leu Thr Asn Ile Ser Glu Met Gly  
                   35                  40                  45

Ile Thr Val Gln Phe Pro Asp Ile Val Ser Lys Ala Lys Pro Lys Pro  
                   50                  55                  60

Val Cys Thr Arg Ala Cys Ala Leu His Thr Asp Trp Leu Ile  
       65                  70                  75

<210> 212  
 <211> 61  
 <212> PRT  
 <213> Homo sapiens

<400> 212  
 Met Ser Arg Leu Pro His Thr Pro Ala Leu Ser Phe Pro Ser Gln Gly  
 1 5 10 15  
 Asn Gly Ser Arg His Thr Pro His Leu Gly Gly Gln Ala Glu Phe Leu  
 20 25 30  
 Ala Gln Gly Arg His Ser Glu Ser Val Glu Arg Lys Asn Asp Val Ala  
 35 40 45  
 Arg Thr Leu Leu Gln Val Ser Ile Gly Asn His Lys Pro  
 50 55 60

<210> 213  
 <211> 79  
 <212> PRT  
 <213> Homo sapiens

<400> 213  
 Met Lys Val Pro Gln Ser Pro Val Leu Gln Leu Leu Ala Gln Asp Leu  
 1 5 10 15  
 Ser Ser Arg Glu Lys Arg Ile Asn Thr Thr Pro Lys Gly Glu Lys Leu  
 20 25 30  
 Leu Leu Ser Ser Ser Gly Asp Leu Ala His Gly Gly Pro Asn Gly Gly  
 35 40 45  
 Pro Ser Leu Ile Ser Asn Ser Pro Ala Asn Ser Pro Leu Asp Thr Arg  
 50 55 60  
 Ala Gly Lys Thr Leu Pro Gln Gly Gln Glu Gly Met Phe Val Ser  
 65 70 75

<210> 214  
 <211> 40  
 <212> PRT  
 <213> Homo sapiens

<400> 214  
 Met Arg Asp Gly Pro Pro Phe Gly Pro Pro Trp Ala Lys Ser Pro Glu

1                      5                      10                      15  
Leu Glu Ser Ser Asn Phe Ser Pro Leu Gly Val Val Leu Ile Leu Phe  
                    20                      25                      30

Ser Leu Glu Leu Lys Val Leu Gly  
                    35                      40

<210> 215  
<211> 72  
<212> PRT  
<213> Homo sapiens

<400> 215  
Met Leu Lys Asn Ser Ser Tyr Asn Leu Phe Tyr Asn Ile Tyr Ser Cys  
1                      5                      10                      15

Thr Tyr Phe Tyr Ile Leu Ser Phe Ile Phe Val Phe Val Ser Phe Ala  
                    20                      25                      30

Thr Leu Cys Thr Ser Leu Ser Glu Glu Gln Ser Phe Ser Pro Phe Tyr  
                    35                      40                      45

Thr Leu Asn Lys Tyr Leu Asn Ser Tyr Tyr Ser Leu Ile Leu Tyr Lys  
                    50                      55                      60

Ala Asp Ser Asn Ile Gly Ser Thr  
65                      70

<210> 216  
<211> 16  
<212> PRT  
<213> Homo sapiens

<400> 216  
Met Ser Trp Leu Leu Ser Tyr Gln Asn Leu Gly Val Ser Tyr Arg Cys  
1                      5                      10                      15

<210> 217  
<211> 39  
<212> PRT  
<213> Homo sapiens

<400> 217  
Met Leu Ser Trp Asn Cys Tyr Ser Pro Pro Ile Ser Ser Leu Ser Ile

1 5 10 15

Cys His Pro Asn His Leu Glu Ala Leu Val Leu Asp Ala Leu Gln Tyr  
20 25 30

Phe Phe Phe Leu Phe Phe Glu  
35

<210> 218

<211> 24

<212> PRT

<213> Homo sapiens

<400> 218

Met Asn Asp Arg Ala Arg Leu Ser Leu Ser Gln Lys Lys Thr Glu Arg  
1 5 10 15

Glu Ser Leu Glu Thr Arg His Ser  
20

<210> 219

<211> 84

<212> PRT

<213> Homo sapiens

<220>

<221> UNSURE

<222> (28)..(79)

<400> 219

Met Asp Arg Ala Leu Pro Leu Trp Gly Ser Gln Glu Pro Ser Glu Pro  
1 5 10 15

Ser Gln Ile Ala Leu Val Ser Ile Leu Val Leu Xaa Xaa Xaa Xaa Xaa  
20 25 30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
35 40 45

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
50 55 60

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ser  
65 70 75 80

Ile Lys Ile Gln

<210> 220  
 <211> 32  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> UNSURE  
 <222> (31)

<400> 220  
 Met Lys Ile Thr Ser Cys Val Tyr Thr Ile Cys Leu His Leu Ala Asn  
           1                  5                  10                  15  
 Thr Gly Leu His Asp Ser Thr Phe Ala Asn Tyr Leu Trp Leu Xaa Asn  
                   20                  25                  30

<210> 221  
 <211> 786  
 <212> PRT  
 <213> Homo sapiens

<400> 221  
 Arg Pro Leu Arg Ser Leu Lys Val Ile Tyr Asp Gly Leu Met Ala Leu  
           1                  5                  10                  15  
 Phe Thr Thr Ser Leu Ile Ala Leu Leu Ser Ser Arg Gly Lys Asn Val  
                   20                  25                  30  
 Ala Ile Glu Tyr Ile Lys Ile His Thr Ile Glu Lys Glu Asp Val His  
           35                  40                  45  
 Phe Cys Lys Gln Lys Ile Thr Asn Arg Met Leu Lys Leu Lys Leu Asp  
           50                  55                  60  
 Tyr Glu Glu Ser Pro Val Tyr Gln Val Tyr Val Gln Ala Lys Asp Leu  
           65                  70                  75                  80  
 Gly Pro Asn Ala Val Pro Ala His Cys Lys Val Ile Val Arg Val Leu  
                   85                  90                  95  
 Asp Ala Asn Asp Asn Ala Pro Glu Ile Ser Phe Ser Thr Val Lys Glu



100	105	110
Ala Val Ser Glu Gly Ala Ala Pro Gly Thr Val Val Ala Leu Phe Ser		
115	120	125
Val Thr Asp Arg Asp Ser Glu Glu Asn Gly Gln Val Gln Cys Glu Leu		
130	135	140
Leu Gly Asp Val Pro Phe Arg Leu Lys Ser Ser Phe Lys Asn Tyr Tyr		
145	150	155
Thr Ile Val Thr Glu Ala Pro Leu Asp Arg Glu Ala Gly Asp Ser Tyr		
165	170	175
Thr Leu Thr Val Val Ala Arg Asp Arg Gly Glu Pro Ala Leu Ser Thr		
180	185	190
Ser Lys Ser Ile Gln Val Gln Val Ser Asp Val Asn Asp Asn Ala Pro		
195	200	205
Arg Phe Ser Gln Pro Val Tyr Asp Val Tyr Val Thr Glu Asn Asn Val		
210	215	220
Pro Gly Ala Tyr Ile Tyr Ala Val Ser Ala Thr Asp Arg Asp Glu Gly		
225	230	235
Ala Asn Ala Gln Leu Ala Tyr Ser Ile Leu Glu Cys Gln Ile Gln Gly		
245	250	255
Met Ser Val Phe Thr Tyr Val Ser Ile Asn Ser Glu Asn Gly Tyr Leu		
260	265	270
Tyr Ala Leu Arg Ser Phe Asp Tyr Glu Gln Leu Lys Asp Phe Ser Phe		
275	280	285
Gln Val Glu Ala Arg Asp Ala Gly Ser Pro Gln Ala Leu Ala Gly Asn		
290	295	300
Ala Thr Val Asn Ile Leu Ile Val Asp Gln Asn Asp Asn Ala Pro Ala		
305	310	315
Ile Val Ala Pro Leu Pro Gly Arg Asn Gly Thr Pro Ala Arg Glu Val		
325	330	335
Leu Pro Arg Ser Ala Glu Pro Gly Tyr Leu Leu Thr Arg Val Ala Ala		
340	345	350
Val Asp Ala Asp Asp Gly Glu Asn Ala Arg Leu Thr Tyr Ser Ile Val		

355                      360                      365  
 Arg Gly Asn Glu Met Asn Leu Phe Arg Met Asp Trp Arg Thr Gly Glu  
 370                      375                      380  
 Leu Arg Thr Ala Arg Arg Val Pro Ala Lys Arg Asp Pro Gln Arg Pro  
 385                      390                      395                      400  
 Tyr Glu Leu Val Ile Glu Val Arg Asp His Gly Gln Pro Pro Leu Ser  
 405                      410                      415  
 Ser Thr Ala Thr Leu Val Val Gln Leu Val Asp Gly Ala Val Glu Pro  
 420                      425                      430  
 Gln Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Glu His Gln Arg  
 435                      440                      445  
 Pro Ser Arg Ser Gly Gly Gly Glu Thr Ser Leu Asp Leu Thr Leu Ile  
 450                      455                      460  
 Leu Ile Ile Ala Leu Gly Ser Val Ser Phe Ile Phe Leu Leu Ala Met  
 465                      470                      475                      480  
 Ile Val Leu Ala Val Arg Cys Gln Lys Glu Lys Lys Leu Asn Ile Tyr  
 485                      490                      495  
 Thr Cys Leu Ala Ser Asp Cys Cys Leu Cys Cys Cys Cys Gly Gly  
 500                      505                      510  
 Gly Gly Ser Thr Cys Cys Gly Arg Gln Ala Arg Ala Arg Lys Lys Lys  
 515                      520                      525  
 Leu Ser Lys Ser Asp Ile Met Leu Val Gln Ser Ser Asn Val Pro Ser  
 530                      535                      540  
 Asn Pro Ala Gln Val Pro Ile Glu Glu Ser Gly Gly Phe Gly Ser His  
 545                      550                      555                      560  
 His His Asn Gln Asn Tyr Cys Tyr Gln Val Cys Leu Thr Pro Glu Ser  
 565                      570                      575  
 Ala Lys Thr Asp Leu Met Phe Leu Lys Pro Cys Ser Pro Ser Arg Ser  
 580                      585                      590  
 Thr Asp Thr Glu His Asn Pro Cys Gly Ala Ile Val Thr Gly Tyr Thr  
 595                      600                      605  
 Asp Gln Gln Pro Asp Ile Ile Ser Asn Gly Ser Ile Leu Ser Asn Glu

610                      615                      620  
 Thr Lys His Gln Arg Ala Glu Leu Ser Tyr Leu Val Asp Arg Pro Arg  
 625                      630                      635                      640  
 Arg Val Asn Ser Ser Ala Phe Gln Glu Ala Asp Ile Val Ser Ser Lys  
 645                      650                      655  
 Asp Ser Gly His Gly Asp Ser Glu Gln Gly Asp Ser Asp His Asp Ala  
 660                      665                      670  
 Thr Asn Arg Ala Gln Ser Ala Gly Met Asp Leu Phe Ser Asn Cys Thr  
 675                      680                      685  
 Glu Glu Cys Lys Ala Leu Gly His Ser Asp Arg Cys Trp Met Pro Ser  
 690                      695                      700  
 Phe Val Pro Ser Asp Gly Arg Gln Ala Ala Asp Tyr Arg Ser Asn Leu  
 705                      710                      715                      720  
 His Val Pro Gly Met Asp Ser Val Pro Asp Thr Glu Val Phe Glu Thr  
 725                      730                      735  
 Pro Glu Ala Gln Pro Gly Ala Glu Arg Ser Phe Ser Thr Phe Gly Lys  
 740                      745                      750  
 Glu Lys Ala Leu His Ser Thr Leu Glu Arg Lys Glu Leu Asp Gly Leu  
 755                      760                      765  
 Leu Thr Asn Thr Arg Ala Pro Tyr Lys Pro Pro Tyr Leu Ser Pro Tyr  
 770                      775                      780  
 Leu Thr  
 785

&lt;210&gt; 222

&lt;211&gt; 80

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 222

Met Tyr Lys Arg Arg Ser Cys Lys Ile Ala Pro Ile Glu Ser Glu Leu  
 1                      5                      10                      15  
 Glu Asn Leu Glu Glu Cys Ala Leu Thr Asn Ala Pro Phe Ser Ser Lys  
 20                      25                      30

Ala His Phe Phe Phe Leu Gln Thr Lys Leu Leu Glu Gln Val Asp Tyr  
 35 40 45

Thr Phe Cys His Ser His Val Trp Lys Asn Lys Asn Gly His Lys Leu  
 50 55 60

Phe Ala Ala Pro Tyr Val Lys Ser Trp Ser Pro Leu Ala Gly Cys Gly  
 65 70 75 80

<210> 223

<211> 87

<212> PRT

<213> Homo sapiens

<400> 223

Met Ser His Pro Phe Leu Ala Ile Leu Gly Cys Trp Thr Ser Gln Leu  
 1 5 10 15

His Phe Leu Leu Ser Cys Leu Asn Phe Tyr Leu Ser Thr Glu Thr Leu  
 20 25 30

Leu Thr Thr Tyr Lys Arg Ala Gly Ile Ser Pro Leu Asp Pro Thr Ile  
 35 40 45

Pro Ser Ser Ser Leu Phe Leu Cys Ile Leu Leu Gln Gln Thr Ser Glu  
 50 55 60

Gly Phe Phe Leu Ser Pro Ile Ser Leu Pro Leu His Leu Gly Phe Cys  
 65 70 75 80

Leu Arg His Phe Asn Lys Thr  
 85

<210> 224

<211> 61

<212> PRT

<213> Homo sapiens

<220>

<221> UNSURE

<222> (8)

<400> 224

Met Thr Gln Leu Ile Cys Thr Xaa Gln His Asp Gln Asn Gln Asn Val  
 1 5 10 15

Gln Phe Phe Glu Ser Arg His Ile Thr Thr Val Asn His Ile Leu Ser  
 20 25 30

Tyr Lys Ala Thr Gln Glu Ile Leu Lys Ile Glu Ile Ile Val Ile Phe  
 35 40 45

Tyr Tyr Ser Ala Phe Lys Ile Glu Ile Asn Lys Glu Leu  
 50 55 60

<210> 225

<211> 78

<212> PRT

<213> Homo sapiens

<400> 225

Met Phe Met Val Ser His Leu Ala Pro Arg Ser Leu Asn Arg Ser His  
 1 5 10 15

Leu Leu His His Leu Val Leu Lys His Leu Tyr Lys Met Gln Phe Thr  
 20 25 30

Ile Leu His Ser Val Gln Phe Asp Pro Phe Gln Ile Gln Tyr Met Gln  
 35 40 45

Thr Phe Pro Gly Gly Asp Val Arg Leu Arg Thr Thr Lys Tyr Val Phe  
 50 55 60

Cys Asn Ile Glu Ser Ile Ser Pro Ile Val Asn Ala Leu Ser  
 65 70 75

<210> 226

<211> 38

<212> PRT

<213> Homo sapiens

<400> 226

Met Leu Ala Asn Met Val Val Tyr Thr Lys Ala Leu Tyr Asp Gln Leu  
 1 5 10 15

Val Asn Lys Ser Leu Tyr Asn Cys Lys Gly Lys Ile Lys Thr Asp Leu  
 20 25 30

Leu Lys Gln Tyr Thr Ile

35

&lt;210&gt; 227

&lt;211&gt; 45

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 227

Met Pro Leu Trp Gln Arg Glu Phe Ser Asn Lys Thr Glu Leu Gly Arg  
1 5 10 15

Arg Glu Trp Asn Tyr Leu Leu Ile Ser Tyr Cys Asp Ile Arg Tyr Cys  
20 25 30

Tyr Ile His Leu Ser Leu Trp Tyr Leu Leu Asn Asn Trp  
35 40 45

&lt;210&gt; 228

&lt;211&gt; 67

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 228

Met Gly Leu Asp Phe Pro Phe His Ala Glu Lys Lys Leu Ser Leu Arg  
1 5 10 15

Glu Cys Ala Glu Gln Ser Gly Pro Arg Lys Ala Thr Thr Asn Ile Leu  
20 25 30

His Ala Lys Lys Glu Ala Lys Glu Glu Val Glu Leu Tyr Pro Asn Met  
35 40 45

Leu Ile Ile Gly Val Ile Leu Ala Glu Leu Val Arg Pro Pro Gly Gly  
50 55 60

Gln Gly Ile  
65

&lt;210&gt; 229

&lt;211&gt; 76

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 229

Lys Asn Lys Gln Lys Lys Lys Arg Lys Lys Arg Lys Lys Lys

1                      5                      10                      15  
 Arg Lys Lys Arg Lys Lys Arg Lys Arg Lys Arg Lys Lys Lys Arg Arg  
                     20                      25                      30  
 Lys Lys Gly Arg Arg Arg Arg Lys Lys Lys Lys Lys Lys Lys Lys Lys  
                     35                      40                      45  
 Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Glu  
                     50                      55                      60  
 Arg Lys Lys Glu Arg Lys Arg Glu Asp Ser Thr Asn  
                     65                      70                      75

<210> 230  
 <211> 20  
 <212> PRT  
 <213> Homo sapiens

<400> 230  
 Met Glu Met His Gly Asn Ala Phe Val Ser Thr Val Leu Glu Arg Leu  
                     1                      5                      10                      15

Lys His Phe Ile  
                     20

<210> 231  
 <211> 61  
 <212> PRT  
 <213> Homo sapiens

<400> 231  
 Met Pro Leu Gln Gly Pro Gln Phe Glu Lys Tyr Tyr Leu Val Lys Phe  
                     1                      5                      10                      15

Trp Leu Leu Cys Lys Asn Phe His Ser Leu Thr Gln Ala Ser Gly Thr  
                     20                      25                      30

Ala Tyr Phe Leu Thr Leu Thr Leu Leu Lys Leu Phe Gln Ser Leu Leu  
                     35                      40                      45

Cys Leu Gln Ala Leu Glu Thr Glu Glu Arg Asn Phe Thr  
                     50                      55                      60

<210> 232

<211> 39  
<212> PRT  
<213> Homo sapiens

<400> 232  
Met Ile Tyr Gly Ile Ile Gly Ile Phe Ile Phe Asn Thr Ile Tyr His  
1 5 10 15

Phe Ser Gly Leu Thr Leu Ser Asp Leu Phe Gly Ile Phe Ser Leu Met  
20 25 30

Thr Lys Phe Ile Asn Gln Trp  
35

<210> 233  
<211> 42  
<212> PRT  
<213> Homo sapiens

<400> 233  
Met Phe His Arg Ile His Gly Gln Arg Ile Arg Gln Ala Phe Glu Met  
1 5 10 15

Asn Arg Ile Ser Leu Thr Ser Pro Ser Phe Cys Gln Phe Val Leu Phe  
20 25 30

Leu Ser His Ile His Gln Leu Ser Pro Ser  
35 40

<210> 234  
<211> 42  
<212> PRT  
<213> Homo sapiens

<400> 234  
Met Phe His Arg Ile His Gly Gln Arg Ile Arg Gln Ala Phe Glu Met  
1 5 10 15

Asn Arg Ile Ser Leu Thr Ser Pro Ser Phe Cys Gln Phe Val Leu Phe  
20 25 30

Leu Ser His Ile His Gln Leu Ser Pro Ser  
35 40

<210> 235



&lt;211&gt; 37

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 235

Met Leu Met Asn Val Lys Val Ala Lys Thr Gln Ala Leu Thr Ile Leu

1

5

10

15

Met Phe Leu Leu Phe Lys Thr Asp Leu Tyr Gly Gln Lys His Arg Asn

20

25

30

Gly Ser Ser Arg Phe

35

&lt;210&gt; 236

&lt;211&gt; 135

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (72)

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (116)

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (131)

&lt;400&gt; 236

Met Lys Pro Ser Leu Cys Pro Arg Ala Val Gln Ala Ala Val Ala

1

5

10

15

Pro Thr Asn Ser Gln Glu Thr Tyr Ser Val Pro Gln Gly Arg Cys Arg

20

25

30

Trp Gln Pro Trp Pro Arg Pro Ala His Arg Lys Pro Thr Leu Cys Pro

35

40

45

Gly Ala Gly Ala Gly Gly Ser His Gly Pro Asp Gln Leu Thr Gly Asn

50

55

60

Leu Leu Cys Cys Pro Arg Gly Xaa Cys Arg Arg Gln Pro Trp Pro Arg

65

70

75

80

Pro Ser Ser His Glu Asn Leu Ser Leu Leu Pro Pro Gly Ala Ile Ala  
85 90 95

Arg Arg Gln Ala Met Ala Pro Thr Ser Ser Gln Glu Thr Tyr Ser Val  
100 105 110

Pro Pro Gly Xaa Leu Pro Leu Ala Ala Met Ala Pro Asn Gln His Thr  
115 120 125

Gly Lys Xaa Thr Gly Thr Leu  
130 135

<210> 237

<211> 419

<212> PRT

<213> Homo sapiens

<400> 237

Met Ala Pro Thr Ser Ser Gln Glu Thr Tyr Ser Val Pro Arg Gly Arg  
1 5 10 15

Cys Arg Gln Gln Pro Trp Pro Arg Pro Ala His Arg Lys Pro Ser Leu  
20 25 30

Cys Pro Arg Ala Val Gln Ala Ala Ala Val Ala Pro Thr Ser Ser Gln  
35 40 45

Glu Thr Tyr Ser Val Pro Gln Gly Arg Cys Arg Trp Gln Pro Trp Pro  
50 55 60

Arg Pro Ala His Arg Lys Pro Thr Leu Cys Pro Arg Ala Gly Ala Gly  
65 70 75 80

Gly Ser Arg Gly Pro Asp Gln Leu Thr Gly Asn Leu Leu Cys Ala Leu  
85 90 95

Gly Gln Gly Arg Cys Arg Arg Gln Pro Trp Pro Arg Pro Ala Pro Thr  
100 105 110

Ser Leu Ser Cys Ser Arg Ser Ala Pro Gly Pro Ala Pro Ser Gly Pro  
115 120 125

Arg Gly Lys Thr Pro Ser Ser Pro Thr Leu Ser Pro Ser Arg Gly Ser  
130 135 140

Pro Leu Leu Leu Arg Glu Pro Ser Leu Val Thr Asp Ser Leu Glu Ala  
145 150 155 160

His Arg Gly Ser Leu Ala Pro Gly Val Leu Trp Thr Ser Gly Thr Ala  
 165 170 175

Ser Gly Ser Lys Ala Ala Pro Pro Pro Gln Glu Gly Leu Met Thr Glu  
 180 185 190

Leu Glu Ser Cys Gly Gly Arg Thr Ala Thr Gly Pro Cys Leu Pro Thr  
 195 200 205

Gly Ser Glu Arg Pro Ser Leu Arg Leu Pro Gly Pro Cys Pro Ser Val  
 210 215 220

Gly His Ser Gln Ala Leu Gly Gln Arg Lys Gln Phe Arg Glu Thr Ala  
 225 230 235 240

Gln Ala Arg Lys Ala Gln Val Ala Trp Glu Pro Arg Ser Ala Glu Ile  
 245 250 255

Glu Leu Glu Lys Gln Glu Ala Trp Pro Gly Pro Pro Ala Ser Lys Gly  
 260 265 270

Glu Arg Gln Ala Pro Gly Val Gly Ser Gly Val Leu Gly Pro His Gln  
 275 280 285

Thr Gly Ile Phe Pro Pro Leu Pro Gly Gly Gly Ala Gly Arg Ala Ser  
 290 295 300

Pro Ala Glu Ala Pro Gly Ser Val Arg Asn Asn Arg Lys Gly Ser Arg  
 305 310 315 320

Gly Thr Gly Thr Ser His Thr Pro His Pro Val His Pro Ile Gly Pro  
 325 330 335

Ile His Pro Val His Pro Val Tyr Pro Ile Tyr Arg His Phe Pro Leu  
 340 345 350

His Ser Gln Leu Ser Arg Leu Leu Thr Leu Glu Glu Leu Asn Ser Gly  
 355 360 365

Leu Ala Ser Cys Leu Gln Cys Gly Thr Leu Cys Ser Ser Thr Trp Glu  
 370 375 380

Pro Gln Gly Ala Arg Ser Val Gly Ile Cys Thr Leu Pro Leu Thr Glu  
 385 390 395 400

Ile Tyr His Ala Glu Thr Ser Asp Leu Arg Gly Thr Ser Ala Gly Pro  
 405 410 415

Trp Val His

&lt;210&gt; 238

&lt;211&gt; 59

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 238

Met Val Ser Asn Asn Tyr Leu Thr Gly Phe Trp Leu Gly Ile Phe Leu  
1 5 10 15

Leu Pro His Thr Val Pro Val Glu Asn Val Glu Val His Phe Gly Leu  
20 25 30

Tyr Ile Phe Met Lys His Leu Glu Gly Trp Gly Gly Gly Cys Gln Val  
35 40 45

Ser Lys Ser Arg Lys Met Tyr Phe Val Arg Leu  
50 55

&lt;210&gt; 239

&lt;211&gt; 59

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 239

Met Val Ser Asn Asn Tyr Leu Thr Gly Phe Trp Leu Gly Ile Phe Leu  
1 5 10 15

Leu Pro His Thr Val Pro Val Glu Asn Val Glu Val His Phe Gly Leu  
20 25 30

Tyr Ile Phe Met Lys His Leu Glu Gly Trp Gly Gly Gly Cys Gln Val  
35 40 45

Ser Lys Ser Arg Lys Met Tyr Phe Val Arg Leu  
50 55

&lt;210&gt; 240

&lt;211&gt; 73

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 240

Met Asn Val Leu Pro Leu Lys Lys Asn Gln Leu Ser His Ile Thr His  
1 5 10 15

Ile Tyr Ile Leu Leu His Asn Asn Val Leu Asn Trp Thr Thr Val Asn  
20 25 30

Gln Arg Val Ile Ala Ala Ser Glu Gly Asp Arg Leu Leu Thr Phe Arg  
35 40 45

Tyr Cys Leu Met Pro Gly Lys Pro Trp Glu Pro Arg Gln Val Asn Leu  
50 55 60

Thr Lys Leu Leu Leu Phe Ser Gln Leu  
65 70

&lt;210&gt; 241

&lt;211&gt; 73

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 241

Met Asn Val Leu Pro Leu Lys Lys Asn Gln Leu Ser His Ile Thr His  
1 5 10 15

Ile Tyr Ile Leu Leu His Asn Asn Val Leu Asn Trp Thr Thr Val Asn  
20 25 30

Gln Arg Val Ile Ala Ala Ser Glu Gly Asp Arg Leu Leu Thr Phe Arg  
35 40 45

Tyr Cys Leu Met Pro Gly Lys Pro Trp Glu Pro Arg Gln Val Asn Leu  
50 55 60

Thr Lys Leu Leu Leu Phe Ser Gln Leu  
65 70

&lt;210&gt; 242

&lt;211&gt; 39

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (2)

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (4) .. (5)

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (7)

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (11)

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (15)

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (17) .. (22)

&lt;400&gt; 242

Met Xaa Thr Xaa Xaa Pro Xaa Ser Trp Met Xaa Ala Phe Lys Xaa Asp  
 1 5 10 15

Xaa Xaa Xaa Xaa Xaa Xaa Arg Trp Asn Leu Ser Ile Arg Gly Ser Phe  
 20 25 30

Ala Thr Asp Phe Ser Asn Gly  
 35

&lt;210&gt; 243

&lt;211&gt; 81

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 243

Met Ile Ile Tyr Asn Tyr Asn Val Tyr Cys Phe Thr Tyr Ile Phe Pro  
 1 5 10 15

Lys Tyr Thr Ile Asn Ala Leu Pro His Phe Ala Leu Phe Thr Lys Tyr  
 20 25 30

Ile Leu Glu Ile Ile Leu Tyr Ser Tyr Ile Lys Ser Phe Ile Val Pro  
 35 40 45

Phe Tyr Gly Cys Lys Met Phe Gln Leu Met Asp Gly Leu Ile Leu Tyr  
 50 55 60

Arg Ala Thr Leu Arg Leu Cys Pro Ile Leu Leu Phe Leu Ile Leu Leu  
 65 70 75 80

Lys

<210> 244

<211> 85

<212> PRT

<213> Homo sapiens

<400> 244

Met Ser Gly Glu Leu Cys Ala Gly Ala Gln Gly Pro Gln Gly Leu Val  
 1 5 10 15

Glu Gly Met Lys Cys Ala His Ile Lys Arg Lys Val Ala Met Gln Ser  
 20 25 30

Lys Glu Gly Gln Val Gln Met Cys Ser Val Asn Leu Ile Leu Arg Glu  
 35 40 45

Gly Arg Gly Phe Gly Leu Gly Gln Asp Pro Lys Glu Gly Ala Glu Asp  
 50 55 60

Met Glu Leu Glu Ala Val Arg Lys Val Val Phe Xaa Glu Gly Ala Val  
 65 70 75 80

Leu Thr Arg Pro Leu  
 85

<210> 245

<211> 70

<212> PRT

<213> Homo sapiens

<220>

<221> UNSURE

<222> (28)..(43)

<400> 245

Met Ser Thr Phe Thr Phe Thr Ala Lys Gln Gly Phe Gln Val Val Phe  
 1 5 10 15

Ser Ser Leu Asn Ser His Leu Pro Lys Met Gln Xaa Xaa Xaa Xaa Xaa  
 20 25 30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ser Gly Trp Leu Ser  
 35 40 45

Glu Ser Pro Asn Asn Pro Met Lys Tyr Glu Arg Phe Leu Glu Arg Leu  
 50 55 60

Leu Val Glu Lys Val Thr  
 65 70

<210> 246

<211> 60

<212> PRT

<213> Homo sapiens

<400> 246

Met Val Pro Gly Gly Gln Arg Ala Gly Gly Leu Cys Leu Lys Arg Ser  
 1 5 10 15

Leu Gln Ile Val Phe Glu Lys Ile Thr Gln Asn Gln Pro Trp Xaa Tyr  
 20 25 30

Leu Arg Gln Glu Gly Lys Tyr Phe Lys Arg Leu Cys Glu Phe Val Ser  
 35 40 45

Val His Leu Phe Phe Val Glu Tyr Ile Leu Leu Ile  
 50 55 60

<210> 247

<211> 48

<212> PRT

<213> Homo sapiens

<400> 247

Met Gln Gln Asp Ser Tyr Ser Val Asn Trp Tyr Ser Leu Tyr Arg Gly  
 1 5 10 15

Gln Leu Lys Lys His Phe Phe Asp Gln Ala Ile Pro Leu Leu Gly Ile  
 20 25 30

His Pro Thr Asp Ile Leu Ser His Ile Leu Lys Asn Arg Pro Gly Thr  
 35 40 45



&lt;210&gt; 248

&lt;211&gt; 103

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 248

Ile Ile Leu Ala Leu Phe Arg Asp Arg Val Ser Pro Ser Phe Arg Leu  
1 5 10 15

Ala Tyr Ser Gly Ala Ile Met Ala His Cys His Leu Gln Leu Leu Gly  
20 25 30

Leu Arg Asp Pro Pro Thr Ser Ala Ser Ala Val Ala Gly Ser Thr Gly  
35 40 45

Gln Cys His His Gly Trp Ala Asn Ala Ala Lys Phe Leu Phe Ser Ile  
50 55 60

Glu Ile Gly Leu Cys His Phe Ala Gln Ala Gly Leu Glu Leu Val Gly  
65 70 75 80

Ala Ser Asn Pro Ala Pro Ser Thr Ser Gln Ser Pro Gly Ile Thr Gly  
85 90 95

Val Ser His Cys Ala Trp Pro  
100

&lt;210&gt; 249

&lt;211&gt; 38

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 249

Met Trp Tyr Met Thr Ile Phe Pro Gly Trp Val Glu Gly Glu Val His  
1 5 10 15

Arg Asp Ser Trp Val Lys Lys Ser Leu Tyr Ser His Leu Leu Leu Lys  
20 25 30

Ala Lys Ser Pro Val Gly  
35

&lt;210&gt; 250

&lt;211&gt; 56

&lt;212&gt; PRT

<213> Homo sapiens

<220>

<221> UNSURE

<222> (11)..(19)

<400> 250

Met Phe Thr Asp Val Leu Glu Leu Lys Val Xaa Xaa Xaa Xaa Xaa Xaa  
1 5 10 15

Xaa Xaa Xaa Gln Asp Met Ser Lys Tyr Ala Trp Leu Phe Ser Ile Met  
20 25 30

Cys Met Leu Ser Ile Ser Leu Leu Ser Val Leu Gly Val Glu Leu Thr  
35 40 45

Val Leu Gly His Phe Ile Glu Phe  
50 55

<210> 251

<211> 37

<212> PRT

<213> Homo sapiens

<400> 251

Met Phe Pro Gly Asn Ile Phe Phe Asn Phe Pro Arg Ser Ser Leu Tyr  
1 5 10 15

Ser Arg Gln Thr Ser Leu Ala Val Ser Gln Ile Gly Gln Ala His Ser  
20 25 30

Cys Ile Arg Ala Phe  
35

<210> 252

<211> 30

<212> PRT

<213> Homo sapiens

<400> 252

Met Val Lys Lys Val Leu Ile Leu Met Thr Leu Tyr Gln Asn Lys Ala  
1 5 10 15

Ser Asp Ile Ser Leu Gly Leu Tyr Leu Asp Asp Gln Leu Thr  
20 25 30

<210> 253  
<211> 28  
<212> PRT  
<213> Homo sapiens

<400> 253  
Met Val Lys Lys Val Leu Ile Leu Met Thr Leu Tyr Gln Asn Lys Ala  
1 5 10 15

Ser Asp Ile Ser Leu Gly Leu Tyr Leu Met Ile Ser  
20 25

<210> 254  
<211> 19  
<212> PRT  
<213> Homo sapiens

<400> 254  
Met Arg Asn Trp Leu Ile Ser Arg Glu Asn Ser Lys Ala His Arg Lys  
1 5 10 15

Ser Arg Cys

<210> 255  
<211> 19  
<212> PRT  
<213> Homo sapiens

<400> 255  
Met Arg Asn Trp Leu Ile Ser Arg Glu Asn Ser Lys Ala His Arg Lys  
1 5 10 15

Ser Arg Cys

<210> 256  
<211> 93  
<212> PRT  
<213> Homo sapiens

<400> 256  
Met Phe Ser Ser Ala Asn Ser Ile Leu Gly Ala Leu Leu Ile Trp Ala  
1 5 10 15

Gly Met Ser Trp Leu Pro Ile Glu Ala Val Cys Arg Tyr Pro Leu Pro  
20 25 30

Ala Ser Val Pro Ser Glu His Arg Arg Asp Leu Pro Cys Val Ser Leu  
35 40 45

His Pro Trp Leu Gln Gly Ser Ser Cys Cys Leu Leu Trp Ser Trp Trp  
50 55 60

Gly Pro His Cys His Pro Trp Ile Pro Ser Cys Arg Gln Pro Ala Val  
65 70 75 80

Leu Ser Ala Leu Gly Gly Gly Gly Ala Leu Trp Leu Cys  
85 90

<210> 257

<211> 121

<212> PRT

<213> Homo sapiens

<400> 257

Met Phe Ser Ser Ala Asn Ser Ile Leu Gly Ala Leu Leu Ile Arg Ala  
1 5 10 15

Gly Met Ser Trp Leu Pro Ile Glu Ala Val Cys Arg Tyr Pro Leu Pro  
20 25 30

Ala Ser Val Pro Ser Glu His Arg Arg Asp Leu Pro Cys Val Ser Leu  
35 40 45

His Pro Trp Leu Gln Gly Ser Ser Cys Cys Leu Leu Trp Ser Trp Trp  
50 55 60

Gly Pro His Cys His Pro Trp Ile Pro Ser Cys Arg Gln Pro Cys Cys  
65 70 75 80

Pro Gln Cys Thr Gly Arg Arg Gly Cys Ala Val Val Val Leu Ser Leu  
85 90 95

His Arg Cys Pro Leu Val Gly Leu Glu Trp Gly Phe Leu Ile Pro Pro  
100 105 110

Ser Met Trp Ile Glu Phe Arg Gly Leu  
115 120

<210> 258  
<211> 20  
<212> PRT  
<213> Homo sapiens

<400> 258  
Met Lys Val Gln Gly Ala Asp Val Ala Ala Ala Ser Tyr Gln Glu  
1 5 10 15

Tyr Leu Thr Lys  
20

<210> 259  
<211> 67  
<212> PRT  
<213> Homo sapiens

<400> 259  
Met Met Pro Ala Trp Val Val Gly Trp Val Gly Ala Glu Ser Thr Pro  
1 5 10 15

Ala Pro Leu Met Lys Arg Gly Gly Arg Cys Phe Leu Ser Leu Val Leu  
20 25 30

Met Cys Pro Leu Gly Trp Trp Gln Leu Gly Leu Leu Arg Ala Thr Pro  
35 40 45

Ser Thr Met Pro Leu Leu Ile Ala Lys Ala Ser Ala Tyr Pro Pro Val  
50 55 60

Leu Asn Thr  
65

<210> 260  
<211> 49  
<212> PRT  
<213> Homo sapiens

<400> 260  
Met Ser Phe Gln Val His Pro Ser Ile Leu Lys His Lys Tyr Pro Thr  
1 5 10 15

Ile Leu Asn Asn Phe Arg Thr Lys Ile Asn Ile Leu Thr Arg Lys Lys  
20 25 30

His Ala Met Thr Ser Cys Asn Leu Ile Lys Lys Asp Lys Glu Trp Ser

35

40

45

Leu

&lt;210&gt; 261

&lt;211&gt; 32

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 261

Met Phe Thr Phe Leu Tyr Leu Val Ile Thr Glu Thr Asn Cys Leu Val  
 1 5 10 15

Thr Phe Glu Ile Asn Glu Ser Xaa Leu Ser Gln Cys Val Ile Asp Asn  
 20 25 30

&lt;210&gt; 262

&lt;211&gt; 47

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 262

Met Ser Ser Met Glu Glu Ala Phe Gly Ser Glu Met Asn Cys Pro Arg  
 1 5 10 15

Ser Arg Gly Glu Glu Leu Gly Pro Gly Leu Thr Gly Phe Cys Ser Val  
 20 25 30

Val Leu Ser Arg Pro Trp Phe Leu Leu Tyr Pro Gly Gly Ala Phe  
 35 40 45

&lt;210&gt; 263

&lt;211&gt; 69

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 263

Met Ala Val Leu Lys Thr Trp His Lys Tyr Met Ser Cys Ala Glu Thr  
 1 5 10 15

Gly Val Ala Pro Ser Phe Ile His Gly Asp Trp Gln Val Thr Thr Pro

20

25

30

Ala Pro Ala Pro Ser Cys Ile Pro Leu Ile Val Arg Lys Arg Glu Gly  
35 40 45

Pro Ser Cys Leu Cys Pro His Ala Cys Val Thr Ala Ser Leu Phe Thr  
50 55 60

Gln Arg Val Val Phe.  
65

<210> 264  
<211> 79  
<212> PRT  
<213> Homo sapiens

<220>  
<221> UNSURE  
<222> (4)

<220>  
<221> UNSURE  
<222> (8)

<220>  
<221> UNSURE  
<222> (22)

<220>  
<221> UNSURE  
<222> (38)

<220>  
<221> UNSURE  
<222> (42)

<220>  
<221> UNSURE  
<222> (46) .. (47)

<220>  
<221> UNSURE  
<222> (52)

<220>  
<221> UNSURE  
<222> (55)

&lt;400&gt; 264

Met Trp Pro Xaa Trp Pro Arg Xaa Lys Pro Gly Gln Lys Glu Lys Gly  
 1 5 10 15

Pro Asn Phe Phe Phe Xaa Val Trp Ile Val Phe Ser Trp Lys Asn Asn  
 20 25 30

Leu Gly Cys Pro Asn Xaa Cys His Phe Xaa Thr Val His Xaa Xaa Ile  
 35 40 45

Thr Ser Ser Xaa Met Ser Xaa Asp Thr Asp Thr Gly Ser Asn Leu Thr  
 50 55 60

Leu Tyr Ser Met Thr Gly Leu Lys Ile Arg Pro Lys Gly Ile Ile  
 65 70 75

&lt;210&gt; 265

&lt;211&gt; 25

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 265

Met Ile Ser Glu Lys Leu Gly Gly Val Lys Cys Pro Gly Lys Lys Gly  
 1 5 10 15

Leu Gly Leu Gln Arg Tyr Thr Gln Met  
 20 25

&lt;210&gt; 266

&lt;211&gt; 59

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 266

Met Ala Thr Thr Thr Leu Thr Leu Ala Tyr Tyr Leu Ile Gln Leu Pro  
 1 5 10 15

Ser Lys Thr Asp Thr Ser Phe Leu Leu His Phe Asp Ile Ile Cys Gln  
 20 25 30

Val Cys Phe Ile Pro Ser Tyr Ile Lys Asn Glu Ser Thr Val Gln Leu  
 35 40 45

Tyr Ser Arg Arg His Leu Ser Tyr Lys Thr Val  
 50 55



<210> 267  
<211> 88  
<212> PRT  
<213> Homo sapiens

<400> 267  
Met Leu Phe Phe Phe Val Asp Phe Lys Ser Glu His Phe Arg Thr Met  
1 5 10 15  
Lys Ile Phe Gln Arg Thr Ser Asp Ser Val Leu Leu Thr Phe Ala Tyr  
20 25 30  
Gly His Ser Asp Thr Ile Thr Ser Ser Ala Tyr Leu Ile Cys Arg Tyr  
35 40 45  
Leu Asp Ser Asn Gln Asp Leu Glu Asn Gln Arg Phe Arg Glu Asn Lys  
50 55 60  
Lys Lys Leu Arg Lys Ala Gln Asn Met Gln Phe Ser Lys Ile Phe Arg  
65 70 75 80  
Leu Ile His Lys Tyr Ser Thr Cys  
85

<210> 268  
<211> 46  
<212> PRT  
<213> Homo sapiens

<400> 268  
Met His His Ser Asn Thr Phe Leu Arg Val Lys Val Ile Ile Lys Asn  
1 5 10 15  
Tyr Leu Tyr Leu Leu Lys Tyr Ser Leu Lys Leu Trp Phe Leu Met Ser  
20 25 30  
Tyr Tyr Ser Ile Phe Glu Gly Ile Met Leu Tyr Leu Ile Asn  
35 40 45

<210> 269  
<211> 60  
<212> PRT  
<213> Homo sapiens

&lt;400&gt; 269

Met Ser Leu Phe Lys Met Ser Phe Thr Ser Ala Gly Gln Glu Gln Ser  
 1 5 10 15

Tyr Met Ala Tyr Pro Gln Met Pro Pro Phe Val Phe Thr Met Thr Ala  
 20 25 30

Asn Gln Gln Leu Thr Thr Gln Ser Leu Val His Pro Val Thr His Ser  
 35 40 45

Leu Lys Pro His Phe Ile Phe Pro Gly Phe Phe Ile  
 50 55 60

&lt;210&gt; 270

&lt;211&gt; 69

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (10)

&lt;400&gt; 270

Met Cys Glu Lys Phe Tyr Ile Lys Cys Xaa Lys Lys Ile Ser Ala Ser  
 1 5 10 15

Met Arg Leu Pro Arg Asn Leu Gly Ala Phe Ile Lys Ile Thr Pro Asn  
 20 25 30

Lys Arg Asn Tyr Arg Arg Lys Lys Glu Lys Met Lys Thr Arg Thr Phe  
 35 40 45

Glu Leu Lys Asn Thr Val Glu Lys Lys Phe Met Glu Lys Met Gln Lys  
 50 55 60

Phe Lys Ile Lys Ile  
 65

&lt;210&gt; 271

&lt;211&gt; 96

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 271

Met Pro Val Tyr Ser Leu Leu Gln Ile Pro Pro Gly Glu Ala Thr Leu  
 1 5 10 15

Lys Ile Pro Asp Lys Leu Lys Phe Ile Asn Leu Ile Leu Leu Ser Pro  
                   20                  25                  30  
 Val Ser Pro Ile Ile Val Pro Ile Ala Asp Thr Ile Pro Asn Leu His  
                   35                  40                  45  
 Ser Cys Ser Ala Arg His Glu Ser Arg Lys Trp Gly Leu Ile Leu Pro  
                   50                  55                  60  
 Ala Thr Leu Val Ser Asn Tyr Ser Glu Lys Glu Val Asp Val Leu Ile  
                   65                  70                  75                  80  
 Asp Gly Lys Ile Glu Met Ile Phe Leu Gly Glu Ile Phe Leu Arg Ser  
                   85                  90                  95

<210> 272  
 <211> 48  
 <212> PRT  
 <213> Homo sapiens

<400> 272  
 Met Gly Tyr Ile Leu Lys Leu Phe His Tyr Leu Asn Pro Leu Val Ser  
           1                  5                  10                  15  
 Val Val Leu Leu Leu Ser Lys Glu Gln Ser Phe Phe Phe His Thr Asn  
                   20                  25                  30  
 Gly Val Gly Gln Asn Ile Lys Ala Ser Val Ile Trp Lys Ser Ser Arg  
           35                  40                  45

<210> 273  
 <211> 38  
 <212> PRT  
 <213> Homo sapiens

<400> 273  
 Met Asn Phe Tyr Arg Pro Arg Asn Ser Ser His Tyr Leu Thr Asn Phe  
           1                  5                  10                  15

WO 02/062945

PCT/US01/45541

Ser Val Cys Val Glu Thr Val Thr Ser Leu Tyr Ser Glu Gly Ile Ala  
20 25 30

Thr Tyr Asn Val Thr Asn  
35

<210> 274

<211> 42

<212> PRT

<213> Homo sapiens

<400> 274

Met Ala Ala Ile Ser Arg Pro Val Lys Ile His Leu Pro Lys Glu Asn  
1 5 10 15

His Ser Phe Phe Phe Phe Phe Trp Arg Trp Ser Phe Ala Leu Val Ala  
20 25 30

Gln Ala Gly Val Pro Arg Pro Arg Pro Arg  
35 40

<210> 275

<211> 30

<212> PRT

<213> Homo sapiens

<400> 275

Met Leu Phe Trp Thr Leu Gly Ser Val Ile Tyr Tyr Val Cys Pro Ser  
1 5 10 15

Ile Glu Val Ser Leu Thr Leu Ser Lys Ile Pro Phe Thr Asn  
20 25 30

<210> 276

<211> 244

<212> PRT

<213> Homo sapiens

<400> 276

Leu Leu Gly Thr Ala Phe Gln Leu Phe Gly Tyr Glu Glu Asn Ala Val  
1 5 10 15

Gln Ser Leu Gln His Leu Leu Lys Phe Met Ala Ser Asn Lys Ala Ala  
20 25 30

Ala Asp Asp Ala Ser Val Ala Ala Ala Ala Gln Ser Phe Phe Gln Arg  
           35                          40                          45  
 Leu Glu Leu Gly Asp Met Gln Ala Leu Ser Leu Trp Gln Lys Phe Arg  
           50                          55                          60  
 Asp Leu Ser Ile Glu Glu Tyr Ile Arg Val Tyr Lys Arg Leu Gly Val  
           65                          70                          75                          80  
 Tyr Phe Asp Glu Tyr Ser Gly Glu Ser Phe Tyr Arg Glu Lys Ser Gln  
                           85                          90                          95  
 Glu Val Leu Lys Leu Leu Glu Ser Lys Gly Leu Leu Leu Lys Thr Ile  
                           100                          105                          110  
 Lys Gly Thr Ala Val Val Asp Leu Ser Gly Asn Gly Asp Pro Ser Ser  
           115                          120                          125  
 Ile Cys Thr Val Met Arg Ser Asp Gly Thr Ser Leu Tyr Ala Thr Arg  
           130                          135                          140  
 Asp Leu Ala Ala Ala Ile Asp Arg Met Asp Lys Tyr Asn Phe Asp Thr  
           145                          150                          155                          160  
 Met Ile Tyr Val Thr Asp Lys Gly Gln Lys Lys His Phe Gln Gln Val  
                           165                          170                          175  
 Phe Gln Met Leu Lys Ile Met Gly Tyr Asp Trp Ala Glu Arg Cys Gln  
           180                          185                          190  
 His Val Pro Phe Gly Val Val Gln Gly Met Lys Thr Arg Arg Gly Asp  
           195                          200                          205  
 Val Thr Phe Leu Glu Asp Val Leu Asn Glu Ile Gln Leu Arg Met Leu  
           210                          215                          220  
 Gln Asn Met Ala Ser Ile Lys Ser Glu Phe Ser Phe Phe Leu Leu Lys  
           225                          230                          235                          240  
 Ser Leu Lys Ser

&lt;210&gt; 277

&lt;211&gt; 35

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

WO 02/062945

PCT/US01/45541

<400> 277

Met Met Gly Leu Leu Glu Ala Trp Ile Pro Gln Asp Ser Thr Ala Glu  
1 5 10 15

Trp Ser Asn Thr Gly Ser Thr Ala Asn Gln Arg Gln Cys Tyr Ile Leu  
20 25 30

Arg Glu Ile  
35